"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B2,US 8398082 B2,195-836-830-039-185,2013-03-19,2013,US 80253310 A,2010-06-08,US 80253310 A;;US 6935508 A;;US 93245307 P;;US 90079507 P,2007-02-09,Linking puzzle game and method,"A linking puzzle game and method of play involving one or more players and including a playing surface having at least one, but preferably, a plurality of puzzle areas of varying degrees of difficulty. A plurality of base zones are disposed in an interconnecting relation to one another on each of the one or more puzzle areas, wherein at least one indicia is associated therewith, such as via a plurality of game pieces randomly distributed thereon. A plurality of action pieces each having predetermined indicia disposed thereon which corresponds to an objective goal which is reached by adding or performing another mathematical operation on the indicia of game pieces disposed on appropriate ones of interconnected base zones.",CABRERA JOSE MANUEL,CABRERA JOSE MANUEL,,https://lens.org/195-836-830-039-185,Granted Patent,yes,9,1,5,5,0,A63F3/0415;;A63F2003/046;;A63F3/0415;;A63F2003/046,A63F3/00,273/275;;X273153 R,0,0,,,,ACTIVE
2,ES,A1,ES 2315210 A1,097-364-794-407-618,2009-03-16,2009,ES 200802511 A,2008-08-28,ES 200802511 A,2008-08-28,"Integral system of construction of housing and similar structure (Machine-translation by Google Translate, not legally binding)","On a foundation slab (1) and through anchoring plates embedded in it, prefabricated pillars (3) equipped with short side brackets (4), for supporting and fixing lintels or beams (5), also prefabricated, are established. Brace the structure and that constitute, with a profile in ""L"", the support elements for self-supporting plates (7), also prefabricated, which are complemented by a perimeter band (9) of tied and with a mesh of distribution ( 11), on which the concrete constituting the compression layer is finally poured, to repeat this process in successive slabs, in the event that these exist. The construction system eliminates the classic need for support struts for the slabs, shortening the duration of the work, improving safety and drastically shortening the time of completion of the same. (Machine-translation by Google Translate, not legally binding)",CABRERA ALCAZAR JOSE,CABRERA ALCAZAR JOSE,,https://lens.org/097-364-794-407-618,Patent Application,no,7,0,2,2,0,E04B1/21;;E04B1/215,E04B1/21,,0,0,,,,INACTIVE
3,ES,U,ES 1061957 U,194-204-603-713-326,2006-05-01,2006,ES 200600058 U,2006-01-11,ES 200600058 U,2006-01-11,"Shower plate (Machine-translation by Google Translate, not legally binding)","Shower; of the type having a quadrangular prismatic body provided with a central recess whose bottom face has a corresponding drainage and also the recess determines an upper peripheral end edge; characterized in that the bottom face of the plate has a progressively increasing circumferential channel height towards the drain which is located in a recessed area is closed with a part that does cover, which is coplanar with the rest of the bottom face, the which presents recesses of preferably irregular shapes and dimensions through which water flows to the shower perimeter channel in connection with the drainage area. (Machine-translation by Google Translate, not legally binding)",MARTIN CABRERA JOSE,MARTIN CABRERA JOSE,,https://lens.org/194-204-603-713-326,Patent Application,no,0,0,2,2,0,,A47K3/40,,0,0,,,,EXPIRED
4,WO,A3,WO 2008/100439 A3,142-271-670-360-878,2008-10-02,2008,US 2008/0001729 W,2008-02-08,US 90079507 P;;US 93245307 P,2007-02-09,LINKING PUZZLE GAME AND METHOD,"A linking puzzle game and method of play involving one or more players and including a playing surface having at least one, but preferably, a plurality of puzzle areas of varying degrees of difficulty. A plurality of base zones are disposed in an interconnecting relation to one another on each of the one or more puzzle areas, wherein at least one indicia is associated therewith, such as via a plurality of game pieces randomly distributed thereon. A plurality of action pieces each having predetermined indicia disposed thereon which corresponds to an objective goal which is reached by adding or performing another mathematical operation on the indicia of game pieces disposed on appropriate ones of interconnected base zones.",CABRERA JOSE MANUEL,CABRERA JOSE MANUEL,,https://lens.org/142-271-670-360-878,Search Report,yes,4,0,5,5,0,A63F3/0415;;A63F2003/046;;A63F3/0415;;A63F2003/046,A63F3/00,,0,0,,,,PENDING
5,US,A,US 2390987 A,009-668-051-134-170,1945-12-18,1945,US 51957044 A,1944-01-24,US 51957044 A,1944-01-24,Folding cover for typewriting machines or the like,,GONZALEZ CABRERA JOSE,GONZALEZ CABRERA JOSE,,https://lens.org/009-668-051-134-170,Granted Patent,no,0,4,1,1,0,B41J29/13;;B41J29/13,B41J29/13,,0,0,,,,EXPIRED
6,ES,Y,ES 1264566 Y,146-764-317-305-318,2021-06-29,2021,ES 202032394 U,2020-11-06,ES 202032394 U,2020-11-06,JUGUETE INTIMO RECIPROCO,,CABRERA MUNUERA JOSE,CABRERA MUNUERA JOSE,,https://lens.org/146-764-317-305-318,Limited Patent,no,0,0,2,2,0,,A61H19/00,,0,0,,,,ACTIVE
7,WO,A2,WO 2008/100439 A2,188-252-065-505-51X,2008-08-21,2008,US 2008/0001729 W,2008-02-08,US 90079507 P;;US 93245307 P,2007-02-09,LINKING PUZZLE GAME AND METHOD,"A linking puzzle game and method of play involving one or more players and including a playing surface having at least one, but preferably, a plurality of puzzle areas of varying degrees of difficulty. A plurality of base zones are disposed in an interconnecting relation to one another on each of the one or more puzzle areas, wherein at least one indicia is associated therewith, such as via a plurality of game pieces randomly distributed thereon. A plurality of action pieces each having predetermined indicia disposed thereon which corresponds to an objective goal which is reached by adding or performing another mathematical operation on the indicia of game pieces disposed on appropriate ones of interconnected base zones.",CABRERA JOSE MANUEL,CABRERA JOSE MANUEL,,https://lens.org/188-252-065-505-51X,Patent Application,yes,0,0,5,5,0,A63F3/0415;;A63F2003/046;;A63F3/0415;;A63F2003/046,A63F9/08,,0,0,,,,PENDING
8,ES,U,ES 1264566 U,148-654-597-682-358,2021-04-08,2021,ES 202032394 U,2020-11-06,ES 202032394 U,2020-11-06,"RECIPROCAL INTIMATE TOY (Machine-translation by Google Translate, not legally binding)","Reciprocal intimate toy characterized in that it comprises two subsets, each one in solidarity, and a Spring (6): a. A ""bearing subassembly"", comprising, in turn, a Harness (2) and a fixed Rod (1). The Harness (2) will be attached to one user. The fixed Stem (1) will be hollow and have a groove serving these qualities as a guide for the movement of the next subassembly. b. A mobile subset that in turn comprises: i. a mobile Stem (3) that will go inside the fixed Stem (1) ii. a Ring-shaped Placeholder (4) that will go around the Fixed Stem (1). iii. An adjustment Rod (5) that fixes the movable Stem (3) and the Position Marker (4) to itself when inserted into the holes of both, and that is inserted into the slot of the fixed Stem (1), achieving a linear movement of the mobile subassembly relative to the bearing subassembly. c. A Spring (6) between the base of the fixed Stem (1) and the Position Marker (4) that forces the movable subassembly to retreat to its most internal position possible within the fixed subassembly. (Machine-translation by Google Translate, not legally binding)",CABRERA MUNUERA JOSE,CABRERA MUNUERA JOSE,,https://lens.org/148-654-597-682-358,Patent Application,no,0,0,2,2,0,,A61H19/00,,0,0,,,,ACTIVE
9,US,A1,US 2008/0203659 A1,125-182-966-502-192,2008-08-28,2008,US 6935508 A,2008-02-08,US 6935508 A;;US 93245307 P;;US 90079507 P,2007-02-09,Linking puzzle game and method,"A linking puzzle game and method of play involving one or more players and including a playing surface having at least one, but preferably, a plurality of puzzle areas of varying degrees of difficulty. A plurality of base zones are disposed in an interconnecting relation to one another on each of the one or more puzzle areas, wherein at least one indicia is associated therewith, such as via a plurality of game pieces randomly distributed thereon. A plurality of action pieces each having predetermined indicia disposed thereon which corresponds to an objective goal which is reached by adding or performing another mathematical operation on the indicia of game pieces disposed on appropriate ones of interconnected base zones.",CABRERA JOSE MANUEL,CABRERA JOSE MANUEL,,https://lens.org/125-182-966-502-192,Patent Application,yes,18,14,5,5,0,A63F3/0415;;A63F2003/046;;A63F3/0415;;A63F2003/046,A63F9/08,273153 R,0,0,,,,DISCONTINUED
10,US,A1,US 2011/0018196 A1,183-080-686-212-71X,2011-01-27,2011,US 80253310 A,2010-06-08,US 80253310 A;;US 6935508 A;;US 93245307 P;;US 90079507 P,2007-02-09,Linking puzzle game and method,"A linking puzzle game and method of play involving one or more players and including a playing surface having at least one, but preferably, a plurality of puzzle areas of varying degrees of difficulty. A plurality of base zones are disposed in an interconnecting relation to one another on each of the one or more puzzle areas, wherein at least one indicia is associated therewith, such as via a plurality of game pieces randomly distributed thereon. A plurality of action pieces each having predetermined indicia disposed thereon which corresponds to an objective goal which is reached by adding or performing another mathematical operation on the indicia of game pieces disposed on appropriate ones of interconnected base zones.",CABRERA JOSE MANUEL,CABRERA JOSE MANUEL,,https://lens.org/183-080-686-212-71X,Patent Application,yes,9,5,5,5,0,A63F3/0415;;A63F2003/046;;A63F3/0415;;A63F2003/046,A63F9/08,273153 R,0,0,,,,ACTIVE
11,ES,Y,ES 1061957 Y,093-189-313-752-461,2006-08-01,2006,ES 200600058 U,2006-01-11,ES 200600058 U,2006-01-11,PLATO DE DUCHA,,MARTIN CABRERA JOSE,MARTIN CABRERA JOSE,,https://lens.org/093-189-313-752-461,Limited Patent,no,0,0,2,2,0,,A47K3/40,,0,0,,,,EXPIRED
12,ES,B1,ES 2315210 B1,035-039-250-933-478,2010-03-16,2010,ES 200802511 A,2008-08-28,ES 200802511 A,2008-08-28,SISTEMA INTEGRAL DE CONSTRUCCION DE LA ESTRUCTURA DE VIVIENDAS Y SIMILARES,,CABRERA ALCAZAR JOSE,CABRERA ALCAZAR JOSE,,https://lens.org/035-039-250-933-478,Granted Patent,no,0,0,2,2,0,E04B1/21;;E04B1/215,E04B1/21,,0,0,,,,INACTIVE
13,DE,D1,DE 60034153 D1,002-016-858-293-246,2007-05-10,2007,DE 60034153 T,2000-12-29,ES 200000799 A;;ES 0000498 W,2000-03-30,ZUSAMMENSTZUNG UND VERFAHREN ZUR ERZEUGUNG VON METALLISCHEN EFFEKTEN IN KERAMISCHEN ZIEGELN UND IHRE VERWENDUNG,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ M JOSE,,https://lens.org/002-016-858-293-246,Granted Patent,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/02;;C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
14,CL,A1,CL 2012003292 A1,036-445-135-323-543,2013-03-08,2013,CL 2012003292 A,2012-11-23,CL 2012003292 A,2012-11-23,"Sistema oleo hidraulico para produccion de energia electrica, opera con una bomba hidraulica a pistones de dos cilindros, un motor hidraulico acoplado a un alternador electrico, el sistema se retroalimenta hidraulica y electricamente en forma permanente y autonoma, sin uso de mayor combustible para su funcionamiento.","Sistema oleohidráulico compacto de producción de energía eléctrica, auto sostenible y no contaminante, comprende un motor de partida montado sobre un estanque de aceite de 100-500 litros con aceite de alto rendimiento, opera con una bomba hidráulica a pistones de 0-350 bar y 50-200 lpm, un torque entre 1800-5000 Nm/bar para producción de alta presión.",CABRERA LOPEZ JOSE BELARMINO,CABRERA LOPEZ JOSE BELARMINO,,https://lens.org/036-445-135-323-543,Patent Application,no,0,0,1,1,0,,F16D31/02,,0,0,,,,PENDING
15,ES,U,ES 1139831 U,145-225-927-766-198,2015-06-10,2015,ES 201500371 U,2015-05-20,ES 201500371 U,2015-05-20,"Opening device with multiple keys (Machine-translation by Google Translate, not legally binding)","Opening device with multiple keys; comprising a prismatic casing (1) delimiting an interior cavity and comprising a front surface (11), a rear surface (12) and side surfaces (13, 14, 15, 16), said casing forming an element support opening of locks; characterized in that it comprises several recessed spreads (2), mounted parallel and with the possibility of longitudinal displacement in respective housing of the housing (1); whose parallel housings have in a first lateral surface (13) of the casing (1) of respective front mouths (17) for the passage of the sprats (2) and in the front surface (11) of the casing (1) of respective slots (18) longitudinal in which are mounted push buttons (3), associated with the respective spindles (2), and displaceable between an operative position in which the corresponding spindle (2) protrudes from the housing (1) and a position inoperative in which the corresponding spreader (2) is disposed inside the corresponding housing. (Machine-translation by Google Translate, not legally binding)",SEGURIDAD Y LLAVES BARCELONA S L,CARVAJAL CABRERA JOSE ANTONIO,,https://lens.org/145-225-927-766-198,Patent Application,no,0,0,2,2,0,,A44B15/00;;E05B19/00,,0,0,,,,INACTIVE
16,MX,A,MX 2007000793 A,159-011-587-251-132,2007-03-21,2007,MX 2007000793 A,2005-07-25,EP 04017561 A;;EP 04017562 A;;US 90227204 A;;US 90227304 A;;EP 04020376 A;;EP 2005008080 W,2004-07-24,USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA.,The present invention refert to the use of compounds active on the sigma receptorfor the treatment of mechanical allodynia.,ESTEVE LABOR DR,CABRERA JOSE MANUEL BAEYENS,,https://lens.org/159-011-587-251-132,Patent Application,no,0,0,8,12,0,A61K31/13;;A61K31/519;;A61K31/7125;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00,A61K31/00;;A61P25/00;;A61P29/00,,0,0,,,,DISCONTINUED
17,ES,B1,ES 2161193 B1,173-072-601-080-015,2002-06-16,2002,ES 200000799 A,2000-03-30,ES 200000799 A,2000-03-30,FORMULACION Y PROCEDIMIENTO PARA LA OBTENCION DE EFECTOS METALICOS EN BALDOSAS CERAMICAS Y SUS APLICACIONES.,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ MARIA JOSE,,https://lens.org/173-072-601-080-015,Granted Patent,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
18,ES,U,ES 1298438 U,056-654-256-275-484,2023-03-17,2023,ES 202330057 U,2023-01-16,ES 202330057 U,2023-01-16,"Fire device for kitchens (Machine-translation by Google Translate, not legally binding)","Fire-fighting device for kitchens, comprising at least one fire-fighting element, characterized in that the fire-fighting element comprises a fire-retardant fabric (6) that can be stretched between a stowed position and an extended position. (Machine-translation by Google Translate, not legally binding)",NIETO CABRERA JOSE ANTONIO,NIETO CABRERA JOSE ANTONIO,,https://lens.org/056-654-256-275-484,Patent Application,no,0,0,2,2,0,,A62C2/18,,0,0,,,,ACTIVE
19,ES,U,ES 1178084 U,073-843-570-767-312,2017-03-07,2017,ES 201730115 U,2017-02-08,ES 201730115 U,2017-02-08,"Folding and transportable stool of carton with integrated closure (Machine-translation by Google Translate, not legally binding)","Foldable and transportable cardboard stool with integrated closure that is characterized by being configured from two cardboard sheets appropriately die cut and provided with various creasing lines that allow the folding in the form of bellows of both sheets, which, after the the smaller size of the sheet in the larger sheet, form a single body that, both in its upper part and in its lower part, has a central rhomboidal space and two triangular lateral spaces both in the assembly process and in its mounted position, spaces that are covered by two main fins that fold towards the interior of the single body forming an angle of 90º and fit, through two secondary fins, into the central rhomboidal space of the single body. (Machine-translation by Google Translate, not legally binding)",MARRERO CABRERA JOSE MIGUEL,MARRERO CABRERA JOSE MIGUEL,,https://lens.org/073-843-570-767-312,Patent Application,no,0,0,2,2,0,,A47C4/04,,0,0,,,,INACTIVE
20,WO,A1,WO 2001/072651 A1,149-580-313-134-358,2001-10-04,2001,ES 0000498 W,2000-12-29,ES 200000799 A,2000-03-30,FORMULATION AND METHOD FOR ACHIEVING METALLIC EFFECTS IN CERAMIC TILES AND THE APPLICATIONS THEREOF,"The formulation comprises a mixture of essential oxides, i.e.: SiO2, Al2O3, Fe2O3 and P2O5, in addition to certain optional oxides, i.e.: CaO, MgO, Na2O and K2O, and contains no noble metals. Said formulation is applied on a support or ceramic tile using a conventional technique and then undergoes a baking process using a monobaking technique. The formulation enables important applications in and provides important advantages for the ceramic industry sector.",VIDRES S A VIDRESA;;CABRERA IBANEZ MA JOSE,CABRERA IBANEZ MA JOSE,,https://lens.org/149-580-313-134-358,Patent Application,yes,3,3,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,PATENTED
21,PT,E,PT 1306355 E,087-881-464-636-584,2007-07-04,2007,PT 00988820 T,2000-12-29,ES 200000799 A,2000-03-30,FORMULATION AND METHOD FOR ACHIEVING METALLIC EFFECTS IN CERAMIC TILES AND THE APPLICATIONS THEREOF,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,IBANEZ M JOSE CABRERA,,https://lens.org/087-881-464-636-584,Granted Patent,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/02;;C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
22,AT,T1,AT E358106 T1,176-201-493-561-344,2007-04-15,2007,AT 00988820 T,2000-12-29,ES 200000799 A,2000-03-30,ZUSAMMENSTZUNG UND VERFAHREN ZUR ERZEUGUNG VON METALLISCHEN EFFEKTEN IN KERAMISCHEN ZIEGELN UND IHRE VERWENDUNG,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ M JOSE,,https://lens.org/176-201-493-561-344,Granted Patent,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
23,US,A1,US 2009/0042898 A1,180-247-907-823-278,2009-02-12,2009,US 65815305 A,2005-07-25,US 65815305 A;;EP 04017561 A;;EP 04017562 A;;EP 04020376 A;;US 90227304 A;;US 90227204 A;;EP 2005008080 W,2004-07-24,USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA,The present invention refert to the use of compounds active on the sigma receptor for the treatment of mechanical allodynia.,ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL,LABORATORIOS DEL DR. ESTEVE S.A (2007-11-12),https://lens.org/180-247-907-823-278,Patent Application,yes,4,1,2,12,0,A61K31/519;;A61K31/519,A61K31/495;;A61K31/135,514/252.12;;514/646,3,3,096-172-455-538-821;;000-002-108-055-409;;016-897-012-508-670,17166129;;10.1111/j.1530-7085.2003.03037.x;;17166125;;10.1016/0731-7085(94)00075-d;;7718634;;10.1016/s0006-8993(98)01175-5;;10082803,"Visser et al. ""Is the second phase of the formalin test useful to predict activity in chronic constriction injury models? A pharamcological comparison in different species,"" Pain Practice, 2003, vol. 3, No. 4, pp 298-309;;Tattah et al. ""Spectrophotometric determination of flunarizine dihydrochloride through the formation of chargetransfer complex with iodine,"" J. Pharm. & Biom. Anal. 1994, Vol. 13, No. 1, pp 53-58;;Weizman et al. ""Pharmacological interation of the calcium channel blockers verapamil and flunarizine with the opoid system,"" Brain Research, 1999, Vol. 818, pp 187-195",DISCONTINUED
24,DE,T2,DE 60034153 T2,010-580-420-626-613,2008-07-17,2008,DE 60034153 T,2000-12-29,ES 200000799 A;;ES 0000498 W,2000-03-30,ZUSAMMENSTZUNG UND VERFAHREN ZUR ERZEUGUNG VON METALLISCHEN EFFEKTEN IN KERAMISCHEN ZIEGELN UND IHRE VERWENDUNG,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ M JOSE,,https://lens.org/010-580-420-626-613,Granted Patent,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/02;;C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
25,MX,A,MX 2009003387 A,047-234-489-226-950,2010-09-30,2010,MX 2009003387 A,2009-03-30,MX 2009003387 A,2009-03-30,AUTOMATED DEHYDRATION CHAMBER WITH A SOLAR HEAT AND/OR FUEL TRANSFERENCE SYSTEM.,"The automated dehydration chamber includes a solar system which is supported by a high efficiency heater in case of required. The optimum operation conditions, within the chamber, for dehydrating the product, such as temperature, humidity, speed and time, are controlled automatically from a control box, which actuates the manipulation pumps, opens and closes fluids, increases and reduces the fans speed, activates the dehumidification system. A heat transferring system was designed for acquiring a maximum efficiency in the dehydrated products, which allows the temperature and humidity to have the same value in any inner point of the chamber. The inventive chamber provides a substantial saving to the dehydration process using solar systems and a highly efficient control of the parameters required by the process. Besides contributing to the environment, the solar systems provide most of the energy and/or the whole energy required in the dehydration process. The chamber was built with hig hly efficient thermal materials for minimizing power loses; the fluid circuits and the accessories inside and outside the chamber were arranged for achieving a high efficiency in the heat transmission, and avoiding energy loses.",VELDUCEA JOSE REFUGIO CABRERA,VELDUCEA JOSE REFUGIO CABRERA,,https://lens.org/047-234-489-226-950,Patent Application,no,0,0,1,1,0,,F28F27/00,,0,0,,,,PENDING
26,ES,U,ES 1118005 U,055-045-328-432-187,2014-07-28,2014,ES 201430649 U,2014-05-14,ES 201430649 U,2014-05-14,"Rotary defense for springs (Machine-translation by Google Translate, not legally binding)","Defense (1) rotary for springs (2), of the type that avoid direct contact between spring (2) and ship (3); characterized in that it comprises a plurality of rotating rollers (4) with an elastomeric surface arranged in the area in contact with the vessel (3), and a structure (5) for supporting said rollers (4) fixed to the spring (2). (Machine-translation by Google Translate, not legally binding)",GARCIA CABRERA RAFAEL JOSE,GARCIA CABRERA RAFAEL JOSE,,https://lens.org/055-045-328-432-187,Patent Application,no,0,3,2,2,0,Y02A30/30,E02B3/26,,0,0,,,,INACTIVE
27,EP,A1,EP 1306355 A1,047-256-343-594-360,2003-05-02,2003,EP 00988820 A,2000-12-29,ES 0000498 W;;ES 200000799 A,2000-03-30,FORMULATION AND METHOD FOR ACHIEVING METALLIC EFFECTS IN CERAMIC TILES AND THE APPLICATIONS THEREOF,"The formulation comprises a mixture of essential oxides, namely: SiO 2 , Al 2 O 3 , Fe 2 O 3  and P 2 O 3 , together with certain optional oxides, namely: CaO, MgO, Na 2 O and K 2 O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ M JOSE,,https://lens.org/047-256-343-594-360,Patent Application,yes,0,7,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
28,MX,A,MX 2021001409 A,134-292-278-123-854,2022-08-04,2022,MX 2021001409 A,2021-02-03,MX 2021001409 A,2021-02-03,CONTAINER COVER.,The present invention relates to a thermoformed plastic container cover. Said cover comprises a sheet-like cover body with a crimping edge extending around its entire periphery. Said edge is suitable for engaging with the periphery portion of a plastic open-top container with a cover edge near the frame of the cover body.,JOSE ALBERTO SERRANO CABRERA,SERRANO CABRERA JOSE ALBERTO,,https://lens.org/134-292-278-123-854,Patent Application,no,0,0,1,1,0,,B65D39/00;;B65D41/00;;B65D43/00,,0,0,,,,PENDING
29,MX,A,MX 2012007611 A,061-321-700-085-392,2013-12-27,2013,MX 2012007611 A,2012-06-28,MX 2012007611 A,2012-06-28,PUNCHING BASE.,"The present invention consists in a punching base, which may be used in automated machines for punching patterns in laminated materials such as natural leather, and synthetic leather, for the manufacture of footwear. The base may grip the laminated material piece in a suitable position for avoiding the material distension, ensuring the punching to be performed in the desired position, this may help to solve the problem of reproducibility in the punch position and increase the operation speed. The punching bases comprise two guide bases and a plate for retaining eight exchangeable modules, in which the pieces to be punched are arranged, then the punching base being located in an automated punching machine.",ROBERTO EDUARDO NOVOA TOSCAN,CABRERA JOSE RAMIRO MARQUEZ,,https://lens.org/061-321-700-085-392,Patent Application,no,0,0,1,1,0,,B21D28/00,,0,0,,,,DISCONTINUED
30,ES,U,ES 1158733 U,058-333-274-529-818,2016-06-14,2016,ES 201630587 U,2016-05-10,ES 201630587 U,2016-05-10,"Support for electric chargers for mobile devices (Machine-translation by Google Translate, not legally binding)","Support (1) for electric chargers of mobile devices; characterized in that it comprises a body with a central housing (2) able to accommodate the transformer of the electric charger, where at least one wall (3, 3 ') of the central housing (2) has an opening (4, 4') for the passage of an electrical cable and where, from opposite walls (5, 5 ') of the central housing (2) perpendicular to the wall showing the opening (4) emerges at least one wing (6, 6') in the shape of ""l ""defining at least one housing (7, 7 '). (Machine-translation by Google Translate, not legally binding)",CABRERA MORENO JOSE ANTONIO,CABRERA MORENO JOSE ANTONIO,,https://lens.org/058-333-274-529-818,Patent Application,no,0,0,2,2,0,,H02J7/02,,0,0,,,,INACTIVE
31,DE,T1,DE 00988820 T1,133-565-224-688-483,2006-07-27,2006,DE 00988820 T,2000-12-29,ES 200000799 A;;ES 0000498 W,2000-03-30,ZUSAMMENSTZUNG UND VERFAHREN ZUR ERZEUGUNG VON METALLISCHEN EFFEKTEN IN KERAMISCHEN ZIEGELN UND IHRE VERWENDUNG,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ M JOSE,,https://lens.org/133-565-224-688-483,Granted Patent,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/02;;C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
32,CN,A,CN 1988896 A,187-065-598-886-44X,2007-06-27,2007,CN 200580024986 A,2005-07-25,EP 04017561 A,2004-07-24,Use of compounds active on the sigma receptor for the treatment of mechanical allodynia,The present invention refert to the use of compounds active on the sigma receptor for the treatment of mechanical allodynia.,ESTEVE LABOR DR,BAEYENS CABRERA JOSE M,,https://lens.org/187-065-598-886-44X,Patent Application,no,0,5,2,12,0,A61K31/519;;A61P25/00;;A61P29/00;;A61K31/519,A61K31/13;;A61K31/7125;;A61P25/00;;A61P29/00,,0,0,,,,DISCONTINUED
33,ES,Y,ES 1039617 Y,043-088-251-374-330,1999-06-01,1999,ES 9800522 U,1998-02-24,ES 9800522 U,1998-02-24,CORTAPUROS PERFECCIONADO.,,CARRERA Y CARRERA S A,CABRERA MOYA JUAN JOSE,,https://lens.org/043-088-251-374-330,Limited Patent,no,0,0,2,2,0,,A24F13/26,,0,0,,,,EXPIRED
34,WO,A1,WO 2012/067478 A1,073-303-290-464-336,2012-05-24,2012,MX 2010000137 W,2010-11-19,MX 2010000137 W,2010-11-19,FOLD-UP TOILET SEAT,"The present invention relates to improvements to a toilet seat such that the latter is capable of accommodating a groove into which is placed one end of an ""L""-shaped laminar body, the other end thereof coinciding with a second groove of a size similar to that of the first and matching the laminar body in order to allow the invention to fold up when it is necessary only to use the sanitaryware for urination.",OSORIO CABRERA JOSE ANTONIO,OSORIO CABRERA JOSE ANTONIO,,https://lens.org/073-303-290-464-336,Patent Application,yes,5,0,1,1,0,A47K13/12,A47K13/12,,0,0,,,,PENDING
35,MX,A,MX JL02000044 A,187-237-381-243-29X,2004-06-09,2004,MX JL02000044 A,2002-12-02,MX JL02000044 A,2002-12-02,GENETIC TRANSFORMATION IN AGAVE GENUS AND PRODUCTION OF HERBICIDE-RESISTANT TRANSGENIC PLANTS.,"The present discloses a development of a protocol of stable transformation in the Agave genus by means of biobalistic, Agrobacterium tumefaciens and Agrobacterium rhizogenes. Embryogenic calluses with a high regeneration capacity are bombarded with tungsten particles covered with AND of plasmid mixtures which can contain marker genes. For the case of the transformation with A. tumefaciens and A. rhizogenes, the embryogenic calluses are co-cultured with the bacteria for periods of 48 hours and then are transferred to selective means to obtain transformed cells. The gens employed in this protocol are: bar gene, which codifies for the acetyl-transferase phosphino citrin, the hpt gene which confers resistance to higromycin, the npt II gene which confers resistance to aminoglycoside antibiotics; as well as the gus reporter gene for detecting the enzymatic activity of beta-glucuronidase. The bar gene expression (which confers resistance to herbicide PPT) can be observed in small plants tran sformed of Agave tequilana from selected calluses, when applying the herbicide BastaTM. It also provides transgenic Agave plants, which are resistant to the mentioned herbicide by means of the incorporation of the bar transgene. This technology of genetic transformation can be largely employed in the genetic enhancement of the Agave genus.",CT INVESTIG Y ESTUDIOS DEL IPN,JOSE LUIS CABRERA PONCE,,https://lens.org/187-237-381-243-29X,Patent Application,no,0,0,1,1,0,,C12N15/82,,0,0,,,,DISCONTINUED
36,WO,A1,WO 2006/010587 A1,033-824-799-274-407,2006-02-02,2006,EP 2005008080 W,2005-07-25,EP 04017561 A;;EP 04017562 A;;EP 04020376 A;;US 90227204 A;;US 90227304 A,2004-07-24,USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA,The present invention refert to the use of compounds active on the sigma receptor for the treatment of mechanical allodynia.,ESTEVE LABOR DR;;BAEYENS CABRERA JOSE MANUEL,BAEYENS CABRERA JOSE MANUEL,,https://lens.org/033-824-799-274-407,Patent Application,yes,4,34,8,12,0,A61K31/13;;A61K31/519;;A61K31/7125;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00,A61K31/13;;A61K31/7125;;A61P25/00;;A61P29/00,,2,2,115-403-502-424-062;;153-708-727-279-412,7892029;;10.1016/0304-3959(94)90084-1;;12625504,"SJOGREN, P. ET AL.: ""Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists"", PAIN, vol. 59, 1994, pages 313 - 316, XP002356374;;STEWART, L.S.A. & MARTIN, W.J.: ""Influence of positive analgesics on development of neuropathic pain in rats"", COMPARATIVE MEDICINE, vol. 53, no. 1, February 2003 (2003-02-01), pages 29 - 36, XP009057765",PENDING
37,WO,A1,WO 2010/082854 A1,050-564-679-203-493,2010-07-22,2010,PH 2009000003 W,2009-03-17,PH 22009000011 U,2009-01-16,WALL PANEL,"This utility model is an upgrading for utility model application no. 2-2008-000269 filed last 02-26-08. This utility model disclosed a wall panel construction which comprises a pair of fiber cement board with recessed edges set for jointing and an arrange polystyrene studs as spacer and are adhesively attached in between the fiber cement board. A vertical connecting fiber cement strip is adhesively attached along the longitudinal one end inner portion of each panel board to define therein a vertical shoulder, the opposing end portion of the panel board being adapted to engage with the vertical shoulder of another panel board and screwed to the vertical connecting fiber cement strip when connecting side by side the wall panel board to another wall panel board. A horizontal connecting fiber cement strip is adhesively attached along the longitudinal top end inner portion of each panel board to define therein a horizontal shoulder, the bottom end portion of the panel board being adapted to engage with the horizontal shoulder of another panel board and screwed to the horizontal connecting fiber cement strip when connecting the wall panel board on top of another wall panel board. Reinforcing bars are provided in between the panel board when concrete mixture is poured therein.",CABRERA JOSE B JR,CABRERA JOSE B JR,,https://lens.org/050-564-679-203-493,Patent Application,yes,4,0,1,1,0,E04C2/044,E04B2/86;;E04B2/00;;E04C2/26;;E04C2/288,,0,0,,,,PENDING
38,CA,A1,CA 2573122 A1,097-452-900-816-790,2006-02-02,2006,CA 2573122 A,2005-07-25,EP 04017561 A;;EP 04017562 A;;US 90227304 A;;US 90227204 A;;EP 04020376 A;;EP 2005008080 W,2004-07-24,USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA,,ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL,,https://lens.org/097-452-900-816-790,Patent Application,no,0,0,8,12,0,A61K31/13;;A61K31/519;;A61K31/7125;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00,A61K31/13;;A61K31/7125;;A61P25/00;;A61P29/00,,0,0,,,,DISCONTINUED
39,ES,Y,ES 1139831 Y,185-765-452-444-723,2015-08-31,2015,ES 201500371 U,2015-05-20,ES 201500371 U,2015-05-20,Dispositivo de apertura con múltiples llaves,,SEGURIDAD Y LLAVES BARCELONA S L,CARVAJAL CABRERA JOSE ANTONIO,,https://lens.org/185-765-452-444-723,Limited Patent,no,0,0,2,2,0,,A44B15/00;;E05B19/00,,0,0,,,,INACTIVE
40,ES,Y,ES 1118005 Y,197-002-799-325-491,2014-10-20,2014,ES 201430649 U,2014-05-14,ES 201430649 U,2014-05-14,DEFENSA ROTATIVA PARA MUELLES,,GARCIA CABRERA RAFAEL JOSE,GARCIA CABRERA RAFAEL JOSE,,https://lens.org/197-002-799-325-491,Limited Patent,no,0,0,2,2,0,Y02A30/30,E02B3/26,,0,0,,,,INACTIVE
41,US,A1,US 2006/0019969 A1,087-827-112-077-080,2006-01-26,2006,US 90227304 A,2004-07-30,EP 04017562 A,2004-07-24,Use of compounds active on the sigma receptor for the treatment of allodynia,The present invention refers to the use of compounds active on the sigma receptor for the treatment of allodynia.,ESTEVE LABOR DR,BAEYENS CABRERA JOSE M,LABORATORIES DR. ESTEVE S.A (2004-12-21),https://lens.org/087-827-112-077-080,Patent Application,yes,4,6,2,12,0,A61K31/519;;A61K31/519,A61K31/519,514/259.41,0,0,,,,DISCONTINUED
42,ES,A1,ES 2160498 A1,159-408-000-377-664,2001-11-01,2001,ES 9901377 A,1999-06-22,ES 9901377 A,1999-06-22,Perfecting a dental implant fastener system.,"Improvements in dental implants fastener systems comprised of the creation of an implant consisting of a screw with diametrically opposed lateral and longitudinal channels, which contains prismatic blades with a pentagonal section that have a sharp edge towards the exterior and with a base containing slanting surfaces to support an axial screw. When this screw is placed into the implant's base the threading pushes the bases of the blades and turns them on the shaft formed by a bolt that goes through the ensemble, opening the blades and providing a triple support, securing it to the bone and achieving greater retention in the bone.",HERNANDEZ CABRERA JOSE MIGUEL,HERNANDEZ CABRERA JOSE MIGUEL,,https://lens.org/159-408-000-377-664,Patent Application,no,5,1,2,2,0,,A61C8/00,,0,0,,,,EXPIRED
43,ES,B1,ES 2160498 B1,004-203-342-335-536,2002-05-16,2002,ES 9901377 A,1999-06-22,ES 9901377 A,1999-06-22,PERFECCIONAMIENTOS EN LOS SISTEMAS DE SUJECION DE IMPLANTES DENTALES.,"Perfeccionamientos en los sistemas de sujeción de implantes dentales, constituidos por la creación de un implante formado por un tornillo dotado de canales laterales y longitudinales diametralmente opuestos, en los que se alojan unas aletas prismáticas de sección pentagonal, ofreciendo una arista viva hacia el exterior, y con base dotada de superficies inclinadas, para apoyo de un tornillo axial que introducido en la base de implante, por roscado del mismo se produzca un empuje sobre las bases de las aletas, que las hace girar sobre su eje formado por un bulón que atraviesa diametralmente al conjunto, abriendose las aletas, y constituyendo en total un triple apoyo y fijación sobre el hueso, obteniendo una mayor retención ósea.",HERNANDEZ CABRERA JOSE MIGUEL,HERNANDEZ CABRERA JOSE MIGUEL,,https://lens.org/004-203-342-335-536,Granted Patent,no,0,0,2,2,0,,A61C8/00,,0,0,,,,EXPIRED
44,CU,A1,CU 21359 A1,042-353-461-074-334,1987-10-12,1987,CU 34765 A,1977-09-19,CU 34765 A,1977-09-19,AUTOMATIC DISCHARGE SYSTEM OF SUGAR-CANE CART,,MINISTERIO IND AZUCARERA,RODRIGUEZ CABRERA JOSE ANTONIO,,https://lens.org/042-353-461-074-334,Limited Patent,no,0,2,1,1,0,,B60S13/02;;B61J3/00;;B65G67/48;;E05B65/14,,0,0,,,,EXPIRED
45,EP,B1,EP 1306355 B1,078-889-254-844-908,2007-03-28,2007,EP 00988820 A,2000-12-29,ES 0000498 W;;ES 200000799 A,2000-03-30,FORMULATION AND METHOD FOR ACHIEVING METALLIC EFFECTS IN CERAMIC TILES AND THE APPLICATIONS THEREOF,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ M JOSE,,https://lens.org/078-889-254-844-908,Granted Patent,yes,3,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/02;;C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
46,ES,B1,ES 2660513 B1,198-260-463-973-709,2018-12-28,2018,ES 201630992 A,2016-07-21,ES 201630992 A,2016-07-21,DISPOSITIVO DE SEGURIDAD TRANSFUSIONAL,,PROPOSIT BIO S L;;PARRADO GONZALEZ CARMELO;;HURTADO MONDEJAR MARIA DEL CARMEN,BUENO CABRERA JOSE LUIS,MARIA DEL CARMEN HURTADO MONDEJAR (2016-11-28),https://lens.org/198-260-463-973-709,Granted Patent,no,0,0,6,6,0,A61M1/02;;A61M1/02;;A61B5/15003;;A61B5/150992;;A61B5/157;;A61M2205/276;;A61M2205/583;;A61M2205/6009;;A61M2205/6072;;G01N33/80,A61M1/02;;G01N33/80,,0,0,,,,INACTIVE
47,ES,A1,ES 2161193 A1,067-928-654-241-41X,2001-11-16,2001,ES 200000799 A,2000-03-30,ES 200000799 A,2000-03-30,FORMULATION AND METHOD FOR ACHIEVING METALLIC EFFECTS IN CERAMIC TILES AND THE APPLICATIONS THEREOF,"The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,CABRERA IBANEZ MARIA JOSE,,https://lens.org/067-928-654-241-41X,Patent Application,no,3,3,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,EXPIRED
48,CL,A1,CL 2008000294 A1,107-467-019-811-647,2008-03-07,2008,CL 2008000294 A,2008-01-31,CL 2008000294 A,2008-01-31,"SISTEMA GENERADOR DE ENERGIA ELECTRICA POR MEDIO DE UN PROCESO NO CONTAMINANTE QUE OPERA CON FUERZAS VERTICALES OPUESTAS QUE COMPRENDE UN EQUIPO FLOTANTE SOBRE UN MEDIO ACUATICO, DONDE DICHO EQUIPO COMPRENDE UNA BOYA DE SOPORTE QUE ESTA FLOTANDO SOBR",,CABRERA LOPEZ JOSE BELARMINO,CABRERA LOPEZ JOSE BELARMINO,,https://lens.org/107-467-019-811-647,Patent Application,no,0,0,1,1,0,,F03C1/00,,0,0,,,,PENDING
49,ES,Y,ES 1158733 Y,103-548-377-443-513,2016-09-09,2016,ES 201630587 U,2016-05-10,ES 201630587 U,2016-05-10,Soporte para cargadores eléctricos de dispositivos móviles,,CABRERA MORENO JOSE ANTONIO,CABRERA MORENO JOSE ANTONIO,,https://lens.org/103-548-377-443-513,Limited Patent,no,0,0,2,2,0,,H02J7/02,,0,0,,,,INACTIVE
50,ES,Y,ES 1138614 Y,113-634-878-950-859,2015-07-13,2015,ES 201500170 U,2015-03-03,ES 201500170 U,2015-03-03,Mando a distancia múltiple,,SEGURIDAD Y LLAVES BARCELONA S L,CARVAJAL CABRERA JOSE ANTONIO,,https://lens.org/113-634-878-950-859,Limited Patent,no,0,0,2,2,0,,G08B17/00,,0,0,,,,INACTIVE
51,ES,A1,ES 2660513 A1,125-928-792-745-087,2018-03-22,2018,ES 201630992 A,2016-07-21,ES 201630992 A,2016-07-21,"TRANSFUSIONAL SECURITY DEVICE (Machine-translation by Google Translate, not legally binding)","Transfusion safety device, to carry out an ABO blood group check of a packed red blood cell (CH) contained in a bag (3) and ABO blood group of the blood of a recipient and determine its compatibility to carry out said transfusion, which it comprises a blood transfusion unit (1), a first blood group verification device (2), for establishing the blood group of the CH contained in the bag (3), a second device for verifying the blood group (4), destined to establish the blood group of the individual recipient of the transfusion, and a control unit (5), intended to perform a reading of the results obtained in the verification devices (2, 4), to establish the compatibility or incompatibility of both Blood groups based on the reading of the results, and to operate a flow regulator (9) to allow or prevent the flow of CH. (Machine-translation by Google Translate, not legally binding)",PROPOSIT BIO S L;;PARRADO GONZALEZ CARMELO;;HURTADO MONDEJAR MARIA DEL CARMEN,BUENO CABRERA JOSE LUIS,MARIA DEL CARMEN HURTADO MONDEJAR (2016-11-28),https://lens.org/125-928-792-745-087,Patent Application,no,5,0,6,6,0,A61M1/02;;A61M1/02;;A61B5/15003;;A61B5/150992;;A61B5/157;;A61M2205/276;;A61M2205/583;;A61M2205/6009;;A61M2205/6072;;G01N33/80,A61M1/02;;G01N33/80,,0,0,,,,INACTIVE
52,BR,A,BR 0011526 A,033-827-427-080-760,2002-03-26,2002,BR 0011526 A,2000-12-29,ES 200000799 A;;ES 0000498 W,2000-03-30,"Formulação para obtenção de efeitos metálicos em revestimentos cerâmicos, seu processo de manufatura e seu uso","The formulation comprises a mixture of essential oxides, namely: SiO2, Al2O3, Fe2O3 and P2O3, together with certain optional oxides, namely: CaO, MgO, Na2O and K2O; and it is free of noble metals. This formulation is applied to a carrier or ceramic tile by a conventional technique and it is subjected to a firing process by the single firing technique. The formulation has important uses and advantages in the sector of the ceramics industry.",VIDRES S A VIDRESA,IBANEZ MARIA JOSE CABRERA,,https://lens.org/033-827-427-080-760,Patent Application,no,0,0,11,11,0,C03C8/08;;C04B41/009;;C04B41/5022;;C04B41/86;;C04B2111/60;;C04B2111/80,C03C8/08;;C04B41/50;;C04B41/86,,0,0,,,,DISCONTINUED
53,FR,A,FR 1187654 A,038-750-930-303-721,1959-09-15,1959,FR 1187654D A,1957-03-20,FR 1187654T A,1957-03-20,Bouchon empêchant le remplissage frauduleux,,,FONTANA JOSE ANTONIO CABRERA,,https://lens.org/038-750-930-303-721,Granted Patent,no,0,0,1,1,0,B65D49/06,B65D49/06,,0,0,,,,EXPIRED
54,FR,A,FR 1136724 A,085-420-470-964-993,1957-05-17,1957,FR 1136724D A,1955-12-09,ES 1136724X A,1954-12-14,Bouchon empêchant le remplissage frauduleux,,,FONTANA JOSE ANTONIO CABRERA,,https://lens.org/085-420-470-964-993,Granted Patent,no,0,0,1,1,0,B65D49/02,B65D49/02,,0,0,,,,EXPIRED
55,MX,A,MX GT03000007 A,084-728-848-341-961,2004-03-31,2004,MX GT03000007 A,2003-07-03,MX GT03000007 A,2003-07-03,YIELD MAPPING SYSTEM FOR HARVESTED CROPS WITH A CONVEYING BELT SYSTEM FOR FIELD COLLECTION.,"The present invention has its application in Precision Agriculture particularly in Yield Mapping. It comprises an agricultural machine for semi-mechanized harvest with conveying belt with the necessary tools for sensing the mass flow and integrating it, having a differential global positioning satellite navigation system and a distance sensor. Harvested weight, position and area are analyzed in a specific data acquisition system for obtaining yield maps, for instance weight/area in function of position. The object of the present invention is providing an agricultural system with a continuous weight system, differential global positioning system and a data acquisition system that while harvesting stores information for generating at the end a yield map of crops where the agricultural machine with conveyor belt can be employed for harvest time.",UNIV GUANAJUATO,JOSE MANUEL CABRERA SIXTO,,https://lens.org/084-728-848-341-961,Patent Application,no,0,0,1,1,0,Y02A40/10,A01D61/00,,0,0,,,,EXPIRED
56,ES,U,ES 1039617 U,102-123-132-628-632,1999-01-01,1999,ES 9800522 U,1998-02-24,ES 9800522 U,1998-02-24,"Cigar cutters perfected. (Machine-translation by Google Translate, not legally binding)","Improved cutter that remain the type of which comprise two scissor blades brazos u (1) with a hinge point (2), and in whose arms or sheets are set, on the one hand, the openings (3 ) introductory fingers for the relevant management of scissors or cutter itself, and counting also runs (4) determined from own hinging point (2) and affected corresponding edges sharp (5) arcuate profile essentially it characterized in that said portions (4) gifted the edges sharp (5) of the scissors, projecting from the pivot point (2) towards the inside of the sections (1) where are carried out openings (3) step fingers for handling for and are those segments (4) arranged between the sections (1) of the openings (3), and these configuration arched for location between concavities referred to segments (4) with sharp edges (5). (Machine-translation by Google Translate, not legally binding)",CARRERA Y CARRERA S A,CABRERA MOYA JUAN JOSE,,https://lens.org/102-123-132-628-632,Patent Application,no,0,0,2,2,0,,A24F13/26,,0,0,,,,EXPIRED
57,US,A1,US 2006/0019968 A1,170-869-257-199-55X,2006-01-26,2006,US 90227204 A,2004-07-30,EP 04017561 A,2004-07-24,Use of compounds active on the sigma receptor for the treatment of neuropathic pain,"The present invention refers to the use of compounds active on the sigma receptor for the treatment of neuropathic pain, especially certain subtypes of neuropathic pain.",ESTEVE LABOR DR,BAEYENS CABRERA JOSE M,LABORATORIOS DR. ESTEVE S.A (2005-06-02),https://lens.org/170-869-257-199-55X,Patent Application,yes,4,10,2,12,0,A61K31/519;;A61P25/00;;A61P29/00;;A61K31/519,A61K31/519,514/259.41,0,0,,,,DISCONTINUED
58,ES,Y,ES 1298438 Y,172-885-786-830-098,2023-06-07,2023,ES 202330057 U,2023-01-16,ES 202330057 U,2023-01-16,Dispositivo contra incendios para cocinas,,NIETO CABRERA JOSE ANTONIO,NIETO CABRERA JOSE ANTONIO,,https://lens.org/172-885-786-830-098,Limited Patent,no,0,0,2,2,0,,A62C2/18,,0,0,,,,ACTIVE
59,ES,Y,ES 1178084 Y,194-064-662-388-971,2017-05-30,2017,ES 201730115 U,2017-02-08,ES 201730115 U,2017-02-08,TABURETE PLEGABLE Y TRANSPORTABLE DE CARTON CON CIERRE INTEGRADO,,MARRERO CABRERA JOSE MIGUEL,MARRERO CABRERA JOSE MIGUEL,,https://lens.org/194-064-662-388-971,Limited Patent,no,0,0,2,2,0,,A47C4/04,,0,0,,,,INACTIVE
60,ES,U,ES 1138614 U,017-475-132-463-602,2015-04-22,2015,ES 201500170 U,2015-03-03,ES 201500170 U,2015-03-03,"Multiple remote control (Machine-translation by Google Translate, not legally binding)","Multiple remote control, comprising a housing in which is mounted a sprat (2) for the mechanical opening of certain locks; and an electronic circuit (4) for the emission of wireless signals; characterized in that it comprises several buttons (31, 32, 33) selectively operable by the user; the programmable electronic circuit (4) comprising a series of switches (41, 42, 43) operable by the respective push buttons (31, 32, 33) and whose actuation causes the emission by the electronic circuit (4) of programmed wireless signals and of certain frequencies. (Machine-translation by Google Translate, not legally binding)",SEGURIDAD Y LLAVES BARCELONA S L,CARVAJAL CABRERA JOSE ANTONIO,,https://lens.org/017-475-132-463-602,Patent Application,no,0,0,2,2,0,,G08B17/00,,0,0,,,,INACTIVE
61,ES,A2,ES 2074937 A2,047-414-076-861-364,1995-09-16,1995,ES 9300551 A,1993-03-16,ES 9300551 A,1993-03-16,Procedure for the manufacture of optical wave guides for the ordinary refractive index of LiNbO3.,"Procedure for the manufacture of optical wave guides for the ordinary refractive index of Lithium Niobate by means of a double ion exchange. A layer several microns thick is generated with an initial deep proton exchange, from which a certain fraction of the lithium ions has been extracted from the material, causing a reduction in the ordinary index of approximately [delta]n [approximately equals] 0.04 (Fig. 1). With a second, less deep exchange than the first, in a lithium-rich solution, the lithium ions are re-introduced and the ordinary index approximately recovers its initial value in a layer less than the first. This last layer together with the rest of the previous layer which forms the actual substrate, constitutes the wave guide (Fig. 2). The wave guide finally has a jump in the ordinary index of [delta]n [approximately equals] 0.03 for [lambda] = 0.6328 [mu]m.",UNIV MADRID,OLIVARES VILLEGAS JOSE;;CABRERA CASTILLO JOSE MANUEL,,https://lens.org/047-414-076-861-364,Patent Application,no,4,0,3,3,0,,G02B6/10,,0,0,,,,EXPIRED
62,ES,A1,ES 2143897 A1,029-494-325-893-747,2000-05-16,2000,ES 9601616 A,1996-07-19,ES 9601616 A,1996-07-19,Beverage-cooling equipment,Equipment which comprises a tank 1 housing coils 6 and 7 for the beverages to be cooled and a coil 2 for cooling cold-producing equipment 3-4. The tank 1 contains a cooling medium 8 consisting of an alcohol-in-water solution. The coil 7 through which runs a liquid with a higher freezing point in the alcohol-in- water solution is protected by means of impermeable insulation.,ROMERO GARRUCHO JOSE MARIA;;ALFEREZ CABRERA JOSE,ROMERO GARRUCHO JOSE MARIA;;ALFEREZ CABRERA JOSE,,https://lens.org/029-494-325-893-747,Patent Application,no,5,0,2,2,0,,B67D1/08;;F25D31/00,,0,0,,,,EXPIRED
63,ES,B1,ES 2143897 B1,159-454-494-552-553,2000-12-01,2000,ES 9601616 A,1996-07-19,ES 9601616 A,1996-07-19,EQUIPO ENFRIADOR DE BEBIDAS.,"Equipo enfriador de bebidas, que comprende un tanque (1) en el que se alojan serpentinas (6 y 7) de las bebidas a enfriar y un serpentín (2) enfriador de un equipo (3-4) productor de frío. El tanque (1) contiene un medio enfriador (8) consistente en una disolución de alcohol en agua. El serpentín (7) a través del que discurre un líquido con punto superior de congelación ante la disolución de alcohol en agua, está protegido mediante un aislante impermeable.",ROMERO GARRUCHO JOSE MARIA;;ALFEREZ CABRERA JOSE,ROMERO GARRUCHO JOSE MARIA;;ALFEREZ CABRERA JOSE,,https://lens.org/159-454-494-552-553,Granted Patent,no,0,0,2,2,0,,B67D1/08;;F25D31/00,,0,0,,,,EXPIRED
64,ES,B1,ES 2074937 B1,141-578-645-131-926,1998-02-16,1998,ES 9300551 A,1993-03-16,ES 9300551 A,1993-03-16,PROCEDIMIENTO PARA LA FABRICACION DE GUIAS DE ONDA OPTICAS PARA EL INDICE DE REFRACCION ORDINARIO DEL LINBO3.,"PROCEDIMIENTO PARA LA FABRICACION DE GUIAS DE ONDA PARA EL INDICE DE REFRACCION ORDINARIO DEL NIOBATO DE LITIO MEDIANTE DOBLE INTERCAMBIO IONICO. CON UN PRIMER INTERCAMBIO PROTONICO PROFUNDO SE GENERA UNA CAPA DE VARIAS MICRAS DE ESPESOR DE LA CUAL SE HA EXTRAIDO UNA CIERTA FRACCION DE LOS IONES LITIO DEL MATERIAL, GENERANDO UNA DISMINUCION DEL INDICE ORDINARIO EN APROXIMADAMENTE DLNO _ 0,04 (FIG. 1). CON UN SEGUNDO INTERCAMBIO MENOS PROFUNDO QUE EL PRIMERO, EN SOLUCION RICA EN LITIO, SE REINTRODUCEN LOS IONES DE LITIO Y SE RECUPERA EL INDICE ORDINARIO APROXIMADAMENTE A SU VALOR INICIAL, EN UNA CAPA MENOR QUE LA PRIMERA. ESTA ULTIMA CAPA JUNTO CON EL RESTO DE LA CAPA ANTERIOR QUE HACE DE SUSTRATO EFECTIVO CONSTITUYE LA GUIA DE ONDAS (FIG. 2). LA GUIA DE ONDAS FINALMENTE TIENE UN SALTO DE INDICE ORDINARIO DE DLNO 0,03 PARA LA = 0,6328 MIM.",UNIV MADRID AUTONOMA,OLIVARES VILLEGAS JOSE;;CABRERA CASTILLO JOSE MANUEL,,https://lens.org/141-578-645-131-926,Granted Patent,no,0,0,3,3,0,,G02B6/10,,0,0,,,,EXPIRED
65,CA,A1,CA 3065893 A1,067-760-093-523-612,2017-12-28,2017,CA 3065893 A,2017-06-23,ES 201630856 A;;ES 2017070460 W,2016-06-23,COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC ULCERS AND STRETCH MARKS,"The invention relates to compositions used to relieve, improve, prevent and/or treat stretch marks and/or skin ulcers preferably of ischemic origin. The invention also relates to the composition, dosage form and uses thereof.",SERVICIO ANDALUZ DE SALUD,BERNABEU WITTEL JOSE;;CABRERA FUENTES RAQUEL,,https://lens.org/067-760-093-523-612,Patent Application,no,0,0,9,9,0,A61K31/554;;A61P9/10;;A61P17/02;;A61P9/10;;A61K8/49;;A61K31/554;;A61Q19/00,A61K31/554;;A61P9/10,,0,0,,,,DISCONTINUED
66,CO,A1,CO 4480005 A1,043-719-146-470-783,1997-07-09,1997,CO 96063404 A,1996-12-03,CO 96063404 A,1996-12-03,PROCEDIMIENTO PARA LA PREPARACION DE CONFITURAS HELADAS Y EL PRODUCTO ASI OBTENIDO,"1. PROCESO PARA LA ELABORACION DE CONFITURAS HE- LADAS CARACTERIZADO PORQUE CONSISTE BASICAMENTE DE LA ELABORACION EN FORMA INDEPENDIENTE DE UNA MER- MELADA DE FRUTAS Y DE UNA MEZCLA DE AGUA Y AZUCAR LAS CUALES POSTERIORMENTE SE UNEN PARA FORMAR UNA MEZCLA TOTAL QUE SE LLEVA A MADURACION DE DONDE SALE PARA SER MOLDEADA COMO PALETA. 2. PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No. 1 CARACTERIZADO PORQUE PARA HACER LA MERMELADA SE LLEVAN A CABO LAS SIGUIENTES ETAPAS: A. RECEPCION Y SELECCION DE LA FRUTA, ESTE PROCE- SO SE HACE MANUALMENTE TENIENDO EN CUENTA TAMANO, ESTADO DE MADURACION Y OPTIMAS CONDICIONES FITOSA- NITARIAS. B. LA FRUTA UNA VEZ SELECCIONADA Y YA COLOCADA SOBRE UNA ESPECIE DE ZARANDA SE SOMETE AL LAVADO CON CHORRO DE AGUA FRIA. C. LUEGO PASA A UN PROCESO DE ESCALDADO EN AGUA A 50 GRADOS CENTIGRADOS DURANTE UN TIEMPO DE 10 A 15 SEGUNDOS. D. EXTRACCION MANUAL DE LA PULPA, QUEDANDO LA PULPA SEPARADA DE LA CORTEZA. E. PROCESO DE LICUADO MEDIANTE EL CUAL LA PULPA SE FRAGMENTA COMPLETAMENTE QUEDANDO SEPARADA DE LA PEPA O SEMILLA. F. DESSEMILLADO POR MEDIO DE FILTRACION UTILIZAN- DO UN FILTRO DE LIENZO TIPO MANGA. G. AL CONCENTRADO DE PULPA DE FRUTA ASI OBTENIDO SE LE ADICIONA AZUCAR EN UNA EN UNA PROPORCION DE DOS PARTES DE FRUTA POR UNA DE AZUCAR, ESTA MEZCLA SE ELABORA EN UNA MARMITA PARA LUEGO SER LLEVADA LENTAMENTE HASTA UNA TEMPERATURA ENTRE 60 Y 85 GRADOS CENTIGRADOS, DONDE UNA VEZ ALCANZADA LA TEMPERATURA SE MANTIENE EN ESE PUNTO DURANTE UN TIEMPO DE 10 A 15 MINUTOS, PARA OBTENER UNA MERME- LADA DE FRUTA. H. LA MERMELADA ASI OBTENIDA SE ENVASA EN TAMBO- RES PLASTICOS O ENVASES DE VIDRIO HERMETICAMENTE CERRADOS Y SE DEJA EN REPOSO POR LO MENOS DURANTE 24 HORAS. 3. PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No. 1 CARACTERIZADO PORQUE SEPARADAMENTE SE PREPARA OTRA MEZCLA COMPUESTA DE AGUA Y AZUCAR, DONDE EL AGUA SE PASA PRIMERO POR UN FILTRO DE CARBON ACTIVADO Y LUEGO POR UN FILTRO DE ARENA, PURIFICADA EL AGUA SE LE ADICIONA EL AZUCAR EN PROPORCION DE CUATRO PARTES DE AGUA POR UNA DE AZUCAR.",SAN JERONIMO CAJICA CABRERA HERMANOS LTDA,CABRERA BAQUERO JOSE RICARDO DE JESUS,,https://lens.org/043-719-146-470-783,Patent Application,no,0,0,1,1,0,,A23G9/04,,0,0,,,,PENDING
67,CO,A1,CO 4480006 A1,033-154-936-876-333,1997-07-09,1997,CO 96063405 A,1996-12-03,CO 96063405 A,1996-12-03,PROCEDIMIENTO PARA LA PREPARACION DE CONFITURAS HELADAS Y EL PRODUCTO ASI OBTENIDO,"1- PROCESO PARA LA ELABORACION DE CONFITURAS HE- LADAS CARACTERIZADO PORQUE CONSISTE BASICAMENTE DE LA ELABORACION EN FORMA INDEPENDIENTE DE UNA MER- MELADA DE FRUTAS Y DE UNA MEZCLA DE CREMA DE LECHE Y LECHE LAS CUALES POSTERIORMENTE SE UNEN PARA FORMAR UNA MEZCLA TOTAL QUE SE LLEVA A MADURACION DE DONDE PASA A UN FREEZER PARA BAJAR TEMPERATURA Y DE ALLI SALE PARA SER MOLDEADA COMO HELADO O CO- MO PALETA. 2- PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No.1 CARACTERIZADO PORQUE PARA LA OBTENCION DE LA MER- MELADA DE FRUTA SE LLEVAN A CABO LAS SIGUIENTES E- TAPAS: A) RECEPCION Y SELECCION DE LA FRUTA, ESTE PROCE- SO SE HACE MANUALMENTE TENIENDO EN CUENTA TAMANO, ESTADO DE MADURACION Y OPTIMAS CONDICIONES FITOSA- NITARIAS. B) LA FRUTA UNA VEZ SELECCIONADA Y YA COLOCADA SOBRE UNA ESPECIE DE ZARANDA SE SOMETE A LAVADO CON CHORRO DE AGUA FRIA. C) LUEGO PASA A UN PROCESO DE ESCALDADO EN AGUA A 50 GRADOS CENTIGRADOS DURANTE UN TIEMPO DE 10 A 15 SEGUNDOS. D) EXTRACCION MANUAL DE LA PULPA, PARA SEPARARLA DE LA CORTEZA. E) PROCESO DE LICUADO O FRAGMENTACION DE LA PULPA EN PEQUENOS TROCITOS. F) AL CONCENTRADO DE PULPA DE FRUTA ASI OBTENIDO SE LE ADICIONA AZUCAR EN UNA PROPORCION DE DOS PARTES DE FRUTA POR UNA DE AZUCAR, ESTA MEZCLA SE ELABORA EN UNA MARMITA PARA LUEGO SER LLEVADA LEN- TAMENTE HASTA UNA TEMPERATURA ENTRE 60 Y 85 GRADOS CENTIGRADOS, DONDE UNA VEZ ALCANZADA DICHA TEMPE- RATURA SE MANTIENE EN ESE PUNTO DURANTE UN TIEMPO DE 10 A 15 MINUTOS, HASTA OBTENER UNA MERMELADA DE FRUTA. G) LA MERMELADA ASI OBTENIDA SE ENVASA EN TAMBO- RES PLASTICOS O ENVASES DE VIDRIO HERMETICAMENTE CERRADOS Y SE DEJA EN REPOSO POR LO MENOS DURANTE 24 HORAS.",SAN JERONIMO CAJICA CABRERA HERMANOS LTDA,CABRERA BAQUERO JOSE RICARDO DE JESUS,,https://lens.org/033-154-936-876-333,Patent Application,no,0,0,1,1,0,,A23G9/04,,0,0,,,,PENDING
68,MX,A,MX 9505318 A,062-821-790-814-217,1997-06-28,1997,MX 9505318 A,1995-12-15,MX 9505318 A,1995-12-15,PRECISION PNEUMATIC GARLIC SOWING MACHINE.,"The present invention discloses a precision pneumatic garlic sowing machine, which comprises coupling devices for coupling it to an useful conventional farm tractor, for two or four furrows having two rows in each furrow, depositing garlic cloves in a controlled, precise way, thus ensuring their uniform distribution along the row and with capacity of up to 20 seeds per second per row.",UNIV GUANAJUATO,SIXTO JOSE MANUEL CABRERA;;SERWATOWSKI RYSZARD,,https://lens.org/062-821-790-814-217,Patent Application,no,0,2,1,1,0,,,,0,0,,,,PENDING
69,ES,Y,ES 1223449 Y,019-920-615-553-018,2019-04-11,2019,ES 201831158 U,2018-07-19,ES 201831158 U,2018-07-19,DISPOSITIVO DE LARGA DURACION PARA RIEGO LOCALIZADO CON TRES PUNTOS DE EMISION ENTERRADOS.,,PAUN MARIAN;;CABRERA SANCHEZ JOSE MANUEL,PAUN MARIAN;;CABRERA SANCHEZ JOSE MANUEL,,https://lens.org/019-920-615-553-018,Limited Patent,no,0,0,2,2,0,Y02A40/22,A01G25/06,,0,0,,,,ACTIVE
70,ES,Y,ES 1217779 Y,077-660-145-250-72X,2018-12-14,2018,ES 201831181 U,2018-07-25,ES 201831181 U,2018-07-25,DISPOSITIVO DE LARGA VIDA PARA RIEGO POR GOTEO EN DOS POSICIONES,,CABRERA SANCHEZ JOSE MANUEL;;PAUN MARIAN,CABRERA SANCHEZ JOSE MANUEL;;PAUN MARIAN,,https://lens.org/077-660-145-250-72X,Limited Patent,no,0,0,2,2,0,Y02A40/22,A01G25/06,,0,0,,,,ACTIVE
71,CN,A,CN 109641001 A,164-272-263-883-05X,2019-04-16,2019,CN 201780052257 A,2017-06-23,ES 201630856 A;;ES 2017070460 W,2016-06-23,COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC ULCERS AND STRETCH MARKS,"The invention relates to compositions used to relieve, improve, prevent and/or treat stretch marks and/or skin ulcers preferably of ischemic origin. The invention also relates to the composition, pharmaceutical form and uses thereof.",SERVICIO ANDALUZ DE SALUD,BERNABEU WITTEL JOSE;;CABRERA FUENTES RAQUEL,,https://lens.org/164-272-263-883-05X,Patent Application,no,4,0,9,9,0,A61K31/554;;A61P9/10;;A61P17/02;;A61P9/10;;A61K8/49;;A61K31/554;;A61Q19/00,A61P9/10;;A61K31/554,,3,0,,,"JAMES P TIERNAN 等: ""Benign anal conditions: haemorrhoids, fissures, perianal abscess, fistula-in-ano and pilonidal sinus"", 《INTESTINAL SURGERY II》;;M JONAS-OBICHERE 等: ""Anal Fissure"", 《THE MEDICINE PUBLISHING COMPANY LTD》;;M.I. FERNÁNDEZ GARCÍA 等: ""Efectividad y seguridad de diltiazem 2 % tópico en fi sura anal"", 《FARMACIA HOSPITALARIA》",DISCONTINUED
72,CO,A1,CO 4480009 A1,124-798-178-525-683,1997-07-09,1997,CO 96063408 A,1996-12-03,CO 96063408 A,1996-12-03,PROCESO PARA LA PREPARACION DE CONFITURAS HELADAS Y EL PRO- DUCTO ASI OBTENIDO,"1. PROCESO PARA LA ELABORACION DE CONFITURAS HE- LADAS CARACTERIZADO PORQUE CONSISTE BASICAMENTE DE LA ELABORACION EN FORMA INDEPENDIENTE DE UNA MEZ- CLA A BASE DE AREQUIPE, CHOCOLATE O VAINILLA Y DE UNA MEZCLA DE CREMA DE LECHE Y LECHE LAS CUALES POSTERIORMENTE SE UNEN PARA FORMAR UNA MEZCLA TO- TAL QUE SE LLEVA A MADURACION DE DONDE PASA A UN FREEZER PARA BAJAR TEMPERATURA Y DE ALLI SALE PARA SER MOLDEADA COMO HELADO O COMO PALETA. 2. PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No. 1 CARACTERIZADO PORQUE PARA LA OBTENCION DE LA PRI- MERA MEZCLA SE PREPARA DE ACUERDO AL COMPONENTE A- REQUIPE, CHOCOLATE O VAINILLA. A. EL AREQUIPE SE ELABORA A BASE DE LECHE Y AZU- CAR MEDIANTE UN PROCESO CASERO. B. LA MEZCLA DE CHOCOLATE PARA EL HELADO SE PRE- PARA MEZCLANDO 50% DE COCOA CON 50% DE AGUA FOR- MANDO UNA PASTA DE CHOCOLATE AMARGO. PARA LA PA- LETA ESTA MEZCLA SE PREPARA CON CHOCOLATE EN POL- VO, LECHE Y AZUCAR. C. PARA LA VAINILLA SE UTILIZA ESENCIA DE VAINI- LLA LIQUIDA, CUYA CANTIDAD SE CALCULA DE ACUERDO CON LA CONCENTRACION DEL PRODUCTO. 3. PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No.1 CARACTERIZADO PORQUE SEPARADAMENTE SE PREPARA OTRA MEZCLA COMPUESTA DE LECHE ENTERA 35%, CREMA DE LE- CHE 20% Y AZUCAR 2%. CUANDO SE TRATA DE AREQUIPA OPCIONALMENTE SE LE ADICIONA AZUCAR. 4. PROCEDIMIENTO DE ACUERDO CON LA REIVINDICACION No. 1 CARACTERIZADO PORQUE A LA MEZCLA ANTERIOR SE LE AGREGA LA PRIMERA MEZCLA EN UNA PROPORCION DEL 40% Y SE PASTEURIZA Y HOMOGENEIZA SALIENDO A UNA TEMPERATURA DE MENOS 3 GRADOS CENTIGRADOS. LA MEZCLA PASA LUEGO A UN TANQUE DE MADURACION PARA HOMOGENEIZACION COMPLETA, DURANTE UN TIEMPO DE 6 A 24 HORAS A UNA TEMPERATURA ENTRE - 3 Y - 4 GRA- DOS CENTIGRADOS.",SAN JERONIMO CAJICA CABRERA HERMANOS LTDA,CABRERA BAQUERO JOSE RICARDO DE JESUS,,https://lens.org/124-798-178-525-683,Patent Application,no,0,0,1,1,0,,A23G9/04,,0,0,,,,PENDING
73,CO,A1,CO 4480008 A1,074-972-000-554-304,1997-07-09,1997,CO 96063407 A,1996-12-03,CO 96063407 A,1996-12-03,PROCESO PARA LA PREPARACION DE CONFITURAS HELADAS Y EL PRODUCTO ASI OBTENIDO,"1. PROCESO PARA LA ELABORACION DE CONFITURAS HE- LADAS CARACTERIZADO PORQUE CONSISTE BASICAMENTE DE LA ELABORACION EN FORMA INDEPENDIENTE DE UNA MEZ- CLA DE JUGO DE LIMON Y AZUCAR Y DE UNA MEZCLA DE CREMA DE LECHE Y LECHE LAS CUALES POSTERIORMENTE SE UNEN PARA FORMAR UNA MEZCLA TOTAL QUE SE LLEVA A MADURACION DE DONDE SALE PARA SER MOLDEADA COMO HELADO O COMO PALETA. 2. PROCEDIMIENTO DE ACUERDO CON LA REIVINDICACION No.1 CARACTERIZADO PORQUE PARA LA EXTRACCION DEL JUGO Y ELABORACION DE LA MEZCLA SE LLEVAN A CABO LAS SIGUIENTES ETAPAS: A- RECEPCION Y SELECCION DE LA FRUTA, ESTE PROCE- SO SE HACE MANUALMENTE TENIENDO EN CUENTA TAMANO, ESTADO DE MADURACION Y OPTIMAS CONDICIONES FITOSA- NITARIAS. B- LA FRUTA UNA VEZ SELECCIONADA Y YA COLOCADA SOBRE UNA ESPECIE DE ZARANDA SE SOMETE A LAVADO CON CHORRO DE AGUA FRIA. C- LUEGO PASA A UN PROCESO DE ESCALDADO EN AGUA A 50 GRADOS CENTIGRADOS DURANTE UN TIEMPO DE 10 A 15 SEGUNDOS. D- CORTAR LOS LIMONES EN TAJADAS Y PASARLOS LUEGO A UN EXTRACTOR SEMIINDUSTRIAL PARA EXTRAER EL JU- GO. E- AL CONCENTRADO DE LA FRUTA ASI OBTENIDO SE LE ADICIONA AZUCAR EN UNA PROPORCION DE UNA PARTE DE JUGO POR UNA DE AZUCAR, OBTENIENDOSE AZUCAR INVER- TIDO (GLUCOSA DE LIMON). 3. PROCEDIMIENTO DE ACUERDO CON LA REIVINDICACION No.1 CARACTERIZADO PORQUE SEPARADAMENTE SE PREPARA OTRA MEZCLA COMPUESTA DE LECHE ENTERA 35%, CREMA DE LECHE 20% Y AZUCAR OPCIONALMENTE. LA MEZCLA DE CREMA Y LECHE PASA LUEGO A UN TANQUE DE MADURACION DONDE SE LE ADICIONA 40% DE MEZCLA DE JUGO DE LI- MON Y PERMANECE CON AGITACION LENTA PARA HOMOGENE- IZACION COMPLETA, DURANTE UN TIEMPO DE 6 A 24 HO- RAS A UNA TEMPERATURA ENTRE 3 Y 5 GRADOS CENTIGRA- DOS. DE LOS TANQUES DE MADURACION LA MEZCLA ANTE- RIOR PASA A UN FREEZER DONDE EL HELADO SE LLEVA A UNA TEMPERATURA DE -4 GRADOS CENTIGRADOS DE DONDE SALE CON UNA CONSISTENCIA MAS VISCOSA O ESPESA Y CREMOSA Y PASA PARA SU ENVASE RESPECTIVO YA SEA COMO HELADO O COMO PALETA. EL PRODUCTO TERMINADO SE COLOCA EN CUARTOS A UNA TEMPERATURA DE -30 GRA- DOS CENTIGRADOS PARA LOGRAR UNA CONGELACION COM- PLETA.",SAN JERONIMO CAJICA CABRERA HERMANOS LTDA,CABRERA BAQUERO JOSE RICARDO DE JESUS,,https://lens.org/074-972-000-554-304,Patent Application,no,0,0,1,1,0,,A23G9/04,,0,0,,,,PENDING
74,ES,Y,ES 1020817 Y,033-130-095-272-351,1993-07-16,1993,ES 9200982 U,1992-03-27,ES 9200982 U,1992-03-27,"MAQUINA EMISORA DE PRODUCTOS DESINFECTANTES, CON DISPOSITIVO EMISOR DE OZONO DE CARACTER POLIVALENTE.",,"S O N R I C H, S.A.",TARASA CABRERA JOSE;;SISON REMON RICARDO,,https://lens.org/033-130-095-272-351,Limited Patent,no,0,0,2,2,0,,A61L9/015;;A61L9/14,,0,0,,,,EXPIRED
75,ES,U,ES 1020817 U,104-761-941-314-157,1992-08-16,1992,ES 9200982 U,1992-03-27,ES 9200982 U,1992-03-27,"Used station disinfectants with ozone emitting device polyvalent character. (Machine-translation by Google Translate, not legally binding)","DISINFECTING PRODUCTS MACHINE, WITH A MULTIPURPOSE OZONE EMITTING DEVICE, CONSTITUTED FROM A CHASSIS OR FRAME PREFERABLY MADE IN A METALLIC MATERIAL, SUITABLE FOR A TRANSPORTATION OF A ROAD CONTROL PANEL FOR MANUAL OPERATION AND DIGITAL PRESENTATION, CONNECTION TO THE NETWORK AND HAVING INSIDE IT A WIDE HOLLOW SPACE, CHARACTERIZED BY BEING IN ITS UPPER AREA WITH A REMOVABLE HOUSING, PROVIDED WITH HANDLES AND ANY CONFIGURATION, EITHER OR NOT OF A PROTECTIVE NETWORK OR MESH, ALSO COUNTING ON THE COVER WITH SOME INFRARED DETECTORS. (Machine-translation by Google Translate, not legally binding)","S O N R I C H, S.A.",TARASA CABRERA JOSE;;SISON REMON RICARDO,,https://lens.org/104-761-941-314-157,Patent Application,no,0,0,2,2,0,,A61L9/015;;A61L9/14,,0,0,,,,EXPIRED
76,ES,U,ES 1217779 U,178-971-620-170-455,2018-09-21,2018,ES 201831181 U,2018-07-25,ES 201831181 U,2018-07-25,"LONG LIFE DEVICE FOR DRIP IRRIGATION IN TWO POSITIONS (Machine-translation by Google Translate, not legally binding)","Long life device for drip irrigation in two positions, characterized because it is formed by three tube sections joined by 45º angles, a stopper and a microtube holder. (Machine-translation by Google Translate, not legally binding)",CABRERA SANCHEZ JOSE MANUEL;;PAUN MARIAN,CABRERA SANCHEZ JOSE MANUEL;;PAUN MARIAN,,https://lens.org/178-971-620-170-455,Patent Application,no,0,0,2,2,0,Y02A40/22,A01G25/06,,0,0,,,,ACTIVE
77,ES,U,ES 1223449 U,023-664-242-532-55X,2019-01-21,2019,ES 201831158 U,2018-07-19,ES 201831158 U,2018-07-19,"LONG-DURATION DEVICE FOR LOCALIZED IRRIGATION WITH THREE BURIED EMISSION POINTS. (Machine-translation by Google Translate, not legally binding)","Long-term device for localized irrigation with three buried emission points, consisting of three independent emission channels under the ground, whose emission zones are separated horizontally and underground. The system is fed with a single microtube, which connects the irrigation branch to the upper part of the system, where it is connected to the drippers that supply water to each of the channels. (Machine-translation by Google Translate, not legally binding)",PAUN MARIAN;;CABRERA SANCHEZ JOSE MANUEL,PAUN MARIAN;;CABRERA SANCHEZ JOSE MANUEL,,https://lens.org/023-664-242-532-55X,Patent Application,no,0,0,2,2,0,Y02A40/22,A01G25/06,,0,0,,,,ACTIVE
78,CO,A1,CO 4480007 A1,051-842-746-690-214,1997-07-09,1997,CO 96063406 A,1996-12-03,CO 96063406 A,1996-12-03,PROCESO PARA LA PREPARACION DE CONFITURAS HELADAS Y EL PRODUCTO ASI OBTENIDO,"1. PROCESO PARA LA ELABORACION DE CONFITURAS HE- LADAS CARACTERIZADO PORQUE CONSISTE BASICAMENTE DE LA ELABORACION EN FORMA INDEPENDIENTE DE UNA MER- MELADA DE FRUTAS Y DE UNA MEZCLA DE CREMA DE LECHE Y LECHE LAS CUALES POSTERIORMENTE SE UNEN PARA FORMAR UNA MEZCLA TOTAL QUE SE LLEVA A MADURACION DE DONDE PASA A UN FREEZER PARA BAJAR TEMPERATURA Y DE ALLI SALE PARA SER MOLDEADA COMO HELADO O CO- MO PALETA 2- PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No.1 CARACTERIZADO PORQUE PARA LA OBTENCION DE LA MER- MELADA DE FRUTA SE LLEVAN A CABO LAS SIGUIENTES E- TAPAS: A) RECEPCION Y SELECCION DE LA FRUTA, ESTE PROCE- SO SE HACE MANUALMENTE TENIENDO EN CUENTA TAMANO, ESTADO DE MADURACION Y OPTIMAS CONDICIONES FITOSA- NITARIAS. B) LA FRUTA UNA VEZ SELECCIONADA Y YA COLOCADA SOBRE UNA ESPECIE DE ZARANDA SE SOMETE A LAVADO CON CHORRO DE AGUA FRIA. C) LUEGO PASA A UN PROCESO DE ESCALDADO EN AGUA A 50 GRADOS CENTIGRADOS DURANTE UN TIEMPO DE 10 A 15 SEGUNDOS. D) PROCESO DE LICUADO O FRAGMENTACION DE LA PULPA EN PEQUENOS TROCITOS. E) DESSEMILLADO POR MEDIO DE FILTRACION UTILIZAN- DO UN FILTRO DE LIENZO TIPO MANGA, DE MANERA QUE LA PULPA QUEDA LIBRE DE SEMILLAS O PEPAS. F) AL CONCENTRADO DE PULPA DE FRUTA ASI OBTENIDO SE LE ADICIONA AZUCAR EN UNA PROPORCION DE DOS PARTES DE FRUTA POR UNA DE AZUCAR, ESTA MEZCLA SE ELABORA EN UNA MARMITA PARA LUEGO SER LLEVADA LEN- TAMENTE HASTA UNA TEMPERATURA ENTRE 60 Y 85 GRADOS CENTIGRADOS, DONDE UNA VEZ ALCANZADA LA TEMPERATU- RA SE MANTIENE EN ESE PUNTO DURANTE UN TIEMPO DE 10 A 15 MINUTOS, PARA OBTENER UNA MERMELADA DE FRUTA. G) LA MERMELADA ASI OBTENIDA SE ENVASA EN TAMBO- RES PLASTICOS O ENVASES DE VIDRIO HERMETICAMENTE CERRADOS Y SE DEJA EN REPOSO POR LO MENOS DURANTE 24 HORAS. 3- PROCEDIMIENTO PARA LA ELABORACION DE CONFITU- RAS HELADAS DE ACUERDO CON LA REIVINDICACION No.1 CARACTERIZADO PORQUE SEPARADAMENTE SE PREPARA OTRA MEZCLA COMPUESTA DE LECHE ENTERA 35%, CREMA DE LE- CHE 20% Y AZUCAR 2%, DICHA MEZCLA SE HOMOGENEIZA Y PASTEURIZA A UNA TEMPERATURA ENTRE 80 Y 85 GRADOS CENTIGRADOS, LUEGO DE LO CUAL LA TEMPERATURA ES BAJADA RAPIDAMENTE HASTA 3 GRADOS CENTIGRADOS Y LLEVADA A UN TANQUE DE MADURACION.",SAN JERONIMO CAJICA CABRERA HERMANOS LTDA,CABRERA BAQUERO JOSE RICARDO DE JESUS,,https://lens.org/051-842-746-690-214,Patent Application,no,0,0,1,1,0,,A23G9/04,,0,0,,,,PENDING
79,ES,U,ES 1078149 U,006-912-005-412-89X,2012-11-29,2012,ES 201201001 U,2012-11-06,ES 201201001 U,2012-11-06,"Device for covering the lens of a camera integrated in computers and mobile telephones (Machine-translation by Google Translate, not legally binding)","Device for covering the lens of a webcam integrated into computers and mobile telephony devices comprising a one-piece structure in the form of an inverted u-shape. (Machine-translation by Google Translate, not legally binding)",UNIV ALICANTE,PEREZ TURPIN JOSE ANTONIO;;ANDREU CABRERA ELISEO,,https://lens.org/006-912-005-412-89X,Patent Application,no,0,0,3,3,0,G03B11/041,H04N5/00;;H04N5/247,,0,0,,,,EXPIRED
80,WO,A1,WO 2005/118313 A1,041-898-599-949-854,2005-12-15,2005,ES 2005000307 W,2005-05-27,ES 200401289 U,2004-05-28,IMPROVED ANTISKID SYSTEM FOR VEHICLES,"The invention relates to an antiskid system for vehicles, which is coupled to the wheel rims, such as to create a novel outer road contact surface which prevents skidding and provides better grip, without requiring the use of chains. Moreover, the inventive system does not require the user to stop and exit the vehicle in order to start the system. For said purpose, the invention comprises a set of blades which are coupled to the rims in a radial manner, said blades being equipped with an L-shaped end or foot having a rough base which extends to meet the roadway.",ABECE FUERTEVENTURA S L;;CABRERA SUAREZ MARIA;;MENDEZ ALTOZANO JOSE LUIS,CABRERA SUAREZ MARIA;;MENDEZ ALTOZANO JOSE LUIS,,https://lens.org/041-898-599-949-854,Patent Application,yes,6,8,3,3,0,B60B15/22;;B60B15/263,B60B15/26;;B60B39/00,,0,0,,,,PENDING
81,DE,A1,DE 102022127012 A1,061-608-288-397-535,2023-10-26,2023,DE 102022127012 A,2022-10-14,US 202217728187 A,2022-04-25,VERSCHACHTELUNG EINER ZWEISTUFIGEN SCHNAPPVERBINDUNG FÜR WARTBARE KOMPONENTEN,"Eine Verkleidungsanordnung eines Fahrzeugs enthält eine erste Komponente, eine zweite Komponente und ein Befestigungselement, das die erste Komponente an der zweiten Komponente befestigt. Das Befestigungselement enthält einen Hauptkörper, der sich von der ersten Komponente bei einem ersten Hauptkörperende des Hauptkörpers erstreckt. Der Hauptkörper enthält Hauptkörperzweige, die sich vom Hauptkörper bei einem zweiten Körperende des Hauptkörpers erstrecken. Ein oder mehrere Nebenkörper sind auf einer lateralen Seite des Hauptkörpers angeordnet und vom Hauptkörper beabstandet. Ein Nebenkörper des einen oder der mehreren Nebenkörper enthält einen Spitzenvorsprung, der bei einem Nebenspitzenende des Nebenkörpers angeordnet ist. Das Befestigungselement ist an einer Befestigungsöffnung in der ersten Komponente montierbar, um die erste Komponente an der zweiten Komponente zu fixieren.",GM GLOBAL TECH OPERATIONS LLC,BARRERA ALEJANDRO;;CABRERA JOSE ROBERTO;;ESCOBAR JUAN,,https://lens.org/061-608-288-397-535,Patent Application,no,0,0,3,3,0,F16B5/0664;;B60R13/0206;;B60R13/0243;;B60R13/0206;;F16B5/0664;;B60R13/0243,B60R13/02;;F16B5/07,,0,0,,,,PENDING
82,ES,A6,ES 2127163 A6,028-018-823-189-919,1999-04-01,1999,ES 9501652 A,1995-08-11,ES 9501652 A,1995-08-11,"Improvements to patent no. 552,294, submitted on 21 February 1986, relating to a machine for removing flesh from olives","The machine comprises a rotary inner drum 1 and a fixed outer drum 2, both of cylindrical configuration and mutually coaxial. These two drums are separated from each other by a distance which is greater than the diameter of the stones (pits). The inner drum 1 has helical ribs or strips 7 for entraining the product to be processed. The outer wall 2 has passages which are sized in order to allow only the passage of the flesh.",JIMENEZ RODRIGUEZ JOSE LUIS;;CABRERA GARRIDO FEDERICO,JIMENEZ RODRIGUEZ JOSE LUIS;;CABRERA GARRIDO FEDERICO,,https://lens.org/028-018-823-189-919,Patent of Addition,no,0,0,1,1,0,,A23N4/08,,0,0,,,,DISCONTINUED
83,MX,A,MX 158624 A,087-638-162-599-853,1989-02-20,1989,MX 19496782 A,1982-10-28,US 33580482 A,1982-09-03,MEJORAS EN MECANISMO PARA EL MANEJO DE ARTICULOS EN UNA MAQUINA PARA FABRICAR ARTICULOS DE VIDRIO,,VITRO TEC FIDEICOMISO,MONTANTE ARMANDO CABRERA;;PEREZ JOSE JAVIER OGUSHI,,https://lens.org/087-638-162-599-853,Granted Patent,no,0,0,2,2,0,C03B9/3841;;C03B9/3891;;C03B9/44;;C03B9/3841;;C03B9/3891;;C03B9/44,C03B9/38;;C03B9/44,,0,0,,,,EXPIRED
84,ES,B1,ES 2235650 B1,080-901-926-868-920,2006-11-01,2006,ES 200303039 A,2003-12-23,ES 200303039 A,2003-12-23,"FORMULACIONES CERAMICAS MODIFICADAS Y PROCEDIMIENTO PARA LA FABRICACION DE PIEZAS CERAMICAS CON EFECTOS METALICOS, ASI COMO LAS PIEZAS CERAMICAS OBTENIDAS.","Formulaciones cerámicas modificadas y procedimiento para la fabricación de piezas cerámicas con efectos metálicos, así como las piezas cerámicas obtenidas. Dichas formulaciones cerámicas modificadas comprenden formulaciones cerámicas convencionales constituidas por una matriz cerámica a base de una mezcla de óxidos en diferentes proporciones, que se han modificado por adición de metales, mezclas de metales y aleaciones de metales inoxidables de puntos de fusión superior a 1100ºC y granulometrías inferiores a 100 micras. Dicho procedimiento comprende la aplicación de dichas formulaciones sobre la pieza cerámica a decorar, seguido de cocción y posterior desbastado. Aplicación en el sector de la industria cerámica.",VIDRES S A,MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,,https://lens.org/080-901-926-868-920,Granted Patent,no,0,1,6,6,0,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/02;;C04B41/5022;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/18;;C03C8/02;;C03C8/04,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/50;;C04B41/86;;C04B41/87,,0,0,,,,EXPIRED
85,ES,B1,ES 2291104 B1,107-905-732-495-501,2009-01-01,2009,ES 200550002 A,2002-10-15,ES 200202452 A,2002-10-15,NUEVO JUEGO DE MESA.,"Nuevo juego de mesa que utiliza un tablero de dos láminas opacas paralelas superpuestas entre las que se introducen una serie de fichas, atraíbles magnéticamente, con abundante información impresa por sus dos caras. La cara inferior es un dibujo-con tamaño variable-coloreado y numerado que funciona como pregunta mientras que la superior es la respuesta (descripción escrita del dibujo) exigida. Unas ranuras especiales situadas en la parte alta de la banda perimetral del tablero permite que sólo se puedan sacar las fichas que el jugador captura deslizando un peón imantado sobre la lámina superior. La gran base del peón puede mostrar la cara-pregunta y ocultar la cara superior hasta que todos han respondido. Ganará quien consiga un número prefijado de fichas respondiendo correctamente según un nivel de dificultad acordado. Los cambios introducidos en estos componentes básicos permiten crear un juego magnético dedicado especialmente al aprendizaje de idiomas.",CABRERA SILVA ESTEBAN,DIAZ RUIZ JOSE RAMON;;CABRERA SILVA ESTEBAN,,https://lens.org/107-905-732-495-501,Granted Patent,no,0,0,6,6,0,A63F9/18;;A63F3/0402;;G09B19/22;;G09B19/06;;G09B1/02,A63F3/02;;A63F3/04;;A63F9/18;;A63F9/34;;G09B1/02;;G09B19/06;;G09B19/22,,0,0,,,,EXPIRED
86,US,A1,US 2019/0384799 A1,172-943-591-469-928,2019-12-19,2019,US 201916555354 A,2019-08-29,US 201916555354 A;;US 201615168644 A,2016-05-31,DYNAMICALLY TAGGING WEBPAGES BASED ON CRITICAL WORDS,A webpage is received. A request to tag a webpage is received. The webpage may be parsed in response to the received request to tag the webpage. One or more critical words may be identified within the parsed webpage. A tag dictionary may be searched for the identified one or more critical words. One or more tags for selection by an end user may be displayed in response to searching the tag dictionary. The parsed webpage may be tagged with a received selection of a tag of the displayed one or more tags.,IBM,MALDONADO CABRERA RAQUEL;;MOSQUEDA MEJIA JOSE R,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-05-27),https://lens.org/172-943-591-469-928,Patent Application,yes,0,0,4,4,0,G06F16/9535;;G06F16/9535,G06F16/9535,,0,0,,,,ACTIVE
87,US,B2,US 10459994 B2,013-854-346-224-126,2019-10-29,2019,US 201615168644 A,2016-05-31,US 201615168644 A,2016-05-31,Dynamically tagging webpages based on critical words,A webpage is received. A request to tag a webpage is received. The webpage may be parsed in response to the received request to tag the webpage. One or more critical words may be identified within the parsed webpage. A tag dictionary may be searched for the identified one or more critical words. One or more tags for selection by an end user may be displayed in response to searching the tag dictionary. The parsed webpage may be tagged with a received selection of a tag of the displayed one or more tags.,IBM,MALDONADO CABRERA RAQUEL;;MOSQUEDA MEJIA JOSE R,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-05-27),https://lens.org/013-854-346-224-126,Granted Patent,yes,17,1,4,4,0,G06F16/9535;;G06F16/9535,G06F16/9535,,3,2,121-885-532-079-812;;004-162-774-362-978,10.1109/wiiat.2008.92;;10.1145/1526709.1526796,"Hsu et al., “Tag Normalization and Prediction for Effective Social Media Retrieval,” IEEE/WIC/ACM International Conference on Web Intelligence and Intelligent Agent Technology, 2008, p. 770-774, IEEE Computer Society.;;Markines et al., “Evaluating Similarity Measures for Emergent Semantics of Social Tagging,” Proceedings of the 18th International Conference on World Wide Web (WWW 2009), Apr. 20-24, 2009, p. 641-650, ACM, Madrid, Spain.;;Mell et al., “The NIST Definition of Cloud Computing,” National Institute of Standards and Technology, Sep. 2011, p. 1-3, Special Publication 800-145.",ACTIVE
88,US,A1,US 2023/0339413 A1,190-916-183-840-141,2023-10-26,2023,US 202217728187 A,2022-04-25,US 202217728187 A,2022-04-25,NESTING TWO-STEP SNAP CONNECTION FOR SERVICEABLE COMPONENTS,"A trim assembly of a vehicle includes a first component, a second component, and an attachment element attaching the first component to the second component. The attachment element includes a main body extending from the first component at a first main body end of the main body. The main body includes main body arms extending from the main body at a second body end of the main body. One or more secondary bodies are located at a lateral side of the main body and spaced apart from the main body. A secondary body of the one or more secondary bodies includes a tip protrusion located at a secondary tip end of the secondary body. The attachment element is installable to an attachment opening in the first component to secure the first component to the second component.",GM GLOBAL TECH OPERATIONS LLC,BARRERA ALEJANDRO;;CABRERA JOSE ROBERTO;;ESCOBAR JUAN,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2022-04-20),https://lens.org/190-916-183-840-141,Patent Application,yes,2,0,3,3,0,F16B5/0664;;B60R13/0206;;B60R13/0243;;B60R13/0206;;F16B5/0664;;B60R13/0243,B60R13/02;;F16B5/06,,1,0,,,KR-1020170047967-A computer translation (Year: 2017),PENDING
89,ES,B8,ES 2338193 B8,177-449-721-575-410,2011-07-19,2011,ES 200800526 A,2008-02-25,ES 200800526 A,2008-02-25,NUEVAS SALES DE AMONAFIDE.,,CT ATLANTICO DEL MEDICAMENTO S A,FERNANDEZ BRANA MIGUEL;;BOLUDA CABRERA CARLOS JOSE,,https://lens.org/177-449-721-575-410,Unknown,no,0,0,3,3,0,A61K31/473;;C07D221/14,C07D221/14;;A61K31/473;;A61P35/00,,0,0,,,,INACTIVE
90,ES,Y,ES 1057687 Y,037-843-701-747-034,2004-12-16,2004,ES 200401289 U,2004-05-28,ES 200401289 U,2004-05-28,SISTEMA ANTIDESLIZAMIENTO PARA VEHICULOS MEJORADO.,,ABECE FUERTEVENTURA SL,MENDEZ ALTOZANO JOSE LUIS;;CABRERA SUAREZ MARIA,,https://lens.org/037-843-701-747-034,Limited Patent,no,0,0,3,3,0,B60B15/22;;B60B15/263,B60B15/26;;B60B39/00,,0,0,,,,EXPIRED
91,US,A,US 4426218 A,084-501-508-772-240,1984-01-17,1984,US 33580482 A,1982-09-03,US 33580482 A,1982-09-03,Machine for handling and cooling hot glasswares articles,"An improved glassware article forming machine employing a hollow arm, one end of which is rigidly carried at the upper end of the vertical hollow shaft, the other end of each hollow arm being provided with a glassware article receiving chuck, and including mechanism for imparting vertical movement to the hollow shaft and associated arm, and mechanism for imparting oscillatory movement to the hollow shaft associated arm, and mechanism for supplying an adjustable amount of air through the hollow shaft and associated hollow arm for circulation into the chuck and about the hot glassware article received from a blow mold to provide an air cushion on which the glassware article will ride while providing cooling for said hot glassware article throughout its vertical and oscillatory movement to a takeout position.",VITRO TEC FIDEICOMISO,CABRERA-MONTANTE ARMANDO;;OGUSHI-PEREZ JOSE J,,https://lens.org/084-501-508-772-240,Granted Patent,yes,4,13,2,2,0,C03B9/3841;;C03B9/3891;;C03B9/44;;C03B9/3841;;C03B9/3891;;C03B9/44,C03B9/38;;C03B9/44,65/241;;65/267,0,0,,,,EXPIRED
92,WO,A1,WO 2005/061402 A1,063-646-649-106-394,2005-07-07,2005,ES 2004000560 W,2004-12-17,ES 200303039 A,2003-12-23,"MODIFIED CERAMIC FORMULATIONS, METHOD OF PRODUCING CERAMIC PARTS WITH METALLIC EFFECTS AND CERAMIC PARTS THUS PRODUCED","The invention relates to modified ceramic formulations comprising standard ceramic formulations which are formed by a ceramic matrix based on a mixture of different quantities of oxides and which are modified with the addition of metals, mixtures of metals and stainless metal alloys having melting points above 1100 °C and grain sizes of less than 100 microns. The inventive method consists in applying said formulations to the ceramic part to be decorated, followed by firing and grinding. The invention is suitable for use in the ceramics industry.",VIDRES S A;;MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,,https://lens.org/063-646-649-106-394,Patent Application,yes,2,1,6,6,0,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/02;;C04B41/5022;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/18;;C03C8/02;;C03C8/04,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/50;;C04B41/87,,0,0,,,,PENDING
93,ES,A1,ES 2338193 A1,144-007-654-562-584,2010-05-04,2010,ES 200800526 A,2008-02-25,ES 200800526 A,2008-02-25,"New amonafide salts. (Machine-translation by Google Translate, not legally binding)","The invention comprises new amonafide salts and their production process. The salts of the invention comprise as a cation the active substance amonafide, a known antitumor drug. The novelty and inventive activity of the present invention is that the anion of the amonafide salt is selected from the carboxylic acid inhibitors of the enzyme histone deacetylase, an enzyme involved in the proliferation of cancer cells. Another aspect of the invention consists in the use of the amonafide salts with acid inhibitors of the enzyme histone deacetylase, in the manufacture of medicaments, compositions and pharmaceutical formulations, useful in the treatment of cancer. (Machine-translation by Google Translate, not legally binding)",CT ATLANTICO DEL MEDICAMENTO S,FERNANDEZ BRANA MIGUEL;;BOLUDA CABRERA CARLOS JOSE,,https://lens.org/144-007-654-562-584,Patent Application,no,2,0,3,3,0,A61K31/473;;C07D221/14,C07D221/14;;A61K31/473;;A61P35/00,,0,0,,,,INACTIVE
94,ES,A1,ES 2326355 A1,046-083-045-537-940,2009-10-07,2009,ES 200800525 A,2008-02-25,ES 200800525 A,2008-02-25,"Acid 1- (di-N-propilacetilaminometil) -cychohexilacetic. (Machine-translation by Google Translate, not legally binding)","1- (di-N-propylacetylaminomethyl) -cyclohexylacetic acid. The present invention relates to a process for the synthesis of 1- (di-N-propylacetylaminomethyl) -cyclohexylacetic acid, derivatives thereof or their pharmaceutically acceptable salts; and its applications for the treatment of conditions or pathologies linked to the central nervous system (cns). Thus, the compound of the invention can be used, for example, as an anticonvulsant, anti-migraine, antimanic agent or for the treatment of neuropathic pains. (Machine-translation by Google Translate, not legally binding)",CT ATLANTICO DEL MEDICAMENTO S,FERNANDEZ BRANA MIGUEL;;BOLUDA CABRERA CARLOS JOSE,,https://lens.org/046-083-045-537-940,Patent Application,no,2,4,2,2,0,A61K31/16;;C07C233/52,C07C233/52;;A61K31/16,,1,1,019-457-970-023-677,10.1002/1098-2299(200011)51:3<143::aid-ddr1>3.0.co;2-3,"G V REKATAS et al., DRUG DEVELOPMENT RESEARCH 2000, vol. 51, págs. 143-148. ""Research on the pharmacochemistry of some GABA and valproic acid derivatives"".",INACTIVE
95,US,A1,US 2009/0242328 A1,152-884-094-906-821,2009-10-01,2009,US 14444408 A,2008-06-23,US 14444408 A;;US 6033108 A,2008-04-01,STABILIZING MECHANISM FOR RIGID FIXED AND EXTENSION LADDERS,A stabilizing mechanism for rigid fixed and extension ladders that includes an anchorage assembly removably mounted to one of the rungs of a ladder. A linkage assembly is mounted to the anchorage assembly and it supports a rigid elongated member that in turn pivotally supports two arched arm members that are selectively locked in place by a locking assembly that can be remotely actuated. The arm members embrace a support member thereby providing a firm engagement of the ladder assembly to the support member. A release mechanism remotely disengages the ladder from the support member once a user descends.,CABRERA PEDRO;;SUAREZ JOSE A;;GUINOVART RUBEN,CABRERA PEDRO;;SUAREZ JOSE A;;GUINOVART RUBEN,,https://lens.org/152-884-094-906-821,Patent Application,yes,13,26,2,3,0,E06C7/06;;E06C7/48;;E06C7/482;;E06C7/06;;E06C7/482;;E06C7/48,E06C7/06,182/111,0,0,,,,DISCONTINUED
96,US,A1,US 2008/0020921 A1,171-504-299-655-220,2008-01-24,2008,US 59669604 A,2004-12-17,ES 200303039 A;;ES 2004000560 W,2003-12-23,Modified ceramic formulations and procedures for the manufacture of ceramic parts with metallic effects and ceramic parts produced,"The aforementioned modified ceramic formulations are conventional and made from a ceramic mold with an oxide mixture base in different proportions that have been modified by adding metals, metal mixtures and non-oxidizing metal alloys with fusion points of greater than 1100° C. and granulometry of less than 100 microns. This procedure consists of the application of the aforementioned formulations upon the ceramic part to be decorated, followed by the firing and subsequent grinding. Its use is for the ceramics industry.",MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,,https://lens.org/171-504-299-655-220,Patent Application,yes,2,1,6,6,0,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/02;;C04B41/5022;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/18;;C03C8/02;;C03C8/04,C03C8/04;;C03C8/02;;C03C8/18;;C04B41/50;;C04B41/86;;C04B41/87,501/135;;501/1,0,0,,,,DISCONTINUED
97,EP,A1,EP 2614724 A1,045-851-497-975-020,2013-07-17,2013,EP 12382010 A,2012-01-13,EP 12382010 A,2012-01-13,Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring,"The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant woman for reducing long term adverse health effects, including obesity and sarcopenia, in the offspring later in life. The carbohydrate system includes a slow rate of digestion simple carbohydrate and a complex carbohydrate in combination with a non-absorbent carbohydrate and/or an indigestible carbohydrate. The carbohydrate system may also be administered to the woman during lactation to further the reduction of long term adverse health effects, including obesity, in the offspring later in life.",ABBOTT LAB,RUEDA-CABRERA RICARDO;;LOPEZ-PEDROSA JOSE MARIA,,https://lens.org/045-851-497-975-020,Patent Application,yes,3,2,1,13,0,A23L29/212;;A23L29/30;;A23L33/10;;A23L33/21;;A23L5/00;;A23L21/00;;A23L33/125;;A23L9/00;;A23L5/00;;A23L21/00;;A23L33/125;;A23L9/00,A23L1/0522;;A23L1/09;;A23L1/30;;A23L1/308,,0,0,,,,DISCONTINUED
98,WO,A1,WO 2010/008466 A1,125-071-908-820-529,2010-01-21,2010,US 2009/0003738 W,2009-06-23,US 14444408 A,2008-06-23,STABILIZING MECHANISM FOR LADDERS,A stabilizing mechanism for rigid fixed and extension ladders that includes an anchorage assembly removably mounted to one of the rungs of a ladder A linkage assembly is mounted to the anchorage assembly through a transversally rotably mounted base that permits the setting in one of several angular positions Two arched arm members are pivotally mounted to a plate with two linkage arms pivotally mounted to a swivel bracket permitting the arch members to move coplanarly between two positions The arm members releasably embrace a support structure providing a firm engagement of the ladder to the support structure A release mechanism remotely disengages the ladder from the support structure The engagement is kept by a locking mechanism that includes a pivoting mounted plate with a central opening A shaft mounted to the ngid plate permits the shaft to move in on direction only.,CABRERA PEDRO;;GUINOVART RUBEN;;SUAREZ JOSE A,CABRERA PEDRO;;GUINOVART RUBEN;;SUAREZ JOSE A,,https://lens.org/125-071-908-820-529,Patent Application,yes,5,0,2,3,0,E06C7/06;;E06C7/48;;E06C7/482;;E06C7/06;;E06C7/482;;E06C7/48,E06C7/06,,0,0,,,,PENDING
99,US,B2,US 11275805 B2,021-608-921-756-863,2022-03-15,2022,US 201916555354 A,2019-08-29,US 201916555354 A;;US 201615168644 A,2016-05-31,Dynamically tagging webpages based on critical words,A webpage is received. A request to tag a webpage is received. The webpage may be parsed in response to the received request to tag the webpage. One or more critical words may be identified within the parsed webpage. A tag dictionary may be searched for the identified one or more critical words. One or more tags for selection by an end user may be displayed in response to searching the tag dictionary. The parsed webpage may be tagged with a received selection of a tag of the displayed one or more tags.,IBM,MALDONADO CABRERA RAQUEL;;MOSQUEDA MEJIA JOSE R,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-05-27),https://lens.org/021-608-921-756-863,Granted Patent,yes,21,0,4,4,0,G06F16/9535;;G06F16/9535,G06F16/9535,,5,3,039-159-205-906-94X;;121-885-532-079-812;;004-162-774-362-978,10.1109/noms.2008.4575160;;10.1109/wiiat.2008.92;;10.1145/1526709.1526796,"Bharat Krishnamurthy et al, “Data tagging architecture for system monitoring in dynamic environment”, NOMS 2008-2008 IEEE Network Operations and Management Symposium. IEEE Xplore Aug. 26, 2008.;;Hsu et al., “Tag Normalization and Prediction for Effective Social Media Retrieval,” IEEE/WIC/ACM International Conference on Web Intelligence and Intelligent Agent Technology, 2008, p. 770-774, IEEE Computer Society.;;Markines et al., “Evaluating Similarity Measures for Emergent Semantics of Social Tagging,” Proceedings of The 18th International Conference on World Wide Web (WWW 2009), Apr. 20-24, 2009, p. 641-650, ACM, Madrid, Spain.;;Mell et al., “The NIST Definition of Cloud Computing,” National Institute of Standards and Technology, Sep. 2011, p. 1-3, Special Publication 800-145.;;List of IBM Patents or Patent Applications Treated as Related, Aug. 28, 2019, 2 pgs.",ACTIVE
100,ES,B1,ES 2326355 B1,044-614-333-745-848,2010-08-10,2010,ES 200800525 A,2008-02-25,ES 200800525 A,2008-02-25,ACIDO 1-(DI-N-PROPILACETILAMINOMETIL)-CICLOHEXILACETICO.,,CT ATLANTICO DEL MEDICAMENTO S,FERNANDEZ BRANA MIGUEL;;BOLUDA CABRERA CARLOS JOSE,,https://lens.org/044-614-333-745-848,Granted Patent,no,0,0,2,2,0,A61K31/16;;C07C233/52,C07C233/52;;A61K31/16,,0,0,,,,INACTIVE
101,ES,U,ES 1057687 U,080-940-621-696-314,2004-09-01,2004,ES 200401289 U,2004-05-28,ES 200401289 U,2004-05-28,IMPROVED ANTISKID SYSTEM FOR VEHICLES,"Improved anti-slip system for vehicles, characterized by being made up of a set of radial pallets anchored to the wheels of the vehicles, at the end of which is an L-shaped foot with a rough surface at its base that extends until it reaches the roadway, on the outside and parallel to the vehicle tires. (Machine-translation by Google Translate, not legally binding)",ABECE FUERTEVENTURA SL,MENDEZ ALTOZANO JOSE LUIS;;CABRERA SUAREZ MARIA,,https://lens.org/080-940-621-696-314,Patent Application,no,0,1,3,3,0,B60B15/22;;B60B15/263,B60B15/26;;B60B39/00,,0,0,,,,EXPIRED
102,ES,B2,ES 2338193 B2,178-239-902-737-432,2011-01-25,2011,ES 200800526 A,2008-02-25,ES 200800526 A,2008-02-25,NUEVAS SALES DE AMONAFIDE.,,CT ATLANTICO DEL MEDICAMENTO S A,FERNANDEZ BRANA MIGUEL;;BOLUDA CABRERA CARLOS JOSE,,https://lens.org/178-239-902-737-432,Granted Patent,no,0,0,3,3,0,A61K31/473;;C07D221/14,C07D221/14;;A61K31/473;;A61P35/00,,0,0,,,,INACTIVE
103,ES,Y,ES 1078149 Y,171-800-971-342-377,2013-02-25,2013,ES 201201001 U,2012-11-06,ES 201201001 U,2012-11-06,Dispositivo para tapar la lente de una cámara integrada en computadoras y disopositivos de telefonía móvil,,UNIV ALICANTE,PEREZ TURPIN JOSE ANTONIO;;ANDREU CABRERA ELISEO,,https://lens.org/171-800-971-342-377,Limited Patent,no,0,0,3,3,0,G03B11/041,H04N5/00;;H04N5/247,,0,0,,,,EXPIRED
104,ES,A1,ES 2235650 A1,025-335-804-101-264,2005-07-01,2005,ES 200303039 A,2003-12-23,ES 200303039 A,2003-12-23,"MODIFIED CERAMIC FORMULATIONS, METHOD OF PRODUCING CERAMIC PARTS WITH METALLIC EFFECTS AND CERAMIC PARTS THUS PRODUCED","The aforementioned modified ceramic formulations are conventional and made from a ceramic mold with an oxide mixture base in different proportions that have been modified by adding metals, metal mixtures and non-oxidizing metal alloys with fusion points of greater than 1100 DEG C and granulometry of less than 100 microns. This procedure consists of the application of the aforementioned formulations upon the ceramic part to be decorated, followed by the firing and subsequent grinding. Its use is for the ceramics industry.",VIDRES S A,MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,,https://lens.org/025-335-804-101-264,Patent Application,no,2,1,6,6,0,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/02;;C04B41/5022;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/18;;C03C8/02;;C03C8/04,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/50;;C04B41/87,,0,0,,,,EXPIRED
105,US,A1,US 2017/0344637 A1,103-429-982-079-666,2017-11-30,2017,US 201615168644 A,2016-05-31,US 201615168644 A,2016-05-31,DYNAMICALLY TAGGING WEBPAGES BASED ON CRITICAL WORDS,A webpage is received. A request to tag a webpage is received. The webpage may be parsed in response to the received request to tag the webpage. One or more critical words may be identified within the parsed webpage. A tag dictionary may be searched for the identified one or more critical words. One or more tags for selection by an end user may be displayed in response to searching the tag dictionary. The parsed webpage may be tagged with a received selection of a tag of the displayed one or more tags.,IBM,MALDONADO CABRERA RAQUEL;;MOSQUEDA MEJIA JOSE R,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-05-27),https://lens.org/103-429-982-079-666,Patent Application,yes,16,1,4,4,0,G06F16/9535;;G06F16/9535,G06F17/30,,0,0,,,,ACTIVE
106,EP,A1,EP 1702896 A1,101-559-757-513-107,2006-09-20,2006,EP 04805103 A,2004-12-17,ES 2004000560 W;;ES 200303039 A,2003-12-23,"MODIFIED CERAMIC FORMULATIONS, METHOD OF PRODUCING CERAMIC PARTS WITH METALLIC EFFECTS AND CERAMIC PARTS THUS PRODUCED","The aforementioned modified ceramic formulations are conventional and made from a ceramic mold with an oxide mixture base in different proportions that have been modified by adding metals, metal mixtures and non-oxidizing metal alloys with fusion points of greater than 1100° C and granulometry of less than 100 microns. This procedure consists of the application of the aforementioned formulations upon the ceramic part to be decorated, followed by the firing and subsequent grinding. Its use is for the ceramics industry.",VIDRES S A VIDRESA,MONTINS NEBOT VICTOR;;CABRERA IBANEZ MARIA JOSE,,https://lens.org/101-559-757-513-107,Patent Application,yes,0,1,6,6,0,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/02;;C04B41/5022;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/18;;C03C8/02;;C03C8/04,C03C8/04;;C03C8/02;;C03C8/18;;C04B41/50;;C04B41/86;;C04B41/87,,0,0,,,,DISCONTINUED
107,MX,A,MX 2010010829 A,123-385-292-028-312,2012-04-12,2012,MX 2010010829 A,2010-10-01,MX 2010010829 A,2010-10-01,FORCED LUBRICATING DEVICE FOR THE PANTOGRAPH IN PNEUMATIC TRAINS.,"Provided are novel and useful improvements in the lubrication of pantographs (positive brush) in pneumatic trains, by means of a forced lubricating device for the pantograph, which basically comprises a forced lubrication cylinder based on a set of holes strategically arranged lengthwise the cylinder, where the axes and the trees include machined grease cavities in each end portion thereof, allowing the arms to be moved, also including bushings designed to support the use and wear, such as sintering bronze bushings.",VAZQUEZ JOSE ANTONIO COSIO,TORRES JOSE LUIS BINZHA;;ESTRADA ADAN CABRERA;;VAZQUEZ JOSE ANTONIO COSIO,,https://lens.org/123-385-292-028-312,Patent Application,no,0,0,1,1,0,,B61C17/08;;B61K3/00,,0,0,,,,DISCONTINUED
108,ES,Y,ES 1053782 Y,083-844-080-142-78X,2003-09-01,2003,ES 200202436 U,2002-10-11,ES 200202436 U,2002-10-11,"MONEDERO PORTADOCUMENTOS, ANTIDESLIZANTE",,SHARK SEVILLA S L,ROJAS CASTRO JOSE CARLOS;;CABRERA PEREZ JUAN;;RAMOS NUNO JOSE SALVADOR,,https://lens.org/083-844-080-142-78X,Limited Patent,no,0,0,2,2,0,,A45C1/02,,0,0,,,,EXPIRED
109,ES,U,ES 1053782 U,151-148-609-807-354,2003-05-16,2003,ES 200202436 U,2002-10-11,ES 200202436 U,2002-10-11,"Wallet city, slip (Machine-translation by Google Translate, not legally binding)","Wallet document holder, non-slip, designed to prevent the loss of these leather goods accessories, thanks to the anti-slip effect it has with respect to another material, characterized in that the material with which it is made totally or partially on the outside, is skin of shark, which has been subjected to a process of industrial tanning and processing. (Machine-translation by Google Translate, not legally binding)",SHARK SEVILLA S L,ROJAS CASTRO JOSE CARLOS;;CABRERA PEREZ JUAN;;RAMOS NUNO JOSE SALVADOR,,https://lens.org/151-148-609-807-354,Patent Application,no,0,0,2,2,0,,A45C1/02,,0,0,,,,EXPIRED
110,EP,A1,EP 2394646 A1,055-412-684-039-527,2011-12-14,2011,EP 11180427 A,2007-03-26,EP 07723608 A;;EP 06384006 A;;EP 06025476 A;;EP 2007002662 W,2006-03-27,Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy,"The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of medicament for the treatment of neuropathic pain resulting from chemotherapy.
",WEX MEDICAL LTD,BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;BAEYENS-CABRERA JOSE MANUEL,"WEX MEDICAL LTD., HK (2020-10-29)",https://lens.org/055-412-684-039-527,Patent Application,yes,15,0,19,19,0,A61K31/337;;A61K31/475;;A61K31/517;;A61K31/52;;A61K31/519;;A61K31/529;;A61K45/06;;A61P25/00;;A61P25/02;;A61P29/00;;A61K33/243;;A61K31/337;;A61K31/475;;A61K31/517;;A61K31/52;;A61K33/243;;A61K33/24;;A61K31/529;;A61K45/06;;A61K31/519,A61K31/337;;A61K31/475;;A61K31/517;;A61K31/529;;A61K33/243;;A61K45/06;;A61P25/00;;A61P25/02,,36,26,017-146-563-540-406;;000-599-377-163-306;;177-310-413-534-709;;037-794-287-010-10X;;120-520-383-362-818;;058-214-268-792-714;;086-169-522-933-128;;031-853-787-629-098;;060-878-175-910-113;;166-858-912-313-059;;015-461-458-759-788;;007-226-349-383-785;;082-817-573-119-019;;155-055-937-309-031;;023-652-211-343-504;;063-897-019-013-181;;004-035-273-862-921;;006-570-780-387-210;;024-044-021-710-067;;021-178-387-937-690;;084-819-015-566-887;;027-908-337-016-973;;144-930-592-111-372;;031-480-719-231-230;;106-912-998-040-933;;025-124-152-392-536,10.1016/s0006-8993(00)02451-3;;10882788;;11797144;;10.1055/s-2002-19594;;10.1016/s1388-2457(00)80014-0;;11011028;;10.1016/s0014-2999(00)00667-1;;15590869;;10.1345/aph.1e319;;16213086;;10.1016/j.pain.2005.09.014;;pmc1201322;;16489372;;10.1602/neurorx.2.4.650;;10.1016/0025-326x(90)90158-5;;5328391;;10.1080/00021369.1989.10869337;;10.1097/00001813-199506000-00003;;7670134;;10.1016/s0006-8993(00)02910-3;;11134612;;7907208;;10.1002/ana.410350310;;10.1016/s0306-4522(01)00425-0;;11738263;;10.1111/j.1460-9568.2004.03169.x;;14984413;;15082137;;10.1016/j.pain.2004.01.029;;10.1023/a:1005805907311;;9266440;;10.1200/jco.1997.15.5.1965;;9164208;;15102312;;10.1046/j.1526-4637.2001.002001008.x;;11731066;;10.1016/s0304-3959(01)00363-3;;7669713;;10.1093/oxfordjournals.annonc.a059220;;10.1007/pl00007853;;11954874;;8102012;;10.1200/jco.1993.11.10.2010;;7692001;;10.1016/j.lfs.2004.01.002;;15041441;;10.1200/jco.1996.14.7.1993;;8683229,"DATABASE WPI Week 200334, Derwent World Patents Index; AN 2003-360529, XP002441695;;LYU YEOUNG SU ET AL: ""Low dose of tetrodotoxin reduces neuropathic pain behaviors in an animal model"", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 871, no. 1, 14 July 2000 (2000-07-14), pages 98 - 103, XP002359713, ISSN: 0006-8993, DOI: 10.1016/S0006-8993(00)02451-3;;ECKEL F ET AL: ""PROPHYLAXE DER OXALIPLATIN-INDUZIERTEN NEUROPATHIE MIT CARBAMAZEPIN EINE PILOTSTUDIE PREVENTION OF OXALIPLATIN-INDUCED NEUROPATHY BY CARBAMAZEPINE: A PILOT STUDY"", DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, GEORG THIEME, STUTTGART,, DE, vol. 127, no. 3, 2002, pages 78 - 82, XP008041942, ISSN: 0012-0472;;""Neuropathies 2"", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE, IE, vol. 111, 1 August 2000 (2000-08-01), pages S41 - S44, XP027216056, ISSN: 1388-2457, [retrieved on 20000801];;ADELSBERGER HELMUTH ET AL: ""The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons"", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 406, no. 1, 6 October 2000 (2000-10-06), pages 25 - 32, XP002441583, ISSN: 0014-2999;;ROBERT J CERSOSIMO, THE ANNALS OF PHARMACOTHERAPY, vol. 39, January 2005 (2005-01-01), pages 128 - 135, XP009086339;;JUNG ET AL: ""Neuropathic pain associated with non-surgical treatment of breast cancer"", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 118, no. 1-2, November 2005 (2005-11-01), pages 10 - 14, XP005151698, ISSN: 0304-3959;;OSSIPOV ET AL: ""Challenges in the Development of Novel Treatment Strategies for Neuropathic Pain"", JOURNAL OF THE AMERICAN SOCIETY FOR EXPERIMENTAL NEUROTHERAPEUTICS, XX, XX, vol. 2, no. 4, October 2005 (2005-10-01), pages 650 - 661, XP005871732, ISSN: 1545-5343;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, pages: 210;;KROGSGAARD-LARSEN ET AL.: ""Textbook of Drugdesign and Discovery"", April 2002, TAYLOR & FRANCIS;;""Handbook of Natural Toxins, Vol. 3: Marine Toxins and Venoms"", vol. 3, 1988, pages: 185 - 210;;KAO, PHARMACOL. REV., vol. 18, 1966, pages 997 - 1049;;YOTSU, M. ET AL., AGRIC. BIOL. CHEM., vol. 53, no. 3, 1989, pages 893 - 895;;HARVARD, J. AM. CHEM. SOC. 1977, vol. 99, 1977, pages 2818;;J. AM. CHEM. SOC., vol. 106, 1984, pages 5594;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, pages: 213;;""JASP, Classification of chronic pain"", 2002, IASP PRESS, pages: 211;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, pages: 211;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, pages: 212;;ALBERTS DS AND NOEL JK: ""Cisplatin-associated neurotoxicity: can it be prevented?"", ANTICANCER DRUGS, vol. 6, no. 3, June 1995 (1995-06-01), pages 369 - 383;;AUTHIER N. ET AL.: ""Description of a short-term Taxol-induced nociceptive neuropathy in rats"", BRAIN RES., vol. 887, no. 2, 29 December 2000 (2000-12-29), pages 239 - 249;;CHAUDHRY V. ET AL.: ""Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies"", ANN NEUROL., vol. 35, no. 3, March 1994 (1994-03-01), pages 304 - 311;;DINA OA, CHEN X, REICHLING D, LEVINE JD: ""Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat"", NEUROSCIENCE, vol. 108, no. 3, 2001, pages 507 - 515;;DINA OA, PARADA CA, YEH J, CHEN X, MCCARTER GC, LEVINE JD: ""lntegrin signaling in inflammatory and neuropathic pain in the rat"", EUR J NEUROSCI., vol. 19, no. 3, February 2004 (2004-02-01), pages 634 - 642;;FLATTERS SJ, BENNETT GJ: ""Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy"", PAIN, vol. 109, no. 1-2, May 2004 (2004-05-01), pages 150 - 161;;FORSYTH PA, BALMACEDA C, PETERSON K, SEIDMAN AD, BRASHER P, DEANGELIS LM: ""Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing"", J NEUROONCOL., vol. 35, no. 1, October 1997 (1997-10-01), pages 47 - 53;;GORDON AN, STRINGER CA, MATTHEWS CM, WILLIS DL, NEMUNAITIS J.: ""Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting"", J CLIRI ONCOL., vol. 15, no. 5, May 1997 (1997-05-01), pages 1965 - 1973;;POLOMANO RC, BENNETT GJ: ""Chemotherapy-evoked painful peripheral neuropathy"", PAIN MED., vol. 2, no. 1, March 2001 (2001-03-01), pages 8 - 14;;POLOMANO RC, MANNES AJ, CLARK US, BENNETT GJ: ""A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel"", PAIN, vol. 94, no. 3, December 2001 (2001-12-01), pages 293 - 304;;POSTMA TJ, VERMORKEN JB, LIEFTING AJ, PINEDO HM, HEIMANS JJ: ""Paclitaxel-induced neuropathy"", ANN ONCOL., vol. 6, no. 5, May 1995 (1995-05-01), pages 489 - 494;;QUASTHOFF S, HARTUNG HP: ""Chemotherapy-induced peripheral neuropathy"", J NEUROL., vol. 249, no. 1, January 2002 (2002-01-01), pages 9 - 17;;ROWINSKY EK, EISENHAUER EA, CHAUDHRY V, ARBUCK SG, DONEHOWER RC: ""Clinical toxicities encountered with paclitaxel (Taxol"", SEMIN ONCOL., vol. 20, no. 4, August 1993 (1993-08-01), pages 1 - 15;;ROWINSKY EK. ET AL.: ""Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting"", J CLIN ONCOL., vol. 11, no. 10, pages 2010 - 2020;;SMITH SB, CRAGER SE, MOGIL JS: ""Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains"", LIFE SCI., vol. 74, no. 21, 9 April 2004 (2004-04-09), pages 2593 - 2604;;WASSERHEIT C. ET AL.: ""Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity"", J CLIN ONCOL., vol. 14, no. 7, July 1996 (1996-07-01), pages 1993 - 1999;;J CLIN ONCOL, vol. 14, no. 12, December 1996 (1996-12-01), pages 3175",ACTIVE
111,BR,A,BR 8604616 A,093-587-895-962-39X,1988-05-10,1988,BR 8604616 A,1986-09-03,BR 8604616 A,1986-09-03,TERMINAL DE CAPTURA DE DADOS E MONITORACAO DE LIGACOES TELEFONICAS EM TELEFONE PUBLICO,,FREDERICO JOSE DE ARAUJO BUCHM;;LUIZ MIGUEL CABRERA,BUCHMANN FREDERICO JOSE DE ARA;;CABRERA LUIZ MIGUEL,,https://lens.org/093-587-895-962-39X,Patent Application,no,0,0,1,1,0,,G07F7/08;;H04M17/00,,0,0,,,,DISCONTINUED
112,ES,Y,ES 1205964 Y,120-298-015-321-137,2018-05-16,2018,ES 201890003 U,2015-07-24,ES 2015070570 W,2015-07-24,CINTA DE CORRER MODULAR,,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,,https://lens.org/120-298-015-321-137,Limited Patent,no,0,0,3,3,0,A63B22/0235;;A63B22/0023;;A63B22/0257;;A63B22/0292;;A63B2225/102,A63B22/02,,0,0,,,,INACTIVE
113,AU,A1,AU 2013/216920 A1,127-221-895-375-641,2014-08-28,2014,AU 2013/216920 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/127-221-895-375-641,Patent Application,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,INACTIVE
114,EP,A1,EP 2812012 A1,141-713-750-248-578,2014-12-17,2014,EP 13706130 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,,GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,"GLOBAL BIO THERAPEUTICS, INC. (2019-03-06)",https://lens.org/141-713-750-248-578,Patent Application,yes,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,3,2,122-456-841-825-226;;003-129-885-683-212,21850051;;10.1038/gt.2011.119;;1316145,"L SOBREVALS ET AL: ""AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers"", GENE THERAPY, vol. 19, no. 4, 18 August 2011 (2011-08-18), GB, pages 411 - 417, XP055390552, ISSN: 0969-7128, DOI: 10.1038/gt.2011.119;;MIYANOHARA A ET AL: ""DIRECT GENE TRANSFER TO THE LIVER WITH HERPES SIMPLEX VIRUS TYPE 1 VECTORS: TRANSIENT PRODUCTION OF PHYSIOLOGICALLY RELEVANT LEVELS OF CIRCULATING FACTOR IX"", THE NEW BIOLOGIST, PHILADELPHIA,PA, US, vol. 4, no. 3, 1 March 1992 (1992-03-01), pages 238 - 246, XP000650666, ISSN: 1043-4674;;See also references of WO 2013119880A1",DISCONTINUED
115,KR,A,KR 20140146062 A,189-767-916-135-537,2014-12-24,2014,KR 20147025109 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,,GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/189-767-916-135-537,Patent Application,no,3,4,35,35,28,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K48/00;;A61K35/76,,1,0,,,"Fabre 외. (2008) Gene Therapy, 15:452-462",ACTIVE
116,CA,A1,CA 2863964 A1,066-699-836-844-77X,2013-08-15,2013,CA 2863964 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/066-699-836-844-77X,Patent Application,no,0,0,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,ACTIVE
117,CN,A,CN 104428009 A,186-469-462-978-972,2015-03-18,2015,CN 201380018970 A,2013-02-07,US 2013/0025234 W;;US 201261633287 P,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/186-469-462-978-972,Patent Application,no,2,8,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K48/00;;A61K35/76;;A61K35/761;;A61P3/00;;A61P17/14;;A61P21/00,,3,3,033-634-785-071-687;;057-205-038-511-760;;034-633-606-331-300,10.1038/sj.gt.3302833;;16871229;;10.1089/10430340260395910;;12490001;;10.1016/j.ymthe.2005.06.475;;16139571,"H YOSHINO, ET AL.: ""Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume"", 《GENE THERAPY》;;SIMON J. EASTMAN, ET AL.: ""Development of Catheter-Based Procedures for Transducing the Isolated Rabbit Liver with Plasmid DNA"", 《HUMAN GENE THERAPY》;;BRADLEY L. HODGES, ET AL.: ""Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver"", 《MOLECULAR THERAPY》",DISCONTINUED
118,NZ,A,NZ 715957 A,134-513-353-056-046,2017-08-25,2017,NZ 71595713 A,2013-02-07,US 201261633287 P;;NZ 62799213 A,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Disclosed is the use of a composition for manufacture of a medicament for increasing muscle production in an animal, increasing hair growth in an animal, increasing wool production in an animal, increasing growth of an animal, or for facilitating nutrient synthesis or utilization in an animal, wherein: -the composition comprises a delivery agent comprising a nucleic acid molecule that encodes a polypeptide that increases muscle production in an animal, increases hair growth in an animal, increases wool production in an animal, increases growth of an animal, or is involved in nutrient synthesis or utilization; -the composition is formulated for as suitable for injection of the delivery agent comprising the nucleic acid molecule into the parenchyma of a compartmentalized tissue, organ, or portion of a tissue or organ sufficient in size to compartmentalize and to effect administration of the composition; -the parenchyma does not include connective tissue, blood vessels, nerves or ducts; and -the compartmentalized tissue or organ or portion of a tissue or organ is isolated from the systemic circulation, whereby the arteries, veins, ducts and/or vessels servicing or traversing the tissue or organ or portion of the tissue or organ are blocked so that blood supply and flow to the tissue or organ or portion thereof is reduced or eliminated.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/134-513-353-056-046,Patent Application,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,DISCONTINUED
119,BR,A,BR 9806557 A,143-540-507-356-624,2000-09-12,2000,BR 9806557 A,1998-11-20,BR 9806557 A,1998-11-20,Cepa mutante de burkholderia sp e método de obtenção da cepa,"''CEPA MUTANTE DE <MU>BURKHOLDERIA<MV> SP E MéTODO DE OBTENçãO DE CEPA MUTANTE'', dita cepa apresentando interrupção em uma de suas vias metabólicas de utilização do propionato como fonte de energia, levando o desvio deste à unidades de hidroxivalerato (3HV), otimizando desta forma, sua utilização no processo de obtenção dos copolímeros P(3HB-co-3HV), apresentando uma porcentagem aumentada de P(3HV) no copolímero, tornando possível assim, uma maior variedade de aplicações industriais deste copolímero a um preço mais competitivo no mercado.",COOPERATIVA DE PRODUTORES DE C;;JOSE GREGORIO CABRERA GOMES,SILVA LUIZIA FERREIRA DA;;GOMES JOSE GREGORIO CABRERA,INSTITUTO DE PESQUISAS TECNOLOGICAS DE SAO PAULO S (2009-08-11),https://lens.org/143-540-507-356-624,Patent Application,no,0,0,2,2,0,,C12N1/20;;C12N15/01;;C12R1/01,,0,0,,,,EXPIRED
120,CU,A,CU 20918 A,021-131-183-152-607,1980-09-08,1980,CU 34713 A,1977-05-19,CU 34713 A,1977-05-19,MONITOR DE CORRIENTE DE CORROSION INSTANTANEA,,CENTRO INVEST QUIMICAS,CABRERA SANTOS GERARDO JOSE;;BORJA RODRIGUEZ ENRIQUE ANTONIO,,https://lens.org/021-131-183-152-607,Unknown,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
121,CU,A,CU 20916 A,035-863-513-476-439,1980-09-08,1980,CU 34711 A,1977-05-19,CU 34711 A,1977-05-19,INSTRUMENTO PARA REALIZAR MEDICIONES POTENCIOSTATICAS Y GALVANOSTATICAS,,CENTRO INVEST QUIMICAS,BORJA RODRIGUEZ ENRIQUE ANTONI;;CABRERA SANTOS GERARDO JOSE,,https://lens.org/035-863-513-476-439,Unknown,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
122,CU,A,CU 20917 A,048-606-397-997-45X,1980-09-08,1980,CU 34712 A,1977-05-19,CU 34712 A,1977-05-19,INSTRUMENTO PARA LA APLICACION CATODICA AUTOMATICA POR EL METODO DE CORRIENTE IMPUESTA,,INVEST QUIMICA CENTRO,BORJA RODRIGUEZ ENRIQUE ANTONI;;CABRERA SANTOS GERARDO JOSE,,https://lens.org/048-606-397-997-45X,Unknown,no,0,0,1,1,0,,C23F13/00;;G05F1/46,,0,0,,,,DISCONTINUED
123,ES,B1,ES 2565015 B1,079-543-542-475-279,2017-01-17,2017,ES 201400693 A,2014-08-27,ES 201400693 A,2014-08-27,Procedimiento para la obtención de una loción capilar en estado líquido para frenar la caída del cabello,,ACEVEDO HERNANDEZ PEDRO ANDRÉS;;CABRERA DONIZ JOSE MANUEL,ACEVEDO HERNANDEZ PEDRO ANDRÉS;;CABRERA DONIZ JOSE MANUEL,,https://lens.org/079-543-542-475-279,Granted Patent,no,0,0,3,3,0,A61K8/9789;;A61K8/9789;;A61Q7/00,A61K8/97,,0,0,,,,INACTIVE
124,SG,A,SG 10201609345Q A,092-539-777-017-562,2017-01-27,2017,SG 10201609345Q A,2013-02-07,US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/092-539-777-017-562,Unknown,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76,,0,0,,,,PENDING
125,AU,B2,AU 2013/216920 B2,177-567-732-968-436,2016-09-22,2016,AU 2013/216920 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/177-567-732-968-436,Granted Patent,no,2,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,6,6,065-310-853-569-912;;070-125-928-713-074;;034-633-606-331-300;;057-205-038-511-760;;033-634-785-071-687;;008-078-869-200-895,10.1248/bpb.29.1728;;16880633;;15812225;;10.1089/hum.2005.16.299;;10.1016/j.ymthe.2005.06.475;;16139571;;10.1089/10430340260395910;;12490001;;10.1038/sj.gt.3302833;;16871229;;18004400;;10.1038/sj.gt.3303079,"Fujita, S. et al., Biological & Pharmaceutical Bulletin, 2006, vol. 29, no. 8, pages 1728-1734.;;Ohashi, K. et al., Human Gene Therapy, 2005, vol. 16, no. 3 pages 299-306.;;Hodges, B. L. et al., Molecular Therapy, 2005, vol. 12, no. 6, pages 1043-1051.;;Eastman, S. J. et al., Human Gene Therapy, 2002, vol. 13, pages 2065-2077.;;Yoshino, H. et al., Gene Therapy, 2006, vol. 13, no. 24, pages 1696-1702.;;Fabre, J. W. et al., Gene Therapy, 2008, vol. 15, no. 6, pages 452-462.",INACTIVE
126,US,A1,US 2018/0055997 A1,004-091-807-207-574,2018-03-01,2018,US 201715804960 A,2017-11-06,US 201715804960 A;;US 201313815206 A;;US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,GLOBAL BIO THERAPEUTICS USA INC. (GBT USA) (2013-02-13);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2013-02-13),https://lens.org/004-091-807-207-574,Patent Application,yes,3,16,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61M5/178;;A61K35/76;;A61K48/00;;A61M5/00;;A61M5/30;;A61M39/00,,0,0,,,,DISCONTINUED
127,EA,B1,EA 033803 B1,021-160-732-469-352,2019-11-27,2019,EA 201400871 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,"COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY, COMPOSITIONS AND USES THEREOF","The invention relates to a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. The invention further relates to uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/021-160-732-469-352,Granted Patent,no,2,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/761;;A61K35/76;;A61K48/00,,6,6,057-205-038-511-760;;034-633-606-331-300;;008-078-869-200-895;;033-634-785-071-687;;070-125-928-713-074;;065-310-853-569-912,10.1089/10430340260395910;;12490001;;10.1016/j.ymthe.2005.06.475;;16139571;;18004400;;10.1038/sj.gt.3303079;;10.1038/sj.gt.3302833;;16871229;;15812225;;10.1089/hum.2005.16.299;;10.1248/bpb.29.1728;;16880633,"EASTMAN S J, ET AL.: ""Development of catheter-based procedures for transducing the isolated rabbit liver plasmid DNA"", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 13, 20 November 2002 (2002-11-20), GB, pages 2065 - 2077, XP002970584, ISSN: 1043-0342, DOI: 10.1089/10430340260395910;;HODGES, B.L. TAYLOR, K.M. CHU, Q. SCULL, S.E. SERRIELLO, R.G. ANDERSON, S.C. WANG, F. SCHEULE, R.K.: ""Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver"", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, CELL PRESS, US, vol. 12, no. 6, 1 December 2005 (2005-12-01), US, pages 1043 - 1051, XP005176612, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2005.06.475;;J W FABRE, GREHAN A, WHITEHORNE M, SAWYER G J, DONG X, SALEHI S, ECKLEY L, ZHANG X, SEDDON M, SHAH A M, DAVENPORT M, RELA M: ""Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava"", GENE THERAPY, MACMILLAN PRESS LTD., vol. 15, no. 6, 1 March 2008 (2008-03-01), pages 452 - 462, XP055058855, ISSN: 09697128, DOI: 10.1038/sj.gt.3303079;;YOSHINO H. ET AL.: ""Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume"", GENE THERAPY, vol. 13, no. 24, December 2006 (2006-12), pages 1696-1702, XP0055058858, ISSN: 0969-7128, page 1701, left-hand column, paragraph 3 - paragraph 4, abstract;;OHASHI K, NAKAI H, COUTO L B, KAY M A: ""Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver"", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 16, no. 3, 5 April 2005 (2005-04-05), GB, pages 299 - 306, XP002695090, ISSN: 1043-0342, DOI: 10.1089/hum.2005.16.299;;FUJITA S, EGUCHI A, OKABE J, HARADA A, SASAKI K, OGIWARA N, INOUE Y, ITO T, MATSUDA H, KATAOKA K, KATO A, HASEGAWA M, NAKANISHI M.: ""Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion"", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO., JP, vol. 29, no. 8, 1 August 2006 (2006-08-01), JP, pages 1728 - 1734, XP002695085, ISSN: 0918-6158, DOI: 10.1248/bpb.29.1728",ACTIVE
128,ES,U,ES 1205962 U,042-815-792-248-750,2018-02-21,2018,ES 201890002 U,2015-07-24,ES 2015070569 W,2015-07-24,ANTI-FALL SAFETY DEVICE FOR TOOLS USED FOR WORK AT HEIGHTS,"The invention relates to a device comprising a central element (2) from which the following elements extend: a first cable section (2) which has a means for attaching to an anchoring point on its free end; and a second cable section (6) which has a means for attaching to a tool-holding means (8) on its free end, where at least one of the cable sections (2), (6) is retractable along the length thereof, i.e. it can be extended from the central element (1), increasing the length thereof, and can be returned into the central element. The device allows tools to be held in a continuous manner that does not affect or prevent the normal use of the tools. It also ensures that the distance required between the tool and the anchoring point can be adapted, and even in the event of loss of control of the tool, prevents and breaks the fall, without causing damage or the like, and is easy to recuperate.",BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,,https://lens.org/042-815-792-248-750,Patent Application,no,0,0,3,3,0,A45F5/004;;A45F5/021;;A45F2200/0575,A45F5/02;;B23B29/12,,0,0,,,,INACTIVE
129,CU,A,CU 20919 A,094-246-705-172-540,1980-10-30,1980,CU 34714D A,1977-05-19,CU 34714D A,1977-05-19,INTEGRADOR DE LECTURA DIGITAL PARA ESTUDIOS ELECTROQUIM ICOS,,CENTRO INVEST QUIMICAS,CABRERA SANTOS GERARDO JOSE;;BORJA RODRIGUEZ ENRIQUE ANTONIO,,https://lens.org/094-246-705-172-540,Unknown,no,0,0,1,1,0,,H03K25/00,,0,0,,,,DISCONTINUED
130,MX,B,MX 367842 B,105-276-671-067-324,2019-09-09,2019,MX 2014009480 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF.,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO,"GLOBAL BIO THERAPEUTICS, INC. (2016-11-14)",https://lens.org/105-276-671-067-324,Granted Patent,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,ACTIVE
131,ES,Y,ES 1060567 Y,186-384-569-056-705,2006-01-16,2006,ES 200501507 U,2005-07-01,ES 200501507 U,2005-07-01,ESCALON CONVERTIBLE,,IDYC ROBOTICA S L,CABRERA RODRIGUEZ DIEGO;;DEL RIO CARRASCO JOSE LUIS,,https://lens.org/186-384-569-056-705,Limited Patent,no,0,0,2,2,0,,E04F11/04,,0,0,,,,EXPIRED
132,SG,A,SG 11201404741V A,009-400-547-237-715,2014-09-26,2014,SG 11201404741V A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,,GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/009-400-547-237-715,Unknown,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,PENDING
133,ES,U,ES 1205964 U,175-588-057-603-889,2018-02-21,2018,ES 201890003 U,2015-07-24,ES 2015070570 W,2015-07-24,MODULAR TREADMILL,"The invention relates to a modular treadmill characterised in that is formed by connecting a number of individual modules (1) that are assembled to one another, each module comprising: a series of inner rollers (4) disposed below the outer belt and, transversely to the direction of travel of the outer belt, a tension roller (6) at one end and, at the other end, a take-up roller (5) connected to a traction motor (2) by means of a transmission belt (3). All of the modules are covered by a single outer belt (7) and each of the modules (1) can be connected to an adjacent module by means of the take-up roller (5), such that a single traction motor can be used to move all of the modules forming part of the modular treadmill. The resulting treadmill can be adapted to different widths and spaces, as well as to different users, such that all users can train in the same way.",BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,,https://lens.org/175-588-057-603-889,Patent Application,no,0,0,3,3,0,A63B22/0235;;A63B22/0023;;A63B22/0257;;A63B22/0292;;A63B2225/102,A63B22/02,,0,0,,,,INACTIVE
134,BR,B1,BR 9806557 B1,082-295-649-721-642,2013-11-05,2013,BR 9806557 A,1998-11-20,BR 9806557 A,1998-11-20,CEPA MUTANTE DE BURKHOLDERIA SP E MÉTODO DE OBTENÇÃO DA CEPA,,,DA SILVA LUIZIANA FERREIRA;;GOMES JOSE GREGORIO CABRERA,INSTITUTO DE PESQUISAS TECNOLOGICAS DE SAO PAULO S (2009-08-11),https://lens.org/082-295-649-721-642,Granted Patent,no,0,0,2,2,0,,C12N15/01;;C12N1/20;;C12R1/01,,0,0,,,,EXPIRED
135,EP,A2,EP 3970734 A2,149-534-415-983-003,2022-03-23,2022,EP 21167237 A,2013-02-07,US 201261633287 P;;EP 13706130 A;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO GUSTAVO JOSE;;SEGURA PACHECO ANGELICA BLANCA,,https://lens.org/149-534-415-983-003,Patent Application,yes,69,0,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61P1/16;;A61P7/00,,185,159,043-531-114-966-819;;019-627-964-331-373;;106-660-583-644-550;;008-078-869-200-895;;000-072-066-141-272;;012-123-366-695-878;;038-673-520-650-409;;012-129-376-902-591;;067-603-709-961-17X;;114-703-023-726-096;;055-742-809-602-734;;062-788-544-041-210;;023-575-418-131-641;;080-129-061-250-097;;006-029-732-402-126;;145-716-192-643-117;;012-123-366-695-878;;066-034-312-854-84X;;046-458-163-541-455;;000-537-085-537-376;;011-184-870-074-176;;094-703-200-965-415;;140-705-500-027-848;;006-579-516-853-244;;042-197-182-119-323;;075-538-369-697-262;;014-592-773-689-568;;013-726-429-545-543;;069-375-144-224-631;;041-050-176-740-479;;031-781-347-077-349;;086-877-348-504-033;;080-769-210-275-665;;004-116-893-363-466;;015-349-205-971-06X;;083-097-272-313-524;;075-732-154-091-916;;019-552-127-353-985;;056-461-188-121-406;;038-087-893-633-108;;091-758-570-049-747;;092-417-835-880-431;;064-048-827-826-930;;001-738-526-943-108;;037-656-744-900-664;;034-033-950-596-544;;106-603-045-026-850;;016-424-552-126-032;;003-380-834-084-48X;;030-248-599-799-901;;048-152-749-258-818;;016-851-294-888-072;;010-646-200-754-815;;095-399-613-845-473;;033-253-568-025-220;;071-426-147-826-012;;025-778-228-640-640;;033-804-842-030-961;;166-149-388-372-252;;060-920-482-666-743;;041-081-762-433-73X;;000-703-365-392-272;;015-649-670-991-87X;;066-916-220-868-595;;007-854-771-178-901;;047-719-284-118-310;;061-166-732-363-142;;120-037-439-200-704;;045-680-536-606-460;;059-845-899-529-100;;060-569-205-222-495;;082-045-101-481-522;;080-194-745-279-238;;010-206-927-147-54X;;009-067-590-048-059;;067-222-985-577-896;;075-025-432-382-623;;004-487-094-299-632;;018-716-516-162-906;;001-076-475-435-735;;027-222-235-706-90X;;028-299-719-713-788;;049-436-722-340-572;;052-176-596-515-633;;135-114-522-815-727;;016-874-764-925-23X;;056-039-600-069-280;;063-428-650-235-497;;057-949-161-732-94X;;024-365-271-215-023;;036-840-721-356-161;;045-729-008-353-740;;022-506-836-404-416;;096-073-292-575-164;;088-736-219-499-999;;041-650-093-859-449;;056-196-064-755-971;;007-539-629-799-758;;097-421-754-978-369;;060-628-737-164-756;;009-852-354-311-269;;079-966-238-639-19X;;047-219-623-013-329;;042-607-068-936-492;;031-728-434-345-37X;;118-697-422-134-52X;;059-860-916-724-975;;038-178-441-399-799;;051-706-438-634-847;;065-063-689-244-933;;111-371-048-925-342;;029-991-841-452-638;;124-145-750-525-628;;013-086-199-764-405;;016-422-946-339-189;;022-797-429-791-642;;061-659-335-987-707;;047-468-694-151-03X;;018-701-464-127-33X;;015-740-822-611-627;;052-218-141-470-099;;018-453-014-574-044;;010-796-076-923-303;;064-803-508-025-788;;060-112-988-563-463;;000-952-882-917-871;;141-721-039-878-404;;065-892-485-270-812;;025-789-871-073-909;;139-345-160-524-722;;059-577-356-951-200;;094-336-962-179-152;;053-422-127-229-578;;006-029-732-402-126;;150-322-251-271-907;;084-396-070-853-182;;017-557-850-023-117;;014-272-363-998-744;;084-128-608-231-270;;048-591-954-565-854;;047-784-779-157-689;;068-127-345-226-159;;014-764-434-610-024;;070-826-217-997-762;;026-343-667-479-469;;112-831-151-480-442;;001-277-568-331-645;;035-207-752-278-848;;013-291-947-279-329;;017-762-631-280-466;;056-533-208-612-721;;038-010-735-348-939;;009-015-597-575-48X;;056-689-145-314-022;;001-857-609-013-135;;003-694-721-416-312;;009-646-280-826-528;;030-091-196-008-121;;079-120-664-904-225,10.1016/s0021-9258(18)54860-2;;1939050;;803646;;10.1038/254034a0;;10.1016/j.jss.2010.01.030;;20363441;;18004400;;10.1038/sj.gt.3303079;;20072160;;10.1038/gt.2009.167;;16941711;;10.1002/hep.21292;;19571403;;10.1248/bpb.32.1298;;10.1186/1750-1164-4-2;;20346153;;pmc2857838;;15062662;;10.1016/s0039-6109(03)00231-7;;10.1001/archsurg.136.5.569;;11343549;;pmc1191702;;10.1097/00000658-199903000-00010;;10077049;;10.1590/s0004-28032003000200013;;14762485;;10.1007/bf02469553;;6513212;;9502789;;10.1172/jci1031;;pmc508702;;11754147;;10.3349/ymj.2001.42.6.634;;pmc2013488;;5774262;;16941711;;10.1002/hep.21292;;pmc2174455;;10.1186/1479-0556-5-10;;17892546;;10.1016/0167-4781(91)90162-f;;1703441;;9144393;;10.1006/bbrc.1997.6361;;10.1016/s0014-5793(98)00284-1;;9563509;;10.1038/nbt0998-867;;9743122;;10.1016/s0764-4469(99)80003-1;;9879468;;10.1073/pnas.96.11.6417;;pmc26896;;10339602;;10.1073/pnas.97.1.354;;10618422;;pmc26667;;10.1006/mthe.2000.0124;;10985947;;10.1182/blood-2002-02-0589;;12176886;;21499295;;10.1038/nrg2988;;10.1038/mt.2008.257;;19050700;;pmc2835071;;10.2174/156652307780859062;;pmc2244792;;17584037;;10.1099/vir.0.003087-0;;19088268;;4415557;;10.1001/archsurg.1974.01360040068017;;10.1016/s0967-2109(02)00070-4;;12453699;;20545612;;10.2174/138945010792006771;;10.2174/1874-470211003010037;;pmc3606625;;20030624;;10.2174/1874467211003010037;;19388880;;10.1517/13543780902855316;;10.1097/bor.0b013e3282e6f495;;17917537;;17045403;;10.1016/j.bbcan.2006.08.008;;10.1093/jnci/djj228;;16788155;;16261406;;10.1007/s10549-005-9011-0;;10.1054/ijom.2002.0244;;12418561;;10.1016/s0090-4295(02)01589-3;;12231066;;10.1038/nrd984;;12509759;;14988743;;10.1016/j.addr.2009.04.018;;19422869;;17404600;;10.1038/cr.2007.13;;pmc391030;;3898082;;10.1073/pnas.82.18.6250;;8119968;;10.1016/s0021-9258(17)37593-2;;11434514;;10.1097/00008571-200106000-00011;;pmc2692765;;10.1002/jcp.21790;;19391103;;19180106;;pmc7097568;;10.1038/nrd2742;;10.1016/1074-5521(95)90043-8;;9383426;;10.1038/sj.gt.3300483;;9349431;;9383577;;10.1002/9780470515396.ch14;;9427689;;10.1182/blood.v91.2.371;;10.1182/blood.v91.2.371.371_371_382;;9384705;;9308362;;10.1016/s0079-6603(08)60032-x;;9352587;;10.1016/s0163-7258(97)00005-3;;9811704;;pmc110480;;10.1128/jvi.72.12.9706-9713.1998;;10.1128/mcb.9.11.4759-4766.1989;;2689864;;10.1128/mcb.9.11.4759;;pmc363624;;10936081;;10.1006/viro.2000.0468;;10.1126/science.275.5304.1320;;9036860;;10.1016/s0021-9258(18)89839-8;;6334081;;1727603;;10.1016/0042-6822(92)90082-z;;8254750;;10.1128/jvi.68.1.379-389.1994;;pmc236298;;10.1006/jmbi.1993.1687;;8263936;;1316261;;10.1007/978-3-642-75608-5_5;;7621239;;10.1128/jvi.61.4.1226-1239.1987;;3029418;;pmc254085;;10.1128/mcb.6.8.2872;;10.1128/mcb.6.8.2872-2883.1986;;pmc367855;;3023952;;10.1128/jvi.57.1.267-274.1986;;3001349;;pmc252723;;8267983;;10.1093/nar/11.17.6003;;6310523;;pmc326332;;10.1016/0014-5793(90)80287-s;;2365091;;8388142;;10.1016/0168-1702(93)90090-a;;10.1073/pnas.90.10.4601;;pmc46560;;7685107;;10.1089/hum.1998.9.13-1909;;9741429;;8942974;;10.1073/pnas.93.24.13565;;pmc19345;;10933960;;10.1006/mthe.2000.0062;;10673715;;10.1038/sj.gt.3301115;;15610604;;10.1089/hum.2004.15.1034;;10.1089/1043034042431146;;10.1128/jvi.71.9.6823-6833.1997;;9261407;;pmc191963;;10.1111/j.1749-6632.1999.tb09409.x;;10667212;;10.1016/0378-1119(91)90411-4;;1829048;;6098454;;10.1002/j.1460-2075.1984.tb02232.x;;pmc557789;;8648763;;10.1128/jvi.70.6.4173-4178.1996;;pmc190312;;9634089;;10.1099/0022-1317-79-6-1461;;10.1634/theoncologist.7-1-46;;11854546;;12108952;;10.2174/1566523013348689;;10.1358/dnp.2009.22.3.1354090;;19440556;;21301435;;10.1038/nbt.1769;;pmc53656;;10.1073/pnas.87.6.2211;;2156265;;12871018;;10.2174/1566523034578285;;8661429;;10.1006/viro.1996.0367;;pmc109378;;10.1128/jvi.72.1.309-319.1998;;9420229;;10.2210/pdb1lp3/pdb;;12192090;;pmc129358;;10.1073/pnas.182412299;;10.1089/hum.1994.5.7-793;;7981305;;pmc416542;;15163731;;10.1128/jvi.78.12.6381-6388.2004;;10.1038/nbt.1515;;19098898;;pmc2895694;;10.1038/mt.2009.71;;pmc2835208;;19367261;;1608446;;10.1038/357455a0;;10.1016/s0093-691x(97)82352-7;;10.1172/jci117016;;8113400;;pmc293889;;8123838;;10.1182/blood.v83.6.1467.1467;;10.1182/blood.v83.6.1467.bloodjournal8361467;;8494923;;10.1089/hum.1993.4.2-129;;8453268;;10.1016/s0959-437x(05)80350-8;;19652199;;10.1182/blood-2009-02-202085;;10753827;;10.1182/blood.v95.8.2499.008k35_2499_2504;;10.1182/blood.v95.8.2499;;10.1634/stemcells.19-3-236;;11359949;;10.1126/science.272.5259.263;;8602510;;15703485;;10.1089/hum.2005.16.17;;17177309;;10.1002/jmv.20767;;16953249;;10.1038/sj.gt.3302838;;10.1158/1078-0432.ccr-07-1441;;18316549;;10.1021/bp060348j;;17269667;;21306284;;10.1517/17425247.2011.554816;;19299149;;10.1016/j.bmc.2009.02.043;;19275541;;10.2174/157016309787581066;;pmc3108242;;pmc2796451;;10.1016/j.biomaterials.2009.10.012;;19850333;;8386298;;10.1016/0076-6879(93)17092-j;;3914646;;10.1016/0163-7258(85)90017-8;;22781695;;pmc3888062;;10.1038/nbt.2287;;10.1158/0008-5472.can-09-3567;;20484030;;12386834;;10.1038/sj.cgt.7700518;;pmc3443373;;21371164;;10.1111/j.1524-475x.2011.00669.x;;pmc2862532;;10.1038/mt.2009.309;;20068553;;10.1038/mt.2012.194;;pmc3464639;;23023051;;pmc3129800;;10.1038/mt.2011.34;;10.1016/s1525-0016(16)36909-x;;21386820;;10.1016/0005-2736(83)90504-7;;6824663;;10.1001/archopht.1987.01060030120040;;3827719;;10.1124/dmd.107.015966;;17627976;;10.1016/s0065-3527(08)60101-3;;pmc7131355;;107731;;pmc114056;;11152523;;10.1128/jvi.75.3.1516-1521.2001;;11754147;;10.3349/ymj.2001.42.6.634;;10.1007/978-1-4419-7107-4_23;;7584986;;10.1038/nm1195-1148;;12704424;;10.1038/sj.gt.3301953;;7533647;;10.1016/1074-7613(94)90074-4;;pmc1224049;;10.1042/bj20031730;;14683523;;pmc24382;;9826709;;10.1073/pnas.95.24.14384;;10.1073/pnas.061014598;;pmc31183;;11274433;;10.1038/sj.gt.3301422;;11571566;;15382177;;10.1002/hep.1840400422;;10.1002/hep.20404;;10.1038/sj.gt.3302121;;14625570;;9569229;;10.1165/ajrcmb.18.5.2874;;10.1016/j.expneurol.2006.09.007;;17069803;;10.1016/s1359-6446(04)03317-3;;15708533;;10.1016/s0093-691x(02)01263-3;;12499023;;6958982;;10.1038/300611a0;;pmc4881848;;11981562;;10.1038/nbt0502-484;;10.1089/fpd.2006.3.384;;17199520;;pmc404050;;10.1073/pnas.0308111101;;15067141;;pmc2976610;;10.1038/nbt1198;;16565727;;12548290;;10.1038/nbt783;;10.1038/90788;;11479566;;17195841;;10.1038/nbt1271;;pmc2813193;;15806099;;10.1038/nbt1078;;11799236;;10.1126/science.1065780;;7621262,"KOZAK, J. BIOL. CHEM., vol. 266, 1991, pages 19867 - 19870;;SHINEDELGARNO, NATURE, vol. 254, no. 5495, 1975, pages 34 - 38;;BIOCHEM., vol. 11, 1972, pages 1726;;KINOSHITA ET AL., J SURG. RES., vol. 160, 2010, pages 47 - 51;;FABRE ET AL., GENE THER., vol. 15, 2008, pages 452 - 62;;SAWYER ET AL., GEN THER., vol. 17, 2010, pages 560 - 4;;CRETTAZ ET AL., HEPATLOGY, vol. 44, 2006, pages 623 - 32;;FUMOTO ET AL., BIOL. PHARM. BULL., vol. 32, 2009, pages 1298 - 302;;CHOUILLARD ET AL., ANNALS OF SURGICAL INNOVATION AND RESEARCH, vol. 4, 2010, pages 2 - 12;;ABDALLA ET AL., SURG. CLIN. N. AM., vol. 84, 2004, pages 563 - 585;;BUELL ET AL., ARCH. SURG., vol. 136, 2001, pages 569 - 575;;BELGHITI ET AL., ANNALS OF SURGERY, vol. 229, 1999, pages 369 - 375;;CHOWDHURY, BSMMU J., vol. 3, 2010, pages 112 - 119;;CHAIB ET AL., ARQ GASTRONENTEROL., vol. 40, 2003, pages 131;;ABDALLA ET AL., SURG. CLIN. N. AM, vol. 84, 2004, pages 563 - 585;;KANEMATSU ET AL., JPN. J. SURG., vol. 14, 1984, pages 432 - 3;;MENG ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1462;;LIU ET AL., YONSEI MEDICAL JOURNAL, vol. 42, 2001, pages 634 - 645;;WILLMS-KRETSCHMERMAJNO, THE AMERICAN JOURNAL OF PATHOLOGY, vol. 54, 1969, pages 327;;TOREN ET AL., CAN. UROL. ASSOC., vol. 4, 2010, pages E133 - E136;;KO ET AL., KOREAN J. UROL., vol. 51, 2010, pages 8 - 14;;JOUNG ET AL., KOREAN J. UROL., vol. 28, 2007, pages 265 - 269;;CRETTAZ ET AL., HEPATOLOGY, vol. 44, 2006, pages 623 - 632;;SEGURA-PANCHECO ET AL., GENET. VACCINES THER., vol. 5, 2007, pages 10;;TITOMIROV, A. V. ET AL., BIOCHIM BIOPHYS ACTA, vol. 1088, 1991, pages 131 - 134;;MURAMATSU, T. ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 233, 1997, pages 45 - 49;;SUZUKI, T. ET AL., FEBS LETT, vol. 425, 1998, pages 436 - 440;;AIHARA, H.MIYAZAKI, J., NAT BIOTECHNOL, vol. 16, 1998, pages 867 - 870;;MIR, L. M. ET AL., C R ACAD SCI III, vol. 321, 1998, pages 893 - 899;;RIZZUTO, G. ET AL., PROC NATL ACAD SCI USA, vol. 96, 1999, pages 6417 - 6422;;GOTO, T. ET AL., PROC NATL ACAD SCI U S A, vol. 97, 2000, pages 354 - 359;;SOMIARI, S. ET AL., MOL THER, vol. 2, 2000, pages 178 - 187;;NATHWANI ET AL., BLOOD, vol. 100, 2002, pages 1662;;ROSEWELL ET AL., J. GENET. SYNDR. GENE THER., vol. S5, 2011, pages 1 - 16;;MINGOZZI ET AL., NATURE REVIEWS GENETICS, vol. 12, 2011, pages 341;;BRUNETTI-PIERRI ET AL., MOLECULAR THERAPY, vol. 17, 2009, pages 327 - 333;;CAMPOS ET AL., CURR. GENE THER., vol. 7, 2007, pages 189 - 204;;RUSSELL WC, J GEN. VIROL., vol. 90, 2009, pages 1 - 20;;HOFFMAN ET AL., AMA ARCH. SURG., vol. 109, 1974, pages 550 - 551;;THOMPSON ET AL., J. UROLOGY, vol. 177, 2006, pages 471 - 476;;BLAISDELL F.W., CARDIOVASCULAR SURGERY, vol. 10, 2002, pages 620 - 630;;BEST ET AL., PROC. SPIE, vol. 7932, 2011, pages 793202;;BAXLEYSERRA, CURR. DRUG TARGETS, vol. 11, no. 9, 2010, pages 1089 - 102;;LO, CURR. MOL. PHARMACOL., vol. 3, no. 1, 2010, pages 37 - 52;;BARAKATKAISER, EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. 5, 2009, pages 637 - 46;;TROJANOWSKAVARGA, CURR. OPIN. RHEUMATOL., vol. 19, no. 6, 2007, pages 568 - 73;;JIMENOHIDALGO, BIOCHIM. BIOPHYS. ACTA, vol. 1766, no. 2, 2006, pages 217 - 29;;FINCHRUBIN, J. NATL. CANCER INST., vol. 98, no. 12, 2006, pages 812 - 24;;LO ET AL., BREAST CANE. RES. TREAT., vol. 95, no. 3, 2006, pages 211 - 8;;SCHILEPHAKE, INT. J. ORAL MAXILLOFAC. SURG., vol. 31, no. 5, 2002, pages 469 - 84;;GEORGE, UROLOGY, vol. 60, no. 3, 2002, pages 115 - 21;;BREKKESANDLIE, NAT. REV. DRUG. DISCOV., vol. 2, no. l, 2003, pages 52 - 62;;MELLSTEDT, DRUGS TODAY, vol. 39, no. C, 2003, pages 1 - 16;;OHPARK, ADV. DRUG. DELIV. REV., vol. 61, no. 10, 2009, pages 850 - 62;;ZHENG ET AL., CELL RESEARCH, vol. 17, 2007, pages 303 - 306;;CANTRELL ET AL., PROC. NATL. ACAD. SCI, vol. 82, 1985, pages 6250 - 4;;GROSKREUTZ ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 6241 - 5;;GONG ET AL., PHARMACOGENTICS, vol. 11, 2001, pages 357 - 68;;GONDIRAO, J. CELL PHYSIOL., vol. 220, no. 2, 2009, pages 285 - 91;;WHITEHEAD ET AL., NAT. REV. DRUG. DISCOV., vol. 8, no. 2, 2009, pages 129 - 38;;SULLENGER, CHEM. BIOL., vol. 2, 1995, pages 249 - 253;;CZUBAYKO ET AL., GENE THERAPY, vol. 4, 1997, pages 943 - 9;;ROSSI, CIBA FOUND. SYMP., vol. 209, 1997, pages 195 - 204;;JAMESGIBSON, BLOOD, vol. 91, 1998, pages 371 - 82;;SULLENGER, CYTOKINES MOL. THER., vol. 2, 1996, pages 201 - 5;;HAMPEL, PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 58, 1998, pages 1 - 39;;CURCIO ET AL., PHARMACOL THERAPY, vol. 74, 1997, pages 317 - 32;;DMITRIEV ET AL., J. VIROL., vol. 72, 1998, pages 9706 - 7915;;HERBOMEL ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 9, 1989, pages 4759 - 4766;;HORWITZ, M. S. ET AL.: ""Virology"", 1990, RAVEN PRESS, article ""Adenoviridae and Their Replication"";;NEMEROW, VIROLOGY, vol. 274, 2000, pages 1 - 4;;BERGELSON ET AL., SCIENCE, vol. 275, 1997, pages 1320 - 1323;;ROBERTS ET AL., J. BIOL. CHEM., vol. 259, 1984, pages 13968 - 13975;;CHROBOCZEK ET AL., VIROLOGY, vol. 186, 1992, pages 280 - 285;;SPRENGEL ET AL., J. VIROL., vol. 68, 1994, pages 510 - 389;;CHILLON ET AL., J. VIROL., vol. 73, 1999, pages 6729 - 6742;;DAVISON ET AL., J. MOL. BIOL., vol. 234, 1993, pages 1308 - 1316;;MUZYCZKA, CURR. TOP. MICRO. IMMUNOL., vol. 158, 1992, pages 97 - 129;;JOLLY ET AL., CANCER GENE THERAPY, vol. 1, 1994, pages 51 - 64;;GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59 - 71;;DAVIDSON ET AL., J. VIROL., vol. 61, 1987, pages 1226 - 39;;MASSIE ET AL., MOL. CELL. BIOL., vol. 6, 1986, pages 2872 - 83;;HAJ-AHMAD ET AL., J. VIROL., vol. 57, 1986, pages 267 - 74;;ZHANG ET AL., BIOTECHNIQUES, vol. 15, 1993, pages 868 - 72;;BERKNER, NUC. ACIDS RES., vol. 11, 1983, pages 6003;;GHOSH-CHOUDHURY, DIOCHEM. BIOPHYS. RES. COMMUN., vol. 147, 1987, pages 964;;GILARDI ET AL., FEBS, vol. 267, 1990, pages 60;;MITTAL, VIRUS RES., vol. 28, 1993, pages 67;;YANG, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 4601;;FALLAUX ET AL., HUM. GENE THER., vol. 10, 1998, pages 1909 - 1907;;KOCHANEK ET AL., PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 13565 - 13570;;FISHER ET AL., J. VIROL., vol. 217, 1996, pages 8944 - 8960;;KRASNYKH ET AL., MOL. THER., vol. 1, 2000, pages 391 - 405;;WICKHAM ET AL., GENE THER., vol. 7, 2000, pages 110 - 4;;MIZUGUCHI ET AL., HUM. GENE THER., vol. 15, 2004, pages 1034 - 44;;CHIORINI ET AL., J. VIROL., vol. 71, 1997, pages 6641 - 6833;;CURIEL, ANN NY ACAD. SCI., vol. 886, 1999, pages 158 - 71;;ETO ET AL., INT. J. PHARM., vol. 354, 2008, pages 3 - 8;;LEVRERO ET AL., GENE, vol. 101, 1991, pages 195;;GRAHAM, EMBO J., vol. 3, 1984, pages 2917;;GORZIGLIA ET AL., J. VIROLOGY, vol. 70, 1996, pages 4173 - 4178;;VON SEGGERN ET AL., J. GEN. VIROL., vol. 79, 1998, pages 1461 - 1468;;VORBURGERHUNT, THE ONCOLOGIST, vol. 7, 2002, pages 46 - 59;;BREYER ET AL., CURRENT GENE THERAPY, vol. 1, 2001, pages 149 - 162;;SHIRAKAWA, DRUGS NEWS PERSPECTIVES, vol. 22, 2009, pages 140 - 5;;WANG ET AL., GENE THERAPY AND MOL. BIOLOGY, vol. 9, 2005, pages 291 - 300;;SHERIDAN, NATURE BIOTECHNOLOGY, vol. 29, 2011, pages 121;;KOTIN ET AL., PROC. NATL. ACAD. SCI., vol. 87, 1990, pages 2211 - 2215;;GRIMM ET AL., CURRENT GENE THERAPY, vol. 3, 2003, pages 281 - 304;;MURAMATSU ET AL., VIROL., vol. 221, 1996, pages 208 - 217;;RUTLEDGE ET AL., J. VIROL, vol. 72, 1998, pages 309 - 319;;GAO ET AL., PROC NATL. ACAD. SCI., vol. 99, 2002, pages 11854 - 11859;;KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;BURGER ET AL., MOL. THER., vol. 10, no. 2, 2004, pages 337 - 43;;""GenBank"", Database accession no. AY530629.1;;GAO ET AL., J. VIROL., vol. 78, 2004, pages 6381 - 6388;;FOUST ET AL., NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 59 - 65;;DUQUE ET AL., MOL. THER., vol. 17, 2009, pages 1187 - 1196;;MILLER, NATURE, vol. 357, 1992, pages 455 - 460;;LEE, THERIOGENOLOGY, vol. 47, 1997, pages 225;;CLOWES ET AL., J. CLIN. INVEST., vol. 93, 1994, pages 644 - 651;;KIEM ET AL., BLOOD, vol. 83, 1994, pages 1467 - 1473;;SALMONSGUNZBERG, HUMAN GENE THERAPY, vol. 4, 1993, pages 129 - 141;;GROSSMANWILSON, CURR. OPIN. IN GENETICS AND DEVEL., vol. 3, 1993, pages 110 - 114;;CASSANI ET AL., BLOOD, vol. 114, 2009, pages 3546 - 3556;;BUCHSHACHERWONG-STAAL, BLOOD, vol. 95, 2000, pages 2499 - 2504;;CHOI ET AL., STEM CELLS, vol. 19, 2001, pages 236 - 46;;NALDINE ET AL., SCIENCE, vol. 272, 1996, pages 263 - 267;;MANILLA ET AL., HUMAN GENE THERAPY, vol. 16, 2005, pages 17 - 25;;SACHDEVA ET AL., JOURNAL OF MEDICAL VIROLOGY, vol. 79, 2007, pages 118 - 26;;LIHUANG, GENE THERAPY, vol. 13, 2006, pages 1313 - 1319;;CHO ET AL., CLIN. CANCER. RES., vol. 14, 2008, pages 1310;;JIN ET AL., BIOTECHNOL. PROG., vol. 23, 2007, pages 32 - 41;;FRANZEN, EXPERT OPIN. DRUG. DELIV., vol. 8, no. 3, 2011, pages 281 - 98;;FARAJIWIPF, BIOORG. MED. CHEM., vol. 17, no. 8, 2009, pages 2950 - 62;;SAJJA ET AL., CURR. DRUG. DISCOV. TECHNOL., vol. 6, no. 1, 2009, pages 43 - 51;;HARRIS ET AL., BIOMATERIALS, vol. 31, 2010, pages 998 - 1006;;PATHAK ET AL., INT. J. NANOMEDICINE, vol. 3, 2008, pages 31 - 49;;COTTEN ET AL., METH. ENZYMOL., vol. 217, 1993, pages 618 - 644;;CLINE, PHARMAC. THER., vol. 29, 1985, pages 69 - 92;;QI ET AL., MODERN ONCOLOGY, vol. 14, 2006, pages 1295 - 1297;;RUSSELL ET AL., NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 658 - 670;;CERULLO ET AL., CANCER RES., vol. 70, 2010, pages 4297;;RASMUSSEN ET AL., CANCER GENE THER., vol. 9, 2002, pages 951 - 7;;BIODRUGS, vol. 16, 2002, pages 75 - 6;;BLUME ET AL., WOUND REPAIR REGEN, vol. 19, 2011, pages 302 - 308;;STERMAN ET AL., MOL. THER., vol. 18, 2010, pages 852 - 860;;YLA-HERTTUALA, MOL. THER., vol. 20, 2012, pages 1831 - 2;;FU ET AL., MOL. THER., vol. 19, 2011, pages 1025 - 33;;NEUMANN ET AL., GENE THERAPY AND MOLECULAR BIOLOGY, vol. 9, 2005, pages 61 - 76;;KIM ET AL., BIOCH. BIOPH. ACTA, vol. 728, 1983, pages 339 - 348;;ASSIL ET AL., ARCH OPHTHALMOL., vol. 105, 1987, pages 400;;SOMERS ET AL., DMD, vol. 35, 2007, pages 1797 - 1805;;""Methods in Cell Biology"", vol. XIII, 1976, ACADEMIC PRESS;;MANDEL ET AL., ADV. VIRUS. RES., vol. 23, 1978, pages 205 - 68;;VINCENT ET AL., J. VIROL., vol. 75, 2001, pages 1516 - 1521;;LIU ET AL., YONSEI MEDICAN JOURNAL, vol. 42, 2001, pages 634 - 645;;NAKAI H.: ""Molecular Pathology of Liver Diseases"", article ""Hepatic Gene Therapy"", pages: 343 - 370;;GROSSMAN ET AL., NAT. MED., vol. 1, 1995, pages 1148 - 1154;;SHICHIRI ET AL., GENE THER., vol. 10, 2003, pages 827 - 31;;YANG ET AL., IMMUNITY, vol. 1, 1994, pages 433 - 442;;YANG ET AL., J. VIROL., vol. 69, 1995, pages 2004 - 2015;;YANG ET AL., BIOCHEM. J., vol. 379, 2004, pages 89 - 97;;SONG ET AL., PROC. NATL. ACAD. SCI., vol. 95, 1998, pages 14384 - 14388;;SONG ET AL., PROC. NATL. ACAD. SCI., vol. 98, 2001, pages 4084 - 8;;SONG ET AL., GENE THER., vol. 8, 2001, pages 1299 - 1306;;SONG ET AL., HEPATOLOGY, vol. 40, 2004, pages 918 - 24;;ZHANG ET AL., GENE THERAPY, vol. 10, 2003, pages 2148 - 52;;FERKOL ET AL., AM. J. RESPIR. CELL MOL. BIOL., vol. 18, 1998, pages 591 - 601;;KIESEIER ET AL., EXP. NEUROL., vol. 203, 2007, pages 1 - 4;;MERCIER J.C.: ""Exploiting New Technologies in Animal Breeding"", 1987, OXFORD UNIVERSITY PRESS, pages: 122 - 131;;LILLICO ET AL., DRUG DISCOVERY TODAY, vol. 10, 2005, pages 191 - 196;;ECHELARD ET AL., BIOPHARM INTERNATIONAL, vol. 19, 2006, pages 36;;PRATHER ET AL., THERIOGENOLOGY, vol. 59, 2003, pages 115 - 123;;PALMITER ET AL., NATURE, vol. 300, 1982, pages 611 - 615;;VAN BERKEL ET AL., NAT. BIOTECH., vol. 20, 2002, pages 484 - 487;;MAGA ET AL., FOODBORNE PATHOG. DIS., vol. 3, 2006, pages 384 - 392;;SAEKI ET AL., PROC. NATL. ACAD. SCI., vol. 101, 2004, pages 6361 - 6366;;LAI ET AL., NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 435 - 436;;BROPHY ET AL., NATURE BIOTECHNOLOGY, vol. 21, 2003, pages 157 - 162;;GOLOVAN ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 741 - 745;;RICHT ET AL., NATURE BIOTECHNOLOGY, vol. 25, 2007, pages 132 - 138;;WALL ET AL., NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 445 - 451;;LAZARIS ET AL., SCIENCE, vol. 295, 2002, pages 472 - 476;;BASS ET AL., CANCER GENE THER., vol. 2, 1995, pages 97 - 104",DISCONTINUED
136,NZ,A,NZ 627992 A,097-577-684-925-181,2017-02-24,2017,NZ 62799213 A,2013-02-07,US 2013/0025234 W;;US 201261633287 P,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Disclosed is the use of a composition for manufacture of a medicament for treating a disease or condition treatable by a therapeutic nucleic acid, wherein: - the composition comprises a delivery agent comprising the therapeutic nucleic acid molecule; - the composition is formulated as suitable for injection of the delivery agent comprising the nucleic acid molecule into the parenchyma of a compartmentalised tissue, organ, or portion of a tissue or organ sufficient in size to compartmentalise and to effect administration of the composition; - the delivery agent is a virus or vector that comprises the therapeutic nucleic acid; - the composition contains 1 x 10^3 to 1 x 10^12 viral particles or vectors; - the composition contains a single dose of the virus or vector; - the parenchyma of a compartmentalised tissue, organ or portion thereof does not include connective tissue, blood vessels, nerves or ducts; - the disease or condition treatable by a therapeutic nucleic acid is selected from among a genetic deficiency, a disease or condition ameliorated by an exogenous gene product, and a disease or condition involving aberrant or altered expression of a gene product in its etiology; and - the compartmentalised tissue or organ or portion of a tissue or organ is isolated from the systemic circulation, wherein the organ is clamped whereby the arteries, veins, ducts and/or vessels servicing or traversing the tissue or organ or portion of the tissue or organ are blocked so that blood supply and flow to the tissue or organ or portion thereof is reduced or eliminated.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/097-577-684-925-181,Patent Application,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,DISCONTINUED
137,JP,A,JP 2017197579 A,116-924-541-243-352,2017-11-02,2017,JP 2017149223 A,2017-08-01,US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD FOR NUCLEIC ACID DELIVERY AND COMPOSITION AND USE THEREOF,"PROBLEM TO BE SOLVED: To provide a method for delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject, and also to provide a use and process for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ.SOLUTION: According to the present invention, a method comprises: (a) compartmentalizing a tissue or organ or portion of the tissue or organ from systemic circulation of the host; and (b) administering a delivered agent directly to the parenchyma of the tissue or organ or portion of the tissue or organ. Here, the delivered agent contains the nucleic acid molecule. Thus, the delivered agent enters parenchymal cells of the compartmentalized tissue or organ or portion of the tissue or organ. According to the present invention, there are also provided a method and use that can be used in the treatment of diseases and conditions and in industrial, agricultural, and veterinary applications. There is further provided a composition comprising an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.SELECTED DRAWING: None",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO,,https://lens.org/116-924-541-243-352,Patent Application,no,7,3,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K48/00;;A61K31/7088;;A61K31/7105;;A61K35/76;;A61K35/761;;A61K35/763;;A61K45/00;;A61K47/26;;A61P3/10;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P11/00;;A61P17/02;;A61P17/14;;A61P19/02;;A61P21/02;;A61P21/06;;A61P25/04;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00,,5,2,024-443-164-425-27X;;031-782-254-770-317,11054646;;10.1677/joe.0.1670315;;9497894;;10.1055/s-2007-979108,"GENE THER., 1998, VOL.5, NO.4, PP.459-464, JPN6016045062, ISSN: 0003776165;;J. ENDOCRINOL., 2000, VOL.167, NO.2, PP.315-320, JPN6016045064, ISSN: 0003776167;;INT. J. NANOMEDICINE, 2008, VOL.3, NO.1, PP.31-49, JPN6016045065, ISSN: 0003776168;;ANTICANCER RES., 2008, VOL.28, NO.2A, PP.665-672, JPN6018012660, ISSN: 0003776169;;HORM. METAB. RES., 1997, VOL.29, NO.12, PP.599-603, JPN6016045063, ISSN: 0003776166",INACTIVE
138,MX,A,MX 2014009480 A,114-564-848-103-435,2015-04-13,2015,MX 2014009480 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF.,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,AQUINO JOSE GUSTAVO CABRERA;;PACHECO BLANCA ANGELICA SEGURA,"GLOBAL BIO THERAPEUTICS, INC. (2016-11-14)",https://lens.org/114-564-848-103-435,Patent Application,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,ACTIVE
139,CA,C,CA 2863964 C,176-714-219-177-239,2021-10-26,2021,CA 2863964 A,2013-02-07,US 201261633287 P;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/176-714-219-177-239,Granted Patent,no,0,0,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K31/7088;;A61K35/76;;A61K38/17;;A61K48/00;;A61P21/06,,0,0,,,,ACTIVE
140,WO,A1,WO 2013/119880 A1,086-686-011-615-967,2013-08-15,2013,US 2013/0025234 W,2013-02-07,US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/086-686-011-615-967,Patent Application,yes,68,9,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,215,175,057-205-038-511-760;;034-633-606-331-300;;008-078-869-200-895;;033-634-785-071-687;;070-125-928-713-074;;065-310-853-569-912;;043-531-114-966-819;;019-627-964-331-373;;008-078-869-200-895;;000-072-066-141-272;;012-123-366-695-878;;038-673-520-650-409;;012-129-376-902-591;;114-703-023-726-096;;055-742-809-602-734;;062-788-544-041-210;;067-603-709-961-17X;;023-575-418-131-641;;080-129-061-250-097;;006-029-732-402-126;;145-716-192-643-117;;012-123-366-695-878;;066-034-312-854-84X;;046-458-163-541-455;;000-537-085-537-376;;011-184-870-074-176;;094-703-200-965-415;;140-705-500-027-848;;006-579-516-853-244;;042-197-182-119-323;;075-538-369-697-262;;014-592-773-689-568;;069-375-144-224-631;;041-050-176-740-479;;031-781-347-077-349;;086-877-348-504-033;;080-769-210-275-665;;004-116-893-363-466;;015-349-205-971-06X;;083-097-272-313-524;;075-732-154-091-916;;019-552-127-353-985;;056-461-188-121-406;;038-087-893-633-108;;091-758-570-049-747;;092-417-835-880-431;;064-048-827-826-930;;001-738-526-943-108;;067-990-525-630-096;;034-033-950-596-544;;106-603-045-026-850;;003-380-834-084-48X;;037-656-744-900-664;;030-248-599-799-901;;048-152-749-258-818;;016-851-294-888-072;;010-646-200-754-815;;095-399-613-845-473;;071-426-147-826-012;;025-778-228-640-640;;033-804-842-030-961;;041-081-762-433-73X;;000-703-365-392-272;;000-703-365-392-272;;015-649-670-991-87X;;066-916-220-868-595;;007-854-771-178-901;;011-669-985-502-084;;047-719-284-118-310;;044-309-620-870-157;;120-037-439-200-704;;044-486-712-598-717;;059-845-899-529-100;;060-569-205-222-495;;045-680-536-606-460;;082-045-101-481-522;;009-067-590-048-059;;067-222-985-577-896;;023-142-333-399-91X;;063-269-243-348-026;;004-487-094-299-632;;013-782-443-253-738;;085-697-375-509-476;;018-716-516-162-906;;001-076-475-435-735;;166-149-388-372-252;;027-222-235-706-90X;;042-884-013-683-243;;049-436-722-340-572;;000-143-673-637-259;;052-176-596-515-633;;135-114-522-815-727;;008-587-496-850-953;;016-874-764-925-23X;;056-039-600-069-280;;063-428-650-235-497;;024-365-271-215-023;;036-840-721-356-161;;045-729-008-353-740;;022-506-836-404-416;;096-073-292-575-164;;028-299-719-713-788;;046-469-152-144-976;;088-736-219-499-999;;072-793-259-948-998;;041-650-093-859-449;;056-196-064-755-971;;007-557-256-778-063;;007-539-629-799-758;;097-421-754-978-369;;060-628-737-164-756;;061-166-732-363-142;;009-852-354-311-269;;047-219-623-013-329;;042-607-068-936-492;;031-728-434-345-37X;;118-697-422-134-52X;;059-860-916-724-975;;082-353-235-883-222;;038-178-441-399-799;;033-471-592-816-052;;051-706-438-634-847;;065-063-689-244-933;;111-371-048-925-342;;029-991-841-452-638;;124-145-750-525-628;;013-086-199-764-405;;016-422-946-339-189;;022-797-429-791-642;;061-659-335-987-707;;018-701-464-127-33X;;094-742-476-378-715;;015-740-822-611-627;;052-218-141-470-099;;018-453-014-574-044;;010-796-076-923-303;;064-803-508-025-788;;060-112-988-563-463;;000-952-882-917-871;;141-721-039-878-404;;065-892-485-270-812;;139-345-160-524-722;;059-577-356-951-200;;094-336-962-179-152;;057-217-560-840-696;;053-422-127-229-578;;006-029-732-402-126;;150-322-251-271-907;;084-396-070-853-182;;017-557-850-023-117;;014-272-363-998-744;;084-128-608-231-270;;048-591-954-565-854;;047-784-779-157-689;;068-127-345-226-159;;014-764-434-610-024;;070-826-217-997-762;;026-343-667-479-469;;112-831-151-480-442;;078-805-074-628-262;;001-277-568-331-645;;035-207-752-278-848;;013-291-947-279-329;;017-762-631-280-466;;056-533-208-612-721;;038-010-735-348-939;;009-015-597-575-48X;;056-689-145-314-022;;001-857-609-013-135;;003-694-721-416-312;;009-646-280-826-528;;030-091-196-008-121;;079-120-664-904-225;;010-380-857-342-06X;;060-920-482-666-743,10.1089/10430340260395910;;12490001;;10.1016/j.ymthe.2005.06.475;;16139571;;18004400;;10.1038/sj.gt.3303079;;10.1038/sj.gt.3302833;;16871229;;15812225;;10.1089/hum.2005.16.299;;10.1248/bpb.29.1728;;16880633;;10.1016/s0021-9258(18)54860-2;;1939050;;803646;;10.1038/254034a0;;18004400;;10.1038/sj.gt.3303079;;20072160;;10.1038/gt.2009.167;;16941711;;10.1002/hep.21292;;19571403;;10.1248/bpb.32.1298;;10.1186/1750-1164-4-2;;20346153;;pmc2857838;;10.1001/archsurg.136.5.569;;11343549;;pmc1191702;;10.1097/00000658-199903000-00010;;10077049;;10.1590/s0004-28032003000200013;;14762485;;15062662;;10.1016/s0039-6109(03)00231-7;;10.1007/bf02469553;;6513212;;9502789;;10.1172/jci1031;;pmc508702;;11754147;;10.3349/ymj.2001.42.6.634;;pmc2013488;;5774262;;16941711;;10.1002/hep.21292;;pmc2174455;;10.1186/1479-0556-5-10;;17892546;;10.1016/0167-4781(91)90162-f;;1703441;;9144393;;10.1006/bbrc.1997.6361;;10.1016/s0014-5793(98)00284-1;;9563509;;10.1038/nbt0998-867;;9743122;;10.1016/s0764-4469(99)80003-1;;9879468;;10.1073/pnas.96.11.6417;;pmc26896;;10339602;;10.1073/pnas.97.1.354;;10618422;;pmc26667;;10.1006/mthe.2000.0124;;10985947;;10.1182/blood-2002-02-0589;;12176886;;10.1038/mt.2008.257;;19050700;;pmc2835071;;10.2174/156652307780859062;;pmc2244792;;17584037;;10.1099/vir.0.003087-0;;19088268;;4415557;;10.1001/archsurg.1974.01360040068017;;10.1016/s0967-2109(02)00070-4;;12453699;;20545612;;10.2174/138945010792006771;;10.2174/1874-470211003010037;;pmc3606625;;20030624;;10.2174/1874467211003010037;;19388880;;10.1517/13543780902855316;;10.1097/bor.0b013e3282e6f495;;17917537;;17045403;;10.1016/j.bbcan.2006.08.008;;10.1093/jnci/djj228;;16788155;;16261406;;10.1007/s10549-005-9011-0;;10.1054/ijom.2002.0244;;12418561;;10.1016/s0090-4295(02)01589-3;;12231066;;10.1038/nrd984;;12509759;;14988743;;10.1007/978-1-59745-554-1;;19350746;;17404600;;10.1038/cr.2007.13;;pmc391030;;3898082;;10.1073/pnas.82.18.6250;;11434514;;10.1097/00008571-200106000-00011;;10.1016/j.addr.2009.04.018;;19422869;;pmc2692765;;10.1002/jcp.21790;;19391103;;19180106;;pmc7097568;;10.1038/nrd2742;;10.1016/1074-5521(95)90043-8;;9383426;;10.1038/sj.gt.3300483;;9349431;;9383577;;10.1002/9780470515396.ch14;;9384705;;9308362;;10.1016/s0079-6603(08)60032-x;;9352587;;10.1016/s0163-7258(97)00005-3;;10936081;;10.1006/viro.2000.0468;;10.1126/science.275.5304.1320;;9036860;;10.1126/science.275.5304.1320;;9036860;;10.1016/s0021-9258(18)89839-8;;6334081;;1727603;;10.1016/0042-6822(92)90082-z;;8254750;;10.1128/jvi.68.1.379-389.1994;;pmc236298;;10.1128/jvi.73.3.2537-2540.1999;;pmc104501;;9971839;;10.1006/jmbi.1993.1687;;8263936;;10.1007/978-3-642-75608-5_3;;1582245;;7621239;;pmc254083;;3029417;;10.1128/jvi.61.4.1213-1220.1987;;10.1128/mcb.6.8.2872;;10.1128/mcb.6.8.2872-2883.1986;;pmc367855;;3023952;;10.1128/jvi.57.1.267-274.1986;;3001349;;pmc252723;;10.1128/jvi.61.4.1226-1239.1987;;3029418;;pmc254085;;8267983;;8388142;;10.1016/0168-1702(93)90090-a;;10.1073/pnas.90.10.4601;;pmc46560;;7685107;;10.1089/hum.1998.9.18-2709;;9874269;;pmc39129;;8650161;;10.1073/pnas.93.12.5731;;8942974;;10.1073/pnas.93.24.13565;;pmc19345;;8971024;;pmc190992;;10.1128/jvi.70.12.8944-8960.1996;;10.1006/viro.1996.0088;;8599194;;10933960;;10.1006/mthe.2000.0062;;10673715;;10.1038/sj.gt.3301115;;9811704;;pmc110480;;10.1128/jvi.72.12.9706-9713.1998;;15610604;;10.1089/hum.2004.15.1034;;10.1089/1043034042431146;;pmc192279;;9343173;;10.1128/jvi.71.11.8221-8229.1997;;10.1111/j.1749-6632.1999.tb09409.x;;10667212;;10.1016/j.ijpharm.2007.08.025;;17904316;;10.1016/0378-1119(91)90411-4;;1829048;;6098454;;10.1002/j.1460-2075.1984.tb02232.x;;pmc557789;;886304;;10.1099/0022-1317-36-1-59;;8648763;;10.1128/jvi.70.6.4173-4178.1996;;pmc190312;;9634089;;10.1099/0022-1317-79-6-1461;;10.1634/theoncologist.7-1-46;;11854546;;10.1358/dnp.2009.22.3.1354090;;19440556;;21301435;;10.1038/nbt.1769;;pmc53656;;10.1073/pnas.87.6.2211;;2156265;;12871018;;10.2174/1566523034578285;;8661429;;10.1006/viro.1996.0367;;10.1128/jvi.71.9.6823-6833.1997;;9261407;;pmc191963;;9882336;;pmc103955;;10.1128/jvi.73.2.1309-1319.1999;;pmc109378;;10.1128/jvi.72.1.309-319.1998;;9420229;;10196295;;pmc104178;;10.1128/jvi.73.5.3994-4003.1999;;10.2210/pdb1lp3/pdb;;12192090;;pmc129358;;10.1073/pnas.182412299;;10.1089/hum.1994.5.7-793;;7981305;;10.1016/j.ymthe.2004.05.024;;15294177;;pmc416542;;15163731;;10.1128/jvi.78.12.6381-6388.2004;;10.1038/nbt.1515;;19098898;;pmc2895694;;10.1038/mt.2009.71;;pmc2835208;;19367261;;1316261;;10.1007/978-3-642-75608-5_5;;1608446;;10.1038/357455a0;;10.1172/jci117016;;8113400;;pmc293889;;8123838;;10.1182/blood.v83.6.1467.1467;;10.1182/blood.v83.6.1467.bloodjournal8361467;;8494923;;10.1089/hum.1993.4.2-129;;8453268;;10.1016/s0959-437x(05)80350-8;;19652199;;10.1182/blood-2009-02-202085;;8254763;;10.1128/jvi.68.1.510-516.1994;;pmc236313;;10753827;;10.1182/blood.v95.8.2499.008k35_2499_2504;;10.1182/blood.v95.8.2499;;pmc191942;;9261386;;10.1128/jvi.71.9.6641-6649.1997;;10.1634/stemcells.19-3-236;;11359949;;10.1126/science.272.5259.263;;8602510;;15703485;;10.1089/hum.2005.16.17;;17177309;;10.1002/jmv.20767;;16953249;;10.1038/sj.gt.3302838;;10.1158/1078-0432.ccr-07-1441;;18316549;;10.1021/bp060348j;;17269667;;21306284;;10.1517/17425247.2011.554816;;19299149;;10.1016/j.bmc.2009.02.043;;pmc2796451;;10.1016/j.biomaterials.2009.10.012;;19850333;;8474352;;10.1016/0076-6879(93)17091-i;;8386298;;10.1016/0076-6879(93)17092-j;;3914646;;10.1016/0163-7258(85)90017-8;;22781695;;pmc3888062;;10.1038/nbt.2287;;10.1158/0008-5472.can-09-3567;;20484030;;12386834;;10.1038/sj.cgt.7700518;;pmc3443373;;21371164;;10.1111/j.1524-475x.2011.00669.x;;pmc2862532;;10.1038/mt.2009.309;;20068553;;10.1038/mt.2012.194;;pmc3464639;;23023051;;pmc3129800;;10.1038/mt.2011.34;;10.1016/s1525-0016(16)36909-x;;21386820;;10.1001/archopht.1987.01060030120040;;3827719;;10.1124/dmd.107.015966;;17627976;;10.1016/s0065-3527(08)60101-3;;pmc7131355;;107731;;pmc112758;;10.1128/jvi.73.8.6729-6742.1999;;10400771;;pmc114056;;11152523;;10.1128/jvi.75.3.1516-1521.2001;;11754147;;10.3349/ymj.2001.42.6.634;;10.1007/978-1-4419-7107-4_23;;7584986;;10.1038/nm1195-1148;;12704424;;10.1038/sj.gt.3301953;;7533647;;10.1016/1074-7613(94)90074-4;;pmc1224049;;10.1042/bj20031730;;14683523;;pmc24382;;9826709;;10.1073/pnas.95.24.14384;;10.1073/pnas.061014598;;pmc31183;;11274433;;10.1038/sj.gt.3301422;;11571566;;15382177;;10.1002/hep.1840400422;;10.1002/hep.20404;;10.1038/sj.gt.3302121;;14625570;;9569229;;10.1165/ajrcmb.18.5.2874;;10.1016/j.expneurol.2006.09.007;;17069803;;15294180;;10.1016/j.ymthe.2004.05.018;;10.1016/s1359-6446(04)03317-3;;15708533;;10.1016/s0093-691x(02)01263-3;;12499023;;6958982;;10.1038/300611a0;;pmc4881848;;11981562;;10.1038/nbt0502-484;;10.1089/fpd.2006.3.384;;17199520;;pmc404050;;10.1073/pnas.0308111101;;15067141;;pmc2976610;;10.1038/nbt1198;;16565727;;12548290;;10.1038/nbt783;;10.1038/90788;;11479566;;17195841;;10.1038/nbt1271;;pmc2813193;;15806099;;10.1038/nbt1078;;11799236;;10.1126/science.1065780;;7621262;;pmc363623;;10.1128/mcb.9.11.4750-4758.1989;;10.1128/mcb.9.11.4750;;2601696;;10.1128/mcb.9.11.4759-4766.1989;;2689864;;10.1128/mcb.9.11.4759;;pmc363624,"EASTMAN S J ET AL: ""Development of catheter-based procedures for transducing the isolated rabbit liver plasmid DNA"", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 13, 20 November 2002 (2002-11-20), pages 2065 - 2077, XP002970584, ISSN: 1043-0342, DOI: 10.1089/10430340260395910;;HODGES ET AL: ""Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 12, no. 6, 1 December 2005 (2005-12-01), pages 1043 - 1051, XP005176612, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2005.06.475;;J W FABRE ET AL: ""Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava"", GENE THERAPY, vol. 15, no. 6, 15 November 2007 (2007-11-15), pages 452 - 462, XP055058855, ISSN: 0969-7128, DOI: 10.1038/sj.gt.3303079;;YOSHINO H ET AL: ""Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume"", GENE THERAPY, vol. 13, no. 24, December 2006 (2006-12-01), pages 1696 - 1702, XP055058858, ISSN: 0969-7128;;OHASHI KAZUO ET AL: ""Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver"", HUMAN GENE THERAPY, vol. 16, no. 3, March 2005 (2005-03-01), pages 299 - 306, XP002695090, ISSN: 1043-0342;;FUJITA SHIGEO ET AL: ""Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion"", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 29, no. 8, August 2006 (2006-08-01), pages 1728 - 1734, XP002695085, ISSN: 0918-6158;;KOZAK, J BIOL. CHEM., vol. 266, 1991, pages 19867 - 19870;;SHINE; DELGARNO, NATURE, vol. 254, no. 5495, 1975, pages 34 - 38;;BIOCHEM., vol. 11, 1972, pages 1726;;KINOSHITA ET AL., J SURG. RES., vol. 60, 2010, pages 47 - 5 1;;FABRE ET AL., GENE THER., vol. 15, 2008, pages 452 - 62;;SAWYER ET AL., GEN THER., vol. 17, 2010, pages 560 - 4;;CRETTAZ ET AL., HEPTALOGY, vol. 44, 2006, pages 623 - 32;;FUMOTO ET AL., BIOL. PHARM. BULL., vol. 32, 2009, pages 1298 - 302;;CHOUILLARD ET AL., ANNALS OF SURGICAL INNOVATION AND RESEARCH, vol. 4, 2010, pages 2 - 12;;ABDALLA ET AL., SURG. CLIN. N. AM., vol. 84, 2004, pages 663 - 585;;BUELL ET AL., ARCH. SURG., vol. 136, 2001, pages 569 - 575;;BELGHITI ET AL., ANNALS OF SURGERY, vol. 229, 1999, pages 369 - 375;;CHOWDHURY, BSMMUJ., vol. 3, 2010, pages 112 - 119;;CHAIB ET AL., ARQ GASTRONENTEROL., vol. 40, 2003, pages 131;;ABDALLA ET AL., SURG. CLON. N. AM, vol. 84, 2004, pages 563 - 585;;KANEMATSU ET AL., JPN. J. SURG., vol. 14, 1984, pages 432 - 3;;MENG ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1462;;LIU ET AL., YONSEI MEDICAL JOURNAL, vol. 42, 2001, pages 634 - 645;;KRETSCHMER; MAJNO, THE AMERICAN JOURNAL OFPATHOLOGY, vol. 54, 1969, pages 327;;KRETSCHMER; MAJNO, THE AMERICAN JOURNAL OF PATHOLOGY, vol. 54, 1969, pages 327;;TOREN ET AL., CAN. UROL. ASSOC., vol. 4, 2010, pages E133 - E136;;KO ET AL., KOREAN J. UROL., vol. 51, 2010, pages 8 - 14;;JOUNG ET AL., KOREAN J. UROL., vol. 28, 2007, pages 265 - 269;;CRETTAZ ET AL., HEPATOLOGY, vol. 44, 2006, pages 623 - 632;;SEGURA-PANCHECO ET AL., GENET. VACCINES THER., vol. 5, 2007, pages 10;;TITOMIROV, A. V. ET AL., BIOCHIM BIOPHYS ACTA, vol. 1088, 1991, pages 131 - 134;;MURAMATSU, T. ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 233, 1997, pages 45 - 49;;SUZUKI, T. ET AL., FEBS LETT, vol. 425, 1998, pages 436 - 440;;AIHARA, H.; MIYAZAKI, J., NAT BIOTECHNOL, vol. 16, 1998, pages 867 - 870;;MIR, L. M. ET AL., C R ACAD SCI III, vol. 321, 1998, pages 893 - 899;;RIZZUTO, G. ET AL., PROC NATL ACAD SCI USA, vol. 96, 1999, pages 6417 - 6422;;GOTO, T. ET AL., PROC NATL ACAD SCI US A, vol. 97, 2000, pages 354 - 359;;SOMIARI, S. ET AL., MOL THER, vol. 2, 2000, pages 178 - 187;;NATHWANI ET AL., BLOOD, vol. 100, 2002, pages 1662;;ROSEWELL ET AL., J GENET. SYNDR. GENE THER., vol. S5, 2011, pages 1 - 16;;NINGOZI ET AL., NATURE REVIEWS GENETICS, vol. 12, 2011, pages 341;;BRUNETTI-PIERRI ET AL., MOLECULAR THERAPY, vol. 17, 2009, pages 327 - 333;;CAMPOS ET AL., CURR GENE THER., vol. 7, 2007, pages 189 - 204;;RUSSELL WC, J GEN. VIROL., vol. 90, 2009, pages 1 - 20;;HOFFMAN ET AL., AMA ARCH. SURG., vol. 109, 1974, pages 550 - 551;;THOMPSON ET AL., J. UROLOGY, vol. 177, 2006, pages 471 - 476;;BLAISDELL F.W., CARDIOVASCULAR SURGERY, vol. 10, 2002, pages 620 - 630;;BEST ET AL., PROC. SPIE, vol. 7932, 2011, pages 793202;;BAXLEY; SERRA, CURR. DRUG TARGETS, vol. 11, no. 9, 2010, pages 1089 - 102;;LO, CURR. MOL. PHARMACOL., vol. 3, no. 1, 2010, pages 37 - 52;;BRAKAT; KAISER, EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. 5, 2009, pages 637 - 46;;TROJANOWSKA; VARGA, CURR. OPIN. RHEUMATOL., vol. 19, no. 6, 2007, pages 568 - 73;;JIMENO; HIDALGO, BIOCHIM. BIOPHYS. ACTA, vol. 1766, no. 2, 2006, pages 217 - 29;;FINCH; RUBIN, J NATL. CANCER INST., vol. 98, no. 12, 2006, pages 812 - 24;;LO ET AL., BREAST CANC. RES. TREAT., vol. 95, no. 3, 2006, pages 211 - 8;;SCHILEPHAKE, INT. J ORAL MAXILLOFAC. SURG., vol. 31, no. 5, 2002, pages 469 - 84;;GEORGE, UROLOGY, vol. 60, no. 3, 2002, pages 115 - 21;;BREKKE; SANDLIE, NAT. REV. DRUG. DISCOV., vol. 2, no. 1, 2003, pages 52 - 62;;MELLSTEDT, DRUGS TODAY, vol. 39, 2003, pages 1 - 16;;DIMITROV, A. S.,: ""Therapeutic Antibodies: Methods and Protocols"", 2009, HUMANA PRESS;;ZHENG ET AL., CELL RESEARCH, vol. 17, 2007, pages 303 - 306;;CANTRELL ET AL., PROC. NATL. ACAD. SCI, vol. 82, 1985, pages 6250 - 4;;GROSKREUTZ ET AL., PROC. NATL. ACAD. SCI., vol. 269, 1994, pages 6241 - 5;;GONG ET AL., PHARMACOGENTICS, vol. 11, 2001, pages 357 - 68;;OH; PARK, ADV. DRUG. DELIV. REV., vol. 61, no. 10, 2009, pages 850 - 62;;GONDI; RAO, J CELL PHYSIOL., vol. 220, no. 2, 2009, pages 285 - 91;;WHITEHEAD ET AL., NAT. REV. DRUG. DISCOV., vol. 8, no. 2, 2009, pages 129 - 38;;SULLENGER, CHEM. BIOL., vol. 2, 1995, pages 249 - 253;;CZUBAYKO ET AL., GENE THERAPY, vol. 4, 1997, pages 943 - 9;;ROSSIE, CIBA FOUND. SYMP., vol. 209, 1997, pages 195 - 204;;FAMES; GIBSON, BLOOD, vol. 91, 1998, pages 371 - 82;;SULLENGER, CYTOKINES MOL. THER., vol. 2, 1996, pages 201 - 5;;HAMPEL, PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 58, 1998, pages 1 - 39;;CURCIO ET AL., PHARMACOL THERAPY, vol. 74, 1997, pages 317 - 32;;AUSUBEL ET AL.: ""Current Protocols in Molecular Biology"", 1998, JOHN WILEY & SONS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR;;HORWITZ, M. S. ET AL.: ""Virology, 2nd edition,"", 1990, RAVEN PRESS, article ""Adenoviridae and Their Replication"";;NEMEROW, VIROLOGY, vol. 274, 2000, pages 1 - 4;;BERGELSON ET AL., SCIENCE, vol. 275, 1997, pages 1320 - 1323;;BERGELSON ET AL., SCIENCE, vol. 275, 1997, pages 1320 - 1323;;ROELVINK ET AL., J. VIROL., vol. 72, 1998, pages 589 - 596;;ROBERTS ET AL., J BIOL. CHEM., vol. 259, 1984, pages 13968 - 13975;;CHROBOCZEK ET AL., VIROLOGY, vol. 186, 1992, pages 28 - 285;;SPRENGEL ET AL., J VIROL., vol. 68, 1994, pages 379 - 389;;CHILLON ET AL., J VIROL., vol. 73, 1999, pages 2537 - 2540;;DAVISON ET AL., J. MOL. BIOL., vol. 234, 1993, pages 1308 - 1316;;BERKNER, CURR. TOP. MICRO. IMMUNOL., vol. 158, 1992, pages 39 - 66;;JOLLY ET AL., CANCER GENE THERAPY, vol. 1, 1994, pages 51 - 64;;GRAHAM ET AL., J GEN. VIROL., vol. 36, 1977, pages 59 - 71;;BERKNER ET AL., J. VIROL., vol. 61, 1987, pages 1213 - 20;;MASSIE ET AL., MOL. CELL. BIOL., vol. 6, 1986, pages 2872 - 83;;HAJ-AHMAD ET AL., J. VIROL., vol. 57, 1986, pages 267 - 74;;DAVIDSON ET AL., J VIROL., vol. 61, 1987, pages 1226 - 39;;ZHANG ET AL., BIOTECHNIQUES, vol. 15, 1993, pages 868 - 72;;BERKNER, NUC. ACIDS RES., vol. 11, 1984, pages 6003;;GHOSHCHOUDHURY, DIOCHEM. BIOPHYS. RES. COMMUN., vol. 147, 1987, pages 964;;GILARDI, FEES, vol. 267, 1990, pages 60;;MITTAL, VIRUS RES., vol. 28, 1993, pages 67;;YANG, PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 4601;;MORRAL ET AL., HUM. GENE THER., vol. 10, 1998, pages 2709 - 2716;;KOCHANEK ET AL., PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 5731 - 5736;;PARKS ET AL., PROC. NATL. ACAD SCI., vol. 93, 1996, pages 13565 - 13570;;LIEBER ET AL., J VIROL., vol. 70, 1996, pages 8944 - 8960;;FISHER ET AL., J VIROL., vol. 217, 1996, pages 11 - 22;;KRASNYKH ET AL., MOL. THER., vol. 1, 2000, pages 391 - 405;;WICKHAM ET AL., GENE THER., vol. 7, 2000, pages 110 - 4;;DMITRIEV ET AL., J VIROL., vol. 72, 1998, pages 9706 - 12;;MIZUGUCHI ET AL., HUM. GENE THER., vol. 15, 2004, pages 1034 - 44;;WICKHAM ET AL., J VIROL., vol. 71, 1997, pages 8221 - 9;;CURIEL, ANN NYACAD. SCI., vol. 886, 1999, pages 158 - 71;;ETO ET AL., INT. J PHARM., 2008, pages 354 - 3,8;;LEVRERO ET AL., GENE, vol. 101, 1991, pages 195;;GRAHAM, EMBO J., vol. 3, 1984, pages 2917;;GRAHAM ET AL., J GEN. VIROL., vol. 36, 1977, pages 59;;FALLAUX ET AL., HUM. GENE THER., vol. 9, 1998, pages 1909 - 1907;;GORZIGLIA ET AL., J VIROLOGY, vol. 70, 1996, pages 4173 - 4178;;VON SEGGERN ET AL., J. GEN. VIROL., vol. 79, 1998, pages 1461 - 1468;;VORBURGER; HUNT, THE ONCOLOGIST, vol. 7, 2002, pages 46 - 59;;BREYER ET AL., CURRENT GENE THERAPY, vol. 1, 2001, pages 1;;SHIRAKAWA, DRUGS NEWS PERSPECTIVES, vol. 22, 2009, pages 140 - 5;;WANG ET AL., GENE THERAPY AND MOL. BIOLOGY, vol. 9, 2005, pages 291 - 300;;SHERIDAN, NATURE BIOTECHNOLOGY, vol. 29, 2011, pages 121;;MUZYCZKA, CURR. TOP. MICRO. IMMUNOL., vol. 158, 1992, pages 97 - 127;;KOTIN ET AL., PROC. NATL. ACAD SCI., vol. 87, 1990, pages 2211 - 2215;;GRIMM ET AL., CURRENT GENE THERAPY, vol. 3, 2003, pages 281 - 304;;MURAMATSU ET AL., VIROL., vol. 221, 1996, pages 208 - 217;;CHIORINI ET AL., J. VIRAL., vol. 71, 1997, pages 6823 - 6833;;CHIORINI, J. VIROL., vol. 73, 1999, pages 1309 - 1319;;RUTLEDGE ET AL., J. VIROL, vol. 72, 1998, pages 309 - 319;;XIAO ET AL., J VIROL., vol. 73, 1999, pages 3994 - 4003;;GAO ET AL., PROC NATL. ACAD. SCI., vol. 99, 2002, pages 11854 - 11859;;KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801;;BURGER ET AL., MOL. THER., vol. 10, 2004, pages 302 - 17;;GAO ET AL., J. VIROL., vol. 78, 2004, pages 6381 - 6388;;FOUST ET AL., NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 59 - 65;;DUQUE ET AL., MOL. THER., vol. 17, 2009, pages 1187 - 1196;;MUZYCZKA, CURR. TOP. MICRO. IMMUNOL., vol. 158, 1992, pages 97 - 129;;MILLER, NATURE, vol. 357, 1992, pages 455 - 460;;COFFIN ET AL.: ""Retorviruses"", 1997, COLD SPRING HARBOR LABORATORY PRESS;;CLOWES, J CLIN. INVEST., vol. 93, 1994, pages 644 - 651;;KIEM ET AL., BLOOD, vol. 83, 1994, pages 1467 - 1473;;SALMONS; GUNZBERG, HUMAN GENE THERAPY, vol. 4, 1993, pages 129 - 141;;GROSSMAN; WILSON, CURR. OPIN. IN GENETICS AND DEVEL., vol. 3, 1993, pages 110 - 114;;CASSANI ET AL., BLOOD, vol. 114, 2009, pages 3546 - 3556;;LEWIS; EMERMAN, J. VIROL., vol. 68, 1994, pages 510 - 6;;BUCHSHACHER; WONG-STAAL, BLOOD, vol. 95, 2000, pages 2499 - 2504;;BLOMER ET AL., J VIROL., vol. 71, 1997, pages 6641 - 9;;CHOI ET AL., STEM CELLS, vol. 19, 2001, pages 236 - 46;;NALDINE ET AL., SCIENCE, vol. 272, 1996, pages 263 - 267;;MANILLA ET AL., HUMAN GENE THERAPY, vol. 16, 2005, pages 17 - 25;;SACHDEVA ET AL., JOURNAL OF MEDICAL VIROLOGY, vol. 79, 2007, pages 118 - 26;;LI; HUANG, GENE THERAPY, vol. 13, 2006, pages 1313 - 1319;;CHO ET AL., CLIN. CANCER. RES., vol. 14, 2008, pages 1310;;JIN ET AL., BIOTECHNOL. PROG., vol. 23, 2007, pages 32 - 41;;FRANZEN, EXPERT OPIN. DRUG. DELIV., vol. 8, no. 3, 2011, pages 281 - 98;;FARAJI; WIPF, BIOORG. MED CHEM., vol. 17, no. 8, 2009, pages 2950 - 62;;SALIJA ET AL., CURR. DRUG. DISCOV. TECHNOL., vol. 6, no. 1, 2009, pages 43 - 51;;HARRIS ET AL., BIOMATERIALS, vol. 31, 2010, pages 998 - 1006;;PATHAK ET AL., INT. J. NANOMEDICINE, vol. 3, 2008, pages 31 - 49;;LOEFFLER; BEHR, METH. ENZYMOL., vol. 217, 1993, pages 599 - 618;;COHEN ET AL., METH. ENZYMOL., vol. 217, 1993, pages 618 - 644;;CLINE, PHARMAC. THER., vol. 29, 1985, pages 69 - 92;;WI ET AL., MODERN ONCOLOGY, vol. 14, 2006, pages 1295 - 1297;;RUSSEL ET AL., NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 658 - 670;;CERULLO ET AL., CANCER RES., vol. 70, 2010, pages 4297;;RASMUSSEN ET AL., CANCER GENE THER., vol. 9, 2002, pages 951 - 7;;BIODRUGS, vol. 16, 2002, pages 75 - 6;;BLUME ET AL., WOUND REPAIR REGEN., vol. 19, 2011, pages 302 - 308;;STERMAN ET AL., MOL. THER., vol. 18, 2010, pages 852 - 860;;YLA-HERTTUALA, MOL. THER., vol. 20, 2012, pages 1831 - 2;;FU ET AL., MOL. THER., vol. 19, 2011, pages 1025 - 33;;DAVID B. TROY,: ""Remington: The Science and Practice of Pharmacy, 21"" Edition,"", 2005, LIPPICOTT WILLIAMS & WILKINS;;KIMM ET AL., BIOCH. BIOPH. ACTA, vol. 728, 1983, pages 339 - 398;;ASSIL ET AL., ARCH OPHTHALMOL., vol. 105, 1987, pages 400;;SOMERS ET AL., DMD, vol. 35, 2007, pages 1797 - 1805;;DAVID M. PRESCOTT: ""Methods in Cell Biology"", vol. XIII, 1976, ACADEMIC PRESS, article ""Preparation of Isolated Rat Liver Cells"", pages: 29 - 83;;MANDEL ET AL., ADV. VIRUS. RES., vol. 23, 1978, pages 205 - 68;;HARVEY ET AL., J VIROL., vol. 73, 1999, pages 6729 - 6742;;VINCENT ET AL., J VIROL., vol. 75, 2001, pages 1516 - 1521;;LIU ET AL., YONSEI MEDICAN JOURNAL, vol. 42, 2001, pages 634 - 645;;NAKAI H.: ""Molecular Pathology of Liver Diseases"", article ""Hepatic Gene Therapy"", pages: 343 - 370;;GROSSMAN ET AL., NAT. MED., vol. 1, 1995, pages 1148 - 1154;;SHICHIRI ET AL., GENE THER., vol. 10, 2003, pages 827 - 31;;YANG ET AL., IMMUNITY, vol. 1, 1994, pages 433 - 442;;YANK ET AL., J VIROL., vol. 69, 1995, pages 2004 - 2015;;YANG ET AL., BIOCHEM. J, vol. 379, 2004, pages 89 - 97;;SONG ET AL., PROC. NATL. ACAD. SCI., vol. 95, 1998, pages 14384 - 14388;;SONG ET AL., PROC. NATL. ACAD SCI., vol. 98, 2001, pages 4084 - 8;;SONG ET AL., GENE THER., vol. 8, 2001, pages 1299 - 1306;;SONG ET AL., HEPATOLOGY, vol. 40, 2004, pages 918 - 24;;ZHANG ET AL., GENE THERAPY, vol. 10, 2003, pages 2148 - 52;;FERKOL ET AL., AM. J RESPIR. CELL MOL. BIOL., vol. 18, 1998, pages 591 - 601;;NEUMANN ET AL., GENE THERAPY AND MOLECULAR BIOLOGY, vol. 9, 2005, pages 61 - 76;;KIESEIER ET AL., EXP. NEUROL., vol. 203, 2007, pages 1 - 4;;JOHANSSON, MOL. THER., vol. 10, no. 2, 2004, pages 337 - 43;;MERCIER J.C.: ""Exploiting New Technologies in Animal Breeding"", 1987, OXFORD UNIVERSITY PRESS, pages: 122 - 131;;LILLICO ET AL., DRUG DISCOVERY TODAY, vol. 10, 2005, pages 191 - 196;;ECHELARD ET AL., BIOPHARM INTERNATIONAL, vol. 19, 2006, pages 36;;PRATHER ET AL., THERIOGENOLOGY, vol. 59, 2003, pages 115 - 123;;LEE, THERIOGENOLOGY, vol. 47, 1997, pages 25;;PALMITER ET AL., NATURE, vol. 300, 1982, pages 611 - 615;;VAN BERKEL ET AL., NAT. BIOTECH., vol. 20, 2002, pages 484 - 487;;MAGA ET AL., FOODBORNE PATHOG. DIS., vol. 3, 2006, pages 384 - 392;;SAEKI ET AL., PROC. NATL. ACAD SCI., vol. 101, 2004, pages 6361 - 6366;;LAI ET AL., NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 435 - 436;;BROPHY ET AL., NATURE BIOTECHNOLOGY, vol. 21, 2003, pages 157 - 162;;GOLOVAN ET AL., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 741 - 745;;RICHT ET AL., NATURE BIOTECHNOLOGY, vol. 25, 2007, pages 132 - 138;;WALL ET AL., NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 445 - 451;;LAZARIS ET AL., SCIENCE, vol. 295, 2002, pages 472 - 476;;BASS ET AL., CANCER GENE THER., vol. 2, 1995, pages 97 - 104;;HERBOMEL ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 9, 1989, pages 4750 - 4758;;TRONCHE ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 9, 1989, pages 4759 - 4766;;See also references of EP 2812012A1",PENDING
141,CN,A,CN 110917362 A,109-696-376-100-984,2020-03-27,2020,CN 201910870752 A,2013-02-07,US 201261633287 P;;CN 201380018970 A,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid moleculeto the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/109-696-376-100-984,Patent Application,no,2,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K48/00;;A61K35/76;;A61P3/10,,3,0,,,"H YOSHINO 等: ""Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume"", 《GENE THERAPY》;;（美）温泽尔: ""《医院内感染的预防与控制（第四版）》"", 31 May 2005;;BRADLEY L. HODGES 等: ""Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver"", 《MOLECULAR THERAPY》",DISCONTINUED
142,WO,A1,WO 2016/030550 A1,127-360-091-453-907,2016-03-03,2016,ES 2015000102 W,2015-08-07,ES 201400693 A,2014-08-27,METHOD FOR PRODUCING A HAIR LOTION IN A LIQUID STATE FOR SLOWING DOWN HAIR LOSS,"In a first phase, 150 grams of Canary balm and 1000 grams of water are mixed such that the composition comprises, in terms of weight, 87% water and 13% Cedronella canariensis (Canary balm), said mixture being brought to the boil until it reaches a temperature of at least 100°C, and left to boil for five minutes. The resulting mixture is then left to rest for 4 hours and is strained.",ACEVEDO HERNÁNDEZ PEDRO ANDRÉS;;CABRERA DONIZ JOSE MANUEL,ACEVEDO HERNÁNDEZ PEDRO ANDRÉS;;CABRERA DONIZ JOSE MANUEL,,https://lens.org/127-360-091-453-907,Patent Application,yes,1,0,3,3,0,A61K8/9789;;A61K8/9789;;A61Q7/00,A61K8/97;;A61Q7/00,,6,3,077-753-130-955-375;;140-943-338-720-727;;027-672-816-308-502,10.1002/ptr.2650050610;;10.1002/(sici)1099-1573(199609)10:6<541::aid-ptr900>3.3.co;2-h;;1434678;;10.1016/0378-8741(92)90045-s,"""ALGARITOFE (Cedronella canariensis)."", 2010, Retrieved from the Internet <URL:http://www.academiacanarialengua.org/palabra/algaritofe> [retrieved on 20151014];;SZLKSM.: ""Modern Herbalist Doctor Skin Expert."", ANTI-DANDRUFF SHAMPOO (CEDRONELLA OIL CONTROLLING, 2011, Retrieved from the Internet <URL:http:Hwww.jsqlk.com/html/ProductView.asp?id=152&SortID=162> [retrieved on 20151014];;LOPEZ-GARCIA, R E ET AL.: ""A preliminary study of Cedronella canariensis (L.) var. canariensis extracts for antiinflammatory and analgesic activity in rats and mice."", PHYTOTHERAPY RESEARCH, vol. 5, no. 6, 1991, pages 273 - 275, ISSN: 0951-418X;;LOPEZ-GARCIA, R E; ET AL.: ""Study of the hypoglycaemic, diuretic and cardiovascular activity of Cedronella canariensis var. canariensis (L.) W. & B."", PHYTOTHERAPY RESEARCH, vol. 10, no. 6, 1996, pages 541 - 543, ISSN: 0951-418X;;LOPEZ GARCIA, R E; HERNANDEZ PEREZ, M. ET AL.: ""Essential oils and antimicrobial activity of two varieties of Cedronella canariensis (L.) W. et B."", JOURNAL OF ETHNOPHARMACOLOGY, vol. 36, no. 3, 1992, pages 207 - 211, XP023745393, ISSN: 0378-8741, DOI: doi:10.1016/0378-8741(92)90045-S;;PEREZ DE PAZ, P L, PEREZ ALONSO, M J ET AL.: ""Variación morfológica and aceites esenciales of Cedronella canariensis (L.) Webb & Berthel (Labiatae)."", ANALES DEL JARDIN BOTÁNICO OF MADRID, vol. 54, no. 1, 1996, pages 303 - 307, ISSN: 0211-1322, Retrieved from the Internet <URL:http://dialnet.unirioja.es/servlet/articulo?codigo=70439>",PENDING
143,US,B2,US 9821114 B2,126-691-270-076-991,2017-11-21,2017,US 201313815206 A,2013-02-07,US 201313815206 A;;US 201261633287 P,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,GLOBAL BIO THERAPEUTICS USA INC. (GBT USA) (2013-02-13);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2013-02-13),https://lens.org/126-691-270-076-991,Granted Patent,yes,107,12,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K31/70;;A61K35/76;;A61K48/00;;A61M5/00;;A61M5/178;;A61M5/30;;A61M31/00;;A61M39/00,,331,243,117-071-389-370-553;;053-446-886-655-152;;027-481-107-296-64X;;004-559-520-459-492;;009-093-712-698-826;;009-652-838-411-630;;050-983-607-561-263;;062-441-802-266-891;;039-448-117-847-792;;001-939-001-941-194;;049-418-961-011-46X;;067-603-709-961-17X;;094-703-200-965-415;;045-330-695-303-344;;139-345-160-524-722;;083-097-272-313-524;;079-120-664-904-225;;004-116-893-363-466;;055-742-809-602-734;;000-703-365-392-272;;044-486-712-598-717;;044-309-620-870-157;;080-194-745-279-238;;080-769-210-275-665;;033-471-592-816-052;;060-112-988-563-463;;064-048-827-826-930;;057-949-161-732-94X;;056-689-145-314-022;;057-127-393-853-190;;069-375-144-224-631;;120-033-002-475-870;;038-178-441-399-799;;114-703-023-726-096;;007-557-256-778-063;;041-050-176-740-479;;106-603-045-026-850;;059-860-916-724-975;;010-796-076-923-303;;062-788-544-041-210;;060-304-024-308-368;;011-669-985-502-084;;046-469-152-144-976;;028-299-719-713-788;;013-086-199-764-405;;051-706-438-634-847;;012-129-376-902-591;;066-916-220-868-595;;052-218-141-470-099;;047-219-623-013-329;;069-172-260-344-323;;015-740-822-611-627;;012-123-366-695-878;;033-804-842-030-961;;049-436-722-340-572;;010-646-200-754-815;;045-680-536-606-460;;047-719-284-118-310;;026-916-714-168-600;;126-075-025-862-172;;166-149-388-372-252;;060-628-737-164-756;;057-205-038-511-760;;000-143-673-637-259;;008-078-869-200-895;;075-025-432-382-623;;061-659-335-987-707;;026-343-667-479-469;;044-296-640-290-256;;056-461-188-121-406;;085-697-375-509-476;;097-421-754-978-369;;022-797-429-791-642;;065-892-485-270-812;;088-637-282-545-034;;065-310-853-569-912;;038-673-520-650-409;;053-171-940-665-379;;007-539-629-799-758;;041-650-093-859-449;;020-466-750-257-711;;092-417-835-880-431;;012-635-293-318-332;;010-206-927-147-54X;;001-857-609-013-135;;030-248-599-799-901;;003-380-834-084-48X;;016-874-764-925-23X;;042-197-182-119-323;;008-587-496-850-953;;135-114-522-815-727;;022-506-836-404-416;;016-424-552-126-032;;084-396-070-853-182;;118-697-422-134-52X;;060-569-205-222-495;;025-778-228-640-640;;018-701-464-127-33X;;057-217-560-840-696;;010-380-857-342-06X;;034-633-606-331-300;;086-877-348-504-033;;070-667-119-680-432;;078-018-407-616-292;;133-710-763-147-377;;033-253-568-025-220;;019-552-127-353-985;;016-422-946-339-189;;078-805-074-628-262;;120-037-439-200-704;;117-437-825-121-283;;036-293-465-131-421;;023-575-418-131-641;;042-607-068-936-492;;112-831-151-480-442;;025-789-871-073-909;;106-660-583-644-550;;106-660-583-644-550;;096-312-053-601-842;;063-269-243-348-026;;045-729-008-353-740;;056-196-064-755-971;;043-531-114-966-819;;018-716-516-162-906;;009-015-597-575-48X;;030-091-196-008-121;;057-714-305-070-871;;079-966-238-639-19X;;006-835-572-249-543;;052-176-596-515-633;;082-353-235-883-222;;124-145-750-525-628;;013-782-443-253-738;;001-277-568-331-645;;006-029-732-402-126;;038-087-893-633-108;;015-349-205-971-06X;;094-742-476-378-715;;056-533-208-612-721;;094-336-962-179-152;;111-371-048-925-342;;059-845-899-529-100;;001-738-526-943-108;;080-129-061-250-097;;013-726-429-545-543;;140-705-500-027-848;;009-067-590-048-059;;027-222-235-706-90X;;112-809-790-791-414;;023-142-333-399-91X;;000-537-085-537-376;;096-073-292-575-164;;061-166-732-363-142;;150-322-251-271-907;;065-063-689-244-933;;014-592-773-689-568;;041-081-762-433-73X;;080-606-753-943-707;;037-656-744-900-664;;070-125-928-713-074;;013-291-947-279-329;;004-487-094-299-632;;084-394-479-101-649;;035-207-752-278-848;;064-803-508-025-788;;030-354-124-542-79X;;035-054-297-323-437;;054-232-793-229-624;;003-694-721-416-312;;006-579-516-853-244;;015-649-670-991-87X;;058-427-866-025-557;;077-732-802-070-113;;095-399-613-845-473;;018-453-014-574-044;;031-781-347-077-349;;088-736-219-499-999;;029-991-841-452-638;;038-010-735-348-939;;047-468-694-151-03X;;031-728-434-345-37X;;000-072-066-141-272;;091-758-570-049-747;;113-102-325-579-028;;066-034-312-854-84X;;010-381-832-570-327;;010-145-185-162-057;;005-999-695-960-532;;036-840-721-356-161;;017-557-850-023-117;;019-627-964-331-373;;024-365-271-215-023;;059-577-356-951-200;;075-538-369-697-262;;047-784-779-157-689;;014-764-434-610-024;;068-127-345-226-159;;048-591-954-565-854;;007-854-771-178-901;;000-952-882-917-871;;016-851-294-888-072;;071-426-147-826-012;;011-184-870-074-176;;035-859-542-295-459;;046-458-163-541-455;;046-764-007-270-871;;075-732-154-091-916;;060-920-482-666-743;;017-762-631-280-466;;025-862-381-450-36X;;053-422-127-229-578;;056-039-600-069-280;;063-428-650-235-497;;009-646-280-826-528;;048-152-749-258-818;;042-884-013-683-243;;001-076-475-435-735;;145-716-192-643-117;;072-793-259-948-998;;067-222-985-577-896;;014-272-363-998-744;;086-808-737-760-162;;084-128-608-231-270;;045-334-685-872-779;;141-721-039-878-404;;033-634-785-071-687;;082-045-101-481-522;;070-826-217-997-762;;034-033-950-596-544;;164-550-441-721-06X;;060-993-551-935-925;;031-098-073-697-690;;146-951-726-024-713;;101-006-563-776-849;;009-852-354-311-269;;047-438-114-479-016;;159-667-239-512-174;;024-443-164-425-27X;;026-332-146-317-807;;031-782-254-770-317;;003-129-885-683-212;;122-456-841-825-226;;001-597-826-889-688,10.1023/a:1007626627643;;10.1016/j.bpobgyn.2007.08.008;;17900991;;15062655;;10.1016/j.suc.2003.11.002;;15520458;;pmc528817;;10.1093/nar/gnh140;;10326848;;10.1016/s0002-9610(99)00043-4;;10.2174/1566523044578077;;15032617;;10.1126/scitranslmed.3000112;;20368179;;pmc2852878;;10.1038/ng1197-314;;9354796;;10.1089/hum.2006.17.601;;16776569;;10.1089/ten.2005.11.1718;;16411817;;10.3748/wjg.v13.i25.3487;;pmc4146785;;17659696;;15062662;;10.1016/s0039-6109(03)00231-7;;10.1038/nbt0998-867;;9743122;;17909539;;10.1038/sj.gt.3303001;;10.1001/archopht.1987.01060030120040;;3827719;;19388880;;10.1517/13543780902855316;;7621262;;20545612;;10.2174/138945010792006771;;pmc1191702;;10.1097/00000658-199903000-00010;;10077049;;10.1126/science.275.5304.1320;;9036860;;pmc254083;;3029417;;10.1128/jvi.61.4.1213-1220.1987;;10.1007/978-3-642-75608-5_3;;1582245;;10.1093/nar/11.17.6003;;6310523;;pmc326332;;10.1016/s0967-2109(02)00070-4;;12453699;;pmc191942;;9261386;;10.1128/jvi.71.9.6641-6649.1997;;pmc3443373;;21371164;;10.1111/j.1524-475x.2011.00669.x;;10.1038/nrd984;;12509759;;12108952;;10.2174/1566523013348689;;12548290;;10.1038/nbt783;;10.1089/10430340460732445;;14965376;;10.1038/mt.2008.257;;19050700;;pmc2835071;;10.1089/hum.2006.17.391;;16610927;;10753827;;10.1182/blood.v95.8.2499.008k35_2499_2504;;10.1182/blood.v95.8.2499;;10.1001/archsurg.136.5.569;;11343549;;10.1016/j.ymthe.2004.05.024;;15294177;;10.2174/156652307780859062;;pmc2244792;;17584037;;pmc391030;;3898082;;10.1073/pnas.82.18.6250;;19652199;;10.1182/blood-2009-02-202085;;10.1158/0008-5472.can-09-3567;;20484030;;10.1590/s0004-28032003000200013;;14762485;;pmc2964135;;10083197;;10.1016/s0041-1345(98)01715-1;;10.1128/jvi.73.3.2537-2540.1999;;pmc104501;;9971839;;9882336;;pmc103955;;10.1128/jvi.73.2.1309-1319.1999;;10.1128/jvi.71.9.6823-6833.1997;;9261407;;pmc191963;;10.1158/1078-0432.ccr-07-1441;;18316549;;10.1634/stemcells.19-3-236;;11359949;;10.1186/1750-1164-4-2;;20346153;;pmc2857838;;1727603;;10.1016/0042-6822(92)90082-z;;3914646;;10.1016/0163-7258(85)90017-8;;10.1172/jci117016;;8113400;;pmc293889;;21637339;;pmc3102659;;10.1371/journal.pone.0018205;;8386298;;10.1016/0076-6879(93)17092-j;;16941711;;10.1002/hep.21292;;9352587;;10.1016/s0163-7258(97)00005-3;;10.1111/j.1749-6632.1999.tb09409.x;;10667212;;10.1038/sj.gt.3300483;;9349431;;10.1128/jvi.61.4.1226-1239.1987;;3029418;;pmc254085;;10.1006/jmbi.1993.1687;;8263936;;10.1111/j.1464-410x.2005.05805.x;;16225524;;15972177;;10.1016/j.amjsurg.2004.10.007;;9811704;;pmc110480;;10.1128/jvi.72.12.9706-9713.1998;;10.1038/mt.2009.71;;pmc2835208;;19367261;;10.1089/10430340260395910;;12490001;;10.1016/j.ijpharm.2007.08.025;;17904316;;18004400;;10.1038/sj.gt.3303079;;10.1089/hum.1998.9.13-1909;;9741429;;19299149;;10.1016/j.bmc.2009.02.043;;9569229;;10.1165/ajrcmb.18.5.2874;;10.1073/pnas.88.19.8377;;pmc52511;;1656443;;10.1093/jnci/djj228;;16788155;;10.1006/viro.1996.0088;;8599194;;10.1038/nbt.1515;;19098898;;pmc2895694;;21306284;;10.1517/17425247.2011.554816;;pmc3129800;;10.1038/mt.2011.34;;10.1016/s1525-0016(16)36909-x;;21386820;;10.1093/ndt/gfl327;;16822795;;10.1248/bpb.29.1728;;16880633;;19571403;;10.1248/bpb.32.1298;;10.2174/1381612033454315;;12871186;;pmc416542;;15163731;;10.1128/jvi.78.12.6381-6388.2004;;10.2210/pdb1lp3/pdb;;12192090;;pmc129358;;10.1073/pnas.182412299;;10.2165/00063030-200216010-00010;;11909005;;10.1016/s0090-4295(02)01589-3;;12231066;;10.1016/s0006-291x(87)80164-x;;3663223;;10.1016/0014-5793(90)80287-s;;2365091;;10.1038/90788;;11479566;;pmc2692765;;10.1002/jcp.21790;;19391103;;11434514;;10.1097/00008571-200106000-00011;;8648763;;10.1128/jvi.70.6.4173-4178.1996;;pmc190312;;10.1073/pnas.97.1.354;;10618422;;pmc26667;;886304;;10.1099/0022-1317-36-1-59;;6098454;;10.1002/j.1460-2075.1984.tb02232.x;;pmc557789;;12871018;;10.2174/1566523034578285;;8119968;;10.1016/s0021-9258(17)37593-2;;7584986;;10.1038/nm1195-1148;;8453268;;10.1016/s0959-437x(05)80350-8;;10.1128/jvi.57.1.267-274.1986;;3001349;;pmc252723;;9308362;;10.1016/s0079-6603(08)60032-x;;pmc2796451;;10.1016/j.biomaterials.2009.10.012;;19850333;;pmc112758;;10.1128/jvi.73.8.6729-6742.1999;;10400771;;pmc363623;;10.1128/mcb.9.11.4750-4758.1989;;10.1128/mcb.9.11.4750;;2601696;;10.1016/j.ymthe.2005.06.475;;16139571;;4415557;;10.1001/archsurg.1974.01360040068017;;10.1038/mt.2008.86;;18461056;;21679994;;10.1016/j.juro.2011.03.162;;10.1021/bi00759a600;;9427689;;10.1182/blood.v91.2.371;;10.1182/blood.v91.2.371.371_371_382;;17045403;;10.1016/j.bbcan.2006.08.008;;10.1021/bp060348j;;17269667;;15294180;;10.1016/j.ymthe.2004.05.018;;7621239;;10.4111/kju.2007.48.3.265;;10.1208/s12248-008-9067-y;;19083101;;pmc2628207;;10.1007/bf02469553;;6513212;;8123838;;10.1182/blood.v83.6.1467.1467;;10.1182/blood.v83.6.1467.bloodjournal8361467;;10.1016/j.expneurol.2006.09.007;;17069803;;10.1016/0005-2736(83)90504-7;;6824663;;10.1016/j.jss.2010.01.030;;20363441;;10.1016/j.jss.2010.01.030;;20363441;;pmc2855471;;10.4111/kju.2010.51.1.8;;20414403;;pmc39129;;8650161;;10.1073/pnas.93.12.5731;;pmc53656;;10.1073/pnas.87.6.2211;;2156265;;10.1089/hum.1994.5.7-793;;7981305;;10.1016/s0021-9258(18)54860-2;;1939050;;10933960;;10.1006/mthe.2000.0062;;pmc2976610;;10.1038/nbt1198;;16565727;;11799236;;10.1126/science.1065780;;16501084;;10.1128/jvi.80.6.2747-2759.2006;;pmc1395461;;10.1016/s0093-691x(97)82352-7;;pmc2727081;;19718355;;10.1111/j.1477-2574.2009.00066.x;;10.1016/0378-1119(91)90411-4;;1829048;;8254763;;10.1128/jvi.68.1.510-516.1994;;pmc236313;;16953249;;10.1038/sj.gt.3302838;;8971024;;pmc190992;;10.1128/jvi.70.12.8944-8960.1996;;10.1016/s1359-6446(04)03317-3;;15708533;;11754147;;10.3349/ymj.2001.42.6.634;;16261406;;10.1007/s10549-005-9011-0;;10.2174/1874-470211003010037;;pmc3606625;;20030624;;10.2174/1874467211003010037;;8474352;;10.1016/0076-6879(93)17091-i;;10.1089/fpd.2006.3.384;;17199520;;10.1016/s0065-3527(08)60101-3;;pmc7131355;;107731;;15703485;;10.1089/hum.2005.16.17;;10.1128/mcb.6.8.2872;;10.1128/mcb.6.8.2872-2883.1986;;pmc367855;;3023952;;14988743;;9502789;;10.1172/jci1031;;pmc508702;;21499295;;10.1038/nrg2988;;10.1016/s0764-4469(99)80003-1;;9879468;;8388142;;10.1016/0168-1702(93)90090-a;;15610604;;10.1089/hum.2004.15.1034;;10.1089/1043034042431146;;10.1097/00000658-196203000-00010;;14475888;;pmc1466065;;10.1089/hum.1998.9.18-2709;;9874269;;9144393;;10.1006/bbrc.1997.6361;;8661429;;10.1006/viro.1996.0367;;1316261;;10.1007/978-3-642-75608-5_5;;10.1007/978-1-4419-7107-4_23;;10.1126/science.272.5259.263;;8602510;;10.1182/blood-2002-02-0589;;12176886;;10936081;;10.1006/viro.2000.0468;;10.1038/sj.gt.3302477;;15789062;;10.1016/j.addr.2009.04.018;;19422869;;15812225;;10.1089/hum.2005.16.299;;6958982;;10.1038/300611a0;;pmc4881848;;8942974;;10.1073/pnas.93.24.13565;;pmc19345;;18488414;;18393665;;10.2147/ijn.s2263;;pmc2526359;;10.2217/17435889.3.1.31;;10.1016/s0093-691x(02)01263-3;;12499023;;12386834;;10.1038/sj.cgt.7700518;;12414631;;10.1038/sj.cgt.7700539;;12522437;;pmc7091735;;0008361167;;10.1006/jsre.1993.1066;;8361167;;17195841;;10.1038/nbt1271;;pmc2813193;;10.1073/pnas.96.11.6417;;pmc26896;;10339602;;10.1016/s0021-9258(18)89839-8;;6334081;;pmc110119;;10.1128/jvi.72.10.7909-7915.1998;;9733828;;10.4172/2157-7412.s5-001;;9383577;;10.1002/9780470515396.ch14;;22781695;;pmc3888062;;10.1038/nbt.2287;;10.1099/vir.0.003087-0;;19088268;;pmc109378;;10.1128/jvi.72.1.309-319.1998;;9420229;;17177309;;10.1002/jmv.20767;;pmc404050;;10.1073/pnas.0308111101;;15067141;;19275541;;10.2174/157016309787581066;;pmc3108242;;8494923;;10.1089/hum.1993.4.2-129;;20072160;;10.1038/gt.2009.167;;10.1054/ijom.2002.0244;;12418561;;10.1016/s0091-679x(08)61797-5;;177845;;pmc2174455;;10.1186/1479-0556-5-10;;17892546;;15336648;;10.1016/j.ymthe.2004.05.029;;pmc1143681;;15919903;;10.1128/jvi.79.12.7478-7491.2005;;10.1128/jvi.78.10.5368-5381.2004;;15113916;;pmc400378;;21301435;;10.1038/nbt.1769;;12704424;;10.1038/sj.gt.3301953;;803646;;10.1038/254034a0;;10.1358/dnp.2009.22.3.1354090;;19440556;;10.1124/dmd.107.015966;;17627976;;10.1006/mthe.2000.0124;;10985947;;10.1073/pnas.061014598;;pmc31183;;11274433;;15382177;;10.1002/hep.1840400422;;10.1002/hep.20404;;10.1038/sj.gt.3301422;;11571566;;pmc24382;;9826709;;10.1073/pnas.95.24.14384;;8254750;;10.1128/jvi.68.1.379-389.1994;;pmc236298;;pmc2862532;;10.1038/mt.2009.309;;20068553;;10.1016/1074-5521(95)90043-8;;9383426;;9384705;;10.1016/s0014-5793(98)00284-1;;9563509;;17222613;;10.1016/j.juro.2006.09.036;;10.1016/0167-4781(91)90162-f;;1703441;;10.5489/cuaj.936;;20944792;;pmc2950775;;10.1097/bor.0b013e3282e6f495;;17917537;;10.1128/mcb.9.11.4759-4766.1989;;2689864;;10.1128/mcb.9.11.4759;;pmc363624;;11981562;;10.1038/nbt0502-484;;17657152;;10.1159/000103658;;pmc114056;;11152523;;10.1128/jvi.75.3.1516-1521.2001;;9634089;;10.1099/0022-1317-79-6-1461;;10.1634/theoncologist.7-1-46;;11854546;;15806099;;10.1038/nbt1078;;19180106;;pmc7097568;;10.1038/nrd2742;;pmc192279;;9343173;;10.1128/jvi.71.11.8221-8229.1997;;10673715;;10.1038/sj.gt.3301115;;pmc2013488;;5774262;;10196295;;pmc104178;;10.1128/jvi.73.5.3994-4003.1999;;10.1073/pnas.90.10.4601;;pmc46560;;7685107;;7533647;;10.1016/1074-7613(94)90074-4;;pmc188865;;10.1128/jvi.69.4.2004-2015.1995;;7884845;;pmc1224049;;10.1042/bj20031730;;14683523;;11841607;;10.1046/j.1523-1755.2002.0610s1016.x;;10.1038/mt.2012.194;;pmc3464639;;23023051;;10.1038/sj.gt.3302833;;16871229;;8267983;;10.1038/sj.gt.3302121;;14625570;;17404600;;10.1038/cr.2007.13;;8732161;;10.1117/12.873566;;18707713;;10.1016/j.juro.2008.06.018;;5091817;;11231461;;10.1067/msy.2001.111697;;1608446;;10.1038/357455a0;;10.1002/jgm.469;;14716673;;10.1016/s1525-0016(16)33932-6;;11054646;;10.1677/joe.0.1670315;;9614569;;10.1038/sj.gt.3300617;;9497894;;10.1055/s-2007-979108;;1316145;;21850051;;10.1038/gt.2011.119;;10.2174/138161211797247532;;21774769,"Kay et al, Nature Genetics, 2000, 24:257-260.;;David, Best Practice and Research Clinical Obstetrics and Gynaecology, 2008, 22:203-218.;;Gagner et al, Surg Clin N Am, 2004, 84:451-462.;;Schiffelers et al, Nucleic Acids Research, 2004, 32:e149.;;Jiao et al, The American Journal of Surgery, 1999, 177:303-306.;;Papadakis et al, Current Gene Therapy, 2004, 4:89-113.;;Kota et al, Sci Transl Med, 2009, 6ra15.;;Kafri et al, Nature Genetics, 1997, 17:314-317.;;Berraondo et al, Human Gene Therapy, 2006, 17:601-610.;;Bruns et al, Tissue Engineering, 2005, 11:1718-1726.;;Kobayashi et al., 2007, World Journal of Gastroenterology, vol. 13, No. 25, p. 3487-3492.;;Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, mailed on Jun. 19, 2013, 2 pages.;;Abdalla et al., “Hepatic vascular occlusion: which technique?” Surg. Clin. N. Am., 84:563-585 (2004).;;Adenovirus Wiki, “Human adenovirus genome sequences and annotations,” Published on Dec. 1, 2010 [online][retrieved on Mar. 21, 2013] Retrieved from:<URL:binf.gmu.edu/wiki/index.php [2 pages].;;Aihara, H. and Miyazaki, J., “Gene transfer into muscle by electroporation in vivo.” Nat Biotechnol 16: 867-870 (1998).;;Alexander et al. (2007) “Progress and prospects: gene therapy clinical trials (part 1),” Gene Ther. 14(20):1439-1447 (2007).;;Assil et al., “Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye.” Arch Ophthalmol. 105:400-403 (1987).;;Barakat, M. and P. Kaiser, “VEGF inhibitors for the treatment of neovascular age-related macular degeneration.” Expert Opin. Investig. Drugs 18(5):637-646 (2009).;;Bass et al., “Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo.” Cancer Gene Ther., 2:97-104 (1995).;;Baxley, S. and R. Serra, “Inhibiting breast cancer progression by exploiting TGFbeta signaling.” Curr. Drug Targets 11(9):1089-1102 (2010).;;Belghiti et al., “Continuous versus intermittent portal triad clamping for liver resection: a controlled study.” Annals of Surgery, 229:369-375 (1999).;;Bergelson et al., “Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5,” Science 275:1320-1323 (1997).;;Berkner et al., “Abundant expression of polyomavirus middle T antigen and dihydrofolate reductase in an adenovirus recombinant,” J. Virol. 61:1213-1220 (1987).;;Berkner et al., “Expression of heterologous sequences in adenoviral vectors.” Curr. Top. Micro. Immunol., 158:39-66 (1992).;;Berkner et al., “Generation of adenovirus by transfection of plasmids,” Nuc. Acids Res. 11:6003-6020 (1983).;;Blaisdell et al., “The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review,” Cardiovascular Surgery, 10:620-630 (2002).;;Blomer et al., “Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector,” J. Virol., 71:6641-6449 (1997).;;Blume et al., “Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers,” Wound Repair Regen., 19:302-308 (2011).;;Brekke, O. and I. Sandlie, “Therapeutic antibodies for human diseases at the dawn of the twenty-first century.” Nat. Rev. Drug. Discov. 2(1):52-62 and Correction (2003).;;Breyer et al., “Adenoviral vector-mediated gene transfer for human gene therapy,” Current Gene Therapy, 1:149-162 (2001).;;Brophy et al., Cloned transgenic cattle produce milk with higher levels of beta-casein and kappa-casein, Nature Biotechnology, 21:157-162 (2003).;;Brunetti-Pierri et al., “Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates,” Hum Gene Ther.15(1):35-46 (2004).;;Brunetti-Pierri et al., “Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates,” Molecular Therapy, 17:327-333 (2009).;;Brunetti-Pierri et al., “Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates,” Hum Gene Ther. 17:391-404 (2006).;;Buchshacher, G. and F. Wong-Staal, “Development of lentiviral vectors for gene therapy for human diseases,” Blood, 95:2499-2504 (2000).;;Buell et al., “Is any method of vascular control superior in hepatic resection of metastatic cancers? Longmire clamping, pringle maneuver, and total vascular isolation,” Arch. Surg., 136:569-575.;;Burger et al., “Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system,” Mol. Ther., 10:302-317 (2004).;;Campos et al., “Current advances and future challenges in Adenoviral vector biology and targeting.” Curr. Gene Ther., 7:189-204 (2007).;;Cantrell et al., “Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor,” Proc. Natl. Acad. Sci, 82:6250-6254 (1985).;;Cassani et al., “Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy,” Blood, 114:3546-3556 (2009).;;Cerullo et al., “Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients,” Cancer Res., 70:4297-4309 (2010).;;Chaib et al., “The main indications and techniques for vascular exclusion of the liver,” Arq Gastronenterol., 40:131-136 (2003).;;Chan et al., “Surgical management of primary hepatocellular carcinoma,” Hepatic Surgery, Hesham Abdeldayem (Ed.), p. 301-326 (2013).;;Chia et al., “Adenoviral-mediated gene delivery to liver isografts: improved model of ex vivo gene transfer,” Transplant Proc. 31:475-476 (1999).;;Chillon et al. (1999) “Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C,” J. Virol., 73:2537-2540 (1999).;;Chiorini et al., “Cloning and characterization of adeno-associated virus type 5,” J. Virol., 73:1309-1319 (1999).;;Chiorini et al., “Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles,” J. Virol., 71:6823-6833 (1997).;;Cho et al., “Therapeutic nanoparticles for drug delivery in cancer,” Clin. Cancer. Res., 14:1310-1316 (2008).;;Choi et al., “Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells,” Stem Cells, 19:236-246 (2001).;;Chouillard et al., “Vascular clamping in liver surgery: physiology, indications and techniques,” Annals of Surgical Innovation and Research, 4:2, 12 pages (2010).;;Chowdhury et al., “Techniques for liver resection,” BSMMU J., 3:112-119 (2010).;;Chroboczek et al., “The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2,” Virology, 186:280-285 (1992).;;Cline, M., “Perspectives for gene therapy: inserting new genetic information into mammalian cells by physical techniques and viral vectors,” Pharmac. Ther. 29:69-92 (1985).;;Clowes et al., “Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes,” J. Clin. Invest. 93:644-651 (1994).;;Corjon et al., “Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction,” PLoS One. 6:e18205, 19 pages.;;Cotten et al., “Receptor-mediated transport of DNA into eukaryotic cells,” Meth. Enzymol. 217:618-644 (1993).;;Crettaz et al., “Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice,” Hepatology, 44:623-632 (2006).;;Curcio et al., “Oligonucleotides as modulators of cancer gene expression,” Pharmacol Therapy, 74:317-332 (1997).;;Curiel, D., “Strategies to adapt adenoviral vectors for targeted delivery,” Ann NY Acad. Sci., 886:158-171 (1999).;;Czubayko et al., “Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation,” Gene Therapy, 4:943-949 (1997).;;Davidson et al., “Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector,” J. Virol. 61:1226-1239 (1987).;;Davison et al., “The DNA sequence of adenovirus type 40,” J. Mol. Biol., 234:1308-1316 (1993).;;Denardi et al., “Nephron-sparing surgery for renal tumours using selective renal parenchymal clamping,” BJU Int. 2005 96:1036-1039 (2005).;;Dixon et al., “Vascular occlusion to decrease blood loss during hepatic resection,” Am J Surg. 190:75-86 (2005).;;Dmitriev et al., “An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism,” J. Virol., 72:9706-9712 (1998).;;Duque et al., “Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons,” Mol. Ther., 17:1187-1196 (2009).;;Eastman et al., “Development of catheter-based procedures for transducing the isolated rabbit liver plasmid DNA,” Human Gene Therapy 13:2065-2077 (2002).;;Echelard et al., “Production of recombinant therapeutic proteins in the milk of transgenic animals,” Biopharm International, 19:36-45 (2006).;;Eto et al., “Development of PEGylated adenovirus vector with targeting ligand,” Int. J. Pharm., 354:3-8 (2008).;;Fabre et al., “Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava,” Gene Ther., 15:452-462 (2008).;;Fallaux et al., “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Hum. Gene Ther. 9:1909-1907 (1998).;;Faraji, A. and P. Wipf, “Nanoparticles in cellular drug delivery,” Bioorg. Med. Chem. 17(8):2950-2962 (2009).;;Ferkol et al., “Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo,” Am. J. Respir. Cell Mol. Biol., 18:591-601 (1998).;;Ferry et al., “Retroviral-mediated gene transfer into hepatocytes in vivo,” Proc. Natl. Acad. Sci. 88:8377-8381 (1991).;;Finch, P. and J. Rubin, “Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors,” J. Natl. Cancer Inst. 98(12):812-824 (2006).;;Fisher et al., “Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis,” J. Virol., 217:11-22 (1996).;;Foust et al., “Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes,” Nature Biotechnology, 27:59-65 (2009).;;Franzen, S., “A comparison of peptide and folate receptor targeting of cancer cells: from single agent to nanoparticle,” Expert Opin. Drug. Deliv. 8(3):281-298 (2011).;;Fu et al., “Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery,” Mol. Ther., 19:1025-1033 (2011).;;Fujii et al., “Targeting of interstitial cells using a simple gene-transfer strategy,” Nephrol Dial Transplant. 21:2745-2753 (2006).;;Fujita et al., “Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion,” Biological & Pharmaceutical Bulletin, 29:1728-1734 (2006).;;Fumoto et al., “Liver- and lobe-specific gene transfer following the continuous microinstillation of Plasmid DNA onto the liver surface in mice: effect of instillation speed,” Biol. Pharm. Bull., 32:1298-1302 (2009).;;Furlan et al., “Gene therapy-mediated modulation of immune processes in the central nervous system,” Curr Pharm Des. 9:2002-2008 (2003).;;Gao et al., “Clades of Adeno-associated viruses are widely disseminated in human tissues,” J. Virol., 78:6381-6388 (2004).;;Gao et al., “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy,” Proc Natl. Acad. Sci., 99:11854-11859 (2002).;;Genbank Accession No. AY530629.1, “Adeno-associated virus isolate hu.9 capsid protein VP1 (cap) gene, complete cds,” Published on Jun. 24, 2004 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:ncbi.nlm.nih.gov/nuccore/AY530629.1[2 pages].;;GENERX, “FGF-4 gene therapy GENERX—Collateral Therapeutics,” BioDrugs 16:75-76 (2002).;;George, D., “Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate,” Urology 60(3 Suppl. 1):115-121 (2002).;;Ghosh-Choudhury et al., “Stable transfer of a mouse dihydrofolate reductase gene into a deficient cell line using human adenovirus vector,” Biochem. Biophys. Res. Commun., 147:964-973 (1987).;;Gilardi et al., “Expression of human alpha 1-antitrypsin using a recombinant adenovirus vector,” FEBS Lett.267:60-62 (1990).;;Golovan et al., “Pigs expressing salivary phytase produce low-phosphorus manure,” Nature Biotechnology, 19:741-745 (2001).;;Gondi, C. and J. Rao, “Concepts in in vivo siRNA delivery for cancer therapy,” J. Cell Physiol. 220(2):285-291 (2009).;;Gong et al., “Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus,” Pharmacogentics, 11:357-368 (2001).;;Gorziglia et al., “Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy,” J. Virology 70:4173-4178 (1996).;;Goto et al., “Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene,” Proc Natl Acad Sci U S A 97:354-359 (2000).;;Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol. 36:59-71 (1977).;;Graham, F., “Covalently closed circles of human adenovirus DNA are infectious,” EMBO J. 3:2917-2922 (1984).;;Grimm, D. and M. Kay, “From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy,” Current Gene Therapy, 3:281-304 (2003).;;Groskreutz et al., “Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin.” J. Biol. Chem., 269:6241-6245 (1994).;;Grossman et al., “A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia,” Nat. Med., 1:1148-1154 (1995).;;Grossman, M. and J. Wilson, “Retroviruses: delivery vehicle to the liver,” Curr. Opin. in Genetics and Devel. 3:110-114 (1993).;;Haj-Ahmad et al., “Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene,” J. Virol. 57:267-274 (1986).;;Hampel, A., “The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy,” Prog. Nucleic Acid Res. Mol. Biol., 58:1-39 (1998).;;Harris et al., “Tissue-specific gene delivery via nanoparticle coating,” Biomaterials, 31:998-1006 (2010).;;Harvey et al., “Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs,” J. Virol., 73:6729-6742 (1999).;;Herbomel et al., “The rat albumin promoter is composed of six distinct positive elements within 130 nucleotides,” Molecular and Cellular Biology, 9:4750-4758 (1989).;;Hodges et al., “Local delivery of viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver,” Mol. Ther. 12:1043-1051 (2005).;;Hoffman et al., “Renal ischemic tolerance,” AMA Arch. Surg., 109:550-551 (1974).;;Hofherr et al., “Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression,” Mol Ther. 16(7):1276-1282 (2008).;;Holzer et al., “Assessment of renal oxygenation during partial nephrectomy using hyperspectral imaging,” Journal of Urology, 186:400-404 (2011).;;IUPAC-IUB Commission on Biochemical Nomenclature, “Symbols for amino-acid derivatives and peptides: recommendations (1971),” Biochem. 11(9):1726-1732 (1972).;;James, H. and I. Gibson, “The therapeutic potential of ribozymes,” Blood, 91:371-382 (1998).;;Jimeno, A. and M. Hidalgo, “Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,” Biochim. Biophys. Acta 1766(2):217-229 (2006).;;Jin et al., “Nanoparticle-mediated drug delivery and gene therapy,” Biotechnol. Prog., 23:32-41 (2007).;;Johansson et al., “Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria,” Mol. Ther. 10(2):337-343 (2004).;;Jolly et al., “Viral vector systems for gene therapy.” Cancer Gene Therapy, 1:51-64 (1994).;;Joung et al., “Partial nephrectomy using parenchymal compression without renal pedicle clamping,” Korean J. Urol., 28:265-269 (2007).;;Kamimura, K. and D. Liu, “Physical approaches for nucleic acid delivery to liver,” AAPS J.10:589-595 (2008).;;Kanematsu et al., “A newly designed clamp facilitates hepatic resection,” Jpn. J. Surg., 14:432-423 (1984).;;Kiem et al., “Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells,” Blood 83:1467-1473 (1994).;;Kieseier et al., “Interferon-beta and neuroprotection in multiple sclerosis—facts, hopes and phantasies,” Exp. Neurol., 203:1-4 (2007).;;Kim et al., “Preparation of multivesicular liposomes,” Bioch. Bioph. Acta 728:339-348 (1983).;;Kinoshita et al., “Targeted gene delivery to selected liver segments via isolated hepatic perfusion with clamping of the portal vein,” Molecular Therapy 9: S119 (2004).;;Kinoshita et al., “Targeted gene delivery to selected liver segments via isolated hepatic perfusion,” J Surg. Res., 160:47-51 (2010).;;Ko et al., “Efficacy of parenchymal compression in open partial nephrectomies: a comparison with conventional vascular clamping,” Korean J. Urol., 51:8-14 (2010).;;Kochanek et al., “A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase,” Proc. Natl. Acad. Sci., 93:5731-5736 (1996).;;Kotin et al., “Site-specific integration by adeno-associated virus,” Proc. Natl. Acad. Sci., 87:2211-2215 (1990).;;Kotin, R., “Prospects for the use of adeno-associated virus as a vector for human gene therapy,” Human Gene Therapy, 5:793-801 (1994).;;Kozak et al., “Structural features in eukaryotic mRNAs that modulate the initiation of translation,” J. Biol. Chem. 266: 19867-19870 (1991).3.;;Krasnykh et al., “Genetic targeting of adenoviral vectors,” Mol. Ther., 1:391-405 (2000).;;Lai et al., “Generation of cloned transgenic pigs rich in omega-3 fatty acids,” Nature Biotechnology, 24:435-436 (2006).;;Lazaris et al., “Spider silk fibers spun from soluble recombinant silk produced in mammalian cells,” Science, 295:472-476 (2002).;;Lecollinet et al., “Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers,” J Virol. 80(6):2747-2759 (2006).;;Lee et al., “Temporal- and spatial-specific expression of bovine beta-casein/bovine growth hormone fusion gene in transgenic mice,” Theriogenology, 47:225, 1 page (1997).;;Lesurtel et al. (2009) “Clamping techniques and protecting strategies in liver surgery,” HPB (Oxford). 11:290-295.;;Levrero et al., Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo, Gene 101:195-202 (1991).;;Lewis, P. and F. Emerman, “Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus,” J. Virol., 68:510-516 (1996).;;Li, S. and L. Huang, “Gene therapy progress and prospects: non-viral gene therapy by systemic delivery,” Gene Therapy, 13:1313-1319 (2006).;;Lieber et al., “Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo,” J. Virol., 70:8944-8960 (1996).;;Lillico et al., “Transgenic chickens as bioreactors for protein-based drugs,” Drug Discovery Today, 10:191-196 (2005).;;Liu et al., “Gene therapy of scarring: a lesson learned from fetal scarless wound healing,” Yonsei Medical Journal, 42:634-645 (2001).;;Lo et al., “EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization,” Breast Canc. Res. Treat. 95(3):211-218 (2006).;;Lo, H., “EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance,” Curr. Mol. Pharmacol. 3(1):37-52 (2010).;;Loeffler, J. and J. Behr, “Gene transfer into primary and established mammalian cell lines with lipopolyamine-coated DNA,” Meth. Enzymol. 217:599-618 (1993).;;Maga et al., “Human lysozyme expressed in the mammary gland of transgenic dairy goats can inhibit the growth of bacteria that causes mastitis and the cold-spoilage of milk,” Foodborne Pathog. Dis.3:384-392 (2006).;;Mandel et al., “Neutralization of animal viruses,” Adv. Virus. Res., 23:205-268 (1978).;;Manilla et al., “Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector,” Human Gene Therapy,16:17-25 and Corrections (2005).;;Massie et al., “Construction of a helper-free recombinant adenovirus that expresses polyomavirus large T antigen,” Mol. Cell. Biol. 6:2872-2883 (1986).;;Mellstedt, H., “Monoclonal antibodies in human cancer,” Drugs Today 39(Supl. C):1-16 (2003).;;Meng et al., “Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10 released from gene-transferred keratinocytes inhibits contact hypersensitivity at distant areas of the skin,” J. Clin. Invest., 101(6):1462-1467 (1998).;;Mercier, J., “Genetic engineering applied to milk producing animals: some expectations,” Found in Exploiting New Technologies in Animal Breeding, Oxford University Press, New York, pp. 122-131 (1987).;;Mingozzi et al., “Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges,” Nature Reviews Genetics, 12:341-355 and Corrigendum (2011).;;Mir et al., “Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle,” C R Acad Sci III 321: 893-899 (1998).;;Mittal et al., “Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter,” Virus Res. 28:67-90 (1993).;;Mizuguchi et al., “Targeted adenovirus vectors,” Hum. Gene Ther., 15:1034-1044 (2004).;;Moreno et al., “Studies on the outflow tracts of the liver. I. On a method for the functional demonstration of the outflow tracts of the liver and its application to the study of hepatic hemodynamics in normal and cirrhotic rats,” Ann Surg. 155:412-426 (1962).;;Morral et al., “High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha 1-antitrypsin with negligible toxicity,” Hum. Gene Ther., 10:2709-2716 (1998).;;Muramatsu et al., “Foreign gene expression in the mouse testis by localized in vivo gene transfer,” Biochem Biophys Res Commun 233: 45-49 (1997).;;Muramatsu et al., “Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3,” Virol., 221:208-217 (1996).;;Muzyczka, N., “Use of adeno-associated virus as a general transduction vector for mammalian cells,” Curr. Top. Micro. Immunol., 1 58:97-129 (1992).;;Nakai, H., “Hepatic Gene Therapy,” pp. 343-370 in Molecular Pathology of Liver Diseases (S.P.S. Monga, ed.) Springer (2010).;;Naldini et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,” Science, 272:263-267 (1996).;;Nathwani et al., “Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques,” Blood, 100:1662-1669 (2002).;;Nemerow, G., “Cell receptors involved in adenovirus entry,” Virology 274:1-4 (2000).;;Neumann et al., “Cytokine gene transfer in the therapy of autoimmune diseases,” Gene Therapy and Molecular Biology, 9:61-76 (2005).;;O'donnell et al., “Efficient, cardiac-specific adenoviral gene transfer in rat heart by isolated retrograde perfusion in vivo,” Gene Therapy, 12:958-964 (2005).;;Oh, Y. and T. Park, “siRNA delivery systems for cancer treatment,” Adv. Drug. Deliv. Rev. 61(10):850-862 (2009).;;Ohashi et al., “Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver,” Human Gene Therapy 16:299-306 (2005).;;Palmiter et al., “Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes,” Nature, 300:611-615 (1982).;;Parks et al., “A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal,” Proc. Natl. Acad. Sci., 93:13565-13570 (1996).;;Pathak et al., “Nano-vectors for efficient liver specific gene transfer,” Int. J. Nanomedicine, 3:31-49 (2008).;;Prather et al., “Transgenic swine for biomedicine and agriculture,” Theriogenology, 59:115-123 (2003).;;Qi et al., “The clinical effect of recombinant human ad p53 agent-Gendicine in advanced cancer patients in 23 cases,” Modern Oncology, 14:1259-1297 (2006). Article in Chinese and abstract in the English language.;;Rasmussen et al., “TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene,” Cancer Gene Ther., 9:951-957 (2002).;;Reid et al., “Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints,” Cancer Res. 62:6070-6079 (2002).;;Reid et al., “Intravascular adenoviral agents in cancer patients: lessons from clinical trials,” Cancer Gene Ther. 9:979-986 (2002).;;Rettinger et al., “In vivo hepatocyte transduction with retrovirus during in-flow occlusion,” J Surg Res. 54:418-425 (1993).;;Richt et al., “Production of cattle lacking prion protein.” Nature Biotechnology, 25:132-138 (2007).;;Rizzuto et al., “Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation,” Proc Natl Acad Sci USA 96: 6417-6422 (1999).;;Roberts et al., “DNA sequences from the adenovirus 2 genome,” J. Biol. Chem., 259:13968-13975 (1984).;;Roelvink et al., “The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F,” J. Virol. 72:7909-7915 (1998).;;Rosewell et al., “Helper-dependent adenoviral vectors,” J. Genet. Syndr. Gene Ther., S5:001, 16 pages (2011).;;Rossi, J., “Therapeutic applications of catalytic antisense RNAs (ribozymes),” Ciba Found. Symp., 209:195-204 (1997).;;Russell et al., “Oncolytic virotherapy,” Nature Biotechnology, 30:658-670 (2012).;;Russell, W., “Adenoviruses: update on structure and function,” J Gen. Virol. 90:1-20 (2009).;;Rutledge et al., “Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2,” J. Virol, 72:309-319 (1998).;;Sachdeva et al., “Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance,” Journal of Medical Virology, 79:118-126 (2007).;;Saeki et al., “Functional expression of a Delta12 fatty acid desaturase gene from spinach in transgenic pigs,” Proc. Natl. Acad. Sci., 101:6361-6366 (2004).;;Sajja et al., “Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect,” Curr. Drug. Discov. Technol. 6(1):43-51(2009).;;Salmons, B. and W. Gunzberg, “Targeting of retroviral vectors for gene therapy,” Human Gene Therapy 4:129-141 (1993).;;Sawyer et al., “Technical requirements for effective regional hydrodynamic gene delivery to the left lateral lobe of the rat liver,” Gen Ther., 17:560-564 (2010).;;Schilephake, H., “Bone growth factors in maxillofacial skeletal reconstruction,” Int. J. Oral Maxillofac. Surg. 31(5):469-484 (2002).;;Seglen, P., Chapter 4, “Preparation of Isolated Rat Liver Cells”, Methods in Cell Biology, vol. XIII, Prescott, D., ed., Academic Press, pp. 29-83 (1976).;;Segura-Pancheco et al., “HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo,” Genet. Vaccines Ther.5:10, 8 pages (2007).;;Sferra et al., “Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse,” Mol. Ther. 10:478-491 (2004).;;Shayakhmetov et al., “Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity,” J. Virol. 79:7478-7491 (2005).;;Shayakhmetov et al., “Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors,” J. Virol. 78:5368-5381 (2004).;;Sheridan, C., “Gene therapy finds its niche,” Nature Biotechnology, 29:121-128 and errata (2011).;;Shichiri et al., “Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene complex,” Gene Ther., 10:827-831 (2003).;;Shine, J. and L. Delgarno, “Determinant of cistron specificity in bacterial ribosomes,” Nature 254(5495):34-38 (1975).;;Shirakawa, T., “Clinical trial design for adenoviral gene therapy products,” Drugs News Perspectives, 22(3):140-145 (2009).;;Somers et al., “A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes,” DMD, 35:1797-1805 (2007).;;Somiari et al., “Theory and in vivo application of electroporative gene delivery,” Mol Ther 2:178-187 (2000).;;Song et al., “Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle,” Proc. Natl. Acad. Sci., 98:4084-4088 (2001).;;Song et al., “Ex vivo transduced liver progenitor cells as a platform for gene therapy in mice,” Hepatology, 40:918-924 (2004).;;Song et al., “Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors,” Gene Ther., 8:1299-1306 (2001).;;Song et al., “Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors,” Proc. Natl. Acad. Sci., 95:14384-14388 (1998).;;Sprengel et al., “Nucleotide sequence of human adenovirus type 12 DNA: comparative functional analysis,” J. Virol., 68:379-389 (1994).;;Sterman et al., “A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions,” Mol. Ther., 18:852-860 (2010).;;Sullenger (1995) “Revising messages traveling along the cellular information superhighway,” Chem. Biol., 2:249-253.;;Sullenger, B., “Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors,” Cytokines Mol. Ther., 2:201-205 (1996).;;Suzuki et al., “Direct gene transfer into rat liver cells by in vivo electroporation,” FEBS Lett 425: 436-440 (1998).;;Thompson et al., “The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study,” J. Urology, 177:471-476 (2006).;;Titomirov et al., “In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA,” Biochim Biophys Acta 1088: 131-134 (1991).;;Toren et al., “Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy,” Can. Urol. Assoc., 4:E133-E136 (2010).;;Trojanowska, M and J. Varga, “Molecular pathways as novel therapeutic targets in systemic sclerosis,” Curr. Opin. Rheumatol. 19(6):568-573 (2007).;;Tronche et al., “The rat albumin promoter: cooperation with upstream elements is required when binding of APF/HNF1 to the proximal element is partially impaired by mutation or bacterial methylation,” Molecular and Cellular Biology, 9:4759-4766 (1989). et al.",ACTIVE
144,WO,A1,WO 2017/017288 A1,098-664-402-413-295,2017-02-02,2017,ES 2015070570 W,2015-07-24,ES 2015070570 W,2015-07-24,MODULAR TREADMILL,"The invention relates to a modular treadmill characterised in that is formed by connecting a number of individual modules (1) that are assembled to one another, each module comprising: a series of inner rollers (4) disposed below the outer belt and, transversely to the direction of travel of the outer belt, a tension roller (6) at one end and, at the other end, a take-up roller (5) connected to a traction motor (2) by means of a transmission belt (3). All of the modules are covered by a single outer belt (7) and each of the modules (1) can be connected to an adjacent module by means of the take-up roller (5), such that a single traction motor can be used to move all of the modules forming part of the modular treadmill. The resulting treadmill can be adapted to different widths and spaces, as well as to different users, such that all users can train in the same way.",BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,,https://lens.org/098-664-402-413-295,Patent Application,yes,7,0,3,3,0,A63B22/0023;;A63B22/0235;;A63B22/0257;;A63B2225/102;;A63B22/0292,A63B22/00;;A61H1/02;;A63B22/02,,0,0,,,,PENDING
145,ES,Y,ES 1205962 Y,140-576-314-770-891,2018-05-16,2018,ES 201890002 U,2015-07-24,ES 2015070569 W,2015-07-24,DISPOSITIVO DE SEGURIDAD ANTICAIDA DE HERRAMIENTAS PARA TRABAJOS EN ALTURA,,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,,https://lens.org/140-576-314-770-891,Limited Patent,no,0,0,3,3,0,A45F5/004;;A45F5/021;;A45F2200/0575,A45F5/02;;B23B29/12,,0,0,,,,INACTIVE
146,BR,A8,BR 112014019431 A8,162-071-650-816-224,2017-07-11,2017,BR 112014019431 A,2013-02-07,US 2013/0025234 W;;US 201261633287 P,2012-02-07,MÉTODO COMPARTIMENTALIZADO DE DISTRIBUIÇÃO DE ÁCIDO NUCLEICO E COMPOSIÇÕES E USOS DESSES,"MÉTODO COMPARTIMENTALIZADO DE DISTRIBUIÇÃO DE ÁCIDO NUCLEICO E COMPOSIÇÕES E USOS DESSES. É provido aqui um método de distribuição de moléculas de ácido nucleico para um tecido ou órgão compartimentalizado de um indivíduo. São também providos aqui usos e processos para distribuir uma molécula de ácido nucleico para o parênquima de um tecido or órgão compartimentalizado. Os métodos e usos podem ser usados no tratamento de doenças e condições e em aplicações industriais, agriculturais e veterinárias. São também providas aqui composições que contêm um adenovírus ou vírus associado com o adeno ou outros vírus recombinantes formulados para administração para o parênquima de um tecido ou órgão.",GLOBAL BIO THERAPEUTICS USA INC;;GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO,"GLOBAL BIO THERAPEUTICS, INC. (US) (2018-07-10)",https://lens.org/162-071-650-816-224,Patent Application,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,DISCONTINUED
147,EP,A3,EP 3970734 A3,174-186-725-968-026,2022-04-20,2022,EP 21167237 A,2013-02-07,US 201261633287 P;;EP 13706130 A;;US 2013/0025234 W,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO GUSTAVO JOSE;;SEGURA PACHECO ANGELICA BLANCA,,https://lens.org/174-186-725-968-026,Search Report,yes,2,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00;;A61P1/16,,6,6,057-205-038-511-760;;034-633-606-331-300;;008-078-869-200-895;;033-634-785-071-687;;070-125-928-713-074;;065-310-853-569-912,10.1089/10430340260395910;;12490001;;10.1016/j.ymthe.2005.06.475;;16139571;;18004400;;10.1038/sj.gt.3303079;;10.1038/sj.gt.3302833;;16871229;;15812225;;10.1089/hum.2005.16.299;;10.1248/bpb.29.1728;;16880633,"EASTMAN S J ET AL: ""Development of catheter-based procedures for transducing the isolated rabbit liver plasmid DNA"", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 13, 20 November 2002 (2002-11-20), pages 2065 - 2077, XP002970584, ISSN: 1043-0342, DOI: 10.1089/10430340260395910;;HODGES ET AL: ""Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver"", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 12, no. 6, 1 December 2005 (2005-12-01), pages 1043 - 1051, XP005176612, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2005.06.475;;J W FABRE ET AL: ""Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava"", GENE THERAPY, vol. 15, no. 6, 15 November 2007 (2007-11-15), pages 452 - 462, XP055058855, ISSN: 0969-7128, DOI: 10.1038/sj.gt.3303079;;YOSHINO H ET AL: ""Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume"", GENE THERAPY, vol. 13, no. 24, December 2006 (2006-12-01), pages 1696 - 1702, XP055058858, ISSN: 0969-7128;;OHASHI KAZUO ET AL: ""Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver"", HUMAN GENE THERAPY, vol. 16, no. 3, March 2005 (2005-03-01), pages 299 - 306, XP002695090, ISSN: 1043-0342;;FUJITA SHIGEO ET AL: ""Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion"", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 29, no. 8, August 2006 (2006-08-01), pages 1728 - 1734, XP002695085, ISSN: 0918-6158",DISCONTINUED
148,HK,A1,HK 1204770 A1,019-705-346-647-62X,2015-12-04,2015,HK 15105338 A,2015-06-04,US 2013/0025234 W;;US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,,GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/019-705-346-647-62X,Patent Application,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76,,0,0,,,,PENDING
149,US,A1,US 2013/0211380 A1,066-709-341-432-585,2013-08-15,2013,US 201313815206 A,2013-02-07,US 201313815206 A;;US 201261633287 P,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,GLOBAL BIO THERAPEUTICS USA INC. (GBT USA) (2013-02-13);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2013-02-13),https://lens.org/066-709-341-432-585,Patent Application,yes,1,43,35,35,14,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61M5/178;;A61K35/76,604/508;;604/522;;604/187;;604/403,11,11,117-071-389-370-553;;053-446-886-655-152;;027-481-107-296-64X;;004-559-520-459-492;;009-093-712-698-826;;009-652-838-411-630;;050-983-607-561-263;;062-441-802-266-891;;039-448-117-847-792;;001-939-001-941-194;;049-418-961-011-46X,10.1023/a:1007626627643;;10.1016/j.bpobgyn.2007.08.008;;17900991;;15062655;;10.1016/j.suc.2003.11.002;;15520458;;pmc528817;;10.1093/nar/gnh140;;10326848;;10.1016/s0002-9610(99)00043-4;;10.2174/1566523044578077;;15032617;;10.1126/scitranslmed.3000112;;20368179;;pmc2852878;;10.1038/ng1197-314;;9354796;;10.1089/hum.2006.17.601;;16776569;;10.1089/ten.2005.11.1718;;16411817;;10.3748/wjg.v13.i25.3487;;pmc4146785;;17659696,"Kay et al, Nature Genetics, 2000, 24:257-260;;David, Best Practice and Research Clinical Obstetrics and Gynaecology, 2008, 22:203-218;;Gagner et al, Surg Clin N Am, 2004, 84:451-462;;Schiffelers et al, Nucleic Acids Research, 2004, 32:e149;;Jiao et al, The American Journal of Surgery, 1999, 177:303-306;;Papadakis et al, Current Gene Therapy, 2004, 4:89-113;;Kota et al, Sci Transl Med, 2009, 6ra15;;Kafri et al, Nature Genetics, 1997, 17:314-317;;Berraondo et al, Human Gene Therapy, 2006, 17:601-610;;Bruns et al, Tissue Engineering, 2005, 11:1718-1726;;Kobayashi et al., 2007, World Journal of Gastroenterology, Vol. 13, No. 25, p. 3487-3492.",ACTIVE
150,ES,U,ES 1060567 U,140-970-612-843-898,2005-10-01,2005,ES 200501507 U,2005-07-01,ES 200501507 U,2005-07-01,"Escalon convertible (Machine-translation by Google Translate, not legally binding)","Convertible step, of the type that can be used, in isolation or as part of a staircase, in access to premises, industries, homes or the like, characterized in that it is made up of a prismatic-rectangular, hollow body, of dimensions commensurate with the of any conventional step, in which its rear wall, its side walls and in its lower wall are fixed, while its upper wall, corresponding to the footprint, and its front wall, corresponding to the riser, are mobile, being the upper wall hingedly joined by its rear edge to the upper marginal area of the rear wall, while the riser is in turn hingedly joined to the front edge of the upper wall or footprint, and incorporating in its interior a mechanism that, acting on said movable parts, allows the upper wall or footprint to adopt an inclined position, becoming a ramp. (Machine-translation by Google Translate, not legally binding)",IDYC ROBOTICA S L,CABRERA RODRIGUEZ DIEGO;;DEL RIO CARRASCO JOSE LUIS,,https://lens.org/140-970-612-843-898,Patent Application,no,0,0,2,2,0,,E04F11/04,,0,0,,,,EXPIRED
151,WO,A1,WO 2017/017287 A1,136-776-417-004-366,2017-02-02,2017,ES 2015070569 W,2015-07-24,ES 2015070569 W,2015-07-24,ANTI-FALL SAFETY DEVICE FOR TOOLS USED FOR WORK AT HEIGHTS,"The invention relates to a device comprising a central element (2) from which the following elements extend: a first cable section (2) which has a means for attaching to an anchoring point on its free end; and a second cable section (6) which has a means for attaching to a tool-holding means (8) on its free end, where at least one of the cable sections (2), (6) is retractable along the length thereof, i.e. it can be extended from the central element (1), increasing the length thereof, and can be returned into the central element. The device allows tools to be held in a continuous manner that does not affect or prevent the normal use of the tools. It also ensures that the distance required between the tool and the anchoring point can be adapted, and even in the event of loss of control of the tool, prevents and breaks the fall, without causing damage or the like, and is easy to recuperate.",BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,BARBERO HOYOS MIGUEL ANGEL;;CABRERA MAYORDOMO JUAN JOSE,,https://lens.org/136-776-417-004-366,Patent Application,yes,4,1,3,3,0,A45F5/004;;A45F5/021;;A45F2200/0575,A45F5/00;;A45F5/02,,0,0,,,,PENDING
152,ES,A1,ES 2565015 A1,162-219-411-789-394,2016-03-30,2016,ES 201400693 A,2014-08-27,ES 201400693 A,2014-08-27,"Procedure for obtaining a hair lotion in liquid state to stop hair loss (Machine-translation by Google Translate, not legally binding)","Procedure for obtaining a capillary lotion in liquid state to stop hair loss. In a first phase 150 grams of algaritofe and 1000 grams of water are mixed, the composition being in relation to the weight of 87% of water and 13% of cedronella canariensis (algaritofe), boiling said mixture until reaching a temperature of at least 100ºC and leaving to boil for five minutes. The resulting mixture is then left to stand for 4 hours and filtered. (Machine-translation by Google Translate, not legally binding)",ACEVEDO HERNANDEZ PEDRO ANDRÉS;;CABRERA DONIZ JOSE MANUEL,ACEVEDO HERNANDEZ PEDRO ANDRÉS;;CABRERA DONIZ JOSE MANUEL,,https://lens.org/162-219-411-789-394,Patent Application,no,0,0,3,3,0,A61K8/9789;;A61K8/9789;;A61Q7/00,A61K8/97,,0,0,,,,INACTIVE
153,WO,A9,WO 2013/119880 A9,167-674-457-801-383,2013-10-03,2013,US 2013/0025234 W,2013-02-07,US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/167-674-457-801-383,Search Report,yes,0,1,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76;;A61K48/00,,0,0,,,,PENDING
154,SG,A,SG 10201604810U A,026-547-230-950-46X,2016-08-30,2016,SG 10201604810U A,2013-02-07,US 201261633287 P,2012-02-07,COMPARTMENTALIZED METHOD OF NUCLEIC ACID DELIVERY AND COMPOSITIONS AND USES THEREOF,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/026-547-230-950-46X,Unknown,no,0,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K35/76,,0,0,,,,PENDING
155,BR,A,BR PI0417860 A,054-008-253-233-271,2007-05-29,2007,BR PI0417860 A,2004-12-17,ES 200303039 A;;ES 2004000560 W,2003-12-23,"formulações cerámicas modificadas e processo para fabricação de peças de cerámica com efeitos metálicos, e as peças de cerámica obtidas","Formulações Cerâmicas Modificadas e Processo para a Fabricação de Peças de Cerâmica com efeitos Metálicos, e as Peças de Cerâmica Obtidas constituindo formulações cerâmicas convencionais constituídas por uma matriz de cerâmica à base de uma mistura de óxidos em diferentes proporções, que foram modificadas pela adição de metais, misturas de metais e ligas de metais inoxidáveis de ponto de fusão superior a <198>C e granulometria inferior a 100 microns. O referido processo compreende a aplicação das referidas formulações sobre a peça de cerâmica a ser decorada, seguida de cozimento e subseqüente desbaste. Aplicação no setor de industria de cerâmicas.",VIDRES S A,NEBOT VICTOR MONTINS;;EZ MARIA JOSE CABRERA IBA,,https://lens.org/054-008-253-233-271,Patent Application,no,0,0,6,6,0,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/02;;C04B41/5022;;C04B41/009;;C04B41/5027;;C04B41/87;;C03C8/18;;C03C8/02;;C03C8/04,C03C8/02;;C03C8/04;;C03C8/18;;C04B41/50;;C04B41/86;;C04B41/87,,0,0,,,,DISCONTINUED
156,CN,A,CN 107982548 A,100-159-782-440-617,2018-05-04,2018,CN 201711235370 A,2013-02-07,US 201261633287 P;;CN 201380018970 A,2012-02-07,Compartmentalized method of nucleic acid delivery and compositions and uses thereof,"Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid moleculeto the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA,,https://lens.org/100-159-782-440-617,Patent Application,no,3,0,35,35,0,A61K35/76;;A61K48/005;;A61K48/0075;;A61M5/00;;A61M5/178;;A61M5/30;;A61M39/00;;A61M2210/1071;;A61P1/16;;A61P7/00;;C12N2799/022;;A61K48/0075;;A61K35/76;;C12N2799/022;;A61P1/16;;A61P7/00;;A61K48/005;;A61M5/00;;A61M39/00;;A61M5/30;;A61M2210/1071;;C12N2799/022;;A61K48/0075;;A61K35/76;;A61P7/00;;A61P1/16;;A61M5/178,A61K48/00;;A61K35/76;;A61P3/10;;A61P7/06,,6,6,008-078-869-200-895;;065-310-853-569-912;;033-634-785-071-687;;057-205-038-511-760;;070-125-928-713-074;;034-633-606-331-300,18004400;;10.1038/sj.gt.3303079;;10.1248/bpb.29.1728;;16880633;;10.1038/sj.gt.3302833;;16871229;;10.1089/10430340260395910;;12490001;;15812225;;10.1089/hum.2005.16.299;;10.1016/j.ymthe.2005.06.475;;16139571,"JW FABRE ET AL.: ""Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava"", 《GENE THERAPY》;;SHIGEO FUJITA ET AL.: ""Sendai Virus-Mediated Gene Delivery into Hepatocytes via Isolated Hepatic Perfusion"", 《BIOL. PHARM. BULL.》;;H YOSHINO ET AL.: ""Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume"", 《GENE THERAPY》;;SIMON J. EASTMAN ET AL.: ""Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA"", 《HUMAN GENE THERAPY》;;KAZUO OHASHI ET AL.: ""Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver"", 《HUMAN GENE THERAPY》;;BRADLEY L. HODGES ET AL.: ""Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver"", 《MOLECULAR THERAPY》",PENDING
157,US,B2,US 9650288 B2,197-746-316-745-988,2017-05-16,2017,US 201314653325 A,2013-12-19,MX 2012015215 A;;MX 2013000190 W,2012-12-19,Aqua blue glass composition,"The present invention relates to an aqua blue glass composition having a base composition of a soda-lime-silica glass having as main coloring agents total iron, expressed as Fe 2 O 3 in the range of 0.30 to 0.60% by weight with a ratio of ferrous (redox) in the range of 20 to 30; FeO in the range of 0.06 to 0.18% by weight; TiO 2 in the range of 0.025 to 1.0% by weight; Co 3 O 4 expressed in the range of 5 to 30% ppm; Se expressed in the range of 0.1 to 10 ppm; CuO in the range of 0 to 400 ppm; and Cr 2 O 3 in the range of 10 to 20 ppm. The glass provides light transmittance, illuminant “A”, greater than 50%, a dominant wavelength (λ) of 487 nm to 498 nm; a solar energy transmittance of less than or equal to 64.4%; an ultraviolet solar transmittance no more than 51.6%; and an excitation purity less than 12 for glass thicknesses from 4 to 12 mm.",VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;TAVARES-CORTES JOSE LUIS,VIDRIO PLANO DE MEXICO S.A. DE C.V (2014-07-24),https://lens.org/197-746-316-745-988,Granted Patent,yes,11,0,4,4,0,C03C4/02;;C03C4/02;;C03C3/087;;C03C3/087,C03C3/087;;C03C4/02,,1,0,,,"PCT/MX2013/000190 International Search Report, mailed May 5, 2014, (2 pgs.).",ACTIVE
158,US,A1,US 2016/0115072 A1,089-444-611-365-495,2016-04-28,2016,US 201314653325 A,2013-12-19,MX 2012015215 A;;MX 2013000190 W,2012-12-19,AQUA BLUE GLASS COMPOSITION,"The present invention relates to an aqua blue glass composition having a base composition of a soda-lime-silica glass having as main coloring agents total iron, expressed as Fe 2 O 3 in the range of 0.30 to 0.60% by weight with a ratio of ferrous (redox) in the range of 20 to 30; FeO in the range of 0.06 to 0.18% by weight; TiO 2 in the range of 0.025 to 1.0% by weight; CO 3 O 4 expressed in the range of 5 to 30% ppm; Se expressed in the range of 0.1 to 10 ppm; CuO in the range of 0 to 400 ppm; and Cr 2 O 3 in the range of 10 to 20 ppm. The glass provides light transmittance, illuminant “A”, greater than 50%, a dominant wavelength (i) of 487 nm to 498 nm; a solar energy transmittance of less than or equal to 64.4%; an ultraviolet solar transmittance no more than 51.6%; and an excitation purity less than 12 for glass thicknesses from 4 to 12 mm.",VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;TAVARES-CORTES JOSE LUIS,VIDRIO PLANO DE MEXICO S.A. DE C.V (2014-07-24),https://lens.org/089-444-611-365-495,Patent Application,yes,4,4,4,4,0,C03C4/02;;C03C4/02;;C03C3/087;;C03C3/087,C03C4/02;;C03C3/087,,0,0,,,,ACTIVE
159,MX,A,MX 2012015215 A,080-317-211-270-834,2014-06-24,2014,MX 2012015215 A,2012-12-19,MX 2012015215 A,2012-12-19,AQUA BLUE GLASS COMPOSITION.,"The invention relates to an aqua blue glass composition having a base composition of a silicon-sodium-calcium glass containing the following main colouring agents: a total of iron, expressed as Fe2O3, in the range from 0.30 to 0.60% by weight, with a percentage ferrous (redox) in the range from 20 to 30; FeO in the range from 0.06 to 0.18% by weight; Ti02 in the range from 0.025 to 1.0 % by weight; CO3O4 expressed in the range from 5 to 30% ppm; Se expressed in the range from 0.1 to 10 ppm; CuO in the range from 0 to 400 ppm; and Cr203 in the range from 10 to 20 ppm. The glass has a light transmission value (illuminant A) greater than 50%; a dominant wavelength ([lambda]) between 487 nm and 498 nm; solar energy transmission of less than or equal to 64.4%; ultraviolet solar transmission of no more than 51.6%; and excitation purity of less than 12 for glass thicknesses between 4 and 12 mm.",VIDRIO PLANO DE MEXICO SA DE CV,LLANOS ROBERTO MARCOS CABRERA;;AGUILAR JOSE GUADALUPE CID;;CORTES JOSE LUIS TAVARES,,https://lens.org/080-317-211-270-834,Patent Application,no,0,0,4,4,0,C03C4/02;;C03C4/02;;C03C3/087;;C03C3/087,C03C1/04;;C03C3/00;;C03C4/00,,0,0,,,,PENDING
160,ES,A2,ES 2051224 A2,032-703-212-523-543,1994-06-01,1994,ES 9201336 A,1992-06-25,ES 9201336 A,1992-06-25,Narrow-band interference filter with photorefractive material,"Narrow-band interference filter with photorefractive material, realised by recording a holographic network onto photorefractive material, which same is subsequently fixed by thermal treatment. By means of two beams 13 and 14, incident on the photorefractive material 23, they produce a variation in the stationary luminous intensity within it. This alteration changes the refractive index due to a photorefractive effect. Effecting this process at high temperature (180 degree C) results in fixing the alteration of the refractive index. The device reflects a narrow band of reflected wavelengths, with a maximum of twice the spacing of the refractive index fringes. Tuning of the filtered band is achieved by using the inverse piezoelectric effect of the material.",UNIV MADRID,MULLER RENE;;ARIZMENDI LOPEZ LUIS;;CABRERA CASTILLO JOSE MANUEL,,https://lens.org/032-703-212-523-543,Patent Application,no,7,0,3,3,0,,G02B5/28,,0,0,,,,EXPIRED
161,US,A1,US 2004/0118262 A1,099-089-345-682-883,2004-06-24,2004,US 68666503 A,2003-10-17,US 68666503 A;;CL 2000003393 A;;US 517601 A,2000-12-07,Device for the maintenance of semi-autogenous grinding mills used in large-scale mining,"
   A nut cold cutter devise is used in the assembly and maintenance of semi-autogenous grinding mills for large-scale mining. The device includes a front body, a back body and a hydraulic cylindrical chamber located between the front and back bodies. The front body has a defined cavity in which there is a movable cutting tool and a fixed cutting tool. The nut to-be-cut is positioned in the space located between the two cutting tools. The hydraulic cylindrical chamber contains a push piston that is sealed to the inside of said hydraulic cylindrical chamber with watertight joints. The push piston is attached to a toolholder axis and the movable cutting tool is attached to the front end of the toolholder axis. 
",CERDA LUIS ORITZ;;GUZMAN JOSE CABRERA;;LUNA JUSTO VARGAS,CERDA LUIS ORITZ;;GUZMAN JOSE CABRERA;;LUNA JUSTO VARGAS,,https://lens.org/099-089-345-682-883,Patent Application,yes,13,1,5,5,0,B23D29/007;;B26B17/02;;Y10T83/8858;;Y10T225/379;;Y10T83/8858;;Y10T225/379;;B26B17/02;;B23D29/007,B23D29/00;;B26B17/02,83/639.1;;30/92.5,0,0,,,,EXPIRED
162,CU,A,CU 20961 A,072-977-014-555-543,1981-09-09,1981,CU 34798 A,1977-11-25,CU 34798 A,1977-11-25,OBTAINMENT OF ALPHA-TERPINEOL FROM LIMONENE BY TREATMENTWITH MALOGENATED DERIVATIVES OF ORGANIC ACIDS,,MINI EDUCACION SUPERIOR,ARMEUTEROS LEON MERCEDES;;PEREZ ZAYAS JOSE;;CABRERA RABI LEILA,,https://lens.org/072-977-014-555-543,Unknown,no,0,0,1,1,0,,C11B9/02,,0,0,,,,DISCONTINUED
163,US,A1,US 2002/0170406 A1,100-181-311-518-896,2002-11-21,2002,US 517601 A,2001-12-07,CL 2000003393 A,2000-12-07,Device for the maintenance of semi-autogenous grinding mills used in large-scale mining,"
   A nut cold cutter devise is used in the assembly and maintenance of semi-autogenous grinding mills for large-scale mining. The device includes a front body, a back body and a hydraulic cylindrical chamber located between the front and back bodies. The front body has a defined cavity in which there is a movable cutting tool and a fixed cutting tool. The nut to-be-cut is positioned in the space located between the two cutting tools. 

   The hydraulic cylindrical chamber contains a push piston that is sealed to the inside of said hydraulic cylindrical chamber with watertight joints. The push piston is attached to a toolholder axis and the movable cutting tool is attached to the front end of the toolholder axis. 
",DEL COBRE CHILE CORP NAC,CERDA LUIS ORITZ;;GUZMAN JOSE CABRERA;;LUNA JUSTO VARGAS,CORPORACION NACIONAL DEL COBRE DE CHILE (2001-12-04),https://lens.org/100-181-311-518-896,Patent Application,yes,6,2,5,5,0,B23D29/007;;B26B17/02;;Y10T83/8858;;Y10T225/379;;Y10T83/8858;;Y10T225/379;;B26B17/02;;B23D29/007,B23D29/00;;B26B17/02,83/639.1;;30/92.5,0,0,,,,DISCONTINUED
164,CN,A,CN 116953471 A,095-169-291-188-859,2023-10-27,2023,CN 202310314352 A,2023-03-28,US 202217720691 A,2022-04-14,Embedded vehicle trailer circuit tester,"The invention provides an embedded vehicle trailer circuit tester. A trailer test module of a vehicle is electrically connected between a trailer towing electrical connector of the vehicle and a wire harness of the vehicle carrying an electrical signal for a trailer such that when the electrical connector of the trailer is attached to the trailer towing electrical connector, the trailer towing electrical connector is electrically connected to the wire harness of the vehicle. The trailer towing electrical connector is between the trailer test module and the electrical connector of the trailer. The trailer test module includes circuitry that replicates the trailer electrical load.",FORD GLOBAL TECH LLC,RUIZ JOSE EDUARDO;;BAUTISTA AMANDA;;GARSA VINCENZO;;CABRERA IVAN,,https://lens.org/095-169-291-188-859,Patent Application,no,0,0,3,3,0,G01R31/44;;G01R31/007;;G01R31/006;;H01R2201/26;;H01R29/00,G01R31/28;;G01R31/00;;G01R31/44,,0,0,,,,PENDING
165,CA,A1,CA 3213326 A1,152-225-481-235-176,2022-10-06,2022,CA 3213326 A,2022-03-31,EP 21382265 A;;US 2022/0022712 W,2021-03-31,METHODS AND COMPOSITIONS FOR IMPROVING INSULIN PRODUCTION AND SECRETION,"A method of improving insulin production in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and beta-hydroxy-beta-methylbutyrate (HMB) to the subject. A method of improving insulin secretion in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and HMB to the subject. A nutritional composition comprises about 0.01 to about 15 wt % HMB, about 0.03 to about 40 wt % lysine, and about 0.02 to about 30 wt % arginine.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;MANZANO MANUEL,,https://lens.org/152-225-481-235-176,Patent Application,no,0,0,4,4,0,A23L33/10;;A23L33/175;;A61P3/10;;A23V2002/00,A23L33/10;;A23L33/175;;A61P3/10,,0,0,,,,PENDING
166,EP,A3,EP 1213078 A3,184-475-458-712-31X,2004-03-24,2004,EP 01500282 A,2001-12-05,CL 2000003393 A,2000-12-07,A nut splitting device,"This invention leads to the creation of an apparatus for the maintenance of semiautogenous grinding mills used in the great mining field. Specifically the invention deals with an apparatus for cold cutting nuts which has a mobile cutting tool and a fixed cutting tool, in which such apparatus is driven by means of a hydraulic force, it is structured by a frontal body, a rear body and a hydraulic cylindrical chamber positioned between both bodies. Furthermore, this tool can be incorporated to a control manipulation or remote station for its easy operation.",DEL COBRE CHILE CORP NAC;;INST DE INNOVACION EN MINERIA,CERDA ORTIZ LUIS;;GUZMAN CABRERA JOSE;;LUNA VARGAS JUSTO,,https://lens.org/184-475-458-712-31X,Search Report,yes,8,0,5,5,0,B23D29/007;;B26B17/02;;Y10T83/8858;;Y10T225/379;;Y10T83/8858;;Y10T225/379;;B26B17/02;;B23D29/007,B23D29/00;;B26B17/02,,0,0,,,,DISCONTINUED
167,ES,B1,ES 2051224 B1,073-108-175-944-349,1997-07-01,1997,ES 9201336 A,1992-06-25,ES 9201336 A,1992-06-25,FILTRO INTERFERENCIAL DE BANDA ESTRECHA CON MATERIAL FOTORREFRACTIVO.,"FILTRO INTERFERENCIAL DE BANDA ESTRECHA CON MATERIAL FOTORREFRACTIVO ESTA REALIZADO GRABANDO UNA RED HOLOGRAFICA EN UN MATERIAL FOTORREFRACTIVO, LA CUAL POSTERIORMENTE ES FIJADA CON UN TRATAMIENTO TERMICO. MEDIANTE DOS HACES (13) Y (14), INCIDIENDO EN EL MATERIAL FOTORREFRACTIVO (23), PRODUCEN UNA VARIACION DE LA INTENSIDAD LUMINOSA ESTACIONARIA EN SU INTERIOR. ESTA MODULACION CAMBIA EL INDICE DE REFRACCION POR EFECTO FOTORREFRACTIVO. EFECTUANDO ESTE PROCESO A ALTA TEMPERATURA (180 C), RESULTA UNA FIJACION DE LA MODULACION DE INDICE DE REFRACCION. EL DISPOSITIVO REFLEJA UNA BANDA ESTRECHA DE LONGITUDES DE ONDA REFLEJADOS, CON EL MAXIMO EN DOS VECES EL ESPACIADO DE LAS FRANJAS DE INDICE DE REFRACCION. SE CONSIGUE UNA SINTONIZACION DE LA BANDA FILTRADA USANDO EL EFECTO PIEZOELECTRICO INVERSO DEL MATERIAL.",UNIV MADRID AUTONOMA,MULLER RENE;;ARIZMENDI LOPEZ LUIS;;CABRERA CASTILLO JOSE MANUEL,,https://lens.org/073-108-175-944-349,Granted Patent,no,0,0,3,3,0,,G02B5/28,,0,0,,,,EXPIRED
168,WO,A2,WO 2011/163183 A2,090-102-500-011-294,2011-12-29,2011,US 2011/0041183 W,2011-06-21,EP 10380083 A,2010-06-21,METHODS FOR DELAYING PROGRESSION OF DIABETES USING SALACIA OBLONGA EXTRACT,Disclosed are nutritional compositions and methods for delaying the onset or progression of type 2 diabetes in a subject. The methods include administering to a glucose intolerant or diabetic subject a nutritional composition comprising an effective amount of a Salacia oblonga extract for increasing the incretin effect (and/or the glucagon-like peptide-1 and/or gastric inhibitory peptide activity) in the subject. The Salacia oblonga extract may also act to reduce the secretion of glucagon by the pancreas thus decreasing the glucose level in the bloodstream of the subject.,ABBOTT LAB;;LOPEZ PEDROSA JOSE;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,LOPEZ PEDROSA JOSE;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,,https://lens.org/090-102-500-011-294,Patent Application,yes,0,10,3,3,0,A23V2002/00;;A61K36/37;;A23L33/40;;A23L33/105;;A61P5/50,A61K36/37;;A23L1/30,,0,0,,,,PENDING
169,WO,A3,WO 2011/163183 A3,003-409-306-865-588,2012-02-16,2012,US 2011/0041183 W,2011-06-21,EP 10380083 A,2010-06-21,METHODS FOR DELAYING PROGRESSION OF DIABETES USING SALACIA OBLONGA EXTRACT,Disclosed are nutritional compositions and methods for delaying the onset or progression of type 2 diabetes in a subject. The methods include administering to a glucose intolerant or diabetic subject a nutritional composition comprising an effective amount of a Salacia oblonga extract for increasing the incretin effect (and/or the glucagon-like peptide-1 and/or gastric inhibitory peptide activity) in the subject. The Salacia oblonga extract may also act to reduce the secretion of glucagon by the pancreas thus decreasing the glucose level in the bloodstream of the subject.,ABBOTT LAB;;LOPEZ PEDROSA JOSE;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,LOPEZ PEDROSA JOSE;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,,https://lens.org/003-409-306-865-588,Search Report,yes,5,0,3,3,0,A23V2002/00;;A61K36/37;;A23L33/40;;A23L33/105;;A61P5/50,A61K36/37;;A23L1/30;;A61P5/50,,6,3,077-462-364-578-410;;052-136-547-002-552;;050-236-042-247-074,10.1093/ajcn/86.1.124;;17616771;;15975493;;10.1016/j.nut.2004.11.018;;10.1111/j.1463-1326.2007.00750.x;;17645561,"DATABASE WPI Week 200212, Derwent World Patents Index; AN 2002-086164, XP002627580;;DATABASE WPI Week 200204, Derwent World Patents Index; AN 2002-029795, XP002627581;;KRISHNAKUMAR K ET AL: ""Hypolipidaemic effect of Salacia oblonga Wall. root bark in streptozotocin diabetic rats"", MEDICAL SCIENCE RESEARCH 2000 GB, vol. 28, no. 1, 2000, pages 65 - 67, XP009145763, ISSN: 0269-8951;;WILLIAMS JENNIFER A ET AL: ""Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes"", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 86, no. 1, July 2007 (2007-07-01), pages 124 - 130, XP002627998, ISSN: 0002-9165;;COLLENE A L ET AL: ""Effects of a nutritional supplement containing Salacia oblonga extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults"", NUTRITION, ELSEVIER INC, US, vol. 21, no. 7-8, 1 July 2005 (2005-07-01), pages 848 - 854, XP025281295, ISSN: 0899-9007, [retrieved on 20050701], DOI: DOI:10.1016/J.NUT.2004.11.018;;T. H. HUANG ET AL: ""Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor"", DIABETES, OBESITY AND METABOLISM, vol. 10, no. 7, 1 July 2008 (2008-07-01), pages 574 - 585, XP055014674, ISSN: 1462-8902, DOI: 10.1111/j.1463-1326.2007.00750.x",PENDING
170,US,B2,US 6869001 B2,017-098-895-164-554,2005-03-22,2005,US 68666503 A,2003-10-17,US 68666503 A;;CL 2000003393 A;;US 517601 A,2000-12-07,Device for the maintenance of semi-autogenous grinding mills used in large-scale mining,"A nut cold cutter devise is used in the assembly and maintenance of semi-autogenous grinding mills for large-scale mining. The device includes a front body, a back body and a hydraulic cylindrical chamber located between the front and back bodies. The front body has a defined cavity in which there is a movable cutting tool and a fixed cutting tool. The nut to-be-cut is positioned in the space located between the two cutting tools. The hydraulic cylindrical chamber contains a push piston that is sealed to the inside of said hydraulic cylindrical chamber with watertight joints. The push piston is attached to a toolholder axis and the movable cutting tool is attached to the front end of the toolholder axis.",DEL COBRE CHILE CORP NAC;;INST DE INNOVACION EN MINERIA,CERDA LUIS ORTIZ;;GUZMAN JOSE CABRERA;;LUNA JUSTO VARGAS,,https://lens.org/017-098-895-164-554,Granted Patent,yes,13,0,5,5,0,B23D29/007;;B26B17/02;;Y10T83/8858;;Y10T225/379;;Y10T83/8858;;Y10T225/379;;B26B17/02;;B23D29/007,B23D29/00;;B26B17/02,225/104;;30/180;;30/182,0,0,,,,EXPIRED
171,EP,A2,EP 1213078 A2,033-907-537-001-701,2002-06-12,2002,EP 01500282 A,2001-12-05,CL 2000003393 A,2000-12-07,A nut splitting device,"This invention leads to the creation of an apparatus for the maintenance of semiautogenous grinding mills used in the great mining field. Specifically the invention deals with an apparatus for cold cutting nuts which has a mobile cutting tool and a fixed cutting tool, in which such apparatus is driven by means of a hydraulic force, it is structured by a frontal body, a rear body and a hydraulic cylindrical chamber positioned between both bodies. Furthermore, this tool can be incorporated to a control manipulation or remote station for its easy operation.",DEL COBRE CHILE CORP NAC;;INST DE INNOVACION EN MINERIA,CERDA ORTIZ LUIS;;GUZMAN CABRERA JOSE;;LUNA VARGAS JUSTO,,https://lens.org/033-907-537-001-701,Patent Application,yes,0,0,5,5,0,B23D29/007;;B26B17/02;;Y10T83/8858;;Y10T225/379;;Y10T83/8858;;Y10T225/379;;B26B17/02;;B23D29/007,B23D29/00;;B26B17/02,,0,0,,,,DISCONTINUED
172,CN,A,CN 107407618 A,007-141-364-248-992,2017-11-28,2017,CN 201680006605 A,2016-01-12,ES 201530075 A;;ES 2016070008 W,2015-01-21,"Device for conditioning the atmosphere in tests of alternative internal combustion engines, method and use of said device","The invention relates to a device for conditioning the atmosphere in the testing of engines, comprising an entry duct connected to an engine inlet, an exit duct connected to the engine outlet, a communication duct that connects the entry duct to the exit duct, a bypass valve in the entry duct, a super-charging turbo assembly in the entry duct, a heat exchanger in the exit duct, and a turbocharger after the heat exchanger. In addition, the device comprises a first three-way valve that connects the entry duct to the exit duct, a valve that is entirely or not at all in the exit duct, a second three-way valve in the exit duct, a regulation valve in a duct that connects the exit duct to the atmosphere, and a section of the exit duct that connects the exchanger to the communication duct.",UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/007-141-364-248-992,Patent Application,no,5,1,15,15,0,G01M15/04;;G01M15/02;;G01M15/048;;G01M15/04;;G01M15/10;;G01M15/04;;G01M15/02;;G01M15/048;;G01M15/09,G01M15/04;;G01M15/10,,0,0,,,,ACTIVE
173,KR,A,KR 20170125022 A,077-701-427-362-082,2017-11-13,2017,KR 20177023062 A,2016-01-12,ES 201530075 A;;ES 2016070008 W,2015-01-21,대체 내연기관의 시험시 공기를 조정하기 위한 장치 및 방법과 상기 장치의 이용.,"본 발명은 왕복 내연기관을 시험할 때 대기를 조정하기 위한 장치에 관한 것이며, 상기 장치는 연소 엔진의 흡기구에 연결되는 유입구 덕트, - 연소 엔진의 배기구에 연결되는 유출구 덕트, 유입구 덕트를 유출구 덕트와 연통시키는 연통 덕트, 상기 유입구 덕트내에 배열된 바이패스 밸브, 유입구 덕트내부의 수퍼 차징 터보 조립체, 유출구 덕트내에 배열된 열교환기, 열교환기 다음에 배열된 터보 차저를 포함한다. 상기 장치는 유입구 덕트를 유출구 덕트에 연결시키는 제1 삼경로 밸브, 유출구 덕트내에 배열된 온/오프 밸브, 유출구 덕트내에 배열되는 제2 삼경로 밸브, 상기 유출구 덕트를 대기와 연결시키는 제어 밸브, 연통 덕트를 상기 열교환기와 연결시키는 유출구 덕트의 섹션를 추가로 포함한다.",UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/077-701-427-362-082,Patent Application,no,1,0,15,15,0,G01M15/04;;G01M15/02;;G01M15/048;;G01M15/04;;G01M15/10;;G01M15/04;;G01M15/02;;G01M15/048;;G01M15/09,G01M15/04;;G01M15/10,,0,0,,,,ACTIVE
174,US,B2,US 10684195 B2,006-207-430-519-432,2020-06-16,2020,US 201615545132 A,2016-01-12,ES 201530075 A;;ES 2016070008 W,2015-01-21,"Device for conditioning the atmosphere in tests of alternative internal combustion engines, method and use of said device","The invention relates to a device for conditioning the atmosphere when testing engines, comprising an inlet duct connected to an engine intake, an outlet duct connected to the exhaust of the engine, a communication duct that connects the inlet duct to the outlet duct, a bypass valve in the inlet duct, a super-charging turbo assembly in the inlet duct, a heat exchanger in the outlet duct, and a turbocharger after the heat exchanger. The device further comprises a first three-way valve that connects the inlet duct to the outlet duct, an on/off valve in the outlet duct, a second three-way valve in the outlet duct, a control valve in a duct that connects the outlet duct to the atmosphere, and a section of the outlet duct that connects the exchanger to the communication duct.",UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,UNIVERSIDAD POLITECNICA DE VALENCIA (2017-07-06),https://lens.org/006-207-430-519-432,Granted Patent,yes,11,0,15,15,0,G01M15/04;;G01M15/02;;G01M15/048;;G01M15/04;;G01M15/10;;G01M15/04;;G01M15/02;;G01M15/048;;G01M15/09,G01M15/09;;G01M15/02;;G01M15/04,,0,0,,,,ACTIVE
175,CA,A1,CA 3203431 A1,088-291-629-972-17X,2022-07-07,2022,CA 3203431 A,2021-12-20,EP 20383180 A;;US 2021/0064354 W,2020-12-31,METHODS FOR ENHANCING MUSCLE PERFORMANCE OR REDUCING CHRONIC FATIGUE BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMES,A method of enhancing muscle performance in a subject in need of improved physical performance comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof. A method of reducing chronic fatigue in a subject recovering or recovered from a viral infection comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject.,ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JORGE,,https://lens.org/088-291-629-972-17X,Patent Application,no,0,0,5,5,0,A23J1/20;;A23C21/00;;A61P11/00;;A61P21/00;;A61P31/00;;A23L33/19;;A23L33/40;;A23C2240/05;;A61P11/00;;A61P21/00;;A61P31/00;;A23J1/20;;A23L33/40;;A23L33/19;;A23C2240/05;;A23C21/00,A23C21/00;;A23J1/20;;A61P11/00;;A61P21/00;;A61P31/00,,0,0,,,,PENDING
176,BR,A2,BR PI0703890 A2,177-544-294-283-24X,2010-08-31,2010,BR PI0703890 A,2007-10-22,MX 2007002289 A,2007-02-23,"queimador para fogões a gás, configuracão de queimadores, método para controlar um conjunto de queimadores e porta para passagem de uma chama em um queimador","QUEIMADOR PARA FOGOES A GAS, CONFIGURAcAO DE QUEIMADORES, MéTODO PARA CONTROLAR UM CONJUNTO DE QUEIMADORES E PORTA PARA PASSAGEM DE UMA CHAMA EM UM QUEIMADOR. A presente invencao se refere a um queimador (2) para tampas de fogões ou similares, de modo a estabelecer uma ampla gama de capacidades caloríficas e uma melhor distribuicao dos queimadores na tampa, apresentando um formato geralmente semi-retangular, contendo uma pluralidade de portas (30,31,32) e uma pluralidade de maneiras de acendimento, capaz de interagir com outros queimadores de distâncias determinadas de comprimento (Z) e altura (H), gerando chamas descontinuas entre os queimadores (1,2)",MABE MEXICO S DE R L DE C V,CALOCA GALINDO VICTOR GERALDO;;ARTUROLONA SANTOYO JOSE;;BOTELLO ROBERTO CABRERA,,https://lens.org/177-544-294-283-24X,Patent Application,no,0,0,5,5,0,F23D14/06;;F23D14/58;;F23D14/06;;F23D14/58,F23D14/02;;F23D14/06;;F24C3/08,,0,0,,,,DISCONTINUED
177,MX,A,MX 2013010831 A,170-085-235-139-059,2013-11-18,2013,MX 2013010831 A,2012-03-20,EP 11380021 A;;US 2012/0029796 W,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING LONG CHAIN POLYUNSATURATED FATTY ACIDS.,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/170-085-235-139-059,Patent Application,no,0,0,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A23L1/30;;A61K31/201;;A61K31/202;;A61P19/00,,0,0,,,,PENDING
178,BR,A2,BR 112014017225 A2,190-839-896-387-694,2017-06-13,2017,BR 112014017225 A,2013-01-11,US 2013/0021166 W;;EP 12382010 A;;EP 12382011 A,2012-01-13,uso de sistemas de carboidrato específicos durante gravidez para efetuar os descendentes,"resumo uso de sistemas de carboidrato específicos durante gravidez para efetuar os descendentes a presente descrição diz respeito a uma combinação de carboidratos (uma taxa de digestão lenta de carboidrato simples, um carboidrato complexo, um carboidrato não absorvente e um oligossacarídeo não digerível) para uso em um método de tratar uma mulher grávida em que o método resulta em uma melhoria na saúde dos descendentes da mulher grávida. a descrição também diz respeito ao uso da combinação de carboidratos para a fabricação de um medicamento para uso no tratamento de uma mulher grávida em que o tratamento resulta em uma melhoria na saúde dos descendentes da mulher grávida. a melhoria pode ser uma redução de pelo menos um efeito de saúde adverso a longo prazo e/ou uma melhoria no desenvolvimento de massa corporal magra e formação dos descendentes. a combinação de carboidratos também pode ser administrada às mulheres durante lactação para ainda melhorar a saúde dos descendentes.",ABBOTT LAB,JOSE MARIA LOPEZ PEDROSA;;MANUELCRISTOBAL MANZANO MARTIN;;RICARDO RUEDA CABRERA,,https://lens.org/190-839-896-387-694,Patent Application,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L33/00,,0,0,,,,DISCONTINUED
179,CN,A,CN 115190765 A,176-798-861-615-516,2022-10-14,2022,CN 202180017344 A,2021-02-26,EP 20382139 A;;US 2021/0019908 W,2020-02-27,Methods of improving bone health,"Provided herein is a method of promoting bone health in a moderate dystrophy subject. The method comprises treating the moderate dystrophy subject with a nutritional composition comprising a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate providing rapid availability of glucose, a source of at least one carbohydrate providing slow availability of glucose, and a source of at least one non-digestible carbohydrate or resistant starch.",ABBOTT LAB,LOPEZ PEDROSA JOSE MANUEL;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,,https://lens.org/176-798-861-615-516,Patent Application,no,23,0,9,9,0,A23L33/18;;A23L33/115;;A23L33/24;;A23L33/21;;A23L33/125;;A23V2002/00;;A23L33/30;;A61K31/7016;;A61K31/702;;A61K31/715;;A61P19/00;;A61P3/02;;A23L33/24;;A23V2002/00;;A23V2250/5108;;A23L33/18;;A23V2250/54;;A23L33/115;;A23V2250/5118;;A23L33/21;;A23V2250/5116;;A23L33/30;;A23V2250/628;;A23V2200/306;;A23L33/125;;A23V2250/62;;A61K31/7016;;A23V2250/5114;;A61P3/02;;A23V2250/5062;;A61P19/00;;A61K31/715;;A23V2250/194;;A61K31/702;;A61K2300/00;;A23L33/24;;A23L33/125;;A61P19/08;;A23V2002/00;;A61K31/7004;;A61K31/7016;;A61K31/702;;A61K31/718,A23L33/125;;A23L33/00;;A23L33/21;;A23L33/24;;A61K31/7016;;A61K31/702;;A61K31/715,,2,0,,,"刘小杰;赵允;童纪峰;: ""菊粉与骨健康的研究"", 中国食品添加剂, no. 1, pages 151 - 153;;吴益群;郁正刚;: ""各类营养物质与骨骼健康"", 中国骨质疏松杂志, vol. 18, no. 09, pages 867 - 874",PENDING
180,TW,A,TW 201244642 A,138-562-893-175-296,2012-11-16,2012,TW 101109738 A,2012-03-21,EP 11038002 A,2011-03-21,Methods for improving bone health in infants using prebiotics,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/138-562-893-175-296,Patent of Addition,no,0,0,2,2,0,,A23L1/30;;A23L33/155;;C07H3/06,,0,0,,,,PENDING
181,US,A1,US 2018/0283990 A1,067-740-128-583-335,2018-10-04,2018,US 201615545132 A,2016-01-12,ES 201530075 A;;ES 2016070008 W,2015-01-21,"DEVICE FOR CONDITIONING THE ATMOSPHERE IN TESTS OF ALTERNATIVE INTERNAL COMBUSTION ENGINES, METHOD AND USE OF SAID DEVICE","The invention relates to a device for conditioning the atmosphere when testing engines, comprising an inlet duct connected to an engine intake, an outlet duct connected to the exhaust of the engine, a communication duct that connects the inlet duct to the outlet duct, a bypass valve in the inlet duct, a super-charging turbo assembly in the inlet duct, a heat exchanger in the outlet duct, and a turbocharger after the heat exchanger. The device further comprises a first three-way valve that connects the inlet duct to the outlet duct, an on/off valve in the outlet duct, a second three-way valve in the outlet duct, a control valve in a duct that connects the outlet duct to the atmosphere, and a section of the outlet duct that connects the exchanger to the communication duct.",UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,UNIVERSIDAD POLITECNICA DE VALENCIA (2017-07-06),https://lens.org/067-740-128-583-335,Patent Application,yes,4,2,15,15,0,G01M15/04;;G01M15/02;;G01M15/048;;G01M15/04;;G01M15/10;;G01M15/04;;G01M15/02;;G01M15/048;;G01M15/09,G01M15/09;;G01M15/04,,0,0,,,,ACTIVE
182,CA,A1,CA 3198544 A1,071-560-900-998-47X,2022-05-27,2022,CA 3198544 A,2021-11-17,EP 20383006 A;;US 2021/0059599 W,2020-11-18,METHODS OF INCREASING HEIGHT AND PROMOTING LINEAR BONE GROWTH,"A method of increasing height in a pediatric subject comprises enterally administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric subject in need thereof. A method of promoting linear bone growth in a pediatric subject comprises enterally administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric subject in need thereof. A method of obtaining an exosome-enriched product from cheese whey comprises subjecting the cheese whey to microfiltration (MF), ultrafiltration (UF), and diafiltration (DF) steps, wherein the MF, UF, and DF steps employ, successively, membranes with cut off values which gradually decrease in size with each filtration step, wherein the cheese whey is sweet cheese whey and has a pH from about 6.0 to about 6.5.",CIPO;;ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JORGE,,https://lens.org/071-560-900-998-47X,Patent Application,no,0,0,6,6,0,A23C9/1425;;A23C2210/206;;A23L33/10;;A61P19/08;;A61K35/20;;A23C9/1425;;A61P19/08;;A61K35/20;;A23C2210/206;;A23L33/10;;A23L33/10;;A23L33/40;;A61P19/00;;B01D61/149;;A23C9/1425;;A23C2210/206;;A61K9/1276;;A61K35/20;;A61K47/183;;A61K47/42;;B01D61/145;;B01D61/147;;B01D2315/16,A23C9/142;;A23L33/10;;A23L33/115;;A61P19/08,,0,0,,,,PENDING
183,WO,A1,WO 2012/129220 A1,112-219-602-302-40X,2012-09-27,2012,US 2012/0029788 W,2012-03-20,EP 11380020 A,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING PREBIOTICS,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB;;PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/112-219-602-302-40X,Patent Application,yes,1,0,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A61K31/733;;A23L1/308;;A61P19/00,,0,0,,,,PENDING
184,CN,A,CN 106415232 A,103-108-506-943-380,2017-02-15,2017,CN 201580005799 A,2015-01-21,ES 201430071 A;;ES 2015070037 W,2014-01-24,"Device for atmosphere conditioning for testing combustion engines, and associated method and use","The invention relates to an atmosphere conditioning device for testing engines, comprising an inflow conduit connected to an engine admission, an outflow conduit connected to the exhaust of the engine and expelling exhaust gases, a communication conduit which communicates the inflow conduit with the outflow conduit, a supercharging turbogenerator comprising a turbine in the inflow conduit, a bypass valve which diverts the circulating air flow towards the turbine, a heat regenerator consisting of heat exchangers in the inlet and outlet conduits, connected by the same circuit of heat transfer fluid, a bypass valve in the outflow conduit together with the heat exchanger thereof, a heat exchanger in the outflow conduit, downstream from the heat regenerator, and a turbocompressor downstream from the heat exchanger.",UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/103-108-506-943-380,Patent Application,no,9,3,13,13,0,F02M35/10242;;G01M15/02;;G01M15/02,G01M15/04;;G01M15/10,,0,0,,,,ACTIVE
185,EP,A1,EP 2502506 A1,133-684-000-375-957,2012-09-26,2012,EP 11380021 A,2011-03-21,EP 11380021 A,2011-03-21,Methods for improving bone health in infants using long chain polyunsaturated fatty acids,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.
",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,,https://lens.org/133-684-000-375-957,Patent Application,yes,2,2,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A61K31/201;;A23L1/30;;A61K31/202;;A61P19/00,,3,3,001-822-226-531-648;;118-980-346-710-620;;034-599-568-043-482,10.1079/bjn20041252;;15522133;;10.1016/j.livsci.2007.01.047;;10.1016/j.bone.2007.04.020,"DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 2004 (2004-10-01), KOROTKOVA M ET AL: ""Dietary n-6:n-3 fatty acid ratio in the perinatal period affects bone parameters in adult female rats."", XP002656439, Database accession no. NLM15522133;;PUZIO ET AL: ""Dietary bioactive substances influenced perinatal bone development in piglets"", LIVESTOCK SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 108, no. 1-3, 29 April 2007 (2007-04-29), pages 72 - 75, XP022052797, ISSN: 1871-1413, DOI: 10.1016/J.LIVSCI.2007.01.047;;BURR ET AL: ""Early life diet enrichment with arachidonic and docosahexaenoic acids attenuates the effects of intrauterine growth restriction on bone mass in weanling guinea pigs"", BONE, PERGAMON PRESS., OXFORD, GB, vol. 40, no. 6, 1 June 2007 (2007-06-01), pages S31, XP022121634, ISSN: 8756-3282, DOI: 10.1016/J.BONE.2007.04.020",DISCONTINUED
186,CA,A1,CA 3187114 A1,149-616-884-376-678,2022-02-03,2022,CA 3187114 A,2021-07-26,EP 20382704 A;;US 2021/0043209 W,2020-07-31,"METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE","A method of preventing, reducing, or delaying the onset of fatty liver disease in a subject comprises enterally administering intact bovine milk-derived exosomes consisting of endogenous cargo to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the intact bovine milk-derived exosomes consisting of endogenous cargo can be administered in an amount effective to reduce de novo lipogenesis in the subject. The intact bovine milk-derived exosomes consisting of endogenous cargo can be administered to the subject directly or in a nutritional composition.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JORGE,,https://lens.org/149-616-884-376-678,Patent Application,no,0,0,7,7,0,A23L33/19;;A23L33/13;;A23L33/115;;A61P1/16;;A61K35/20;;A61P1/16;;A61K9/16;;A61K35/20,A23L33/115;;A23L33/13;;A23L33/19;;A61P1/16,,0,0,,,,PENDING
187,TW,A,TW 201244643 A,173-907-591-241-366,2012-11-16,2012,TW 101109739 A,2012-03-21,EP 11038002 A,2011-03-21,Methods for improving bone health in infants using long chain polyunsaturated fatty acids,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/173-907-591-241-366,Patent of Addition,no,0,0,2,2,0,,A23L1/30;;A23L33/155;;C07C11/00,,0,0,,,,PENDING
188,BR,A2,BR 112013024189 A2,093-771-859-636-546,2016-12-13,2016,BR 112013024189 A,2012-03-20,US 2012/0029796 W;;EP 11380021 A,2011-03-21,métodos para aprimorar saúde óssea em crianças com o uso de ácidos graxos poli-insaturados de cadeia longa,"resumo métodos para aprimorar saúde óssea em crianças com o uso de ácidos graxos poli-insaturados de cadeia longa são revelados métodos para aprimorar a saúde, a resistência e a formação ósseas em uma criança que pode ser suscetível ao desenvolvimento de problemas de saúde óssea da concepção até a adolescência. os métodos incluem a administração de uma formulação nutricional que inclui pelo menos um lcpufa a uma mulher durante a gestação e opcio-nalmente durante a lactação e a amamentação de uma criança.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/093-771-859-636-546,Patent Application,no,0,0,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A61K31/201;;A61K31/202;;A61P19/00,,0,0,,,,DISCONTINUED
189,CN,A,CN 103561592 A,023-492-267-658-855,2014-02-05,2014,CN 201280024316 A,2012-03-20,US 2012/0029788 W;;EP 11380020 A,2011-03-21,Methods for improving bone health in infants using prebiotics,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/023-492-267-658-855,Patent Application,no,3,3,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A23L1/308;;A61K31/733;;A61P19/00,,1,0,,,"庞明利: ""益生元在奶粉中的应用"", 《中国食品添加剂》",DISCONTINUED
190,CA,A1,CA 2829598 A1,083-626-188-701-824,2012-09-27,2012,CA 2829598 A,2012-03-20,EP 11380020 A;;US 2012/0029788 W,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING PREBIOTICS,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/083-626-188-701-824,Patent Application,no,0,0,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A23L1/308;;A61K31/733;;A61P19/00,,0,0,,,,DISCONTINUED
191,NZ,A,NZ 615194 A,110-807-810-020-034,2015-02-27,2015,NZ 61519412 A,2012-03-20,US 2012/0029788 W;;EP 11380020 A,2011-03-21,Methods for improving bone health in infants using prebiotics,"Disclosed is the use of a prebiotic in the manufacture of a medicament for improving bone health, increasing bone strength, or promoting bone formation in an infant, where the medication is a nutritional formulation administered to a pregnant woman.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/110-807-810-020-034,Patent Application,no,0,0,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A23L1/308;;A61K31/733;;A61P19/00,,0,0,,,,DISCONTINUED
192,CN,A,CN 104135872 A,116-266-859-288-276,2014-11-05,2014,CN 201380011154 A,2013-01-11,US 2013/0021166 W;;EP 12382010 A;;EP 12382011 A,2012-01-13,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR EFFECTING THE OFFSPRING,"The present disclosure is directed to a combination of carbohydrates (a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide) for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the offspring of the pregnant woman. The disclosure is also directed to use of the combination of carbohydrates for the manufacture of a medicament for use in the treatment of a pregnant woman wherein the treatment results in an improvement in the health of the offspring of the pregnant woman. The improvement can be a reduction of at least one long term adverse health effect and/or an improvement in lean body mass development and formation of the offspring. The combination of carbohydrates may also be administered to the woman during lactation to further the improvement in the health of the offspring.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA;;MARTIN MANUELCRISTOBAL MANZANO,,https://lens.org/116-266-859-288-276,Patent Application,no,4,1,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L1/0522;;A23L1/09;;A23L1/30;;A23L1/308;;A23L33/00,,1,0,,,"陈仁惇: ""《营养保健食品》"", 31 December 2001, 北京：中国轻工业出版社",DISCONTINUED
193,TW,A,TW 201332555 A,117-865-236-520-762,2013-08-16,2013,TW 102101222 A,2013-01-11,EP 12382010 A;;EP 12382011 A,2012-01-13,Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring,"The present disclosure is directed to the combination of a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the offspring of the pregnant woman. The disclosure is also directed to use of the combination of a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide for the manufacture of a medicament for use in the treatment of a pregnant woman wherein the treatment results in an improvement in the health of the offspring of the pregnant woman. The improvement in the health of the offspring can be a reduction of at least one long term adverse health effect and/or an improvement in lean body mass development and formation of the offspring. The combination of carbohydrates includes a slow rate of digestion simple carbohydrate and a complex carbohydrate in combination with a non-absorbent carbohydrate and/or an indigestible carbohydrate. The carbohydrates may also be administered during lactation to further the improvement in the health of the offspring.",ABBOTT LAB,LOPEZ-PEDROSA JOSE MARIA;;RUEDA-CABRERA RICARDO;;MARTIN MANUELCRISTOBAL MANZANO,,https://lens.org/117-865-236-520-762,Patent of Addition,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A61K31/718;;A23L1/09;;A23L1/308;;A23L33/00;;A61K31/7016;;A61K31/702;;A61P3/04;;A61P43/00,,0,0,,,,PENDING
194,CN,A,CN 115361879 A,039-851-879-914-365,2022-11-18,2022,CN 202180027612 A,2021-04-01,EP 20382267 A;;EP 20382934 A;;US 2021/0025300 W,2020-04-03,"Milk exosome products and methods, nutritional compositions and methods of treatment","A method of obtaining an exosome-rich product comprises providing a whey-containing milk fraction, subjecting the whey-containing milk fraction to a first centrifugation to obtain a whey intermediate fraction, subjecting the whey intermediate fraction to a second centrifugation at an increased rate to obtain a concentrated whey fraction, and subjecting the concentrated whey fraction to a third centrifugation to obtain an exosome-rich product. Filtering the concentrated whey fraction to obtain a filtered whey fraction, and subjecting the filtered whey fraction to a third centrifugation at a further increased rate to obtain an exosome-rich product. The exosome-rich product comprises intact exosomes and less than 5% by weight of casein, based on the total weight of proteins in the exosome-rich product. Nutritional compositions comprise proteins, carbohydrates and/or fats and exosomes provided by addition of the exosome-rich product. A method of improving insulin sensitivity in a subject comprises administering a nutritional composition comprising the exosome-rich product.",ABBOTT LAB,LOPEZ PEDROSA JOSE MANUEL;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JAVIER,,https://lens.org/039-851-879-914-365,Patent Application,no,0,1,8,8,0,A23L33/13;;A23C9/20;;A23C9/1512;;A61K9/1276;;A61K35/20;;A23L33/40;;A61P3/10;;A61K9/0095;;A61K35/12;;A23L33/13;;A61K9/1276;;A61K35/12;;A61K9/0095;;A61P3/10;;A23L33/40;;A61K35/20;;A23C9/1512;;A23C9/20;;A23L33/40;;A61P3/10;;A23C9/1425;;A61K35/20,A23L33/13;;A23C9/15;;A23C9/20;;A23L33/00;;A61K9/127;;A61K31/7105;;A61K35/20;;A61P3/10,,0,0,,,,DISCONTINUED
195,CA,A1,CA 2829794 A1,176-315-258-120-843,2012-09-27,2012,CA 2829794 A,2012-03-20,EP 11380021 A;;US 2012/0029796 W,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING LONG CHAIN POLYUNSATURATED FATTY ACIDS,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/176-315-258-120-843,Patent Application,no,0,0,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A23L1/30;;A61K31/201;;A61K31/202;;A61P19/00,,0,0,,,,DISCONTINUED
196,CA,A1,CA 3172602 A1,189-975-735-565-235,2021-10-07,2021,CA 3172602 A,2021-04-01,EP 20382267 A;;EP 20382934 A;;US 2021/0025300 W,2020-04-03,"BOVINE MILK EXOSOME PRODUCTS AND METHODS, NUTRITIONAL COMPOSITIONS, AND THERAPEUTIC METHODS","A method of obtaining an exosome-enriched product comprises providing a whey-containing bovine milk fraction, conducting a first centrifugation of the whey-containing bovine milk fraction to obtain a whey middle fraction, conducting a second centrifugation of the whey middle fraction at an increased speed to obtain a concentrated whey fraction, filtering the concentrated whey fraction to obtain a filtered whey fraction, and conducting a third centrifugation of the filtered whey fraction at a further increased speed to obtain an exosome-enriched product. The exosome-enriched product comprises intact exosomes and less than 5 wt% casein based on the total weight of protein in the exosome-enriched product. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes provided by addition of the exosome-enriched product. A method of improving insulin sensitivity in a subject comprises administering a nutritional composition comprising the exosome-enriched product.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JORGE,,https://lens.org/189-975-735-565-235,Patent Application,no,0,0,8,8,0,A23L33/13;;A23C9/20;;A23C9/1512;;A61K9/1276;;A61K35/20;;A23L33/40;;A61P3/10;;A61K9/0095;;A61K35/12;;A23L33/13;;A61K9/1276;;A61K35/12;;A61K9/0095;;A61P3/10;;A23L33/40;;A61K35/20;;A23C9/1512;;A23C9/20;;A23L33/40;;A61P3/10;;A23C9/1425;;A61K35/20,A23L33/13;;A23C9/15;;A23C9/20;;A61P3/10,,0,0,,,,PENDING
197,ES,B2,ES 2401871 B2,080-002-000-482-486,2013-09-09,2013,ES 201131537 A,2011-09-23,ES 201131537 A,2011-09-23,DISPOSITIVO DE TRATAMIENTO DE GASES DE ESCAPE DE LOS MCIA DIESEL TURBO-SOBREALIMENTADOS,,UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/080-002-000-482-486,Granted Patent,no,0,0,3,3,0,F01N3/035;;F01N13/10;;F01N13/1805;;F02M26/15,F01N13/14;;F01N3/035;;F01N13/10;;F02M25/07,,0,0,,,,ACTIVE
198,WO,A3,WO 2007/064184 A3,015-064-125-323-370,2007-07-19,2007,MX 2006000134 W,2006-11-29,MX GT05000016 A,2005-11-30,PNEUMATIC SEED METERING UNIT FOR PRECISION SEEDERS,"The invention relates to a pneumatic metering unit which forms an essential component of an automatic precision seeder and which is particularly suitable for large seeds having an atypical shape, such as garlic, onion and similar. The invention makes use of a hopper with an oscillating base and an adjustable hatch in order to facilitate and control the flow of seeds being supplied. The invention is primarily used to meter seeds (separation of individual seeds and ordered delivery) and said operation is performed satisfactorily using various different factors, such as: a suitable, constant seed level in the separation chamber; seed mixing by means of the vibration of the oscillating plate with an amplitude and frequency in accordance with the properties of the seed; the shape and kinematic parameters of the dispensing disks which are mounted in pairs and which combine suction adhesion with mechanical support; the geometric configuration of the periphery of the disks (backs) and the cover (chute), which eliminates double-amount-type errors; the continuous cleaning of the ducts using an air jet, which prevents permanent clogging and which significantly reduces breakdown-type errors; suitable values for the generated pressure and vacuum; and checking of the sealing system in order to prevent suction losses. The suction and pressure generated by the centrifugal fans are conveyed to the metering unit through flexible corrugated pipes which are connected to the dispenser and are subsequently directed through the axially-divided central hollow shaft to the respective ducts of the rotating metering disks. The rotational movement of the dispensing disks is generated from follower wheels by means of a suitable standard transmission system in accordance with the desired seeding rate. The components of the metering unit can be assembled in different arrangements such as to be adapted to furrow planting with two rows or bed planting with multiple rows.",UNIV GUANAJUATO;;CABRERA SIXTO JOSE MANUEL;;CALDERON REYES EFRAIN;;SERWATOWSKI HLAWINSKA RYSZARD,CABRERA SIXTO JOSE MANUEL;;CALDERON REYES EFRAIN;;SERWATOWSKI HLAWINSKA RYSZARD,,https://lens.org/015-064-125-323-370,Search Report,yes,5,0,4,4,0,A01C7/044,A01C7/04,,0,0,,,,PENDING
199,ES,B1,ES 2136501 B1,028-525-768-408-07X,2000-07-01,2000,ES 9601525 A,1996-07-09,ES 9601525 A,1996-07-09,PROCEDIMIENTO MEJORADO DE SEPARACION DEL CARBON Y LOS ESTERILES EN UNA EXTRACCION CARBONIFERA.,"Procedimiento mejorado de separación del carbón y los estériles en una extracción carbonífera. El procedimiento consisteesencialmente en hacer una separación densimétrica del todo-uno extraído en la mina, de forma, en que una balsa de flotación, que contiene un medio denso de densidad controlada (entre 1,35-1,60 g/cm{sup,3 ), se vierte el material a tratarproduciéndose la flotación del carbón, con una densidad media de 1,25 g/cm{sup,3 , y la sedimentación de los estériles, con una densidad media de 2,5 g/cm{sup,3 . La porción de carbón flotada se recoge en la superficie de la balsa con un medio mecánico, se lava con agua y se escurre, obteniéndoseel carbón vendible. La porción sedimentada (los estériles) se extraen mecánicamente de forma continua, llevándose a lasescombreras.El producto utilizado para la formación del medio denso en la balsa de flotación es una marga arcillosa obtenido junto con el carbón en el material extraído en la mina.El procedimiento se usa para tratar los materialesextraídosen cuencas carboníferas del bajo segre.",CARBONIFERA DEL EBRO S A,CABRERA DOMINGO JOSE;;IBARS PLA EMILI;;IBARS PLA JOSEP MARIA,,https://lens.org/028-525-768-408-07X,Granted Patent,no,0,0,2,2,0,,B03B5/30;;B03B9/00,,0,0,,,,EXPIRED
200,BR,A8,BR 112014017225 A8,010-334-045-815-602,2017-07-04,2017,BR 112014017225 A,2013-01-11,US 2013/0021166 W;;EP 12382010 A;;EP 12382011 A,2012-01-13,uso de sistemas de carboidrato específicos durante gravidez para efetuar os descendentes,"resumo uso de sistemas de carboidrato específicos durante gravidez para efetuar os descendentes a presente descrição diz respeito a uma combinação de carboidratos (uma taxa de digestão lenta de carboidrato simples, um carboidrato complexo, um carboidrato não absorvente e um oligossacarídeo não digerível) para uso em um método de tratar uma mulher grávida em que o método resulta em uma melhoria na saúde dos descendentes da mulher grávida. a descrição também diz respeito ao uso da combinação de carboidratos para a fabricação de um medicamento para uso no tratamento de uma mulher grávida em que o tratamento resulta em uma melhoria na saúde dos descendentes da mulher grávida. a melhoria pode ser uma redução de pelo menos um efeito de saúde adverso a longo prazo e/ou uma melhoria no desenvolvimento de massa corporal magra e formação dos descendentes. a combinação de carboidratos também pode ser administrada às mulheres durante lactação para ainda melhorar a saúde dos descendentes.",ABBOTT LAB,JOSE MARIA LOPEZ PEDROSA;;MANUELCRISTOBAL MANZANO MARTIN;;RICARDO RUEDA CABRERA,,https://lens.org/010-334-045-815-602,Patent Application,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L33/00,,0,0,,,,DISCONTINUED
201,CN,A,CN 103533853 A,092-508-797-803-550,2014-01-22,2014,CN 201280024423 A,2012-03-20,US 2012/0029796 W;;EP 11380021 A,2011-03-21,Methods for improving bone health in infants using long chain polyunsaturated fatty acids,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/092-508-797-803-550,Patent Application,no,3,0,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A23L1/30;;A61K31/201;;A61K31/202;;A61P19/00,,3,3,034-599-568-043-482;;118-980-346-710-620;;001-822-226-531-648,10.1016/j.bone.2007.04.020;;10.1016/j.livsci.2007.01.047;;10.1079/bjn20041252;;15522133,"BURR ET AL: ""Early life diet enrichment with arachidonic and docosahexaenoic acids attenuates the effects of intrauterine growth restriction on bone mass in weanling guinea pigs"", 《PERGAMON PRESS》, vol. 4, no. 6, 31 December 2007 (2007-12-31), pages 31;;PUZIO ET AL: ""Dietary bioactive substances influenced perinatal bone development in piglets"", 《LIVESTOCK SCIENCE》, vol. 108, no. 13, 31 December 2007 (2007-12-31), pages 72 - 75;;KOROTKOVA M ET AL: ""Dietary n-6:n-3 fatty acid ratio in the perinatal period affects bone parameters in adult female rats"", 《US NATIONAL LIBRARY OF MEDICINE》, vol. 92, no. 4, 31 December 2004 (2004-12-31), pages 643 - 648",DISCONTINUED
202,WO,A1,WO 2013/041747 A1,053-588-426-398-048,2013-03-28,2013,ES 2012070589 W,2012-07-30,ES 201131537 A,2011-09-23,DEVICE FOR TREATING EXHAUST GASES FROM DIESEL TURBO-SUPERCHARGED RECIPROCATING INTERNAL COMBUSTION ENGINES (RICE),"The invention relates to a device for treating exhaust gases (1) from diesel turbo-supercharged reciprocating internal combustion engines (RICE), comprising an outer shell (2) joined to the cylinder head of the engine and the turbine by means of joining (3) and fixing (4) flanges, at least one inlet branch (10) containing at least one oxidation pre-catalyst (12), at least one particle filter (14), at least one oxidation post-catalyst (13) downstream of the particle filters (14), at least one outlet conduit (20) comprising at least some vents (9) through which recirculated exhaust gases (EGR) circulate, and at least one insulating chamber (8) used to regulate the recirculated exhaust gases (EGR) and arranged between the shell (2) and an inner wall (7). Said device is characterised by empty spaces (15), (18) and (19) arranged such that they enable the expansion, contraction, lateral diffusion and homogenisation of the flow of the exhaust gases at the outlet and inlet of the channels.",UNIV VALENCIA POLITECNICA;;DESANTES FERNANDEZ JOSE MARIA;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,DESANTES FERNANDEZ JOSE MARIA;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/053-588-426-398-048,Patent Application,yes,7,0,3,3,0,F01N3/035;;F01N13/10;;F01N13/1805;;F02M26/15,F01N13/14;;F01N3/035;;F01N13/10;;F02M25/07,,0,0,,,,PENDING
203,US,A1,US 2012/0245123 A1,153-937-396-514-703,2012-09-27,2012,US 201213424891 A,2012-03-20,EP 11380020 A,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING PREBIOTICS,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",LOPEZ PEDROSA JOSE MARIA;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA;;ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,ABBOTT LABORATORIES (2012-04-04),https://lens.org/153-937-396-514-703,Patent Application,yes,1,12,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A61K31/702;;A61K31/718;;A61P19/00,514/60;;514/54,6,3,003-146-367-557-069;;099-463-184-692-075;;039-826-906-815-297,10.12968/bjom.2007.15.6.23684;;10.1203/01.pdr.0000185129.73971.74;;16306203;;8134190;;10.1203/00006450-199401000-00027,"Abrams (Therapeutic Microbiology (2008), 175-182) (abstact sent).;;Hale (British Journal of Midwifery, Vol. 15, No. 6, 07 Jun 2007, pp 368 - 371).(abstract sent).;;Scholz-Ahrens et al. (The Journal of Nutrition; Mar 2007; 137, 3S, 838S-846S).;;Weiler et al. (Pediatric Research (2005) Vol. 58, No. 6, 1254-1258).;;Kovacs (Am J Clin Nutr 2008;88(suppl):520S- 8S);;Pohlandt (Pediatric Research; Vol. 35, No. 1, 1994, pages 125-129).",DISCONTINUED
204,WO,A2,WO 2007/064184 A2,023-427-825-347-410,2007-06-07,2007,MX 2006000134 W,2006-11-29,MX GT05000016 A,2005-11-30,PNEUMATIC SEED METERING UNIT FOR PRECISION SEEDERS,"The invention relates to a pneumatic metering unit which forms an essential component of an automatic precision seeder and which is particularly suitable for large seeds having an atypical shape, such as garlic, onion and similar. The invention makes use of a hopper with an oscillating base and an adjustable hatch in order to facilitate and control the flow of seeds being supplied. The invention is primarily used to meter seeds (separation of individual seeds and ordered delivery) and said operation is performed satisfactorily using various different factors, such as: a suitable, constant seed level in the separation chamber; seed mixing by means of the vibration of the oscillating plate with an amplitude and frequency in accordance with the properties of the seed; the shape and kinematic parameters of the dispensing disks which are mounted in pairs and which combine suction adhesion with mechanical support; the geometric configuration of the periphery of the disks (backs) and the cover (chute), which eliminates double-amount-type errors; the continuous cleaning of the ducts using an air jet, which prevents permanent clogging and which significantly reduces breakdown-type errors; suitable values for the generated pressure and vacuum; and checking of the sealing system in order to prevent suction losses. The suction and pressure generated by the centrifugal fans are conveyed to the metering unit through flexible corrugated pipes which are connected to the dispenser and are subsequently directed through the axially-divided central hollow shaft to the respective ducts of the rotating metering disks. The rotational movement of the dispensing disks is generated from follower wheels by means of a suitable standard transmission system in accordance with the desired seeding rate. The components of the metering unit can be assembled in different arrangements such as to be adapted to furrow planting with two rows or bed planting with multiple rows.",UNIV GUANAJUATO;;CABRERA SIXTO JOSE MANUEL;;CALDERON REYES EFRAIN;;SERWATOWSKI HLAWINSKA RYSZARD,CABRERA SIXTO JOSE MANUEL;;CALDERON REYES EFRAIN;;SERWATOWSKI HLAWINSKA RYSZARD,,https://lens.org/023-427-825-347-410,Patent Application,yes,0,21,4,4,0,A01C7/044,A01C7/04,,0,0,,,,PENDING
205,BR,A,BR PI0517713 A,036-140-858-807-501,2008-10-21,2008,BR PI0517713 A,2005-11-29,CU 20040277 A;;CU 2005000010 W,2004-12-08,inoculante micorrìzico lìquido,"INOCULANTE MICORRìZICO LìQUIDO. A solução técnica proposta se relaciona com o ramo da agricultura, a biotecnologia do solo e especificamente com a produção e aplicação dos fungos micorrízicos arbusculares, microorganismo que melhora a eficiência na captação de nutrientes pelas plantas, nível hidrico, produção vegetal, proteção contra alguma das doenças da raiz, etc. Ele consiste em um produto líquido para a aplicação dos fungos micorrízicos arbusculares,partindo da utilização de um meio aquoso que permite obter uma estabilização dos propágulos micorrízicos que possibilita a formação de agregados de solos e uma viabilidade comprovada em meio líquido entre 12 e18 meses que se pode utilizar nos sistemas de irrigação e ferti-irrigação,aplicando-se de forma direta em campos ou estufas de cultivo protegido, além de permitir a superação dos mecanismos de dormência dos esporos e obter um elevado nível de concentração que permite e facilita seu manejo e transporte.Com a aplicação deste produto, pode-se manejar os fungos micorrizicos em cultivos sob sistemas de irrigação em grande escala, com uma melhoria produtiva e ambiental.",INST NAC DE CIENCIAS AGRICOLAS,MARTIN FELIX FERNANDEZ;;DELL'AMICO RODRIGUEZ JOSE MIGUEL;;CABRERA YUNIESKY PEREZ,,https://lens.org/036-140-858-807-501,Patent Application,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C05F11/08;;A01N63/30;;A01N65/00;;C05G3/80;;C12N1/14,,0,0,,,,INACTIVE
206,WO,A1,WO 2013/106663 A1,058-405-799-420-84X,2013-07-18,2013,US 2013/0021166 W,2013-01-11,EP 12382010 A;;EP 12382011 A,2012-01-13,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR EFFECTING THE OFFSPRING,"The present disclosure is directed to a combination of carbohydrates (a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide) for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the offspring of the pregnant woman. The disclosure is also directed to use of the combination of carbohydrates for the manufacture of a medicament for use in the treatment of a pregnant woman wherein the treatment results in an improvement in the health of the offspring of the pregnant woman. The improvement can be a reduction of at least one long term adverse health effect and/or an improvement in lean body mass development and formation of the offspring. The combination of carbohydrates may also be administered to the woman during lactation to further the improvement in the health of the offspring.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA;;MARTIN MANUELCRISTOBAL MANZANO,,https://lens.org/058-405-799-420-84X,Patent Application,yes,3,2,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L1/0522;;A23L1/09;;A23L1/30;;A23L1/308;;A23L33/00,,0,0,,,,PENDING
207,MX,A,MX 2013010830 A,106-048-837-004-035,2014-03-27,2014,MX 2013010830 A,2012-03-20,EP 11380020 A;;US 2012/0029788 W,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING PREBIOTICS.,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/106-048-837-004-035,Patent Application,no,0,0,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A61K31/733;;A23L1/308;;A61P19/00,,0,0,,,,DISCONTINUED
208,CA,A1,CA 3203434 A1,160-121-161-832-768,2022-07-07,2022,CA 3203434 A,2021-12-20,EP 20383181 A;;US 2021/0064374 W,2020-12-31,METHOD FOR IMPROVING JOINT HEALTH BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMES,A method of improving joint health in a subject in need thereof comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof.,ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JORGE,,https://lens.org/160-121-161-832-768,Patent Application,no,0,0,6,6,0,A61K35/20;;A61P19/02;;A61K35/20;;A61P19/02;;A61P19/02;;A61K35/20,A61K35/20;;A61P19/02,,0,0,,,,PENDING
209,CA,A1,CA 2863286 A1,169-013-149-159-91X,2013-07-18,2013,CA 2863286 A,2013-01-11,EP 12382010 A;;EP 12382011 A;;US 2013/0021166 W,2012-01-13,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR EFFECTING THE OFFSPRING,"The present disclosure is directed to a combination of carbohydrates (a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide) for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the offspring of the pregnant woman. The disclosure is also directed to use of the combination of carbohydrates for the manufacture of a medicament for use in the treatment of a pregnant woman wherein the treatment results in an improvement in the health of the offspring of the pregnant woman. The improvement can be a reduction of at least one long term adverse health effect and/or an improvement in lean body mass development and formation of the offspring. The combination of carbohydrates may also be administered to the woman during lactation to further the improvement in the health of the offspring.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA;;MARTIN MANUELCRISTOBAL MANZANO,,https://lens.org/169-013-149-159-91X,Patent Application,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L1/09;;A23L1/0522;;A23L1/30;;A23L1/308;;A23L33/00,,0,0,,,,DISCONTINUED
210,ES,A1,ES 2408243 A1,007-989-704-225-665,2013-06-19,2013,ES 201330164 A,2013-02-11,ES 201330164 A,2013-02-11,PARTICLE FILTER SYSTEM FOR ENGINES AND METHOD FOR REDUCING PRESSURE LOSS IN SAID FILTER,"The invention relates to a particle filter system for engines and a method for reducing pressure loss in said filter. The system comprises a filter in an exhaust line of the engine, a water injector at the inlet of the filter, a conduit between a water supply source and the injector, an injection pump, pressure sensors in the inlet and the outlet of the filter for determining a pressure loss in the filter, and a control unit for controlling the actuation of the pump. The method comprises detecting a pressure loss between the inlet and the outlet of the filter, injecting pressurised water into the filter inlet when the pressure loss reaches a permitted maximum value and controlling the operating conditions required for filter regeneration in order to re-start the soot build-up process in the filter.",UNIV POLITECNIA DE VALENCIA,DESANTES FERNANDEZ JOSE MARIA;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/007-989-704-225-665,Patent Application,no,5,0,7,7,0,F01N3/0296;;F01N3/0293;;F01N3/0293;;F01N9/002;;F01N2240/02;;F01N2900/1606;;Y02T10/40,F01N3/029;;F01N3/033,,0,0,,,,ACTIVE
211,ES,A1,ES 2401871 A1,100-428-549-467-832,2013-04-25,2013,ES 201131537 A,2011-09-23,ES 201131537 A,2011-09-23,DEVICE FOR TREATING EXHAUST GASES FROM DIESEL TURBO-SUPERCHARGED RECIPROCATING INTERNAL COMBUSTION ENGINES (RICE),"The invention relates to a device for treating exhaust gases (1) from diesel turbo-supercharged reciprocating internal combustion engines (RICE), comprising an outer shell (2) joined to the cylinder head of the engine and the turbine by means of joining (3) and fixing (4) flanges, at least one inlet branch (10) containing at least one oxidation pre-catalyst (12), at least one particle filter (14), at least one oxidation post-catalyst (13) downstream of the particle filters (14), at least one outlet conduit (20) comprising at least some vents (9) through which recirculated exhaust gases (EGR) circulate, and at least one insulating chamber (8) used to regulate the recirculated exhaust gases (EGR) and arranged between the shell (2) and an inner wall (7). Said device is characterised by empty spaces (15), (18) and (19) arranged such that they enable the expansion, contraction, lateral diffusion and homogenisation of the flow of the exhaust gases at the outlet and inlet of the channels.",UNIV VALENCIA POLITECNICA,DESANTES FERNANDEZ JOSE MARIA;;PAYRI GONZALEZ FRANCISCO;;PIQUERAS CABRERA PEDRO;;SERRANO CRUZ JOSE RAMON,,https://lens.org/100-428-549-467-832,Patent Application,no,0,0,3,3,0,F01N3/035;;F01N13/10;;F01N13/1805;;F02M26/15,F01N13/14;;F01N3/035;;F01N13/10;;F02M25/07,,0,0,,,,ACTIVE
212,BR,A2,BR PI0705327 A2,137-893-483-556-571,2009-01-20,2009,BR PI0705327 A,2007-05-29,BR PI0705327 A,2007-05-29,mÉtodo de produÇço de ramnolipÍdios com diferentes composiÇÕes de forma controlada,"MÉTODO DE PRODUÇçO DE RAMNOLIPÍDIOS COM DIFERENTES COMPOSIÇÕES DE FORMA CONTROLADA. Pertencente ao setor de bãotecnologia, descreve método utiiizando linhagens bacterianas especialmente selecionadas para a produção de ramnolipidios, onde óleos vegetais ou carboidratos ou suas misturas como óleos de mamona, soja, milho, girassol, canola, algodão, pinhão manso e outros, e glicose, frutose, dissacarídios ou polissacaridios, cuja hidrólise gerem glicose ou frutose, ou ainda a mistura deles são utilizados como principal fonte de carbono para produção dos ramnolipídios. Neste método de produção são obtidos de forma controlada ramnolipídios de composição variada, tanto na relação ramnose/3-hídroxialcanoatos como nos 3-hidroxialcanoatos presentes, também por meio de mutante de Pseudomonas aerugínosas afetado no metabolismo de biossíntese de polihiroxialcanoatos, aumentando o espectro de aplicações para os produtos, nos campos de biorremediação, alimentos, aromas, cosméticos e farmacéuticos.",INST PESQUISAS TECH,STRELEC TATIANA;;CABRERA GOMES JOSE GREGORIO;;TACIRO MARILDA KEICO;;DA CRUZ PRADELLA JOSE GERALDO,,https://lens.org/137-893-483-556-571,Patent Application,no,0,0,1,1,0,,C12P19/44;;C12P19/00;;C12P19/04;;C12R1/385,,0,0,,,,DISCONTINUED
213,SG,A,SG 11201404016U A,014-340-048-509-455,2014-08-28,2014,SG 11201404016U A,2013-01-11,EP 12382010 A;;EP 12382011 A;;US 2013/0021166 W,2012-01-13,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR EFFECTING THE OFFSPRING,,ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA;;MARTIN MANUELCRISTOBAL MANZANO,,https://lens.org/014-340-048-509-455,Unknown,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L1/09;;A23L1/0522;;A23L1/30;;A23L1/308;;A23L33/00,,0,0,,,,PENDING
214,EP,A1,EP 2502507 A1,059-833-210-104-033,2012-09-26,2012,EP 11380020 A,2011-03-21,EP 11380020 A,2011-03-21,Methods for improving bone health in infants using prebiotics,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including a prebiotic to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.
",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,,https://lens.org/059-833-210-104-033,Patent Application,yes,1,3,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A23L1/308;;A61K31/733;;A61P19/00,,0,0,,,,DISCONTINUED
215,WO,A1,WO 2012/129222 A1,057-816-985-145-706,2012-09-27,2012,US 2012/0029796 W,2012-03-20,EP 11380021 A,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING LONG CHAIN POLYUNSATURATED FATTY ACIDS,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",ABBOTT LAB;;PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/057-816-985-145-706,Patent Application,yes,2,1,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A23L1/30;;A61K31/201;;A61K31/202;;A61P19/00,,3,3,001-822-226-531-648;;118-980-346-710-620;;034-599-568-043-482,10.1079/bjn20041252;;15522133;;10.1016/j.livsci.2007.01.047;;10.1016/j.bone.2007.04.020,"DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 2004 (2004-10-01), KOROTKOVA M ET AL: ""Dietary n-6:n-3 fatty acid ratio in the perinatal period affects bone parameters in adult female rats."", XP002656439, Database accession no. NLM15522133;;PUZIO ET AL: ""Dietary bioactive substances influenced perinatal bone development in piglets"", LIVESTOCK SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 108, no. 1-3, 29 April 2007 (2007-04-29), pages 72 - 75, XP022052797, ISSN: 1871-1413, DOI: 10.1016/J.LIVSCI.2007.01.047;;BURR ET AL: ""Early life diet enrichment with arachidonic and docosahexaenoic acids attenuates the effects of intrauterine growth restriction on bone mass in weanling guinea pigs"", BONE, PERGAMON PRESS., OXFORD, GB, vol. 40, no. 6, 1 June 2007 (2007-06-01), pages S31, XP022121634, ISSN: 8756-3282, DOI: 10.1016/J.BONE.2007.04.020",PENDING
216,ES,A1,ES 2136501 A1,066-168-202-738-753,1999-11-16,1999,ES 9601525 A,1996-07-09,ES 9601525 A,1996-07-09,Improved process for separating out coal and tailings in a coal mine,"The procedure consists essentially in performing a separation by density of the bulk material extracted from the mine, in which a flotation tank containing a dense medium of controlled density (between 1.35 and 1.60 g/cm3), receives the material to be processed, giving rise to the flotation of the coal, with a mean density of 1.25g/cm3, and the sedimentation of the tailings which have an average density of 2.5 gm/cm3. The floating coal portion is collected from the surface of the tank by mechanical means, is washed with water and drained to give saleable coal. The sedimentary portion (the tailings) is continuously extracted mechanically and sent to the slag heaps. The product used to form the dense medium in the flotation tank is a clay marl obtained together with the coal in the material extracted from the mine. The procedure is used to treat materials extracted from coal fields in the Bajo Segre.",CARBONIFERA DEL EBRO S A,CABRERA DOMINGO JOSE;;IBARS PLA EMILI;;IBARS PLA JOSEP MARIA,,https://lens.org/066-168-202-738-753,Patent Application,no,5,0,2,2,0,,B03B5/30;;B03B9/00,,0,0,,,,EXPIRED
217,US,A1,US 2003/0134851 A1,128-151-807-377-168,2003-07-17,2003,US 26631702 A,2002-10-08,US 26631702 A;;US 97310501 A,2001-10-09,Methods and compositions for providing glutamine,"
   Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day. 
",BAXTER JEFFREY H.;;PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA,BAXTER JEFFREY H;;PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA,,https://lens.org/128-151-807-377-168,Patent Application,yes,4,16,1,3,0,A23V2002/00;;A61K31/198;;A23L33/40;;A23L33/175;;A61K31/198;;A23V2002/00;;A23L33/175;;A23L33/40,A23L1/305;;A23L33/00;;A61K31/198,514/231.2;;514/563;;514/252.12;;514/315;;514/537,0,0,,,,DISCONTINUED
218,BR,A2,BR 112013024199 A2,145-602-521-652-992,2016-12-13,2016,BR 112013024199 A,2012-03-20,US 2012/0029788 W;;EP 11380020 A,2011-03-21,métodos para melhorar a saúde óssea em bebês usando prebióticos,"resumo métodos para melhorar a saúde óssea em bebês usando prebióticos são divulgados métodos para melhorar a saúde óssea, resistência e a formação em um bebê que pode ser suscetível a desenvolver problemas de saúde óssea da concepção à adolescência. os métodos incluem a administração de uma formulação nutricional incluindo um prebiótico à uma mulher durante a gravidez e, opcionalmente, durante a lactação e amamentação de um bebê.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,,https://lens.org/145-602-521-652-992,Patent Application,no,0,0,9,9,0,A23L33/30;;A23L29/30;;A23V2002/00;;A23V2002/00;;A61K31/733;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/21;;A23L33/22;;A61P19/00;;A61K31/733;;A23V2002/00;;A23L33/40;;A23L33/12;;A23L33/115;;A23L33/155;;A23L33/22;;A23L33/21;;A23L33/16,A61K31/733;;A61P19/00,,0,0,,,,DISCONTINUED
219,CN,A,CN 115968262 A,166-295-404-453-948,2023-04-14,2023,CN 202180051348 A,2021-07-26,EP 20382704 A;;US 2021/0043209 W,2020-07-31,"Method for preventing, reducing or delaying fatty liver disease","A method of preventing, reducing or delaying the onset of fatty liver disease in a subject, the method comprising enterally administering to a subject in need thereof an exosome of intact milk origin consisting of an endogenous cargo in an amount effective to reduce liver lipid accumulation. In a specific embodiment, the exosome of intact milk origin consisting of an endogenous cargo can be administered in an amount effective to reduce de novo adipogenesis in the subject. The exosomes of intact milk origin, consisting of endogenous cargo, may be administered to the subject either directly or in a nutritional composition.",ABBOTT LAB,LOPEZ PEDROSA JOSE MANUEL;;RUEDA CABRERA RICARDO;;GARCIA MARTINEZ JAVIER,,https://lens.org/166-295-404-453-948,Patent Application,no,0,0,7,7,0,A23L33/19;;A23L33/13;;A23L33/115;;A61P1/16;;A61K35/20;;A61P1/16;;A61K9/16;;A61K35/20,A23L33/13,,0,0,,,,DISCONTINUED
220,CA,A1,CA 3169069 A1,035-460-919-731-886,2021-09-02,2021,CA 3169069 A,2021-02-26,EP 20382139 A;;US 2021/0019908 W,2020-02-27,METHODS OF IMPROVING BONE HEALTH,"A method of promoting bone health in a moderately malnourished individual is provided. The method includes treating the moderately malnourished individual with a nutritional composition that contains a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL;;RUEDA CABRERA RICARDO,,https://lens.org/035-460-919-731-886,Patent Application,no,0,0,9,9,0,A23L33/18;;A23L33/115;;A23L33/24;;A23L33/21;;A23L33/125;;A23V2002/00;;A23L33/30;;A61K31/7016;;A61K31/702;;A61K31/715;;A61P19/00;;A61P3/02;;A23L33/24;;A23V2002/00;;A23V2250/5108;;A23L33/18;;A23V2250/54;;A23L33/115;;A23V2250/5118;;A23L33/21;;A23V2250/5116;;A23L33/30;;A23V2250/628;;A23V2200/306;;A23L33/125;;A23V2250/62;;A61K31/7016;;A23V2250/5114;;A61P3/02;;A23V2250/5062;;A61P19/00;;A61K31/715;;A23V2250/194;;A61K31/702;;A61K2300/00;;A23L33/24;;A23L33/125;;A61P19/08;;A23V2002/00;;A61K31/7004;;A61K31/7016;;A61K31/702;;A61K31/718,A23L33/125;;A23L33/21;;A23L33/24,,0,0,,,,PENDING
221,EP,A1,EP 2397039 A1,081-343-740-133-523,2011-12-21,2011,EP 10380083 A,2010-06-21,EP 10380083 A,2010-06-21,Compositions for delaying progression of diabetes using Salacia oblonga extract,"Disclosed are nutritional compositions and methods for delaying the onset or progression of type 2 diabetes in a subject. The methods include administering to a glucose intolerant or diabetic subject a nutritional composition comprising an effective amount of a  Salacia oblonga  extract for increasing the incretin effect (and/or the glucagon-like peptide-1 and/or gastric inhibitory peptide activity) in the subject. The  Salacia oblonga  extract may also act to reduce the secretion of glucagon by the pancreas thus decreasing the glucose level in the bloodstream of the subject.
",ABBOTT LAB,RUEDA CABRERA RICARDO;;MANZANO MARTIN MANUEL;;LOPEZ PEDROSA JOSE MARIA,,https://lens.org/081-343-740-133-523,Patent Application,yes,5,5,3,3,0,A23V2002/00;;A61K36/37;;A23L33/40;;A23L33/105;;A61P5/50,A23L1/30;;A61K36/37,,11,3,077-462-364-578-410;;052-136-547-002-552;;050-236-042-247-074,10.1093/ajcn/86.1.124;;17616771;;15975493;;10.1016/j.nut.2004.11.018;;10.1111/j.1463-1326.2007.00750.x;;17645561,"DATABASE WPI Week 200212, Derwent World Patents Index; AN 2002-086164, XP002627580;;DATABASE WPI Week 200204, Derwent World Patents Index; AN 2002-029795, XP002627581;;KRISHNAKUMAR K ET AL: ""Hypolipidaemic effect of Salacia oblonga Wall. root bark in streptozotocin diabetic rats"", MEDICAL SCIENCE RESEARCH 2000 GB, vol. 28, no. 1, 2000, pages 65 - 67, XP009145763, ISSN: 0269-8951;;WILLIAMS JENNIFER A ET AL: ""Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes"", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 86, no. 1, July 2007 (2007-07-01), pages 124 - 130, XP002627998, ISSN: 0002-9165;;COLLENE A L ET AL: ""Effects of a nutritional supplement containing Salacia oblonga extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults"", NUTRITION, ELSEVIER INC, US, vol. 21, no. 7-8, 1 July 2005 (2005-07-01), pages 848 - 854, XP025281295, ISSN: 0899-9007, [retrieved on 20050701], DOI: 10.1016/J.NUT.2004.11.018;;HUANG T H ET AL: ""Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor."", DIABETES, OBESITY & METABOLISM JUL 2008, vol. 10, no. 7, July 2008 (2008-07-01), pages 574 - 585, XP024895988, ISSN: 1463-1326;;DATABASE TKDL [online] ""neerizhivukku Kasayam"", XP003030622, Database accession no. GP08/84;;DATABASE TKDL [online] ""Neerazhivu kudineer 3"", XP003030623, Database accession no. BS01/71;;DATABASE TKDL [online] ""Neerizhivukku Karkam"", XP003030624, Database accession no. PD04/39;;DATABASE TKDL [online] ""Mathumegapattai Thool"", XP003030625, Database accession no. SR09/153;;DATABASE TKDL [online] ""Iya Piramegathirku Kudineer -5"", XP003030626, Database accession no. AM05/1657",DISCONTINUED
222,WO,A8,WO 2007/064184 A8,183-181-100-245-737,2007-09-13,2007,MX 2006000134 W,2006-11-29,MX GT05000016 A,2005-11-30,PNEUMATIC SEED METERING UNIT FOR PRECISION SEEDERS,"The invention relates to a pneumatic metering unit for a precision seeder, including: a hopper (1) with an oscillating base (2) and an adjustable hatch (4), as well as a vibration generator (3) in order to facilitate and control the flow of seeds from the hopper to the separation chamber; and a set of metering disks, formed by two identical, co-axial disks (5) which are offset in relation to one another and which are joined by means of a cylinder (13); and a central shaft (7) formed by a hollow tube provided with incisions (17), which is designed to convey suction and pressure from the dispenser (29, 30) to the disks (5) and a smooth cover (6) which is designed to define the seed separation chambers and to direct the seed to the desired location.",UNIV GUANAJUATO;;CABRERA SIXTO JOSE MANUEL;;CALDERON REYES EFRAIN;;SERWATOWSKI HLAWINSKA RYSZARD,CABRERA SIXTO JOSE MANUEL;;CALDERON REYES EFRAIN;;SERWATOWSKI HLAWINSKA RYSZARD,,https://lens.org/183-181-100-245-737,Patent Application,no,0,1,4,4,0,A01C7/044,A01C7/04,,0,0,,,,PENDING
223,US,A1,US 2012/0245121 A1,181-765-991-534-212,2012-09-27,2012,US 201213424847 A,2012-03-20,EP 11380021 A,2011-03-21,METHODS FOR IMPROVING BONE HEALTH IN INFANTS USING LONG CHAIN POLYUNSATURATED FATTY ACIDS,"Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.",LOPEZ PEDROSA JOSE MARIA;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA;;ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MARTIN MANUEL MANZANO;;CABRERA RICARDO RUEDA,ABBOTT LABORATORIES (2012-04-04),https://lens.org/181-765-991-534-212,Patent Application,yes,0,23,8,8,0,A23L33/12;;A23L33/30;;A23L33/40;;A61K31/201;;A61K31/202;;A23V2002/00;;A23V2002/00;;A61K31/201;;A23L33/40;;A23L33/12;;A23L33/155;;A23L33/16;;A23L33/22;;A61P19/00;;A61K31/201;;A23V2002/00;;A23L33/22;;A23L33/40;;A23L33/12;;A23L33/16;;A23L33/155,A61K31/202;;A61K31/715;;A61P19/00,514/54;;514/560,3,3,099-463-184-692-075;;059-771-925-397-895;;110-576-888-942-201,10.1203/01.pdr.0000185129.73971.74;;16306203;;18184094;;10.1515/jpm.2008.001;;10.1111/j.1753-4887.2009.00212.x;;19566599,"Weiler et al. (Pediatric Research (2005) Vol. 58, No. 6, 1254-1258).;;Koletzko et al. (J Perinat Med. (2008); 36(1): 5-14).(abstract sent).;;Brownawell et al. (Nutrition reviews, (2009 Jul) Vol. 67, No. 7, pp. 391-7).",DISCONTINUED
224,PH,A1,PH 12014501611 A1,146-648-775-803-56X,2014-10-20,2014,PH 12014501611 A,2014-07-11,EP 12382011 A;;EP 12382010 A;;US 2013/0021166 W,2012-01-13,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR EFFECTING THE OFFSPRING,"The present disclosure is directed to a combination of carbohydrates (a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide) for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the offspring of the pregnant woman. The disclosure is also directed to use of the combination of carbohydrates for the manufacture of a medicament for use in the treatment of a pregnant woman wherein the treatment results in an improvement in the health of the offspring of the pregnant woman. The improvement can be a reduction of at least one long term adverse health effect and/or an improvement in lean body mass development and formation of the offspring. The combination of carbohydrates may also be administered to the woman during lactation to further the improvement in the health of the offspring.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;MANZANO MARTIN MANUELCRISTOBAL,,https://lens.org/146-648-775-803-56X,Patent Application,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L1/0522;;A23L1/09;;A23L1/30;;A23L1/308;;A23L33/00,,0,0,,,,PENDING
225,US,A1,US 2018/0256856 A1,111-978-811-885-091,2018-09-13,2018,US 201715782901 A,2017-10-13,US 201715782901 A;;MX 2013000051 U;;US 201514762765 A;;MX 2014000031 W,2013-01-30,PERIPHERAL INTRAVENOUS CATHETER WITH BELLOWS-TYPE PASSIVE SAFETY SYSTEM IVCBTS,"A peripheral intravenous catheter with bellows-type passive safety system IVCBTS, characterized by including: a retractable puncturing cannula ( 4 ) on a manual mechanism of a flexible billows tube ( 3 ) in order to prevent its reuse, accidental puncture wounds and assure safe disposal. This IVCBTS has the advantages of: (a) a device which has a passive protection system for preventing accidental puncture wounds, (b) being easily handled. The IVCBTS peripheral intravenous catheter with a passive billows safety system presents two embodiments which are the puncturing and catheterization embodiment and the safety embodiment for the safe disposal of the used puncturing cannula ( 4 ). The parts which make up the IVCBTS in its two embodiments are: ( 1 ) catheter, ( 2 ) affixing body, ( 3 ) flexible billows tube, ( 4 ) puncturing cannula, ( 5 ) mounting body, ( 6 ) flashback chamber and filter and ( 7 ) filter paper.",EQUIPOS MEDICOS VIZCARRA S A,ARELLANO CABRERA JOSE ANTONIO;;RODRIGUEZ LELIS JOSE MARIA;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/111-978-811-885-091,Patent Application,yes,0,0,6,6,0,A61M25/0631;;A61M25/0631;;A61M5/1626;;A61M5/50;;A61M25/0054;;A61M25/0606;;A61M25/0606;;A61M2205/273;;A61M2205/75;;A61M2210/12,A61M25/06;;A61M5/162;;A61M5/50;;A61M25/00,,0,0,,,,DISCONTINUED
226,IL,A0,IL 243362 A0,193-995-044-265-922,2016-02-29,2016,IL 24336215 A,2015-12-27,EP 13382246 A;;EP 2014063360 W,2013-06-26,Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps),,ESTEVE PHARMACEUTICALS SA;;JOSE MIGUEL VELA HERNANDEZ;;MANUEL MERLOS ROCA;;JOSE MANUEL BAEYENS CABRERA;;CRUZ MIGUEL CENDAN MARTINEZ,JOSE-MIGUEL VELA-HERNANDEZ;;MANUEL MERLOS-ROCA;;JOSE-MANUEL BAEYENS-CABRERA;;CRUZ-MIGUEL CENDAN-MARTINEZ,,https://lens.org/193-995-044-265-922,Patent Application,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,,,0,0,,,,PENDING
227,AU,A1,AU 2014/301220 A1,178-294-665-298-49X,2016-02-18,2016,AU 2014/301220 A,2014-06-25,EP 13382246 A;;EP 2014063360 W,2013-06-26,Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS),"The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS).",ESTEVE LABOR DR,VELA-HERNANDEZ JOSE-MIGUEL;;MERLOS-ROCA MANUEL;;BAEYENS-CABRERA JOSE-MANUEL;;CENDAN-MARTINEZ CRUZ-MIGUEL,,https://lens.org/178-294-665-298-49X,Patent Application,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P29/00,,0,0,,,,DISCONTINUED
228,US,A1,US 2018/0250499 A1,011-555-208-857-424,2018-09-06,2018,US 201715730962 A,2017-10-12,US 201715730962 A;;MX 2013001219 A;;US 201414762757 A;;MX 2014000033 W,2013-01-30,CLOSED PERIPHERAL INTRAVENOUS CATHETER WITH SAFETY SYSTEM CPIVCSS,"The present invention refers to a system for placing an intravenous catheter, specifically a closed system for placing an intravenous catheter which prevents exposure by medical personnel to the patient's bodily fluids during the placement of the catheter; and with a retractable needle cannula in a manual billows mechanism for preventing its reuse, accidental puncture wounds and assuring safe disposal. This CPIVCSS has the advantages of (a) preventing medical personnel from being exposed to the contaminated bodily fluids or blood during the placing of the catheter in the patient; (b) reducing the possibility of multiple punctures and; (c) having an easily usable safety system. The Closed Peripheral Intravenous Catheter with Safety System includes two systems, one the piercing and safety system made up of: ( 2 ) piercing cannula, ( 10 ) mounting body, ( 11 ) affixing body, ( 9 ) flexible billows tube, ( 8 ) flashback chamber and filter and ( 13 ) filter paper; and the closed peripheral intravenous catheter made up of: ( 3 ) the catheter cube or hub, ( 1 ) the catheter tube, ( 12 ) the hub seal, ( 4 ) the affixing wings, ( 5 ) the flow tube, ( 6 ) flow safety valve and ( 7 ) the multi-piercing connector.",EQUIPOS MEDICOS VIZCARRA S A,ARELLANO CABRERA JOSE ANTONIO;;RODRIGUEZ LELIS JOSE MARIA;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/011-555-208-857-424,Patent Application,yes,0,0,6,6,0,A61M25/0631;;A61M25/0631;;A61M5/1626;;A61M5/50;;A61M25/0054;;A61M25/0606;;A61M2205/273;;A61M2210/12,A61M25/06,,0,0,,,,DISCONTINUED
229,KR,A,KR 20160023839 A,070-831-452-076-409,2016-03-03,2016,KR 20167001865 A,2014-06-25,EP 13382246 A;;EP 2014063360 W,2013-06-26,USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS),"본 발명은 간질성 방광염/방광통증 증후군(IC/BPS)과 관련된 통증의 예방 및/또는 치료를 위한 시그마 리간드, 특히 화학식 (I)의 시그마 리간드의 용도에 관한 것이다.(Ⅰ)",ESTEVE LABOR DR,JOSE MIGUEL VELA HERNANDEZ;;MANUEL MERLOS ROCA;;JOSE MANUEL BAEYENS CABRERA;;CRUZ MIGUEL CENDAN MARTINEZ,,https://lens.org/070-831-452-076-409,Patent Application,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/415;;A61K31/485;;A61K31/5377,,0,0,,,,DISCONTINUED
230,CA,A1,CA 2916568 A1,100-797-901-809-453,2014-12-31,2014,CA 2916568 A,2014-06-25,EP 13382246 A;;EP 2014063360 W,2013-06-26,USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS),"The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS).",ESTEVE LABOR DR,VELA-HERNANDEZ JOSE-MIGUEL;;MERLOS-ROCA MANUEL;;BAEYENS-CABRERA JOSE-MANUEL;;CENDAN-MARTINEZ CRUZ-MIGUEL,,https://lens.org/100-797-901-809-453,Patent Application,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P29/00,,0,0,,,,DISCONTINUED
231,US,A1,US 2018/0361122 A1,185-684-258-584-306,2018-12-20,2018,US 201815869326 A,2018-01-12,US 201815869326 A;;MX 2012007851 A;;US 201414412352 A;;MX 2013000079 W,2012-07-04,"EXTRACTION DEVICE FOR COLLECTING BLOOD SAMPLES, INCLUDING A CATHETER AND A SAFETY SYSTEM","Provided is an Extraction Device for Collecting Blood Samples, including a Catheter and a Safety System “EDCBSCSS” wherein a catheter is inserted through a cannula, which retracts once the catheter is inside a vein, by means of a spring and safety latch mechanism, retaining the cannula within a housing. The retracted cannula remains immobile within the housing thus avoiding reutilization of the devise and accidental puncture wounds during its disposal. This EDCBSCSS has the advantages (a) among others of assuring that the cutting element has been disabled; (b) possessing a safety system for medical personal so that after the procedure no accidental puncture wounds occur and (c) being easy to handle. The EDCBSCSS is made up of three sequential operational systems, which are puncturing and retracting system which are located within housings and comprise a puncturing cannula; a catheter; a catheter space, a spring and a safety latch.",EQUIPOS MEDICOS VIZCARRA S A,RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/185-684-258-584-306,Patent Application,yes,10,0,10,10,0,A61M25/0606;;A61M25/0606;;A61B5/15003;;A61B5/15003;;A61B5/150259;;A61B5/150259;;A61B5/150351;;A61B5/150389;;A61B5/150389;;A61B5/150473;;A61B5/150473;;A61B5/150587;;A61B5/150587;;A61B5/150595;;A61B5/150595;;A61B5/150717;;A61B5/150717;;A61B5/150732;;A61B5/150732;;A61B5/150992;;A61B5/153;;A61B5/153;;A61B5/155;;A61B5/155;;A61M25/06;;A61M25/0631;;A61M25/0631;;A61M25/065,A61M25/06;;A61B5/15;;A61B5/153;;A61B5/155,,0,0,,,,DISCONTINUED
232,CN,A,CN 105377257 A,151-279-969-220-020,2016-03-02,2016,CN 201480040098 A,2014-06-25,EP 2014063360 W;;EP 13382246 A,2013-06-26,Use of sigma receptor ligands for prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps),"The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS).",ESTEVE LABOR DR,VELA-HERNANDEZ JOSE-MIGUEL;;MERLOS-ROCA MANUEL;;BAEYENS-CABRERA JOSE-MANUEL;;CENDAN-MARTINEZ CRUZ-MIGUEL,,https://lens.org/151-279-969-220-020,Patent Application,no,9,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P29/00,,3,0,,,"孙凤艳: ""《医学神经生物学》"", 31 March 2008, 上海科学技术出版社;;ISAO SHIMIZU等: ""Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis"", 《LIFE SCIENCES》;;RAFAEL GONZÁLEZ-CANO等: ""σ1 Receptors Are Involved in the Visceral Pain Induced by Intracolonic Administration of Capsaicin in Mice"", 《ANESTHESIOLOGY》",DISCONTINUED
233,MA,A1,MA 38711 A1,153-830-711-528-823,2017-12-29,2017,MA 38711 A,2014-06-25,EP 13382246 A;;EP 2014063360 W,2013-06-26,Utilisation des ligands des récepteurs sigma pour prévenir et traiter la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps).,"L'invention porte sur l'utilisation d'un ligand sigma, en particulier d'un ligand sigma de formule (i) pour prévenir et/ou traiter une douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (ic/bps).",ESTEVE LABOR DR,VELA HERNÁNDEZ JOSE MIGUEL;;MERLOS ROCA MANUEL;;BAEYENS CABRERA JOSE MANUEL;;CENDÁN MARTÍNEZ CRUZ MIGUEL,,https://lens.org/153-830-711-528-823,Patent Application,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P29/00,,0,0,,,,PENDING
234,WO,A1,WO 2014/007601 A1,157-743-924-384-19X,2014-01-09,2014,MX 2013000079 W,2013-07-04,MX 2012007851 A,2012-07-04,"EXTRACTION DEVICE FOR COLLECTING BLOOD SAMPLES, INCLUDING A CATHETER AND A SAFETY SYSTEM","The invention relates to an extraction device for collecting blood samples, including a catheter and a safety system, which device uses a flexible catheter instead of a metal cannula with sharp edges for the extraction of blood. The catheter is inserted through a traditional cannula which is then retracted once the catheter is in the vein, by means of a spring and lock mechanism, with the cannula being housed inside a rigid casing. Once retracted, the cannula remains immobile inside the rigid casing, preventing the device from being re-used. The device of the invention is advantageous in that it: (a) reduces or eliminates the use of a metal cannula with sharp edges that stays in the vein during the entire procedure; (b) uses a plastic catheter or cannula in order to extract the blood sample, which is more comfortable for the patient and is safer since the sharp pointed element is disabled; (c) has a safety system for medical personnel such as to prevent any additional punctures following the procedure; and (d) is easy to use.",EQUIPOS MEDICOS VIZCARRA S A,RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/157-743-924-384-19X,Patent Application,no,14,2,10,10,0,A61B5/15003;;A61B5/150259;;A61B5/150389;;A61B5/150473;;A61B5/150717;;A61B5/150732;;A61B5/153;;A61B5/155;;A61B5/150587;;A61M25/0631;;A61B5/150595;;A61M25/0606;;A61M25/06;;A61B5/15003;;A61B5/150259;;A61B5/150389;;A61B5/150473;;A61B5/150717;;A61B5/150732;;A61B5/153;;A61B5/155;;A61B5/150587;;A61M25/0631;;A61B5/150351;;A61B5/150595;;A61B5/150992;;A61M25/0606;;A61M25/065,A61B5/15;;A61M25/06;;A61M5/32,,3,2,012-861-715-653-663;;064-855-546-880-843,16134421;;10.7748/ns2005.08.19.49.55.c3936;;10.5858/2005-129-1222-tibcca;;16196507,"LAVERY I; INGRAM P: ""Blood sampling: best practice"", NURSING STANDARD, vol. 19, 2005, pages 55 65;;BERKERIS L ET AL.: ""Trends in blood culture contamination. A College of American Pathologist Q-tracks study of 356 institutions"", ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, vol. 123, 2005, pages 1222 - 1226;;MCCALL, R. E.; TANKERSLEY, C. M.: ""Phlebotomy Essentials, 3rd ed."", 2003, LIPPINCOTT WILLIAMS & WILKINS",PENDING
235,PH,A1,PH 12015502815 A1,166-560-145-974-910,2016-03-21,2016,PH 12015502815 A,2015-12-17,EP 13382246 A;;EP 2014063360 W,2013-06-26,USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS),"The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS).",ESTEVE LABOR DR,JOSE-MIGUEL VELA-HERNANDEZ;;MANUEL MERLOS-ROCA;;JOSE-MANUEL BAEYENS-CABRERA;;CRUZ-MIGUEL CENDAN-MARTINEZ,,https://lens.org/166-560-145-974-910,Patent Application,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P29/00,,0,0,,,,PENDING
236,US,A1,US 2015/0165165 A1,072-969-130-848-941,2015-06-18,2015,US 201314412352 A,2013-07-04,MX 2012007851 A;;MX 2013000079 W,2012-07-04,"EXTRACTION DEVICE FOR COLLECTING BLOOD SAMPLES, INCLUDING A CATHETER AND A SAFETY SYSTEM","The Extraction Device for Collecting Blood Samples, including a Catheter and a Safety System in which a flexible catheter instead of a metallic cannula with sharp edges for extracting blood is presented. This catheter is inserted through a traditional cannula, which retracts once the catheter is inside the vein, by means of a spring and safety latch mechanism, retaining the cannula within a rigid housing. The retracted cannula remains immobile within the rigid housing thus avoiding reutilization of the devise and accidental puncture wounds during its disposal. This EDCBSCSS has the advantages of (a) reducing it) or eliminating the use of a metallic cannula with sharp edges, which remains inside the vein during the entire procedure; (b) using a plastic cannula or catheter for extracting the blood sample which provides greater comfort for the patient and the assurance that the cutting element has been disabled; (c) possessing a safety system for medical personal so that after the procedure no accidental puncture wounds occur and (d) being easy to handle. The EDCBSCSS is made up of three sequential operational systems, which are the puncturing and retracting system which are located within housings ( 4 ) and ( 5 ) and are comprised of ( 1 ) a puncturing cannula; ( 2 ) a catheter; ( 3 ) a catheter space, ( 9 ) a spring and ( 8 ) a safety latch.",EQUIPOS MEDICOS VIZCARRA S A,RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/072-969-130-848-941,Patent Application,yes,3,3,10,10,0,A61M25/0606;;A61M25/0606;;A61B5/15003;;A61B5/15003;;A61B5/150259;;A61B5/150259;;A61B5/150351;;A61B5/150389;;A61B5/150389;;A61B5/150473;;A61B5/150473;;A61B5/150587;;A61B5/150587;;A61B5/150595;;A61B5/150595;;A61B5/150717;;A61B5/150717;;A61B5/150732;;A61B5/150732;;A61B5/150992;;A61B5/153;;A61B5/153;;A61B5/155;;A61B5/155;;A61M25/06;;A61M25/0631;;A61M25/0631;;A61M25/065,A61M25/06;;A61B5/15;;A61B5/153,,0,0,,,,DISCONTINUED
237,US,A1,US 2015/0360005 A1,082-316-657-043-01X,2015-12-17,2015,US 201414762765 A,2014-01-29,MX 2013000051 U;;MX 2014000031 W,2013-01-30,PERIPHERAL INTRAVENOUS CATHETER WITH BELLOWS-TYPE PASSIVE SAFETY SYSTEM IVCBTS,"A peripheral intravenous catheter with bellows-type passive safety system IVCBTS, characterized by including: a retractable puncturing cannula ( 4 ) on a manual mechanism of a flexible billows tube ( 3 ) in order to prevent its reuse, accidental puncture wounds and assure safe disposal. This IVCBTS has the advantages of (a) a device which has a passive protection system for preventing accidental puncture wounds, (b) being easily handled. The IVCBTS peripheral intravenous catheter with a passive billows safety system presents two embodiments which are the puncturing and catheterization embodiment and the safety embodiment for the safe disposal of the used puncturing cannula ( 4 ). The parts which make up the IVCBTS in its two embodiments are: ( 1 ) catheter, ( 2 ) affixing body, ( 3 ) flexible billows tube, ( 4 ) puncturing cannula, ( 5 ) mounting body, ( 6 ) flashback chamber and filter and ( 7 ) filter paper.",EQUIPOS MÉDICOS VIZCARRA S A,ARELLANO CABRERA JOSE ANTONIO;;RODRIGUEZ LELIS JOSE MARIA;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/082-316-657-043-01X,Patent Application,yes,4,24,6,6,0,A61M25/0631;;A61M25/0631;;A61M5/1626;;A61M5/50;;A61M25/0054;;A61M25/0606;;A61M25/0606;;A61M2205/273;;A61M2205/75;;A61M2210/12,A61M25/06;;A61M25/00,,0,0,,,,DISCONTINUED
238,TW,A,TW 201536295 A,133-031-749-627-660,2015-10-01,2015,TW 103121723 A,2014-06-24,EP 13382246 A,2013-06-26,Use of sigma ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS),"The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS).",ESTEVE LABOR DR,VELA HERNANDEZ JOSE MIGUEL;;MERLOS-ROCA MANUEL;;BAEYENS-CABRERA JOSE MANUEL;;CENDAN-MARTINEZ CRUZ MIGUEL,,https://lens.org/133-031-749-627-660,Patent of Addition,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,A61K31/5377;;A61P13/10;;C07D231/22,,0,0,,,,INACTIVE
239,US,A1,US 2017/0028169 A1,112-206-225-615-669,2017-02-02,2017,US 201515302265 A,2015-04-06,MX 2014004232 A;;MX 2015000058 W,2014-04-08,HYDROPHOBIC TEXTURISED FOLEY CATHETER WITH LOW MICROBIAL ADHESION,"The invention relates to medical equipment for treatment, specifically medical equipment for extracting and draining fluids contained in the bladder of a patient. The Foley catheter according to the invention comprises tubing, with at least two lumens, made of a biocompatible polymer material with a length of between 100 and 400 mm and outer diameters of between 1 and 15 mm. The surface of the tubing has a high-relief texture with a maximum height of 30 micrometers and patterns designed to generate the property of hydrophobicity and to reduce the adhesion of bacteria to said surface. A collecting funnel with at least two channels, made from medical-grade polymer material, is fixed to the distal end of the tip of the tubing, while the tip of the tubing is closed in such a way that it forms a rounded tip. A flexible inflatable balloon is arranged upstream of the tip, for the anchoring of the catheter.",EQUIPOS MEDICOS VIZCARRA S A,ARELLANO CABRERA JOSE ANTONIO;;RODRIGUEZ LELIS JOSE MARIA;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/112-206-225-615-669,Patent Application,yes,0,1,3,3,0,A61M25/0017;;A61M25/0017,A61M25/00,,0,0,,,,DISCONTINUED
240,US,A1,US 2015/0352333 A1,102-035-972-773-365,2015-12-10,2015,US 201414762757 A,2014-01-29,MX 2013001219 A;;MX 2014000033 W,2013-01-30,CLOSED PERIPHERAL INTRAVENOUS CATHETER WITH SAFETY SYSTEM CPIVCSS,"The present invention refers to a system for placing an intravenous catheter, specifically a closed system for placing an intravenous catheter which prevents exposure by medical personnel to the patient's bodily fluids during the placement of the catheter; and with a retractable needle cannula in a manual billows mechanism for preventing its reuse, accidental puncture wounds and assuring safe disposal. This CPIVCSS has the advantages of (a) preventing medical personnel from being exposed to the contaminated bodily fluids or blood during the placing of the catheter in the patient; (b) reducing the possibility of multiple punctures and; (c) having an easily usable safety system. The closed Peripheral Intravenous Catheter with Safety System includes two systems, one the piercing and safety system made up of: ( 2 ) piercing cannula, ( 10 ) mounting body, ( 11 ) affixing body, ( 9 ) flexible billows tube, ( 8 ) flashback chamber and filter and ( 13 ) filter paper; and the closed peripheral intravenous catheter made up of: ( 3 ) the catheter cube or hub, ( 1 ) the catheter tube, ( 12 ) the hub seal, ( 4 ) the affixing wings, ( 5 ) the flow tube, ( 6 ) flow safety valve and ( 7 ) the multi-piercing connector.",EQUIPOS MÉDICOS VIZCARRA S A,ARELLANO CABRERA JOSE ANTONIO;;RODRIGUEZ LELIS JOSE MARIA;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO,,https://lens.org/102-035-972-773-365,Patent Application,yes,14,11,6,6,0,A61M25/0631;;A61M25/0631;;A61M5/1626;;A61M5/50;;A61M25/0054;;A61M25/0606;;A61M2205/273;;A61M2210/12,A61M25/06;;A61M5/50;;A61M25/00,,0,0,,,,DISCONTINUED
241,TW,B,TW I629984 B,110-910-294-807-193,2018-07-21,2018,TW 103121723 A,2014-06-24,EP 13382246 A,2013-06-26,Use of sigma ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps),,ESTEVE LABOR DR,VELA HERNANDEZ JOSE MIGUEL;;MERLOS-ROCA MANUEL;;BAEYENS-CABRERA JOSE MANUEL;;CENDAN-MARTINEZ CRUZ MIGUEL,,https://lens.org/110-910-294-807-193,Granted Patent,no,0,0,23,23,0,A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61P13/10;;A61P25/00;;A61P25/02;;A61P29/00;;A61P43/00;;A61K31/415;;A61K31/4155;;A61K31/485;;A61K31/5377;;A61K45/06;;A61K31/4155;;A61K31/415;;A61K31/485;;A61K31/5377;;A61K45/06,,,1,0,,,"Shimizu Isao et al.;""Effects of AH-9700,(+)-pentazocine,DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis"";Life Sciences,69(2001)1691-1697. Diaz Jose Luis et al.;""Synthesis and Biological Evaluation of the 1-Arylpyrazole Class ofσ1 Receptor Antagonists:Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine(S1RA,E-52862)"";Journal of Medicinal Chemistry,2012,55,8211-8224.",INACTIVE
242,CA,C,CA 2763071 C,003-202-379-765-950,2018-02-27,2018,CA 2763071 A,2010-05-21,US 45476909 A;;MX 2010000043 W,2009-05-22,A COLORLESS GLASS COMPOSITION,"The is a colorless glass composition having a base glass composition, comprising, in weight percentage, from about 0.005 to about 0.08 % wt of ferric oxide, from 0.00002 to about 0.0004 % wt of Se, from about 0.00003 to about 0.0010 % wt of Co3O4, from 0 to about 0.01 % wt of CuO, from about 0 to about 0.6 of CeO2, from 0.02 to about 1 of TiO2, and from about 0 to about 2 of NaNO3. The glass having a visible light transmission of at least 87%; a ultraviolet radiation transmittance less than 85%; and a solar direct transmittance of no more than 90%.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/003-202-379-765-950,Granted Patent,no,0,0,12,13,0,C03C3/087;;C03C3/087,C03C4/00;;C03C3/00,,0,0,,,,ACTIVE
243,CA,C,CA 2590192 C,134-559-580-622-654,2012-05-15,2012,CA 2590192 A,2005-11-29,CU 20040277 A;;CU 2005000010 W,2004-12-08,LIQUID MYCORRHIZAL INOCULANT,"The invention relates to the field of agriculture, soil biotechnology and, specifically, the production and application of arbuscular mycorrhizal fungi, a micro-organism which improves efficiency in nutrient uptake by plants, moisture level, crop production and protection against certain root diseases, etc. The invention consists of a liquid product which is applied to arbuscular mycorrhizal fungi, using an aqueous medium which can achieve stabilisation of the mycorrhizal propagules, thereby enabling the formation of soil aggregates, and a demonstrated viability in liquid medium of between 12 and 18 months and which can be used in irrigation and fertigation systems. The inventive inoculant is applied directly to fields or greenhouses under protected cultivation and can also be used to overcome spore dormancy mechanisms and to obtain an increased concentration level which enables and facilitates handling and transport. The inventive product can be applied in order to manage mycorrhizal fungi in crops under large-scale irrigation system with improved productivity and environmental impacts.",INST NAC DE CIENCIAS AGRICOLAS INCA,FERNANDEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGUEL;;PEREZ CABRERA YUNIESKY,,https://lens.org/134-559-580-622-654,Granted Patent,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C05F11/08;;A01N63/30;;C05G3/80;;C12N1/14,,0,0,,,,INACTIVE
244,TN,A1,TN SN07218 A1,190-486-838-208-239,2008-11-21,2008,TN SN07218 A,2007-06-07,CU 2005000010 W;;CU 20040277 A,2004-12-08,LIQUID MYCORRHIZAL INOCULANT,"The invention relates to the field of agriculture, soil biotechnology and, specifically, the production and application of arbuscular mycorrhizal fungi, a micro-organism which improves efficiency in nutrient uptake by plants, moisture level, crop production and protection against certain root diseases, etc. The invention consists of a liquid product which is applied to arbuscular mycorrhizal fungi, using an aqueous medium which can achieve stabilisation of the mycorrhizal propagules, thereby enabling the formation of soil aggregates, and a demonstrated viability in liquid medium of between 12 and 18 months and which can be used in irrigation and fertigation systems. The inventive inoculant is applied directly to fields or greenhouses under protected cultivation and can also be used to overcome spore dormancy mechanisms and to obtain an increased concentration level which enables and facilitates handling and transport. The inventive product can be applied in order to manage mycorrhizal fungi in crops under large-scale irrigation system with improved productivity and environmental impacts.",INST NAC DE CIENCIAS AGRICOLAS INCA,FERNANDEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGUEL;;PEREZ CABRERA YUNIESKY,,https://lens.org/190-486-838-208-239,Patent Application,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,A01N65/00;;A01N63/30;;C05F11/08;;C05G3/80;;C12N1/14,,0,0,,,,PENDING
245,CA,C,CA 2801244 C,059-651-355-570-820,2021-02-09,2021,CA 2801244 A,2011-06-01,US 79194910 A;;MX 2011000068 W,2010-06-02,DARK GREEN SOLAR CONTROL GLASS COMPOSITION,"The present invention provides a dark green colored glass composition having a soda-lime-silica glass composition, wherein the coloring compounds comprises in weight percentage: from 0.71 to 1.50% of total iron expressed as Fe2O3; from 22 to 30% of ferrous-ferric ratio and from 0.15 to 0.50% of FeO expressed as Fe2O3; from 0.10 to 0.20% of S03 without affecting the refining properties and ability of the SO3 to eliminate bubbles; about 0 to 1.0 wt. % TiO2; about 0.0004 to 0.03 wt. % Cr203; and also 0.0004 to 0.015 wt. % CuO.",VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,,https://lens.org/059-651-355-570-820,Granted Patent,no,0,0,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,C03C4/02,,0,0,,,,ACTIVE
246,BR,A2,BR PI1003968 A2,145-716-078-362-610,2013-01-29,2013,BR PI1003968 A,2010-09-28,MX 2009014047 A,2009-12-18,queimador de tres setores de chama,"QUEIMADOR DE TRES SETORES DE CHAMA. A invenção refere-se ao campo dos queimadores, particularmente queimadores destinados a uso doméstico, tal como fogões. É descrito um queimador de três anéis (1), o qual produz chamas mais compridas e mais inclinadas pelo que é obtido um aquecimento mais eficiente; portas de combustão (5,9,10) nos anéis com disposições retas ou helicoidais; onde o anel interno pode funcionar em conjunto com ou independentemente dos outros dois anéis de chama, desta forma controlando a intensidade de aquecimento e a chama por meio do controle da velocidade da corrente de gás-ar; compreendendo como partes principais: uma parte de cima do queimador (4) , a qual contém três anéis concêntricos, um anel interno (62), um anel intermediário e um anel externo (5), cada anel de chama contendo portas de combustão, a pluralidade de portas de combustão (5,9,10) é helicoidal tanto em seus anéis internos quanto em seus anéis externos, duas tampas sobre a parte de cima do queimador (4) , uma interna e a outra externa; uma cobertura para os queimadores que forma a superfície do aparelho de aquecimento; dutos Venturi (11,12,13) na parte inferior da parte de cima do queimador (4); um suporte firmemente fixo à superfície do aparelho de aquecimento, neste suporte estão alojados os dutos Venturi (11,12,13) da parte de cima do queimador (4) ; um distribuidor de gás alojado na parte inferior do suporte (32), onde o distribuidor de gás (14) contém três saidas de gás, duas laterais (15,16) e uma central (17).",MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLLO ROBERTO,,https://lens.org/145-716-078-362-610,Patent Application,no,0,0,7,7,0,F23D14/06;;F23D2900/14062;;F23D2900/14063;;F23D14/06;;F23D2900/14063;;F23D2900/14062,F23D14/58,,0,0,,,,DISCONTINUED
247,CR,A,CR 9106 A,177-518-341-074-813,2007-10-31,2007,CR 9106 A,2007-05-08,CU 20040277 A;;CU 2005000010 W,2004-12-08,INOCULANTE MICORRIZOGENO LIQUIDO,"La solucion tecnica propuesta se relaciona con la rama de la agricultura, la biotecnologia del suelo y especificamente con la produccion y aplicacion de los hongos micorrizogenos arbusculares, microorganismo que mejora la eficiencia en la toma de nutrientes por las plantas, nivel hidrico, produccion vegetal, proteccion contra alguna de las enfermedades de la raiz, etc.",INST NAC DE CIENCIA AGRICOLA INCA,FERNANDEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGUEL;;PEREZ CABRERA YUNIESKY,,https://lens.org/177-518-341-074-813,Patent Application,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,A01N63/30;;A01N65/00;;C05F11/08;;C05G3/80;;C12N1/14,,0,0,,,,PENDING
248,US,A1,US 2018/0230520 A1,027-969-992-330-212,2018-08-16,2018,US 201815877851 A,2018-01-23,US 201815877851 A;;ES 201232077 A;;US 201514758458 A;;IB 2014000230 W,2012-12-31,PRIMERS FOR THE DETECTION AND TYPING OF CARBAPENEMASE-PRODUCING BACTERIAL STRAINS AND DETECTION METHOD AND KIT,"Some pairs of primers are provided, being used for detection of carbapenemase genes and carbapenemase-producing bacterial strains, and a diagnosis method using said set of primers. Furthermore, there is also disclosed, preferably, the use of probes within each amplification reaction, more preferably multiplex PCR, for selective identification and detection of carbapenemase genes from a biological sample. The primers object of this invention may be used for preparing a kit for carbapenemase genes identification and detection, preferably carbapenemases contained in bacterial strains producing said enzymes.",FUNDACION PARA EL FOMENTO DE LA INVESTIG SANITARIA Y BIOMEDICA DE LA COMMUNITAT VALENCIANA,ROYO GARCIA GLORIA;;RODRIGUEZ DIAZ JUAN CARLOS;;GALIANA CABRERA ANTONIO JOSE,,https://lens.org/027-969-992-330-212,Patent Application,yes,0,0,12,12,77,C12Q1/689;;C12Q1/689;;C12Q2600/156;;C12Q2600/156;;C12Q2600/16;;C12Q2600/16,C12Q1/689,,0,0,,,,DISCONTINUED
249,ES,A1,ES 2143914 A1,051-843-786-524-741,2000-05-16,2000,ES 9700889 A,1997-04-24,ES 9700889 A,1997-04-24,"Portable receptacle for canine excrement, with disposable bags","Receptacle formed by five structural components: a long handle a sleeve sliding along the handle and which can be fixed in an appropriate position a short U-profile portion with non-identical fins, which is connected permanently to the sleeve and which has its longitudinal axis perpendicular to that of the sleeve a rod clamp formed by two superposed Us connected via their branches and a bag with a side perforation. The clamp may be locked in two alternative positions: parallel to the handle, for transportation thereof, or perpendicular to it for use thereof, securing the bag. In this latter arrangement, it is placed under the haunches of the dog when said dog adopts a defecation position, the excrement entering the bag via its side perforation and not falling onto the ground. When evacuation is complete, the receptacle is placed over a rubbish container and the bag retention is unlocked, the bag falling inside the rubbish container.",TORNER CABRERA JOSE LUIS;;BORT CALLEJO A ORENCIO;;SAUBI PUIGMITJA ISIDRO,TORNER CABRERA JOSE LUIS;;BORT CALLEJO A ORENCIO;;SAUBI PUIGMITJA ISIDRO,,https://lens.org/051-843-786-524-741,Patent Application,no,1,2,2,2,0,,A01K23/00;;E01H1/12,,0,0,,,,EXPIRED
250,ES,B1,ES 2143914 B1,150-325-199-977-737,2000-12-16,2000,ES 9700889 A,1997-04-24,ES 9700889 A,1997-04-24,"RECEPTOR PORTATIL DE HECES CANINAS, CON BOLSAS DESECHABLES.","El objeto de la presente Patente de Invención es un receptor portátil de heces caninas, con bolsas desechables, formado por cinco componentes estructurales: un mango largo; un manguito deslizante a lo largo de él y fijable en la posición conveniente; un corto tramo de perfil U de alas desiguales, unido inseparablemente al manguito y con su eje longitudinal perpendicular al de este; una pinza de varilla, formando dos U superpuestas y enlazadas por sus ramas; y una bolsa, con una perforación lateral. La pinza puede enclavarse en dos posiciones alternativas paralela al mango, para su transporte, o perpendicular a este para su uso, sujetando la bolsa. En esta última disposición se coloca bajo las ancas del perro cuando este adopta la posición de defecar, penetrando las heces en la bolsa por su perforación lateral, sin caer al suelo. Al finalizar la evacuación se sitúa el receptor sobre un contenedor de basura y se desenclava la retención de la bolsa, que cae en su interior.",TORNER CABRERA JOSE LUIS;;BORT CALLEJO A ORENCIO;;SAUBI PUIGMITJA ISIDRO,TORNER CABRERA JOSE LUIS;;BORT CALLEJO A ORENCIO;;SAUBI PUIGMITJA ISIDRO,,https://lens.org/150-325-199-977-737,Granted Patent,no,0,0,2,2,0,,A01K23/00;;E01H1/12,,0,0,,,,EXPIRED
251,CA,A1,CA 3056864 A1,175-991-865-062-54X,2020-04-19,2020,CA 3056864 A,2019-09-26,EP 18382747 A,2018-10-19,METHOD AND SYSTEM FOR REWORKING A COMPOSITE LAMINATE,"Method for reworking a composite laminate (1) comprising a plurality of tapes (2), the method comprising the following steps: - detecting the occurrence of a defect (3) on a tape (4) of composite material while the tape (4) is being laid up, - continuing the lay-up of the defective tape (4) until a tape (4) length which surpasses a manufacturing length (L) of the tape (4), - catching the part of the defective tape (4) that surpasses the manufacturing length (L) of the tape (4), - cutting the defective tape (4) in the part of the defective tape (4) that surpasses the manufacturing length (L) of the tape (4), - removing from the laminate (1) the caught defective tape (4) by the catching system, and - laying-up a replacement tape (2) in the place of the removed defective tape (4).",AIRBUS OPERATIONS SL,MENENDEZ MARTIN JOSE MANUEL;;CABANAS CONTRERAS RAUL ALBERTO;;CABRERA RODRIGUEZ PEDRO,,https://lens.org/175-991-865-062-54X,Patent Application,no,0,0,8,8,0,B29C70/386;;B29C70/34;;B29C70/388;;B29C70/54;;B29C70/545;;B29C2793/0081;;B32B43/00;;B32B5/26;;B32B2041/04;;B32B2260/021;;B32B2260/046;;B32B2305/08;;B32B2605/18;;B29C70/388;;B29C70/545;;B29C73/12;;B29C2793/0081;;B29C70/386;;B29C70/545;;B29C73/12;;B29C70/388;;B29C70/54,B32B41/00;;B29C73/10;;B32B38/10,,0,0,,,,PENDING
252,MX,A,MX GT05000016 A,034-898-025-364-183,2007-05-30,2007,MX GT05000016 A,2005-11-30,MX GT05000016 A,2005-11-30,SEED PNEUMATIC DISPENSER FOR A PRECISION SOWING MACHINE.,"The present invention refers to a pneumatic dispensing device, which is an important component of an automatic precision sowing machine, which is particularly useful for large atypical-shaped seeds, such as garlic, onion and the like seeds. The invention includes an oscillating bottom hoper and an adjustable gate for facilitating and controlling the flow of the seed to be fed. The main action including the seed dispense (individualization and controlled delivery) is satisfactorily performed by using several factors such as: a suitable and constant seed level in the separation chamber; the seed agitation by the vibration of the oscillating lever including an amplitude and frequency according to the seed properties; cinematic forms and parameters of the dispensing discs which are arranged in pairs, and which combine the factor of adherence by suction resulting in a mechanical backing effect; a geometrical configuration of the discs periphery (back) and cover (slider) useful for removing ""folding"" type errors; a continuous duct cleaning by air streams for avoiding permanent obstructions, and substantially reducing ""Flaw"" type errors; the use of correct values for the generated vacuum and pressure; a suitable sealing system for avoiding suction lose. The suction and vacuum generated by centrifugal fans are led to the dispenser by means of threaded elastic hoses, these latter elements being connected to the dispenser so as to be directed towards the respective ducts of the rotating dispensing discs through a hollow central axis, which is axially divided. The rotating movement of the dispensing discs is obtained from wheels using a conventional transmission system suitable and according to the required sowing rate. The dispenser components allow the device to be assembled in different arrangements, in order to be adapted to furrows having two rows, or beds having a plurality of rows.",UNIV GUANAJUATO,SIXTO JOSE MANUEL CABRERA;;REYES EFRAIN CALDERON;;HLAWEINSKA RYSZARD JERZY SERWA,,https://lens.org/034-898-025-364-183,Patent Application,no,0,0,4,4,0,A01C7/044,A01C7/04,,0,0,,,,ACTIVE
253,WO,A1,WO 2020/264005 A1,071-180-338-848-647,2020-12-30,2020,US 2020/0039393 W,2020-06-24,US 201962867334 P,2019-06-27,MULTIFUNCTIONAL BIOMESH FOR SURGICAL HERNIA REPAIR,"Embodiments of the disclosure include methods and compositions related to repair of weakenings or openings in a tissue of an individual, including at least a muscular wall, for example. In specific cases, a mesh comprising phosphate crosslinked poly(vinyl alcohol) polymer (PVA-P) is utilized for such methods, including for hernia repair of any kind. In particular embodiments, one side of the mesh comprises decellularized gel matrix to provide for enhanced tissue healing.",BAYLOR COLLEGE MEDICINE,ACHARYA GHANASHYAM;;SHIN CRYSTAL S;;SCOTT BRADFORD GLENN;;CABRERA FERNANDO JOSE,,https://lens.org/071-180-338-848-647,Patent Application,yes,2,0,3,3,0,A61K35/12;;C08K3/32;;C09D129/04;;C08K2003/321;;A61L31/048;;A61L31/16;;A61L31/005;;A61L2400/12;;A61L2300/414;;A61L2300/406;;A61L2300/41;;A61L2300/402;;A61F2250/0051;;A61F2250/0067;;A61F2210/0004;;A61F2/0063;;B33Y70/00;;B33Y80/00;;A61F2/0063;;A61F2210/0004;;A61F2250/0067;;A61L31/043;;A61L31/048;;A61L31/10;;A61L31/16;;A61L2300/402;;A61L2300/406;;A61L2300/41;;A61L2300/414;;A61L2300/604;;A61L2400/12,A61K35/12;;A61F2/08;;A61L27/58;;A61L31/12;;C08L29/04,,3,3,091-700-936-218-241;;018-288-021-963-076;;033-367-947-623-090,10.1002/adfm.200701261;;pmc6336671;;10.1002/btm2.10110;;30680321;;25147814;;10.1155/2014/762189;;pmc4131468,"MARC CHAOUAT, CATHERINE LE VISAGE, WILMS E. BAILLE ,BRIGITTE ESCOUBET ,FRÉDÉRIC CHAUBET ,MIRCEA ALEXANDRU, MATEESCU DIDIER LETOUR: ""A novel cross-linked poly(vinyl alcohol) (PVA) for Vascular Grafts"", ADVANCED FUNCTIONAL MATERIALS, vol. 18, no. 19, 6 October 2008 (2008-10-06), pages 2855 - 2861, XP055780195, ISSN: 1616-301X, DOI: 10.1002/adfm.200701261;;KIM YU SEON, MAJID MARJAN, MELCHIORRI ANTHONY J., MIKOS ANTONIOS G: ""Applications of decellularized extracellular matrix in bone and cartilage tissue engineering"", BIOENGINEERING & TRANSLATIONAL MEDICINE, vol. 4, no. 1, 6 August 2018 (2018-08-06), pages 83 - 95, XP055780197, ISSN: 2380-6761, DOI: 10.1002/btm2.10110;;ELENA STOCCO; SILVIA BARBON; DANIELE DALZOPPO; SILVANO LORA; LEONARDO SARTORE; MARCELLA FOLIN; PIER PAOLO PARNIGOTTO; CLAUDIO GRAN: ""Tailored PVA/ECM Scaffolds for Cartilage Regeneration"", BIOMED RESEARCH INTERNATIONAL, vol. 2014, 762189, 1 January 2014 (2014-01-01), pages 1 - 12, XP055416923, ISSN: 2314-6133, DOI: 10.1155/2014/762189",PENDING
254,US,A1,US 2022/0192811 A1,073-606-828-979-461,2022-06-23,2022,US 202017596923 A,2020-06-24,US 202017596923 A;;US 201962867334 P;;US 2020/0039393 W,2019-06-27,MULTIFUNCTIONAL BIOMESH FOR SURGICAL HERNIA REPAIR,"Embodiments of the disclosure include methods and compositions related to repair of weakenings or openings in a tissue of an individual, including at least a muscular wall, for example. In specific cases, a mesh comprising phosphate crosslinked poly(vinyl alcohol) polymer (PVA-P) is utilized for such methods, including for hernia repair of any kind. In particular embodiments, one side of the mesh comprises decellularized gel matrix to provide for enhanced tissue healing.",BAYLOR COLLEGE MEDICINE,ACHARYA GHANASHYAM;;SHIN CRYATAL S;;SCOTT BRADFORD GLENN;;CABRERA FERNANDO JOSE,BAYLOR COLLEGE OF MEDICINE (2020-06-04),https://lens.org/073-606-828-979-461,Patent Application,yes,0,0,3,3,0,A61K35/12;;C08K3/32;;C09D129/04;;C08K2003/321;;A61L31/048;;A61L31/16;;A61L31/005;;A61L2400/12;;A61L2300/414;;A61L2300/406;;A61L2300/41;;A61L2300/402;;A61F2250/0051;;A61F2250/0067;;A61F2210/0004;;A61F2/0063;;B33Y70/00;;B33Y80/00;;A61F2/0063;;A61F2210/0004;;A61F2250/0067;;A61L31/043;;A61L31/048;;A61L31/10;;A61L31/16;;A61L2300/402;;A61L2300/406;;A61L2300/41;;A61L2300/414;;A61L2300/604;;A61L2400/12,A61L31/04;;A61F2/00;;A61L31/10;;A61L31/16;;B33Y70/00;;B33Y80/00,,0,0,,,,PENDING
255,EP,A4,EP 2433915 A4,084-692-670-523-984,2013-03-06,2013,EP 10777983 A,2010-05-21,MX 2010000043 W;;US 45476909 A,2009-05-22,COLOURLESS GLASS COMPOSITION,,VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/084-692-670-523-984,Search Report,no,4,0,12,13,0,C03C3/087;;C03C3/087,C03C4/00;;C03C3/00;;C03C3/087,,1,0,,,See also references of WO 2010134796A1,ACTIVE
256,US,A1,US 2011/0151385 A1,172-232-305-180-429,2011-06-23,2011,US 97031110 A,2010-12-16,MX 2009014047 A,2009-12-18,Triple Flame Section Burner,"The present invention relates to the field of burners, particularly in burners intended for household use, such as stoves. A three ring burner is described, which produces longer and more inclined flames through which a more efficient heating is accomplished; combustion ports in the rings with straight or helicoid arrangements; where the inner ring can function in conjunction with or independently from the other two flame rings, thus controlling the heating intensity and the flame by means of controlling the velocity of the gas-air current; as main parts comprising; a burner head, which contains three concentric flame rings, one inner ring, one intermediate ring and one outer ring, each flame ring containing combustion ports, the collection of combustion ports are helicoid both in their inner ring as well as the outer ring, two lids on the burner head, one inner and the other outer; one cover for the burners which forms the surface of the heating apparatus; Venturi ducts on the lower part of the burner head; a support firmly joined to the surface of the heating apparatus, in this support are lodged Venturi ducts from the burner head; a gas distributor lodged in the lower part of the support, where the gas distributor has three gas exits, two laterals and one central.",LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2010-07-14),https://lens.org/172-232-305-180-429,Patent Application,yes,29,26,7,7,0,F23D14/06;;F23D2900/14062;;F23D2900/14063;;F23D14/06;;F23D2900/14063;;F23D2900/14062,F24C3/00;;F23C5/00,431/2;;X126 39  E,0,0,,,,INACTIVE
257,ES,Y,ES 1291283 Y,016-741-778-258-168,2022-09-19,2022,ES 202230773 U,2020-10-26,ES 202230773 U,2020-10-26,DISPOSITIVO PORTABLE DE ACTUACION FRENTE A SITUACIONES DE EMERGENCIA,,CABRERA MAYORDOMO JUAN JOSE;;BARBERO HOYOS MIGUEL ANGEL,AGUILAR CORDÓN JOAQUÍN;;CABRERA MAYORDOMO JUAN JOSE;;BARBERO HOYOS MIGUEL ANGEL,,https://lens.org/016-741-778-258-168,Limited Patent,no,0,0,3,3,0,,G08B7/06;;G08B21/00,,0,0,,,,ACTIVE
258,CA,C,CA 2712208 C,029-669-612-612-858,2016-04-05,2016,CA 2712208 A,2010-08-05,MX 2009014047 A,2009-12-18,TRIPLE FLAME SECTION BURNER,"The present invention relates to the field of burners, particularly in burners intended for household use, such as stoves. A three ring burner is described, which produces longer and more inclined flames through which a more efficient heating is accomplished; combustion ports in the rings with straight or helicoid arrangements; where the inner ring can function in conjunction with or independently from the other two flame rings, thus controlling the heating intensity and the flame by means of controlling the velocity of the gas-air current; as main parts comprising; a burner head, which contains three concentric flame rings, one inner ring, one intermediate ring and one outer ring, each flame ring containing combustion ports, the collection of combustion ports are helicoid both in their inner ring as well as the outer ring, two lids on the burner head, one inner and the other outer; one cover for the burners which forms the surface of the heating apparatus; Venturi ducts on the lower part of the burner head; a support firmly joined to the surface of the heating apparatus, in this support are lodged Venturi ducts from the burner head; a gas distributor lodged in the lower part of the support, where the gas distributor has three gas exits, two laterals and one central.",MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,,https://lens.org/029-669-612-612-858,Granted Patent,no,0,0,7,7,0,F23D14/06;;F23D2900/14062;;F23D2900/14063;;F23D14/06;;F23D2900/14063;;F23D2900/14062,F23D14/12;;F23D14/58;;F23D14/84,,0,0,,,,INACTIVE
259,US,A1,US 2008/0202495 A1,049-610-443-736-882,2008-08-28,2008,US 3403508 A,2008-02-20,MX 2007002289 A,2007-02-23,DOUBLE FLAME PERIMETER BURNER,"A burner for range covers or similar, to allow a broad range of calorific capacities, and a better burner distribution in the cover, with a generally semi-rectangular form, and containing a plurality of ports and a plurality of manners to ignite it, wherein the burner is capable of interacting with other burners at determined length and height distances, creating discontinuous flames between the burners.",CALOCA GALINDO VICTOR GERARDO;;SANTOYO JOSE ARTURO LONA;;BOTELLO ROBERTO CABRERA,CALOCA GALINDO VICTOR GERARDO;;SANTOYO JOSE ARTURO LONA;;BOTELLO ROBERTO CABRERA,MABE MEXICO S. DE R.L. DE C.V (2008-01-25),https://lens.org/049-610-443-736-882,Patent Application,yes,9,29,5,5,0,F23D14/06;;F23D14/58;;F23D14/06;;F23D14/58,F23D14/62;;F24C3/08;;F23Q1/00,126 39 E;;431/354;;431/273,0,0,,,,INACTIVE
260,US,S,US D0678722 S,094-815-590-088-791,2013-03-26,2013,US 201229418736 F,2012-04-20,MX 2011003415 F,2011-10-20,Delta gas burner,,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO;;MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2012-05-28),https://lens.org/094-815-590-088-791,Design Right,no,0,4,4,4,0,,,0702;;D 7407,0,0,,,,ACTIVE
261,CN,A,CN 111070731 A,131-994-709-242-167,2020-04-28,2020,CN 201910994173 A,2019-10-18,EP 18382747 A,2018-10-19,Method and system for reworking composite laminate and automated tape placement machine,"The invention relates to a method and system for reworking a composite laminate and an automated tape placement machine. In one aspect, a method is provided for reworking a composite laminate (1) comprising a plurality of tapes (2), the method comprising the following steps: detecting the occurrence of a defect (3) on a tape (4) of composite material while the tape (4) is being laid up; continuingthe lay-up of the defective tape (4) until a tape (4) length which surpasses a manufacturing length (L) of the tape (4); catching the part of the defective tape (4) that surpasses the manufacturing length (L) of the tape (4); cutting the defective tape (4) in the part of the defective tape (4) that surpasses the manufacturing length (L) of the tape (4); removing from the laminate (1) the caught defective tape (4) by the catching system, and laying-up a replacement tape (2) in the place of the removed defective tape (4).",AIRBUS OPERATIONS SL,MENENDEZ MARTIN JOSE MANUEL;;CABANAS CONTRERAS RAUL ALBERTO;;CABRERA RODRIGUEZ PEDRO,,https://lens.org/131-994-709-242-167,Patent Application,no,4,1,8,8,0,B29C70/386;;B29C70/34;;B29C70/388;;B29C70/54;;B29C70/545;;B29C2793/0081;;B32B43/00;;B32B5/26;;B32B2041/04;;B32B2260/021;;B32B2260/046;;B32B2305/08;;B32B2605/18;;B29C70/388;;B29C70/545;;B29C73/12;;B29C2793/0081;;B29C70/386;;B29C70/545;;B29C73/12;;B29C70/388;;B29C70/54,B29C70/38;;B29C70/34,,0,0,,,,ACTIVE
262,EP,A1,EP 2647374 A1,132-512-539-605-157,2013-10-09,2013,EP 12382138 A,2012-04-04,EP 12382138 A,2012-04-04,Nutritional compositions including beta-hydroxy-beta-methylbutyrate for regulating transcription factors,"Disclosed are nutritional compositions that include beta-hydroxy-beta-methylbutyrate. The nutritional compositions may be administered to prevent and/or reduce and/or treat diseases and conditions associated with downregulation of serine-threonine kinase protein kinase B (Akt/PKB) signaling pathways, with the concomitant FOXO transcription factors activation, such as muscle wasting, diabetes, infertility, neurodegeneration, and immune system dysfunction.
",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;MANZANO MARTIN MANUEL CRISTOBAL,ABBOTT LABORATORIES (2014-09-03),https://lens.org/132-512-539-605-157,Patent Application,yes,2,9,1,1,0,A61K31/19;;A23L33/175;;A23V2002/00;;A61P3/10;;A61P15/08;;A61P25/00;;A61P37/04,A61K31/19;;A61P3/10;;A61P15/08;;A61P25/00;;A61P37/04,,7,7,129-543-839-124-818;;093-735-873-511-792;;031-863-756-506-617;;005-729-660-409-61X;;023-373-018-223-656;;025-536-363-673-865;;054-472-963-255-837,20857835;;10.1515/jpem.2010.23.7.641;;19211028;;10.1016/j.bbamcr.2008.12.017;;10.33549/physiolres.930582;;15717836;;10.1016/j.ejphar.2010.07.018;;20655898;;18160256;;10.1016/j.cellsig.2007.11.004;;pmc1964795;;17399794;;10.1016/j.pharmthera.2007.02.002;;10.1016/j.nbd.2007.09.008;;18023354,"PORTAL SHAWN ET AL: ""Effect of HMB supplementation on body composition, fitness, hormonal profile and muscle damage indices."", JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM : JPEM JUL 2010 LNKD- PUBMED:20857835, vol. 23, no. 7, July 2010 (2010-07-01), pages 641 - 650, XP002677002, ISSN: 0334-018X;;KORNASIO R ET AL: ""beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways"", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1793, no. 5, 1 May 2009 (2009-05-01), pages 755 - 763, XP026106487, ISSN: 0167-4889, [retrieved on 20090103], DOI: 10.1016/J.BBAMCR.2008.12.017;;ZDYCHOVÀ J ET AL: ""Emerging role of Akt Kinase / Protein Kinase B signaling in pathophysiology of Diabetes and its complications"", PHYSIOLOGICAL RESEARCH, ACADEMIA, PRAGUE, CZ, vol. 54, no. 1, 1 February 2005 (2005-02-01), pages 1 - 16, XP002409949, ISSN: 0862-8408;;TANAKA H ET AL: ""Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice"", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 645, no. 1-3, 25 October 2010 (2010-10-25), pages 185 - 191, XP027247568, ISSN: 0014-2999, [retrieved on 20100723];;NAWA ET AL: ""A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2A-mediated dephosphorylation of Akt/PKB"", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 20, no. 3, 17 November 2007 (2007-11-17), pages 493 - 505, XP022425193, ISSN: 0898-6568;;BURKE ET AL: ""Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease"", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 114, no. 3, 1 June 2007 (2007-06-01), pages 261 - 277, XP022101140, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2007.02.002;;DAMJANAC ET AL: ""Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease"", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 29, no. 2, 11 October 2007 (2007-10-11), pages 354 - 367, XP022422306, ISSN: 0969-9961, DOI: 10.1016/J.NBD.2007.09.008",DISCONTINUED
263,US,A1,US 2018/0179583 A1,027-978-461-008-317,2018-06-28,2018,US 201815877834 A,2018-01-23,US 201815877834 A;;US 201514758458 A;;IB 2014000230 W;;ES 201232077 A,2012-12-31,PRIMERS FOR THE DETECTION AND TYPING OF CARBAPENEMASE-PRODUCING BACTERIAL STRAINS AND DETECTION METHOD AND KIT,"Some pairs of primers are provided, being used for detection of carbapenemase genes and carbapenemase-producing bacterial strains, and a diagnosis method using said set of primers. Furthermore, there is also disclosed, preferably, the use of probes within each amplification reaction, more preferably multiplex PCR, for selective identification and detection of carbapenemase genes from a biological sample. The primers object of this invention may be used for preparing a kit for carbapenemase genes identification and detection, preferably carbapenemases contained in bacterial strains producing said enzymes.",FUNDACION PARA EL FOMENTO DE LA INVESTIG SANITARIA Y BIOMEDICA DE LA COMMUNITAT VALENCIANA,ROYO GARCIA GLORIA;;RODRIGUEZ DIAZ JUAN CARLOS;;GALIANA CABRERA ANTONIO JOSE,,https://lens.org/027-978-461-008-317,Patent Application,yes,0,0,12,12,77,C12Q1/689;;C12Q1/689;;C12Q2600/156;;C12Q2600/156;;C12Q2600/16;;C12Q2600/16,C12Q1/689,,0,0,,,,DISCONTINUED
264,ES,A1,ES 2092443 A1,056-104-672-060-38X,1996-11-16,1996,ES 9402572 A,1994-12-16,ES 9400888 A,1994-04-27,NEEDLE AND TUBE-CARRIER ASSEMBLY,"Needle and tube-carrier assembly modified for the vacuum extraction of blood and other organic fluids, comprising a bayonet-type needle (1, 1') and a tube-carrier (10 or 10'), in association with a tube (20), the needle (1) being comprised of a front bevelled needle (4), a transparent connector with side wings (2), a threaded hollow holding part (3 or 3'), a rear needle connection (5) with external rubber sleeve and a rear needle (6) with closed bevel and side openings, the tube-carrier (10) being provided with a needle connection female cone of the thread type (13) or the clip type (13'), with internal damping pad (11), tube-carrier fixing grooves (17) and rotary fixing wings (12) the tube-carrier may also be formed, in a second embodiment, as a single piece body (27) which presents at one of its extremities an element configured as a delta wing (22) from which arises a cone (24) through which passes a conduit (23) to the inside of the sample-holder tube (27), thereby saving a damping pad (28), the conduit (23) being connected to the needle (25) through which circulates the sample flow to the inside of the sample tube (30), thereby saving a protection head (29).",GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON DOLORES;;CABRERA DE CASTRO FRANCISCO,GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON DOLORES;;CABRERA DE CASTRO FRANCISCO,,https://lens.org/056-104-672-060-38X,Ambiguous,no,2,0,6,6,0,A61B5/150488;;A61B5/15003;;A61B5/150389;;A61B5/150496;;A61B5/150572;;A61B5/150732;;A61B5/154;;A61B10/0045,A61B5/15;;A61M5/14,,0,0,,,,EXPIRED
265,WO,A1,WO 2010/134796 A1,156-193-012-342-851,2010-11-25,2010,MX 2010000043 W,2010-05-21,US 45476909 A,2009-05-22,COLOURLESS GLASS COMPOSITION,"The invention relates to a colourless glass composition having a base glass composition containing: from approximately 0.005 to approximately 0.08 wt.-% iron oxide; from approximately 0.00002 to approximately 0.0004 wt.-% Se; from approximately 0.00003 to approximately 0.001 wt.-% Co3O4; from approximately 0 to approximately 0.01 wt.-% CuO; from approximately 0 to approximately 0.6 wt.-% CeO2; from 0.02 to approximately 1 wt.-% TiO2; and from approximately 0 to approximately 2 wt.-% NaNO3. The glass has a visible light transmission of at least 87%, ultraviolet transmittance of at least 85% and direct solar transmission of no more than 90%.",VIDRIO PLANO DE MEXICO SA DE CV;;CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;KIYAMA RODRIGUEZ MIGUEL ANGEL,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/156-193-012-342-851,Patent Application,yes,14,2,12,13,0,C03C3/087;;C03C3/087,C03C4/00;;C03C3/00,,6,1,106-860-409-063-650,10.1111/j.1151-2916.1921.tb17326.x,"N. E. DENSEM: ""The equilibrium between ferrous and ferric oxides in glasses"", JOURNAL OF THE SOCIETY OF GLASS TECHNOLOGY, GLASGOW, ENGLAND, May 1937 (1937-05-01), pages 374 - 389;;J. C. HOSTETTER; H. S. ROBERTS: ""Note on the dissociation of Ferric Oxide dissolved in glass and its relation to the color of iron-bearing glasses"", JOURNAL OF THE AMERICAN CERAMIC SOCIETY, USA, September 1921 (1921-09-01), pages 927 - 938;;STRIPLE, J. H.: ""Titanium dioxide its effect on the transmission of various glasses"", THE GLASS INDUSTRY, April 1964 (1964-04-01), pages 193 - 196;;M. D. BEALS: ""Effects of Titanium Dioxide in Glass"", THE GLASS INDUSTRY, September 1963 (1963-09-01), pages 495 - 53;;ARTHUR C. HARDY: ""Handbook of Colorimetry"", 1936, MASSACHUSETTS INSTITUTE OF TECHNOLOGY;;See also references of EP 2433915A4",PENDING
266,MX,A,MX 2011010941 A,037-427-246-048-035,2013-04-15,2013,MX 2011010941 A,2011-10-14,MX 2011010941 A,2011-10-14,DELTA BURNER.,"A gas burner for household use equipment which contains a zone for the mixture of combustible gas with primary air to form an air-gas mixture, an inner chamber with an inner table, three sides with crenellated walls, each side with two ends, a vertex is formed on each end of the side and each side is formed by at least two curved surfaces which are intersected by each other, a port zone on an upper face of the crenellated wall, the port zone with main ports, the main ports are substantially centric regarding the vertexes, the symmetry axis of each one of the main ports is aligned towards the vertex closest to each one of the ports and the ports having an equidistant space between each other, a lid which closes the inner chamber of and allows the passage of the mixture through the main ports. In embodiments, the curved surfaces may be different types of curves. In other embodiments, the lid is set with a cavity unto which a central burner s placed. The central burner may be similar to the main burner.",MABE SA DE CV,SANTOYO JOSE ARTURO LONA;;CAMPO ERNESTO ARIAS DEL;;BOTELLO ROBERTO CABRERA,,https://lens.org/037-427-246-048-035,Patent Application,no,0,0,6,6,0,F24C3/085;;F24C3/085;;F23D14/06;;F23D14/06;;F23D14/58;;F23D14/58;;F23D14/64;;F23D14/64;;F23D2213/00;;F23D2213/00;;F23D2900/00003;;F23D2900/00003;;F23D2900/14062;;F23D2900/14062;;F23D2900/14064;;F23D2900/14064,F23D14/06,,0,0,,,,ACTIVE
267,US,S,US D0685225 S,145-462-544-241-633,2013-07-02,2013,US 201229440771 F,2012-12-27,US 201229440771 F;;MX 2011003415 F;;US 201229418736 F,2011-10-20,Delta gas burner,,MABE SA DE CV,SANTOYO JOSE ARTURO LONA;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2012-05-28),https://lens.org/145-462-544-241-633,Design Right,no,0,16,4,4,0,,,0702;;D 7407,0,0,,,,ACTIVE
268,EP,A1,EP 2433915 A1,172-152-721-668-749,2012-03-28,2012,EP 10777983 A,2010-05-21,MX 2010000043 W;;US 45476909 A,2009-05-22,COLOURLESS GLASS COMPOSITION,"The is a colorless glass composition having a base glass composition, comprising, in weight percentage, from about 0.005 to about 0.08 % wt of ferric oxide, from 0.00002 to about 0.0004 % wt of Se, from about 0.00003 to about 0.0010 % wt of Co 3 O 4 , from 0 to about 0.01 % wt of CuO, from about 0 to about 0.6 of CeO 2 , from 0.02 to about 1 of TiO 2 , and from about 0 to about 2 of NaNO 3 . The glass having a visible light transmission of at least 87%; a ultraviolet radiation transmittance less than 85%; and a solar direct transmittance of no more than 90%.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/172-152-721-668-749,Patent Application,yes,0,0,12,13,0,C03C3/087;;C03C3/087,C03C4/00;;C03C3/00;;C03C3/087,,0,0,,,,ACTIVE
269,CA,A1,CA 2590192 A1,103-740-184-628-503,2006-06-15,2006,CA 2590192 A,2005-11-29,CU 20040277 A;;CU 2005000010 W,2004-12-08,LIQUID MYCORRHIZAL INOCULANT,,INST NAC DE CIENCIAS AGRICOLAS,PEREZ CABRERA YUNIESKY;;DELL AMICO RODRIGUEZ JOSE MIGU;;FERNANDEZ MARTIN FELIX,,https://lens.org/103-740-184-628-503,Patent Application,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C05F11/08;;A01N63/30;;A01N65/00;;C05G3/80;;C12N1/14,,0,0,,,,INACTIVE
270,CA,C,CA 2618038 C,133-678-085-871-560,2014-09-09,2014,CA 2618038 A,2008-01-11,MX 2007002289 A,2007-02-23,DOUBLE FLAME PERIMETER BURNER,"A burner for range covers or similar, to allow a broad range of calorific capacities, and a better burner distribution in the cover, with a generally semi--rectangular form, and containing a plurality of ports and a plurality of manners to ignite it, wherein the burner is capable of interacting with other burners at determined length and height distances, creating discontinuous flames between the burners.",MABE MEXICO S DE R L DE C V,GALINDO VICTOR GERARDO CALOCA;;SANTOYO JOSE ARTURO LONA;;BOTELLO ROBERTO CABRERA,,https://lens.org/133-678-085-871-560,Granted Patent,no,0,2,5,5,0,F23D14/06;;F23D14/58;;F23D14/06;;F23D14/58,F23D14/02;;F23D14/14;;F23D14/58;;F24C3/08,,0,0,,,,INACTIVE
271,CA,A1,CA 3145199 A1,174-216-251-207-878,2020-12-30,2020,CA 3145199 A,2020-06-24,US 201962867334 P;;US 2020/0039393 W,2019-06-27,MULTIFUNCTIONAL BIOMESH FOR SURGICAL HERNIA REPAIR,"Embodiments of the disclosure include methods and compositions related to repair of weakenings or openings in a tissue of an individual, including at least a muscular wall, for example. In specific cases, a mesh comprising phosphate crosslinked poly(vinyl alcohol) polymer (PVA-P) is utilized for such methods, including for hernia repair of any kind. In particular embodiments, one side of the mesh comprises decellularized gel matrix to provide for enhanced tissue healing.",BAYLOR COLLEGE MEDICINE,ACHARYA GHANASHYAM;;SHIN CRYSTAL S;;SCOTT BRADFORD GLENN;;CABRERA FERNANDO JOSE,,https://lens.org/174-216-251-207-878,Patent Application,no,0,0,3,3,0,A61K35/12;;C08K3/32;;C09D129/04;;C08K2003/321;;A61L31/048;;A61L31/16;;A61L31/005;;A61L2400/12;;A61L2300/414;;A61L2300/406;;A61L2300/41;;A61L2300/402;;A61F2250/0051;;A61F2250/0067;;A61F2210/0004;;A61F2/0063;;B33Y70/00;;B33Y80/00;;A61F2/0063;;A61F2210/0004;;A61F2250/0067;;A61L31/043;;A61L31/048;;A61L31/10;;A61L31/16;;A61L2300/402;;A61L2300/406;;A61L2300/41;;A61L2300/414;;A61L2300/604;;A61L2400/12,A61F2/08;;A61K35/12;;A61L27/58;;A61L31/12;;C08L29/04,,0,0,,,,PENDING
272,CA,A1,CA 2618038 A1,006-343-563-684-059,2008-08-23,2008,CA 2618038 A,2008-01-11,MX 2007002289 A,2007-02-23,DOUBLE FLAME PERIMETER BURNER,"A burner for range covers or similar, to allow a broad range of calorific capacities, and a better burner distribution in the cover, with a generally semi--rectangular form, and containing a plurality of ports and a plurality of manners to ignite it, wherein the burner is capable of interacting with other burners at determined length and height distances, creating discontinuous flames between the burners.",MABE MEXICO S DE R L DE C V,BOTELLO ROBERTO CABRERA;;GALINDO VICTOR GERARDO CALOCA;;SANTOYO JOSE ARTURO LONA,,https://lens.org/006-343-563-684-059,Patent Application,no,0,1,5,5,0,F23D14/06;;F23D14/58;;F23D14/06;;F23D14/58,F23D14/02;;F23D14/14;;F23D14/58;;F24C3/08,,0,0,,,,INACTIVE
273,CA,A1,CA 2791972 A1,030-308-577-927-601,2013-04-14,2013,CA 2791972 A,2012-10-04,MX 2011010941 A,2011-10-14,DELTA BURNER,"A gas burner for household use equipment which contains a zone for the mixture of combustible gas with primary air to form an air-gas mixture, an inner chamber with an inner table, three sides with crenellated walls, each side with two ends, a vertex is formed on each end of the side and each side is formed by at least two curved surfaces which are intersected by each other, a port zone on an upper face of the crenellated wall, the port zone with main ports, the main ports are substantially centric regarding the vertexes, the symmetry axis of each one of the main ports is aligned towards the vertex closest to each one of the ports and the ports having an equidistant space between each other, a lid which closes the inner chamber of and allows the passage of the mixture through the main ports. In embodiments, the curved surfaces may be different types of curves. In other embodiments, the lid is set with a cavity unto which a central burner s placed. The central burner may be similar to the main burner.",MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,,https://lens.org/030-308-577-927-601,Patent Application,no,0,0,6,6,0,F24C3/085;;F24C3/085;;F23D14/06;;F23D14/06;;F23D14/58;;F23D14/58;;F23D14/64;;F23D14/64;;F23D2213/00;;F23D2213/00;;F23D2900/00003;;F23D2900/00003;;F23D2900/14062;;F23D2900/14062;;F23D2900/14064;;F23D2900/14064,F23D14/06;;F23D14/46;;F23D14/58;;F24C3/08,,0,0,,,,DISCONTINUED
274,ES,B1,ES 2092443 B1,056-017-987-654-224,1997-08-01,1997,ES 9402572 A,1994-12-16,ES 9400888 A,1994-04-27,"MEJORAS INTRODUCIDAS EN LA PATENTE DE INVENCION N-9400888, RELATIVA A UN CONJUNTO DE AGUJA Y PORTATUBOS MODIFICADO PARA LA EXTRACCION AL VACIO DE SANGRE Y OTROS FLUIDOS ORGANICOS.","MEJORAS INTRODUCIDAS EN LA PATENTE DE INVENCION NUMERO 9400888, RELATIVA A UN CONJUNTO DE AGUJA Y PORTATUBOS MODIFICADO PARA LE EXTRACCION AL VACIO DE SANGRE Y OTROS FLUIDOS ORGANICOS. CONSISTE EN UN CUERPO MONOBLOQUE (7) QUE PRESENTA EN UNO DE SUS EXTREMOS UN AREA QUE ADOPTA LA FORMA DE UN ALA DELTA (2) DE LA QUE SE DIMANA UN TRONCO DE CONO (4) PASANDO UNA CANALIZACION (3) HASTA EL INTERIOR DEL TUBO PORTAMUESTRAS (7) SALVANDO UNA ALMOHADILLA AMORTIGUADORA (8) Y ESTANDO CONECTADA LA CANALIZACION (3) CON LA AGUJA (5), POR LA CUAL PASA EL FLUJO DE MUESTRAS HASTA EL INTERIOR DEL TUBO DE MUESTRAS (10) SALVANDO UNA CABEZA PROTECTORA (9).",GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON DOLORES;;CABRERA DE CASTRO FRANCISCO,GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON DOLORES;;CABRERA DE CASTRO FRANCISCO,,https://lens.org/056-017-987-654-224,Granted Patent,no,0,0,6,6,0,A61B5/150488;;A61B5/15003;;A61B5/150389;;A61B5/150496;;A61B5/150572;;A61B5/150732;;A61B5/154;;A61B10/0045,A61B5/15;;A61M5/14,,0,0,,,,EXPIRED
275,CA,A1,CA 3206564 A1,063-569-968-855-484,2022-08-04,2022,CA 3206564 A,2022-01-21,US 202163142548 P;;US 2022/0013286 W,2021-01-28,METHODS AND NUTRITIONAL COMPOSITIONS FOR IMPROVING MUSCLE ENERGY PRODUCTION AND/OR STRENGTH,"A method of for improving muscle energy production and/or muscle strength in a subject, and/or for reducing muscle loss in a subject comprises administering beta-hydroxy beta-methylbutyrate (HMB) and at least one citrus flavonoid to the subject. A nutritional composition comprises protein, fat, carbohydrate, HMB, and at least one citrus flavonoid.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MANUEL;;PEREIRA SUZETTE;;RUEDA CABRERA RICARDO,,https://lens.org/063-569-968-855-484,Patent Application,no,0,0,4,4,0,A61K31/19;;A61K31/352;;A61K31/7048;;A61P21/00,A61K31/19;;A61K31/7048,,0,0,,,,PENDING
276,ES,U9,ES 1291283 U9,050-746-005-061-65X,2022-10-03,2022,ES 202230773 U,2020-10-26,ES 202230773 U,2020-10-26,DISPOSITIVO PORTABLE DE ACTUACION FRENTE A SITUACIONES DE EMERGENCIA,,CABRERA MAYORDOMO JUAN JOSE;;BARBERO HOYOS MIGUEL ANGEL,AGUILAR CORDÓN JOAQUÍN;;CABRERA MAYORDOMO JUAN JOSE;;BARBERO HOYOS MIGUEL ANGEL,,https://lens.org/050-746-005-061-65X,Unknown,no,0,0,3,3,0,,G08B7/06;;G08B21/00,,0,0,,,,ACTIVE
277,MX,A,MX 2011012420 A,084-885-343-767-536,2012-02-08,2012,MX 2011012420 A,2011-11-22,US 45476909 A;;MX 2010000043 W;;MX 2011012420 A,2009-05-22,COLOURLESS GLASS COMPOSITION.,"The invention relates to a colourless glass composition having a base glass composition containing: from approximately 0.005 to approximately 0.08 wt.-% iron oxide; from approximately 0.00002 to approximately 0.0004 wt.-% Se; from approximately 0.00003 to approximately 0.001 wt.-% Co3O4; from approximately 0 to approximately 0.01 wt.-% CuO; from approximately 0 to approximately 0.6 wt.-% CeO2; from 0.02 to approximately 1 wt.-% TiO2; and from approximately 0 to approximately 2 wt.-% NaNO3. The glass has a visible light transmission of at least 87%, ultraviolet transmittance of at least 85% and direct solar transmission of no more than 90%.",VIDRIO PLANO DE MEXICO SA DE CV,LLANOS ROBERTO CABRERA;;AGUILAR JOSE GUADALUPE CID;;RODRIGUEZ MIGUEL ANGEL KIYAMA,,https://lens.org/084-885-343-767-536,Patent Application,no,0,0,1,13,0,,C03C4/00;;C03C3/00,,0,0,,,,ACTIVE
278,MA,B1,MA 29118 B1,091-533-921-542-721,2007-12-03,2007,MA 30039 A,2007-06-28,CU 20040277 A,2004-12-08,INOCULUM MYCORHIZOGENE LIQUIDE,,INST NAC DE CIENCIAS AGRICOLAS INCA,FERNANDEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGUEL;;PEREZ CABRERA YUNIESKY,,https://lens.org/091-533-921-542-721,Granted Patent,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,A01N63/30;;C05G3/80,,0,0,,,,ACTIVE
279,CA,A1,CA 2763071 A1,181-220-455-096-730,2010-11-25,2010,CA 2763071 A,2010-05-21,US 45476909 A;;MX 2010000043 W,2009-05-22,A COLORLESS GLASS COMPOSITION,"The invention relates to a colourless glass composition having a base glass composition containing: from approximately 0.005 to approximately 0.08 wt.-% iron oxide; from approximately 0.00002 to approximately 0.0004 wt.-% Se; from approximately 0.00003 to approximately 0.001 wt.-% Co3O4; from approximately 0 to approximately 0.01 wt.-% CuO; from approximately 0 to approximately 0.6 wt.-% CeO2; from 0.02 to approximately 1 wt.-% TiO2; and from approximately 0 to approximately 2 wt.-% NaNO3. The glass has a visible light transmission of at least 87%, ultraviolet transmittance of at least 85% and direct solar transmission of no more than 90%.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/181-220-455-096-730,Patent Application,no,0,0,12,13,0,C03C3/087;;C03C3/087,C03C4/00;;C03C3/00,,0,0,,,,ACTIVE
280,CN,B,CN 101072739 B,185-113-393-212-59X,2010-06-16,2010,CN 200580042068 A,2005-11-29,CU 2005000010 W;;CU 20040277 A,2004-12-08,Liquid mycorrhizal inoculant,"A bumped semiconductor device contact structure is disclosed including at least one non-planar contact pad having a plurality of projections extending therefrom for contacting at least one solder ballof a bumped integrated circuit (IC) device, such as a bumped die and a bumped packaged IC device. The projections are arranged to make electrical contact with the solder balls of a bumped IC device without substantially deforming the solder ball. Accordingly, reflow of solder balls to reform the solder balls is not necessary with the contact pad of the present invention. Such a contact pad may beprovided on various testing equipment such as probes and the like and may be used for both temporary and permanent connections. Also disclosed is an improved method of forming the contact pads by etching and deposition.",INST NAC DE CIENCIAS AGRICOLAS,MIGU DELL AMICO RODRIGUEZ JOSE;;YUNIESKY PEREZ CABRERA;;FELIX FERNANDEZ MARTIN,,https://lens.org/185-113-393-212-59X,Granted Patent,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C12N1/14;;A01N63/30;;A01N65/00;;C05F11/08;;C05G3/80,,0,0,,,,INACTIVE
281,WO,A1,WO 2017/030432 A1,057-235-544-458-867,2017-02-23,2017,MX 2016050009 W,2016-07-13,MX 2015010739 A,2015-08-19,"SUSTAINED RELEASE SYSTEM FOR THE INTEGRATED MANAGEMENT OF AGRICULTURE AND LIVESTOCK PESTS, FOREST PESTS AND URBAN PESTS","The invention relates to a system for the sustained release of semiochemicals, characterised in that it is a composite material made up of a continuous phase and a disperse phase, for use in the integrated management of agricultural pests, livestock pests, forest pests and urban pests. In the composite material of the sustained release system, produced at a temperature below 55°C, the continuous phase can be a hydrophobic gel or an oil of a range of viscosities obtained by the addition of a series of thickeners, gelling agents or viscosity modifiers, and the disperse phase consists of a support with a porous or cross-linked structure, which can be an organic cross-linked polymer or an inorganic sorbent. The example of application of the sustained release system involves semiochemicals that attract A. obliqua fruit flies, and the material comprises, in weight percentage: a) at least 13.0 to 25.0% of a disperse polymer phase; b) food preservatives such as benzoate and potassium sorbate, each one amounting to between 0.15 and 3.0%; c) between 0.15 and 3.0% of any food colouring agent; d) a semiochemical; and e) the continuous phase which amounts to between 13.0 and 26%. The invention relates to the composite material, to the sustained release system, to the use thereof with semiochemicals and insecticides, and to the production method carried out at a temperature below 55°C.",HERRANZ PIÑ0N JOSE ELOY;;CABRERA MIRELES HECTOR;;ORTEGA ZALETA DORA ALICIA,HERRANZ PIÑ0N JOSE ELOY;;CABRERA MIRELES HECTOR;;ORTEGA ZALETA DORA ALICIA,,https://lens.org/057-235-544-458-867,Patent Application,yes,6,0,2,2,0,A01M1/02;;A01N25/04;;A01N25/18,A01N25/18;;A01M1/02;;A01N25/04,,0,0,,,,PENDING
282,US,A1,US 2013/0092149 A1,089-089-718-005-824,2013-04-18,2013,US 201213650214 A,2012-10-12,MX 2011010941 A,2011-10-14,DELTA BURNER,"A gas burner for household may include a zone for mixing combustible gas with air to form an air-gas mixture, an inner chamber with an inner table, and including sides with crenellated walls. A vertex may be formed on each end of the sides, which may be formed by intersecting curved surfaces. A port zone may be on an upper face of the crenellated walls. The port zone includes main ports, which may be centric relative to the vertexes. The symmetry axes of the main ports may be aligned towards the vertex closest to a corresponding port. The ports may be equidistant relative to one another. A lid may close the inner chamber and pass the mixture through the ports. The curved surfaces may have different geometries. The lid may include a cavity, where another burner may be placed.",MABE SA DE CV;;MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2012-10-05),https://lens.org/089-089-718-005-824,Patent Application,yes,1,10,6,6,0,F24C3/085;;F24C3/085;;F23D14/06;;F23D14/06;;F23D14/58;;F23D14/58;;F23D14/64;;F23D14/64;;F23D2213/00;;F23D2213/00;;F23D2900/00003;;F23D2900/00003;;F23D2900/14062;;F23D2900/14062;;F23D2900/14064;;F23D2900/14064,F24C3/08;;F23D14/04,126 39 E,0,0,,,,INACTIVE
283,US,B2,US 8011358 B2,149-348-563-882-862,2011-09-06,2011,US 3403508 A,2008-02-20,MX 2007002289 A,2007-02-23,Double flame perimeter burner,"A burner for range covers or similar, to allow a broad range of calorific capacities, and a better burner distribution in the cover, with a generally semi-rectangular form, and containing a plurality of ports and a plurality of manners to ignite it, wherein the burner is capable of interacting with other burners at determined length and height distances, creating discontinuous flames between the burners.",MABE MEXICO S DE R L DE C V,GALINDO VICTOR GERARDO CALOCA;;SANTOYO JOSE ARTURO LONA;;BOTELLO ROBERTO CABRERA,MABE MEXICO S. DE R.L. DE C.V (2008-01-25),https://lens.org/149-348-563-882-862,Granted Patent,yes,16,11,5,5,0,F23D14/06;;F23D14/58;;F23D14/06;;F23D14/58,F23Q3/00;;F23D14/06,126 39E;;X126 39 H;;X126 39 R;;126/40;;431/266;;431/264;;431/283;;431/60;;431/278,0,0,,,,INACTIVE
284,CO,A2,CO 6480915 A2,060-848-829-309-144,2012-07-16,2012,CO 11176311 A,2011-12-21,US 45476909 A,2009-05-22,UNA COMPOSICION DE VIDRIO SIN COLOR,"La presente invención se refiere a una composición de vidrio sin color teniendo una composición de vidrio base, la cual comprende, en porcentaje en peso, de alrededor de 0,005 a alrededor de 0,08 % en peso de óxido férrico; de alrededor de 0,00002 a alrededor de 0,0004 % en peso de Se, de alrededor de 0,00003 a alrededor de 0,0010% en peso de Co304; de alrededor de 0 a alrededor de 0,01 % en peso de CuO; de alrededor de 0 a alrededor de 0,6 de Ce02, de 0,02 a alrededor de 1 de TiO2, y de alrededor de 0 a alrededor 2 de NaNO3 El vidrio teniendo una transmisión de luz visible de al menos 87%; una trasmitancia de radiación ultravioleta de menos de 85% y una transmisión solar directa de no más de 90%.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;KIYAMA RODRIGUEZ MIGUEL ANGEL;;CABRERA LLANOS ROBERTO,,https://lens.org/060-848-829-309-144,Patent Application,no,0,0,12,13,0,C03C3/087;;C03C3/087,C03C3/00;;C03C4/00,,0,0,,,,ACTIVE
285,MX,A,MX 2014008519 A,093-285-875-973-346,2015-01-19,2015,MX 2014008519 A,2013-01-11,EP 12382011 A;;EP 12382010 A;;US 2013/0021166 W,2012-01-13,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR EFFECTING THE OFFSPRING.,"The present disclosure is directed to a combination of carbohydrates (a slow rate of digestion simple carbohydrate, a complex carbohydrate, a nonabsorbent carbohydrate, and an indigestible oligosaccharide) for use in a method of treating a pregnant woman wherein the method results in an improvement in the health of the offspring of the pregnant woman. The disclosure is also directed to use of the combination of carbohydrates for the manufacture of a medicament for use in the treatment of a pregnant woman wherein the treatment results in an improvement in the health of the offspring of the pregnant woman. The improvement can be a reduction of at least one long term adverse health effect and/or an improvement in lean body mass development and formation of the offspring. The combination of carbohydrates may also be administered to the woman during lactation to further the improvement in the health of the offspring.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;CABRERA RICARDO RUEDA;;MARTIN MANUEL CRISTOBAL MANZANO,,https://lens.org/093-285-875-973-346,Patent Application,no,0,0,11,13,0,A23L33/10;;A23L29/30;;A23L29/212;;A23L33/21;;A23L29/212;;A23L29/30;;A23L33/30;;A23L33/40;;A23L33/10;;A23L33/21;;A23L5/00;;A23L33/125;;A61P3/04;;A61P43/00;;A23L5/00;;A23L33/125;;A23L29/30;;A23L29/212;;A23L33/10;;A23L33/21;;A23L33/40;;A23L33/30;;A23V2002/00,A23L1/09;;A23L1/0522;;A23L1/30;;A23L1/308;;A23L33/00,,0,0,,,,PENDING
286,CU,A1,CU 23479 A1,160-833-596-414-050,2010-01-22,2010,CU 20040277 A,2004-12-08,CU 20040277 A,2004-12-08,INOCULANTE MICORRIZÓGENO LÍQUIDO,"La solución técnica propuesta se relaciona con la rama de la agricultura, la biotecnología del suelo y específicamente con la producción y aplicación de los hongos micorrizógenos arbuculares, microorganismo que mejora la eficiencia en la toma de nutrientes por las plantas, nivel hídrico, producción vegetal, protección contra algunas enfermedades de la raíz, etc. Consiste en un producto líquido para la aplicación de hongos micorrizógenos arbusculares, partiendo de la utilización de un medio acuoso que permite lograr una estabilización de los propágulos micorrízicos y que posibilita el mantenimiento de la viabilidad hasta 12 meses y por ende su almacenamiento. Este producto se puede aplicar a través de los sistemas de riego y fertiriego, o en forma directa en campos o invernaderos de cultivo protegido, además de permitir la superación de los mecanismos de dormancia de las esporas y de lograr un elevado nivel de concentración que permite y facilita su manejo y transportación. Con la aplicación de este producto, se pueden manejar los hongos micorrizógenos en cultivos bajo sistemas de riego a gran escala, con una mejora productiva y ambiental. El producto asimismo se puede utilizar para aplicaciones en cultivos de siembra directa como granos y cereales vía recubrimiento de las semillas.",INST NAC DE CIENCIAS AGRICOLAS,PEREZ CABRERA YUNIESKY;;DELL AMICO RODRIGUEZ JOSE MIGUEL;;FERNANDEZ MARTIN FELIX,,https://lens.org/160-833-596-414-050,Limited Patent,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,A01N63/30;;A01N65/00;;C05F11/08;;C05G3/80;;C12N1/14,,0,0,,,,ACTIVE
287,US,B2,US 8747108 B2,040-994-452-463-810,2014-06-10,2014,US 97031110 A,2010-12-16,MX 2009014047 A,2009-12-18,Triple flame section burner,"The present invention relates to the field of burners, particularly in burners intended for household use, such as stoves. A three ring burner is described, which produces longer and more inclined flames through which a more efficient heating is accomplished; combustion ports in the rings with straight or helicoid arrangements; where the inner ring can function in conjunction with or independently from the other two flame rings, thus controlling the heating intensity and the flame by means of controlling the velocity of the gas-air current; as main parts comprising; a burner head, which contains three concentric flame rings, one inner ring, one intermediate ring and one outer ring, each flame ring containing combustion ports, the collection of combustion ports are helicoid both in their inner ring as well as the outer ring, two lids on the burner head, one inner and the other outer; one cover for the burners which forms the surface of the heating apparatus; Venturi ducts on the lower part of the burner head; a support firmly joined to the surface of the heating apparatus, in this support are lodged Venturi ducts from the burner head; a gas distributor lodged in the lower part of the support, where the gas distributor has three gas exits, two laterals and one central.",LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO;;MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2010-07-14),https://lens.org/040-994-452-463-810,Granted Patent,yes,40,35,7,7,0,F23D14/06;;F23D2900/14062;;F23D2900/14063;;F23D14/06;;F23D2900/14063;;F23D2900/14062,F23Q9/00,431/284;;431/2;;431/285;;431/354;;X126 39 B;;X126 39 E;;X126 39 R,0,0,,,,INACTIVE
288,KR,A,KR 20200045402 A,111-281-358-546-63X,2020-05-04,2020,KR 20190125755 A,2019-10-11,EP 18382747 A,2018-10-19,METHOD AND SYSTEM FOR REWORKING A COMPOSITE LAMINATE,"The present invention relates to a method for reworking a composite laminate (1) including a plurality of tapes (2), which comprises the steps of: detecting the occurrence of a defect portion (3) on a composite tape (4) when the tape (4) is disposed; keeping a process of disposing the tape (4) until the length of the tape (4) including the defect portion exceeds a manufacturing length (L) of the tape (4); capturing the defect portion out of the tape (4) exceeding the manufacturing length (L) of the tape (4); severing the defect portion of the tape (4) at a position that the tape (4) including the defect portion exceeds the manufacturing length (L) of the tape (4); removing the defect portion of the tape (4) captured by a capturing system from a laminate (1); and disposing a replacement tape (2) in place of the removed defect portion of the tape (4).",AIRBUS OPERATIONS SL,MENENDEZ MARTIN JOSE MANUEL;;CABANAS CONTRERAS RAUL ALBERTO;;CABRERA RODRIGUEZ PEDRO,,https://lens.org/111-281-358-546-63X,Patent Application,no,3,0,8,8,0,B29C70/386;;B29C70/34;;B29C70/388;;B29C70/54;;B29C70/545;;B29C2793/0081;;B32B43/00;;B32B5/26;;B32B2041/04;;B32B2260/021;;B32B2260/046;;B32B2305/08;;B32B2605/18;;B29C70/388;;B29C70/545;;B29C73/12;;B29C2793/0081;;B29C70/386;;B29C70/545;;B29C73/12;;B29C70/388;;B29C70/54,B32B43/00;;B32B5/26,,0,0,,,,ACTIVE
289,WO,A1,WO 2006/060968 A1,111-184-642-261-012,2006-06-15,2006,CU 2005000010 W,2005-11-29,CU 20040277 A,2004-12-08,LIQUID MYCORRHIZAL INOCULANT,"The invention relates to the field of agriculture, soil biotechnology and, specifically, the production and application of arbuscular mycorrhizal fungi, a micro-organism which improves efficiency in nutrient uptake by plants, moisture level, crop production and protection against certain root diseases, etc. The invention consists of a liquid product which is applied to arbuscular mycorrhizal fungi, using an aqueous medium which can achieve stabilisation of the mycorrhizal propagules, thereby enabling the formation of soil aggregates, and a demonstrated viability in liquid medium of between 12 and 18 months and which can be used in irrigation and fertigation systems. The inventive inoculant is applied directly to fields or greenhouses under protected cultivation and can also be used to overcome spore dormancy mechanisms and to obtain an increased concentration level which enables and facilitates handling and transport. The inventive product can be applied in order to manage mycorrhizal fungi in crops under large-scale irrigation system with improved productivity and environmental impacts.",INST NAC DE CIENCIAS AGRICOLAS;;FERNANDEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGU;;PEREZ CABRERA YUNIESKY,FERNANDEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGU;;PEREZ CABRERA YUNIESKY,,https://lens.org/111-184-642-261-012,Patent Application,yes,2,3,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C05F11/08;;A01N63/30;;A01N65/00;;C05G3/80;;C12N1/14,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2003, no. 04;;PATENT ABSTRACTS OF JAPAN vol. 016, no. 257",PENDING
290,CA,A1,CA 2712208 A1,161-238-340-295-326,2011-06-18,2011,CA 2712208 A,2010-08-05,MX 2009014047 A,2009-12-18,TRIPLE FLAME SECTION BURNER,"The present invention relates to the field of burners, particularly in burners intended for household use, such as stoves. A three ring burner is described, which produces longer and more inclined flames through which a more efficient heating is accomplished; combustion ports in the rings with straight or helicoid arrangements; where the inner ring can function in conjunction with or independently from the other two flame rings, thus controlling the heating intensity and the flame by means of controlling the velocity of the gas-air current; as main parts comprising; a burner head, which contains three concentric flame rings, one inner ring, one intermediate ring and one outer ring, each flame ring containing combustion ports, the collection of combustion ports are helicoid both in their inner ring as well as the outer ring, two lids on the burner head, one inner and the other outer; one cover for the burners which forms the surface of the heating apparatus; Venturi ducts on the lower part of the burner head; a support firmly joined to the surface of the heating apparatus, in this support are lodged Venturi ducts from the burner head; a gas distributor lodged in the lower part of the support, where the gas distributor has three gas exits, two laterals and one central.",MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,,https://lens.org/161-238-340-295-326,Patent Application,no,0,2,7,7,0,F23D14/06;;F23D2900/14062;;F23D2900/14063;;F23D14/06;;F23D2900/14063;;F23D2900/14062,F23D14/12;;F23D14/58;;F23D14/84,,0,0,,,,INACTIVE
291,ES,U,ES 1291283 U,199-527-171-505-272,2022-06-01,2022,ES 202230773 U,2020-10-26,ES 202230773 U,2020-10-26,"Portable device of action in emergency situations (Machine-translation by Google Translate, not legally binding)","Action procedure in situations of work emergency and a geolocated portable device by ultra-canch band pulses characterized by streamlining the rescue by rapid care in emergency situations and imminent risk by sending or receiving patterns of electromagnetic pulses programmed in a way that activate certain protocols or sensory indicators of warning. (Machine-translation by Google Translate, not legally binding)",CABRERA MAYORDOMO JUAN JOSE;;BARBERO HOYOS MIGUEL ANGEL,AGUILAR CORDÓN JOAQUÍN;;CABRERA MAYORDOMO JUAN JOSE;;BARBERO HOYOS MIGUEL ANGEL,,https://lens.org/199-527-171-505-272,Patent Application,no,0,0,3,3,0,,G08B7/06;;G08B21/00,,0,0,,,,ACTIVE
292,EP,A1,EP 2614725 A1,023-718-078-434-018,2013-07-17,2013,EP 12382011 A,2012-01-13,EP 12382011 A,2012-01-13,Use of specific carbohydrate systems during pregnancy for improving lean body mass development and formation and reducing adverse health effects later in life in offspring,"The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant woman for improving the lean body mass development and formation in an offspring and reducing long term adverse health effects, including obesity and sarcopenia, in the offspring later in life. The carbohydrate system includes a slow rate of digestion simple carbohydrate and a complex carbohydrate in combination with a non-absorbent carbohydrate and/or an indigestible carbohydrate. The carbohydrate system may also be administered to the woman during lactation to further the reduction of long term adverse health effects, including obesity, in the offspring later in life.",ABBOTT LAB,LOPEZ-PEDROSA JOSE MARIA;;RUEDA-CABRERA RICARDO;;MANZANO MARTIN MANUEL CRISTOBAL,,https://lens.org/023-718-078-434-018,Patent Application,yes,3,2,1,13,0,A23L29/212;;A23L29/30;;A23L33/10;;A23L33/21;;A23L21/00;;A23L33/125;;A23L9/00;;A23L21/00;;A23L33/125;;A23L9/00,A23L1/0522;;A23L1/09;;A23L1/30;;A23L1/308,,0,0,,,,DISCONTINUED
293,MX,A,MX 2009014047 A,077-742-556-051-206,2011-06-24,2011,MX 2009014047 A,2009-12-18,MX 2009014047 A,2009-12-18,TRIPLE FLAME SECTION BURNER.,"The present invention relates to the field of burners, particularly in burners intended for household use, such as stoves. The purposes of the invention are: providing a three ring burner, which produces longer and more inclined flames through which a more efficient heating is accomplished; combustion ports in the rings with straight or helicoid arrangements; where the inner ring can function in conjunction with or independently from the other two flame rings, thus controlling the heating intensity and the flame by means of controlling the velocity of the gas-air current; as main parts comprising; a burner head, which contains three concentric flame rings, one inner ring, one intermediate ring and one outer ring, each flame ring containing combustion ports, the collection of combustion ports are helicoid both in their inner ring as well as the outer ring, two lids on the burner head, one inner and the other outer; one cover for the burners which forms the surface of the heating appara tus; Venturi ducts on the lower part of the burner head; a support firmly joined to the surface of the heating apparatus, in this support are lodged Venturi ducts from the burner head; a gas distributor lodged in the lower part of the support, where the gas distributor has three gas exits, two laterals and one central.",MABE SA DE CV,SANTOYO JOSE ARTURO LONA;;CAMPO ERNESTO ARIAS DEL;;BOTELLO ROBERTO CABRERA,,https://lens.org/077-742-556-051-206,Patent Application,no,0,0,7,7,0,F23D14/06;;F23D2900/14062;;F23D2900/14063;;F23D14/06;;F23D2900/14063;;F23D2900/14062,F23D14/10,,0,0,,,,ACTIVE
294,US,S,US D0697369 S,158-786-230-929-681,2014-01-14,2014,US 201329459215 F,2013-06-27,US 201329459215 F;;MX 2011003415 F;;US 201229440771 F;;US 201229418736 F,2011-10-20,Delta gas burner,,MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2012-05-28),https://lens.org/158-786-230-929-681,Design Right,no,0,3,4,4,0,,,0702;;D 7407,0,0,,,,ACTIVE
295,US,B2,US 9086221 B2,192-400-022-132-764,2015-07-21,2015,US 201213650214 A,2012-10-12,MX 2011010941 A,2011-10-14,Delta burner,"A gas burner for household may include a zone for mixing combustible gas with air to form an air-gas mixture, an inner chamber with an inner table, and including sides with crenellated walls. A vertex may be formed on each end of the sides, which may be formed by intersecting curved surfaces. A port zone may be on an upper face of the crenellated walls. The port zone includes main ports, which may be centric relative to the vertexes. The symmetry axes of the main ports may be aligned towards the vertex closest to a corresponding port. The ports may be equidistant relative to one another. A lid may close the inner chamber and pass the mixture through the ports. The curved surfaces may have different geometries. The lid may include a cavity, where another burner may be placed.",MABE SA DE CV,LONA SANTOYO JOSE ARTURO;;ARIAS DEL CAMPO ERNESTO;;CABRERA BOTELLO ROBERTO,MABE S.A. DE C.V (2012-10-05),https://lens.org/192-400-022-132-764,Granted Patent,yes,5,3,6,6,0,F24C3/085;;F24C3/085;;F23D14/06;;F23D14/06;;F23D14/58;;F23D14/58;;F23D14/64;;F23D14/64;;F23D2213/00;;F23D2213/00;;F23D2900/00003;;F23D2900/00003;;F23D2900/14062;;F23D2900/14062;;F23D2900/14064;;F23D2900/14064,F24C3/08;;F23D14/06;;F23D14/58;;F23D14/64,,0,0,,,,INACTIVE
296,US,A1,US 2010/0297415 A1,119-019-608-236-181,2010-11-25,2010,US 45476909 A,2009-05-22,US 45476909 A,2009-05-22,Colorless glass composition,"The is a colorless glass composition having a base glass composition, comprising, in weight percentage, from about 0.005 to about 0.08% wt of ferric oxide, from 0.00002 to about 0.0004% wt of Se, from about 0.00003 to about 0.0010% wt of Co 3 O 4 , from 0 to about 0.01% wt of CuO, from about 0 to about 0.6 of CeO 2 , from 0.02 to about 1 of TiO 2 , and from about 0 to about 2 of NaNO 3 . The glass having a visible light transmission of at least 87%; a ultraviolet radiation transmittance less than 85%; and a solar direct transmittance of no more than 90%.",VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,VIDRIO PLANO DE MEXICO S.A. DE C.V (2009-05-20),https://lens.org/119-019-608-236-181,Patent Application,yes,5,14,12,13,0,C03C3/087;;C03C3/087,C03C3/12;;B32B17/00,428/220;;501/41,0,0,,,,ACTIVE
297,MX,B,MX 366880 B,179-542-211-374-108,2019-07-29,2019,MX 2016001666 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF.,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO;;STEVEN GERKEN;;STEVEN MASTERSON,,https://lens.org/179-542-211-374-108,Granted Patent,no,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34,,0,0,,,,ACTIVE
298,EP,A1,EP 1840110 A1,171-468-342-198-307,2007-10-03,2007,EP 05817114 A,2005-11-29,CU 2005000010 W;;CU 20040277 A,2004-12-08,LIQUID MYCORRHIZAL INOCULANT,"The technical solution proposed is related with agriculture, soil biotechnology, and specifically with the production and application of arbuscular mycorrhizal fungi, a microorganism that improves the efficiency of plant nutrient absorption, water level, vegetable production, protection against some root diseases, etc. It consists of a liquid product to apply arbuscular mycorrhizal fungi, starting from using an aqueous medium that allows to achieve a mycorrhizal propagule stabilization, which enables soil aggregate development and a checked viability in liquid medium between 12 and 18 months that can be used in irrigation and fertigation systems; it can be applied directly in the field or protected crop greenhouses, besides allowing the improvement of spore dormancy mechanisms and achieving a high concentration level that enables its handling and transportation. By applying this product, mycorrhizal fungi can be managed in crop under large scale irrigation systems, achieving better productive and environmental conditions.",INST NAC DE CIENCIAS AGRICOLAS,PEREZ CABRERA YUNIESKY;;DELL AMICO RODRIGUEZ JOSE MIGU;;FERNANDEZ MARTIN FELIICA CARRE,,https://lens.org/171-468-342-198-307,Patent Application,yes,0,7,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C05F11/08;;A01N63/30;;A01N65/00;;C05G3/80;;C12N1/14,,0,0,,,,DISCONTINUED
299,WO,A2,WO 2015/021448 A2,190-818-917-256-683,2015-02-12,2015,US 2014/0050446 W,2014-08-08,US 201361863888 P,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/190-818-917-256-683,Patent Application,yes,0,3,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34,,0,0,,,,PENDING
300,US,A1,US 2008/0195487 A1,005-753-028-309-519,2008-08-14,2008,US 1210508 A,2008-01-31,US 1210508 A;;US 7814202 A;;US 27102601 P,2001-02-22,Internet shopping assistance technology and e-mail place,"The present invention is a customizable system and method for direct access to a specified Internet website and related/alternate websites and to reach e-mail addresses utilizing telephone numbers as primary search queries. The browser's graphical elements and layout can be customized to suit the user's preferences or other criteria such as geographical circumstances, language, or to match the specified website's graphical elements and layout. The browser system is preferably embodied in a comprehensive Internet portal offering an instantly created referential and search-helping directories system structure that is formed around a website as it is entered from the portal by means of either: its domain name or URL-numeric, or a common telephone number belonging to such website. It also includes an e-mail organizing function based on the same basic system. The e-mail function is capable of concentrating in a customizable website a plurality of e-mail boxes belonging to the same owner in order to provide a classification service for his incoming messages.",AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,,https://lens.org/005-753-028-309-519,Patent Application,yes,6,2,8,8,0,G06Q30/0256;;G06Q30/0264;;G06F16/9566;;G06Q30/0256;;G06Q30/0264;;G06F16/9566,G06F13/00;;G06F17/30;;G06Q30/02,705/14;;707/3;;X707E17014,0,0,,,,DISCONTINUED
301,MX,A,MX 2016001666 A,054-539-713-746-186,2016-12-14,2016,MX 2016001666 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF.,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO;;STEVEN GERKEN;;STEVEN MASTERSON,,https://lens.org/054-539-713-746-186,Patent Application,no,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/178;;A61B17/34,,0,0,,,,ACTIVE
302,ES,U,ES 1047263 U,032-566-311-035-862,2001-03-16,2001,ES 200001360 U,2000-05-23,VE 95200 A,2000-05-02,"Braille board. (Machine-translation by Google Translate, not legally binding)","Table for braille writing, characterized in that it is constituted by a base body formed by two parallel rectangular plates (16 and 19) that have respective separation plates (13 and 21) between them, arranged in the upper part and in both sides, the lateral plates (13) forming two longitudinal grooves between the plates (16 and 19); and because on the base body (16 and 19) there is a strip formed by a transverse elongated alveolar plate (7) and a plate (1) with superimposed coincidental perforated cells, for the formation of braille characters in a sheet inserted between both plates, which are associated with each other, the perforated plate (1) having two lugs (2) emerging at the bottom and crossing the alveolar plate (7), said lugs (2) being found, one on each side of the plate ( 1), suitable for successive fitting in a series of holes (14) arranged in two columns on the upper plate (16) of the body of the table; and in that the strip formed by the plates (1 and 7) has on its respective sides fins (6) u-shaped longitudinally, the elbow section of each of said fins (6) being housed in one of the lateral grooves of the body ( 16 and 19) of the table. (Machine-translation by Google Translate, not legally binding)",QUILEN MYERSTON SILVIA ELENA,SUCRE CABRERA MARIA TERESA;;BOCCARDO IRIGOYEN RENZO JOSE;;TORREALBA ALGARRA RAFAEL RICAR,,https://lens.org/032-566-311-035-862,Patent Application,no,0,0,2,2,0,,B41J3/32;;G09B21/02,,0,0,,,,EXPIRED
303,US,A1,US 2014/0342896 A1,094-939-558-064-284,2014-11-20,2014,US 201414209502 A,2014-03-13,MX 2011000108 W,2011-09-14,NEUTRAL GREY GLASS COMPOSITIONS,"The present invention relates to a neutral grey glass composition which has a basic composition containing the following main coloring agents: 0.40 to 0.80% of Fe 2 O 3 ; 0.05 to 2.0% of TiO 2 ; 0.2 to 2.5% of Er 2 O 3 ; 20 to 200 ppm of CuO; 0.08% to 0 0.1% charcoal; and 15% to 50% of ferrous (redox), in which the glass has light transmission “A” greater than 65%, solar transmission (T S ) <55%, and ultraviolet transmission <40%, having color values a*=−4 to 3 and b*=4 to −2.",CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL;;VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,VIDRIO PLANO DE MEXICO S.A. DE C.V (2014-03-19),https://lens.org/094-939-558-064-284,Patent Application,yes,5,0,7,7,0,C03C3/095;;C03C3/095;;C03C3/078;;C03C3/087;;C03C4/02;;C03C4/02;;C03C2204/00,C03C3/095;;C03C4/02,501/64,0,0,,,,ACTIVE
304,US,B2,US 8361915 B2,144-705-087-416-406,2013-01-29,2013,US 45476909 A,2009-05-22,US 45476909 A,2009-05-22,Glass composition,"The present invention provides a glass composition having a base glass composition, comprising, in weight percentage, from about 0.005 to about 0.08% wt of ferric oxide, from 0.00002 to about 0.0004% wt of Se, from about 0.00003 to about 0.0010% wt of Co 3 O 4 , from 0 to about 0.01% wt of CuO, from about 0 to about 0.6 of CeO 2 , from 0.02 to about 1 of TiO 2 , and from about 0 to about 2 of NaNO 3 . The glass having a visible light transmission of at least 87%; a ultraviolet radiation transmittance less than 85%; and a solar direct transmittance of no more than 90%.",VIDRIO PLANO MEXICO SA DE CV;;CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,VIDRIO PLANO DE MEXICO S.A. DE C.V (2009-05-20),https://lens.org/144-705-087-416-406,Granted Patent,yes,5,4,12,13,0,C03C3/087;;C03C3/087,C03C3/095;;C03C3/087,501/71;;501/64,0,0,,,,ACTIVE
305,CA,A1,CA 2801244 A1,159-067-289-988-956,2011-12-08,2011,CA 2801244 A,2011-06-01,US 79194910 A;;MX 2011000068 W,2010-06-02,DARK GREEN SOLAR CONTROL GLASS COMPOSITION,,VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO MARCOS;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/159-067-289-988-956,Patent Application,no,0,0,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,C03C4/02,,0,0,,,,ACTIVE
306,US,A1,US 2015/0045769 A1,003-918-705-971-877,2015-02-12,2015,US 201414455865 A,2014-08-08,US 201414455865 A;;US 201361863888 P,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/003-918-705-971-877,Patent Application,yes,0,18,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/46;;A61D7/00;;A61M5/315;;A61M5/32,604/506;;604/117,0,0,,,,INACTIVE
307,CN,A,CN 105899154 A,044-970-685-218-145,2016-08-24,2016,CN 201480055640 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,Injection device for minimally invasive procedures and uses thereof,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/044-970-685-218-145,Patent Application,no,5,4,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34;;A61M5/178,,0,0,,,,INACTIVE
308,HK,B,HK 1225257 B,100-437-433-787-02X,2017-09-08,2017,HK 16113717 A,2016-12-01,US 201361863888 P,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/100-437-433-787-02X,Granted Patent,no,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M/;;A61B/,,0,0,,,,INACTIVE
309,CA,C,CA 3000806 C,046-579-118-235-96X,2023-06-27,2023,CA 3000806 A,2016-10-04,US 201514876254 A;;MX 2016000104 W,2015-10-06,AN UV ABSORBENT GREEN SOLAR CONTROL GLASS COMPOSITION,"The present invention provides an UV absorbent green solar control glass with low UV transmittance composition having a soda-lime-silica glass composition, wherein the coloring compounds comprises in weight percentage: from 0.50 to 1.30% of total iron expressed as Fe2O3;; from 0.12 to 0.45% of FeO expressed as Fe2O3; from about 0.04 to 1.8 wt. % TiO2; about 0.20 to 2.0 % wt CeO2; about 0.0004 to 0.0015 wt. % CuO; and about 0.010 to 0.10% C. The glass composition having a redox value (FeO/Total Fe2O3 from 10 to 35 %.",VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;BETANCOURT-CARRIZALES LUIS URBANO,,https://lens.org/046-579-118-235-96X,Granted Patent,no,0,0,13,13,0,C03C3/095;;C03C4/082;;C03C4/085;;C03C4/02;;C03C4/085;;C03C4/02;;C03C3/085;;C03C3/095;;C03C4/082,C03C4/08;;C03C3/087,,0,0,,,,PENDING
310,ES,Y,ES 1078145 Y,055-545-138-701-543,2013-02-25,2013,ES 201231111 U,2012-10-23,ES 201231111 U,2012-10-23,EQUIPO DE SALVAMENTO,,UNIV CASTILLA LA MANCHA,GARRIDO SAENZ IGNACIO;;MATA CABRERA FRANCISCO;;TEJERO MANZANARES JOSE;;MARJALIZO CERRATO PABLO,,https://lens.org/055-545-138-701-543,Limited Patent,no,0,0,2,2,0,,A62B1/06,,0,0,,,,EXPIRED
311,EA,B1,EA 032285 B1,099-265-293-510-974,2019-05-31,2019,EA 201600139 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/099-265-293-510-974,Granted Patent,no,11,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34;;A61M5/178,,0,0,,,,ACTIVE
312,ES,T3,ES 2647789 T3,189-941-902-830-281,2017-12-26,2017,ES 14756174 T,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,Dispositivo de inyección para procedimientos mínimamente invasivos,"Un dispositivo de inyección, que comprende: un cilindro de jeringa (91), en donde el cilindro de jeringa proporciona un depósito de fluido; un émbolo (92) configurado para ser controlado por el operador del dispositivo y para desplazarse dentro del cilindro de jeringa para cargar y liberar fluido desde el depósito de fluido en el cilindro de jeringa; y se caracteriza por comprender además: a) una aguja de inyección (81) que está fija y operativamente acoplada al cilindro de jeringa (91) proporcionando una ruta de fluido para el fluido contenido en el cilindro de jeringa a inyectar en un tejido diana cuando el émbolo (92) se presiona, donde la extracción o retracción de la aguja es independiente del movimiento del émbolo; b) una vaina alargada (72), que comprende una luz interna (723) que contiene la aguja de inyección y que tiene una punta distal que contiene una abertura para la aguja de inyección, donde: la vaina se puede mover alrededor de la aguja de inyección; y el control de la vaina es independiente del movimiento del émbolo; y c) un controlador (71) para colocar la vaina, que comprende: una carcasa (710), que comprende al menos un primer (715) y un segundo (716) tope para controlar la exposición de la aguja de inyección y que están provistas en el interior de la carcasa a una distancia predeterminada entre sí, donde las detenciones pueden estar bloqueadas; una luz central (717) en la carcasa que comprende un elemento de conexión, donde el elemento de conexión (713) está configurado para desplazarse en la luz central en la carcasa y está acoplado con la vaina, donde el extremo proximal de la vaina está acoplado con el extremo distal del elemento de conexión de forma que el movimiento del elemento de conexión controla el movimiento de la vaina; y un colocador (711) montado dentro de la carcasa configurado para moverse hacia delante hacia el extremo distal del controlador y hacia atrás hacia el extremo proximal del controlador, entre los topes de la carcasa, donde el colocador está conectado operativamente al elemento de conexión para guiar el movimiento del elemento de conexión en la misma dirección, por lo que el movimiento del colocador hacia delante hacia el extremo distal se acopla al primer tope y desplaza la vaina para encerrar la aguja de inyección dentro de la luz de la vaina (711a, 72a), y el movimiento del colocador hacia atrás hacia el extremo proximal se acopla con el segundo tope y desplaza la vaina para exponer no más de una longitud predeterminada de la punta distal de la aguja de inyección (711c, 72c) a través de la abertura en la aguja de inyección para la inyección en el tejido.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/189-941-902-830-281,Granted Patent,no,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34;;A61M5/178,,0,0,,,,ACTIVE
313,EP,A1,EP 1410257 A1,075-858-668-809-845,2004-04-21,2004,EP 02701478 A,2002-02-20,IB 0200539 W;;US 27102601 P,2001-02-22,SYSTEM FOR ACCESSING WEB PAGES AND SENDING E-MAILS USING TELEPHONE NUMBERS,,AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,,https://lens.org/075-858-668-809-845,Patent Application,yes,0,0,8,8,0,G06Q30/0256;;G06Q30/0264;;G06F16/9566;;G06Q30/0256;;G06Q30/0264;;G06F16/9566,G06F13/00;;G06F17/30;;G06Q30/02,,0,0,,,,DISCONTINUED
314,US,B2,US 8318054 B2,095-156-996-728-63X,2012-11-27,2012,US 79194910 A,2010-06-02,US 79194910 A,2010-06-02,Dark green solar control glass composition,"The present invention provides a dark green colored glass composition having a soda-lime-silica glass composition, wherein the coloring compounds comprises in weight percentage: from 0.71 to 1.50% of total iron expressed as Fe 2 O 3 ; from 22 to 30% of ferrous-ferric ratio and from 0.15 to 0.50% of expressed as FeO; from 0.10 to 0.20% of SO 3 without affecting the refining properties and ability of the SO 3 to eliminate bubbles; about 0 to 1.0 wt. % TiO 2 ; about 0.0004 to 0.03 wt. % Cr 2 O 3 ; and also 0.0004 to 0.015 wt. % CuO.",CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL;;VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,VIDRIO PLANO DE MEXICO S.A. DE C.V (2010-05-10),https://lens.org/095-156-996-728-63X,Granted Patent,yes,4,5,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,C03C3/078;;F21V9/04;;F21V9/06;;G02B5/22;;G02B5/26,252/588;;428/230;;428/426;;501/72;;501/905,0,0,,,,ACTIVE
315,EP,B1,EP 3030171 B1,108-732-575-403-75X,2017-11-01,2017,EP 14756174 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/108-732-575-403-75X,Granted Patent,yes,11,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/178;;A61B17/34,,0,0,,,,ACTIVE
316,ES,U,ES 1078145 U,116-856-985-942-312,2012-11-28,2012,ES 201231111 U,2012-10-23,ES 201231111 U,2012-10-23,"Rescue equipment (Machine-translation by Google Translate, not legally binding)","Rescue equipment, specially designed for use in confined spaces, characterized in that it comprises: - a lightweight chassis (1) mounted on wheels (2) and towable, - a covering hood (12), mounted on the chassis (1), and which is provided with access doors (3) to the interior, which additionally comprises, linked to the chassis (1): - a compressor (4) of breathable air intended to boost and enrich the surrounding air, - a fan-extractor (5) to introduce clean air or extract stale air, - an electric generator (7) in charge of providing electrical power to the rescue equipment, as well as comprising a control unit (6) that controls the operation of the compressor (4), the fan-extractor (5) and the electric generator (7), where said control unit (6) consists of a main computer and a plc, as well as incorporating an internal modem for wireless communication in the confined space, and a remote communication modem capable of communication and data exchange with an external remote station. (Machine-translation by Google Translate, not legally binding)",UNIV CASTILLA LA MANCHA,GARRIDO SAENZ IGNACIO;;MATA CABRERA FRANCISCO;;TEJERO MANZANARES JOSE;;MARJALIZO CERRATO PABLO,,https://lens.org/116-856-985-942-312,Patent Application,no,0,1,2,2,0,,A62B1/06,,0,0,,,,EXPIRED
317,US,A1,US 2018/0365241 A1,094-244-560-028-548,2018-12-20,2018,US 201715627868 A,2017-06-20,US 201715627868 A,2017-06-20,SENTIMENT ANALYSIS AS A QUALITY INDICATOR IN USABILITY TESTING,"Various embodiments for enhancing accuracy in usability testing, by a processor device, are provided. Sentiment information is collected by a wearable device configured to be worn by a test user while a set of operations of a test case are executed, the test case evaluating usability of a product or service. Upon completion of the set of operations, a quality for the evaluation of the usability is determined using the sentiment information collected from the wearable device corresponding to input received from the executed set of operations.",IBM,ASTIGARRAGA TARA;;MALDONADO CABRERA RAQUEL;;MOSQUEDA MEJIA JOSE R;;SIEWRATTAN SHARIFFA B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2017-06-01),https://lens.org/094-244-560-028-548,Patent Application,yes,5,2,2,2,0,G06Q30/0278;;G06Q30/0278;;G06F16/436,G06F17/30;;G06Q30/02,,0,0,,,,ACTIVE
318,EP,A2,EP 3030171 A2,113-919-149-688-773,2016-06-15,2016,EP 14756174 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/113-919-149-688-773,Patent Application,yes,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/178;;A61B17/34,,0,0,,,,ACTIVE
319,US,A1,US 2002/0123904 A1,100-373-394-004-386,2002-09-05,2002,US 7814202 A,2002-02-19,US 7814202 A;;US 27102601 P,2001-02-22,Internet shopping assistance technology and e-mail place,"
   The present invention is a customizable system and method for direct access to a specified Internet website and related/alternate websites and to reach e-mail addresses utilizing telephone numbers as primary search queries. The browser's graphical elements and layout can be customized to suit the user's preferences or other criteria such as geographical circumstances, language, or to match the specified website's graphical elements and layout. The browser system is preferably embodied in a comprehensive Internet portal offering an instantly created referential and search-helping directories system structure that is formed around a website as it is entered from the portal by means of either: its domain name or URL-numeric, or a common telephone number belonging to such website. It also includes an e-mail organizing function based on the same basic system. The e-mail function is capable of concentrating in a customizable website a plurality of e-mail boxes belonging to the same owner in order to provide a classification service for his incoming messages. 
",AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,PROCTER & GAMBLE COMPANY THE (2005-04-05),https://lens.org/100-373-394-004-386,Patent Application,yes,7,52,8,8,0,G06Q30/0256;;G06Q30/0264;;G06F16/9566;;G06Q30/0256;;G06Q30/0264;;G06F16/9566,G06F13/00;;G06F17/30;;G06Q30/02,705/1,0,0,,,,DISCONTINUED
320,US,B2,US 9115021 B2,020-049-293-345-136,2015-08-25,2015,US 201414209502 A,2014-03-13,MX 2011000108 W,2011-09-14,Neutral grey glass compositions,"The present invention relates to a neutral grey glass composition which has a basic composition containing the following main coloring agents: 0.40 to 0.80% of Fe 2 O 3 ; 0.05 to 2.0% of TiO 2 ; 0.2 to 2.5% of Er 2 O 3 ; 20 to 200 ppm of CuO; 0.08% to 0 0.1% charcoal; and 15% to 50% of ferrous (redox), in which the glass has light transmission “A” greater than 65%, solar transmission (T S ) <55%, and ultraviolet transmission <40%, having color values a*=−4 to 3 and b*=4 to −2.",CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL;;VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;KIYAMA-RODRIGUEZ MIGUEL ANGEL,VIDRIO PLANO DE MEXICO S.A. DE C.V (2014-03-19),https://lens.org/020-049-293-345-136,Granted Patent,yes,8,1,7,7,0,C03C3/095;;C03C3/095;;C03C3/078;;C03C3/087;;C03C4/02;;C03C4/02;;C03C2204/00,C03C3/095;;C03C3/078;;C03C3/087;;C03C4/02,,1,0,,,"International Search Report of PCT/MX2011/000108, dated May 18, 2012 (1 pg.).",ACTIVE
321,CA,A1,CA 2920303 A1,033-561-814-805-738,2015-02-12,2015,CA 2920303 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BIANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/033-561-814-805-738,Patent Application,no,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34;;A61M5/178,,0,0,,,,ACTIVE
322,MX,A,MX 2018003652 A,045-533-221-019-026,2018-06-15,2018,MX 2018003652 A,2016-10-04,US 201514876254 A;;MX 2016000104 W,2015-10-06,COMPOSITION OF GREEN UV-ABSORBENT GLASS FOR SOLAR CONTROL.,"The present invention relates to a green solar control glass with a composition having low UV transmittance, which has a base-glass composition, the colouring compounds comprising, in percentage by weight: 0.50 to 1.30% total iron expressed as Fe2O3; 0.12 to 0.450% FeO expressed as Fe2O3; approximately 0.04 to 1.8% by weight TiO2; approximately 0.2 to 2% by weight CeO2; approximately 0.0004 to 0.015% by weight CuO; and approximately 0.01 to 0.1% by weight C. The glass composition has a redox value (FeO/total Fe2O3) of 10 to 35%.",VIDRIO PLANO MEXICO SA DE CV,ROBERTO MARCOS CABRERA LLANOS;;JOSE GUADALUPE CID AGUILAR;;LUIS URBANO BETANCOURT CARRIZALEZ,,https://lens.org/045-533-221-019-026,Patent Application,no,0,0,13,13,0,C03C3/095;;C03C4/082;;C03C4/085;;C03C4/02;;C03C4/085;;C03C4/02;;C03C3/085;;C03C3/095;;C03C4/082,C03C4/08;;C03C3/087,,0,0,,,,PENDING
323,ES,A1,ES 2078184 A1,075-146-607-160-573,1995-12-01,1995,ES 9400888 A,1994-04-27,ES 9400888 A,1994-04-27,Modified needle and tube-carrier assembly for the vacuum extraction of blood and other organic fluids,"The assembly consists in a bayonet needle 1, 1' and a tube carrier 10 or 10', in collaboration with a tube 20, the bayonet-type needle 1 consisting of an anterior bevelled needle 4, a transparent connection with lateral wings 2, a hollow fastening thread 3 or 3', a connection to the posterior needle 5 with outer rubber cover and a posterior needle 6 with closed bevel and lateral openings, the tube carrier 10 having a thread-type 13 or clip-type 13' female needle-connection cone with internal damper pad 11, fastening notches and tube carrier 17 and rotary securing wings 12.",GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON M DOLORES;;CABRERA DE CASTRO FRANCISCO,GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON M DOLORES;;CABRERA DE CASTRO FRANCISCO,,https://lens.org/075-146-607-160-573,Ambiguous,no,2,0,6,6,0,A61B5/150488;;A61B5/15003;;A61B5/150389;;A61B5/150496;;A61B5/150572;;A61B5/150732;;A61B5/154;;A61B10/0045,A61B5/15;;A61M5/14,,0,0,,,,EXPIRED
324,WO,A2,WO 2011/152698 A2,141-842-461-887-761,2011-12-08,2011,MX 2011000068 W,2011-06-01,US 79194910 A,2010-06-02,DARK GREEN SOLAR CONTROL GLASS COMPOSITION,"The invention relates to a dark green glass composition having a silica-sodic-calcic base and wherein the colorant compounds comprise, in weight percentage of the total amount: between 0.71 and 1.50% of iron expressed as Fe 2 O 3 ; between 22 and 30% of a ferric-ferrous relation and between 0.15 and 0.50% of FeO, expressed as Fe 2 O 3 ; between 0.10 and approximately 0.20% of SO 3 without affecting the refining properties of SO 3 and its ability to eliminate bubbles; between approximately 0 and approximately 1.0 in weight percentage of TiO 2 ; between approximately 0.0004 and approximately 0.03 in weight percentage of Cr2O3; and also between 0.0004 and 0.015 in weight percentage of CuO.",VIDRIO PLANO DE MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO MARCOS;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/141-842-461-887-761,Patent Application,yes,0,1,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,,,0,0,,,,PENDING
325,WO,A1,WO 2002/067144 A1,171-366-809-930-462,2002-08-29,2002,IB 0200539 W,2002-02-20,US 27102601 P,2001-02-22,SYSTEM FOR ACCESSING WEB PAGES AND SENDING E-MAILS USNING TELEPHONE NUMBERS,"The present invention is a customizable system and method for direct access to a specified Internet website and related/alternate websites and to reach e-mail addresses utilizing telephone numbers as primary search queries. The browser's graphical elements and layout can be customized to suit the user's preferences or other criteria such as geographical circumstances, language, or to match the specified website's graphical element and layout. The browser system is preferably embodied in a comprehensive Internet portal offering an instantly created referential and search-helping directories system structure that is formed around a website as it is entered from the portal by means of either: its domain name or URL-numeric, or a common telephone number belonging to such website. It also includes an e-mail organizing function based on the same basic system. The e-mail function is capable of concentrating in a customizable website a plurality of e-mail boxes belonging to the same owner in order to provide a classification service for his incoming messages.",AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,,https://lens.org/171-366-809-930-462,Patent Application,yes,5,0,8,8,0,G06Q30/0256;;G06Q30/0264;;G06F16/9566;;G06Q30/0256;;G06Q30/0264;;G06F16/9566,G06F13/00;;G06F17/30;;G06Q30/02,,2,2,034-618-813-086-55X;;067-096-944-867-788,10.1108/10662249810217867;;10.1016/s1389-1286(99)00022-5,"BENBOW S M P: ""File not found: the problems of changing URLs for the World Wide Web"", INTERNET RESEARCH: ELECTRONIC NETWORKING APPLICATIONS AND POLICY, XX, XX, vol. 8, no. 3, 1998, pages 247 - 250, XP002113396, ISSN: 1066-2243;;DEAN J ET AL: ""Finding related pages in the World Wide Web"", COMPUTER NETWORKS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 31, no. 11-16, 17 May 1999 (1999-05-17), pages 1467 - 1479, XP004304567, ISSN: 1389-1286",PENDING
326,CN,A,CN 105813572 A,187-663-827-990-671,2016-07-27,2016,CN 201480067139 A,2014-12-08,US 201361913452 P;;IB 2014066691 W,2013-12-09,Image compounding based on image information,"An image compounding apparatus acquires, via ultrasound, pixel-based images (126-130) of a region of interest for, by compounding, forming a composite image of the region. The image includes composite pixels (191) that spatially correspond respectively to pixels of the images. Further included is a pixel processor for beamforming with respect to a pixel from among the pixels, and for assessing, with respect to the composite pixel and from the data acquired (146), amounts of local information content of respective ones of the images. The processor determines, based on the assessment, weights for respective application, in the forming, to the pixels, of the images, that spatially correspond to the composite pixel. In some embodiments, the assessing commences operating on the data no later than upon the beamforming. In some embodiments, brightness values are assigned to the spatially corresponding pixels; and, in spatial correspondence, the maximum and the mean values are determined. They are then utilized in weighting the compounding.",KONINKLIJKE PHILIPS NV,CABRERA AQUINO JOSE GUSTAVO;;HOU WILLIAM;;MASTERSON STEVEN;;ROZENBERG ALLAN;;CAO JI,,https://lens.org/187-663-827-990-671,Patent Application,no,5,5,5,5,0,A61B8/483;;A61B8/5269;;G01S15/8995;;G01S7/52047;;G01S15/8915;;G10K11/346;;A61B8/5253;;A61B8/5269;;A61B8/5253;;A61B8/483;;G01S15/8915;;G10K11/346;;G01S15/8995;;G01S7/52047;;G06T7/11;;G06T5/20;;G06T2207/10132;;G06T2207/20024,A61B8/00;;A61B8/08;;A61B8/13;;A61B8/14;;G01S15/89,,1,0,,,"VICENTE GRAU等: ""Adaptive Multiscale Ultrasound Compounding Using Phase Information"", 《MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION-MICCAI 2005》",DISCONTINUED
327,CA,A1,CA 3000806 A1,068-864-145-782-898,2017-04-13,2017,CA 3000806 A,2016-10-04,US 201514876254 A;;MX 2016000104 W,2015-10-06,AN UV ABSORBENT GREEN SOLAR CONTROL GLASS COMPOSITION,"The present invention provides an UV absorbent green solar control glass with low UV transmittance composition having a soda-lime-silica glass composition, wherein the coloring compounds comprises in weight percentage: from 0.50 to 1.30% of total iron expressed as Fe2O3;; from 0.12 to 0.45% of FeO expressed as Fe2O3; from about 0.04 to 1.8 wt. % TiO2; about 0.20 to 2.0 % wt CeO2; about 0.0004 to 0.0015 wt. % CuO; and about 0.010 to 0.10% C. The glass composition having a redox value (FeO/Total Fe2O3 from 10 to 35 %.",VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;BETANCOURT-CARRIZALES LUIS URBANO,,https://lens.org/068-864-145-782-898,Patent Application,no,0,0,13,13,0,C03C3/095;;C03C4/082;;C03C4/085;;C03C4/02;;C03C4/085;;C03C4/02;;C03C3/085;;C03C3/095;;C03C4/082,C03C4/08;;C03C3/087,,0,0,,,,PENDING
328,MX,A,MX 2012013935 A,090-215-539-142-436,2013-02-07,2013,MX 2012013935 A,2012-11-30,US 79194910 A;;MX 2011000068 W;;MX 2012013935 A,2010-06-02,DARK GREEN SOLAR CONTROL GLASS COMPOSITION.,"The invention relates to a dark green glass composition having a silica-sodic-calcic base and wherein the colorant compounds comprise, in weight percentage of the total amount: between 0.71 and 1.50% of iron expressed as Fe<sub>2</sub>O<sub>3</sub>; between 22 and 30% of a ferric-ferrous relation and between 0.15 and 0.50% of FeO, expressed as Fe<sub>2</sub>O<sub>3</sub>; between 0.10 and approximately 0.20% of SO<sub>3</sub> without affecting the refining properties of SO<sub>3</sub> and its ability to eliminate bubbles; between approximately 0 and approximately 1.0 in weight percentage of TiO<sub>2</sub>; between approximately 0.0004 and approximately 0.03 in weight percentage of Cr2O3; and also between 0.0004 and 0.015 in weight percentage of CuO.",VIDRIO PLANO DE MEXICO SA DE CV,LLANOS ROBERTO MARCOS CABRERA;;AGUILAR JOSE GUADALUPE CID;;RODRIGUEZ MIGUEL ANGEL KIYAMA,,https://lens.org/090-215-539-142-436,Patent Application,no,0,0,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,C03C3/078;;C03C3/087;;C03C4/02;;C03C4/08;;G02B5/22,,0,0,,,,ACTIVE
329,MX,A,MX 2014003090 A,134-296-794-587-274,2014-05-30,2014,MX 2014003090 A,2011-09-14,MX 2011000108 W,2011-09-14,NEUTRAL GREY GLASS COMPOSITIONS.,"The present invention relates to a neutral grey glass composition which has a basic composition containing the following main colouring agents: 0.40 % to 0.80% of Fe2O3; 0.05 % to 2.0 % of TiO2; 0.2 % to 2.5 % of Er2O3; 20 to 200 ppm of CuO; 0.08 % to 0.1 % of charcoal; and 15 % to 50 % of ferrous (redox), in which the glass has light transmission under illuminant ""A"" greater than 65 %, solar transmission (Ts) < 55%; and ultraviolet transmission < 40%, having colour values a* = -4 to 3 and b* = 4 to -2.",VIDRIO PLANO MEXICO SA DE CV,LLANOS ROBERTO MARCOS CABRERA;;AGUILAR JOSE GUADALUPE CID;;RODRIGUEZ MIGUEL ANGEL KIYAMA,,https://lens.org/134-296-794-587-274,Patent Application,no,0,0,7,7,0,C03C3/095;;C03C3/095;;C03C3/078;;C03C3/087;;C03C4/02;;C03C4/02;;C03C2204/00,C03C4/02;;C03C3/087,,0,0,,,,ACTIVE
330,CA,A1,CA 2438953 A1,162-881-729-471-403,2002-08-29,2002,CA 2438953 A,2002-02-20,IB 0200539 W;;US 27102601 P,2001-02-22,SYSTEM FOR ACCESSING WEB PAGES AND SENDING E-MAILS USING TELEPHONE NUMBERS,"The present invention is a customizable system and method for direct access to a specified Internet website and related/alternate websites and to reach e-mail addresses utilizing telephone numbers as primary search queries. The browser's graphical elements and layout can be customized to suit the user's preferences or other criteria such as geographical circumstances, language, or to match the specified website's graphical element and layout. The browser system is preferably embodied in a comprehensive Internet portal offering an instantly created referential and search-helping directories system structure that is formed around a website as it is entered from the portal by means of either: its domain name or URL-numeric, or a common telephone number belonging to such website. It also includes an e-mail organizing function based on the same basic system. The e-mail function is capable of concentrating in a customizable website a plurality of e-mail boxes belonging to the same owner in order to provide a classification service for his incoming messages.",CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA;;ARNAL EDUARDO;;CABRERA RONALD;;AMENGUAL JUAN,CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA;;ARNAL EDUARDO;;CABRERA RONALD;;AMENGUAL JUAN,,https://lens.org/162-881-729-471-403,Patent Application,no,0,0,8,8,0,G06Q30/0256;;G06Q30/0264;;G06F16/9566;;G06Q30/0256;;G06Q30/0264;;G06F16/9566,G06F13/00;;G06F17/30;;G06Q30/02,,0,0,,,,DISCONTINUED
331,KR,A,KR 20070101238 A,188-603-821-569-941,2007-10-16,2007,KR 20077010326 A,2005-11-29,CU 20040277 A;;CU 2005000010 W,2004-12-08,LIQUID MYCORRHIZAL INOCULANT,"The invention relates to the field of agriculture, soil biotechnology and, specifically, the production and application of arbuscular mycorrhizal fungi, a micro-organism which improves efficiency in nutrient uptake by plants, moisture level, crop production and protection against certain root diseases, etc. The invention consists of a liquid product which is applied to arbuscular mycorrhizal fungi, using an aqueous medium which can achieve stabilisation of the mycorrhizal propagules, thereby enabling the formation of soil aggregates, and a demonstrated viability in liquid medium of between 12 and 18 months and which can be used in irrigation and fertigation systems. The inventive inoculant is applied directly to fields or greenhouses under protected cultivation and can also be used to overcome spore dormancy mechanisms and to obtain an increased concentration level which enables and facilitates handling and transport. The inventive product can be applied in order to manage mycorrhizal fungi in crops under large-scale irrigation system with improved productivity and environmental impacts.",INST NAC DE CIENCIAS AGRICO LA,FERNAN DEZ MARTIN FELIX;;DELL AMICO RODRIGUEZ JOSE MIGU;;PEREZ CABRERA YUNIESKY,,https://lens.org/188-603-821-569-941,Patent Application,no,0,0,15,15,0,C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08;;C12N1/14;;A01N63/30;;C05F11/08,C05F11/08;;A01N63/30;;A01N65/00;;C05G3/80;;C12N1/14,,0,0,,,,INACTIVE
332,CA,C,CA 2920303 C,199-409-658-546-853,2017-08-29,2017,CA 2920303 A,2014-08-08,US 201361863888 P;;US 2014/0050446 W,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BIANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/199-409-658-546-853,Granted Patent,no,0,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61B17/34;;A61M5/178,,0,0,,,,ACTIVE
333,WO,A1,WO 1995/028881 A1,021-125-082-182-953,1995-11-02,1995,ES 9500047 W,1995-04-26,ES 9400888 A;;ES 9402572 A,1994-04-27,NEEDLE AND TUBE-CARRIER ASSEMBLY,"Needle and tube-carrier assembly modified for the vacuum extraction of blood and other organic fluids, comprising a bayonet-type needle (1, 1') and a tube-carrier (10 or 10'), in association with a tube (20), the needle (1) being comprised of a front bevelled needle (4), a transparent connector with side wings (2), a threaded hollow holding part (3 or 3'), a rear needle connection (5) with external rubber sleeve and a rear needle (6) with closed bevel and side openings, the tube-carrier (10) being provided with a needle connection female cone of the thread type (13) or the clip type (13'), with internal damping pad (11), tube-carrier fixing grooves (17) and rotary fixing wings (12); the tube-carrier may also be formed, in a second embodiment, as a single piece body (27) which presents at one of its extremities an element configured as a delta wing (22) from which arises a cone (24) through which passes a conduit (23) to the inside of the sample-holder tube (27), thereby saving a damping pad (28), the conduit (23) being connected to the needle (25) through which circulates the sample flow to the inside of the sample tube (30), thereby saving a protection head (29).",GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON MARIA DOLORES;;CABRERA DE CASTRO FRANCISCO,GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON MARIA DOLORES;;CABRERA DE CASTRO FRANCISCO,,https://lens.org/021-125-082-182-953,Patent Application,yes,6,4,6,6,0,A61B5/150488;;A61B5/15003;;A61B5/150389;;A61B5/150496;;A61B5/150572;;A61B5/150732;;A61B5/154;;A61B10/0045,A61B5/15;;A61M5/14,,0,0,,,,PENDING
334,MX,B,MX 346414 B,016-110-177-738-43X,2017-02-27,2017,MX 2014003090 A,2011-09-14,MX 2011000108 W,2011-09-14,NEUTRAL GREY GLASS COMPOSITIONS.,"The present invention relates to a neutral grey glass composition which has a basic composition containing the following main colouring agents: 0.40 % to 0.80% of Fe2O3; 0.05 % to 2.0 % of TiO2; 0.2 % to 2.5 % of Er2O3; 20 to 200 ppm of CuO; 0.08 % to 0.1 % of charcoal; and 15 % to 50 % of ferrous (redox), in which the glass has light transmission under illuminant ""A"" greater than 65 %, solar transmission (Ts) < 55%; and ultraviolet transmission < 40%, having colour values a* = -4 to 3 and b* = 4 to -2.",VIDRIO PLANO MEXICO SA DE CV,ROBERTO MARCOS CABRERA LLANOS;;JOSE GUADALUPE CID AGUILAR;;MIGUEL ANGEL KIYAMA RODRIGUEZ,,https://lens.org/016-110-177-738-43X,Granted Patent,no,0,0,7,7,0,C03C3/095;;C03C3/095;;C03C3/078;;C03C3/087;;C03C4/02;;C03C4/02;;C03C2204/00,C03C4/02;;C03C3/087,,0,0,,,,ACTIVE
335,WO,A3,WO 2015/021448 A3,031-264-350-727-925,2015-05-21,2015,US 2014/0050446 W,2014-08-08,US 201361863888 P,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,,https://lens.org/031-264-350-727-925,Search Report,yes,11,0,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/178;;A61B17/34,,0,0,,,,PENDING
336,US,B1,US 9573841 B1,048-760-289-316-00X,2017-02-21,2017,US 201514876254 A,2015-10-06,US 201514876254 A,2015-10-06,UV absorbent green solar control glass composition,"The present invention provides an UV absorbent green solar control glass with low UV transmittance composition having a soda-lime-silica glass composition, wherein the coloring compounds comprises in weight percentage: from 0.50 to 1.30% of total iron expressed as Fe 2 O 3 ; from 0.12 to 0.45% of FeO expressed as Fe 2 O 3 ; from about 0.04 to 1.8 wt. % TiO 2 ; about 0.20 to 2.0% wt CeO 2 ; about 0.0004 to 0.0015 wt. % CuO; and about 0.010 to 0.10% C. The glass composition having a redox value (FeO/Total Fe 2 O 3 from 10 to 35%.",VIDRIO PLANO MEXICO SA DE CV;;VIDRIO PLANO MEXICO SA DE CV,CID-AGUILAR JOSE GUADALUPE;;CABRERA-LLANOS ROBERTO MARCOS;;BETANCOURT-CARRIZALES LUIS URBANO,VIDRIO PLANO DE MEXICO S.A. DE C.V (2016-02-19),https://lens.org/048-760-289-316-00X,Granted Patent,yes,15,9,13,13,0,C03C3/095;;C03C4/082;;C03C4/085;;C03C4/02;;C03C4/085;;C03C4/02;;C03C3/085;;C03C3/095;;C03C4/082,C03C3/087;;C03C3/085;;C03C4/02;;C03C4/08,,8,1,106-860-409-063-650,10.1111/j.1151-2916.1921.tb17326.x,"W.A. Weyl, Coloured Glasses, Society of Glass Technology, reprinted 1992, pp. 60-61 and 132-143.;;C.R. Bamford, Colour Generation and Control in Glass, Glass Science and Technology, Elsevier Science Publishing Co., Amsterdam, 1977, pp. 48-50.;;K.M. Fyles, Modern Automotive Glasses, Glass Technology, vol. 37, Feb. 1996, pp. 2-6.;;Werner Vogel, Chemistry of Glass, The American Ceramic Society, Inc., 1985, pp. 154-157.;;Gordon F. Brewster, et al., The color of iron-containing glasses of varying composition, Journal of the Society of Glass Technology, New York, Apr. 1950, pp. 332-406.;;N.E. Densem, The equilibrium between ferrous and ferric oxide in glasses, Journal of the Society of Glass Technology, Glassgow, England, May 1937, pp. 374-389.;;J.C. Hostetter and H.S. Roberts, Notes on the dissociation of ferric oxide dissolved in glass and its relation to the color of iron-bearing glasses, Journal of the American Ceramic Society, USA, Sep. 1921, pp. 927-938.;;M.D. Beals, Effects of Titanium Dioxide in Glass, The Glass Industry, Sep. 1963, pp. 495-531.",ACTIVE
337,AU,A,AU 1995/022586 A,072-834-784-860-140,1995-11-16,1995,AU 1995/022586 A,1995-04-26,ES 9400888 A;;ES 9402572 A;;ES 9500047 W,1994-04-27,Needle and tube-carrier assembly,,JOSE CARLOS GIMENA APARICIO;;FRANCISCO CABRERA DE CASTRO;;MARIA DOLORES TORRICO INVERNON,APARICIO JOSE CARLOS GIMENA;;INVERNON MARIA DOLORES TORRICO;;CASTRO FRANCISCO CABRERA DE,,https://lens.org/072-834-784-860-140,Patent Application,no,0,0,6,6,0,A61B5/150488;;A61B5/15003;;A61B5/150389;;A61B5/150496;;A61B5/150572;;A61B5/150732;;A61B5/154;;A61B10/0045,A61B5/15;;A61M5/14,,0,0,,,,PENDING
338,PE,A1,PE 20180859 A1,119-410-065-366-319,2018-05-22,2018,PE 2018000500 A,2016-10-04,US 201514876254 A,2015-10-06,UNA COMPOSICION DE VIDRIO VERDE PARA CONTROL SOLAR ABSORBENTE DE UV,"La presente invencion se relaciona con un vidrio de control solar verde con una composicion de baja transmitancia de UV teniendo una composicion de vidrio base, en donde los compuestos colorantes comprenden, en porcentaje en peso: de 0.50 a 1.30% del hierro total expresado como Fe2O3; de 0.12 a 0.450 % de FeO expresado como Fe2O3; de alrededor de 0.04 a 1.8 % en peso de TiO2; de alrededor de 0.2 a 2 % en peso de CeO2; de alrededor de 0.0004 a 0.015 de % en peso de CuO; y de alrededor de 0.01 a 0.1% en peso de C. La composicion de vidrio teniendo un valor redox (FeO/Total Fe2O3) de 10 a 35 %.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO MARCOS;;BETANCOURT CARRIZALEZ LUIS URBANO,,https://lens.org/119-410-065-366-319,Patent Application,no,0,0,13,13,0,C03C3/095;;C03C4/082;;C03C4/085;;C03C4/02;;C03C4/085;;C03C4/02;;C03C3/085;;C03C3/095;;C03C4/082,C03C4/08;;C03C3/087,,0,0,,,,PENDING
339,CO,A2,CO 6640267 A2,118-929-932-157-641,2013-03-22,2013,CO 12223412 A,2012-12-10,US 79194910 A,2010-06-02,Composición de vidrio de control solar verde obscuro,"La presente invención se refiere a una composición de vidrio de color verde obscuro teniendo una composición de vidrio base sílica-sodica-cálcica y en donde los compuestos colorantes comprenden, en porcentaje en peso: de 0.71 a 1.50% del total de hierro expresado como Fe203; de 22 a 30% de una relación férricoferroso y de 0.15 a 0.50% of FeO, expresado como Fe203; de 0.10 a alrededor de 0.20% de SO3 sin afectar las propiedades de refinamiento y habilidad del S03 para eliminar las burbujas; de alrededor de 0 a alrededor de 1.0 in porcentaje en peso de TiO2; de alrededor de 0.0004 a alrededor de 0.03 in porcentaje en peso de Cr2O3; y también de 0.0004 a 0.015 de porcentaje en peso de CuO.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO MARCOS;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/118-929-932-157-641,Patent Application,no,0,0,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,C03C4/02;;C03C4/08,,0,0,,,,ACTIVE
340,US,A9,US 2015/0352293 A9,150-445-235-588-998,2015-12-10,2015,US 201414455865 A,2014-08-08,US 201414455865 A;;US 201361863888 P,2013-08-08,INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,NOVO ENGINEERING INC (2014-09-24);;GLOBAL BIOTHERAPEUTICS USA INC. (GBT USA) (2014-09-26);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2014-09-02),https://lens.org/150-445-235-588-998,Amended Application,yes,0,3,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/46;;A61D7/00;;A61M5/315;;A61M5/32,,0,0,,,,INACTIVE
341,MX,B,MX 345667 B,008-844-815-804-052,2017-01-24,2017,MX 2012013935 A,2012-11-30,US 79194910 A;;MX 2011000068 W;;MX 2012013935 A,2010-06-02,DARK GREEN SOLAR CONTROL GLASS COMPOSITION.,"The invention relates to a dark green glass composition having a silica-sodic-calcic base and wherein the colorant compounds comprise, in weight percentage of the total amount: between 0.71 and 1.50% of iron expressed as Fe2</sub>O3</sub>; between 22 and 30% of a ferric-ferrous relation and between 0.15 and 0.50% of FeO, expressed as Fe2</sub>O3</sub>; between 0.10 and approximately 0.20% of SO3</sub> without affecting the refining properties of SO3</sub> and its ability to eliminate bubbles; between approximately 0 and approximately 1.0 in weight percentage of TiO2</sub>; between approximately 0.0004 and approximately 0.03 in weight percentage of Cr2O3; and also between 0.0004 and 0.015 in weight percentage of CuO.",VIDRIO PLANO DE MEXICO SA DE CV,ROBERTO MARCOS CABRERA LLANOS;;JOSE GUADALUPE CID AGUILAR;;MIGUEL ANGEL KIYAMA RODRIGUEZ,,https://lens.org/008-844-815-804-052,Granted Patent,no,0,0,11,11,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085,C03C3/078;;C03C3/087;;C03C4/02;;C03C4/08;;G02B5/22,,0,0,,,,ACTIVE
342,US,B2,US 10740382 B2,069-900-630-522-813,2020-08-11,2020,US 201715627868 A,2017-06-20,US 201715627868 A,2017-06-20,Sentiment analysis as a quality indicator in usability testing,"Various embodiments for enhancing accuracy in usability testing, by a processor device, are provided. Sentiment information is collected by a wearable device configured to be worn by a test user while a set of operations of a test case are executed, the test case evaluating usability of a product or service. Upon completion of the set of operations, a quality for the evaluation of the usability is determined using the sentiment information collected from the wearable device corresponding to input received from the executed set of operations.",IBM,ASTIGARRAGA TARA;;MALDONADO CABRERA RAQUEL;;MOSQUEDA MEJIA JOSE R;;SIEWRATTAN SHARIFFA B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2017-06-01),https://lens.org/069-900-630-522-813,Granted Patent,yes,6,0,2,2,0,G06Q30/0278;;G06Q30/0278;;G06F16/436,G06F16/00;;G06F16/435;;G06Q30/02,,1,0,,,"Raviart, “Infosys Applying Al to Test Automation,” Linkedln, Jun. 7, 2016 (2 pages).",ACTIVE
343,US,B2,US 10245388 B2,168-512-221-285-743,2019-04-02,2019,US 201414455865 A,2014-08-08,US 201414455865 A;;US 201361863888 P,2013-08-08,Injection device for minimally invasive procedures and uses thereof,"Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN;;GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;GERKEN STEVEN;;MASTERSON STEVEN,NOVO ENGINEERING INC (2014-09-24);;GLOBAL BIOTHERAPEUTICS USA INC. (GBT USA) (2014-09-26);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2014-09-02),https://lens.org/168-512-221-285-743,Granted Patent,yes,55,3,19,19,0,A61B17/3478;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61B2017/00247;;A61M2005/31598;;A61M2210/1039;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/02;;A61M2210/166;;A61M2210/1089;;A61M2210/1071;;A61M2210/1433;;A61M2210/125;;A61M2202/206;;A61B2090/034;;A61B2090/08021;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166;;A61P11/00;;A61P17/14;;A61P19/02;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/04;;A61P29/00;;A61P31/12;;A61P31/18;;A61P37/04;;A61P43/00;;A61P7/04;;A61P7/06;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10;;A61B17/3478;;A61B2017/00247;;A61B2090/034;;A61B2090/08021;;A61D7/00;;A61M5/31511;;A61M5/3202;;A61M5/46;;A61M2005/31598;;A61M2202/206;;A61M2210/02;;A61M2210/04;;A61M2210/0693;;A61M2210/1003;;A61M2210/1039;;A61M2210/1071;;A61M2210/1089;;A61M2210/125;;A61M2210/1433;;A61M2210/166,A61M5/46;;A61B17/00;;A61B17/34;;A61B90/00;;A61D7/00;;A61M5/315;;A61M5/32,,64,17,101-006-563-776-849;;053-446-886-655-152;;057-205-038-511-760;;008-078-869-200-895;;065-310-853-569-912;;027-481-107-296-64X;;034-633-606-331-300;;009-093-712-698-826;;140-532-058-597-991;;106-660-583-644-550;;050-983-607-561-263;;070-125-928-713-074;;009-652-838-411-630;;047-438-114-479-016;;004-559-520-459-492;;010-145-185-162-057;;033-634-785-071-687,11231461;;10.1067/msy.2001.111697;;10.1016/j.bpobgyn.2007.08.008;;17900991;;10.1089/10430340260395910;;12490001;;18004400;;10.1038/sj.gt.3303079;;10.1248/bpb.29.1728;;16880633;;15062655;;10.1016/j.suc.2003.11.002;;10.1016/j.ymthe.2005.06.475;;16139571;;10326848;;10.1016/s0002-9610(99)00043-4;;10700178;;10.1038/73464;;10.1016/j.jss.2010.01.030;;20363441;;10.1126/scitranslmed.3000112;;20368179;;pmc2852878;;15812225;;10.1089/hum.2005.16.299;;10.2174/1566523044578077;;15032617;;10.1002/jgm.469;;14716673;;15520458;;pmc528817;;10.1093/nar/gnh140;;pmc1143681;;15919903;;10.1128/jvi.79.12.7478-7491.2005;;10.1038/sj.gt.3302833;;16871229,"Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, mailed on Oct. 26, 2015, 2 pages.;;International Search Report and Written Opinion, dated Nov. 5, 2014, in connection with International Patent Application No. PCT/US2014/050441, 15 pages.;;International Search Report and Written Opinion, dated Mar. 30, 2015, in connection with corresponding International Patent Application No. PCT/US2014/050446, 15 pages.;;Final Office Action, dated Apr. 28, 2015, in connection with U.S. Appl. No. 13/815,206, 54 pages.;;Response to International Search Report and Written Opinion, dated Jun. 8, 2015, in connection with International Patent Application No. PCT/US2014/050441, 49 pages.;;Response to International Search Report and Written Opinion, dated Jun. 30, 2015, in connection with corresponding International Patent Application No. PCT/US2014/050446, 43 pages.;;Written Opinion, dated Jul. 7, 2015, in connection with International Patent Application No. PCT/US2014/050441, 9 pages.;;Response, dated Sep. 7, 2015, to the second Written Opinion, dated Jul. 7, 2015, in connection with International Patent Application No. PCT/US2014/050441, 40 pages.;;International Report on Patentability, dated Sep. 29, 2015, in connection with corresponding International Patent Application No. PCT/US2014/050446, 35 pages.;;U.S. Appl. No. 14/455,871, filed Aug. 8, 2014, 2015/0066056, Mar. 5, 2015.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Jul. 12, 2017, 2 pages.;;News Article, “Spotlight: Global BioTherapeutics—Cultivating Entrepreneurship in Gene Therapy,” Published Sep. 30, 2015 [online] Retrieved from: <URL: mexicosalud.com/spotlight-global-biotherapeutics-cultivating-entrepreneurship-in-gene-therapy/, May 25, 2016, 6 pages.;;Examination Report, dated Oct. 20, 2016, in connection with Canadian Patent Application No. 2,920,303, 3 pages.;;Response, filed Nov. 28, 2016, to Examination Report, dated Oct. 20, 2016, in connection with Canadian Patent Application No. 2,920,303, 23 pages.;;Notice of Allowance, dated Jan. 19, 2017, in connection with Canadian Patent Application No. 2,920,303, 1 page.;;Examination Report, dated Nov. 17, 2016, in connection with European Patent Application No. 14 756 174.0, 3 pages.;;Response, filed Feb. 23, 2017, to Examination Report, dated Nov. 17, 2016, in connection with European Patent Application No. 14 756 174.0, 208 pages.;;Communication Pursuant to Rule 71(3) EPC (Intention to Grant), dated Apr. 28, 2017, in connection with European Patent Application No. 14 756 174.0, 7 pages.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Apr. 28, 2012, 2 pages.;;International Preliminary Report on Patentability, dated Nov. 12, 2015, in connection with International Patent Application No. PCT/US2014/050441, 36 pages.;;U.S. Appl. No. 13/815,206. filed Feb. 7, 2013, 2013/0211380, Aug. 15, 2013.;;U.S. Appl. No. 14/455,871, filed Aug. 8, 2014.;;Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, mailed on Nov. 26, 2014, 3 pages.;;Brooks et al., “Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: implications for local gene therapy.” Surgery 129(3):324-334 (2001).;;David et al., “Gene therapy for the fetus: is there a future?” Best Pract Res Clin Obstet Gynaecol. 22(1):203-218 (2008).;;Eastman et al., “Development of catheter-based procedures for transducing the isolated rabbit liver plasmid DNA,” Human Gene Therapy 13:2065-2077 (2002).;;Fabre et al., “Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava,” Gene Ther., 15:452-462 (2008).;;Fujita et al., “Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion,” Biological & Pharmaceutical Bulletin, 29:1728-1734 (2006).;;Gagner et al., “Laparoscopic liver resection: benefits and controversies.” Surg Clin North Am. 84(2):451-462 (2004).;;Hodges et al., “Local delivery of viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver,” Mol. Ther. 12:1043-1051 (2005).;;Invalidity Search Report prepared by a third-party, “Invalidity Search—Provisional Application—Injectcion Device, Global Bio Therapeutics,” redacted, dated May 21, 2014, 10 pages.;;Jiao et al., “Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors.” Am J Surg. 177(4):303-306 (1999).;;Kay et al., “Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.” Nat Genet. 24(3):257-261 (2000).;;Kinoshita et al., “Targeted gene delivery to selected liver segments via isolated hepatic perfusion,” J Surg. Res., 160:47-51 (2010).;;Kota et al., “Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.” Sci Transl Med. 1(6):6ra15, 8 pages (2009).;;Ohashi et al., “Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver,” Human Gene Therapy 16:299-306 (2005).;;Papadakis et al., “Promoters and control elements: designing expression cassettes for gene therapy.” Curr Gene Ther. 4(1):89-113 (2004).;;Podevin et al., “Factors influencing immune response after in vivo retrovirus-mediated gene transfer to the liver.” J Gene Med. 6(1):16-21 (2004).;;Schiffelers et al., “Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.” Nucleic Acids Res.32(19):e149, 10 pages (2004).;;Shayakhmetov et al., “Adenovirus binding to blood factors results in liver cell infection and Hepatotoxicity,” J. Virol. 79:7478-7491 (2005).;;Yoshino et al., “Naked plasmid DNA transfers to the porcine liver using rapid injection with large volume,” Gene Ther.13:1696-1702 (2006).;;International Search Report and Written Opinion, dated May 23, 2013, in connection with International Patent Application No. PCT/US2013/025234, 24 pages.;;Restriction Requirement, dated Sep. 19, 2013, in connection with U.S. Appl. No. 13/815,206, 6 pages.;;Response to Restriction Requirement, dated Oct. 21, 2013, in connection with U.S. Appl. No. 13/815,206, 13 pages.;;Response to International Search Report and Written Opinion, dated Dec. 9, 2013, in connection with International Patent Application No. PCT/US2013/025234, 49 pages.;;Written Opinion, dated Jan. 27, 2014, in connection with International Patent Application No. PCT/US2013/025234, 9 pages.;;Response to Written Opinion, dated Mar. 27, 2014, in connection with International Patent Application No. PCT/US2013/025234, 45 pages.;;Office Action, dated Apr. 22, 2014, in connection with U.S. Appl. No. 13/815,206, 47 pages.;;International Preliminary Report on Patentability, dated May 6, 2014, in connection with International Patent Application No. PCT/US2013/025234, 10 pages.;;Response to Office Action, dated Oct. 22, 2014, in connection with U.S. Appl. No. 13/815,206, 31 pages.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Mar. 15, 2018, 2 pages.;;Machine-generated English translation of Japanese Patent No. JP 2000-070336, published on Mar. 7, 2000, generated on Nov. 28, 2017, 7 pages.;;Office Action, dated Dec. 1, 2017, in connection with corresponding Chinese Patent Application No. 201480055640.0 [English translation and original document in Chinese], 8 pages.;;Decision to Grant a European Patent Pursuant to Article 97(1) EPC, dated Oct. 6, 2017, in connection with corresponding European Patent Application No. 14 756 174.0, 2 pages.;;Office Action, dated Oct. 3, 2017, in connection with corresponding Japanese Patent Application No. 2016-533484 [English summary, English translation and original document in Japanese], 14 pages.;;Response, filed Dec. 22, 2017, to Office Action, dated Oct. 3, 2017, in connection with corresponding Japanese Patent Application No. 2016-533484 [English instructions and claims as sent Dec. 13, 2017, amended set of English claims as sent Dec. 20, 2017 and document as originally filed in Japanese with the Syringe Needle Gauge Chart of the Lab Basics Technical Library from Sigma-Aldrich], 52 pages.;;Decision to Grant, dated Jan. 16, 2018, in connection with corresponding Japanese Patent Application No. 2016-533484 [English reporting letter and translation with original document in Japanese], 5 pages.;;Office Action, dated Jan. 31, 2018, in connection with corresponding Eurasian Patent Application No. 201600139 [English translation and original document in Russian], 6 pages.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Oct. 4, 2018, 2 pages.;;Response, filed Feb. 24, 2018, to Office Action, dated Dec. 1, 2017, in connection with corresponding Chinese Patent Application No. 201480055640.0 [English instructions and document as filed in Chinese], 28 pages.;;Notice of Allowance, dated Jun. 6, 2018, in connection with corresponding Chinese Patent Application No. 201480055640.0 [English translation and original document in Chinese], 4 pages.;;Response, filed May 24, 2018, to Office Action, dated Jan. 31, 2018, in connection with corresponding Eurasian Patent Application No. 201600139 [English instructions and original document in Russian], 32 pages.;;Letter, reporting Notice of Allowance, dated Aug. 8, 2018, in connection with corresponding Eurasian Patent Application No. 201600139 [English reporting letter and original document in Russian], 2 pages.;;Certificate of Grant, dated May 11, 2018, in connection with corresponding Hong Kong Patent Application No. 16113717.7, 2 pages.",INACTIVE
344,ES,A1,ES 2698150 A1,146-124-267-643-646,2019-01-31,2019,ES 201831140 A,2018-11-23,ES 201831140 A,2018-11-23,"MICROWAVE OVEN FOR THE HEATING OF CONTINUOUS LIQUID AND SEMI-SOLID FLOWS (Machine-translation by Google Translate, not legally binding)","Microwave oven for heating continuous flows of liquids and semisolids. Industrially applicable microwave oven for heating continuous flows of liquids and semisolids, whose resonant cavity has a section with circular arcs that allow the concentration of multimodal microwave radiation in its central axis; where the furnace has metallic cylindrical waveguides to the cut as electromagnetic filters that allow the passage of the hollow dielectric tube and the product to be processed, preventing microwave radiation to the outside, dielectric and/or metallic tuners for the adjustment of the distribution multimodal energy inside the cavity, and lossless dielectric supports; where the microwave energy propagates through a rectangular waveguide powered by a microwave generator system; and wherein said waveguide is short-circuited at the end thereof and communicates with the quasi-cylindrical cavity through slots. (Machine-translation by Google Translate, not legally binding)",UNIV CARTAGENA POLITECNICA;;UNIV VALLADOLID,ALVAREZ MARTIN ANA;;COCERO ALONSO MARIA JOSE;;FAYOS FERNANDEZ JOSE;;MATO CHAIN RAFAEL BARTOLOME;;MONZO CABRERA JUAN,,https://lens.org/146-124-267-643-646,Patent Application,no,5,0,2,2,0,A23L3/01;;A61L2/12;;B01J19/126;;H05B6/802,H05B6/80;;A23L3/01;;A61L2/12;;B01J19/12,,0,0,,,,ACTIVE
345,WO,A1,WO 2013/039371 A1,001-165-419-167-259,2013-03-21,2013,MX 2011000108 W,2011-09-14,MX 2011000108 W,2011-09-14,NEUTRAL GREY GLASS COMPOSITIONS,"The present invention relates to a neutral grey glass composition which has a basic composition containing the following main colouring agents: 0.40 % to 0.80% of Fe 2 O 3 ; 0.05 % to 2.0 % of TiO 2 ; 0.2 % to 2.5 % of Er 2 O 3 ; 20 to 200 ppm of CuO; 0.08 % to 0.1 % of charcoal; and 15 % to 50 % of ferrous (redox), in which the glass has light transmission under illuminant ""A"" greater than 65 %, solar transmission (T s ) < 55%; and ultraviolet transmission < 40%, having colour values a* = -4 to 3 and b* = 4 to -2.",VIDRIO PLANO MEXICO SA DE CV;;CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO MARCOS;;KIYAMA RODRIGUEZ MIGUEL ANGEL,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO MARCOS;;KIYAMA RODRIGUEZ MIGUEL ANGEL,,https://lens.org/001-165-419-167-259,Patent Application,yes,4,1,7,7,0,C03C3/095;;C03C3/095;;C03C3/078;;C03C3/087;;C03C4/02;;C03C4/02;;C03C2204/00,C03C4/02;;C03C3/087,,0,0,,,,PENDING
346,ES,B1,ES 2078184 B1,050-394-321-693-214,1996-07-01,1996,ES 9400888 A,1994-04-27,ES 9400888 A,1994-04-27,CONJUNTO DE AGUJA Y PORTATUBOS MODIFICADO PARA LA EXTRACCION AL VACIO DE SANGRE Y OTROS FLUIDOS ORGANICOS.,"CONJUNTO DE AGUA Y PORTATUBOS MODIFICADO POR LA EXTRACCION AL VACIO DE SANGRE Y OTROS FLUIDOS ORGANICOS. CONJUNTO DE AGUJA Y PORTATUBOS MODIFICADO PARA LA EXTRACCION AL VACIO DE SANGRE Y OTROS FLUIDOS ORGANICOS CONSISTE EN UNA AGUJA DE BAYONETA (1) (1'') Y UN PORTATUBOS (10) O (10''), EN COLABORACION CON UN TUBO (20), ESTANDO CONSTITUIDA LA AGUJA (1) EN BAYONETA POR UNA AGUJA BISELADA ANTERIOR (4), UN RACORD TRANSPARENTE CON ALAS LATERALES (2), UNA ROSCA HUECA DE FIJACION (3) O (3''), UNA CONEXION A LA AGUJA POSTERIOR (5) CON FUNDA EXTERNA DE GOMA Y UNA AGUJA POSTERIOR (6) CON BISEL CERRADO Y APERTURAS LATERALES, DISPONIENDO EL PORTATUBOS (10) DE UN CONO HEMBRA DE CONEXION DE AGUJA TIPO ROSCA (13) O TIPO CLIP (13''), CON ALMOHADILLA DE AMORTIGUACION INTERNA (11), HENDIDURAS DE FIJACION Y PORTATUBOS (17) Y ALAS DE SUJECION GIRATORIAS (12).",GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON M DOLORES;;CABRERA DE CASTRO FRANCISCO,GIMENA APARICIO JOSE CARLOS;;TORRICO INVERNON M DOLORES;;CABRERA DE CASTRO FRANCISCO,,https://lens.org/050-394-321-693-214,Granted Patent,no,0,0,6,6,0,A61B5/150488;;A61B5/15003;;A61B5/150389;;A61B5/150496;;A61B5/150572;;A61B5/150732;;A61B5/154;;A61B10/0045,A61B5/15;;A61M5/14,,0,0,,,,EXPIRED
347,BR,A,BR 0207771 A,077-595-085-562-095,2004-06-01,2004,BR 0207771 A,2002-02-20,IB 0200539 W;;US 27102601 P,2001-02-22,Sistema para acessar páginas da web e enviar e-mails usando números de telefone,"""SISTEMA PARA ACESSAR PáGINAS DA WEB E ENVIAR E-MAILS USANDO NúMEROS DE TELEFONE"". A presente invenção refere-se a um sistema e método personalizável para acessar diretamente a um determinado site da Web de Internet, e a sites da Web relacionados / alternativos, e para acessar a endereços de correio eletrónico usando números telefónicos como enunciados primários de busca. Os elementos gráficos e de apresentação do navegador pode ser personalizados para adaptar-se às preferências dos usuários ou outros critérios, tais como as circunstâncias geográficas, linguagem ou para fazer jogo com os elementos gráficos e de apresentação gráfica de um site da Web específico. O sistema de navegador se forma preferivelmente em um portal de Internet compreensivo que oferece a criação instantânea de uma estrutura de sistemas de diretórios referenciais e auxiliares de busca que se formam ao redor de um site da Web quando este é ingressado desde um portal por meio de seu nome de domínio ou URL - numérico, ou um número telefónico comum que pertence a tal site da Web. Também inclui uma função de organização de correio eletrónico baseada no mesmo sistema básico. A função de correio eletrónico é capaz de concentrar em uma site da Web, personalizável, uma pluralidade de caixas de correio eletrónico que pertencem ao mesmo proprietário, para assim proporcionar um serviço de classificação para as suas mensagens que entram.",AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,AMENGUAL JUAN;;ARNAL EDUARDO;;CABRERA RONALD;;CARRASCO DANIEL;;MARQUEZ JOSE;;PUIG ANA,,https://lens.org/077-595-085-562-095,Patent Application,no,0,0,8,8,0,G06Q30/0256;;G06Q30/0264;;G06F16/9566;;G06Q30/0256;;G06Q30/0264;;G06F16/9566,G06F13/00;;G06F17/30;;G06Q30/02,,0,0,,,,DISCONTINUED
348,HU,T2,HU E036546 T2,051-514-397-846-993,2018-07-30,2018,HU E09712762 A,2009-02-17,EP 08384001 A;;EP 08008682 A,2008-02-18,USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT;;VELA-HERNANDEZ JOSE-MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,,https://lens.org/051-514-397-846-993,Amended Patent,no,0,0,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/40;;A61K31/46;;A61P25/02;;A61P29/02,,0,0,,,,PENDING
349,ES,B2,ES 2698150 B2,127-175-279-838-29X,2019-05-17,2019,ES 201831140 A,2018-11-23,ES 201831140 A,2018-11-23,HORNO MICROONDAS PARA EL CALENTAMIENTO DE FLUJOS CONTINUOS DE LIQUIDOS Y SEMISOLIDOS,,UNIV CARTAGENA POLITECNICA;;UNIV VALLADOLID,ALVAREZ MARTIN ANA;;COCERO ALONSO MARIA JOSE;;FAYOS FERNANDEZ JOSE;;MATO CHAIN RAFAEL BARTOLOME;;MONZO CABRERA JUAN,,https://lens.org/127-175-279-838-29X,Granted Patent,no,0,0,2,2,0,A23L3/01;;A61L2/12;;B01J19/126;;H05B6/802,H05B6/80;;A23L3/01;;A61L2/12;;B01J19/12,,0,0,,,,ACTIVE
350,CN,A,CN 101951908 A,115-429-785-589-865,2011-01-19,2011,CN 200980105506 A,2009-02-17,EP 2009001109 W;;EP 08384001 A;;EP 08008682 A,2008-02-18,Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,ESTEVE LABOR DR,MANUEL BAEYENS-CABRERA JOSE;;BUSCHMANN HELMUT H;;JOSE-MIGUEL VELA-HERNANDEZ;;DANIEL ZAMANILLO-CASTANEDO;;RAFAEL NIETO-LOPEZ FRANCISCO,,https://lens.org/115-429-785-589-865,Patent Application,no,0,0,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/495;;A61P25/02;;A61P29/02,,0,0,,,,DISCONTINUED
351,ZA,B,ZA 201200843 B,140-920-441-077-256,2012-10-31,2012,ZA 201200843 A,2012-02-03,EP 09382144 A;;EP 2010061720 W,2009-08-14,SOGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/140-920-441-077-256,Granted Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243,,0,0,,,,ACTIVE
352,EP,A1,EP 2090311 A1,156-154-095-374-901,2009-08-19,2009,EP 08384001 A,2008-02-18,EP 08384001 A,2008-02-18,Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,,https://lens.org/156-154-095-374-901,Patent Application,yes,2,17,1,22,0,A61K31/495;;A61P25/02;;A61P29/02,A61K31/495;;A61P25/02;;A61P29/02,,2,1,012-158-489-880-352,10.1097/00002820-200603002-00015,"POLOMANO R C ET AL: ""Pain and neuropathy in cancer survivors: Surgery, radiation, and chemotherapy can cause pain; research could improve its detection and treatment"", CANCER NURSING, LIPPINCOTT-RAVEN PUB., HAGERSTOWN, MD, US, vol. 29, no. 2, suppl, 1 March 2006 (2006-03-01), pages 39 - 47, XP009107315, ISSN: 0162-220X;;""Chemotherapy at home, pain and its treatment"", SOINS, OFFICE DE PUBLICITE GENERALE, PARIS, FR, no. 528, 1 September 1989 (1989-09-01), pages 17 - 20, XP009107313, ISSN: 0038-0814",DISCONTINUED
353,AR,A1,AR 077876 A1,011-925-696-910-110,2011-09-28,2011,AR P100102983 A,2010-08-13,EP 09382144 A,2009-08-14,LIGANDOS DEL RECEPTOR SIGMA PARA LA PREVENCION O EL TRATAMIENTO DE DOLOR INDUCIDO POR QUIMIOTERAPIA,"Uso de un ligando del receptor sigma de formula (1) para prevenir o tratar dolor inducido por un agente quimioterápico, especialmente dolor inducido por taxanos, alcaloides de la vinca o fármacos quimioterápicos de platino. Reivindicacion 1: Combinacion de al menos un ligando sigma y al menos un fármaco quimioterápico para su administracion simultánea, separada o secuencial, en la que el ligando sigma tiene la formula general (1), en la que R1 se selecciona del grupo formado por hidrogeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo no aromático sustituido o no sustituido, heterociclilo aromático sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR8, -C(O)OR8, -C(O)NR8R9, -C=NR8, -CN, -OR8, -OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9 y halogeno; R2 se selecciona del grupo formado por hidrogeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR8, -C(O)OR8, -C(O)NR8R9, -C=NR8, -CN, -OR8, -OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9 y halogeno; R3 y R4 se seleccionan independientemente del grupo formado por hidrogeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR8, -C(O)OR8, -C(O)NR8R9, -C=NR8, -CN, -OR8, -OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9 y halogeno, o juntos forman un sistema de anillos condensados opcionalmente sustituido; R5 y R6 se seleccionan independientemente del grupo formado por hidrogeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, ,arilalquilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, -COR8, -C(O)OR8, -C(O)NR8R9, -C=NR8, -CN, -OR8, -OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9 y halogeno, o juntos forman, con el átomo de nitrogeno al que están unidos, un grupo heterociclilo sustituido o no sustituido; n se selecciona de 1, 2, 3, 4, 5, 6, 7 y 8; t es 1, 2 o 3; R8 y R9 se seleccionan cada uno independientemente de hidrogeno, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, arilo sustituido o no sustituido, heterociclilo aromático o no aromático, sustituido o no sustituido, alcoxilo sustituido o no sustituido, ariloxilo sustituido o no sustituido y halogeno; o una sal, isomero, profármaco o solvato farmacéuticamente aceptable del mismo. Reivindicacion 14: Compuesto de formula (1) segun cualquiera de las reivindicaciones 1 a 7, o una sal, isomero, profármaco o solvato farmacéuticamente aceptable del mismo, para su uso en el tratamiento o la prevencion de dolor inducido por quimioterapia.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/011-925-696-910-110,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243,,0,0,,,,PENDING
354,US,A1,US 2012/0141606 A1,175-921-750-166-900,2012-06-07,2012,US 201013389733 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,LABORATORIOS DEL DR. ESTEVE S.A (2012-01-23),https://lens.org/175-921-750-166-900,Patent Application,yes,2,9,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/4152;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/4545;;A61K31/475;;A61K31/496;;A61K31/5377;;A61K31/541;;A61K31/69;;A61K33/243;;A61P35/00,424/649;;514/236.5;;514/407;;514/326;;514/397;;514/303;;514/254.05;;514/227.8;;514/283;;514/64;;514/323,5,5,023-314-960-057-474;;111-802-677-934-809;;067-467-754-425-209;;027-633-180-185-452;;029-307-446-890-335,10.1097/aln.0b013e3181895a83;;18946301;;18571399;;10.1016/j.ejca.2008.04.018;;10.1038/277665a0;;423966;;10.1001/archoto.2008.514;;19153315;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x,"Roh et al., Intrathecal Injection of the sigma Receptor Antagonist BD1047 Blocks both Mechanical Allodynia and Increases in Spinal NR1 Expression during the Induction Phase of Rodent Neuropatic Pain, Anesthesiology, 2008, 109, 879-889.;;Wolf et al., Chemotherapy-induced peripheral neuropathy: Prevention and Treatment strategies, European Journal of Cancer, 2008, 44, 1507-1515.;;Schiff et al. Nature Vol 277 Pages 665-667. Publication date: 02/22/1979.;;Kuruvilla et al. Arch Otolaryngol Head Neck Surg. January 2009; 135(1): 101-105.;;Carrle and Bielack. Int Orthopaedics Vol 30, pase 445-451. publication year: 2006",DISCONTINUED
355,TN,A1,TN 2012000048 A1,180-113-806-033-425,2013-09-19,2013,TN 2012000048 A,2012-01-31,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/180-113-806-033-425,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,PENDING
356,SG,A1,SG 178338 A1,036-114-134-592-657,2012-03-29,2012,SG 2012009098 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/036-114-134-592-657,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243,,0,0,,,,PENDING
357,EP,A1,EP 2464356 A1,135-047-575-333-206,2012-06-20,2012,EP 10744560 A,2010-08-12,EP 09382144 A;;EP 2010061720 W;;EP 10744560 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,"ESTEVE PHARMACEUTICALS, S.A., ES (2019-01-14);;ESTEVE PHARMACEUTICALS, S.A.; ES (2019-02-12);;ESTEVE PHARMACEUTICALS, S.A. (2018-10-16);;LABORATORIOS DEL DR. ESTEVE, S.A. (2015-05-20)",https://lens.org/135-047-575-333-206,Patent Application,yes,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K31/337;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,ACTIVE
358,AR,A1,AR 035788 A1,059-661-241-882-18X,2004-07-14,2004,AR P020101012 A,2002-03-20,AR P020101012 A,2002-03-20,PREPARACION DE SALES DE BIS-AMONIO CUATERNARIAS EN MEDIO MICROEMULSION Y/O MICELAR ACUOSO,"Sales de bis-amonio cuaternarias de cadena larga y espaciador del tipo 2-hidroxialquil son preparadas por un nuevo método a partir de alquilaminas terciarias de cadena larga y haloalquilepóxidos tales como epiclorhidrina, utilizando el clorhidrato de la amina como agente surfactante funcional para el establecimiento del medio de reacción microemulsión y/o micelar acuoso. El uso de solventes polares apróticos tales como alcoholes, o sus mezclas acuosas, es convenientemente evitado conduciendo a reacción de cuaternización en medio micelar acuoso, en medio microemulsión acuoso, y/o combinaciones de ambos, a temperaturas comprendidas entre 20 y 90°C, preferentemente entre 40 y 80°C.",FUNDACION PARA LA PROMOCION Y,RICCI CLAUDIA GUADALUPE;;CABRERA MARIA INES;;LUNA JULIO ALBERTO;;GRAU RICARDO JOSE ANTONIO,,https://lens.org/059-661-241-882-18X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
359,ES,A1,ES 2360781 A1,106-704-714-067-661,2011-06-09,2011,ES 200902211 A,2009-11-13,ES 200902211 A,2009-11-13,COMPOSITION AND PROCESS FOR OBTAINING MATERIALS FOR COATING CERAMIC BODIES AND THE ARTICLES THUS OBTAINED,"This invention relates to a base composition of oxides and the products derived from said composition, characterised in that following its application on a ceramic substrate and its subsequent firing, crystal formations of Russellite are obtained on the surface of the ceramic part that provide it with an appearance that is rich in chromatic hues, iridescent, metallic and shiny depending on the amount and size of the crystals present.",VIDRES S A,CABRERA IBANEZ MARIA JOSE;;MARTI SIDRO VICTOR;;SOLSONA MONZONIS DANIEL;;MONTINS NEBOT VICTOR,,https://lens.org/106-704-714-067-661,Patent Application,no,3,1,4,4,0,C03C8/00;;C04B41/85;;C04B41/5023;;C03C3/062;;C03C8/02;;C03C10/00;;C04B41/009;;C04B41/86;;C04B2111/0025;;C04B2111/82,C04B41/85;;C03C8/00,,0,0,,,,INACTIVE
360,US,A1,US 2021/0360991 A1,106-198-343-804-984,2021-11-25,2021,US 201816757291 A,2018-10-11,US 201816757291 A;;US 201762572409 P;;IB 2018057871 W,2017-10-13,FLUID-ACTUATED IMPACT PROTECTION SYSTEM AND METHOD,"The subject disclosure describes, among other things, illustrative embodiments of an impact protection device that comprises the following elements: a machine, a protective structural member, and a fluid holding member. The impact protection device is designed to protect a user from an impact to the protective structural member by dissipating a portion of the kinetic energy of the impact. Machine operation translates into a controlled movement between elements of the impact protection device that deform the fluid holding member, thereby displacing a fluid. This controlled movement also dictates a throttling profile that regulates the amount of damping; thereby managing the portion of kinetic energy dissipated. The machine can be a mechanical assembly incorporating levers, cams and or computerized controllers.",TITON CORP S A;;TITON IDEAS INC,MINI TOWNSON JUAN FRANCISCO JAVIER;;ARAGON CABRERA JOSE RODRIGO;;ALFARO SAMAYOA JUAN PABLO,TITON CORP (2020-06-02);;TITON IDEAS INC (2019-09-26);;MINI TOWNSON JUAN FRANCISCO JAVIER (2019-06-27),https://lens.org/106-198-343-804-984,Patent Application,yes,0,0,3,3,0,A42B3/121;;F16F13/10;;F41H1/02;;F41H1/04;;F41H5/013;;F41H5/08;;F16F9/049;;A41D13/015;;A42B3/121;;F41H1/02;;F41H1/04;;F41H5/013,A41D13/015;;A42B3/12,,0,0,,,,ACTIVE
361,BG,A,BG 100289 A,023-260-731-674-910,1996-12-31,1996,BG 10028996 A,1996-01-17,ES 9400084 W;;ES 9401078 A,1994-05-17,OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,CABRERA ANTONIO L;;CABELLO GEMMA T;;VALLET MAS JOSE A;;BERGAMINI MICHAEL V,,https://lens.org/023-260-731-674-910,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,PENDING
362,US,A,US 5112029 A,122-633-644-924-705,1992-05-12,1992,US 73342391 A,1991-07-22,US 73342391 A,1991-07-22,Quick fluid injection assembly replacement in metallurgical reacters,"The present invention relates to a method and a fluid injection device for quick replacement, even in the red hot conditions, in a metallurgical reactor. The method comprises the external extraction of the injection device which is composed of an inner extractable blowing element and wear resistant block, element the blowing element secured in the wear resistant block and forming together the injection device. The quick interchange is first performed by extracting the inner blowing element, then installing a special extractor device in the space where the blowing element was and then extracting the wear resistant block by applying a force, in the opposite direction of the gas flow, through the bottom end of the extractor device. The extractor device has a special design so, when a force is applied at its bottom end, an expansive occurs at the upper end making the external extraction of said wear resistant block easier.",INSTITUO MEXICANO DE INVESTIGA,LAZCANO-NAVARRO ARTURO;;VARGAS-GUTIERREZ GREGORIO;;HERNANDEZ-RUIZ JOSE E;;MAROTO-CABRERA CARLOS,INSTITUTO MEXICANO DE INVESTIGACIONES S/N (1991-06-28),https://lens.org/122-633-644-924-705,Granted Patent,yes,2,9,1,1,0,B22D1/005;;C21C5/35;;C21C5/35;;B22D1/005,B22D1/00;;C21C5/35,266/47;;266/265;;266/270,0,0,,,,EXPIRED
363,MX,A,MX 2010009325 A,125-070-808-847-64X,2011-03-03,2011,MX 2010009325 A,2008-02-25,ES 2008000104 W,2008-02-25,PHOTOVOLTAIC CONCENTRATION MODULE AND DEVICE.,"The invention relates to a photovoltaic concentration module and device. The device includes: a primary lens (10) configured to concentrate incident solar radiation and to generate a first concentrated radiation; a solar cell (30) configured to collect the first concentrated radiation; and a substrate (40) enabling the electrical connection and thermal dissipation of the solar cell, whereby the solar cell (30) and the substrate (40) are electrically associated so as to form an electric power generation unit. The photovoltaic concentration module includes a series of the aforementioned devices.",ISOFOTON S A STAR,VICENTE DIAZ LUQUE;;JAVIER CABRERA GODOY;;DAVID EXPOSITO CORRAL;;JOSE LUIS ALVARES RICO,,https://lens.org/125-070-808-847-64X,Patent Application,no,0,0,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/052,,0,0,,,,DISCONTINUED
364,CA,A1,CA 3187132 A1,166-445-258-872-271,2022-02-03,2022,CA 3187132 A,2021-07-26,US 202063059264 P;;US 2021/0043228 W,2020-07-31,"METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE","A method of reducing or delaying the onset of fatty liver disease in a subject comprises enterally administering at least one human milk oligosaccharide (HMO) to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the at least one HMO is administered in an amount effective to reduce de novo lipogenesis in the subject. The at least one HMO can be administered to the subject directly or in a nutritional composition.",ABBOTT LAB,MANZANO MANUEL;;HERNANDEZ ENRIQUE;;LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;BUCK RACHAEL,,https://lens.org/166-445-258-872-271,Patent Application,no,0,0,7,7,0,A61K31/702;;A61K45/06;;A61P1/16;;A61P3/10;;A61P5/14;;A61P3/06;;A61P1/16;;A61P3/06;;A61K9/0053;;A61K31/702;;A61K45/06,A61K31/702;;A61K45/06;;A61L33/12;;A61P1/16;;A61P3/06;;A61P3/10;;A61P5/14,,0,0,,,,PENDING
365,WO,A1,WO 2011/018488 A1,076-698-550-729-854,2011-02-17,2011,EP 2010061724 W,2010-08-12,EP 09382145 A,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treatpain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum derivatives chemotherapeutic drugs.",ESTEVE LABOR DR;;BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/076-698-550-729-854,Patent Application,yes,2,2,4,4,0,A61K31/337;;A61K31/5377;;A61K45/06;;A61K31/5377;;A61P25/02,A61K31/5377;;A61K45/06;;A61P25/02,,24,22,085-872-310-203-674;;023-314-960-057-474;;043-077-705-511-421;;127-737-008-781-342;;080-964-082-647-80X;;080-975-278-133-871;;024-044-021-710-067;;040-974-495-617-674;;027-908-337-016-973;;015-461-458-759-788;;084-819-015-566-887;;004-035-273-862-921;;073-228-490-035-58X;;065-370-056-423-560;;111-802-677-934-809;;031-480-719-231-230;;025-124-152-392-536;;006-570-780-387-210;;082-817-573-119-019;;032-620-320-110-961;;120-520-383-362-818;;000-839-833-305-962,16892345;;10.1002/cmdc.200500034;;10.1097/aln.0b013e3181895a83;;18946301;;10.1248/bpb.32.732;;19336915;;10.1007/978-1-60761-880-5_8;;10.1038/sj.mt.6300019;;17164777;;10.1016/j.clinph.2008.10.095;;15102312;;10.1046/j.1526-4637.2001.002001008.x;;10.2174/092986708786848569;;19075655;;10.1007/pl00007853;;11954874;;10.1097/00001813-199506000-00003;;7670134;;7669713;;10.1093/oxfordjournals.annonc.a059220;;10.1023/a:1005805907311;;9266440;;10.1016/j.ejca.2005.06.030;;16293411;;18574024;;10.1182/blood-2008-04-149385;;18571399;;10.1016/j.ejca.2008.04.018;;10.1200/jco.1993.11.10.2010;;7692001;;10.1200/jco.1996.14.7.1993;;8683229;;10.1200/jco.1997.15.5.1965;;9164208;;7907208;;10.1002/ana.410350310;;15082135;;10.1016/j.pain.2004.01.021;;15590869;;10.1345/aph.1e319;;10.1016/j.pain.2007.10.012;;18037242,"CORBERA JORDI ET AL: ""A medicinal-chemistry-guided approach to selective and druglike sigma 1 ligands."", CHEMMEDCHEM JAN 2006, vol. 1, no. 1, January 2006 (2006-01-01), pages 140 - 154, XP002567219, ISSN: 1860-7179;;ROH D-H ET AL: ""Intrathecal injection of the [sigma]1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain"", ANESTHESIOLOGY, AMERICAN SOCIETY OF ANESTHESIOLOGISTS, PHILADELPHIA, PA, US, vol. 109, no. 5, 1 January 2008 (2008-01-01), pages 879 - 889, XP009128580, ISSN: 0003-3022;;GAUCHAN PUNAM ET AL: ""Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit."", BIOLOGICAL & PHARMACEUTICAL BULLETIN APR 2009, vol. 32, no. 4, April 2009 (2009-04-01), pages 732 - 734, XP002567073, ISSN: 0918-6158;;PACHARINSAK CHOLAWAT ET AL: ""Animal models of cancer pain."", COMPARATIVE MEDICINE JUN 2008, vol. 58, no. 3, June 2008 (2008-06-01), pages 220 - 233, XP002567074, ISSN: 1532-0820;;KIRCHMAIR RUDOLF ET AL: ""Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF"", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 15, no. 1, 1 January 2007 (2007-01-01), pages 69 - 75, XP002588572, ISSN: 1525-0024, DOI: DOI:10.1038/SJ.MT.6300019;;CHAUDHRY V ET AL: ""77. Bortezomib and thalidomide-induced subacute demyelinating polyneuropathy"", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE, IE, vol. 120, no. 2, 1 February 2009 (2009-02-01), pages E111, XP025912377, ISSN: 1388-2457, [retrieved on 20090201], DOI: DOI:10.1016/J.CLINPH.2008.10.095;;POLOMANO; BENNETT, PAIN MED., vol. 2, no. 1, 2001, pages 8 - 14;;PARK ET AL., CURR. MED. CHEM, vol. 15, no. 29, 2008, pages 3081 - 94;;QUASTHOFF; HARTUNG, J. NEUROL., vol. 249, no. 1, 2002, pages 9 - 17;;ALBERTS ET AL., ANTICANCER DRUGS, vol. 6, no. 3, 1995, pages 369 - 83;;POSTMA ET AL., ANN. ONCOL., vol. 6, no. 5, 1995, pages 489 - 94;;FORSYTH ET AL., J. NEUROONCOL., vol. 35, no. 1, 1997, pages 47 - 53;;MIELKE ET AL., EUR. J. CANCER, vol. 42, no. 1, 2006, pages 24 - 30;;PARK ET AL., CURR. MED. CHEM., vol. 15, no. 29, 2008, pages 3081 - 94;;ARGYRIOU ET AL., BLOOD, vol. 112, no. 5, 2008, pages 1593 - 9;;WOLF ET AL., EUR. J. CANCER, vol. 44, no. 11, 2008, pages 1507 - 15;;ROWINSKY ET AL., SEMIN. ONCOL., vol. 29 4, no. 3, 1993, pages 1 - 15;;ROWINSKY ET AL., J. CLIN. ONCOL., vol. 11, no. 10, 1993, pages 2010 - 20;;WASSERHEIT ET AL., J. CLIN. ONCOL., vol. 14, no. 7, 1996, pages 1993 - 9;;GORDON ET AL., J. CLIN. ONCOL., vol. 15, no. 5, 1997, pages 1965 - 73;;CHAUDHRY ET AL., ANN. NEUROL., vol. 35, no. 3, 1994, pages 304 - 11;;DOUGHERTY ET AL., PAIN, vol. 109, no. 1-2, 2004, pages 132 - 42;;CERSOSIMO RJ., ANN. PHARMACOTHER., vol. 39, no. 1, 2005, pages 128 - 135;;NIETO ET AL., PAIN, vol. 137, no. 3, 2008, pages 520 - 31",PENDING
366,AU,A1,AU 2010/283761 A1,010-896-922-843-678,2012-03-08,2012,AU 2010/283761 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/010-896-922-843-678,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,INACTIVE
367,AU,B2,AU 2009/217031 B2,089-362-001-456-876,2013-12-19,2013,AU 2009/217031 A,2009-02-17,EP 08384001 A;;EP 08008682 A;;EP 2009001109 W,2008-02-18,Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,ESTEVE LABOR DR,ZAMANILLO-CASTANEDO DANIEL;;BAEYENS-CABRERA JOSE MANUEL;;VELA-HERNANDEZ JOSE-MIGUEL;;NIETO-LOPEZ FRANCISCO RAFAEL;;BUSCHMANN HELMUT H,,https://lens.org/089-362-001-456-876,Granted Patent,no,2,0,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/495;;A61P25/02;;A61P29/02,,0,0,,,,INACTIVE
368,IN,A,IN 2149DEN2012 A,163-197-850-821-757,2015-08-07,2015,IN 2149DEN2012 A,2012-03-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,"""SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY""","The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/163-197-850-821-757,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/537;;A61K33/243,,0,0,,,,PENDING
369,HU,T2,HU E025642 T2,192-986-240-387-15X,2016-04-28,2016,HU E10744560 A,2010-08-12,EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO- CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/192-986-240-387-15X,Amended Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,PENDING
370,US,A1,US 2011/0052723 A1,174-061-113-067-797,2011-03-03,2011,US 73582409 A,2009-02-17,EP 08384001 A;;EP 08008682 A;;EP 2009001109 W,2008-02-18,USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA-HERNANDEZ JOSE-MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA-HERNANDEZ JOSE-MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,LABORATORIOS DEL DR. ESTEVE S.A (2010-10-15),https://lens.org/174-061-113-067-797,Patent Application,yes,3,9,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/495;;A61K33/24;;A61P25/00;;A61P25/02;;A61P29/02,424/649;;514/252.12,3,3,064-612-482-967-125;;063-839-553-564-236;;024-044-021-710-067,10.1016/0091-3057(95)00085-b;;7501662;;16820527;;10.1093/ageing/afl090;;15102312;;10.1046/j.1526-4637.2001.002001008.x,"Kest et. al., Pharmacology Biochemistry, and Behavior, 1995, Pergamon, vol. 52, no. 1, pp. 175-178;;Kuloor et. al., Age and Aging, 2006, Oxford University Press, vol. 35, pp. 639-640;;Polomano et. al., Pain Medicine, 2001, Blackwell Science, vol. 2(1), pp. 8-14",DISCONTINUED
371,KR,A,KR 20110008166 A,006-259-645-505-198,2011-01-26,2011,KR 20107020880 A,2009-02-17,EP 08008682 A;;EP 08384001 A,2008-02-18,USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY,,ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO CASTANEDO DANIEL;;NIETO LOPEZ FRANCISCO RAFAEL,,https://lens.org/006-259-645-505-198,Patent Application,no,0,1,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61P25/02;;A61P29/02,,0,0,,,,DISCONTINUED
372,WO,A1,WO 2011/018487 A1,009-545-073-121-231,2011-02-17,2011,EP 2010061720 W,2010-08-12,EP 09382144 A,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR;;BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/009-545-073-121-231,Patent Application,yes,3,13,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,24,22,023-314-960-057-474;;029-464-109-139-398;;043-077-705-511-421;;127-737-008-781-342;;080-964-082-647-80X;;080-975-278-133-871;;024-044-021-710-067;;040-974-495-617-674;;027-908-337-016-973;;015-461-458-759-788;;084-819-015-566-887;;004-035-273-862-921;;073-228-490-035-58X;;065-370-056-423-560;;111-802-677-934-809;;031-480-719-231-230;;025-124-152-392-536;;006-570-780-387-210;;082-817-573-119-019;;032-620-320-110-961;;120-520-383-362-818;;000-839-833-305-962,10.1097/aln.0b013e3181895a83;;18946301;;10.1016/j.pain.2009.05.013;;19505761;;10.1248/bpb.32.732;;19336915;;10.1007/978-1-60761-880-5_8;;10.1038/sj.mt.6300019;;17164777;;10.1016/j.clinph.2008.10.095;;15102312;;10.1046/j.1526-4637.2001.002001008.x;;10.2174/092986708786848569;;19075655;;10.1007/pl00007853;;11954874;;10.1097/00001813-199506000-00003;;7670134;;7669713;;10.1093/oxfordjournals.annonc.a059220;;10.1023/a:1005805907311;;9266440;;10.1016/j.ejca.2005.06.030;;16293411;;18574024;;10.1182/blood-2008-04-149385;;18571399;;10.1016/j.ejca.2008.04.018;;10.1200/jco.1993.11.10.2010;;7692001;;10.1200/jco.1996.14.7.1993;;8683229;;10.1200/jco.1997.15.5.1965;;9164208;;7907208;;10.1002/ana.410350310;;15082135;;10.1016/j.pain.2004.01.021;;15590869;;10.1345/aph.1e319;;10.1016/j.pain.2007.10.012;;18037242,"ROH D-H ET AL: ""Intrathecal injection of the [sigma]1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain"", ANESTHESIOLOGY, AMERICAN SOCIETY OF ANESTHESIOLOGISTS, PHILADELPHIA, PA, US, vol. 109, no. 5, 1 January 2008 (2008-01-01), pages 879 - 889, XP009128580, ISSN: 0003-3022;;PUENTE B D L ET AL: ""Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury"", PAIN 2009 ELSEVIER NLD, vol. 145, no. 3, 19 June 2009 (2009-06-19), pages 294 - 303, XP002567072, ISSN: 0304-3959;;GAUCHAN PUNAM ET AL: ""Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit."", BIOLOGICAL & PHARMACEUTICAL BULLETIN APR 2009, vol. 32, no. 4, April 2009 (2009-04-01), pages 732 - 734, XP002567073, ISSN: 0918-6158;;PACHARINSAK CHOLAWAT ET AL: ""Animal models of cancer pain"", COMPARATIVE MEDICINE (MEMPHIS), vol. 58, no. 3, June 2008 (2008-06-01), pages 220 - 233, XP002567074, ISSN: 1532-0820;;KIRCHMAIR RUDOLF ET AL: ""Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF"", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 15, no. 1, 1 January 2007 (2007-01-01), pages 69 - 75, XP002588572, ISSN: 1525-0024, DOI: DOI:10.1038/SJ.MT.6300019;;CHAUDHRY V ET AL: ""77. Bortezomib and thalidomide-induced subacute demyelinating polyneuropathy"", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE, IE, vol. 120, no. 2, 1 February 2009 (2009-02-01), pages E111, XP025912377, ISSN: 1388-2457, [retrieved on 20090201], DOI: DOI:10.1016/J.CLINPH.2008.10.095;;POLOMANO; BENNETT, PAIN MED., vol. 2, no. 1, 2001, pages 8 - 14;;PARK ET AL., CURR. MED. CHEM, vol. 15, no. 29, 2008, pages 3081 - 94;;QUASTHOFF; HARTUNG, J. NEUROL., vol. 249, no. 1, 2002, pages 9 - 17;;ALBERTS ET AL., ANTICANCER DRUGS, vol. 6, no. 3, 1995, pages 369 - 83;;POSTMA ET AL., ANN. ONCOL., vol. 6, no. 5, 1995, pages 489 - 94;;FORSYTH ET AL., J. NEUROONCOL., vol. 35, no. 1, 1997, pages 47 - 53;;MIELKE ET AL., EUR. J. CANCER, vol. 42, no. 1, 2006, pages 24 - 30;;PARK ET AL., CURR. MED. CHEM., vol. 15, no. 29, 2008, pages 3081 - 94;;ARGYRIOU ET AL., BLOOD, vol. 112, no. 5, 2008, pages 1593 - 9;;WOLF ET AL., EUR. J. CANCER, vol. 44, no. 11, 2008, pages 1507 - 15;;ROWINSKY ET AL., SEMIN. ONCOL., vol. 29 4, no. 3, 1993, pages 1 - 15;;ROWINSKY ET AL., J. CLIN. ONCOL., vol. 11, no. 10, 1993, pages 2010 - 20;;WASSERHEIT ET AL., J. CLIN. ONCOL., vol. 14, no. 7, 1996, pages 1993 - 9;;GORDON ET AL., J. CLIN. ONCOL., vol. 15, no. 5, 1997, pages 1965 - 73;;CHAUDHRY ET AL., ANN. NEUROL., vol. 35, no. 3, 1994, pages 304 - 11;;DOUGHERTY ET AL., PAIN, vol. 109, no. 1-2, 2004, pages 132 - 42;;CERSOSIMO RJ., ANN. PHARMACOTHER., vol. 39, no. 1, 2005, pages 128 - 135;;NIETO ET AL., PAIN, vol. 137, no. 3, 2008, pages 520 - 31",PENDING
373,AU,A1,AU 2009/217031 A1,126-915-588-437-435,2009-08-27,2009,AU 2009/217031 A,2009-02-17,EP 08384001 A;;EP 08008682 A;;EP 2009001109 W,2008-02-18,Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy,,ESTEVE LABOR DR,BUSCHMANN HELMUT H;;ZAMANILLO-CASTANEDO DANIEL;;VELA-HERNANDEZ JOSE-MIGUEL;;NIETO-LOPEZ FRANCISCO RAFAEL;;BAEYENS-CABRERA JOSE MANUEL,,https://lens.org/126-915-588-437-435,Patent Application,no,0,0,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/495;;A61P25/02;;A61P29/02,,0,0,,,,INACTIVE
374,KR,A,KR 20150140419 A,173-079-048-002-864,2015-12-15,2015,KR 20157034281 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"본 발명은 화학치료제에 의해 유도되는 통증, 특히 탁산, 빈카 알칼로이드 또는 백금-함유 화학치료 약물에 의해 유도되는 통증을 예방 또는 치료하기 위한 화학식 (I)의 시그마 리간드의 용도에 관한 것이다.",ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO CASTANEDO DANIEL;;NIETO LOPEZ FRANCISCO RAFAEL,,https://lens.org/173-079-048-002-864,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/282;;A61K31/337;;A61K31/4155;;A61K33/243,,0,0,,,,DISCONTINUED
375,EP,A1,EP 2292236 A1,179-172-233-656-40X,2011-03-09,2011,EP 09382144 A,2009-08-14,EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
 ",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/179-172-233-656-40X,Patent Application,yes,4,14,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,38,21,023-314-960-057-474;;029-464-109-139-398;;043-077-705-511-421;;127-737-008-781-342;;024-044-021-710-067;;040-974-495-617-674;;027-908-337-016-973;;015-461-458-759-788;;084-819-015-566-887;;004-035-273-862-921;;073-228-490-035-58X;;065-370-056-423-560;;111-802-677-934-809;;031-480-719-231-230;;025-124-152-392-536;;006-570-780-387-210;;082-817-573-119-019;;032-620-320-110-961;;000-839-833-305-962;;024-044-021-710-067;;106-912-998-040-933,10.1097/aln.0b013e3181895a83;;18946301;;10.1016/j.pain.2009.05.013;;19505761;;10.1248/bpb.32.732;;19336915;;10.1007/978-1-60761-880-5_8;;15102312;;10.1046/j.1526-4637.2001.002001008.x;;10.2174/092986708786848569;;19075655;;10.1007/pl00007853;;11954874;;10.1097/00001813-199506000-00003;;7670134;;7669713;;10.1093/oxfordjournals.annonc.a059220;;10.1023/a:1005805907311;;9266440;;10.1016/j.ejca.2005.06.030;;16293411;;18574024;;10.1182/blood-2008-04-149385;;18571399;;10.1016/j.ejca.2008.04.018;;10.1200/jco.1993.11.10.2010;;7692001;;10.1200/jco.1996.14.7.1993;;8683229;;10.1200/jco.1997.15.5.1965;;9164208;;7907208;;10.1002/ana.410350310;;15082135;;10.1016/j.pain.2004.01.021;;10.1016/j.pain.2007.10.012;;18037242;;15102312;;10.1046/j.1526-4637.2001.002001008.x;;10.1016/j.lfs.2004.01.002;;15041441,"ROH D-H ET AL: ""Intrathecal injection of the [sigma]1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain"", ANESTHESIOLOGY, AMERICAN SOCIETY OF ANESTHESIOLOGISTS, PHILADELPHIA, PA, US, vol. 109, no. 5, 1 January 2008 (2008-01-01), pages 879 - 889, XP009128580, ISSN: 0003-3022;;PUENTE B D L ET AL: ""Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury"", PAIN 2009 ELSEVIER NLD, vol. 145, no. 3, 19 June 2009 (2009-06-19), pages 294 - 303, XP002567072, ISSN: 0304-3959;;GAUCHAN PUNAM ET AL: ""Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit."", BIOLOGICAL & PHARMACEUTICAL BULLETIN APR 2009, vol. 32, no. 4, April 2009 (2009-04-01), pages 732 - 734, XP002567073, ISSN: 0918-6158;;PACHARINSAK CHOLAWAT ET AL: ""Animal models of cancer pain"", COMPARATIVE MEDICINE (MEMPHIS), vol. 58, no. 3, June 2008 (2008-06-01), pages 220 - 233, XP002567074, ISSN: 1532-0820;;""Classification of chronic pain"", 2002, IASP PRESS, article ""an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage"", pages: 210;;POLOMANO; BENNETT, PAIN MED., vol. 2, no. 1, 2001, pages 8 - 14;;PARK ET AL., CURR. MED. CHEM, vol. 15, no. 29, 2008, pages 3081 - 94;;QUASTHOFF; HARTUNG, J. NEUROL., vol. 249, no. 1, 2002, pages 9 - 17;;ALBERTS ET AL., ANTICANCER DRUGS, vol. 6, no. 3, 1995, pages 369 - 83;;POSTMA ET AL., ANN. ONCOL., vol. 6, no. 5, 1995, pages 489 - 94;;FORSYTH ET AL., J. NEUROONCOL., vol. 35, no. 1, 1997, pages 47 - 53;;MIELKE ET AL., EUR. J. CANCER, vol. 42, no. 1, 2006, pages 24 - 30;;PARK ET AL., CURR. MED. CHEM., vol. 15, no. 29, 2008, pages 3081 - 94;;ARGYRIOU ET AL., BLOOD, vol. 112, no. 5, 2008, pages 1593 - 9;;WOLF ET AL., EUR. J. CANCER, vol. 44, no. 11, 2008, pages 1507 - 15;;BURGER: ""Medicinal Chemistry and Drug Discovery"", 2001, WILEY;;""Design and Applications of Prodrugs"", 1985, HARWOOD ACADEMIC PUBLISHERS;;ROWINSKY ET AL., SEMIN. ONCOL., vol. 29, 1993, pages 1 - 15;;ROWINSKY ET AL., J. CLIN. ONCOL., vol. 11, no. 10, 1993, pages 2010 - 20;;WASSERHEIT ET AL., J. CLIN. ONCOL., vol. 14, no. 7, 1996, pages 1993 - 9;;GORDON ET AL., J. CLIN. ONCOL., vol. 15, no. 5, 1997, pages 1965 - 73;;ROWINSKY ET AL., SEMIN. ONCOL., vol. 29, no. 3, 1993, pages 1 - 15;;CHAUDHRY ET AL., ANN. NEUROL., vol. 35, no. 3, 1994, pages 304 - 11;;DOUGHERTY ET AL., PAIN, vol. 109, no. 1-2, 2004, pages 132 - 42;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""pain initiated or caused by a primary lesion or dysfunction in the nervous system"", pages: 210;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""a pain due to a stimulus which does not normally provoke pain"", pages: 210;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""a pain initiated or caused by a primary lesion, dysfunction or transitory perturbation in the peripheral nervous system"", pages: 213;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""a syndrome of sustained burning pain, allodynia and hyperpathia after a traumatic nerve lesion, often combined with vasomotor and sudomotor dysfunction and later trophic changes"", pages: 210;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""an increased response to a stimulus which is normally painful"", pages: 211;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""increased sensitivity to stimulation, excluding the senses"", pages: 211;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""a painful syndrome characterized by an abnormally painful reaction to a stimulus, especially a repetitive stimulus, as well as an increased threshold"", pages: 212;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""hyperalgesia"" and ""hyperpathia"", pages: 212;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""pain in the distribution of a nerve or nerves"", pages: 212;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""inflammation of a nerve or nerves"", pages: 212;;""IASP, Classification of chronic pain"", 2002, IASP PRESS, article ""a disturbance of function or pathological change in a nerve: in one nerve mononeuropathy, in several nerves mononeuropthy multiplex, if diffuse and bilateral, polyneuropathy"", pages: 212;;NIETO ET AL., PAIN, vol. 137, no. 3, 2008, pages 520 - 31;;POLOMANO ET AL., PAIN MED., vol. 2, no. 1, 2001, pages 8 - 14;;SMITH ET AL., LIFE SCI., vol. 74, no. 21, 2004, pages 2593 - 604",DISCONTINUED
376,CO,A2,CO 6511240 A2,190-636-874-334-540,2012-08-31,2012,CO 12044528 A,2012-03-14,EP 09382144 A,2009-08-14,LIGANDOS SIGMA PARA LA PREVENCIÓN O EL TRATAMIENTO DE DOLOR INDUCIDO POR QUIMIOTERAPIA,"La invención se refiere al uso de un ligando sigma de fórmula (l) para prevenir o tratar dolor inducido por un agente quimioterápico, especialmente dolor inducido por taxanos, alcaloides de la vinca o fármacos quimioterápicos de platino.",ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO LOPEZ FRANCISCO RAFAEL,,https://lens.org/190-636-874-334-540,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,DISCONTINUED
377,SM,T1,SM T201500189 T1,196-235-461-059-510,2015-09-07,2015,SM 201500189 T,2015-08-05,EP 2010061720 W;;EP 10755460 A;;EP 09382144 A,2009-08-14,Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSHCMANN HELMUT HEINRICH;;BELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/196-235-461-059-510,Granted Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243,,0,0,,,,ACTIVE
378,MX,A,MX 2010009026 A,195-194-105-494-298,2010-09-24,2010,MX 2010009026 A,2009-02-17,EP 08384001 A;;EP 08008682 A;;EP 2009001109 W,2008-02-18,USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY.,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,ESTEVE LABOR DR,BUSCHMANN HELMUT H;;ZAMANILLO-CASTANEDO DANIEL;;BAEYENS-CABRERA JOSE MANUEL;;VELA-HERNANDEZ JOSE-MIGUEL;;NIETO-LOPEZ FRANCISCO RAFAEL,,https://lens.org/195-194-105-494-298,Patent Application,no,0,0,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61P25/02;;A61K31/495;;A61P29/02,,0,0,,,,ACTIVE
379,AU,B2,AU 2010/283761 B2,036-463-748-824-315,2016-10-13,2016,AU 2010/283761 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/036-463-748-824-315,Granted Patent,no,1,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,2,2,023-314-960-057-474;;029-464-109-139-398,10.1097/aln.0b013e3181895a83;;18946301;;10.1016/j.pain.2009.05.013;;19505761,"ROH, D.-H. et al., Anesthesiology (2008) Vol.109 No.5, pages 879-889;;DE LA PUENTE, B. et al. ""Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury"" PAIN (2009) Vol.145 No.3 pages 294 to 303",INACTIVE
380,ES,A1,ES 2388253 A1,110-330-316-844-614,2012-10-11,2012,ES 201290006 A,2010-08-12,EP 09382145 A;;EP 2010061724 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treatpain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum derivatives chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,"ESTEVE PHARMACEUTICALS, S.A. (2018-10-16)",https://lens.org/110-330-316-844-614,Patent Application,no,1,0,4,4,0,A61K31/337;;A61K31/5377;;A61K45/06;;A61K31/5377;;A61P25/02,A61K31/5377;;A61K31/337;;A61P25/02,,5,2,023-314-960-057-474;;085-872-310-203-674,10.1097/aln.0b013e3181895a83;;18946301;;16892345;;10.1002/cmdc.200500034,"ROH, D.H. ET AL.:""Intracathecal injection of the (sigma 1) rec eptor antagonist BD1047 bolocks both mechanical allodynia and increases in spinal NR! expression during the induction phase of rodent neuropathic pain"". Anesthesiology, 2008, vol. 109, páginas 879-889, página 888, columna izquierda, párrafo 1, resumen conclusiones;;PACHARINSAK, CH. ET AL.:""Animal models of cancer pain"". Comparative Medicine, 2008,vol. 58, nº 3, páginas 220-233, página 226, columna derecha, párrafo 4, página 228, columna izquierda, párrafo 3;;CORBERA, J. ET AL.:""A medicinal chemistry guided approach to selective and gruglike sigma 1 ligands"". Chemical Medical Chemistry, 2006, vol. 1, páginas 140-154, página 143, fórmula 7f, página 147, columna derecha, párrafo 1.;;GAUCHAN, P. ET AL.:""Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectivenesss of gabapentin and different expression of voltage-dependent calcium channel alfa (2) delta-1 subunit"". Biological and pharmaceutical bulletin, 2009, vol. 32, nº 4, páginas 732-734, página 734, columna derecha , párrafo 3.;;KIRCHMAIR, R. ET AL.:""Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol and thalidomide induced injury of casa nervorum is ameliorated by VEGF"". Molecular Therapy, 2007, vol. 15, nº 1, páginas 69-75, resumen.",INACTIVE
381,ES,B1,ES 2388253 B1,063-693-815-959-686,2013-06-13,2013,ES 201290006 A,2010-08-12,EP 09382145 A;;EP 2010061724 W,2009-08-14,Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,"ESTEVE PHARMACEUTICALS, S.A. (2018-10-16)",https://lens.org/063-693-815-959-686,Granted Patent,no,0,0,4,4,0,A61K31/337;;A61K31/5377;;A61K45/06;;A61K31/5377;;A61P25/02,A61K31/5377;;A61K31/337;;A61P25/02,,0,0,,,,INACTIVE
382,MX,A,MX 2012001877 A,076-466-067-712-451,2012-04-11,2012,MX 2012001877 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY.,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BUSCHMANN HELMUT HEINRICH;;ZAMANILLO-CASTANEDO DANIEL;;BAEYENS-CABRERA JOSE MANUEL;;HERNANDEZ JOSE MIGUEL VELA;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/076-466-067-712-451,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,ACTIVE
383,EP,A1,EP 2292237 A1,115-916-234-098-566,2011-03-09,2011,EP 09382145 A,2009-08-14,EP 09382145 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum derivatives chemotherapeutic drugs.
 ",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/115-916-234-098-566,Patent Application,yes,3,4,4,4,0,A61K31/337;;A61K31/5377;;A61K45/06;;A61K31/5377;;A61P25/02,A61K31/5377;;A61K45/06;;A61P25/02,,36,19,085-872-310-203-674;;023-314-960-057-474;;043-077-705-511-421;;127-737-008-781-342;;024-044-021-710-067;;040-974-495-617-674;;027-908-337-016-973;;015-461-458-759-788;;084-819-015-566-887;;004-035-273-862-921;;073-228-490-035-58X;;065-370-056-423-560;;111-802-677-934-809;;031-480-719-231-230;;025-124-152-392-536;;006-570-780-387-210;;082-817-573-119-019;;032-620-320-110-961;;106-912-998-040-933,16892345;;10.1002/cmdc.200500034;;10.1097/aln.0b013e3181895a83;;18946301;;10.1248/bpb.32.732;;19336915;;10.1007/978-1-60761-880-5_8;;15102312;;10.1046/j.1526-4637.2001.002001008.x;;10.2174/092986708786848569;;19075655;;10.1007/pl00007853;;11954874;;10.1097/00001813-199506000-00003;;7670134;;7669713;;10.1093/oxfordjournals.annonc.a059220;;10.1023/a:1005805907311;;9266440;;10.1016/j.ejca.2005.06.030;;16293411;;18574024;;10.1182/blood-2008-04-149385;;18571399;;10.1016/j.ejca.2008.04.018;;10.1200/jco.1993.11.10.2010;;7692001;;10.1200/jco.1996.14.7.1993;;8683229;;10.1200/jco.1997.15.5.1965;;9164208;;7907208;;10.1002/ana.410350310;;15082135;;10.1016/j.pain.2004.01.021;;10.1016/j.lfs.2004.01.002;;15041441,"CORBERA JORDI ET AL: ""A medicinal-chemistry-guided approach to selective and druglike sigma 1 ligands."", CHEMMEDCHEM JAN 2006, vol. 1, no. 1, January 2006 (2006-01-01), pages 140 - 154, XP002567219, ISSN: 1860-7179;;ROH D-H ET AL: ""Intrathecal injection of the [sigma]1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain"", ANESTHESIOLOGY, AMERICAN SOCIETY OF ANESTHESIOLOGISTS, PHILADELPHIA, PA, US, vol. 109, no. 5, 1 January 2008 (2008-01-01), pages 879 - 889, XP009128580, ISSN: 0003-3022;;GAUCHAN PUNAM ET AL: ""Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit."", BIOLOGICAL & PHARMACEUTICAL BULLETIN APR 2009, vol. 32, no. 4, April 2009 (2009-04-01), pages 732 - 734, XP002567073, ISSN: 0918-6158;;PACHARINSAK CHOLAWAT ET AL: ""Animal models of cancer pain."", COMPARATIVE MEDICINE JUN 2008, vol. 58, no. 3, June 2008 (2008-06-01), pages 220 - 233, XP002567074, ISSN: 1532-0820;;""Classification of chronic pain"", 2002, IASP PRESS, article ""an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage"", pages: 210;;POLOMANO; BENNETT, PAIN MED., vol. 2, no. 1, 2001, pages 8 - 14;;PARK ET AL., CURR. MED. CHEM, vol. 15, no. 29, 2008, pages 3081 - 94;;QUASTHOFF; HARTUNG, J. NEUROL., vol. 249, no. 1, 2002, pages 9 - 17;;ALBERTS ET AL., ANTICANCER DRUGS, vol. 6, no. 3, 1995, pages 369 - 83;;POSTMA ET AL., ANN. ONCOL., vol. 6, no. 5, 1995, pages 489 - 94;;FORSYTH ET AL., J. NEUROONCOL., vol. 35, no. 1, 1997, pages 47 - 53;;MIELKE ET AL., EUR. J. CANCER, vol. 42, no. 1, 2006, pages 24 - 30;;PARK ET AL., CURR. MED. CHEM., vol. 15, no. 29, 2008, pages 3081 - 94;;ARGYRIOU ET AL., BLOOD, vol. 112, no. 5, 2008, pages 1593 - 9;;WOLF ET AL., EUR. J. CANCER, vol. 44, no. 11, 2008, pages 1507 - 15;;BURGER: ""Medicinal Chemistry and Drug Discovery"", 2001, WILEY, article ""Medicinal Chemistry and Drug Discovery"";;""Design and Applications of Prodrugs"", 1985, HARWOOD ACADEMIC PUBLISHERS;;ROWINSKY ET AL., SEMIN. ONCOL., vol. 29 4, no. 3, 1993, pages 1 - 15;;ROWINSKY ET AL., J. CLIN. ONCOL., vol. 11, no. 10, 1993, pages 2010 - 20;;WASSERHEIT ET AL., J. CLIN. ONCOL., vol. 14, no. 7, 1996, pages 1993 - 9;;GORDON ET AL., J. CLIN. ONCOL., vol. 15, no. 5, 1997, pages 1965 - 73;;ROWINSKY ET AL., SEMIN. ONCOL., vol. 29, 1993, pages 1 - 15;;CHAUDHRY ET AL., ANN. NEUROL., vol. 35, no. 3, 1994, pages 304 - 11;;DOUGHERTY ET AL., PAIN, vol. 109, no. 1-2, 2004, pages 132 - 42;;""Classification of chronic pain"", 2002, IASP PRESS, article ""Neuropathic pain"" is defined by the IASP as ""pain initiated or caused by a primary lesion or dysfunction in the nervous system"", pages: 210;;""Classification of chronic pain"", 2002, IASP PRESS, article ""a pain due to a stimulus which does not normally provoke pain"", pages: 210;;""Classification of chronic pain"", 2002, IASP PRESS, article ""a pain initiated or caused by a primary lesion, dysfunction or transitory perturbation in the peripheral nervous system"", pages: 213;;""Classification of chronic pain"", 2002, IASP PRESS, article ""a syndrome of sustained burning pain, allodynia and hyperpathia after a traumatic nerve lesion, often combined with vasomotor and sudomotor dysfunction and later trophic changes"", pages: 210;;""Classification of chronic pain"", 2002, IASP PRESS, article ""an increased response to a stimulus which is normally painful"", pages: 211;;""Classification of chronic pain"", 2002, IASP PRESS, article ""increased sensitivity to stimulation, excluding the senses"", pages: 211;;""Classification of chronic pain"", 2002, IASP PRESS, article ""a painful syndrome characterized by an abnormally painful reaction to a stimulus, especially a repetitive stimulus, as well as an increased threshold"", pages: 212;;""Classification of chronic pain"", 2002, IASP PRESS, article ""hyperalgesia"" and ""hyperpathia"", pages: 212;;""Classification of chronic pain"", 2002, IASP PRESS, article ""pain in the distribution of a nerve or nerves"", pages: 212;;""Classification of chronic pain"", 2002, IASP PRESS, article ""inflammation of a nerve or nerves"", pages: 212;;""Classification of chronic pain"", 2002, IASP PRESS, article ""a disturbance of function or pathological change in a nerve: in one nerve mononeuropathy, in several nerves mononeuropthy multiplex, if diffuse and bilateral, polyneuropathy"", pages: 212;;SMITH ET AL., LIFE SCI., vol. 74, no. 21, 2004, pages 2593 - 604",DISCONTINUED
384,CN,A,CN 102497864 A,156-741-393-260-036,2012-06-13,2012,CN 201080036098 A,2010-08-12,EP 2010061720 W;;EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,MANUEL BAEYENS-CABRERA JOSE;;HEINRICH BUSCHMANN HELMUT;;MIGUEL VELA HERNANDEZ JOSE;;DANIEL ZAMANILLO-CASTANEDO;;FRANCISCO-RAFAEL NIETO-LOPEZ,,https://lens.org/156-741-393-260-036,Patent Application,no,2,2,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,4,0,,,"《ANESTHESIOLOGY》 20081130 ROH D-H et al Intrathecal injection of the sigma1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain 879-889 1-19 第109卷, 第5期;;ROH D-H ET AL: ""Intrathecal injection of the σ1 receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain"", 《ANESTHESIOLOGY》, vol. 109, no. 5, 30 November 2008 (2008-11-30), pages 879 - 889, XP009128580, DOI: 10.1097/ALN.0b013e3181895a83;;李大鹏: ""胶质细胞在化疗所致神经病理性疼痛发病机制中的应用"", 《华中科技大学硕士学位论文》, vol. 2006, 19 February 2008 (2008-02-19), pages 24;;李旭英: ""如何应对化疗副作用"", 《大众卫生报》, 21 February 2006 (2006-02-21), pages 003",ACTIVE
385,EP,A1,EP 2249399 A1,114-979-829-452-837,2010-11-10,2010,EP 08736706 A,2008-02-25,ES 2008000104 W,2008-02-25,PHOTOVOLTAIC CONCENTRATION MODULE AND DEVICE,"The invention relates to a photovoltaic concentration module and device. The device includes: a primary lens (10) configured to concentrate incident solar radiation and to generate a first concentrated radiation; a solar cell (30) configured to collect the first concentrated radiation; and a substrate (40) enabling the electrical connection and thermal dissipation of the solar cell, whereby the solar cell (30) and the substrate (40) are :Mectrically associated so as to form an electric power generation unit. The photovoltaic concentration module includes a series of the aforementioned devices.",ISOFOTON,DIAZ LUQUE VICENTE;;CABRERA GODOY JAVIER;;EXPOSITO CORRAL DAVID;;ALVARES RICO JOSE LUIS,,https://lens.org/114-979-829-452-837,Patent Application,yes,0,2,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/052,,0,0,,,,DISCONTINUED
386,CN,A,CN 116157166 A,016-668-772-261-624,2023-05-23,2023,CN 202180053086 A,2021-07-26,US 202063059264 P;;US 2021/0043228 W,2020-07-31,"Method for preventing, reducing or delaying fatty liver disease","A method of reducing or delaying the onset of fatty liver disease in a subject, the method comprising enterally administering to a subject in need thereof at least one human milk oligosaccharide (HMO) in an amount effective to reduce liver lipid accumulation. In one particular embodiment, the at least one HMO is administered in an amount effective to reduce de novo adipogenesis in the subject. The at least one HMO may be administered to the subject either directly or in a nutritional composition.",ABBOTT LAB,MANZANO MARIO;;HERNANDEZ ENRIQUE;;LOPEZ PEDROSA JOSE MANUEL;;RUEDA CABRERA RICARDO;;BUCK REINER,,https://lens.org/016-668-772-261-624,Patent Application,no,0,0,7,7,0,A61K31/702;;A61K45/06;;A61P1/16;;A61P3/10;;A61P5/14;;A61P3/06;;A61P1/16;;A61P3/06;;A61K9/0053;;A61K31/702;;A61K45/06,A61L33/12,,0,0,,,,DISCONTINUED
387,US,A1,US 2011/0048500 A1,052-554-447-254-949,2011-03-03,2011,US 91911608 A,2008-02-25,ES 2008000104 W,2008-02-25,PHOTOVOLTAIC CONCENTRATION MODULE AND DEVICE,"The invention relates to a photovoltaic concentration module and device. The device includes: a primary lens ( 10 ) configured to concentrate incident solar radiation and to generate a first concentrated radiation; a solar cell ( 30 ) configured to collect the first concentrated radiation; and a substrate ( 40 ) enabling the electrical connection and thermal dissipation of the solar cell, whereby the solar cell ( 30 ) and the substrate ( 40 ) are electrically associated so as to form an electric power generation unit. The photovoltaic concentration module includes a series of the aforementioned devices.",ISOFOTON,DIAZ LUQUE VICENTE;;CABRERA GODOY JAVIER;;CORRAL EXPOSITO DAVID;;ALVARES RICO JOSE LUIS,ISOFOTON (2010-08-19),https://lens.org/052-554-447-254-949,Patent Application,yes,4,0,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/0232;;H01L31/052,136/246;;136/259;;X257E31127,0,0,,,,DISCONTINUED
388,US,A1,US 2018/0042326 A1,179-183-147-245-86X,2018-02-15,2018,US 201615380907 A,2016-12-15,US 201615380907 A;;US 201662375240 P,2016-08-15,MECHANICALLY-ACTIVATED SHOCK ABATEMENT SYSTEM AND METHOD,"Aspects of the subject disclosure may include, for example, a process in which a helmet system including a machine is provided, that when worn by a user, positions the machine in a proximate relationship to a head portion, a neck portion, or both of the user. The helmet system provides a redistributing of a force responsive to a collision received along a first direction, wherein the force results from kinetic energy of an impact encountered at an external surface of the helmet system. The force induces an actuation of the machine, wherein the redistributing of the received collision force is based on the actuation of the machine. Energy transferred to the head portion, the neck portion, or both, resulting from the kinetic energy of the impact, is reduced, e.g., absorbed, based on the actuation of the machine. Other embodiments are disclosed.",TITON CORP,MINI TOWNSON JUAN FRANCISCO JAVIER;;ARAGÓN CABRERA JOSE RODRIGO;;ALFARO SAMAYOA JUAN PABLO,TITON CORP (2016-12-15);;TOWNSON JUAN FRANCISCO JAVIER MINI (2019-08-20);;TITON IDEAS INC (2019-09-26),https://lens.org/179-183-147-245-86X,Patent Application,yes,0,4,11,11,0,A42B3/064;;A42B3/125;;A42B3/14;;A42B3/125;;A42B3/063;;A42B3/064;;A42B3/121;;F16F13/005;;A42B3/046,A42B3/04;;A42B3/06;;A42B3/12;;A42B3/14,,0,0,,,,ACTIVE
389,TW,A,TW 201121959 A,001-908-610-597-438,2011-07-01,2011,TW 99126632 A,2010-08-10,EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/001-908-610-597-438,Patent of Addition,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,C07D413/12;;A61K31/5377;;A61K33/243;;A61P29/00;;C07D413/06,,0,0,,,,INACTIVE
390,KR,A,KR 20170125951 A,067-994-227-206-842,2017-11-15,2017,KR 20177028558 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"본 발명은 화학치료제에 의해 유도되는 통증, 특히 탁산, 빈카 알칼로이드 또는 백금-함유 화학치료 약물에 의해 유도되는 통증을 예방 또는 치료하기 위한 화학식 (I)의 시그마 리간드의 용도에 관한 것이다.",ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO CASTANEDO DANIEL;;NIETO LOPEZ FRANCISCO RAFAEL,,https://lens.org/067-994-227-206-842,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K33/243;;A61K45/06,,0,0,,,,DISCONTINUED
391,WO,A1,WO 2009/103487 A1,096-650-606-636-546,2009-08-27,2009,EP 2009001109 W,2009-02-17,EP 08384001 A;;EP 08008682 A,2008-02-18,USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,ESTEVE LABOR DR;;BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA-HERNANDEZ JOSE-MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA-HERNANDEZ JOSE-MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,,https://lens.org/096-650-606-636-546,Patent Application,yes,4,21,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/495;;A61P25/02;;A61P29/02,,2,1,012-158-489-880-352,10.1097/00002820-200603002-00015,"POLOMANO R C ET AL: ""Pain and neuropathy in cancer survivors: Surgery, radiation, and chemotherapy can cause pain; research could improve its detection and treatment"", CANCER NURSING, LIPPINCOTT-RAVEN PUB., HAGERSTOWN, MD, US, vol. 29, no. 2, suppl, 1 March 2006 (2006-03-01), pages 39 - 47, XP009107315, ISSN: 0162-220X;;""Chemotherapy at home, pain and its treatment"", SOINS, OFFICE DE PUBLICITE GENERALE, PARIS, FR, no. 528, 1 September 1989 (1989-09-01), pages 17 - 20, XP009107313, ISSN: 0038-0814",PENDING
392,CA,C,CA 2770441 C,108-366-924-527-308,2017-12-12,2017,CA 2770441 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/108-366-924-527-308,Granted Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,INACTIVE
393,KR,A,KR 20120055692 A,144-356-604-607-727,2012-05-31,2012,KR 20127006715 A,2010-08-12,EP 09382144 A,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,,ESTEVE LABOR DR,BAEYENS CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO CASTANEDO DANIEL;;NIETO LOPEZ FRANCISCO RAFAEL,,https://lens.org/144-356-604-607-727,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,INACTIVE
394,TW,B,TW I529168 B,161-752-917-592-117,2016-04-11,2016,TW 99126632 A,2010-08-10,EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/161-752-917-592-117,Granted Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K33/243,,0,0,,,,INACTIVE
395,CA,A1,CA 2712640 A1,012-381-252-864-524,2009-08-27,2009,CA 2712640 A,2009-02-17,EP 08384001 A;;EP 08008682 A;;EP 2009001109 W,2008-02-18,USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY,The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT H;;VELA-HERNANDEZ JOSE-MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO RAFAEL,,https://lens.org/012-381-252-864-524,Patent Application,no,0,0,21,22,0,A61K31/137;;A61K31/40;;A61K31/445;;A61K31/4453;;A61K31/451;;A61K31/4515;;A61K31/454;;A61K31/46;;A61K31/5415;;A61K31/495;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/02;;A61K31/454;;A61K31/4453;;A61K31/46;;A61K31/445;;A61K31/40;;A61K31/137;;A61K31/5415;;A61K31/451;;A61K31/4515;;A61K31/495,A61K31/495;;A61P25/02;;A61P29/02,,0,0,,,,DISCONTINUED
396,WO,A1,WO 2009/106648 A1,117-008-719-467-306,2009-09-03,2009,ES 2008000104 W,2008-02-25,ES 2008000104 W,2008-02-25,PHOTOVOLTAIC CONCENTRATION MODULE AND DEVICE,"The invention relates to a photovoltaic concentration module and device. The device includes: a primary lens (10) configured to concentrate incident solar radiation and to generate a first concentrated radiation; a solar cell (30) configured to collect the first concentrated radiation; and a substrate (40) enabling the electrical connection and thermal dissipation of the solar cell, whereby the solar cell (30) and the substrate (40) are electrically associated so as to form an electric power generation unit. The photovoltaic concentration module includes a series of the aforementioned devices.",ISOFOTON;;DIAZ LUQUE VICENTE;;CABRERA GODOY JAVIER;;EXPOSITO CORRAL DAVID;;ALVARES RICO JOSE LUIS,DIAZ LUQUE VICENTE;;CABRERA GODOY JAVIER;;EXPOSITO CORRAL DAVID;;ALVARES RICO JOSE LUIS,,https://lens.org/117-008-719-467-306,Patent Application,yes,6,1,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/052,,0,0,,,,PENDING
397,EP,A1,EP 2499106 A1,005-431-204-628-382,2012-09-19,2012,EP 10781604 A,2010-11-02,ES 200902211 A;;EP 2010006661 W,2009-11-13,COATED CERAMIC BODIES AND PROCESS FOR OBTAINING COATED CERAMIC BODIES,,VIDRES S A,CABRERA IBANEZ MARIA JOSE;;SOLSONA MONZONIS DANIEL;;MONTINS NEBOT VICTOR;;MARTI SIDRO VICTOR,,https://lens.org/005-431-204-628-382,Patent Application,yes,0,1,4,4,0,C03C8/00;;C04B41/85;;C04B41/5023;;C03C3/062;;C03C8/02;;C03C10/00;;C04B41/009;;C04B41/86;;C04B2111/0025;;C04B2111/82,C04B41/50;;C03C8/02;;C03C10/00;;C04B41/86,,1,0,,,See references of WO 2011057730A1,DISCONTINUED
398,WO,A1,WO 2019/073425 A1,034-111-112-155-804,2019-04-18,2019,IB 2018057871 W,2018-10-11,US 201762572409 P,2017-10-13,FLUID-ACTUATED IMPACT PROTECTION SYSTEM AND METHOD,"The subject disclosure describes, among other things, illustrative embodiments of an impact protection device that comprises the following elements: a machine, a protective structural member, and a fluid holding member. The impact protection device is designed to protect a user from an impact to the protective structural member by dissipating a portion of the kinetic energy of the impact. Machine operation translates into a controlled movement between elements of the impact protection device that deform the fluid holding member, thereby displacing a fluid. This controlled movement also dictates a throttling profile that regulates the amount of damping; thereby managing the portion of kinetic energy dissipated. The machine can be a mechanical assembly incorporating levers, cams and or computerized controllers.",TITON CORP S A,MINI TOWNSON JUAN FRANCISCO JAVIER;;ARAGON CABRERA JOSE RODRIGO;;ALFARO SAMAYOA JUAN PABLO,,https://lens.org/034-111-112-155-804,Patent Application,yes,10,0,3,3,0,A42B3/121;;F16F13/10;;F41H1/02;;F41H1/04;;F41H5/013;;F41H5/08;;F16F9/049;;A41D13/015;;A42B3/121;;F41H1/02;;F41H1/04;;F41H5/013,A42B3/12;;A42B3/00;;F16F9/00;;F16F13/10;;F41H1/00;;F41H5/00,,0,0,,,,PENDING
399,AU,A1,AU 2008/351529 A1,022-489-143-139-849,2009-09-03,2009,AU 2008/351529 A,2008-02-25,ES 2008000104 W,2008-02-25,Photovoltaic concentration module and device,,ISOFOTON,LUQUE VICENTE DIAZ;;GODOY JAVIER CABRERA;;CORRAL DAVID EXPOSITO;;RICO JOSE LUIS ALVARES,,https://lens.org/022-489-143-139-849,Patent Application,no,0,0,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/052,,0,0,,,,DISCONTINUED
400,CN,B,CN 101981708 B,045-849-104-557-432,2012-08-29,2012,CN 200880128220 A,2008-02-25,ES 2008000104 W,2008-02-25,Photovoltaic concentration module and device,"The invention relates to a photovoltaic concentration module and device. The device includes: a primary lens (10) configured to concentrate incident solar radiation and to generate a first concentrated radiation; a solar cell (30) configured to collect the first concentrated radiation; and a substrate (40) enabling the electrical connection and thermal dissipation of the solar cell, whereby the solar cell (30) and the substrate (40) are electrically associated so as to form an electric power generation unit. The photovoltaic concentration module includes a series of the aforementioned devices.",ISOFOTON,VICENTE DIAZ LUQUE;;JAVIER CABRERA GODOY;;DAVID EXPOSITO CORRAL;;LUIS ALVARES RICO JOSE,,https://lens.org/045-849-104-557-432,Granted Patent,no,0,0,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/052,,0,0,,,,INACTIVE
401,US,A1,US 2018/0042332 A1,051-180-543-263-298,2018-02-15,2018,US 201715669272 A,2017-08-04,US 201715669272 A;;US 201615380967 A;;US 201662375240 P,2016-08-15,LEVER-ACTIVATED SHOCK ABATEMENT SYSTEM AND METHOD,"Aspects of the subject disclosure may include, for example, devices and processes that abate impact shocks by enacting a machine that redirects at least a portion of an impact force imposed along one trajectory to a reaction force distributed along another trajectory. Other embodiments are disclosed.",TITON CORP,MINI TOWNSON JUAN FRANCISCO JAVIER;;ARAGÓN CABRERA JOSE RODRIGO;;ALFARO SAMAYOA JUAN PABLO,TITON CORP (2016-12-15);;TOWNSON JUAN FRANCISCO JAVIER MINI (2019-08-20);;TITON IDEAS INC (2019-09-26),https://lens.org/051-180-543-263-298,Patent Application,yes,37,0,11,11,0,A42B3/064;;A42B3/125;;A42B3/14;;A42B3/125;;A42B3/063;;A42B3/064;;A42B3/121;;F16F13/005;;A42B3/046,A42B3/14;;A42B3/06;;A42B3/12;;F16F13/00,,0,0,,,,ACTIVE
402,WO,A1,WO 2018/033830 A1,072-377-695-786-099,2018-02-22,2018,IB 2017054850 W,2017-08-09,US 201662375240 P;;US 201615380907 A;;US 201615380967 A;;US 201715669272 A,2016-08-15,MECHANICALLY-ACTIVATED SHOCK ABATEMENT SYSTEM AND METHOD,"A helmet system (102), comprising: a shock abatement assembly (500) comprising: a plurality of levers (504) comprising a plurality of elongated members, each elongated member of the plurality of elongated members extending along a respective length between one end and another end; a fulcrum engaging one of the plurality of elongated members at a pivot location (520) along a length of the one of the plurality of elongated members, wherein the one of the plurality of elongated members, responsive to an application of an impact force along a direction, moves about the fulcrum to obtain a lever response based on a collision between a protective shell and an object; an end portion positioned at the one end of the one of the plurality of elongated members, wherein the end portion defines a surface having a non-parallel orientation with respect to a line extending between the one end and the another end, wherein the end portion, in response to the application of the impact force, facilitates a reaction force comprising a directed force determined in part by the direction and in part by the non-parallel orientation of the surface; and a deformable member (506) in communication with the one of the plurality of levers and adapted to deform to obtain a deformation based on the lever response, wherein the deformation absorbs a non-trivial portion of a kinetic energy of the collision.",TITON CORP S A,MINI TOWNSON JUAN FRANCISCO JAVIER;;ARAGÓN CABRERA JOSE RODRIGO;;ALFARO SAMAYOA JUAN PABLO,,https://lens.org/072-377-695-786-099,Patent Application,yes,16,0,11,11,0,A42B3/064;;A42B3/125;;A42B3/14;;A42B3/125;;A42B3/063;;A42B3/064;;A42B3/121;;F16F13/005;;A42B3/046,A42B3/06,,0,0,,,,PENDING
403,SI,T1,SI 2464356 T1,008-034-692-977-150,2015-08-31,2015,SI 201030977 T,2010-08-12,EP 09382144 A;;EP 2010061720 W;;EP 10744560 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/008-034-692-977-150,Granted Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/00;;A61K33/00;;A61K33/243;;A61K45/00;;A61P25/00,,0,0,,,,ACTIVE
404,NZ,A,NZ 598213 A,034-682-258-102-464,2014-05-30,2014,NZ 59821310 A,2010-08-12,EP 2010061720 W;;EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,"Disclosed herein is the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs. In one embodiment the sigma ligand is 4-{ 2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/034-682-258-102-464,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,DISCONTINUED
405,CN,B,CN 102497864 B,046-281-108-404-051,2015-07-22,2015,CN 201080036098 A,2010-08-12,EP 2010061720 W;;EP 09382144 A,2009-08-14,Sigma ligands for the prevention or treatment of pain induced by chemotherapy,,ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/046-281-108-404-051,Granted Patent,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,ACTIVE
406,CA,A1,CA 2770441 A1,177-687-806-924-222,2011-02-17,2011,CA 2770441 A,2010-08-12,EP 09382144 A;;EP 2010061720 W,2009-08-14,SIGMA LIGANDS FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY,"The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.",ESTEVE LABOR DR,BAEYENS-CABRERA JOSE MANUEL;;BUSCHMANN HELMUT HEINRICH;;VELA HERNANDEZ JOSE MIGUEL;;ZAMANILLO-CASTANEDO DANIEL;;NIETO-LOPEZ FRANCISCO-RAFAEL,,https://lens.org/177-687-806-924-222,Patent Application,no,0,0,49,49,0,A61K31/337;;A61K45/06;;A61K31/5377;;A61P25/00;;A61P25/02;;A61P25/04;;A61P29/00;;A61P29/02;;A61P35/00;;A61P43/00;;A61K33/243;;A61K31/282;;A61K31/337;;A61K31/4155;;A61K31/5377;;A61K45/06;;A61K33/243;;A61K31/337;;A61K45/06;;A61K33/243;;A61K31/5377,A61K31/5377;;A61K33/243;;A61K45/06;;A61P25/02,,0,0,,,,INACTIVE
407,US,B2,US 11547158 B2,112-240-896-775-603,2023-01-10,2023,US 201816757291 A,2018-10-11,US 201816757291 A;;US 201762572409 P;;IB 2018057871 W,2017-10-13,Fluid-actuated impact protection system and method,"The subject disclosure describes, among other things, illustrative embodiments of an impact protection device that comprises the following elements: a machine, a protective structural member, and a fluid holding member. The impact protection device is designed to protect a user from an impact to the protective structural member by dissipating a portion of the kinetic energy of the impact. Machine operation translates into a controlled movement between elements of the impact protection device that deform the fluid holding member, thereby displacing a fluid. This controlled movement also dictates a throttling profile that regulates the amount of damping; thereby managing the portion of kinetic energy dissipated. The machine can be a mechanical assembly incorporating levers, cams and or computerized controllers.",TITON IDEAS INC,MINI TOWNSON JUAN FRANCISCO JAVIER;;ARAGON CABRERA JOSE RODRIGO;;ALFARO SAMAYOA JUAN PABLO,TITON CORP (2020-06-02);;TITON IDEAS INC (2019-09-26);;MINI TOWNSON JUAN FRANCISCO JAVIER (2019-06-27),https://lens.org/112-240-896-775-603,Granted Patent,yes,17,0,3,3,0,A42B3/121;;F16F13/10;;F41H1/02;;F41H1/04;;F41H5/013;;F41H5/08;;F16F9/049;;A41D13/015;;A42B3/121;;F41H1/02;;F41H1/04;;F41H5/013,A42B3/12;;A41D13/015;;F41H1/02;;F41H1/04;;F41H5/013,,0,0,,,,ACTIVE
408,AR,A1,AR 048276 A1,128-921-992-061-074,2006-04-12,2006,AR P050101059 A,2005-03-18,AR P050101059 A,2005-03-18,METODO PARA LA PREPARACION DE SURFACTANTES POLIANIONICAS MULTIARMADOS A PARTIR DE MONOACETALES DEL PENTAERITROL POR CATALISIS DE TRANSFERENCIA DE FASES Y POSTERIOR HIDROFOBIZACION SEGUIDA DE SULFONACION.,"Reivindicacion 1: Un método mejorado para la preparacion de surfactantes polianionicos multiarmados a partir de monacetales del pentaeritritol, que tienen las formulas generales I y II donde R1= CnH2n con n=1 a 3; y R2=CnH2n+1 con n=8 a 16. Reivindicacion 2: Un método mejorado para la preparacion de surfactantes polianionicos multiarmados, acorde con la reivindicacion 1, caracterizado porque la reaccion de eterificacion de los monoacetales del pentaeritritol 1, preferentemente 1,5- dioxaspiro[5.5] undecano-3,3-dimetanol, con compuestos de bifuncionalidad halo-epoxido, preferentemente epiclorhidrina, es llevada a cabo bajo condiciones de catálisis por transferencia de fases. Reivindicacion 6: Un método mejorado para la preparacion de surfactantes polianionicos multiarmados, acorde con las reivindicaciones 1 a 5 inclusive, caracterizado proque además la secuencia de síntesis comprende (1) una hidrofobizacion con alcoholes de cadena larga en medio alcalino, preferentemente alcoholes con cadenas hidrocarbonadas conteniendo entre C8-16, y potasio metálico como agente alcalinizante; (2) una ulterior sulfonacion, preferentemente con ácido clorosulfonico disuelto en un solvente polar aprotico, para conferirles el carácter anionico. Particularmente, cuando se trata de obtener surfactantes con cuatro grupos anionicos, en lugar de dos, la secuencia de síntesis incorpora; (3)una desproteccion del monoacetal en medio ácido, preferentemente en solucion acuosa de ácido acético.",FUNDACION PARA LA PROMOCION Y,MURGUIA MARCELO CESAR;;CABRERA MARIA INES;;LUNA JULIO ALBERTO;;GRAU RICARDO JOSE ANTONIO,,https://lens.org/128-921-992-061-074,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
409,CN,A,CN 101981708 A,146-501-594-738-15X,2011-02-23,2011,CN 200880128220 A,2008-02-25,ES 2008000104 W,2008-02-25,Photovoltaic concentration module and device,"The invention relates to a photovoltaic concentration module and device. The device includes: a primary lens (10) configured to concentrate incident solar radiation and to generate a first concentrated radiation; a solar cell (30) configured to collect the first concentrated radiation; and a substrate (40) enabling the electrical connection and thermal dissipation of the solar cell, whereby the solar cell (30) and the substrate (40) are electrically associated so as to form an electric power generation unit. The photovoltaic concentration module includes a series of the aforementioned devices.",ISOFOTON,VICENTE DIAZ LUQUE;;JAVIER CABRERA GODOY;;DAVID EXPOSITO CORRAL;;LUIS ALVARES RICO JOSE,,https://lens.org/146-501-594-738-15X,Patent Application,no,0,0,9,9,0,Y02E10/52;;H01L31/0543;;H01L31/0547;;H01L31/0543;;Y02E10/52;;H01L31/0547,H01L31/052,,0,0,,,,INACTIVE
410,WO,A1,WO 2011/057730 A1,093-843-740-180-561,2011-05-19,2011,EP 2010006661 W,2010-11-02,ES 200902211 A,2009-11-13,COMPOSITION AND PROCESS FOR OBTAINING MATERIALS FOR COATING CERAMIC BODIES AND THE ARTICLES THUS OBTAINED,"This invention relates to a base composition of oxides and the products derived from said composition, characterised in that following its application on a ceramic substrate and its subsequent firing, crystal formations of Russellite are obtained on the surface of the ceramic part that provide it with an appearance that is rich in chromatic hues, iridescent, metallic and shiny depending on the amount and size of the crystals present.",VIDRES S A;;CABRERA IBANEZ MARIA JOSE;;SOLSONA MONZONIS DANIEL;;MONTINS NEBOT VICTOR;;MARTI SIDRO VICTOR,CABRERA IBANEZ MARIA JOSE;;SOLSONA MONZONIS DANIEL;;MONTINS NEBOT VICTOR;;MARTI SIDRO VICTOR,,https://lens.org/093-843-740-180-561,Patent Application,yes,28,11,4,4,0,C03C8/00;;C04B41/85;;C04B41/5023;;C03C3/062;;C03C8/02;;C03C10/00;;C04B41/009;;C04B41/86;;C04B2111/0025;;C04B2111/82,C04B41/50;;C03C8/02;;C03C10/00;;C04B41/86,,11,6,103-518-117-777-915;;062-304-170-133-431;;116-319-828-273-393;;088-164-681-659-55X;;059-115-507-657-003;;104-717-636-629-058,10.3989/cyv.2004.v43.i5.412;;10.1007/bf01111924;;10.1016/s0025-5408(98)00109-3;;10.1007/bf01209246;;10.1180/minmag.1970.037.290.08;;10.1180/minmag.1992.056.384.13,"""Russellite"", MINERAL DATA PUBLISHING, VERSION 1, 2002, XP002620526;;F. LUCAS; A. BELDA; F. J. TORRES; J. ALARC6N: ""Estudio y caracterizacion de vidriados vitroceramicos basados en piroxeno"", BOL. SOC. ESP. CERAM. V., vol. 43, no. 5, 2004, pages 849 - 854;;J. MA. RINC6N: ""Principles of Nucleation and Controlled Crystallization of Glasses"", POYM.-PLAST. TECHNOL. ENG., vol. 31, no. 3-4, 1992, pages 309 - 357;;VICENTE-MINGARRO; P. CALLEJAS; J. MA. RINC6N: ""Materiales Vitrocerámicos: EI proceso Vitroceramico"", BOL. SOC. ESP. CERAM. V., vol. 32, no. 3, 1993, pages 157 - 167;;H. S. KIM; R. D. RAWLING; P.S. ROGERS: ""Sintering and Crystallization Phenomena in Silceram Glass"", J. MATER. SCI., vol. 23, 1988, pages 2622 - 2630;;J. MA. RINC6N; M. ROMERO; J. MARCO; V. CABALLER: ""Some aspects of crystallization microstructure on new glass-ceramic glazes"", MAT. RES. BULL., vol. 33, no. 8, 1998, pages 1159 - 1164, XP004156831, DOI: doi:10.1016/S0025-5408(98)00109-3;;G. BALDI; E. GENERALLI; C. LEONELLI; T. MANFREDINI; G. C. PELLACANI; C.SILIGARDI: ""Effects of nucleating agents on diopside crystallization in new glass- ceramics for tile-glaze application"", J. MATER, SCI., vol. 30, 1995, pages 3251 - 3255, XP000941135, DOI: doi:10.1007/BF01209246;;""Russellite"", MINERAL DATA PUBLISHING;;PALACHE, C.; H. BERMAN; C.FRONDEL: ""Dana's system of mineralogy (7th edition),"", vol. I, 1944, pages: 604 - 605;;HODGE, L.C.: ""Russellite: a second occurrence"", MINERAL. MAG., vol. 37, 1970, pages 705 - 707;;KNIGHT, K.S.: ""The crystal structure of russellite; a re-determination using neutron powder diffraction of synthetic Bi2WO6"", MINERAL. MAG., vol. 56, 1992, pages 399 - 409",PENDING
411,ES,B1,ES 2360781 B1,021-785-405-850-404,2012-05-25,2012,ES 200902211 A,2009-11-13,ES 200902211 A,2009-11-13,COMPOSICION Y PROCEDIMIENTO PARA LA OBTENCION DE MATERIALES PARA EL RECUBRIMIENTO DE CUERPOS CERAMICOS Y LOS ARTICULOS ASI OBTENIDOS.,,VIDRES S A,CABRERA IBANEZ MARIA JOSE;;SOLSONA MONZONIS DANIEL;;MONTINS NEBOT VICTOR;;MARTI SIDRO VICTOR,,https://lens.org/021-785-405-850-404,Granted Patent,no,0,0,4,4,0,C03C8/00;;C04B41/85;;C04B41/5023;;C03C3/062;;C03C8/02;;C03C10/00;;C04B41/009;;C04B41/86;;C04B2111/0025;;C04B2111/82,C04B41/85;;C03C8/00,,0,0,,,,INACTIVE
412,BR,B1,BR 0207356 B1,024-494-194-390-071,2015-02-10,2015,BR 0207356 A,2002-09-24,BR 0207356 A,2002-09-24,PROCESSO DE PRODUÇÃO DE POLIHIDROXIBUTIRATO E SEU COPOLÍMERO POLIHIDROXIBUTIRATO-CO-HIDROXIVALERATO A PARTIR DE HIDROLISADOS DE BAGAÇO DE CANA-DE-AÇÚCAR,,INST PESQUISAS TECH;;FUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO FAPESP,SILVA LUIZIANA FERREIRA DA;;TACIRO MARILDA KEICO;;PRADELLA JOSE GERALDO DA CRUZ;;GOMEZ JOSE GREGORIO CABRERA;;CARTER JOSE MARCIO;;RAMOS MARIA ELISABETH MICHELIN,,https://lens.org/024-494-194-390-071,Granted Patent,no,0,0,2,2,0,,C12P7/62;;C12R1/025,,0,0,,,,EXPIRED
413,BR,A,BR 0207356 A,024-588-620-480-668,2004-09-08,2004,BR 0207356 A,2002-09-24,BR 0207356 A,2002-09-24,Processo de produção de polihidroxibutirato e seu copolìmero polihidroxibutirato-co-hidroxivalerato a partir de hidrolisados de bagaço de cana-de-açúcar,"""PROCESSO DE PRODUçãO DE POLIHIDROXIBUTIRATO E SEU COPOLìMERO POLIHIDROXIBUTIRATO-CO-HIDROXIVALERATO A PARTIR DE HIDROLISADOS DE BAGAçO DE CANA-DE-AçúCAR"". Invenção que descreve o processo para obtenção de polihidroxibutirato e polihidroxibutirato-co-hidroxivalerato, por via microbiana, caracterizado por empregar como principal matéria-prima o hidrolisado de bagaço de cana-de-açúcar e os principais açúcares nele contidos, bem como bactérias do gênero Burkholderia e Achromobacter. Quando hidrolisado de bagaço é empregado no processo, a eliminação de componentes tóxicos nele presentes, pelo uso de procedimentos físicos e químicos pode ser necessária. As bactérias são cultivadas em meio nutritivo contendo como fontes de carbono o hidrolisado de bagaço de cana-de-açúcar e os principais açúcares nele contidos, além de outros componentes como nitrogênio, fósforo, enxofre, magnésio, potássio e oxigênio, além de micronutrientes como, molibdênio, manganês, cobalto, zinco, níquel, cobre, boro para que ocorra a multiplicação da biomassa celular, bem como precursores de hidroxivalerato como ácidos carboxílicos, álcoois ou hidrocarbonetos com número ímpar de carbono na cadeia principal, quando o copolímero for o produto alvo. A produção de até 80% da biomassa seca em polímero é induzida por meio da limitação ou exaustão, simultânea ou não, no meio de cultura, de um ou mais dos nutrientes essenciais ao crescimento, porém com fornecimento da fonte de carbono. O material produzido é concentrado por métodos convencionais (filtração, centrifugação, sedimentação), extraído empregando-se um solvente orgânico seguido de precipitação com um agente orgânico não solvente. Enzimas (proteases, lipases e lacases, entre outras), em conjunto ou não, podem também ser utilizadas para o rompimento celular, auxiliadas ou não pela presença de tensoativos. A mistura deverá sofrer sedimentação, centrifugação ou filtração, seguidas por uma operação de secagem dos grânulos.",INST PESQUISAS TECH;;FUNDACAO DE AMPARO A PESQUISA,SILVA LUIZIANA FERREIRA DA;;TACIRO MARILDA KEICO;;PRADELLA JOSE GERALDO DA CRUZ;;GOMEZ JOSE GREGORIO CABRERA;;CARTER JOSE MARCIO;;RAMOS MARIA ELISABETH MICHELIN,,https://lens.org/024-588-620-480-668,Patent Application,no,0,0,2,2,0,,C12P7/62;;C12R1/025,,0,0,,,,EXPIRED
414,MX,A,MX 2011013724 A,185-896-078-589-454,2013-06-17,2013,MX 2011013724 A,2011-12-15,MX 2011013724 A,2011-12-15,COATING OF MATERIALS PERFORMED DURING THE ABRASION CUT.,"The present invention refers to a coating technique by abrasion. The abrasion cut is quite common in pieces requiring to be sharpened and rectified, amongst others, and it is known that this operation generates the conditions necessary to diffuse a filler material over a working piece, whit which it is possible to deposit materials in powder, at a surface level, over pieces that require special properties upon interacting with other surfaces. The coating acquired with this technique is advantageous over those forming a film: The coatings by abrasion form an alloy, at a surface level of the filler material, with the material of the working piece, so that having more mechanical strength and a reduced possibility of detachment, which may occur only in advanced stages of superficial wear.",EQUIPOS MEDICOS VIZCARRA S A,LELIS JOSE MARIA RODRIGUEZ;;CABRERA JOSE ANTONIO ARELLANO;;JIMENEZ MARIA TERESA LUCAS;;VIZCARRA ALFREDO CHALITA;;PEREGRINO VICTOR HUGO OLIVARES,,https://lens.org/185-896-078-589-454,Patent Application,no,0,0,1,1,0,,C08J7/00,,0,0,,,,DISCONTINUED
415,WO,A1,WO 2019/097452 A1,134-625-462-576-098,2019-05-23,2019,IB 2018059006 W,2018-11-15,CO 2017011635 A,2017-11-15,"PORTABLE FOLDING CHAIR WITH ACCESSORIES, AND AN AUTOMATED LENDING AND STORAGE STATION","The present invention relates to an item of furniture of the portable folding chair type with accessories, as well as a modular storage station for the storage and automated lending of the folding furniture, and also to a method for borrowing and returning furniture using the lending station. The station can be used to charge batteries provided in the chair or in the station. Both the chair and the lending station are suitable for use not just in indoor spaces but also in outdoor spaces used by a large number of people. The chairs are designed to be used for rest and relaxation or to study, without being complicated or inconvenient to use, move and store. The invention offers different services in order to ensure a pleasant experience and to meet the additional needs and comforts of today's students, services such as a storage compartment and a charger, for which purpose each chair is provided with a bank of batteries together with one or more output terminals. In addition, the present invention can use solar energy, promoting the optimal use of renewable energy.",PONTIFICIA UNIV JAVERIANA,GARCÍA CIFUENTES JUAN PABLO;;ORREGO DUQUE JUAN JOSE;;ARIZA CABRERA JOSE LUIS;;CASTAÑO VALENCIA JUAN PABLO;;NEGRETE PADILLA JULIANA,,https://lens.org/134-625-462-576-098,Patent Application,yes,7,0,2,2,0,A47C1/00;;A47C1/02;;A47C3/16;;A47C4/00;;A47C4/04;;A47C4/28,A47C1/00;;A47C1/02;;A47C3/16,,1,0,,,"DATABASE WPI Week 87159, Derwent World Patents Index; AN 2009-K87159",PENDING
416,HU,A,HU T74164 A,037-427-601-177-983,1996-11-28,1996,HU 9600095 A,1994-09-07,ES 9401078 A,1994-05-17,OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,BERGAMINI MICHAEL VAN WIE;;LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO,,https://lens.org/037-427-601-177-983,Unknown,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,DISCONTINUED
417,MX,A,MX 2008005077 A,077-201-956-972-854,2009-10-21,2009,MX 2008005077 A,2008-04-18,MX 2008005077 A,2008-04-18,UNIT FOR BAREROOT TRANSPLANTING OVER MULCH SOIL.,"The present invention refers to a mechanical device which includes a unit (module) of a machine for transplanting seedlings at bareroot in polyethylene film-mulch soils. The operation principle of the machine is based on a module, which is brought into contact with soil for a predetermined time and which has mechanisms that perform in an automatic manner operations for opening and fastening a plastic cut, locating the seedling and the filler, and compacting the space around the same. The seedling feeding is manually performed using an operator by each row. The modules are attached together (articulated), thereby forming a train of interconnected links that are guided in the machine frame and actuated by the displacement thereof. The relative displacement speed between the module and the frame must be equal to the displacement speed of the machine and in an opposite direction so as to remove the relative motion between the module and the soil. The relative motion between the module and the machine frame is used as a source for sequentially driving the mechanisms of the module upon displacing said module through a track system of fixed guides attached to the frame, which by means of ball bearings control the position of the mobile elements of the mechanisms pertaining to the transplanting unit.",UNIV GUANAJUATO,ROBLES NOE SALDANA;;HLAWINSKA RYSZARD JERZY SERWATOWSKI;;SIXTO JOSE MANUEL CABRERA;;VACA CESAR GUTIERREZ,,https://lens.org/077-201-956-972-854,Patent Application,no,0,0,2,2,0,,B65B43/00;;B65B11/00,,0,0,,,,ACTIVE
418,WO,A1,WO 1995/031179 A1,081-783-680-604-141,1995-11-23,1995,ES 9400084 W,1994-09-07,ES 9401078 A,1994-05-17,OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS,"The ophthalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac obtained from Diclofenac itself or an isomer, or a derivative or one of the pharmaceutically acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramycin, obtained from Tobramycin itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB;;LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/081-783-680-604-141,Patent Application,yes,1,2,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,PATENTED
419,EP,A1,EP 0661055 A1,138-354-489-922-919,1995-07-05,1995,EP 94203756 A,1994-12-23,ES 9302735 A,1993-12-31,Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof.,"The composition comprises: 0.001-5.0 % Clobetasone or an isomer or a derivative or one of the pharmaceutically acceptable salts thereof; 0.05-5.0 % Tobramycin or an isomer or a derivative or one of the pharmaceutically acceptable salts thereof; and, optionally, one or more ingredients selected from among isotonizing agents, pH buffers, viscosity modifying agents, wetting agents, chelating agents, antioxidants, preservatives, solubility agents, aside from one or several excipients suitable to the pharmaceutical form for application of the formulation. Said formulation has a pH between 4 and 9. Application in the treatment of eye and ear processes accompanied by infection.",CUSI LAB,VAN WIE BERGAMINI MICHAEL;;LOPEZ CABRERA ANTONIO;;VALLET MAS JOSE ALBERTO;;OROS LAGUENS CARMEN,,https://lens.org/138-354-489-922-919,Patent Application,yes,1,15,4,4,0,A61K31/70;;A61K9/0048;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/04;;Y02A50/30,A61K9/06;;A61K9/00;;A61K9/08;;A61K9/107;;A61K31/57;;A61K31/70;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/04;;B82B1/00,,0,0,,,,DISCONTINUED
420,ES,U,ES 1067655 U,095-553-805-305-706,2008-06-01,2008,ES 200800741 U,2008-04-10,ES 200800741 U,2008-04-10,"Autonomous backrest for fire vehicles (Machine-translation by Google Translate, not legally binding)","Stand-alone backup for fire-fighting vehicles, of the type that determine an anchoring, between some lower support rods (5) and an upper cylindrical ring (2) that is capable of moving in height by means of an operating lever (4), for the fastening of the oxygen bottle (6) that the firemen (7) carry fastened to the back when they go on duty, characterized in that a safety belt (15) is provided on the backrest to establish a securing fastening of the user firefighter (7) independently of the anchor holding the oxygen bottle (6), going over the cylindrical ring (2) of the anchor holding the oxygen bottle (6) a headrest (11) incorporated with possibility of vertical displacement to regulate its positioning in height. (Machine-translation by Google Translate, not legally binding)",REDONDO MOYA ALEJANDRO J;;CABRERA NAVARRO JOSE MARIA;;MONTOYA ESTEBAN SEBASTIAN;;MONTOYA REDONDO RAUL,REDONDO MOYA ALEJANDRO J;;CABRERA NAVARRO JOSE MARIA;;MONTOYA ESTEBAN SEBASTIAN;;MONTOYA REDONDO RAUL,,https://lens.org/095-553-805-305-706,Patent Application,no,0,0,2,2,0,,B60N2/433,,0,0,,,,EXPIRED
421,BR,A,BR 9407330 A,108-127-799-554-252,1996-06-18,1996,BR 9407330 A,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,Solução oftálmica baseada em diclofenaco e tobramicina e formulação oftálmica,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/108-127-799-554-252,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,DISCONTINUED
422,OA,A,OA 10570 A,188-517-316-365-218,2002-06-20,2002,OA 60766 A,1996-01-17,ES 9401078 A,1994-05-17,Ophtalmic solution based on diclofenac and tobramycin and its applications,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",LABORATIORIOS CUSI S A,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELA;;MAS ALBERTO JOSE VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/188-517-316-365-218,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
423,FI,A0,FI 960232 A0,001-485-993-740-710,1996-01-17,1996,FI 960232 A,1996-01-17,ES 9401078 A;;ES 9400084 W,1994-05-17,Diklofenaakkiin ja tobramisiiniin perustuva oftalminen liuos ja sen käytöt,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/001-485-993-740-710,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
424,ES,A1,ES 2362831 A1,136-321-748-804-850,2011-07-13,2011,ES 200803151 A,2008-10-10,ES 200803151 A,2008-10-10,METHOD FOR MOUNTING PLASTIC FILM USED TO COVER GREENHOUSES,"Method for mounting plastic film used to cover greenhouses. The present invention aims to increase working safety during the plastic film renewal operations by means of mechanization thereof. The method envisages the simultaneous use of a platform and a plastic-changing apparatus. The platform has a winding roller (1) for supporting the reel of plastic film (2) and another top roller (3) for facilitating unwinding and unfolding of the film. The changing apparatus is used as a working base and matches perfectly the form of the roof so that it can be used as support base for performing all those working operations involved in renewal of the plastic film, i.e. both the extension operations performed beforehand and the operations for tensioning and fixing to the metal structure performed afterwards.",UNIV ALMERIA,CALLEJON FERRE ANGEL JESUS;;CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIER,,https://lens.org/136-321-748-804-850,Patent Application,no,8,1,3,3,0,A01G9/1407;;A01G9/1407;;A01G2009/1484;;Y02A40/25,A01G9/14;;E04D15/06,,0,0,,,,ACTIVE
425,NO,B1,NO 308645 B1,075-330-423-895-268,2000-10-09,2000,NO 960207 A,1996-01-17,ES 9401078 A;;ES 9400084 W,1994-05-17,Oftalmisk løsning basert pÕ diclofenac og tobramycin samt anvendelse av denne,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELLA;;MAS JOSE ALBERTO VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/075-330-423-895-268,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
426,NO,L,NO 960207 L,130-788-555-974-256,1996-03-15,1996,NO 960207 A,1996-01-17,ES 9401078 A;;ES 9400084 W,1994-05-17,Oftalmisk lösning basert på diklofenak og tobramycin samt anvendelse av denne,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELLA;;MAS JOSE ALBERTO VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/130-788-555-974-256,Abstract,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
427,ES,B1,ES 2079320 B1,132-585-053-840-955,1996-10-16,1996,ES 9401078 A,1994-05-17,ES 9401078 A,1994-05-17,DISOLUCION OFTALMICA A BASE DE UN DICLOFENACO Y TOBRAMICINA Y SUS APLICACIONES.,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/132-585-053-840-955,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
428,AT,T1,AT E198417 T1,032-036-341-647-933,2001-01-15,2001,AT 94926248 T,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,"OPHTHALMISCHE LÖSUNG, DIE DICLOFENAC UND TOBRAMYCIN ENTHÄLT, UND IHRE VERWENDUNG","The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/032-036-341-647-933,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,DISCONTINUED
429,GR,T3,GR 3035633 T3,063-999-149-742-531,2001-06-29,2001,GR 20010400478 T,2001-03-23,ES 9401078 A;;ES 9400084 W,1994-05-17,OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/063-999-149-742-531,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
430,ES,Y,ES 1067655 Y,088-452-194-314-913,2008-09-01,2008,ES 200800741 U,2008-04-10,ES 200800741 U,2008-04-10,RESPALDO AUTONOMO PARA VEHICULOS DE BOMBEROS,,REDONDO MOYA ALEJANDRO J;;CABRERA NAVARRO JOSE MARIA;;MONTOYA ESTEBAN SEBASTIAN;;MONTOYA REDONDO RAUL,REDONDO MOYA ALEJANDRO J;;CABRERA NAVARRO JOSE MARIA;;MONTOYA ESTEBAN SEBASTIAN;;MONTOYA REDONDO RAUL,,https://lens.org/088-452-194-314-913,Limited Patent,no,0,0,2,2,0,,B60N2/433,,0,0,,,,EXPIRED
431,ES,B1,ES 2362767 B1,103-468-896-037-541,2012-05-30,2012,ES 200802891 A,2008-10-03,ES 200802891 A,2008-10-03,EQUIPO PARA DISPOSICION DEL PLASTICO DE CUBIERTA DE INVERNADEROS.,,UNIV ALMERIA,CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIER;;CALLEJON FERRER ANGEL JESUS,,https://lens.org/103-468-896-037-541,Granted Patent,no,0,0,3,3,0,A01G9/1407;;A01G9/1407;;Y02A40/25,A01G9/14;;E04D15/06,,0,0,,,,ACTIVE
432,PL,A1,PL 312615 A1,133-327-570-137-517,1996-04-29,1996,PL 31261594 A,1994-09-07,ES 9401078 A,1994-05-17,"OPHTHALMOLOGIC SOLUTION BASED ON DICLOFENAC AND TOBRAMYCINE, AND ITS APPLICATIONS","The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/133-327-570-137-517,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,PENDING
433,AU,A,AU 1994/076160 A,125-667-645-937-019,1995-12-05,1995,AU 1994/076160 A,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,Ophtalmic solution based on diclofenac and tobramicine and its applications,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",LABORATORIOS CUSI S A,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELLA;;MAS JOSE ALBERTO VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/125-667-645-937-019,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
434,EP,A3,EP 2011632 A3,025-688-376-368-563,2011-02-23,2011,EP 08010894 A,2008-06-16,ES 200701911 A,2007-07-06,Process for manufacturing aggregate slabs by means of microwave irradiation and resulting aggregate slabs,"The present invention relates to a process for manufacturing aggregate slabs by means of microwave irradiation and aggregate slabs manufactured by means of microwave irradiation, by means of which process the resins contained in an aggregate slab mass are cured by means of microwave irradiation.",COSENTINO SA,CABRERA JUAN MONZO;;MORENO JOSE LUIS RAMON;;FERNANDEZ JESUS ROMERA;;RODRIGUEZ GARCIA SALVADOR CRISTOBAL,,https://lens.org/025-688-376-368-563,Search Report,yes,4,0,4,4,0,B28B11/24;;B28B11/241;;B29C67/04;;B29C67/242;;B29C2035/0855;;C04B26/18;;C04B2111/542;;B28B11/24;;B29C35/08;;C08J5/24,B29C67/24;;B28B11/24,,0,0,,,,DISCONTINUED
435,ES,A1,ES 2955856 A1,011-765-234-511-406,2023-12-07,2023,ES 202330117 A,2023-02-16,ES 202330117 A,2023-02-16,"Magnetic system in the form of a multilayer and obtaining method to control the magnetization reversal process (Machine-translation by Google Translate, not legally binding)","Magnetic system in the form of a multilayer and obtaining method to control the magnetization reversal process. One of the great drawbacks of multilayer systems is that, in the magnetization reversal process, independent jumps may appear from the separate magnetic behavior of each type of constituent material, which means that the applications to be developed are limited. The present invention presents a multilayer system of magnetic materials and its method of obtaining, based on coupling magnetostrictive layers of magnetic materials whose magnetostriction coefficients are of opposite sign. This magnetic coupling means that in the hysteresis cycle the inversion processes of each layer do not appear independently and that the thickness of the layers is not limited to their exchange length, domain wall or other characteristic length that governs the properties of the freak. (Machine-translation by Google Translate, not legally binding)",UNIV MADRID COMPLUTENSE;;UNIV CASTILLA LA MANCHA,RANCHAL SANHEZ ROCIO;;COTON SANCHEZ NOELIA;;CABRERA GALLARDO ALEJANDRO JOSE;;ANDRES GONZALEZ JUAN PEDRO,,https://lens.org/011-765-234-511-406,Patent Application,no,0,0,1,1,0,H01F10/32,H01F10/32,,4,4,132-497-084-007-069;;033-987-862-346-810;;006-712-013-842-121;;020-889-777-365-653,10.1016/s0304-8853(00)00498-4;;10.1109/20.914349;;10.1063/1.4984298;;10.1063/5.0011873,"MANDAL K ET AL. Development of a tensile-stress-induced anisotropy in amorphous magnetic thin films. Journal of Magnetism and Magnetic Materials, 20001001 ELSEVIER, AMSTERDAM, NL. Dempsey Nora; Zhang Yuepeng, 01/10/2000, Vol. 220, Páginas 152 - 160 [en línea][recuperado el 24-11-2023]. ISSN 0304-8853, (DOI: doi:10.1016/S0304-8853(00)00498-4) figuras 5a y 6c.;;VAZQUEZ M ET AL. Magnetic Anisotropies in Single and Multilayered Thin Films Grown by Bowed-Substrate Sputtering. IEEE Transactions on Magnetics, 20001101 IEEE, USA. , 01/11/2000, Vol. 36, [en línea][recuperado el 24-11-2023]. ISSN 0018-9464,;;REMENTER COLIN R ET AL. Tuning static and dynamic properties of FeGa/NiFe heterostructures. Applied Physics Letters, 20170613 American Institute of Physics, 2 Huntington Quadrangle, Melville, NY 11747. , 13/06/2017, Vol. 110, [en línea][recuperado el 24-11-2023]. ISSN 0003-6951, (DOI: doi:10.1063/1.4984298);;ACOSTA ADRIAN ET AL. Underlayer effect on the soft magnetic, high frequency, and magnetostrictive properties of FeGa thin films. Journal of Applied Physics, 20200702 American Institute of Physics, 2 Huntington Quadrangle, Melville, NY 11747. , 02/07/2020, Vol. 128, [en línea][recuperado el 24-11-2023]. ISSN 0021-8979, (DOI: doi:10.1063/5.0011873)",PENDING
436,DK,T3,DK 0711546 T3,086-331-970-618-343,2001-04-23,2001,DK 94926248 T,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,Ophthalmisk opløsning på grundlag af diclofenac og tobramycin samt dens anvendelse,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,VALLET MAS JOSE ALBERTO;;LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/086-331-970-618-343,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
437,US,B1,US 11398990 B1,077-332-607-236-20X,2022-07-26,2022,US 201916586594 A,2019-09-27,US 201916586594 A,2019-09-27,Detecting and diagnosing anomalies in utilization levels of network-based resources,"This disclosure describes systems, devices, and techniques for detecting and diagnosing anomalies in utilization levels of network-based resources. In an example method, at least one utilization level of one or more computer resources by an account during a time interval may be received. A possible anomaly can be detected if the at least one utilization level is determined to be outside of a predetermined range. The anomaly can be confirmed determining that at least a threshold number of multiple discrimination layers identify an anomaly in the at least one utilization level. An action can be performed in response to confirming the anomaly.",AMAZON TECH INC,CABRERA JUAN JOSE;;FORD RACHEL SHAERRIE;;HUMEAU MATTHIEU BENOIT;;SHAO LI;;UNG JEREMY JON,AMAZON TECHNOLOGIES INC (2019-09-23),https://lens.org/077-332-607-236-20X,Granted Patent,yes,19,6,1,1,0,H04L47/822;;H04L47/826;;H04L43/0876;;H04L43/16;;H04L41/0631;;H04L41/145;;H04L41/147;;H04L43/028;;H04L43/20;;H04L47/822;;H04L43/0817;;H04L47/826;;G06F18/2411,H04L47/70;;G06K9/62;;H04L43/0817,,0,0,,,,ACTIVE
438,WO,A1,WO 2010/040876 A1,179-755-122-305-724,2010-04-15,2010,ES 2009000509 W,2009-09-30,ES 200803151 A,2008-10-10,METHOD FOR MOUNTING PLASTIC FILM USED TO COVER GREENHOUSES,"Method for mounting plastic film used to cover greenhouses. The present invention aims to increase working safety during the plastic film renewal operations by means of mechanization thereof. The method envisages the simultaneous use of a platform and a plastic-changing apparatus. The platform has a winding roller (1) for supporting the reel of plastic film (2) and another top roller (3) for facilitating unwinding and unfolding of the film. The changing apparatus is used as a working base and matches perfectly the form of the roof so that it can be used as support base for performing all those working operations involved in renewal of the plastic film, i.e. both the extension operations performed beforehand and the operations for tensioning and fixing to the metal structure performed afterwards.",UNIV ALMERIA;;CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIE;;CALLEJON FERRE ANGEL JESUS,CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIER;;CALLEJON FERRE ANGEL JESUS,,https://lens.org/179-755-122-305-724,Patent Application,yes,8,0,3,3,0,A01G9/1407;;A01G9/1407;;A01G2009/1484;;Y02A40/25,E04D15/06;;A01G9/14,,0,0,,,,PENDING
439,MX,A,MX 2010007911 A,009-388-522-033-100,2012-01-23,2012,MX 2010007911 A,2010-07-08,MX 2010007911 A,2010-07-08,TOTAL HIP REPLACEMENT WHICH IS DAMPENED AND OF LOW FRICTIONAL TORQUE.,"The present invention refers to a total hip replacement intended for the recovery of people with arthrosis or articular traumas. The design of the replacement allows the three main problems associated to the hip replacement to be attacked, which are the following: Contact efforts, shielding efforts in the bone-prosthesis interface and impact loads generated during each start-up cycle. The total hip replacement presented in this document comprises: (1) polymer femoral stem with inclusions that allow contact and shielding efforts to be dissipated, also absorbing the dynamic loads generated during the start-up cycle and (2) a ceramic femoral head coated with DLC for reducing the friction forces in the contact with the acetabular cup. The invention also contains a polymer acetabular cup (3) with inclusions that allow contact efforts to be dissipated between the femoral head and the acetabular cup; the acetabular cup includes an additional metallic cup (4) between the femoral head and the acetabular cup, which reduces the frictional torque generated during the start-up cycle.",LELIS JOSE MARIA RODRIGUEZ,LELIS JOSE MARIA RODRIGUEZ;;PLIEGO ARTURO ABUNDEZ;;CABRERA JOSE ANTONIO ARELLANO;;RIVERA MIGUEL ANGEL OCAMPO;;TREVINO MARCIANO VARGAS;;TORRES JOSE NAVARRO;;PLIEGO CLAUDIA ABUNDEZ,,https://lens.org/009-388-522-033-100,Patent Application,no,0,0,1,1,0,,A61F2/32,,0,0,,,,DISCONTINUED
440,FR,A1,FR 2749590 A1,020-427-102-437-181,1997-12-12,1997,FR 9707124 A,1997-06-09,US 66145796 A,1996-06-11,"PROCEDE POUR PRODUIRE DE L'ESSENCE REFORMULEE EN REDUISANT LA TENEUR EN SOUFRE, EN AZOTE ET EN OLEFINE","<P>Un procédé pour revaloriser une charge d'alimentation de naphta lourd riche en azote et en soufre consiste à fournir une charge d'alimentation à teneur initiale en azote, en soufre et à indice d'octane initial; mettre en contact la charge d'alimentation avec une source d'acide pour fournir une charge d'alimentation à teneur en azote inférieure à la teneur initiale en azote; mettre en contact la charge d'alimentation à teneur en azote réduite avec un catalyseur d'hydroconversion sous une atmosphère d'hydrogène, une température et une pression fournissant un produit final à teneur finale en azote inférieure à la teneur initiale en azote, à teneur finale en soufre inférieure à la teneur initiale en soufre, et à indice d'octane final pratiquement égal ou supérieur à l'indice d'octane initial, le produit final présentant plus d'isomères et pratiquement pas d'augmentation de la teneur en produits aromatiques par rapport à la charge d'alimentation.</P>",INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/020-427-102-437-181,Patent Application,no,7,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
441,FI,B,FI 116884 B,060-919-843-310-593,2006-03-31,2006,FI 960232 A,1996-01-17,ES 9401078 A;;ES 9400084 W,1994-05-17,Menetelmä diklofenaakkiin ja tobramysiiniin perustuvan silmätippaliuoksen valmistamiseksi,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/060-919-843-310-593,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K31/7036;;A61K9/00;;A61K9/08;;A61K31/196,,0,0,,,,EXPIRED
442,NL,A1,NL 1006263 A1,083-046-928-930-526,1997-12-17,1997,NL 1006263 A,1997-06-09,US 66145796 A,1996-06-11,"Proces voor de productie van gereformeerde benzine door het verlagen van het zwavel-, stikstof- en alkeengehalte.",,INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS MIGUEL;;PALMISANO EUSEBIO;;GRACIA WOLFGANG JESUS;;SOLARI RODOLFO BRUNO,,https://lens.org/083-046-928-930-526,Granted Patent,no,0,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/06;;B01J29/46;;C07B61/00;;B01J29/48;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
443,EP,A2,EP 2620421 A2,101-235-382-699-433,2013-07-31,2013,EP 13152347 A,2013-01-23,ES 201230096 A,2012-01-24,Coating for ceramic bodies,"Coating for ceramic bodies that comprises in its composition a mixture of oxides obtained from frits, raw materials, additives, colouring agents and, as substantial elements of this composition, some particles with different expansion coefficients that can present phase changes in the firing stage and have a different morphology and particle size between 20 and 500 microns, although a particles size from 50 to 350 microns is preferred, wherein the composition of these particles comprises at least one of the following types of oxides: ceramic oxides such as zinc oxide, silicon oxide, zirconium oxide, yttrium oxide, halfnium oxide or cerium oxide.
",VIDRES S A,CABRERA IBANEZ MARIA JOSE;;MONTINS NEBOT VICTOR;;SOLSONA MONZONIS DANIEL;;SALA INIESTA JUAN MIGUEL,,https://lens.org/101-235-382-699-433,Patent Application,yes,10,0,4,4,0,C03C8/14;;C04B41/009;;C04B41/5022;;C04B41/52;;C04B41/86;;C04B2111/80,C04B41/86;;C03C8/14;;C04B41/00;;C04B41/50;;C04B111/80,,2,1,042-096-797-328-970,10.1111/j.1151-2916.1988.tb05022.x,"CLEVELAND; BRADT, J. AMER. CER., vol. 61, 1978, pages 478;;V. TVERGAARD; J.W. HUTCHINSON: ""Microcraking in Ceramics Induced by Thermal Expansion or Elastic Anisotropy"", JOURNAL OF THE AMERICAN CERAMIC SOCIETY, vol. 71, no. 3, March 1988 (1988-03-01)",DISCONTINUED
444,FR,B1,FR 2749590 B1,178-833-658-121-282,2004-08-27,2004,FR 9707124 A,1997-06-09,US 66145796 A,1996-06-11,"PROCEDE POUR PRODUIRE DE L'ESSENCE REFORMULEE EN REDUISANT LA TENEUR EN SOUFRE, EN AZOTE ET EN OLEFINE",,INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/178-833-658-121-282,Granted Patent,no,0,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
445,ES,A1,ES 2398032 A1,025-031-477-613-04X,2013-03-13,2013,ES 200901210 A,2009-05-07,ES 200901210 A,2009-05-07,"System that allows the application of visual effects in objects or static subjects or in motion in real time without the need of brands. (Machine-translation by Google Translate, not legally binding)","The present invention is based on a system that allows the application of visual effects on objects or subjects static or moving in real time without the need for marks achieving a natural interaction between the object or the subject and the input and output devices for that computer vision techniques are used. The system comprises an input device that allows the capture of images, in any format and in real time, a scenario configured in such a way that the lighting and the background are controlled, a module for real-time image processing and motion detection through the implementation of filters and an output device where the processed images are projected with the corresponding visual effect. (Machine-translation by Google Translate, not legally binding)",UNIV LA LAGUNA,GONZALEZ GONZALEZ CARINA SOLEDAD;;CABRERA PRIMO DAVID;;RIVERO GUTIERREZ MELVIN;;SIGUT SAAVEDRA JOSE FRANCISCO,,https://lens.org/025-031-477-613-04X,Patent Application,no,3,0,2,2,0,G06T7/254;;G06T19/006;;G06V40/20,G06T19/00;;G06K9/00;;G06T7/20,,1,1,129-416-650-498-777,10.1109/cvpr.2008.4587566,"23/06/2008, EISERT P et al. 3-D Tracking of shoes for Virtual Mirror applications. Computer Vision and Pattern Recognition, 2008. CVPR 2008. IEEE Conference on, 23/06/2008 VOL: Pags: 1 - 6 ISBN 978-1-4244-2242-5 ; ISBN 1-4244-2242-6 Zhen Lei; Qinqun Bai; Ran He; Li S Z",ACTIVE
446,ES,B1,ES 2362831 B1,092-907-441-109-590,2012-05-30,2012,ES 200803151 A,2008-10-10,ES 200803151 A,2008-10-10,METODO DE INSTALACION DEL FILM PLASTICO DE CUBIERTA PARA INVERNADEROS.,,UNIV ALMERIA,CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIER;;CALLEJON FERRE ANGEL JESUS,,https://lens.org/092-907-441-109-590,Granted Patent,no,0,0,3,3,0,A01G9/1407;;A01G9/1407;;A01G2009/1484;;Y02A40/25,A01G9/14;;E04D15/06,,0,0,,,,ACTIVE
447,ES,A1,ES 2384924 A1,139-634-566-262-399,2012-07-16,2012,ES 201001587 A,2010-12-17,ES 201001587 A,2010-12-17,DEVICE FOR CONTROLLING THE DYNAMIC STABILITY OF THE LUMBAR SPINE,"The invention relates to a device formed by a band (1) of semi-flexible fabric, which is tapered at the ends (2) thereof, said ends including complementary securing means (3) for the size-adjustable securing of the band (1) to a user's waist. The body defining the band (1) contains pressure sensors aligned with an intermediate raised transverse zone (5) intended to come into contact with the user's waist. In addition, luminous bands (7), vibration-transmitting elements (8) and a chip (9), which can be used to interpret pressure levels and to send said information to a computer means, are provided closer to the ends of the band.",UNIV ALICANTE,CORTELL TORMO JUAN MANUEL;;PEREZ TURPIN JOSE ANTONIO;;SUAREZ LLORCA CONCEPCION;;ANDREU CABRERA ELISEO,,https://lens.org/139-634-566-262-399,Patent Application,no,5,0,3,3,0,A61B5/1126;;A61B5/4566;;A61B5/6804;;A61B5/6843,A61B5/11,,0,0,,,,ACTIVE
448,EP,A2,EP 2011632 A2,162-208-279-490-534,2009-01-07,2009,EP 08010894 A,2008-06-16,ES 200701911 A,2007-07-06,Process for manufacturing aggregate slabs by means of microwave irradiation and resulting aggregate slabs,"The present invention relates to a process for manufacturing aggregate slabs by means of microwave irradiation and aggregate slabs manufactured by means of microwave irradiation, by means of which process the resins contained in an aggregate slab mass are cured by means of microwave irradiation.",COSENTINO SA,CABRERA JUAN MONZO;;MORENO JOSE LUIS RAMON;;FERNANDEZ JESUS ROMERA;;RODRIGUEZ GARCIA SALVADOR CRIS,,https://lens.org/162-208-279-490-534,Patent Application,yes,3,12,4,4,0,B28B11/24;;B28B11/241;;B29C67/04;;B29C67/242;;B29C2035/0855;;C04B26/18;;C04B2111/542;;B28B11/24;;B29C35/08;;C08J5/24,B29C67/24;;B28B11/24,,0,0,,,,DISCONTINUED
449,GB,B,GB 2314089 B,156-992-329-818-441,2000-02-16,2000,GB 9711543 A,1997-06-04,US 66145796 A,1996-06-11,Process for upgrading nitrogen and sulfur rich heavy naphtha feedstock,,INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/156-992-329-818-441,Granted Patent,no,11,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,C5E ERB           ERB;;C5E ERD           ERD;;C5E ETB           ETB;;C5E E401          ETB;;C5E E405          ETB,0,0,,,,EXPIRED
450,US,A,US 5597560 A,149-565-220-774-051,1997-01-28,1997,US 41938795 A,1995-04-10,ES 9401078 A,1994-05-17,Diclofenac and tobramycin formulations for ophthalmic and otic topicaluse,"This invention includes a pharmaceutically acceptable formulation of Diclofenac, Tobramycin, a solubility agent and, optionally, excipients, tonicifiers, buffers, viscosity modifying agents, preservatives, and chelating agents, at a pH from greater than 7.0 to about 9. The invention also discloses the use of this pharmaceutically acceptable formulation of an antibiotic and NSAIDs to treat eye and ear conditions accompanied by infection and inflammation.",CUSI LAB,BERGAMINI MICHAEL V W;;VALLET MAS JOSE A;;CABELLO GEMMA T;;CABRERA ANTONIO L,LABORATORIOS CUSI S.A (1995-03-31),https://lens.org/149-565-220-774-051,Granted Patent,yes,9,142,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,424/78.04;;424/78.05;;514/912;;514/914,18,11,001-749-807-716-861;;020-295-794-347-563;;002-742-428-825-034;;009-192-640-166-524;;004-918-922-228-728;;058-230-924-828-747;;001-800-507-111-781;;032-134-088-739-592;;165-200-102-859-52X;;001-595-655-834-543;;130-161-240-892-45X,10.1001/archopht.1976.03910040526011;;184771;;10.1055/s-2008-1045766;;1614101;;10.1089/jop.1991.7.77;;2061692;;2619149;;10.1007/bf01956489;;3562200;;8320865;;10.1111/j.2042-7158.1992.tb05484.x;;1359085;;10.3109/03639049209040849;;10.1007/bf01197160;;8121927;;10.1016/0031-6865(94)90041-8;;5947096,"Human Conjunctivitis, Howard M. Leibowitz, MD, et al., Arch Ophthalmol, vol. 94, Oct. 1976, pp. 1752 1756.;;Association diclofenac dexamethasone dans le traitement de l inflammation postop e ratoire: e tude prospective en double insu, Dr. Philippe Othenin Girard, et al., Klin. Mbl. Augenheilk, 200, 1992, pp. 362 366.;;The Effect of 0.1 % Indomethacin Eyedrops on Cataract Surgery, Journal of Ocular Pharmacology, vol. 7, No. 1, 1991, pp. 77 81.;;The Effect of Ketorolac Tromethamine in Reducing Postoperative Inflamation: Double Mask Parallel Comparison with Dexamethasone, Allan J. Flach, MD, et al., Ann Ophthalmol 1989; 21:407 411.;;Infections of the Eye 35. Endophthalmitis, David W. Parke II, et al., pp. 563 583.;;Incompatibility of indometacin and benzalkonium in eye drops due to ion pair formation, S. M. Dreijer Van Der Glas, et al., vol. 9, 1987, Pharmaceutisch Weekblad Scientific Edition, pp. 29 32.;;Effects of Pretreatment with Mydriatics on Intraocular Penetration of 0.1 % Pranoprofen, Takahiro Ogawa, et al., Jpn J Ophthalmol, vol. 37: 47 55, 1993.;;Prediction of Skin Permeability of Drugs: Comparison of Human and Hairless Rat Skin, Yasunori Morimoto, et al., J. Pharm. Pharmacol. 1992, 44: 634 639.;;Binary Diclogenac Diethylamine Water Systems: Micelles, Vesicles and Lyotropic Liquid Crystals, Katrin Kriwet, et al., Eur. J. Pharm. Biopharm, 39 (6) 234 238, 1993.;;Degradation of Tobramycin in Aqueous Solution, Michael Brandl and Leo Gu, Drug Development and Industrial Pharmacy, 18(13), 1423 1436, 1992.;;Spectrophotometric Method for Determination of Tobramycin, Apramycin and Kanamycin in Formulations, P. R. Bontchev, et al., Mikrochimica Acta (wien) 1984 III, 459 465.;;The Top Ten NSAIDs A molecular modelling study, S. Winiwarter, et al., Pharmaceutica Acta Helvetiae 68 (1994) 181 189.;;Conjunctival Disorders, Current Veterinary Therapy X Small Animal Practice, Cecil P. Moore, D.V.M., 1989, pp. 673 678.;;A New Corticosteroid Antibiotic Preparation in Eye and Ear Infections, General Practitioner Clinical Trials, Alexander, J. et al., Jul., 1966, vol. 197: 94 96.;;Canine Conjunctiva and Nictitating Membrane, Veterinary Ophthalmology, Dennis E. Brooke, pp. 290 304, 1991.;;Diseases of the Ear, Textbook of Veterinary Internal Medicine Diseases of the Dog and Cat, vol. I, Dennis W. Macy, pp. 246 257.;;American Academy of Ophthalmology, Final Program, Scientific Posters, p. 101.;;XXVIIth International Congress of Ophthalmology 94, Final Program, Scientific Papers.",EXPIRED
451,DE,T2,DE 69426529 T2,009-504-857-723-221,2001-08-09,2001,DE 69426529 T,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,"OPHTHALMISCHE LÖSUNG, DIE DICLOFENAC UND TOBRAMYCIN ENTHÄLT, UND IHRE VERWENDUNG","The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/009-504-857-723-221,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
452,ES,A1,ES 2065846 A1,011-387-270-560-410,1995-02-16,1995,ES 9300826 A,1993-04-20,ES 9300826 A,1993-04-20,Pharmaceutical formulation based on a steroidal or non- steroidal anti-inflammatory agent and an antibiotic belonging to the DNA Girase inhibitors group for topical ophthalmic use,"Pharmaceutical formulation based on a steroidal or non- steroidal anti-inflammatory agent and an antibiotic belonging to the DNA Girase inhibitors group for topical ophthalmic use. It comprises: 0.001-5.0% of a steroidal or non-steroidal anti-inflammatory agent or an isomer, or an ester, or one of the pharmaceutically acceptable salts thereof 0.05-5.0% of a DNA Girase inhibitor, or an isomer, or an ester or one of the pharmaceutically acceptable salts thereof and optionally, one or more ingredients selected from isotonizing agents, pH buffers, viscosifiers, wetting agents, chelating agents, antioxidants and/or preservatives, in addition to one or more excipients appropriate for the form of pharmaceutical presentation of the formulation. Said formulation has a pH between 4 and 9. Application in the treatment of ocular inflammatory processes accompanied by infection.",CUSI LAB,VAN WIE BERGAMINI MICHAEL;;VALLET MAS JOSE ALBERTO;;OROS LAGUENS CARMEN;;LOPEZ CABRERA ANTONIO,,https://lens.org/011-387-270-560-410,Ambiguous,no,3,26,2,2,0,,A61K31/19;;A61K31/38;;A61K31/40;;A61K31/405;;A61K31/47;;A61K31/54;;A61K31/57,,0,0,,,,EXPIRED
453,ES,A1,ES 2079320 A1,032-057-550-760-089,1996-01-01,1996,ES 9401078 A,1994-05-17,ES 9401078 A,1994-05-17,OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/032-057-550-760-089,Ambiguous,no,3,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
454,ES,B1,ES 2319368 B1,048-777-492-182-909,2010-01-08,2010,ES 200701911 A,2007-07-06,ES 200701911 A,2007-07-06,PROCEDIMIENTO PARA LA FABRICACION DE TABLAS DE AGLOMERADO MEDIANTE RADIACION CON MICROONDAS Y TABLA DE AGLOMERADO FABRICADA MEDIANTE RADIACION CON MICROONDAS.,,COSENTINO SA,MONZO CABRERA JUAN;;RAMON MORENO JOSE LUIS;;ROMERA FERNANDEZ JESUS;;RODRIGUEZ GARCIA SALVADOR CRISTO,,https://lens.org/048-777-492-182-909,Granted Patent,no,0,0,4,4,0,B28B11/24;;B28B11/241;;B29C67/04;;B29C67/242;;B29C2035/0855;;C04B26/18;;C04B2111/542;;B28B11/24;;B29C35/08;;C08J5/24,B29C35/08;;B28B11/24;;C08J5/24,,0,0,,,,INACTIVE
455,CA,A1,CA 2167383 A1,112-525-127-153-497,1995-11-23,1995,CA 2167383 A,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMYCIN AND ITS APPLICATIONS,"The ophthalmic solution comprises (a) the equivalent to 0.001-0.14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceutically acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramycine, obtained from Tobramycine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/112-525-127-153-497,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
456,ES,A1,ES 2362767 A1,006-419-396-721-999,2011-07-13,2011,ES 200802891 A,2008-10-03,ES 200802891 A,2008-10-03,APPARATUS FOR ARRANGING THE PLASTIC FOR COVERING GREENHOUSES,"Apparatus for arranging the plastic for covering greenhouses. The invention aims to mechanize in a safe manner the work involved in arranging the plastic film for covering greenhouses. The invention comprises the coordinated use of two components, a platform and a changing apparatus. The platform is provided with a reeling/unfolding system able to supply plastic film to the changing apparatus arranged on the roof, allowing the latter to be used not only for performing film-stretching operations but also for performing subsequent operations involving tensioning and fixing to the support structure. The platform is composed of a double rectangular frame (1) which is linearly hinged in its central zone by means of extendable bars with a locking mechanism (2). The base structure has, connected thereto, a bottom reeling winch (10), a top reeling/unfolding winch (5) and, on both sides, fixed stairs (6), hoists (7) and the corresponding safety rails (8/9). The changing apparatus is composed of a double curved gantry (11) linked by means of a stairway (12) and resting on pairs of rolling wheels (14).",UNIV ALMERIA,CALLEJON FERRER ANGEL JESUS;;CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIER,,https://lens.org/006-419-396-721-999,Patent Application,no,8,0,3,3,0,A01G9/1407;;A01G9/1407;;Y02A40/25,A01G9/14;;E04D15/06,,0,0,,,,ACTIVE
457,ES,B1,ES 2065846 B1,115-749-864-039-338,1995-10-01,1995,ES 9300826 A,1993-04-20,ES 9300826 A,1993-04-20,FORMULACION FARMACEUTICA A BASE DE UN AGENTE ANTIINFLAMATORIO ESTEROIDICO O NO ESTEROIDICO Y UN ANTIBIOTICO PERTENCIENTE AL GRUPO DE LOS INHIBIDORES DE LA ADN GIRASA PARA SU UTILIZACION TOPICA OFTALMICA.,"FORMULACION FARMACEUTICA A BASE DE UN AGENTE ANTIINFLAMATORIO ESTEROIDICO O NO ESTEROIDICO Y UN ANTIBIOTICO PERTENECIENTE AL GRUPO DE LOS INHIBIDORES DE LA ADN GIRASA PARA SU UTILIZACION TOPICA OFTALMICA COMPRENDE: 0,001-5,0% DE UN AGENTE ANTIINFLAMATORIO ESTEROIDICO O NO ESTEROIDICO O UN ISOMERO, O UN ESTER, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; 0,05-5,0% DE UN INHIBIDOR DE LA ADN GIRASA, O UN ISOMERO, O UN ESTER O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y OPCIONALMENTE, UNO O MAS INGREDIENTES SELECCIONADOS ENTRE AGENTES ISOTONIZANTES, AMORTIGUADORES DEL PH, AGENTES VISCOSIZANTES, AGENTES HUMECTANTES, AGENTES QUELANTES, AGENTES ANTIOXIDANTES Y/O AGENTES CONSERVADORES, ADEMAS DE UNO O VARIOS EXCIPIENTES ADECUADOS A LA FORMA DE PRESENTACION FARMACEUTICA DE LA FORMULACION. DICHA FORMULACION PRESENTA UN PH COMPRENDIDO ENTRE 4 Y 9. APLICACION EN EL TRATAMIENTO DE PROCESOS INFLAMATORIOS OCULARES ACOMPAÑADOS DE INFECCION.",CUSI LAB,VAN WIE BERGAMINI MICHAEL;;VALLET MAS JOSE ALBERTO;;OROS LAGUENS CARMEN;;LOPEZ CABRERA ANTONIO,,https://lens.org/115-749-864-039-338,Granted Patent,no,0,0,2,2,0,,A61K31/19;;A61K31/38;;A61K31/40;;A61K31/405;;A61K31/47;;A61K31/54;;A61K31/57,,0,0,,,,EXPIRED
458,BR,A,BR 9703532 A,009-639-370-699-643,1998-08-25,1998,BR 9703532 A,1997-06-11,US 66145796 A,1996-06-11,Processo para o beneficiamento de uma carga de nafta pesada rica em nitrogênio e enxofre e processo para remoção de nitrogênio de uma carga de nafta rica em nitrogênio,,INTEVEP SA,CABRERA LUIS M;;PALMISANO EUSEBIO;;SALAZAR JOSE ARMANDO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/009-639-370-699-643,Patent Application,no,0,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
459,EP,B1,EP 0711546 B1,024-114-595-111-355,2001-01-03,2001,EP 94926248 A,1994-09-07,ES 9400084 W;;ES 9401078 A,1994-05-17,OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMYCINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,"ALCON CUSI, S.A. (1998-04-08)",https://lens.org/024-114-595-111-355,Granted Patent,yes,1,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
460,PT,E,PT 711546 E,059-380-340-021-130,2001-06-29,2001,PT 94926248 T,1994-09-07,ES 9401078 A,1994-05-17,SOLUCAO OFTALMICA BASEADA EM DICLOFENAC E TOBRAMICINA E AS SUAS APLICACOES,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELLA;;MAS JOSE ALBERTO VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/059-380-340-021-130,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
461,CA,C,CA 2167383 C,153-182-235-707-616,2001-11-20,2001,CA 2167383 A,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMYCINE AND ITS APPLICATIONS,"The ophthalmic solution comprises (a) the equivalent to 0.001-0.14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceutically acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramycine, obtained from Tobramycine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/153-182-235-707-616,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
462,ES,B1,ES 2384924 B1,017-443-905-213-079,2013-07-01,2013,ES 201001587 A,2010-12-17,ES 201001587 A,2010-12-17,DISPOSITIVO PARA EL CONTROL DE LA ESTABILIDAD DINAMICA DEL RAQUIS LUMBAR,,UNIV ALICANTE,CORTELL TORMO JUAN MANUEL;;PEREZ TURPIN JOSE ANTONIO;;SUAREZ LLORCA CONCEPCION;;ANDREU CABRERA ELISEO,,https://lens.org/017-443-905-213-079,Granted Patent,no,0,0,3,3,0,A61B5/1126;;A61B5/4566;;A61B5/6804;;A61B5/6843,A61B5/11,,0,0,,,,ACTIVE
463,DE,A1,DE 19724683 A1,026-654-217-105-468,1997-12-18,1997,DE 19724683 A,1997-06-11,US 66145796 A,1996-06-11,Verfahren zum Veredeln eines Stickstoff und Schwefel enthaltenden Naphta-Ausgangsstoffes,"A naphtha feedstock is contacted with acid so as to remove N 2 . The N 2 -containing aqueous solution is separated from the oil. The nitrogen reduced feedstock is then subjected to a hydroconversion catalyst to produce a final product having a reduced sulphur and nitrogen content, increased octane number and increased isomerised component but no increase in aromatic content. Catalytic elements comprise a matrix, preferably gamma alumina, having a support medium distributed therethrough, preferably a zeolite. The support medium, and preferably the matrix, contain at least one group IIIA metal, preferably gallium, and one group VIB metal. The catalytic elements are preferably also impregnated with further metals selected from groups VA, VII and VIII.",INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/026-654-217-105-468,Patent Application,no,0,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
464,JP,A,JP H1060457 A,033-290-984-937-475,1998-03-03,1998,JP 15418497 A,1997-06-11,US 66145796 A,1996-06-11,"PRODUCTION OF MODIFIED GASOLINE REDUCED IN SULFUR, NITROGEN AND OLEFIN CONTENTS","PROBLEM TO BE SOLVED: To provide a method for modifying a heavy naphtha raw material rich in nitrogen and sulfur contents. SOLUTION: This method for producing a modified gasoline reduced in sulfur, nitrogen and olefin contents contains a step for feeding a naphtha raw material having an initial nitrogen content, an initial sulfur content and an initial octane value, a step for bringing the led naphtha raw material into contact with an acidic source to produce a nitrogen-reduced raw material having a smaller nitrogen content than the initial nitrogen content, and a step for bringing the nitrogen-reduced raw material into contact with a hydroconversion catalyst system in a hydrogen atmosphere to produce the final product having a larger final octane value than the initial octane value of the raw material. Isomerized components in the final product are increased in comparison with those of the raw material, and the contents of aromatic components are substantially not increased.",INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/033-290-984-937-475,Patent Application,no,0,13,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
465,AU,B2,AU 696853 B2,070-985-699-984-427,1998-09-17,1998,AU 1994/076160 A,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,Ophtalmic solution based on diclofenac and tobramycin and its applications,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELLA;;MAS JOSE ALBERTO VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/070-985-699-984-427,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
466,GB,A,GB 2314089 A,124-645-507-747-803,1997-12-17,1997,GB 9711543 A,1997-06-04,US 66145796 A,1996-06-11,Reforming naphtha comprising an acid pre-treatment step,,INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALAMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/124-645-507-747-803,Patent Application,no,3,3,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,C5E ERB           ERB;;C5E ERD           ERD;;C5E ETB           ETB;;C5E E401          ETB;;C5E E405          ETB,0,0,,,,EXPIRED
467,MX,B,MX 337332 B,004-036-898-377-760,2016-01-19,2016,MX 2008005077 A,2008-04-18,MX 2008005077 A,2008-04-18,UNIT FOR BAREROOT TRANSPLANTING OVER MULCH SOIL.,"The present invention refers to a mechanical device which includes a unit (module) of a machine for transplanting seedlings at bareroot in polyethylene film-mulch soils. The operation principle of the machine is based on a module, which is brought into contact with soil for a predetermined time and which has mechanisms that perform in an automatic manner operations for opening and fastening a plastic cut, locating the seedling and the filler, and compacting the space around the same. The seedling feeding is manually performed using an operator by each row. The modules are attached together (articulated), thereby forming a train of interconnected links that are guided in the machine frame and actuated by the displacement thereof. The relative displacement speed between the module and the frame must be equal to the displacement speed of the machine and in an opposite direction so as to remove the relative motion between the module and the soil. The relative motion between the module and the machine frame is used as a source for sequentially driving the mechanisms of the module upon displacing said module through a track system of fixed guides attached to the frame, which by means of ball bearings control the position of the mobile elements of the mechanisms pertaining to the transplanting unit.",UNIV GUANAJUATO,ROBLES NOE SALDAÑA;;HLAWINSKA RYSZARD JERZY SERWATOWSKI;;SIXTO JOSE MANUEL CABRERA;;VACA CESAR GUTIERREZ,,https://lens.org/004-036-898-377-760,Granted Patent,no,0,0,2,2,0,,B65B43/00;;B65B11/00,,0,0,,,,ACTIVE
468,MX,A,MX 9704294 A,002-953-981-050-828,1998-06-30,1998,MX 9704294 A,1997-06-10,US 66145796 A,1996-06-11,"PROCESS FOR PRODUCING REFORMULATED GASOLINE BY REDUCING SULFUR, NITROGEN AND OLEFIN.","A process for upgrading a nitrogen and sulfur rich heavy naphtha feedstock includes the steps of providing a naphtha feedstock having an initial nitrogen content, an initial sulfur content and an initial octane number; contacting the naphtha feedstock with an acid source so as to provide a reduced nitrogen feedstock having a reduced nitrogen content which is less then the initial nitrogen content; contacting the reduced nitrogen feedstock with a hydroconversion catalyst system under a hydrogen atmosphere, temperature a and pressure so as to provide a final product having a final nitrogen content which is less then the initial nitrogen content, a final sulfur content which is less than the initial sulfur content, an having a final octane number which is substantially equal to or greater than the initial octane number of the feedstock, land wherein the final product has an increased isomerized component and substantially no increase in aromatic content with respect to the feedstock.",INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/002-953-981-050-828,Patent Application,no,0,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/06;;B01J29/48;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
469,WO,A1,WO 2010/037883 A1,032-575-575-260-136,2010-04-08,2010,ES 2009000508 W,2009-09-30,ES 200802891 A,2008-10-03,APPARATUS FOR ARRANGING THE PLASTIC FOR COVERING GREENHOUSES,"Apparatus for arranging the plastic for covering greenhouses. The invention aims to mechanize in a safe manner the work involved in arranging the plastic film for covering greenhouses. The invention comprises the coordinated use of two components, a platform and a changing apparatus. The platform is provided with a reeling/unfolding system able to supply plastic film to the changing apparatus arranged on the roof, allowing the latter to be used not only for performing film-stretching operations but also for performing subsequent operations involving tensioning and fixing to the support structure. The platform is composed of a double rectangular frame (1) which is linearly hinged in its central zone by means of extendable bars with a locking mechanism (2). The base structure has, connected thereto, a bottom reeling winch (10), a top reeling/unfolding winch (5) and, on both sides, fixed stairs (6), hoists (7) and the corresponding safety rails (8/9). The changing apparatus is composed of a double curved gantry (11) linked by means of a stairway (12) and resting on pairs of rolling wheels (14).",UNIV ALMERIA;;CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIE;;CALLEJON FERRE ANGEL JESUS,CARRENO ORTEGA ANGEL;;PEREZ ALONSO JOSE;;VAZQUEZ CABRERA FERNANDO JAVIER;;CALLEJON FERRE ANGEL JESUS,,https://lens.org/032-575-575-260-136,Patent Application,yes,8,1,3,3,0,A01G9/1407;;A01G9/1407;;Y02A40/25,A61G13/02;;A01G9/14;;E04D15/06,,0,0,,,,PENDING
470,DE,D1,DE 69426529 D1,067-767-580-078-191,2001-02-08,2001,DE 69426529 T,1994-09-07,ES 9401078 A;;ES 9400084 W,1994-05-17,"OPHTHALMISCHE LÖSUNG, DIE DICLOFENAC UND TOBRAMYCIN ENTHÄLT, UND IHRE VERWENDUNG","The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/067-767-580-078-191,Granted Patent,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
471,NL,C2,NL 1006263 C2,182-672-080-383-904,1999-07-22,1999,NL 1006263 A,1997-06-09,US 66145796 A,1996-06-11,"Proces voor de productie van gereformeerde benzine door het verlagen van het zwavel-, stikstof- en alkeengehalte.",,INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS MIGUEL;;PALMISANO EUSEBIO;;GRACIA WOLFGANG JESUS;;SOLARI RODOLFO BRUNO,,https://lens.org/182-672-080-383-904,Granted Patent,no,7,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;B01J29/48;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
472,WO,A1,WO 2012/080540 A1,003-961-032-843-38X,2012-06-21,2012,ES 2011070777 W,2011-11-11,ES 201001587 A,2010-12-17,DEVICE FOR CONTROLLING THE DYNAMIC STABILITY OF THE LUMBAR SPINE,"The invention relates to a device formed by a band (1) of semi-flexible fabric, which is tapered at the ends (2) thereof, said ends including complementary securing means (3) for the size-adjustable securing of the band (1) to a user's waist. The body defining the band (1) contains pressure sensors aligned with an intermediate raised transverse zone (5) intended to come into contact with the user's waist. In addition, luminous bands (7), vibration-transmitting elements (8) and a chip (9), which can be used to interpret pressure levels and to send said information to a computer means, are provided closer to the ends of the band.",UNIV ALICANTE;;CORTELL TORMO JUAN MANUEL;;PEREZ TURPIN JOSE ANTONIO;;SUAREZ LLORCA CONCEPCION;;ANDREU CABRERA ELISEO,CORTELL TORMO JUAN MANUEL;;PEREZ TURPIN JOSE ANTONIO;;SUAREZ LLORCA CONCEPCION;;ANDREU CABRERA ELISEO,,https://lens.org/003-961-032-843-38X,Patent Application,yes,5,0,3,3,0,A61B5/1126;;A61B5/4566;;A61B5/6804;;A61B5/6843,A61B5/11,,0,0,,,,PENDING
473,ES,B1,ES 2078175 B1,034-961-324-583-035,1996-10-16,1996,ES 9302735 A,1993-12-31,ES 9302735 A,1993-12-31,FORMULACION FARMACEUTICA CONTENIENDO CLOBETASONA Y TOBRAMICINA Y SUS APLICACIONES.,"FORMULACION FARMACEUTICA CONTENIENDO CLOBETASONA Y TOBRAMICINA Y SUS APLICACIONES. LA COMPOSICION COMPRENDE: 0,001-5,0 POR CIENTO DE CLOBETASONA O UN ISOMERO O UN DERIVADO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; 0,05-5,0 POR CIENTO DE TOBRAMICINA O UN ISOMERO O UN DERIVADO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y, OPCIONALMENTE, UNO O MAS INGREDIENTES SELECCIONADOS ENTRE AGENTES ISOTONIZANTES, AMORTIGUADORES DEL PH, VISCOSIZANTES, HUMECTANTES, QUELANTES, ANTIOXIDANTES, CONSERVADORES, SOLUBILIZANTES, ADEMAS DE UNO O VARIOS EXCIPIENTES ADECUADOS A LA FORMA DE PRESENTACION FARMACEUTICA DE LA FORMULACION. DICHA FORMULACION PRESENTA UN PH COMPRENDIDO ENTRE 4 Y 9. APLICACION PARA EL TRATAMIENTO DE LOS PROCESOS INFLAMATORIOS OCULARES Y OTICOS ACOMPAÑADOS DE INFECCION.",CUSI LAB,BERGAMINI MICHAEL VAN WIE;;LOPEZ CABRERA ANTONIO;;VALLET MAS JOSE ALBERTO;;OROS LAGUENS CARMEN,,https://lens.org/034-961-324-583-035,Granted Patent,no,0,0,4,4,0,A61K31/70;;A61K9/0048;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/04;;Y02A50/30,A61K9/06;;A61K9/00;;A61K9/08;;A61K9/107;;A61K31/57;;A61K31/70;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/04;;B82B1/00,,0,0,,,,EXPIRED
474,ES,A1,ES 2078175 A1,049-735-046-704-309,1995-12-01,1995,ES 9302735 A,1993-12-31,ES 9302735 A,1993-12-31,Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof.,"The composition comprises: 0.001-5.0 % Clobetasone or an isomer or a derivative or one of the pharmaceutically acceptable salts thereof 0.05-5.0 % Tobramycin or an isomer or a derivative or one of the pharmaceutically acceptable salts thereof and, optionally, one or more ingredients selected from among isotonizing agents, pH buffers, viscosity modifying agents, wetting agents, chelating agents, antioxidants, preservatives, solubility agents, aside from one or several excipients suitable to the pharmaceutical form for application of the formulation. Said formulation has a pH between 4 and 9. Application in the treatment of eye and ear processes accompanied by infection.",CUSI LAB,BERGAMINI MICHAEL VAN WIE;;LOPEZ CABRERA ANTONIO;;VALLET MAS JOSE ALBERTO;;OROS LAGUENS CARMEN,,https://lens.org/049-735-046-704-309,Ambiguous,no,4,0,4,4,0,A61K31/70;;A61K9/0048;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/04;;Y02A50/30,A61K9/06;;A61K9/00;;A61K9/08;;A61K9/107;;A61K31/57;;A61K31/70;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/04;;B82B1/00,,0,0,,,,EXPIRED
475,HK,A1,HK 1017806 A1,084-092-635-867-934,1999-11-26,1999,HK 98113200 A,1998-12-11,ES 9400084 W;;ES 9401078 A,1994-05-17,OPHTHALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMCINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",ALCON CUSI S A,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/084-092-635-867-934,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
476,EP,A1,EP 0711546 A1,023-659-588-511-08X,1996-05-15,1996,EP 94926248 A,1994-09-07,ES 9400084 W;;ES 9401078 A,1994-05-17,OPHTALMIC SOLUTION BASED ON DICLOFENAC AND TOBRAMICINE AND ITS APPLICATIONS,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,"ALCON CUSI, S.A. (1998-04-08)",https://lens.org/023-659-588-511-08X,Patent Application,yes,0,13,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
477,ES,A1,ES 2319368 A1,033-775-822-025-68X,2009-05-06,2009,ES 200701911 A,2007-07-06,ES 200701911 A,2007-07-06,Process for manufacturing aggregate slabs by means of microwave irradiation and resulting aggregate slabs,"The present invention relates to a process for manufacturing aggregate slabs by means of microwave irradiation and aggregate slabs manufactured by means of microwave irradiation, by means of which process the resins contained in an aggregate slab mass are cured by means of microwave irradiation.",COSENTINO SA,MONZO CABRERA JUAN;;RAMON MORENO JOSE LUIS;;ROMERA FERNANDEZ JESUS;;RODRIGUEZ GARCIA SALVADOR CRISTO,,https://lens.org/033-775-822-025-68X,Patent Application,no,3,0,4,4,0,B28B11/24;;B28B11/241;;B29C67/04;;B29C67/242;;B29C2035/0855;;C04B26/18;;C04B2111/542;;B28B11/24;;B29C35/08;;C08J5/24,B29C35/08;;B28B11/24;;C08J5/24,,0,0,,,,INACTIVE
478,ES,A1,ES 2415984 A1,126-425-857-390-590,2013-07-29,2013,ES 201230096 A,2012-01-24,ES 201230096 A,2012-01-24,Coating for ceramic bodies,"Coating for ceramic bodies that comprises in its composition a mixture of oxides obtained from frits, raw materials, additives, colouring agents and, as substantial elements of this composition, some particles with different expansion coefficients that can present phase changes in the firing stage and have a different morphology and particle size between 20 and 500 microns, although a particles size from 50 to 350 microns is preferred, wherein the composition of these particles comprises at least one of the following types of oxides: ceramic oxides such as zinc oxide, silicon oxide, zirconium oxide, yttrium oxide, halfnium oxide or cerium oxide.",VIDRES SA,CABRERA IBANEZ MARIA JOSE;;MONTINS NEBOT VICTOR;;SOLSONA MONZONIS DANIEL;;SALA INIESTA JUAN MIGUEL,,https://lens.org/126-425-857-390-590,Patent Application,no,4,0,4,4,0,C03C8/14;;C04B41/009;;C04B41/5022;;C04B41/52;;C04B41/86;;C04B2111/80,C04B41/52,,0,0,,,,INACTIVE
479,FI,A,FI 960232 A,134-692-907-425-541,1996-03-15,1996,FI 960232 A,1996-01-17,ES 9401078 A;;ES 9400084 W,1994-05-17,Diklofenaakkiin ja tobramisiiniin perustuva oftalminen liuos ja sen käytöt,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,LOPEZ CABRERA ANTONIO;;TORRELLA CABELLO GEMMA;;VALLET MAS JOSE ALBERTO;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/134-692-907-425-541,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
480,NO,D0,NO 960207 D0,064-002-530-296-728,1996-01-17,1996,NO 960207 A,1996-01-17,ES 9401078 A;;ES 9400084 W,1994-05-17,Oftalmisk lösning basert på diklofenak og tobramycin samt anvendelse av denne,"The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an isomer or a derivative or one of its pharmaceutically acceptable salts thereof; (c) optionally a solubilizer, an isotonizer, a pH damper, a viscosizer, a chelator, a preserving agent, and/or an excipient for pharmaceutical hydrogels. Application to the treatment of ocular and otic inflammations and/or infections.",CUSI LAB,CABRERA ANTONIO LOPEZ;;CABELLO GEMMA TORRELLA;;MAS JOSE ALBERTO VALLET;;BERGAMINI MICHAEL VAN WIE,,https://lens.org/064-002-530-296-728,Patent Application,no,0,0,32,32,0,A61K9/0048;;A61K31/70;;A61P27/00;;A61P27/02;;A61P27/16;;A61P31/02;;A61K31/19;;A61K31/70;;A61K9/0048;;A61K31/70,A61K9/00,,0,0,,,,EXPIRED
481,ES,B1,ES 2398032 B1,107-207-870-263-145,2014-02-12,2014,ES 200901210 A,2009-05-07,ES 200901210 A,2009-05-07,SISTEMA QUE PERMITE LA APLICACION DE EFECTOS VISUALES EN OBJETOS O SUJETOS ESTATICOS O EN MOVIMIENTO EN TIEMPO REAL SIN NECESIDAD DE MARCAS.,,UNIV LA LAGUNA,GONZALEZ GONZALEZ CARINA SOLEDAD;;CABRERA PRIMO DAVID;;RIVERO GUTIERREZ MELVIN;;SIGUT SAAVEDRA JOSE FRANCISCO,,https://lens.org/107-207-870-263-145,Granted Patent,no,0,0,2,2,0,G06T7/254;;G06T19/006;;G06V40/20,G06T19/00;;G06K9/00;;G06T7/20,,0,0,,,,ACTIVE
482,DE,B4,DE 19724683 B4,105-136-792-024-123,2005-06-30,2005,DE 19724683 A,1997-06-11,US 66145796 A,1996-06-11,Verfahren zum Veredeln eines Stickstoff und Schwefel enthaltenden Naphta-Ausgangsstoffes,,INTEVEP SA,SALAZAR JOSE ARMANDO;;CABRERA LUIS M;;PALMISANO EUSEBIO;;GARCIA WOLFGANG J;;SOLARI RODOLFO BRUNO,,https://lens.org/105-136-792-024-123,Granted Patent,no,6,0,14,14,0,B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04;;B01J29/061;;C10G35/095;;C10G47/20;;C10G61/04,B01J29/48;;B01J29/06;;B01J29/46;;C07B61/00;;C10G17/00;;C10G35/04;;C10G35/095;;C10G45/12;;C10G47/20;;C10G61/04;;C10G67/08,,0,0,,,,EXPIRED
483,BR,A,BR PI0504054 A,154-329-665-934-827,2007-05-22,2007,BR PI0504054 A,2005-09-15,BR PI0504054 A,2005-09-15,processo de produção de polihidroxialcanoatos a partir de óleos vegetais,"PROCESSO DE PRODUçãO DE POLIHIDROXIALCANOATOS A PARTIR DE óLEOS VEGETAIS Esta invenção trata de um processo de produção de polihidroxialcanoatos, genericamente chamados de PHA, tendo como fonte de carbono (I) óleos vegetais brutos ou refinados, ou (II) resíduos de processamento da produção destes óleos vegetais, ou III) ácidos graxos derivados do óleo vegetais ou IV) suas misturas, e compreendendo as Etapas: I) cultivar previamente linhagem bacteriana dos gêneros Wautersia, e Burkholderia selecionadas ou seus mutantes em um biorreator de preparação de inóculo; II) transferir a suspensão bacteriana para um segundo biorreator que possua em seu interior meio de cultura contendo, além da fonte de carbono, outros nutrientes para aporte de nitrogênio, fósforo, enxofre, magnésio, potássio e oxigênio, e de micronutrientes para aporte de elementos como manganês, cobalto, zinco, molibdênio, níquel, cobre, boro, de modo que ocorra um crescimento balanceado da biomassa; III) promover o esgotamento de um ou mais nutrientes essenciais ao crescimento para promover o acúmulo de PHA; IV) separar a biomassa do caldo fermentativo, extrair e purificar o PHA. Durante a Etapa III, o PHA produzido é constituído, principalmente, de monómeros de 3-hidroxibutirato. O processo de síntese prossegue até que o contéudo de PHA intracelular atinja um valor entre 20% e 80% da massa seca da biomassa produzida sendo, então, a biomassa concentrada e o material polimérico extraído pelos métodos convencionais descritos na literatura.",INST PESQUISAS TECH,PRADELLA JOSE GERALDO DA CRUZ;;TACIRO MARILDA KEICO;;GOMEZ JOSE GREGORIO CABRERA;;PICOLLI ROSANE APARECIDA MONIZ;;DELGADO CECILIA CLAUDIA ROMERO,,https://lens.org/154-329-665-934-827,Patent Application,no,0,0,1,1,0,,C12P7/62,,0,0,,,,DISCONTINUED
484,DE,D1,DE 69813011 D1,155-171-911-884-829,2003-05-08,2003,DE 69813011 T,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,NEUTRALGRAUE GLASZUSAMMENSETZUNG MIT NIEDRIGER LICHTDURCHLÄSSIGKEIT,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: - Fe2O3 from 1.20 to 2.0% - FeO from 18 to 28% (Reduction Percentage). - Co3O4 from 0.020 to 0.030% - Se from 0.0025 to 0.010% - CuO from 0.0050 to 0.050% - This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",TECNOLOGIA VITRO VIDRIO Y CRIS,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,,https://lens.org/155-171-911-884-829,Granted Patent,no,0,0,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
485,MX,A,MX 2010008209 A,126-016-445-655-591,2012-01-27,2012,MX 2010008209 A,2010-07-28,MX 2010008209 A,2010-07-28,"FOOD SUPPLEMENT IN GEL MADE OF THE FOLLOWING FRUITS: CITRUS AURANTUM L, CITRUS SINENSIS, FRAGARIA S, DRIED PRUNUS DOMESTICA AND HONEY, ADDED WITH AMINO ACIDS OF BRANCHED CHAIN.","The present invention refers to a food supplement that is intended to ensure and develop an optimum supply of the substances required by the body for those who do exercise, thus providing a higher supply of energy as well as antioxidants. The food supplement is formed by fruit, natural fibre, antioxidants, sweeteners, gelling agents and a power source, the same preventing the central fatigue from occurring in the consumers, which are mainly athletes.",SANCHEZ JONATHAN LLAMAS,SANCHEZ JONATHAN LLAMAS;;SANCHEZ ANDRES SEPULVEDA;;MEZA ALMA ROSA DEL ANGEL;;GONZALEZ JOSE LUIS CABRERA,,https://lens.org/126-016-445-655-591,Patent Application,no,0,0,1,1,0,,A23L1/00,,0,0,,,,DISCONTINUED
486,WO,A1,WO 1999/028257 A1,097-336-754-213-159,1999-06-10,1999,MX 9800053 W,1998-12-02,US 98261297 A,1997-12-02,LOW LIGHT-TRANSMITTING NEUTRAL GREY GLASS COMPOSITION,"The invention relates to a glass comprised of silicon, sodium and calcium of neutral grey colour with low light transmission (less than 20 %). The glass reduces the solar energy transmission such as for example the transmission of near infrared radiation (less than 14 %) and to a large extent the transmission of ultraviolet radiation transmission (less than 12 %). This glass comprises the following components expressed in percentages by weight: Fe2O3 between 1.20 and 2.0 %; FeO between 18 and 28 % (reduction percentage); Co3O4 between 0.020 and 0.030 %; selenium between 0.0025 and 0.010 %; CuO between 0.0050 and 0.050 %. The glass of the invention avoids using colorant compounds such as nickel, chromium and manganese.",VIDRIO PLANO DE MEXICO S A DE,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,,https://lens.org/097-336-754-213-159,Patent Application,yes,3,1,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,PATENTED
487,MX,A,MX 2021005577 A,001-025-935-963-10X,2021-12-10,2021,MX 2021005577 A,2021-05-12,MX 2021005577 A,2021-05-12,CNC CYLINDRICAL GRINDING CENTER.,"The present invention relates to a two-axis CNC cylindrical grinding center with translational and rotational kinematics that generate degrees of freedom, arranged to perform four cylindrical grinding processes between centers, cantilever, centerless, and internal on a single platform. Said system is ingenious, simple, functional, and has an easy-to-operate design, which reduces components, cost, and maintenance. Also, it possesses proven technology for improving solidity, reducing vibrations, minimizing efforts, and increasing the effectiveness of the cut to guarantee the demanding requirements of precision and surface roughness. Herein, the axis of the abrasive cutting wheel has a vertical disposition and a rotating mechanism for positioning the cutting face thereof. The said circumstance improves the roughing operation and favors surface roughness in the finishing operation, using an independent motorized drive system for rotating the work piece and minimizing vibrations to the fix ed-point head. In addition, it uses a secondary motorized spindle with an abrasive wheel for dressing, blunting, and profiling the abrasive cutting wheel.",INTEGRACION E INGENIERIAS PMS S A DE C V,JARAMILLO LORANCA BLANCA ESTELA;;CABRERA LÓPEZ FERNANDO RAYBEL;;LÓPEZ FALCON RAMÓN;;CRUZ DÍAZ JOSE LUIS,,https://lens.org/001-025-935-963-10X,Patent Application,no,0,0,1,1,0,,B24B19/00,,0,0,,,,PENDING
488,ES,A1,ES 2408281 A1,082-402-963-045-25X,2013-06-19,2013,ES 201131785 A,2011-11-08,ES 201131785 A,2011-11-08,"USE OF A CHEMICAL COMPOUND DERIVED FROM A 1,2,3,5-TETRASUBSTITUTED PYROLE IN THE PREPARATION OF A DRUG FOR USE IN TREATING INFLAMMATORY DISEASES INVOLVING PROCESSES OF CELLULAR APOPTOSIS","The present invention relates to the use of compounds derived from 1,2,3,5-tetrasubstituted pyroles in conjunction with pharmaceutically acceptable excipients in the production of a drug that can be used to treat inflammatory diseases involving processes of cellular apoptosis, preferably diseases arising through sepsis caused by Gram-negative bacteria. Said diseases include acute sepsis-induced pulmonary diseases, acute sepsis-induced respiratory distress syndrome, endotoxic or endotoxemic shock, septic peritonitis or trauma. The invention also comprises the pharmaceutical composition for treating said diseases.",CIBERES CT DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES RESPIRATORIAS;;SERVICIO CANARIO DE SALUD;;UNIV LA LAGUNA,CABRERA BENITEZ NURIA ESTHER;;RAMOS NUEZ ANGELA MA;;VILLAR HERNANDEZ JESUS;;PADRON CARRILLO JOSE MANUEL,,https://lens.org/082-402-963-045-25X,Patent Application,no,0,0,3,3,0,A61K31/40;;A61K31/40;;A61P35/00;;C07D207/34;;C07D207/34;;C07D413/06,A61K31/40;;A61P35/00;;C07D207/34,,4,2,021-037-663-852-126;;075-701-567-508-781,10.2174/157018005774479122;;15863302;;10.1016/j.bmcl.2005.03.069,"30/11/2008, TEJEDOR DAVID et al. From conjugated tertiary skipped diynes to chain-functionalizedtetrasubstituted pyrroles.. Chemistry (Weinheim an der Bergstrasse, Germany) 00/00/2009 VOL: 15 No: 4 Pags: 838 - 842 ISSN 1521-3765 (Electronic) Doi: doi:10.1002/chem.200802262pubmed:19086044, página 839, esquema 1, tabla 1, compuesto 1 y página 840, esquema 2.;;14/07/2004, TEJEDOR DAVID et al. A diversity-oriented strategy for the construction of tetrasubstitutedpyrroles via coupled domino processes.. Journal of the American Chemical Society 14/07/2004 VOL: 126 No: 27 Pags: 8390 - 8391 ISSN 0002-7863 (Print) Doi: pubmed:15237991,  esquemas 1 y 2.;;31/10/2005, PADRON J M et al. Synthesis and anti-breast cancer activity of tetrasubstituted pyrrolederivatives. Letters in Drug Design and Discovery 00/11/2005 VOL: 2 No: 7 Pags: 529 - 532 ISSN 1570-1808 (print) Doi: doi:10.2174/157018005774479122, página 531, columna 2 y tabla 1.;;16/05/2005, PADRON J M et al. Antiproliferative activity in HL60 cells by tetrasubstituted pyrroles:a structure-activity relationship study. BIOORGANIC MEDICINAL CHEMISTRY LETTERS, 16/05/2005 VOL: 15 No: 10 Pags: 2487 - 2490 ISSN 0960-894X, página 2488, tabla 1, página 2489, columna 2.",ACTIVE
489,EP,B1,EP 1036045 B1,111-660-780-550-589,2003-04-02,2003,EP 98958396 A,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,LOW LIGHT-TRANSMITTING NEUTRAL GREY GLASS COMPOSITION,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: - Fe2O3 from 1.20 to 2.0% - FeO from 18 to 28% (Reduction Percentage). - Co3O4 from 0.020 to 0.030% - Se from 0.0025 to 0.010% - CuO from 0.0050 to 0.050% - This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",TECNOLOGIA VITRO VIDRIO Y CRIS,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,"TECNOLOGIA VITRO VIDRIO Y CRISTAL, S.A. DE C.V. (2002-04-17)",https://lens.org/111-660-780-550-589,Granted Patent,yes,3,1,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
490,MX,A,MX 2011013382 A,031-966-987-541-18X,2013-06-20,2013,MX 2011013382 A,2011-12-12,MX 2011013382 A,2011-12-12,"SAFETY PERIPHERAL INTRAVENOUS CATHETER HAVING A QUICK, PAINLESS PUNCTURE SYSTEM.","A Peripheral Intravenous Safety Catheter with Quick, Painless Puncture System (PISCQPPS) and a cannula with a retractile needle mounted in a manually operated bellows mechanism to prevent re-use, avoid accidental perforation and ensure safe disposal. The PISCQPPS offers the advantages of reducing or eliminating pain; reducing the possibility of multiple perforation; reducing the need for experience and technical know-how in the matter of injection; Being fitted with a safety system; and easy to use. The PISCQPPS consists of two sequential operating systems -namely, a painless insertion system that is located inside a case, consisting of: a catheter; a catheter holder; a trigger guard, a trigger-guard holder, a catheter-holder tube, a cannula, a cannula holder, a spring, a filter holder, and a filter; along with a safety system inside whose case the cannula holder, the cannula and the bellows all operated at the same time.",EQUIPOS MEDICOS VIZCARRA S A,LELIS JOSE MARIA RODRIGUEZ;;CABRERA JOSE ANTONIO ARELLANO;;JIMENEZ MARIA TERESA LUCAS;;VIZCARRA ALFREDO CHALITA;;QUIROZ HUGO SOLORZANO;;HERNANDEZ ROCIO CASSAIGNE,,https://lens.org/031-966-987-541-18X,Patent Application,no,0,1,7,7,0,A61B5/1411;;A61B5/15;;A61B5/15003;;A61B5/150389;;A61B5/150351;;A61M25/0113;;A61M25/0606;;A61M25/0631;;A61M25/0631;;A61M25/0606;;A61M25/0113,A61M5/00,,0,0,,,,ACTIVE
491,EP,A1,EP 2604307 A1,165-014-541-703-018,2013-06-19,2013,EP 12382423 A,2012-10-31,MX 2011013382 A,2011-12-12,"Peripheral intravenous safety catheter with quick, painless puncture system","We here present the Peripheral Intravenous Safety Catheter with Quick, Painless Puncture System (PISCQPPS) and a cannula with a retractile needle mounted in a manually operated bellows mechanism in order to prevent re-use, avoid accidental perforation and ensure safe disposal. This PISCQPPS offers the advantages of: (a) reducing or eliminating pain; (b) reducing the possibility of multiple perforation; reducing the need for experience and technical know-how in the matter of injection; (c) being fitted with a safety system; and (d) being easy to use. The Peripheral Intravenous Safety Catheter with Quick, Painless Puncture System consists of two sequential operating systems - namely, a painless insertion system that is located inside a case (9), consisting of (1) a catheter, (2) a catheter holder, (3 and 4) a trigger guard, (5) a trigger-guard holder, (6) a catheter-holder tube, (7) a cannula, (8) a cannula holder, (11) a spring, (12) a filter holder, and (13) a filter; along with a safety system inside whose case (9) the cannula holder (8), the cannula (7) and the bellows (10) all operate at the same time.
",EQUIPOS MEDICOS VIZCARRA S A,RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO,,https://lens.org/165-014-541-703-018,Patent Application,yes,13,0,7,7,0,A61B5/1411;;A61B5/15;;A61B5/15003;;A61B5/150389;;A61B5/150351;;A61M25/0113;;A61M25/0606;;A61M25/0631;;A61M25/0631;;A61M25/0606;;A61M25/0113,A61M25/01;;A61M5/20;;A61M5/32;;A61M25/06,,3,2,058-034-025-744-728;;034-878-198-127-778,16265830;;10.1007/3-540-45786-0_27,"A. M. RIVERA; K. W. STRAUSS; A. VAN ZUNDERT; E. MORTIER: ""The history of peripheral intravenous catheters : How little plastic tubes revolutionized medicine"", ACTA ANAESTH. BELG., vol. 56, 2005, pages 271 - 282;;HIROYUKI KATAOKA: ""Measurement of the tip and friction force acting on a needle during penetration"", NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, MICCAI '02 PROCEEDINGS OF THE 5TH INTERNATIONAL CONFERENCE ON MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION-PART I, 2002;;DAVIS, S. P.: ""Ph.D. Thesis"", 2003, GEORGIA INSTITUTE OF TECHNOLOGY, article ""Hollow microneedles for molecular transport across skin""",ACTIVE
492,CA,C,CA 2312899 C,016-047-990-266-720,2004-09-21,2004,CA 2312899 A,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,LOW LIGHT TRANSMISSION NEUTRAL GRAY GLASS,"The invention relates to a glass comprised of silicon, sodium and calcium of neutral grey colour with low light transmission (less than 20 %). The glass reduces the solar energy transmission such as for example t he transmission of neat infrared radiation (less than 14 %) and to a large extent the transmission of ultraviolet radiation transmission (less than 12 %). This glass comprises the following components expressed in percentages by weight Fe2O3 between 1.20 and 2.0 %; FeO between 18 and 28 % (reduction percentage); Co3O4 between 0.020 and 0.030 %; selenium between 0.0025 and 0.010 %; CuO between 0.0050 a nd 0.050 %. The glass of the invention avoids using colorant compounds such as nickel, chromium and manganese.",VIDRIO PLANO DE MEXICO S A DE,CABRERA LLANOS ROBERTO MARCOS;;PINTO NEGROE RAFAEL ENRIQUE;;CID AGUILAR JOSE GUADELUPE;;SCHEFFLER HUDLET HERBERT,,https://lens.org/016-047-990-266-720,Granted Patent,no,0,0,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
493,MX,A,MX GT06000012 A,067-413-728-352-751,2008-01-31,2008,MX GT06000012 A,2006-08-01,MX GT06000012 A,2006-08-01,"DEVICE FOR MEASURING AND MAPPING SOIL COMPACTION, ENGAGEABLE TO AN AGRICULTURAL TRACTOR.","Described is a device for measuring and mapping soil compaction, which is engageable to a tractor, allowing an intense sampling of the soil compaction degree to be carried out. The inventive device comprises a structure for allowing the same to be engaged to a tractor; an hydraulic cylinder mounted to the aforementioned structure, which allows a compaction sensor to be displaced; a compaction sensor (penetrometer); and a structure mounted at the free end portion of the mobile bar pertaining to the cylinder, which is useful for mounting the compaction sensor. The present device may also be used for mapping compaction, including the aforementioned elements and a GPS used for determining the position where the compaction measurement is performed; as well as a data acquisition system for registering the compaction and positioning data. The hydraulic system of the tractor is used for measuring and mapping compaction, thus removing the stress performed by an operator using the manual method , assuring a constant speed while penetrating the soil, and improving the penetration vertical, thereby allowing the penetration test standard (ASAE EP542) to be followed, thus obtaining more reliable readings. The present device also allows an intensive sampling of the soil compaction and a compaction map to be performed.",UNIV GUANAJUATO,SIXTO JOSE MANUEL CABRERA;;HLAWINSKA RYSZARD JERZY SERWAT;;ROBLES NOE SALDANA;;CHAVEZ EROS EMMANUEL PORRAS,,https://lens.org/067-413-728-352-751,Patent Application,no,0,27,1,1,0,,G01N3/00,,0,0,,,,DISCONTINUED
494,DE,T2,DE 69813011 T2,086-029-161-075-521,2004-03-11,2004,DE 69813011 T,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,NEUTRALGRAUE GLASZUSAMMENSETZUNG MIT NIEDRIGER LICHTDURCHLÄSSIGKEIT,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: - Fe2O3 from 1.20 to 2.0% - FeO from 18 to 28% (Reduction Percentage). - Co3O4 from 0.020 to 0.030% - Se from 0.0025 to 0.010% - CuO from 0.0050 to 0.050% - This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",TECNOLOGIA VITRO VIDRIO Y CRIS,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,,https://lens.org/086-029-161-075-521,Granted Patent,no,0,0,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
495,CU,A1,CU 22804 A1,009-852-897-012-839,2002-12-19,2002,CU 1999018 A,1999-02-24,CU 1999018 A,1999-02-24,MÉTODO DE LIMPIEZA DE SUPERFICIE DE LÁMINAS DE MATERIALES TRANSPARENTES EN LA ZONA VISIBLE E INFRARROJA DEL ESPECTRO EMPLEANDO UN LÁSER QUE INCIDE A TRAVÉS DE LA LÁMINA,"Método para limpiar la superficie de láminas de materiales transparentes en la zona visible e infrarroja del espectro como planchas u objetos de vidrio, acrílico u otro material transparente al láser, utilizando la luz del láser como medio para realizar la limpieza y realizando la incidencia de éste a tavés del material, o sea limpiando la capa de suciedad o del material que se desea retirar por detrás. La limpieza se realiza por un método de ablación: la potencia de luz láser provoca la evaporación de la capa de suciedad o del material que se desea retirar. El procedimiento de limpieza es utilizado eficientemente en ventanas, puertas, paredes, mesas, etc.",INST DE MATERIALES Y REACTIVOS PARA LA ELECTRONICA,BILMES GABRIEL;;FLORES REYES TERESA;;ARRONTE GARCIA MIGUEL;;PICANS SUSACASA JOSE;;PONCE CABRERA LUIS VIDAL,,https://lens.org/009-852-897-012-839,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
496,ES,B1,ES 2611759 B1,182-733-459-812-140,2018-02-27,2018,ES 201531458 A,2015-10-09,ES 201531458 A,2015-10-09,"Uso de variantes alélicas (SNPs) en la región 6p21.33 para el diagnóstico, pronóstico y tratamiento de la Enfermedad de Ménière.",,SERVICIO ANDALUZ DE SALUD;;FUNDACION PÚBLICA ANDALUZA PROGRESO Y SALUD,LÓPEZ ESCÁMEZ JOSE ANTONIO;;CABRERA MARTÍNEZ SONIA;;ALARCÓN RIQUELME MARTA EUGENIA;;REQUENA NAVARRO MARÍA TERESA,,https://lens.org/182-733-459-812-140,Granted Patent,no,0,0,4,4,0,C12Q2600/156;;C12Q1/6883;;C12Q2600/118;;C12Q2600/156;;C12N15/1089;;C12Q1/6883;;C12Q2600/118,C12Q1/68,,0,0,,,,ACTIVE
497,BR,A2,BR 102012031692 A2,011-369-685-118-22X,2015-10-20,2015,BR 102012031692 A,2012-12-12,MX 2011013382 A,2011-12-12,cateter intravenoso periférico de segurança com sistema de punção indolor e rápido,"cateter intravenoso periférico de segurança com sistema de punçao indolor e rápido. é apresentado o cateter intravenoso periférico de segurança com sistema de punção indolor e rápido (piscqpps) e uma cânula com uma agulha retrátil montada em um mecanismo em forma de fole acionado manualmente de modo a impedir reutilização, evitar perfuração acidental e assegurar descarte seguro. o piscqpps oferece a vantagem de: (a) reduzir ou eliminar a dor; (b) reduzir a possibilidade de várias perfuraçôes; reduzir a necessidade de experiência e perícia técnica na matéria de injeção; (c) ser dotado de um sistema de segurança; e (d) ser fácil de utilizar, o cateter intravenoso periférico de segurança com sistema de punção indolor e rápido consiste em dois sistemas operacionais sequenciais a saber, um sistema de inserção indolor que élocalizado no interior de uma caixa (9), que qonsiste em (1) um cateter, (2) um porta-cateter, (3 e 4) um protetor de gatilho, (5) um porta-protetor de gatilho, (6) um tubo portador de cateter, (7) uma cânula, (8) um porta-cânula, (11) uma mola, (12) um porta-filtro e (13) um filtro; juntamente com um sistema de segurança no interior de cuja caixa (9) o porta-cânula (8), a cânula (7) e o fole (10) funcionam todos ao mesmo tempo.",EQUIPOS MEDICOS VIZCARRA S A,VIZCARRA ALFREDO CHALITA;;QUIROZ HUGO SOLORZANO;;CABRERA JOSE ANTONI ARELLANO;;LELIS JOSE MARIA RODRIGUES;;JIMENEZ MARIA TERESA LUCAS;;HERNANDEZ ROCIO CASSAIGNE,,https://lens.org/011-369-685-118-22X,Patent Application,no,0,0,7,7,0,A61B5/1411;;A61B5/15;;A61B5/15003;;A61B5/150389;;A61B5/150351;;A61M25/0113;;A61M25/0606;;A61M25/0631;;A61M25/0631;;A61M25/0606;;A61M25/0113,A61B5/15,,0,0,,,,DISCONTINUED
498,WO,A1,WO 2013/089541 A1,134-603-447-423-678,2013-06-20,2013,MX 2011000157 W,2011-12-13,MX 2011013382 A,2011-12-12,"SAFETY PERIPHERAL INTRAVENOUS CATHETER HAVING A QUICK, PAINLESS PUNCTURE SYSTEM","The invention relates to a safety peripheral intravenous catheter having a quick, painless puncture system, which includes a catheter (1) connected to a catheter holder (2) which is inserted into a safety holder (5) which in turn contains the activation device made up of two complementary parts (3). The catheter holder (2) is, in turn, connected to the catheter-holder tube (6) and the cannula is inside the catheter (1). At the end opposite the free end thereof, the cannula (7) is attached to a cannula holder. The elements are housed in a casing (9). Between the casing and the cannula holder (8) is a bellows (10) and a spring is provided at one end of the cannula holder.",EQUIPOS MEDICOS VIZCARRA S A;;LUCAS JIMENEZ MARIA TERESA;;RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO,LUCAS JIMENEZ MARIA TERESA;;RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO,,https://lens.org/134-603-447-423-678,Patent Application,yes,5,0,7,7,0,A61B5/1411;;A61B5/15;;A61B5/15003;;A61B5/150389;;A61B5/150351;;A61M25/0113;;A61M25/0606;;A61M25/0631;;A61M25/0631;;A61M25/0606;;A61M25/0113,A61M25/01,,1,0,,,"DATABASE WPI Derwent World Patents Index; AN 2005-421581, XP003031244, RETRIEVED",PENDING
499,ES,A1,ES 2333638 A1,134-827-650-415-035,2010-02-24,2010,ES 200901745 A,2009-07-29,ES 200901745 A,2009-07-29,"USE OF MASLINIC ACID FOR TREATING NOCICEPTIVE, INFLAMMATORY AND NEUROGENIC PAIN","Use of maslinic acid for treating nociceptive, inflammatory and neurogenic pain. The present invention relates to the use of maslinic acid and any of the derivatives thereof for treating painful pathological processes of a (1) nociceptive, (2) inflammatory or (3) neurogenic nature by any galenically acceptable means and very especially topically, including compositions that contain maslinic acid, any of the derivates thereof, or natural, synthetic or semi-synthetic mixtures rich in maslinic acid or the derivatives thereof.",UNIV GRANADA,NIETO LOPEZ FRANCISCO MANUE;;BAEYENS CABRERA JOSE MANUEL;;GARCIA-GRANADOS LOPEZ DE HIERRO ANDRES;;ENTRENA FERNANDEZ JOSE MANUEL;;COBOS DEL MORAL ENRIQUE JOSE;;MARTINEZ RODRIGUEZ ANTONIO,,https://lens.org/134-827-650-415-035,Patent Application,no,1,1,4,4,0,A61K31/56;;A61K31/19,A61K31/56,,3,1,063-119-127-759-916,17978478;;10.1248/bpb.30.2075,"(en línea) Recuperado el 26.10.2009. Recuperado de EPO EPODOC Database & WO 03057224 A1 (NISSHIN OILLIO LTD) 17.07.2003 (resumen);;JUN, L. et al.: ""Maslinic acid reduces blood glucose in KK-AY mice"". Biol. Pharm. Bull, 2007, vol. 30, páginas 2075-2078, página 2075, primera columna, segunda columna, líneas 1-5.;;LUTTERODT, G.D. et al.: ""Effects on mice locomotor activity of a narcotic-like principle from Psidium Guajava leaves"". Journal of Ethnopharmacology, 1988, vol. 24, páginas 219-231, páginas 220, 3º y 4º párrafo.",ACTIVE
500,EP,A1,EP 1036045 A1,137-471-355-962-305,2000-09-20,2000,EP 98958396 A,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,LOW LIGHT-TRANSMITTING NEUTRAL GREY GLASS COMPOSITION,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: - Fe2O3 from 1.20 to 2.0% - FeO from 18 to 28% (Reduction Percentage). - Co3O4 from 0.020 to 0.030% - Se from 0.0025 to 0.010% - CuO from 0.0050 to 0.050% - This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",VIDRIO PLANO DE MEXICO S A DE,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,"TECNOLOGIA VITRO VIDRIO Y CRISTAL, S.A. DE C.V. (2002-04-17)",https://lens.org/137-471-355-962-305,Patent Application,yes,0,1,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
501,ES,T3,ES 2209224 T3,193-873-079-981-288,2004-06-16,2004,ES 98958396 T,1998-12-02,US 98261297 A,1997-12-02,COMPOSICION DE VIDRIO GRIS NEUTRO DE BAJA TRANSMISION DE LUZ.,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: - Fe2O3 from 1.20 to 2.0% - FeO from 18 to 28% (Reduction Percentage). - Co3O4 from 0.020 to 0.030% - Se from 0.0025 to 0.010% - CuO from 0.0050 to 0.050% - This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",IP VITRO VIDRIO Y CRISTAL LTD,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,,https://lens.org/193-873-079-981-288,Granted Patent,no,0,0,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
502,US,A,US 6080695 A,188-121-074-282-274,2000-06-27,2000,US 98261297 A,1997-12-02,US 98261297 A,1997-12-02,Low light transmission neutral gray glass,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: ______________________________________ Fe.sub.2 O.sub.3 from 1.20 to 2.0% FeO from 18 to 28% (Reduction Percentage). Co.sub.3 O.sub.4 from 0.020 to 0.030% Se from 0.0025 to 0.010% CuO from 0.0050 to 0.050% ______________________________________ This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",VIDRIO PLANO DE MEXICO S A DE,SCHEFFLER-HUDLET HERBERT;;CABRERA-LLANOS ROBERTO-MARCOS;;CID-AGUILAR JOSE-GUADALUPE;;PINTO-NEGROE RAFAEL-ENRIQUE,VIDRIO PLANO DE MEXICO S.A. DE C.V (1997-11-25);;TECHNOLOGIA VITRO VIDRIO Y CRISTAL LTD (2001-12-12);;IP VITRO VIDRIO Y CRISTAL LTD (2003-02-27),https://lens.org/188-121-074-282-274,Granted Patent,yes,5,25,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,501/71;;501/70;;501/904;;501/905,0,0,,,,EXPIRED
503,US,B2,US 8585644 B2,159-452-033-243-759,2013-11-19,2013,US 201213560434 A,2012-07-27,MX 2011013382 A,2011-12-12,"Peripheral intravenous safety catheter with quick, painless puncture system","A Peripheral Intravenous Safety Catheter with Quick, Painless Puncture System (PISCQPPS) and a cannula with a retractile needle mounted in a manually operated bellows mechanism to prevent re-use, avoid accidental perforation and ensure safe disposal. This PISCQPPS offers the advantages of reducing or eliminating pain; reducing the possibility of multiple perforation; reducing the need for experience and technical know-how in the matter of injection; being fitted with a safety system; and easy to use. The PISCQPPS consists of two sequential operating systems-namely, a painless insertion system that is located inside a case, consisting of a catheter, a catheter holder, a trigger guard, a trigger-guard holder, a catheter-holder tube, a cannula, a cannula holder, a spring, a filter holder, and a filter; along with a safety system inside whose case the cannula holder, the cannula and the bellows all operate at the same time.",RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO;;EQUIPOS MEDICOS VIZCARRA S A,RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO,EQUIPOS MEDICOS VIZCARRA S.A (2012-07-04),https://lens.org/159-452-033-243-759,Granted Patent,yes,2,14,7,7,0,A61B5/1411;;A61B5/15;;A61B5/15003;;A61B5/150389;;A61B5/150351;;A61M25/0113;;A61M25/0606;;A61M25/0631;;A61M25/0631;;A61M25/0606;;A61M25/0113,A61M5/50,604/110;;604/164.01,0,0,,,,INACTIVE
504,WO,A1,WO 2013/068621 A1,112-104-430-277-040,2013-05-16,2013,ES 2012070767 W,2012-10-31,ES 201131785 A,2011-11-08,"USE OF A CHEMICAL COMPOUND DERIVED FROM A 1,2,3,5-TETRASUBSTITUTED PYROLE IN THE PREPARATION OF A DRUG FOR USE IN TREATING INFLAMMATORY DISEASES INVOLVING PROCESSES OF CELLULAR APOPTOSIS","The present invention relates to the use of compounds derived from 1,2,3,5-tetrasubstituted pyroles in conjunction with pharmaceutically acceptable excipients in the production of a drug that can be used to treat inflammatory diseases involving processes of cellular apoptosis, preferably diseases arising through sepsis caused by Gram‑negative bacteria. Said diseases include acute sepsis‑induced pulmonary diseases, acute sepsis‑induced respiratory distress syndrome, endotoxic or endotoxemic shock, septic peritonitis or trauma. The invention also comprises the pharmaceutical composition for treating said diseases.",CIBER DE ENFERMEDADES RESPIRATORIAS;;UNIV LA LAGUNA;;SERVICIO CANARIO DE SALUD,CABRERA BENITEZ NURIA ESTHER;;RAMOS NUEZ ANGELA MARIA;;VILLAR HERNANDEZ JESUS;;PADRON CARRILLO JOSE MANUEL,,https://lens.org/112-104-430-277-040,Patent Application,yes,0,0,3,3,0,A61K31/40;;A61K31/40;;A61P35/00;;C07D207/34;;C07D207/34;;C07D413/06,A61K31/40;;A61P35/00;;C07D207/34,,4,3,065-517-010-313-36X;;020-093-312-619-218;;075-701-567-508-781,19086044;;10.1002/chem.200802262;;15237991;;10.1021/ja047396p;;15863302;;10.1016/j.bmcl.2005.03.069,"TEJEDOR DAVID ET AL.: ""From conjugated tertiary skipped diynes to chain-functionalizedtetrasubstituted pyrroles.."", CHEMISTRY (WEINHEIM AN DER BERGSTRASSE, GERMANY), vol. 15, no. 4, 30 November 2008 (2008-11-30), pages 838 - 842;;TEJEDOR DAVID ET AL.: ""A diversity-oriented strategy for the construction of tetrasubstitutedpyrroles via coupled domino processes.."", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 27, 14 July 2004 (2004-07-14), pages 8390 - 8391;;PADRON J M ET AL.: ""Synthesis and anti-breast cancer activity of tetrasubstituted pyrrolederivatives."", LETTERS IN DRUG DESIGN AND DISCOVERY, vol. 2, no. 7, 31 October 2005 (2005-10-31), pages 529 - 532;;PADRON J M ET AL.: ""Antiproliferative activity in HL60 cells by tetrasubstituted pyrroles:a structure-activity relationship study."", BIOORGANIC MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 10, 16 May 2005 (2005-05-16), pages 2487 - 2490, XP025314314, DOI: doi:10.1016/j.bmcl.2005.03.069",PENDING
505,AT,T1,AT E236095 T1,151-476-899-537-956,2003-04-15,2003,AT 98958396 T,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,NEUTRALGRAUE GLASZUSAMMENSETZUNG MIT NIEDRIGER LICHTDURCHLÄSSIGKEIT,"A neutral gray soda-lime-silica glass having a low light transmission (less than 20%), which reduces the transmission of solar energy, such as the transmission of near infrared radiation (less than 14%) and, in a greater degree, the transmission of ultraviolet radiation (less than 12%), comprising the following components in weight percentage: - Fe2O3 from 1.20 to 2.0% - FeO from 18 to 28% (Reduction Percentage). - Co3O4 from 0.020 to 0.030% - Se from 0.0025 to 0.010% - CuO from 0.0050 to 0.050% - This glass avoids the use of the coloring compounds such as the nickel, chromium and manganese.",TECNOLOGIA VITRO VIDRIO Y CRIS,SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS;;CID AGUILAR JOSE GUADALUPE;;PINTO NEGROE RAFAEL ENRIQUE,,https://lens.org/151-476-899-537-956,Granted Patent,no,0,0,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,PENDING
506,US,A1,US 2013/0150784 A1,182-609-083-533-961,2013-06-13,2013,US 201213560434 A,2012-07-27,MX 2011013382 A,2011-12-12,"PERIPHERAL INTRAVENOUS SAFETY CATHETER WITH QUICK, PAINLESS PUNCTURE SYSTEM","A Peripheral Intravenous Safety Catheter with Quick, Painless Puncture System (PISCQPPS) and a cannula with a retractile needle mounted in a manually operated bellows mechanism to prevent re-use, avoid accidental perforation and ensure safe disposal. This PISCQPPS offers the advantages of reducing or eliminating pain; reducing the possibility of multiple perforation; reducing the need for experience and technical know-how in the matter of injection; being fitted with a safety system; and easy to use. The PISCQPPS consists of two sequential operating systems - namely, a painless insertion system that is located inside a case, consisting of a catheter, a catheter holder, a trigger guard, a trigger-guard holder, a catheter-holder tube, a cannula, a cannula holder, a spring, a filter holder, and a filter; along with a safety system inside whose case the cannula holder, the cannula and the bellows all operate at the same time.",RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO;;EQUIPOS MEDICOS VIZCARRA S A,RODRIGUEZ LELIS JOSE MARIA;;ARELLANO CABRERA JOSE ANTONIO;;LUCAS JIMENEZ MARIA TERESA;;CHALITA VIZCARRA ALFREDO;;SOLORZANO QUIROZ HUGO;;CASSAIGNE HERNANDEZ ROCIO,EQUIPOS MEDICOS VIZCARRA S.A (2012-07-04),https://lens.org/182-609-083-533-961,Patent Application,yes,2,27,7,7,0,A61B5/1411;;A61B5/15;;A61B5/15003;;A61B5/150389;;A61B5/150351;;A61M25/0113;;A61M25/0606;;A61M25/0631;;A61M25/0631;;A61M25/0606;;A61M25/0113,A61M5/50,604/110,0,0,,,,INACTIVE
507,CA,A1,CA 2312899 A1,173-104-189-446-903,1999-06-10,1999,CA 2312899 A,1998-12-02,MX 9800053 W;;US 98261297 A,1997-12-02,LOW LIGHT TRANSMISSION NEUTRAL GRAY GLASS,"The invention relates to a glass comprised of silicon, sodium and calcium of neutral grey colour with low light transmission (less than 20 %). The glass reduces the solar energy transmission such as for example the transmission of near infrared radiation (less than 14 %) and to a large extent the transmission of ultraviolet radiation transmission (less than 12 %). This glass comprises the following components expressed in percentages by weight: Fe2O3 between 1.20 and 2.0 %; FeO between 18 and 28 % (reduction percentage); Co3O4 between 0.020 and 0.030 %; selenium between 0.0025 and 0.010 %; CuO between 0.0050 and 0.050 %. The glass of the invention avoids using colorant compounds such as nickel, chromium and manganese.",VIDRIO PLANO DE MEXICO S A DE,PINTO NEGROE RAFAEL ENRIQUE;;CID AGUILAR JOSE GUADELUPE;;SCHEFFLER HUDLET HERBERT;;CABRERA LLANOS ROBERTO MARCOS,,https://lens.org/173-104-189-446-903,Patent Application,no,0,1,10,10,0,C03C3/087;;C03C4/02;;C03C4/082;;C03C4/085;;Y10S501/904;;Y10S501/905;;C03C4/02;;C03C3/087;;C03C4/085;;C03C4/082;;Y10S501/905;;Y10S501/904,C03C3/087;;C03C4/02;;C03C4/08,,0,0,,,,EXPIRED
508,ES,B2,ES 2333638 B2,020-045-719-430-605,2010-10-21,2010,ES 200901745 A,2009-07-29,ES 200901745 A,2009-07-29,"USO DEL ACIDO MASLINICO PARA EL TRATAMIENTO DE DOLORES DE NATURALEZA NOCICEPTIVA, INFLAMATORIA Y NEUROGENICA",,UNIV GRANADA,NIETO LOPEZ FRANCISCO RAFAE;;BAEYENS CABRERA JOSE MANUEL;;GARCIA-GRANADOS LOPEZ DE HIERRO ANDRES;;ENTRENA FERNANDEZ JOSE MANUEL;;COBOS DEL MORAL ENRIQUE JOSE;;MARTINEZ RODRIGUEZ ANTONIO,,https://lens.org/020-045-719-430-605,Granted Patent,no,0,0,4,4,0,A61K31/56;;A61K31/19,A61K31/56,,0,0,,,,ACTIVE
509,US,A1,US 2020/0284787 A1,137-397-631-085-642,2020-09-10,2020,US 201816762851 A,2018-11-08,EP 17382758 A;;EP 2018080662 W,2017-11-10,METHOD FOR DETECTION OF AN ANALYTE,"The present invention provides a method for in vitro detection and/or quantification of an analyte in aqueous or biological fluids based on monitoring the variation of the dynamical magnetisation signal of functionalized magnetic nanoparticles after their specific interaction with an analyte. The invention also provides a method for measuring the efficacy of a treatment of a disease in a subject, a method of diagnosis of a disease in a subject, as well as an apparatus for carrying out the three methods.",FUND IMDEA NANOCIENCIA,CABRERA CARRASCO DAVID;;AIRES TRAPOTE ANTONIO;;ARTES IBANEZ EMILIO JOSE;;CAMARERO DE DIEGO JULIO;;LOPEZ CORTAJARENA AITZIBER;;TERAN GARCINUNO FRANCISCO JOSE,FUNDACION IMDEA NANOCIENCIA (2020-05-13),https://lens.org/137-397-631-085-642,Patent Application,yes,4,3,3,3,0,G01R33/16;;G01N33/54326;;G01N27/745;;G01N33/54326;;G01N33/54346;;G01N33/553;;G01N2800/52,G01N33/543;;G01N27/74;;G01N33/553,,3,3,088-195-180-413-529;;025-860-461-491-584;;045-773-864-182-639,18754596;;10.1021/nl8022498;;pmc5336471;;10.1063/1.4978003;;28344854;;25273736;;10.1063/1.4895656,"Fornara et al., “Tailored Magnetic Nanoparticles for Direct and Sensitive Detection of Biomolecules in Biological Samples”, NANOLETTERS, 2008, Vol. 8, No. 10, 3423-3428;;Garraud et al. “Design and validation of magnetic particle spectrometer for characterization of magnetic nanoparticle relaxation dynamics”, AIP Advances 7, 056730 (2017);;Connord et al., “An air-cooled Litz wire coil for measuring the high frequency hysteresis loops of magnetic samples-A useful setup for magnetic hyperthermia applications”, Review of Scientific Instruments 85, 093904 (2014)",DISCONTINUED
510,CN,A,CN 110418710 A,064-562-873-176-977,2019-11-05,2019,CN 201680091742 A,2016-12-20,MX 2016000188 W,2016-12-20,LOW-EMISSIVITY COATING FOR A GLASS SUBSTRATE,"The present invention relates to a glass substrate provided with a stack of thin coating layers formed by a first layer of anti-reflective dielectric material, with a refractive index of 1.65 to 2.65,located above the glass substrate. At least one structure of two layers formed by a first layer of an anti-reflective transparent dielectric material with a refractive index of 1.32 to 1.55, locatedin the bottom position, and a second layer of a metal functional film with reflective properties in the infrared range, located in the top position, said structure being located above the first layerof anti-reflective dielectric material. A second layer of absorbent material forming an anti-corrosion barrier for protecting the metal functional film against oxidation and corrosion. A third layer of an anti-reflective material, said layer being selected from a metal oxide with a refractive index of 1.32 to 1.55, a metal oxide with a refractive index of 1.65 to 1.95 or an aluminium-doped zinc oxide (AZO); and a fourth protective layer made of an anti-reflective material, for increasing the transmission of visible light and the scratch resistance of the substrate, having high transmission ofvisible light (60%), a solar transmission of less than 60%, a resistance of less than 10 per square and an emissivity of less than 0.10.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;HERNANDEZ CARRILLO RUBI AGLAE;;TAVARES CORTEZ JOSE LUIS;;JERG CARMEN;;WEGENER INGO;;XU JIA LIN,,https://lens.org/064-562-873-176-977,Patent Application,no,10,3,13,13,0,B32B15/00;;B32B17/06;;C03C17/36;;C03C17/3644;;C03C17/366;;C03C17/3655;;C03C17/3652;;C03C17/3639;;B32B17/061;;C03C17/3615;;C03C17/3636;;C03C17/3644;;C03C17/366,B32B15/00;;B32B17/06;;C03C17/36,,3,0,,,"朱洪法 主编: ""《催化剂手册》"", 31 August 2008, 金盾出版社;;张杏芬 编译: ""《国外火炸药原材料性能手册》"", 30 November 1991, 兵器工业出版社;;李惠军 编著: ""《现代集成电路制造工艺原理》"", 28 February 2007, 山东大学出版社",PENDING
511,MX,A,MX 2019007308 A,135-691-850-210-399,2019-08-26,2019,MX 2019007308 A,2016-12-20,MX 2016000188 W,2016-12-20,LOW-EMISSIVITY COATING FOR A GLASS SUBSTRATE.,"The present invention relates to a glass substrate provided with a stack of thin coating layers formed by a first layer of anti-reflective dielectric material, with a refractive index of 1.65 to 2.65, located above the glass substrate. At least one structure of two layers formed by a first layer of an anti-reflective transparent dielectric material with a refractive index of 1.32 to 1.55, located in the bottom position, and a second layer of a metal functional film with reflective properties in the infrared range, located in the top position, said structure being located above the first layer of anti-reflective dielectric material. A second layer of absorbent material forming an anti-corrosion barrier for protecting the metal functional film against oxidation and corrosion. A third layer of an anti-reflective material, said layer being selected from a metal oxide with a refractive index of 1.32 to 1.55, a metal oxide with a refractive index of 1.65 to 1.95 or an aluminium-doped zinc oxide (AZO); and a fourth protective layer made of an anti-reflective material, for increasing the transmission of visible light and the scratch resistance of the substrate, having high transmission of visible light (60%), a solar transmission of less than 60%, a resistance of less than 10 per square and an emissivity of less than 0.10.",VIDRIO PLANO MEXICO SA DE CV,ROBERTO CABRERA LLANOS;;JOSE GUADALUPE CID AGUILAR;;HERNÁNDEZ CARRILLO RUBI AGLAÉ;;INGO WEGENER;;JIA LIN XU;;JOSE LUIS TAVARES CORTEZ;;CARMEN JERG,,https://lens.org/135-691-850-210-399,Patent Application,no,0,0,13,13,0,B32B15/00;;B32B17/06;;C03C17/36;;C03C17/3644;;C03C17/366;;C03C17/3655;;C03C17/3652;;C03C17/3639;;B32B17/061;;C03C17/3615;;C03C17/3636;;C03C17/3644;;C03C17/366,B32B15/00;;B32B17/06;;C03C17/36,,0,0,,,,PENDING
512,CA,A1,CA 3047603 A1,088-028-311-637-701,2018-06-28,2018,CA 3047603 A,2016-12-20,MX 2016000188 W,2016-12-20,LOW-EMISSIVITY COATING FOR A GLASS SUBSTRATE,"The present invention relates to a glass substrate provided with a stack of thin coating layers formed by a first layer of anti-reflective dielectric material, with a refractive index of 1.65 to 2.65, located above the glass substrate. At least one structure of two layers formed by a first layer of an anti-reflective transparent dielectric material with a refractive index of 1.32 to 1.55, located in the bottom position, and a second layer of a metal functional film with reflective properties in the infrared range, located in the top position, said structure being located above the first layer of anti-reflective dielectric material. A second layer of absorbent material forming an anti-corrosion barrier for protecting the metal functional film against oxidation and corrosion. A third layer of an anti-reflective material, said layer being selected from a metal oxide with a refractive index of 1.32 to 1.55, a metal oxide with a refractive index of 1.65 to 1.95 or an aluminium-doped zinc oxide (AZO); and a fourth protective layer made of an anti-reflective material, for increasing the transmission of visible light and the scratch resistance of the substrate, having high transmission of visible light (60%), a solar transmission of less than 60%, a resistance of less than 10 per square and an emissivity of less than 0.10.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSE GUADALUPE;;CABRERA LLANOS ROBERTO;;HERNANDEZ CARRILLO RUBI AGLAE;;TAVARES CORTEZ JOSE LUIS;;JERG CARMEN;;WEGENER INGO;;XU JIA LIN,,https://lens.org/088-028-311-637-701,Patent Application,no,0,0,13,13,0,B32B15/00;;B32B17/06;;C03C17/36;;C03C17/3644;;C03C17/366;;C03C17/3655;;C03C17/3652;;C03C17/3639;;B32B17/061;;C03C17/3615;;C03C17/3636;;C03C17/3644;;C03C17/366,B32B15/00;;B32B17/06;;C03C17/36,,0,0,,,,PENDING
513,CN,A,CN 105813579 A,069-096-378-904-750,2016-07-27,2016,CN 201480055532 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,Clamp device for minimally invasive procedures and uses thereof,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. The clamp device comprises an elongate surface member, a deformable article that rests on the surface member at the distal end of the surface member and a flexible band. The distal end of the flexible band is connected to the distal end of the surface member and the flexible band forms a closed loop with the deformable article. The proximal end of the flexible band is configured to be adjustably tensioned so that the portion of the flexible band that forms a closed loop with the deformable article can be shortened or lengthened. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/069-096-378-904-750,Patent Application,no,5,4,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,INACTIVE
514,WO,A1,WO 2012/100194 A1,090-767-241-196-832,2012-07-26,2012,US 2012/0022077 W,2012-01-20,US 201161434704 P,2011-01-20,MICROFLUIDIC TRANSDUCER,Methods and apparatus for fragmenting nucleic acids or disrupting cells in a disposable microfluidic device are disclosed. The apparatus is designed to position a sample to be in direct contact with a high frequency vibrating element that emits an ultrasonic frequency into the sample such that the vibrational energy transduced into the sample results in fragmenting nucleic acids or disrupting cells.,IBIS BIOSCIENCES INC;;ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY,ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY,,https://lens.org/090-767-241-196-832,Patent Application,yes,4,1,4,4,0,C12N1/066;;C12N13/00;;Y10T436/25;;C12M47/06;;Y10T436/25;;C12N1/066;;C12N13/00;;C12M47/06;;B01L3/502715;;B01L2200/027;;B01L2300/06;;B01L2300/0816;;C12Q1/6806;;G01N1/30;;G01N1/31,C12N13/00;;C12M1/33,,1,1,038-298-913-388-390,10.1021/ac990347o;;10517145,"BELGRADER ET AL.: ""A Minisonicator To Rapidly Disrupt Bacterial Spores for DNA Analysis."", ANAL CHEM, vol. 71, no. 19, 1 October 1999 (1999-10-01), pages 4232 - 4236",PENDING
515,US,A1,US 2014/0249223 A1,181-330-546-745-043,2014-09-04,2014,US 201213984906 A,2012-02-13,US 201213984906 A;;US 201161443762 P;;US 2012/0024817 W,2011-02-17,METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HYDROXY-BETA METHYLBUTYRATE,"Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.",PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA;;ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,ABBOTT LABORATORIES (2011-11-08),https://lens.org/181-330-546-745-043,Patent Application,yes,0,7,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A61K31/19,514/557,0,0,,,,ACTIVE
516,US,B2,US 9326956 B2,026-658-345-661-90X,2016-05-03,2016,US 201213984906 A,2012-02-13,US 201213984906 A;;US 201161443762 P;;US 2012/0024817 W,2011-02-17,Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate,"Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.",PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA;;ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,ABBOTT LABORATORIES (2011-11-08),https://lens.org/026-658-345-661-90X,Granted Patent,yes,22,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A61K31/19,,32,8,041-937-900-678-838;;025-536-363-673-865;;093-735-873-511-792;;014-020-169-142-503;;129-543-839-124-818;;009-368-970-100-17X;;074-496-871-320-699;;064-108-681-398-233,10.1097/ta.0b013e31802dca93;;17215743;;pmc1964795;;17399794;;10.1016/j.pharmthera.2007.02.002;;19211028;;10.1016/j.bbamcr.2008.12.017;;10.1161/atvbaha.107.150748;;17717296;;20857835;;10.1515/jpem.2010.23.7.641;;10.1073/pnas.0802876105;;18599437;;pmc2453715;;10.1001/archneur.58.3.397;;11255443;;21603181;;pmc3096057;;10.1155/2011/928523,"Rule 161 and 162 communication for EP App. No. 12705748.7 dated Mar. 6, 2014, 2 pages.;;Office Action in VN 1-2013-02808 dated Dec. 20, 2013, 1 page.;;International Search Report and Written Opinion for PCT/US2012/024817 dated Jun. 6, 2012 (6 pages).;;International Preliminary Report on Patentability for PCT/US2012/024817 dated Aug. 21, 2013 (4 pages).;;Extended Search Report for EP Application No. 12382531.7 dated Apr. 15, 2013 (4 pages).;;Rule 161 and 162 communication for EP App. No. 12705748.7 dated Sep. 25, 2013 (2 pages).;;Kuhls, et al., ""Beta-hydroxy-beta-methylbutyrate supplementation in critically ill trauma patients,"" Journal of Trauma Injury Infection and Critical Care, vol. 62(1), pp. 125-132 (Jan. 2007).;;English abstract for Japanese Patent No. 2009155336 Tsujido Chemical Corp.;;Office Action in CA 2,825,734 dated Nov. 14, 2014 (4 pages).;;First Office Action in CA 201280009207.4 dated Sep. 1, 2014 (8 pages).;;Second Office Action in CN 201280009207.4 dated Feb. 4, 2015 (5 pages).;;Search Report and Written Opinion in SG Application No. 2013062377 dated Aug. 12, 2014 (9 pages).;;Burke et al., ""Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease,"" Pharmacology and Therapeutics, vol. 114, No. 3, pp. 261-277 (2007).;;Kornasio et al., ""B-hydroxy-B-methylbutyrate (Hmb) Stimulates Myogenic Cell Proliferation, Differentiation and Survival via the Mapk/Erk and P13K/Akt Pathways,"" Biochimica et Biophysica Acta, vol. 1793, No. 5, pp. 755-763 (2009).;;Zeng Zhigang et al., ""Physiological Efficacy of Supplemental Beta-hydroxy-beta-methylbutyrate (HMB) in Sports Training,"" Chinese Journal of Sports Medicine, vol. 26, No. 1 (Jan. 10, 2007), pp. 120-123.;;Zhang et al., ""The Pi3K/Akt Pathway Mediates the Neuroprotective Effect of Atovastatin in Extending Thrombolytic Therapy after Embolic Stroke in the Rat,"" Anterioscler Thromb Vasc Biol., vol. 27, pp. 2470-2475 (2007).;;International Search Report, Written Opinion and Notification for PCTUS2013/060120 dated Nov. 15, 2013 (12 pages).;;International Preliminary Report on Patentability for PCT/US2013/060120 dated Mar. 17, 2015 (7 pages).;;Portal, Shawn et al., ""Effect of HMB supplementation on body composition, fitness, hormonal profile and muscle damage indices,"" Journal of Pediatric Endocrinology and Metabolism, vol. 23, No. 7 (2010), pp. 641-650.;;Rule 161 and 162 communication for EP App. No. 13766463.7 dated May 6, 2015 (2 pages).;;Further Search Report and Written Opinion in SG Application No. 2013062377 dated Apr. 15, 2015 (6 pages).;;""Disorders of the Nervous System"" http://web.archive.org/web/20090616094835/http://www.dartmouth.edu/dons/figures/chapt-24/Table-24-2.htm (last accessed May 13, 2015) (2 pages).;;Li et al., ""Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo,"" PNAS, Jul. 8, 2008, vol. 105, No. 27, pp. 9397-9402.;;Morris, et al., ""Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease,"" Arch. Neurol., Mar. 2001, vol. 58(3), pp. 397-405.;;English-language machine translation from Lexis Nexis of Chinese Patent No. 101785566 (8 pages).;;English-language translation of Abstract from Espacenet-European Patent Office-of Taiwan Patent No. 201117736 (1 page).;;English language abstract for Zeng Zhigang et al., ""Physiological Efficacy of Supplemental Beta-hydroxy-beta-methylbutyrate (HMB) in Sports Training,"" Chinese Journal of Sports Medicine, vol. 26, No. 1 (Jan. 10, 2007), pp. 120-123 (1 page).;;Office Action in U.S. Appl. No. 14/428,535 dated Sep. 3, 2015.;;English translation of Office Action for JP Application No. 2013-554520 dated Jan. 19, 2016.;;Final Examination Report for SG Application No. 2013062377 dated Jan. 26, 2016.;;Search Report and Examination Report in SG Application No. 11201502069 dated Dec. 22, 2015 (Search Report dated Oct. 15, 2015 but received from foreign associate Dec. 22, 2015).;;Van Weenen, De Leeuw, et al., ""Pharmacological modulation of dopamine receptor D2-medicated transmissions alters the metabolic phenotype of diet induced obese and diet resistant C57B16 mice,"" Experimental Diabetes Research (2011), vol. 2011 pp. 1-10.",ACTIVE
517,CN,A,CN 105007756 A,047-887-277-015-180,2015-10-28,2015,CN 201480015076 A,2014-03-11,US 2014/0023007 W;;EP 13382090 A,2013-03-15,Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women,"Disclosed herein are methods related to the administration of specific carbohydrate systems to a pregnant woman for preventing or limiting fat accumulation. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, a non-absorbent carbohydrate, and/or an indigestible carbohydrate. The compositions may be administered before, during, or after gestation.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL CRISTOBAL MANZANO;;VARGAS MARIA DEL PILAR BUENO;;CABRERA RICARDO RUEDA,,https://lens.org/047-887-277-015-180,Patent Application,no,3,1,11,11,0,A23L29/212;;A23L29/30;;A23L29/35;;A23L33/30;;A23L33/40;;A23L33/21;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A61P3/04;;A61P3/10;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A23L29/30;;A23L33/40;;A23L33/21;;A23L29/35;;A23L33/30;;A23L29/212,A61K31/70;;A61P3/04;;A61P3/10,,0,0,,,,DISCONTINUED
518,CN,A,CN 117154611 A,135-515-115-881-759,2023-12-01,2023,CN 202310578746 A,2023-05-22,US 202217829703 A,2022-06-01,MODULAR RAIL FOR WIRE HARNESS RETENTION,"The present disclosure provides a modular rail for wire harness retention. A clip and a lacing strip are used as a modular rail for a wire harness mounting system. Each clamp has a clamp post that engages the mounting hole and a clamp head. The modular rail has a plurality of rail sections sequentially connected by a tool-free interlock disposed at each longitudinal end of each rail section. Each rail section has a plurality of apertures at longitudinally spaced locations for receiving a respective lacing strip adapted to surround a wire harness. The interlocking members have complementary clasp features including latch tabs that deflect to enable engagement with each respective interlocking member. The bottom surface of each rail section has a plurality of longitudinally spaced carriages, each carriage having a slide rail configured to secure a clamp head along a series of positions on the slide rail. The top surface of each rail section receives a wire harness when the wire harness is secured by a lacing strip inserted through a corresponding aperture.",FORD GLOBAL TECH LLC,LEDEZMA JASON L;;GARCIA VISENCIO MIGUEL;;CABRERA MELENDEZ RUBEN ANDRES;;GARCIA MAURICIO;;LOPEZ SANCHEZ JOSE ANTONIO,,https://lens.org/135-515-115-881-759,Patent Application,no,0,0,3,3,0,H02G3/32;;B60R16/0215;;B60R16/0215;;H02G3/32;;B60R16/0207,H02G3/04;;B60R16/02;;H02G3/02,,0,0,,,,PENDING
519,US,A1,US 2012/0190126 A1,180-916-060-573-642,2012-07-26,2012,US 201213355261 A,2012-01-20,US 201213355261 A;;US 201161434704 P,2011-01-20,MICROFLUIDIC TRANSDUCER,"Provided herein are apparatuses and methods for fragmenting nucleic acids or disrupting cells. For example, some embodiments provide a disposable microfluidic device designed to position a sample to be in direct contact with a high frequency vibrating element that emits an ultrasonic frequency into the sample such that the vibrational energy transduced into the sample results in fragmenting nucleic acids or disrupting cells.",ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY;;IBIS BIOSCIENCES INC,ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY,IBIS BIOSCIENCES INC (2012-03-09),https://lens.org/180-916-060-573-642,Patent Application,no,1,2,4,4,0,C12N1/066;;C12N13/00;;Y10T436/25;;C12M47/06;;Y10T436/25;;C12N1/066;;C12N13/00;;C12M47/06;;B01L3/502715;;B01L2200/027;;B01L2300/06;;B01L2300/0816;;C12Q1/6806;;G01N1/30;;G01N1/31,G01N1/28;;B01L3/00;;C12M1/00,436/174;;435/306.1;;422/500;;422/547;;422/502,4,4,038-298-913-388-390;;018-172-278-005-135;;071-670-278-749-859;;054-306-386-671-297,10.1021/ac990347o;;10517145;;10.1089/dna.1989.8.697;;2693020;;pmc310446;;1741307;;10.1093/nar/20.3.623;;10.1016/j.ultrasmedbio.2005.05.005;;16176793,"Belgrader, Phillip et al. ""A minisonicator to rapidly disrupt bacterial spores for DNA analysis."" Analytical Chemistry (1999) 71 4232-4236.;;Elsner, Henrik I. et al. ""Ultrasonic degradation of DNA."" DNA (1989) 8 697-701.;;Ponce, Maria R. et al. ""PCR amplification of long DNA fragments."" Nucleic Acids Research (1992) 623.;;Marentis, Theodore Cosmo et al. ""Microfluidic sonicator for real-time disruption of eukaryotic cells and bacterial spores for DNA analysis."" Ultrasound in Medicine and Biology (2005) 31 1265-1277.",INACTIVE
520,US,A1,US 2016/0178488 A1,182-934-128-035-579,2016-06-23,2016,US 201514977254 A,2015-12-21,US 201514977254 A;;US 201213355261 A;;US 201161434704 P,2011-01-20,MICROFLUIDIC TRANSDUCER,"Provided herein are apparatuses and methods for fragmenting nucleic acids or disrupting cells. For example, some embodiments provide a disposable microfluidic device designed to position a sample to be in direct contact with a high frequency vibrating element that emits an ultrasonic frequency into the sample such that the vibrational energy transduced into the sample results in fragmenting nucleic acids or disrupting cells.",IBIS BIOSCIENCES INC,ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY,IBIS BIOSCIENCES INC (2016-04-14),https://lens.org/182-934-128-035-579,Patent Application,yes,4,0,4,4,0,C12N1/066;;C12N13/00;;Y10T436/25;;C12M47/06;;Y10T436/25;;C12N1/066;;C12N13/00;;C12M47/06;;B01L3/502715;;B01L2200/027;;B01L2300/06;;B01L2300/0816;;C12Q1/6806;;G01N1/30;;G01N1/31,B01L3/00;;G01N1/31;;C12Q1/68;;G01N1/30,,0,0,,,,DISCONTINUED
521,MX,B,MX 348708 B,003-195-613-876-040,2017-06-26,2017,MX 2013009528 A,2012-02-13,US 201161443762 P;;US 2012/0024817 W,2011-02-17,METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HYDROXY-BETA-METHYLBUTYRATE.,"Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.",ABBOTT LAB,JOSE MARIA LOPEZ PEDROSA;;MANUEL MANZANO MARTIN;;ALEJANDRO BARRANCO PEREZ;;MARIA RAMIREZ GONZALEZ;;RICARDO RUEDA CABRERA,,https://lens.org/003-195-613-876-040,Granted Patent,no,0,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A23L33/17;;A23L33/10,,0,0,,,,ACTIVE
522,EP,A1,EP 3030163 A1,094-193-952-380-64X,2016-06-15,2016,EP 14752772 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,"GLOBAL BIO THERAPEUTICS, INC. (2019-03-20)",https://lens.org/094-193-952-380-64X,Patent Application,yes,0,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
523,JP,A,JP 2018110875 A,129-032-307-046-631,2018-07-19,2018,JP 2018028509 A,2018-02-21,US 201361863903 P,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURE AND ITS USE,"PROBLEM TO BE SOLVED: To provide a clamp device that can be used for clamping a tissue or an organ, or part of a tissue or an organ in a minimally invasive procedure including surgery such as laparoscopic surgery.SOLUTION: A band clamp device 10 includes a slender surface member 41, a variable shape body placed on the surface member at the tip of the surface member, and a flexible band 42. The tip of the flexible band is connected to the tip of the surface member, and the flexible band forms a closed loop together with the variable shape body. The base end part of the flexible band is configured so as to be adjustably pulled, and a portion of the flexible band that forms a closed loop with the variable shape body can be shortened or lengthened. There is also provided a system for performing minimally invasive surgery including a clamp device for minimally invasive surgery and an injection device configured so as to access an endoscope port for minimally invasive surgery.SELECTED DRAWING: Figure 1B",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO;;STEVEN MASTERSON;;ALLAN ROZENBERG;;PAUL FAUCHER;;JOHN HOFFMAN,,https://lens.org/129-032-307-046-631,Patent Application,no,8,0,20,20,2,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/29,,0,0,,,,INACTIVE
524,TW,B,TW I565420 B,102-706-106-848-425,2017-01-11,2017,TW 101105347 A,2012-02-17,US 201161443762 P,2011-02-17,Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate,,ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,,https://lens.org/102-706-106-848-425,Granted Patent,no,1,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,,,0,0,,,,INACTIVE
525,PH,A1,PH 12015502160 A1,131-438-644-914-665,2016-01-25,2016,PH 12015502160 A,2015-09-15,EP 13382090 A;;US 2014/0023007 W,2013-03-15,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR PREVENTING FAT ACCUMULATION IN PREGNANT WOMEN,"Disclosed herein are methods related to the administration of specific carbohydrate systems to a pregnant woman for preventing or limiting fat accumulation. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, a non-absorbent carbohydrate, and/or an indigestible carbohydrate. The compositions may be administered before, during, or after gestation.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL CRISTOBAL;;BUENO VARGAS MARIA DEL PILAR;;RUEDA CABRERA RICARDO,,https://lens.org/131-438-644-914-665,Patent Application,no,0,0,11,11,0,A23L29/212;;A23L29/30;;A23L29/35;;A23L33/30;;A23L33/40;;A23L33/21;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A61P3/04;;A61P3/10;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A23L29/30;;A23L33/40;;A23L33/21;;A23L29/35;;A23L33/30;;A23L29/212,A61K31/70;;A61P3/04;;A61P3/10,,0,0,,,,PENDING
526,ES,Y,ES 1076911 Y,140-704-542-734-95X,2012-08-07,2012,ES 201230275 U,2012-03-13,ES 201230275 U,2012-03-13,MAQUINA INTERACTIVA DE TOMA DE IMAGENES,,INGENIATIC DESARROLLO S L;;CERDAN CARTAGENA JOSE FERNANDO;;SUARDIAZ MURO JUAN;;LUJAN FERNANDEZ SERGIO;;CABRERA LOZOYA ANDRES;;GARCIA SANCHEZ DIEGO,CERDAN CARTAGENA JOSE FERNANDO;;SUARDIAZ MURO JUAN;;LUJAN FERNANDEZ SERGIO;;CABRERA LOZOYA ANDRES;;GARCIA SANCHEZ DIEGO,,https://lens.org/140-704-542-734-95X,Limited Patent,no,0,0,2,2,0,,G03B17/53;;G07F17/26,,0,0,,,,EXPIRED
527,HK,B,HK 1225258 B,164-911-971-161-144,2017-09-08,2017,HK 16113718 A,2016-12-01,US 201361863903 P,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/164-911-971-161-144,Granted Patent,no,0,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B/,,0,0,,,,ACTIVE
528,TW,A,TW 201309212 A,057-996-234-597-50X,2013-03-01,2013,TW 101105347 A,2012-02-17,US 201161443762 P,2011-02-17,Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate,"Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,,https://lens.org/057-996-234-597-50X,Patent of Addition,no,0,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A23L1/30;;A61K31/19;;A61P25/28;;C07C59/01,,0,0,,,,INACTIVE
529,CA,C,CA 2920261 C,089-180-748-072-339,2018-04-03,2018,CA 2920261 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. The clamp device comprises an elongate surface member, a deformable article that rests on the surface member at the distal end of the surface member and a flexible band. The distal end of the flexible band is connected to the distal end of the surface member and the flexible band forms a closed loop with the deformable article. The proximal end of the flexible band is configured to be adjustably tensioned so that the portion of the flexible band that forms a closed loop with the deformable article can be shortened or lengthened. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/089-180-748-072-339,Granted Patent,no,0,0,20,20,2,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
530,WO,A1,WO 2023/077129 A1,190-960-011-743-431,2023-05-04,2023,US 2022/0078995 W,2022-10-31,US 202163273785 P;;US 202163273792 P;;US 202263315482 P;;US 202263391136 P,2021-10-29,TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD,"The present disclosure relates generally to targeting moieties for bioorthogonal delivery of a payload to a targeted location in a subject. The compositions and methods have applications in the treatment of cancer, tumor growths, and immunotherapy.",TAMBO INC,ONETO JOSE MANUEL MEJIA;;ZAKHARIAN MICHAEL;;MCFARLAND JESSE M;;MAHMOODI AMIR;;CORICOR GEORGE;;CABRERA-PARDO JAIME,,https://lens.org/190-960-011-743-431,Patent Application,yes,11,0,1,1,16,A61K47/6855;;A61K47/6803;;A61P35/00,A61K47/68;;A61P35/00,,13,6,110-466-408-866-514;;006-176-752-586-401;;047-962-661-157-885;;020-042-016-336-723;;013-247-525-206-156;;050-247-819-044-289,27431745;;10.1039/c6ob01411a;;26947912;;pmc4780193;;10.1038/srep22675;;10.1101/2020.12.01.405423;;pmc3296471;;10.7150/thno.4068;;22400063;;10.1146/annurev-immunol-032712-100008;;23157435;;10.1002/0470053488,"AGNESE MAGGI ET AL: ""Development of a novel antibody-tetrazine conjugate for bioorthogonal pretargeting"", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 14, no. 31, 12 July 2016 (2016-07-12), pages 7544 - 7551, XP055385205, ISSN: 1477-0520, DOI: 10.1039/C6OB01411A;;JESSIE A. G. L. VAN BUGGENUM ET AL: ""A covalent and cleavable antibody-DNA conjugation strategy for sensitive protein detection via immuno-PCR"", SCIENTIFIC REPORTS, vol. 6, no. 22675, 7 March 2016 (2016-03-07), pages 1 - 12, XP055463311, DOI: 10.1038/srep22675;;LIU LUPING ET AL: ""Light-activated tetrazines enable live-cell spatiotemporal control of bioorthogonal reactions"", BIORXIV, 2 December 2020 (2020-12-02), XP055928506, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.12.01.405423v1.full.pdf> [retrieved on 20220607], DOI: 10.1101/2020.12.01.405423;;THOMAS SORRELL: ""Handbook of Chemistry and Physics"", 1999, UNIVERSITY SCIENCE BOOKS;;SMITHMARCH: ""March's Advanced Organic Chemistry"", 2001, JOHN WILEY & SONS;;FURNISSHANNAFORDSMITHTATCHELL: ""Vogel's Textbook of Practical Organic Chemistry"", 1989, LONGMAN SCIENTIFIC & TECHNICAL;;CARRUTHERS: ""Some Modern Methods of Organic Synthesis"", 1987, CAMBRIDGE UNIVERSITY PRESS;;PURE APPL. CHEM., vol. 45, 1976, pages 13 - 30;;CHOI ET AL., THERANOSTICS, vol. 2, no. 2, 2012, pages 156 - 178;;POLYMER ADVANCED TECHNOLOGY, vol. 25, 2014, pages 448 - 460;;KROEMER ET AL., ANNU. REV. IMMUNOL., no. 31, 2013, pages 51 - 72;;WUTS, P. G. M.GREENE, T. W.GREENE, T. W.: ""Greene's protective groups in organic synthesis"", 2006, HOBOKEN, N.J., WILEY;;SRINIVASAN ET AL., ADV. THERAP., 2021",PENDING
531,JP,A,JP 2017061483 A,022-412-669-226-044,2017-03-30,2017,JP 2016209276 A,2016-10-26,US 201161443762 P,2011-02-17,METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING β-HYDROXY-β-METHYLBUTYRATE,"PROBLEM TO BE SOLVED: To provide compositions and methods for easily and effectively improving cognition.SOLUTION: Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising β-hydroxy-β-methylbutyrate (HMB) to the individual. The compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.SELECTED DRAWING: Figure 1",ABBOTT LAB,JOSE MARIA LOPEZ PEDROSA;;MANUEL MANZANO MARTIN;;ALEJANDRO BARRANCO PEREZ;;MARIA RAMIREZ GONZALEZ;;RICARDO RUEDA CABRERA,,https://lens.org/022-412-669-226-044,Patent Application,no,4,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A61K31/19;;A23L33/10;;A61K9/08;;A61K9/107;;A61K9/14;;A61P9/00;;A61P9/10;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28,,0,0,,,,ACTIVE
532,EA,B1,EA 035829 B1,011-699-204-136-104,2020-08-18,2020,EA 201600138 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/011-699-204-136-104,Granted Patent,no,4,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
533,ES,B1,ES 2421187 B1,122-465-354-986-705,2014-11-26,2014,ES 201230275 A,2012-02-23,ES 201230275 A,2012-02-23,METODO PARA MEJORAR EL DESARROLLO CEREBRAL Y LA FUNCION COGNITIVA USANDO BETA-HIDROXI-BETA-METILBUTIRATO,,ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL;;BARRANCO PEREZ ALEJANDRO;;RAMIREZ GONZALEZ MARIA;;RUEDA CABRERA RICARDO,,https://lens.org/122-465-354-986-705,Granted Patent,no,0,0,2,2,0,A23L33/17;;A61K31/19,A61K31/19;;A23L33/175,,0,0,,,,INACTIVE
534,ES,A1,ES 2421187 A1,123-801-372-343-339,2013-08-29,2013,ES 201230275 A,2012-02-23,ES 201230275 A,2012-02-23,"Method for improving cerebral development and cognitive function using beta-hydroxy-beta-methylbutyrate (Machine-translation by Google Translate, not legally binding)","Methods for increasing neural function in an individual, such as an elderly adult, are disclosed. The methods include administering nutritional compositions comprising hmb to the individual. Nutritional compositions provide benefits for individuals who have or may be at risk of cognitive decline, cognitive impairment and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases. (Machine-translation by Google Translate, not legally binding)",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL;;BARRANCO PEREZ ALEJANDRO;;RAMIREZ GONZALEZ MARIA;;RUEDA CABRERA RICARDO,,https://lens.org/123-801-372-343-339,Patent Application,no,4,0,2,2,0,A23L33/17;;A61K31/19,A61K31/19;;A23L33/175,,0,0,,,,INACTIVE
535,MX,A,MX 2019008194 A,145-911-270-533-196,2019-09-11,2019,MX 2019008194 A,2016-02-05,US 201361863903 P,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF.,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. The clamp device comprises an elongate surface member, a deformable article that rests on the surface member at the distal end of the surface member and a flexible band. The distal end of the flexible band is connected to the distal end of the surface member and the flexible band forms a closed loop with the deformable article. The proximal end of the flexible band is configured to be adjustably tensioned so that the portion of the flexible band that forms a closed loop with the deformable article can be shortened or lengthened. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO;;STEVEN MASTERSON;;ALLAN ROZENBERG;;PAUL FAUCHER;;JOHN HOFFMAN,,https://lens.org/145-911-270-533-196,Patent Application,no,0,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,PENDING
536,MX,A,MX 2016001667 A,139-222-613-808-817,2016-11-07,2016,MX 2016001667 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF.,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. The clamp device comprises an elongate surface member, a deformable article that rests on the surface member at the distal end of the surface member and a flexible band. The distal end of the flexible band is connected to the distal end of the surface member and the flexible band forms a closed loop with the deformable article. The proximal end of the flexible band is configured to be adjustably tensioned so that the portion of the flexible band that forms a closed loop with the deformable article can be shortened or lengthened. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS INC,JOSE GUSTAVO CABRERA AQUINO;;BLANCA ANGELICA SEGURA PACHECO;;STEVEN MASTERSON;;ALLAN ROZENBERG;;PAUL FAUCHER;;JOHN HOFFMAN,,https://lens.org/139-222-613-808-817,Patent Application,no,0,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,PENDING
537,EP,A1,EP 2675298 A1,137-278-531-896-016,2013-12-25,2013,EP 12705748 A,2012-02-13,US 201161443762 P;;US 2012/0024817 W,2011-02-17,METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HYDROXY-BETA-METHYLBUTYRATE,,ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,,https://lens.org/137-278-531-896-016,Patent Application,yes,0,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A23L1/305,,0,0,,,,DISCONTINUED
538,ES,T3,ES 2733911 T3,035-139-287-812-23X,2019-12-03,2019,ES 14752772 T,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,Dispositivo de sujeción para procedimientos minimamente invasivos,"Un dispositivo de sujeción (10) para cirugía mínimamente invasiva, incluyendo: a) un elemento de superficie alargado (41) que tiene un extremo próximo y un extremo distal; b) un artículo deformable biocompatible (4) que descansa en el elemento de superficie en el extremo distal del elemento de superficie; y c) una banda flexible (42) que tiene un extremo próximo y un extremo distal, donde: el extremo distal de la banda flexible está conectado al extremo distal del elemento de superficie; la banda flexible forma un bucle cerrado con el artículo deformable biocompatible en el elemento de superficie, el bucle cerrado es capaz de ajustar en un tejido o un órgano o porción del mismo durante cirugía mínimamente invasiva; y el extremo próximo de la banda flexible está configurado para ser tensado de forma ajustable de modo que la porción de la banda flexible que forma un bucle cerrado con el artículo deformable biocompatible pueda ser acortada o alargada, por lo que el bucle puede sujetar un tejido o un órgano o porción del mismo; y se caracteriza porque el elemento de superficie alargado es cóncavo para formar un estabilizador (45) sobre la que el artículo deformable biocompatible descansa.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/035-139-287-812-23X,Granted Patent,no,0,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
539,WO,A1,WO 2015/021443 A1,191-521-329-392-610,2015-02-12,2015,US 2014/0050441 W,2014-08-08,US 201361863903 P,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. The clamp device comprises an elongate surface member, a deformable article that rests on the surface member at the distal end of the surface member and a flexible band. The distal end of the flexible band is connected to the distal end of the surface member and the flexible band forms a closed loop with the deformable article. The proximal end of the flexible band is configured to be adjustably tensioned so that the portion of the flexible band that forms a closed loop with the deformable article can be shortened or lengthened. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS USA INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/191-521-329-392-610,Patent Application,yes,4,3,20,20,2,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,PENDING
540,WO,A8,WO 2012/112419 A8,158-115-580-235-72X,2014-03-06,2014,US 2012/0024817 W,2012-02-13,US 201161443762 P,2011-02-17,METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HYDROXY-BETA-METHYLBUTYRATE,"Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.",ABBOTT LAB;;PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,,https://lens.org/158-115-580-235-72X,Amended Application,yes,0,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A23L1/305,,0,0,,,,PENDING
541,AR,A1,AR 085297 A1,035-640-928-653-97X,2013-09-18,2013,AR P120100566 A,2012-02-17,US 201161443762 P,2011-02-17,METODOS PARA MEJORAR EL DESARROLLO DEL CEREBRO Y LA FUNCION COGNITIVA EN LOS QUE SE EMPLEA b-HIDROXI-b-METILBUTIRATO,"Métodos para mejorar la función neural en un individuo, tal como un adulto mayor. Los métodos comprenden administrarle composiciones nutritivas que comprenden HMB al individuo. Las composiciones nutritivas les proveen beneficios a los individuos que padecen declinaciones cognitivas, alteraciones en la cognición o disfunciones neurales, que típicamente son el resultado de enfermedades de la cognición asociadas a enfermedades neurodegenerativas, así como a los individuos que se encuentran en riesgo de contraer los trastornos mencionados.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL;;BARRANCO PEREZ ALEJANDRO;;RAMIREZ GONZALEZ MARIA;;RUEDA CABRERA RICARDO,,https://lens.org/035-640-928-653-97X,Patent Application,no,0,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,A61K31/19;;A23L1/305;;A61P3/02,,0,0,,,,DISCONTINUED
542,ES,U,ES 1076911 U,053-215-350-331-24X,2012-05-10,2012,ES 201230275 U,2012-03-13,ES 201230275 U,2012-03-13,"Interactive image taking machine (Machine-translation by Google Translate, not legally binding)","Interactive image taking machine of simple transport and installation, composed of different independent modules that can be separated for transport and is characterized in that the first module (1) is the foot of the machine, the second module (2) is the body of the machine and comprises most of the elements of the machine, and the third module (3) is located at the top of the machine and serves as support for a screen (9); the second module has an outer casing (4) with a tray (5) for the output of printed photographs and on it the casing is placed a camera (6) for taking images, a touch screen (7), a computer ( 8) and a printer (10); and where in the third module a television screen (9) or a computer monitor is placed. (Machine-translation by Google Translate, not legally binding)",INGENIATIC DESARROLLO S L;;CERDAN CARTAGENA JOSE FERNANDO;;SUARDIAZ MURO JUAN;;LUJAN FERNANDEZ SERGIO;;CABRERA LOZOYA ANDRES;;GARCIA SANCHEZ DIEGO,CERDAN CARTAGENA JOSE FERNANDO;;SUARDIAZ MURO JUAN;;LUJAN FERNANDEZ SERGIO;;CABRERA LOZOYA ANDRES;;GARCIA SANCHEZ DIEGO,,https://lens.org/053-215-350-331-24X,Patent Application,no,0,1,2,2,0,,G03B17/53;;G07F17/26,,0,0,,,,EXPIRED
543,DK,T3,DK 3030163 T3,157-931-416-708-854,2019-07-01,2019,DK 14752772 T,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,Klemmeindretning til minimalt invasive procedurer,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN;;MASTERSON STEVEN,,https://lens.org/157-931-416-708-854,Granted Patent,no,0,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
544,CA,A1,CA 2904021 A1,046-201-616-166-94X,2014-09-25,2014,CA 2904021 A,2014-03-11,EP 13382090 A;;US 2014/0023007 W,2013-03-15,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR PREVENTING FAT ACCUMULATION IN PREGNANT WOMEN,"Disclosed herein are methods related to the administration of specific carbohydrate systems to a pregnant woman for preventing or limiting fat accumulation. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, a non-absorbent carbohydrate, and/or an indigestible carbohydrate. The compositions may be administered before, during, or after gestation.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL CRISTOBAL MANZANO;;VARGAS MARIA DEL PILAR BUENO;;CABRERA RICARDO RUEDA,,https://lens.org/046-201-616-166-94X,Patent Application,no,0,0,11,11,0,A23L29/212;;A23L29/30;;A23L29/35;;A23L33/30;;A23L33/40;;A23L33/21;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A61P3/04;;A61P3/10;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A23L29/30;;A23L33/40;;A23L33/21;;A23L29/35;;A23L33/30;;A23L29/212,A23L1/09;;A61K31/70;;A61P3/04;;A61P3/10,,0,0,,,,DISCONTINUED
545,EP,B1,EP 3030163 B1,044-435-506-156-483,2019-03-20,2019,EP 14752772 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES,,GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,"GLOBAL BIO THERAPEUTICS, INC. (2019-03-20)",https://lens.org/044-435-506-156-483,Granted Patent,yes,4,0,20,20,0,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
546,US,B2,US 11364032 B2,138-425-237-555-732,2022-06-21,2022,US 201414455871 A,2014-08-08,US 201414455871 A;;US 201361863903 P,2013-08-08,Clamp device for minimally invasive procedures and uses thereof,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN;;GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,NOVO ENGINEERING INC (2014-11-12);;GLOBAL BIO THERAPEUTICS USA INC. (GBT USA) (2014-09-30);;GLOBAL BIO THERAPEUTICS INC. (GBT USA) (2014-11-12);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2014-09-30),https://lens.org/138-425-237-555-732,Granted Patent,yes,124,3,20,20,2,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12;;A61B17/00,,253,151,067-603-709-961-17X;;139-345-160-524-722;;083-097-272-313-524;;004-116-893-363-466;;055-742-809-602-734;;000-703-365-392-272;;044-486-712-598-717;;044-309-620-870-157;;080-194-745-279-238;;060-993-551-935-925;;080-769-210-275-665;;033-471-592-816-052;;060-112-988-563-463;;064-048-827-826-930;;057-949-161-732-94X;;101-006-563-776-849;;038-178-441-399-799;;114-703-023-726-096;;007-557-256-778-063;;041-050-176-740-479;;106-603-045-026-850;;059-860-916-724-975;;010-796-076-923-303;;011-669-985-502-084;;046-469-152-144-976;;028-299-719-713-788;;013-086-199-764-405;;051-706-438-634-847;;066-916-220-868-595;;047-219-623-013-329;;033-804-842-030-961;;049-436-722-340-572;;010-646-200-754-815;;057-888-365-163-295;;053-446-886-655-152;;045-680-536-606-460;;047-719-284-118-310;;026-916-714-168-600;;166-149-388-372-252;;060-628-737-164-756;;057-205-038-511-760;;000-143-673-637-259;;008-078-869-200-895;;075-025-432-382-623;;061-659-335-987-707;;056-461-188-121-406;;085-697-375-509-476;;097-421-754-978-369;;022-797-429-791-642;;065-892-485-270-812;;065-310-853-569-912;;027-481-107-296-64X;;007-539-629-799-758;;041-650-093-859-449;;020-466-750-257-711;;092-417-835-880-431;;012-635-293-318-332;;010-206-927-147-54X;;030-248-599-799-901;;003-380-834-084-48X;;016-874-764-925-23X;;008-587-496-850-953;;135-114-522-815-727;;022-506-836-404-416;;016-424-552-126-032;;118-697-422-134-52X;;060-569-205-222-495;;025-778-228-640-640;;018-701-464-127-33X;;034-633-606-331-300;;086-877-348-504-033;;033-253-568-025-220;;009-093-712-698-826;;019-552-127-353-985;;016-422-946-339-189;;120-037-439-200-704;;117-437-825-121-283;;023-575-418-131-641;;140-532-058-597-991;;042-607-068-936-492;;025-789-871-073-909;;106-660-583-644-550;;106-660-583-644-550;;096-312-053-601-842;;063-269-243-348-026;;050-983-607-561-263;;045-729-008-353-740;;056-196-064-755-971;;018-716-516-162-906;;031-098-073-697-690;;006-835-572-249-543;;052-176-596-515-633;;082-353-235-883-222;;124-145-750-525-628;;013-782-443-253-738;;038-087-893-633-108;;015-349-205-971-06X;;111-371-048-925-342;;059-845-899-529-100;;001-738-526-943-108;;009-852-354-311-269;;009-067-590-048-059;;027-222-235-706-90X;;023-142-333-399-91X;;096-073-292-575-164;;061-166-732-363-142;;065-063-689-244-933;;014-592-773-689-568;;041-081-762-433-73X;;037-656-744-900-664;;070-125-928-713-074;;009-652-838-411-630;;004-487-094-299-632;;084-394-479-101-649;;047-438-114-479-016;;064-803-508-025-788;;015-649-670-991-87X;;058-427-866-025-557;;095-399-613-845-473;;018-453-014-574-044;;031-781-347-077-349;;088-736-219-499-999;;029-991-841-452-638;;047-468-694-151-03X;;031-728-434-345-37X;;004-559-520-459-492;;091-758-570-049-747;;066-034-312-854-84X;;010-145-185-162-057;;036-840-721-356-161;;024-365-271-215-023;;007-854-771-178-901;;000-952-882-917-871;;146-951-726-024-713;;016-851-294-888-072;;071-426-147-826-012;;035-859-542-295-459;;046-764-007-270-871;;075-732-154-091-916;;056-039-600-069-280;;063-428-650-235-497;;048-152-749-258-818;;042-884-013-683-243;;001-076-475-435-735;;072-793-259-948-998;;067-222-985-577-896;;141-721-039-878-404;;033-634-785-071-687;;082-045-101-481-522;;034-033-950-596-544;;122-944-137-218-214,15062662;;10.1016/s0039-6109(03)00231-7;;10.1001/archopht.1987.01060030120040;;3827719;;19388880;;10.1517/13543780902855316;;20545612;;10.2174/138945010792006771;;pmc1191702;;10.1097/00000658-199903000-00010;;10077049;;10.1126/science.275.5304.1320;;9036860;;pmc254083;;3029417;;10.1128/jvi.61.4.1213-1220.1987;;10.1007/978-3-642-75608-5_3;;1582245;;10.1093/nar/11.17.6003;;6310523;;pmc326332;;10.1117/12.873566;;10.1016/s0967-2109(02)00070-4;;12453699;;pmc191942;;9261386;;10.1128/jvi.71.9.6641-6649.1997;;pmc3443373;;21371164;;10.1111/j.1524-475x.2011.00669.x;;10.1038/nrd984;;12509759;;12108952;;10.2174/1566523013348689;;11231461;;10.1067/msy.2001.111697;;10753827;;10.1182/blood.v95.8.2499.008k35_2499_2504;;10.1182/blood.v95.8.2499;;10.1001/archsurg.136.5.569;;11343549;;10.1016/j.ymthe.2004.05.024;;15294177;;10.2174/156652307780859062;;pmc2244792;;17584037;;pmc391030;;3898082;;10.1073/pnas.82.18.6250;;19652199;;10.1182/blood-2009-02-202085;;10.1158/0008-5472.can-09-3567;;20484030;;10.1128/jvi.73.3.2537-2540.1999;;pmc104501;;9971839;;9882336;;pmc103955;;10.1128/jvi.73.2.1309-1319.1999;;10.1128/jvi.71.9.6823-6833.1997;;9261407;;pmc191963;;10.1158/1078-0432.ccr-07-1441;;18316549;;10.1634/stemcells.19-3-236;;11359949;;1727603;;10.1016/0042-6822(92)90082-z;;10.1172/jci117016;;8113400;;pmc293889;;9352587;;10.1016/s0163-7258(97)00005-3;;10.1111/j.1749-6632.1999.tb09409.x;;10667212;;10.1038/sj.gt.3300483;;9349431;;15253267;;10.1007/s10016-004-0015-8;;10.1016/j.bpobgyn.2007.08.008;;17900991;;10.1128/jvi.61.4.1226-1239.1987;;3029418;;pmc254085;;10.1006/jmbi.1993.1687;;8263936;;10.1111/j.1464-410x.2005.05805.x;;16225524;;9811704;;pmc110480;;10.1128/jvi.72.12.9706-9713.1998;;10.1038/mt.2009.71;;pmc2835208;;19367261;;10.1089/10430340260395910;;12490001;;10.1016/j.ijpharm.2007.08.025;;17904316;;18004400;;10.1038/sj.gt.3303079;;10.1089/hum.1998.9.13-1909;;9741429;;19299149;;10.1016/j.bmc.2009.02.043;;10.1093/jnci/djj228;;16788155;;10.1006/viro.1996.0088;;8599194;;10.1038/nbt.1515;;19098898;;pmc2895694;;21306284;;10.1517/17425247.2011.554816;;pmc3129800;;10.1038/mt.2011.34;;10.1016/s1525-0016(16)36909-x;;21386820;;10.1248/bpb.29.1728;;16880633;;15062655;;10.1016/j.suc.2003.11.002;;pmc416542;;15163731;;10.1128/jvi.78.12.6381-6388.2004;;10.2210/pdb1lp3/pdb;;12192090;;pmc129358;;10.1073/pnas.182412299;;10.2165/00063030-200216010-00010;;11909005;;10.1016/s0090-4295(02)01589-3;;12231066;;10.1016/s0006-291x(87)80164-x;;3663223;;10.1016/0014-5793(90)80287-s;;2365091;;pmc2692765;;10.1002/jcp.21790;;19391103;;11434514;;10.1097/00008571-200106000-00011;;8648763;;10.1128/jvi.70.6.4173-4178.1996;;pmc190312;;886304;;10.1099/0022-1317-36-1-59;;6098454;;10.1002/j.1460-2075.1984.tb02232.x;;pmc557789;;12871018;;10.2174/1566523034578285;;8119968;;10.1016/s0021-9258(17)37593-2;;8453268;;10.1016/s0959-437x(05)80350-8;;10.1128/jvi.57.1.267-274.1986;;3001349;;pmc252723;;9308362;;10.1016/s0079-6603(08)60032-x;;pmc2796451;;10.1016/j.biomaterials.2009.10.012;;19850333;;10.1016/j.ymthe.2005.06.475;;16139571;;4415557;;10.1001/archsurg.1974.01360040068017;;9427689;;10.1182/blood.v91.2.371;;10.1182/blood.v91.2.371.371_371_382;;10326848;;10.1016/s0002-9610(99)00043-4;;17045403;;10.1016/j.bbcan.2006.08.008;;10.1021/bp060348j;;17269667;;7621239;;10.4111/kju.2007.48.3.265;;10.1007/bf02469553;;6513212;;10700178;;10.1038/73464;;8123838;;10.1182/blood.v83.6.1467.1467;;10.1182/blood.v83.6.1467.bloodjournal8361467;;10.1016/0005-2736(83)90504-7;;6824663;;10.1016/j.jss.2010.01.030;;20363441;;10.1016/j.jss.2010.01.030;;20363441;;pmc2855471;;10.4111/kju.2010.51.1.8;;20414403;;pmc39129;;8650161;;10.1073/pnas.93.12.5731;;10.1126/scitranslmed.3000112;;20368179;;pmc2852878;;pmc53656;;10.1073/pnas.87.6.2211;;2156265;;10.1089/hum.1994.5.7-793;;7981305;;10933960;;10.1006/mthe.2000.0062;;18707713;;10.1016/j.juro.2008.06.018;;pmc2727081;;19718355;;10.1111/j.1477-2574.2009.00066.x;;10.1016/0378-1119(91)90411-4;;1829048;;8254763;;10.1128/jvi.68.1.510-516.1994;;pmc236313;;16953249;;10.1038/sj.gt.3302838;;8971024;;pmc190992;;10.1128/jvi.70.12.8944-8960.1996;;16261406;;10.1007/s10549-005-9011-0;;10.2174/1874-470211003010037;;pmc3606625;;20030624;;10.2174/1874467211003010037;;15703485;;10.1089/hum.2005.16.17;;10.1128/mcb.6.8.2872;;10.1128/mcb.6.8.2872-2883.1986;;pmc367855;;3023952;;14988743;;1608446;;10.1038/357455a0;;8388142;;10.1016/0168-1702(93)90090-a;;15610604;;10.1089/hum.2004.15.1034;;10.1089/1043034042431146;;10.1089/hum.1998.9.18-2709;;9874269;;8661429;;10.1006/viro.1996.0367;;1316261;;10.1007/978-3-642-75608-5_5;;10.1126/science.272.5259.263;;8602510;;10.1182/blood-2002-02-0589;;12176886;;10936081;;10.1006/viro.2000.0468;;10.1016/j.addr.2009.04.018;;19422869;;15812225;;10.1089/hum.2005.16.299;;10.2174/1566523044578077;;15032617;;8942974;;10.1073/pnas.93.24.13565;;pmc19345;;18488414;;18393665;;10.2147/ijn.s2263;;pmc2526359;;10.2217/17435889.3.1.31;;10.1002/jgm.469;;14716673;;12386834;;10.1038/sj.cgt.7700518;;10.1016/s0021-9258(18)89839-8;;6334081;;pmc110119;;10.1128/jvi.72.10.7909-7915.1998;;9733828;;9383577;;10.1002/9780470515396.ch14;;22781695;;pmc3888062;;10.1038/nbt.2287;;10.1099/vir.0.003087-0;;19088268;;pmc109378;;10.1128/jvi.72.1.309-319.1998;;9420229;;17177309;;10.1002/jmv.20767;;19275541;;10.2174/157016309787581066;;pmc3108242;;8494923;;10.1089/hum.1993.4.2-129;;15520458;;pmc528817;;10.1093/nar/gnh140;;10.1054/ijom.2002.0244;;12418561;;pmc2174455;;10.1186/1479-0556-5-10;;17892546;;pmc1143681;;15919903;;10.1128/jvi.79.12.7478-7491.2005;;21301435;;10.1038/nbt.1769;;10.1358/dnp.2009.22.3.1354090;;19440556;;8254750;;10.1128/jvi.68.1.379-389.1994;;pmc236298;;pmc2862532;;10.1038/mt.2009.309;;20068553;;5091817;;10.1016/1074-5521(95)90043-8;;9383426;;9384705;;17222613;;10.1016/j.juro.2006.09.036;;10.5489/cuaj.936;;20944792;;pmc2950775;;10.1097/bor.0b013e3282e6f495;;17917537;;9634089;;10.1099/0022-1317-79-6-1461;;10.1634/theoncologist.7-1-46;;11854546;;19180106;;pmc7097568;;10.1038/nrd2742;;pmc192279;;9343173;;10.1128/jvi.71.11.8221-8229.1997;;10673715;;10.1038/sj.gt.3301115;;10196295;;pmc104178;;10.1128/jvi.73.5.3994-4003.1999;;10.1073/pnas.90.10.4601;;pmc46560;;7685107;;10.1038/mt.2012.194;;pmc3464639;;23023051;;10.1038/sj.gt.3302833;;16871229;;8267983;;17404600;;10.1038/cr.2007.13;;23472646;;10.7196/sajs.1334,"U.S. Appl. No. 13/815,206, filed Feb. 7, 2013, 2013/0211380, Aug. 15, 2013.;;U.S. Appl. No. 14/455,865, filed Aug. 8, 2014.;;Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, dated Nov. 24, 2014, 3 pages.;;Abdalla et al., “Hepatic vascular occlusion: which technique?” Surg. Clin. N. Am., 84:563-585 (2004).;;Adenovirus Wiki, “Human adenovirus genome sequences and annotations,” Published on Dec. 1, 2010 [online][retrieved on Mar. 21, 2013] Retrieved from:<URL:binf.gmu.edu/wiki/index.php [1 page].;;Assil et al., “Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye,” Arch Ophthalmol. 105:400-403 (1987).;;Barakat, M. and P. Kaiser, “VEGF inhibitors for the treatment of neovascular age-related macular degeneration,” Expert Opin. Investig. Drugs 18(5):637-646 (2009).;;Baxley, S. and R. Serra, “Inhibiting breast cancer progression by exploiting TGFbeta signaling,” Curr. Drug Targets 11(9):1089-1102 (2010).;;Belghiti et al., “Continuous versus intermittent portal triad clamping for liver resection: a controlled study,” Annals of Surgery, 229:369-375 (1999).;;Bergelson et al., “Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5,” Science 275:1320-1323 (1997).;;Berkner et al., “Abundant expression of polyomavirus middle T antigen and dihydrofolate reductase in an adenovirus recombinant,” J. Virol. 61:1213-1220 (1987).;;Berkner et al., “Expression of heterologous sequences in adenoviral vectors,” Curr. Top. Micro. Immunol., 158:39-66 (1992).;;Berkner et al., “Generation of adenovirus by transfection of plasmids,” Nuc. Acids Res. 11:6003-6020 (1983).;;Best et al. “Assessment of renal oxygenation during partial nephrectomy using DLP hyperspectral imaging.” Proc. SPIE, 7932, Emerging Digital Micromirror Device Based Systems and Applications III, 793202, 8 pages (2011).;;Blaisdell et al., “The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review,” Cardiovascular Surgery, 10:620-630 (2002).;;Blomer et al., “Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector,” J. Virol., 71:6641-6449 (1997).;;Blume et al., “Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers,” Wound Repair Regen., 19:302-308 (2011).;;Brekke, O. and I. Sandlie, “Therapeutic antibodies for human diseases at the dawn of the twenty-first century,” Nat. Rev. Drug. Discov. 2(1):52-62 and Correction (2003).;;Breyer et al., “Adenoviral vector-mediated gene transfer for human gene therapy,” Current Gene Therapy, 1:149-162 (2001).;;Brooks et al., “Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: implications for local gene therapy,” Surgery 129(3):324-334 (2001).;;Buchshacher, G. and F. Wong-Staal, “Development of lentiviral vectors for gene therapy for human diseases,” Blood, 95:2499-2504 (2000).;;Buell et al., “Is any method of vascular control superior in hepatic resection of metastatic cancers? Longmire clamping, pringle maneuver, and total vascular isolation,”Arch. Surg., 136:569-575 (2001).;;Burger et al., “Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system,” Mol. Ther., 10:302-317 (2004).;;Campos et al., “Current advances and future challenges in Adenoviral vector biology and targeting,” Curr. Gene Ther., 7:189-204 (2007).;;Cantrell et al., “Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor,” Proc. Natl. Acad. Sci, 82:6250-6254 (1985).;;Cassani et al., “Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy,” Blood, 114:3546-3556 (2009).;;Cerullo et al., “Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients,” Cancer Res., 70:4297-4309 (2010).;;Chillon et al. “Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C,” J. Virol., 73:2537-2540 (1999).;;Chiorini et al., “Cloning and characterization of adeno-associated virus type 5,” J. Virol., 73:1309-1319 (1999).;;Chiorini et al., “Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles,” J. Virol., 71:6823-6833 (1997).;;Cho et al., “Therapeutic nanoparticles for drug delivery in cancer,” Clin. Cancer. Res., 14:1310-1316 (2008).;;Choi et al., “Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells,” Stem Cells, 19:236-246 (2001).;;Chroboczek et al., “The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2,” Virology, 186:280-285 (1992).;;Clowes et al., “Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes,” J. Clin. Invest. 93:644-651 (1994).;;Curcio et al., “Oligonucleotides as modulators of cancer gene expression,” Pharmacol Therapy, 74:317-332 (1997).;;Curiel, D., “Strategies to adapt adenoviral vectors for targeted delivery,” Ann NY Acad. Sci., 886:158-171 (1999).;;Czubayko et al., “Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation,” Gene Therapy, 4:943-949 (1997).;;Darcin et al. “Pressure-controlled vascular clamp: a novel device for atraumatic vessel occlusion,” Ann Vase Surg. 18(2):254-256 (2004).;;David et al., “Gene therapy for the fetus: is there a future?” Best Pract Res Clin Obstet Gynaecol. 22(1):203-218 (2008).;;Davidson et al., “Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector,” J. Virol. 61:1226-1239 (1987).;;Davison et al., “The DNA sequence of adenovirus type 40,” J. Mol. Biol., 234:1308-1316 (1993).;;Denardi et al., “Nephron-sparing surgery for renal tumours using selective renal parenchymal clamping,” BJU Int. 2005 96:1036-1039 (2005).;;Dmitriev et al., “An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism,” J. Virol., 72:9706-9712 (1998).;;Duque et al., “Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons,” Mol. Ther., 17:1187-1196 (2009).;;Eastman et al., “Development of catheter-based procedures for transducing the isolated rabbit liver plasmid DNA,” Human Gene Therapy 13:2065-2077 (2002).;;Eto et al., “Development of PEGylated adenovirus vector with targeting ligand,” Int. J. Pharm., 354:3-8 (2008).;;Fabre et al., “Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava,” Gene Ther., 15:452-462 (2008).;;Fallaux et al., “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Hum. Gene Ther. 9:1909-1907(1998).;;Faraji, A. and P. Wipf, “Nanoparticles in cellular drug delivery,” Bioorg. Med. Chem. 17(8):2950-2962 (2009).;;Finch, P. and J. Rubin, “Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors,” J. Natl. Cancer Inst. 98(12):812-824 (2006).;;Fisher et al., “Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis,” J. Virol., 217:11-22 (1996).;;Foust et al., “Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes,” Nature Biotechnology, 27:59-65 (2009).;;Franzen, S., “A comparison of peptide and folate receptor targeting of cancer cells: from single agent to nanoparticle,” Expert Opin. Drug. Deliv. 8(3):281-298 (2011).;;Fu et al., “Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery,” Mol. Ther., 19:1025-1033 (2011).;;Fujita et al., “Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion,” Biological & Pharmaceutical Bulletin, 29:1728-1734 (2006).;;Gagner et al., “Laparoscopic liver resection: benefits and controversies.” Surg Clin North Am. 84(2):451-462 (2004).;;Gao et al., “Clades of Adeno-associated viruses are widely disseminated in human tissues,” J. Virol., 78:6381-6388 (2004).;;Gao et al., “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy,” Proc Natl. Acad. Sci., 99:11854-11859 (2002).;;GenBank Accession No. AB685372.1, “Human adenovirus 5 gene hexon, partial cds, strain: 11_02402/Mongolia/hexon,” Published on Oct. 8, 2013 [online][retrieved on Aug. 22, 2014] Retrieved from:<URL:ncbi.nlm.nih.gov/nuccore/AB685372.1 [2 pages].;;Genbank Accession No. AY530629.1, “Adeno-associated virus isolate hu.9 capsid protein VP1 (cap) gene, complete cds,” Published on Jun. 24, 2004 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:ncbi.nlm.nih.gov/nuccore/AY530629.1[2 pages].;;Genbank accession No. AF517770.1, “Sus scrofa alpha-fetoprotein precursor, mRNA, complete cds,” Published on Dec. 30, 2002 [online][retrieved on Aug. 22, 2014] Retrieved from:<URL: http://www.ncbi.nlm.nih.gov/nuccore/AF517770.1[2 pages].;;Genbank accession No. AY033476.1, “Sus scrofa serum albumin gene, promoter region,” Published on May 5, 2002 [online][retrieved on Aug. 22, 2014] Retrieved from:<URL:ncbi.nlm.nih.gov/nuccore/AY033476.1 [2 pages].;;Generx, “FGF-4 gene therapy GENERX—Collateral Therapeutics,” BioDrugs 16:75-76 (2002).;;George, D., “Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate,” Urology 60(3 Suppl. 1):115-121 (2002).;;Ghosh-Choudhury et al., “Stable transfer of a mouse dihydrofolate reductase gene into a deficient cell line using human adenovirus vector,” Biochem. Biophys. Res. Commun., 147:964-973 (1987).;;Gilardi et al., “Expression of human alpha 1-antitrypsin using a recombinant adenovirus vector,” FEBS Lett.267:60-62 (1990).;;Gondi, C. and J. Rao, “Concepts in in vivo siRNA delivery for cancer therapy,” J. Cell Physiol. 220(2):285-291. (2009).;;Gong et al., “Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus,” Pharmacogentics, 11:357-368 (2001).;;Gorziglia et al., “Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy,” J. Virology 70:4173-4178 (1996).;;Graham et al., “Characteristics of a human cell line transformed by DNA from human adenovirus Type 5,” J. Gen. Virol. 36:59-72 (1977).;;Graham, F., “Covalently closed circles of human adenovirus DNA are infectious,” EMBO J. 3:2917-2922 (1984).;;Grimm, D. and M. Kay, “From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy,” Current Gene Therapy, 3:281-304 (2003).;;Groskreutz et al., “Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin.” J. Biol. Chem., 269:6241-6245 (1994).;;Grossman, M. and J. Wilson, “Retroviruses: delivery vehicle to the liver,” Curr. Opin. in Genetics and Devel. 3:110-114 (1993).;;Haj-Ahmad et al., “Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene,” J. Virol. 57:267-274 (1986).;;Hampel, A., “The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy,” Prog. Nucleic Acid Res. Mol. Biol., 58:1-39 (1998).;;Harris et al., “Tissue-specific gene delivery via nanoparticle coating,” Biomaterials, 31:998-1006 (2010).;;Hodges et al., “Local delivery of viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver,” Mol. Ther. 12:1043-1051 (2005).;;Hoffman et al., “Renal ischemic tolerance,” AMA Arch. Surg., 109:550-551 (1974).;;Invalidity Search Report prepared by a third-party, “Invalidity Search—Provisional Application—Clamping Device, Global Bio Therapeutics,” redacted, dated May 21, 2014, 13 pages.;;Invalidity Search Report prepared by a third-party, “Invalidity Search—Provisional Application—Injectcion Device, Global Bio Therapeutics,” redacted, dated May 21, 2014, 10 pages.;;James, H. and I. Gibson, “The therapeutic potential of ribozymes,” Blood, 91:371-382 (1998).;;Jiao et al., “Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors,” Am J Surg. 177(4):303-306 (1999).;;Jimeno, A. and M. Hidalgo, “Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,” Biochim. Biophys. Acta 1766(2):217-229 (2006).;;Jin et al., “Nanoparticle-mediated drug delivery and gene therapy,” Biotechnol. Prog., 23:32-41 (2007).;;Jolly et al., “Viral vector systems for gene therapy,” Cancer Gene Therapy, 1:51-64 (1994).;;Joung et al., “Partial nephrectomy using parenchymal compression without renal pedicle clamping,” Korean J. Urol., 28:265-269 (2007).;;Kanematsu et al., “A newly designed clamp facilitates hepatic resection,” Jpn. J. Surg., 14:432-423 (1984).;;Kay et al., “Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector,” Nat Genet. 24(3):257-261 (2000).;;Kiem et al., “Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells,” Blood 83:1467-1473 (1994).;;Kim et al., “Preparation of multivesicular liposomes,” Bioch. Bioph. Acta 728:339-348 (1983).;;Kinoshita et al., “Targeted gene delivery to selected liver segments via isolated hepatic perfusion with clamping of the portal vein,” Molecular Therapy 9: S119 (2004).;;Kinoshita et al., “Targeted gene delivery to selected liver segments via isolated hepatic perfusion,” J Surg. Res., 160:47-51 (2010).;;Ko et al., “Efficacy of parenchymal compression in open partial nephrectomies: a comparison with conventional vascular clamping,” Korean J. Urol., 51:8-14 (2010).;;Kochanek et al., “A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase,” Proc. Natl. Acad. Sci., 93:5731-5736 (1996).;;Kota et al., “Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.” Sci Transl Med. 1(6):6ra15, 8 pages (2009).;;Kotin et al., “Site-specific integration by adeno-associated virus,” Proc. Natl. Acad. Sci., 87:2211-2215 (1990).;;Kotin, R., “Prospects for the use of adeno-associated virus as a vector for human gene therapy,” Human Gene Therapy, 5:793-801 (1994).;;Krasnykh et al., “Genetic targeting of adenoviral vectors,” Mol. Ther., 1:391-405 (2000).;;Lee et al., “Laboratory evaluation of laparoscopic vascular clamps using a load-cell device—are all clamps the same?” J. Urol. 180:1267-1272 (2008).;;Lesurtel et al. (2009) “Clamping techniques and protecting strategies in liver surgery,” HPB (Oxford). 11:290-295.;;Levrero et al., Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo, Gene 101:195-202 (1991).;;Lewis, P. and F. Emerman, “Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus,” J. Virol., 68:510-516 (1996).;;Li, S. and L. Huang, “Gene therapy progress and prospects: non-viral gene therapy by systemic delivery,” Gene Therapy, 13:1313-1319 (2006).;;Lieber et al., “Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo,” J. Virol., 70:8944-8960 (1996).;;Lo et al., “EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization,” Breast Canc. Res. Treat. 95(3):211-218 (2006).;;Lo, H., “EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance,” Curr. Mol. Pharmacol. 3(1):37-52 (2010).;;Manilla et al., “Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector,” Human Gene Therapy, 16:17-25 and Corrections (2005).;;Massie et al., “Construction of a helper-free recombinant adenovirus that expresses polyomavirus large T antigen,” Mol. Cell. Biol. 6:2872-2883 (1986).;;Mellstedt, H., “Monoclonal antibodies in human cancer,” Drugs Today 39(Supl. C):1-16 (2003).;;Miller, A, “Human gene therapy comes of age,” Nature 357(6378):455-460 (1992).;;Mittal et al., “Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter,” Virus Res. 28:67-90 (1993).;;Mizuguchi et al., “Targeted adenovirus vectors,” Hum. Gene Ther., 15:1034-1044 (2004).;;Morral et al., “High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity,” Hum. Gene Ther., 10:2709-2716 (1998).;;Muramatsu et al., “Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3,” Virol., 221:208-217 (1996).;;Muzyczka, N., “Use of adeno-associated virus as a general transduction vector for mammalian cells,” Curr. Top. Micro. Immunol., 1 58:97-129 (1992).;;Naldini et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,” Science, 272:263-267 (1996).;;Nathwani et al., “Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques,” Blood, 100:1662-1669 (2002).;;Nemerow, G., “Cell receptors involved in adenovirus entry,” Virology 274:1-4 (2000).;;Oh, Y. and T. Park, “siRNA delivery systems for cancer treatment,” Adv. Drug. Deliv. Rev. 61(10):850-862 (2009).;;Ohashi et al., “Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver,” Human Gene Therapy 16:299-306 (2005).;;Papadakis et al., “Promoters and control elements: designing expression cassettes for gene therapy.” Curr Gene Ther. 4(1):89-113 (2004).;;Parks et al., “A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal,” Proc. Natl. Acad. Sci., 93:13565-13570 (1996).;;Pathak et al., “Nano-vectors for efficient liver specific gene transfer,” Int. J. Nanomedicine, 3:31-49 (2008).;;Podevin et al., “Factors influencing immune response after in vivo retrovirus-mediated gene transfer to the liver,” J Gene Med. 6(1):16-21 (2004).;;Qi et al., “The clinical effect of recombinant human ad p53 agent-Gendicine in advanced cancer patients in 23 cases,” Modern Oncology, 14:1295-1297 (2006) [Article in Chinese with abstract in the English language].;;Rasmussen et al., “TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene,” Cancer Gene Ther., 9:951-957 (2002).;;Roberts et al., “DNA sequences from the adenovirus 2 genome,” J. Biol. Chem., 259:13968-13975 (1984).;;Roelvink et al., “The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F,” J. Virol. 72:7909-7915 (1998).;;Rossi, J., “Therapeutic applications of catalytic antisense RNAs (ribozymes),” Ciba Found. Symp., 209:195-204 (1997).;;Russell et al., “Oncolytic virotherapy,” Nature Biotechnology, 30:658-670 (2012).;;Russell, W., “Adenoviruses: update on structure and function,” J Gen. Virol. 90:1-20 (2009).;;Rutledge et al., “Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2,” J. Virol, 72:309-319 (1998).;;Sachdeva et al., “Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance,” Journal of Medical Virology, 79:118-126 (2007).;;Sajja et al., “Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect,” Curr. Drug. Discov. Technol. 6(1):43-51(2009).;;Salmons, B. and W. Gunzberg, “Targeting of retroviral vectors for gene therapy,” Human Gene Therapy 4:129-141 (1993).;;Schiffelers et al., “Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle,” Nucleic Acids Res.32(19):e149, 10 pages (2004).;;Schilephake, H., “Bone growth factors in maxillofacial skeletal reconstruction,” Int. J. Oral Maxillofac. Surg. 31(5):469-484 (2002).;;Segura-Pancheco et al., “HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo,” Genet. Vaccines Ther.5:10, 8 pages (2007).;;Shayakhmetov et al., “Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity,” J. Virol. 79:7478-7491 (2005).;;Sheridan, C., “Gene therapy finds its niche,” Nature Biotechnology, 29:121-128 and errata (2011).;;Shirakawa, T., “Clinical trial design for adenoviral gene therapy products,” Drugs News Perspectives, 22(3):140-145 (2009).;;Sprengel et al., “Nucleotide sequence of human adenovirus type 12 DNA: comparative functional analysis,” J. Virol., 68:379-389 (1994).;;Sterman et al., “A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions,” Mol. Ther., 18:852-860 (2010).;;Storm et al. “A simplified clamp for hepatic resection,” Surg Gynecol Obstet.133(1):103-104 (1971).;;Sullenger “Revising messages traveling along the cellular information superhighway,” Chem. Biol., 2:249-253 (1995).;;Sullenger, B., “Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors,” Cytokines Mol. Ther., 2:201-205 (1996).;;Thompson et al., “The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study,” J. Urology, 177:471-476 (2006).;;Toren et al., “Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy,” Can. Urol. Assoc., 4:E133-E136 (2010).;;Trojanowska, M and J. Varga, “Molecular pathways as novel therapeutic targets in systemic sclerosis,” Curr. Opin. Rheumatol. 19(6):568-573 (2007).;;Uniprot Accession No. P00451, “Coagulation factor VIII,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P00451 [22 pages].;;Uniprot Accession No. P00740, “Coagulation factor IX,” Last Modified on Jul. 9, 2014 [online][retrieved on Aug. 22, 2014] Retrieved from:<URL:uniprot.org/uniprot/P00740 [17 pages].;;Uniprot Accession No. P00749, “Urokinase-type plasminogen activator,” Last Modified on Jul. 9, 2014 [online][retrieved on Aug. 22, 2014] Retrieved from:<URL:uniprot.org/uniprot/P00749 [12 pages].;;Uniprot Accession No. P00750, “Tissue-type plasminogen activator,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P00750 [10 pages].;;Uniprot Accession No. P01241, “Somatotropin,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P01241 [9 pages].;;Uniprot Accession No. P01242, “Growth hormone variant,” Last Modified on Mar. 6, 2013 [online] [retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P01242[6 pages].;;Uniprot Accession No. P01308, “Insulin,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P01308[11 pages].;;Uniprot Accession No. P01583, “Interleukin-1 alpha,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P01583[6 pages].;;Uniprot Accession No. P01584, “Interleukin-1 beta,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P01584 [14 pages].;;Uniprot Accession No. P01588, “Erythropoietin,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P01588 [6 pages].;;Uniprot Accession No. P04141, “Granulocyte-macrophage colony-stimulating factor,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P04141 [5 pages].;;Uniprot Accession No. P04275, “von Willebrand factor,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P04275 [12 pages].;;Uniprot Accession No. P05112, “Interleukin-4,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P05112 [7 pages].;;Uniprot Accession No. P08700, “Interleukin-3,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P08700 [5 pages].;;Uniprot Accession No. P09919, “Granulocyte colony-stimulating factor,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P09919 [6 pages].;;Uniprot Accession No. P13232, “Interleukin-7,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P13232 [5 pages].;;Uniprot Accession No. P60568, “Interleukin-2,” Last Modified on Mar. 6, 2013 [online][retrieved on Mar. 19, 2013] Retrieved from:<URL:uniprot.org/uniprot/P60568 [6 pages].;;Von Seggern et al., “Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein,” J. Gen. Virol. 79:1461-1468 (1998).;;Vorburger, S. and K. Hunt, “Adenoviral gene therapy,” The Oncologist, 7:46-59 (2002).;;Wang et al., “Adenoviral vector systems for gene therapy,” Gene Therapy and Mol. Biology, 9:291-300 (2005).;;Whitehead et al., “Knocking down barriers: advances in siRNA delivery,” Nat. Rev. Drug. Discov. 8(2):129-138 including corrigendum and errata (2009).;;Wickham et al., “Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins,” J. Virol., 71:8221-8229 (1997).;;Wickham, T., “Targeting adenovirus,” Gene Ther., 7:110-114 (2000).;;Xiao et al., “Gene therapy vectors based on adeno-associated virus type 1,” J. Virol., 73:3994-4003 (1999).;;Yang et al., “An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer,” Proc. Natl. Acad. Sci. USA 90:4601-4605 (1993).;;Yla-Herttuala, S., “Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union,” Mol. Ther., 20:1831-1832 (2012).;;Yoshino et al., “Naked plasmid DNA transfers to the porcine liver using rapid injection with large volume,” Gene Ther.13:1696-1702 (2006).;;Zhang et al., “Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis,” BioTechniques 15(5):868-872 (1993).;;Zheng et al., “Antibody gene therapy: an attractive approach for the treatment of cancers and other chronic diseases, ” Cell Research, 17:303-306 (2007).;;Zhou et al. “A comparative study assessing a new tool for occluding parenchymal blood flow during liver resection for hepatocellular carcinoma,” S Afr J Surg. 51(1):12-15 (2013).;;International Search Report and Written Opinion, dated May 23, 2013, in connection with International Patent Application No. PCT/US2013/025234, 24 pages.;;Restriction Requirement, dated Sep. 19, 2013, in connection with U.S. Appl. No. 13/815,206, 6 pages.;;Response to Restriction Requirement, dated Oct. 21, 2013, in connection with U.S. Appl. No. 13/815,206, 13 pages.;;Response to International Search Report and Written Opinion, dated Dec. 9, 2013, in connection with International Patent Application No. PCT/US2013/025234, 49 pages.;;Written Opinion, dated Jan. 27, 2014, in connection with International Patent Application No. PCT/US2013/025234, 9 pages.;;Response to Written Opinion, dated Mar. 27, 2014, in connection with International Patent Application No. PCT/US2013/025234, 45 pages.;;Office Action, dated Apr. 22, 2014, in connection with U.S. Appl. No. 13/815,206, 47 pages.;;International Preliminary Report on Patentability, dated May 6, 2014, in connection with International Patent Application No. PCT/US2013/025234, 10 pages.;;Response to Office Action, dated Oct. 22, 2014, in connection with U.S. Appl. No. 13/815,206, 31 pages.;;Letter/Written Disclosure of the Information Disclosure Statement for the above-referenced application, dated Oct. 26, 2015, 2 pages.;;International Search Report and Written Opinion, dated Nov. 5, 2014, in connection with corresponding International Patent Application No. PCT/US2014/050441, 15 pages.;;International Search Report and Written Opinion, dated Mar. 30, 2015, in connection with International Patent Application No. PCT/US2014/050446, 15 pages.;;Final Office Action, dated Apr. 28, 2015, in connection with U.S. Appl. No. 13/815,206, 54 pages.;;Response to International Search Report and Written Opinion, dated Jun. 8, 2015, in connection with corresponding International Patent Application No. PCT/US2014/050441, 49 pages.;;Response to International Search Report and Written Opinion, dated Jun. 30, 2015, in connection with International Patent Application No. PCT/US2014/050446, 43 pages.;;Written Opinion, dated Jul. 7, 2015, in connection with corresponding International Patent Application No. PCT/US2014/050441, 9 pages.;;Response, dated Sep. 7, 2015, to the second Written Opinion, dated Jul. 7, 2015, in connection with corresponding International Patent Application No. PCT/US2014/050441, 40 pages.;;International Report on Patentability, dated Sep. 29, 2015, in connection with International Patent Application No. PCT/US2014/050446, 35 pages.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Aug. 10, 2017, 2 pages.;;News Article, “Spotlight: Global BioTherapeutics—Cultivating Entrepreneurship in Gene Therapy,” Published Sep. 30, 2015 [online] Retrieved on May 25, 2016 from: <URL:mexicosalud.com/spotlight-global-biotherapeutics-cultivating-entrepreneurship-in-gene-therapy/, 6 pages.;;Examiner's Report, dated Oct. 21, 2016, in connection with corresponding Canadian Patent Application No. 2920261, 4 pages.;;Reponse, filed Jan. 19, 2017, Examiner's Report, dated Oct. 21, 2016, in connection with corresponding Canadian Patent Application No. 2920261, 36 pages.;;Examiner's Report, dated Feb. 9, 2017, in connection with corresponding Canadian Patent Application No. 2920261, 3 pages.;;Response, filed Aug. 3, 2017, to Examiner's Report, dated Feb. 9, 2017, in connection with corresponding Canadian Patent Application No. 2920261, 33 pages.;;Communication pursuant to Article 94(3) EPC (Examination Report), dated May 3, 2017, in connection with corresponding European Patent Application No. 14 752 772.5, 5 pages.;;U.S. Appl. No. 14/455,865, filed Aug. 8, 2014, 2015/0045769, Feb. 12, 2015.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Apr. 28, 2016, 2 pages.;;International Preliminary Report on Patentability, dated Nov. 12, 2015, in connection with International Patent Application No. PCT/US2014/050441, 36 pages.;;Letter/Written Disclosure of the Supplemental Information Disclosure Statement for the above-referenced application, filed herewith on Apr. 23, 2018, 2 pages.;;Machine-generated English language translation of Japanese Patent No. JP S62-32944 (A), published on Feb. 12, 1987, generated from Espacenet on Jan. 3, 2018, 6 pages.;;Notice of Allowance, dated Aug. 16, 2017, in connection with corresponding Canadian Patent Application No. 2,920,261, 1 page.;;Office Action, dated Nov. 17, 2017, in connection with corresponding Chinese Patent Application No. 201480055532.3 [English translation and original document in Chinese], 7 pages. et al.",ACTIVE
547,PE,Z,PE 20210770 Z,169-828-320-846-54X,2021-04-20,2021,PE 2020002073 U,2020-12-15,PE 2020002073 U,2020-12-15,UNA COCINA ARTESANAL CON FILTRO CONICO PARA REDUCCION DE EMISIONES,"Una cocina artesanal del tipo que comprende una cubierta externa (1), un filtro (5) de humo para reduccion de emisiones, y una base circular (7) donde se deposita el combustible, caracterizado porque la cubierta externa (1) presenta una forma conica para reduccion de emisiones, y al menos dos asas (2); el filtro (5) presenta una forma conica para reduccion de emisiones, estando ubicado en el interior de la cubierta externa (1); y la base circular (7) presenta una forma circular para favorecer la evacuacion del humo, una hendidura (9), en la cual esta dispuesta la base del filtro (5), y unas patas (10) como punto de contacto con la superficie del suelo.",UNIV NACIONAL DE TRUJILLO,BUCHELLI PERALES ORIVEL JACKSON;;CABRERA LAZARO JOSE CARLO;;ROBLES LORA MARCOS ALEJANDRO;;BERMEO RODRIGUEZ JANETT ERIKA,,https://lens.org/169-828-320-846-54X,Patent Application,no,0,0,1,1,0,,,,0,0,,,,PENDING
548,US,A1,US 2015/0066056 A1,017-582-311-650-191,2015-03-05,2015,US 201414455871 A,2014-08-08,US 201414455871 A;;US 201361863903 P,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,NOVO ENGINEERING INC (2014-11-12);;GLOBAL BIO THERAPEUTICS USA INC. (GBT USA) (2014-09-30);;GLOBAL BIO THERAPEUTICS INC. (GBT USA) (2014-11-12);;GLOBAL BIO THERAPEUTICS INC (2015-05-07);;GLOBAL BIOTHERAPEUTICS S.A. DE C.V. (GBT MEX) (2014-09-30),https://lens.org/017-582-311-650-191,Patent Application,yes,4,11,20,20,2,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,606/140,0,0,,,,ACTIVE
549,CL,A1,CL 2010000753 A1,096-375-370-186-118,2011-05-06,2011,CL 2010000753 A,2010-07-14,CL 2010000753 A,2010-07-14,Extracto preparado de dechamsia antarctica que comprende un grupo de compuestos biologicamente activos identificados por hplc; composicion antineoplasica que comprende dicho extracto; metodo para prevenir la proliferacion de celulas cancerosas mediante el tratamiento con dicha composicion.,Extracto preparado de dechamsia antarctica que comprende un grupo de compuestos biológicamente activos identificados por HPLC; composición antineoplásica que comprende dicho extracto; método para prevenir la proliferación de células cancerosas mediante el tratamiento con dicha composición.,MANUEL GIDEKEL HELGA WEBER GUSTAVO CABRERA ANA GUTIERREZ JENIFER OSORIO JOSE BECERRA OSVALDO PODHAJC,JOSE BECERRA;;MANUEL GIDEKEL;;HELGA WEBER;;GUSTAVO CABRERA;;ANA GUTIERREZ;;JENIFER OSORIO;;OSVALDO PODHAJCER;;EDUARDO CAFFERAT,,https://lens.org/096-375-370-186-118,Patent Application,no,0,0,1,12,0,,A61K31/352;;A61K31/355;;A61P35/00,,0,0,,,,PENDING
550,CA,C,CA 2825734 C,059-934-441-674-968,2016-05-17,2016,CA 2825734 A,2012-02-13,US 201161443762 P;;US 2012/0024817 W,2011-02-17,METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HYDROXY-BETA-METHYLBUTYRATE,"Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL MANZANO;;PEREZ ALEJANDRO BARRANCO;;GONZALEZ MARIA RAMIREZ;;CABRERA RICARDO RUEDA,,https://lens.org/059-934-441-674-968,Granted Patent,no,0,0,20,20,0,A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19;;A61P21/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P3/02;;A61P9/00;;A61P9/10;;A23V2002/00;;A23L33/40;;A23L33/10;;A23L33/175;;A61K31/19,,,0,0,,,,INACTIVE
551,CA,A1,CA 2920261 A1,136-060-950-280-242,2015-02-12,2015,CA 2920261 A,2014-08-08,US 201361863903 P;;US 2014/0050441 W,2013-08-08,CLAMP DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF,"Provided herein is a clamp device that can be used in minimally invasive procedures, including surgeries such as laparoscopic surgeries, for clamping a tissue or an organ or a portion of a tissue or organ. The clamp device comprises an elongate surface member, a deformable article that rests on the surface member at the distal end of the surface member and a flexible band. The distal end of the flexible band is connected to the distal end of the surface member and the flexible band forms a closed loop with the deformable article. The proximal end of the flexible band is configured to be adjustably tensioned so that the portion of the flexible band that forms a closed loop with the deformable article can be shortened or lengthened. Also provided herein are methods of clamping a tissue or an organ or a portion thereof during minimally invasive surgery using the clamp device provided herein. Also provided are systems for performing a minimally invasive surgery that include the clamp device for minimally invasive surgery provided herein and an injection device configured to access an endoscopic port for the minimally invasive surgery.",GLOBAL BIO THERAPEUTICS INC,CABRERA AQUINO JOSE GUSTAVO;;SEGURA PACHECO BLANCA ANGELICA;;MASTERSON STEVEN;;ROZENBERG ALLAN;;FAUCHER PAUL;;HOFFMAN JOHN,,https://lens.org/136-060-950-280-242,Patent Application,no,0,0,20,20,2,A61B17/12013;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B2017/00407;;A61B2017/00557;;A61B2017/00862;;A61B2017/12004;;A61B17/12013;;A61B17/12013;;A61B2017/12004;;A61B2017/00862;;A61B2017/00557;;A61B2017/00407,A61B17/12,,0,0,,,,ACTIVE
552,ES,A1,ES 2958165 A1,168-149-513-171-664,2024-02-02,2024,ES 202230612 A,2022-07-05,ES 202230612 A,2022-07-05,Soluciones para diálisis peritoneal que contienen un flavonoide natural como agente osmótico,Soluciones para diálisis peritoneal que contienen un flavonoide natural como agente osmótico. La presente invención se refiere a soluciones de diálisis peritoneal que comprenden troxerutina o vitamina P4 como agente osmótico. La invención también se refiere al procedimiento para preparar dichas soluciones y al nuevo uso de la troxerutina.,CONSEJO SUPERIOR INVESTIGACION;;UNIV ALCALA HENARES,SUCUNZA SAENZ DAVID;;VAQUERO LOPEZ JUAN JOSE;;LOPEZ CABRERA MANUEL;;GONZALEZ MATEO GUADALUPE TIRMA;;KOPYTINA VALERIA,,https://lens.org/168-149-513-171-664,Patent Application,no,4,0,2,2,0,A61P7/08;;A61M1/28;;A61K31/7042;;A61K9/08;;A61K9/08;;A61K31/7048;;A61P7/08;;A61M1/28,A61K9/08;;A61K31/7042;;A61M1/28;;A61P7/08,,0,0,,,,PENDING
553,BR,A2,BR 112015023005 A2,131-791-476-877-355,2017-07-18,2017,BR 112015023005 A,2014-03-11,US 2014/0023007 W;;EP 13382090 A,2013-03-15,uso de sistemas específicos de carboidratos durante a gravidez para prevenção do acúmulo de gorduras em gestantes,"resumo uso de sistemas específicos de carboidratos durante a gravidez para prevenção do acúmulo de gorduras em gestantes são aqui divulgados métodos relacionados com a administração de especí-ficos sistemas de carboidratos a uma gestante para impedir ou limitar a acumulação de gordura. o sistema de carboidratos pode incluir um carboidrato simples de taxa de digestão lenta, um carboidrato complexo, um carboidrato não absorvente, e/ou um carboidrato não digerível. as composições podem ser administradas antes, du-rante, ou após a gestação.",ABBOTT LAB,JOSE MARIA LOPEZ PEDROSA;;MANUEL CRISTÓBAL MANZANO MARTÍN;;MARIA DEL PILAR BUENO VARGAS;;RICARDO RUEDA CABRERA,,https://lens.org/131-791-476-877-355,Patent Application,no,0,0,11,11,0,A23L29/212;;A23L29/30;;A23L29/35;;A23L33/30;;A23L33/40;;A23L33/21;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A61P3/04;;A61P3/10;;A23L5/00;;A23L7/00;;A23L33/125;;A23L9/00;;A23L29/30;;A23L33/40;;A23L33/21;;A23L29/35;;A23L33/30;;A23L29/212,A61K31/70;;A61P3/04;;A61P3/10,,0,0,,,,DISCONTINUED
554,ES,A1,ES 2385443 A1,019-430-864-684-64X,2012-07-25,2012,ES 201031978 A,2010-12-28,ES 201031978 A,2010-12-28,PYRIMIDINE UREA-DERIVED COMPOUND FOR TREATING INFLAMMATORY DISEASES,"The present invention relates to a pyrimidine urea-derived compound for treating inflammatory diseases. The compound of the invention can be used for preparing a pharmaceutical composition for treating said inflammatory diseases, preferably sepsis caused by Gram-negative bacteria, arthritis, renal infections, acute sepsis-induced pulmonary diseases, acute sepsis-induced respiratory distress syndrome, endotoxic or endotoxemic shock, septic peritonitis, acute hepatitis, acute septic-shock-induced myocardial dysfunction and necrotizing enterocolitis.",CIBER DE ENFERMEDADES RESPIRATORIAS;;SERVICIO CANARIO DE SALUD;;UNIV LA LAGUNA,VILLAR HERNANDEZ JESUS;;PADRON CARRILLO JOSE MANUEL;;CASULA MILENA;;CABRERA BENITEZ NURIA ESTHER;;RAMOS NUEZ ANGELA MARIA,,https://lens.org/019-430-864-684-64X,Patent Application,no,1,0,3,3,0,A61K31/505;;A61K31/513;;A61P29/00;;C07D239/54;;C07D239/54,C07D239/54;;A61K31/505;;A61P29/00,,4,4,003-364-212-505-905;;022-107-002-021-12X;;067-973-337-022-662;;041-565-073-522-498,10.3998/ark.5550190.0011.b04;;16682201;;10.1016/j.bmcl.2006.04.072;;10.1002/chin.200638147;;10.1007/bf02708284,"JAKUBNIENE, V. et al. ¿Synthesis of (pyrimidin-4-yloxy)-and (pyrimidin-3-yl)acetyl azides and their rearrangement to carbamates and ureas¿. ARKIVOC, Volumen 2010, Parte (xi), páginas 39-48. [Publicado el 06.09.2010]. Ver página 40, esquema 1; página 41, esquema 2, página 42, esquema 3.;;MAIER, J.A. et al. ¿Development of N-4,6-pyrimidine-N-alkyl-N¿-phenylureas as orally active inhibitors of lymphocytespecific tyrosine kinase.¿ Bioorganic & Medicinal Chemistry Letters 2006, Volumen 16, páginas 3646-3650. [Disponible en línea el 08.05.2006]. Ver página 3646, figura 1; página 3647, tabla 1; página 3650, columna 2, párrafo 3.;;BRUGEL, T.A. et al. ¿Development of N-2,4-pyrimidine-N-alkyl-N¿-phenylureas as inhibitors of tumor necrosis factor alpha (TNF-¿)synthesis. Part 1.¿ Bioorganic & Medicinal Chemistry Letters 2006,Volumen 16, páginas 3510-3513. [Disponible en línea el 02.05.2006]. Ver página 3510, columna 1, párrafo 1; página 3511, tabla 1.;;LATTHE, P.R. et al. ¿Curtius rearrangement reactions of 3-(4-azidocarbonyl) phenylsydnone. Synthesis of 4-(sydnon-3-yl) phenyl carbamates, N-aryl-N¿-[4-(sydnon-3-yl)] phenyl ureas andtheir antimicrobial and insecticidal activities¿. Journal of Chemical Sciences 2006, Volumen 118, Número 3, páginas 249-256. Ver página 249, resumen; página 250, esquema 1.",INACTIVE
555,WO,A1,WO 2014/044892 A1,087-123-076-618-699,2014-03-27,2014,ES 2013070653 W,2013-09-19,ES 201231466 A,2012-09-21,METHOD FOR THE PRODUCTION OF COMPLEX REPERTOIRES OF RECOMBINANT MOLECULES,"The invention relates to a method for the production of complex repertoires of recombinant molecules in a consistent and reproducible manner, comprising the transient generation of multi-transgenic plants that generate somatic mosaics induced by viral replicons that are mutually exclusive. The invention also relates to the multi-transgenic plant or a fragment of same obtained in this way, as well as to extracts or purified fractions thereof, which represent complex repertoires of recombinant molecules, preferably recombinant proteins selected from among: enzymes, immunoglobulins, membrane receptors, intracellular receptors, lectins, polyclonal antibodies, antidotes based on anti-serums, immunological serums for passive immunity, and intravenous immunoglobulins.",CONSEJO SUPERIOR INVESTIGACION;;UNIV VALENCIA POLITECNICA;;UNIV LAS PALMAS GRAN CANARIA,ORZAEZ CALATAYUD DIEGO VICENTE;;JULVE PARRENO JOSE MANUEL;;GRANELL RICHART ANTONIO;;SARRION-PERDIGONES ALEJANDRO;;GUTIERREZ CABRERA CARLOS,,https://lens.org/087-123-076-618-699,Patent Application,yes,5,0,3,3,16,C12N15/8258,C12N15/82,,0,0,,,,PENDING
556,ES,A1,ES 2456823 A1,158-883-896-991-750,2014-04-23,2014,ES 201231466 A,2012-09-21,ES 201231466 A,2012-09-21,METHOD FOR THE PRODUCTION OF COMPLEX REPERTOIRES OF RECOMBINANT MOLECULES,"The invention relates to a method for the production of complex repertoires of recombinant molecules in a consistent and reproducible manner, comprising the transient generation of multi-transgenic plants that generate somatic mosaics induced by viral replicons that are mutually exclusive. The invention also relates to the multi-transgenic plant or a fragment of same obtained in this way, as well as to extracts or purified fractions thereof, which represent complex repertoires of recombinant molecules, preferably recombinant proteins selected from among: enzymes, immunoglobulins, membrane receptors, intracellular receptors, lectins, polyclonal antibodies, antidotes based on anti-serums, immunological serums for passive immunity, and intravenous immunoglobulins.",CONSEJO SUPERIOR INVESTIGACION;;UNIV VALENCIA POLITECNICA;;UNIV LAS PALMAS GRAN CANARIA,ORZAEZ CALATAYUD DIEGO VICENTE;;JULVE PARRENO JOSE MANUEL;;GRANELL RICHART ANTONIO;;SARRION-PERDIGONES ALEJANDRO;;GUTIERREZ CABRERA CARLOS,,https://lens.org/158-883-896-991-750,Patent Application,no,0,0,3,3,0,C12N15/8258,C12N15/82,,0,0,,,,ACTIVE
557,WO,A1,WO 2012/089876 A1,195-516-996-689-951,2012-07-05,2012,ES 2011070822 W,2011-11-25,ES 201031978 A,2010-12-28,PYRIMIDINE UREA-DERIVED COMPOUND FOR TREATING INFLAMMATORY DISEASES,"The present invention relates to a pyrimidine urea‑derived compound for treating inflammatory diseases. The compound of the invention can be used for preparing a pharmaceutical composition for treating said inflammatory diseases, preferably sepsis caused by Gram‑negative bacteria, arthritis, renal infections, acute sepsis‑induced pulmonary diseases, acute sepsis‑induced respiratory distress syndrome, endotoxic or endotoxemic shock, septic peritonitis, acute hepatitis, acute septic‑shock‑induced myocardial dysfunction and necrotizing enterocolitis.",CIBER DE ENFERMEDADES RESPIRATORIAS;;SERVICIO CANARIO DE SALUD;;UNIV LA LAGUNA;;VILLAR HERNANDEZ JESUS;;PADRON CARRILLO JOSE MANUEL;;CASULA MILENA;;CABRERA BENITEZ NURIA ESTHER;;RAMOS NUEZ ANGELA MARIA,VILLAR HERNANDEZ JESUS;;PADRON CARRILLO JOSE MANUEL;;CASULA MILENA;;CABRERA BENITEZ NURIA ESTHER;;RAMOS NUEZ ANGELA MARIA,,https://lens.org/195-516-996-689-951,Patent Application,yes,1,0,3,3,0,A61K31/505;;A61K31/513;;A61P29/00;;C07D239/54;;C07D239/54,C07D239/54;;A61K31/505;;A61P29/00,,4,4,003-364-212-505-905;;022-107-002-021-12X;;067-973-337-022-662;;041-565-073-522-498,10.3998/ark.5550190.0011.b04;;16682201;;10.1016/j.bmcl.2006.04.072;;10.1002/chin.200638147;;10.1007/bf02708284,"JAKUBNIENE, V. ET AL.: ""Synthesis of (pyrimidin-4-yloxy) and (pyrimidin-3-yl)acetyl azides and their rearrangement to carbamates and ureas"", ARKIVOC, vol. 2010, pages 39 - 48;;MAIER, J.A. ET AL.: ""Development of N-4,6-pyrimidine-N-alkyl- N'-phenylureas as orally active inhibitors of lymphocyte specific tyrosine kinase."", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 3646 - 3650;;BRUGEL, T.A. ET AL.: ""Development of N-2,4-pyrimidine-N-alkyl -N'-phenylureas as inhibitors of tumor necrosis factor alpha (TNF-a) synthesis. Part I."", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 3510 - 3513;;LATTHE, P.R. ET AL.: ""Curtius rearrangement reactions of 3-(4-azidocarbonyl) phenylsydnone. Synthesis of 4-(sydnon-3-yl) phenyl carbamates, N-aryl-N'-[4-(sydnon-3-yl)] phenyl ureas and their antimicrobial and insecticidal activities"", JOURNAL OF CHEMICAL SCIENCES, vol. 118, no. 3, 2006, pages 249 - 256",PENDING
558,MX,A,MX 2009013153 A,188-689-808-797-587,2011-05-25,2011,MX 2009013153 A,2009-11-12,MX 2009013153 A,2009-11-12,TOTAL KNEE REPLACEMENT WHICH IS DAMPENED AND OF LOW FRICTIONAL TORQUE.,"The present invention refers to a total knee replacement intended for the recovery of people with arthrosis or articular traumas. The design of the replacement allows the three main problems associated to the knee replacement to be attacked, which are the following: Contact efforts, shielding efforts in the bone-prosthesis interface and impact loads generated during each start-up cycle. The total knee replacement presented in this document comprises: (1) a femoral component made of polymer with inclusions for dissipating contact and shielding efforts, and absorbing the dynamic loads generated during the start-up cycle; also has a relief surface with half inclusions in the whole bone contact area. In addition, the invention contains a tibia insert made of the same material of the femoral component, with which the knee joint is formed; the tibia insert is fixed to the tibia component, which is fixed at pressure to the spinal canal in the proximal end of tibia.",LELIS JOSE MARIA RODRIGUEZ,LELIS JOSE MARIA RODRIGUEZ;;PLIEGO ARTURO ABUNDEZ;;CABRERA ANTONIO ARELLANO;;MALDONADO MIGUEL ANGEL MORALES;;TREVINO MARCIANO VARGAS,,https://lens.org/188-689-808-797-587,Patent Application,no,0,0,1,1,0,,A61F2/00,,0,0,,,,PENDING
559,ES,B2,ES 2385443 B2,083-042-121-619-237,2013-05-16,2013,ES 201031978 A,2010-12-28,ES 201031978 A,2010-12-28,USO DE COMPUESTOS DERIVADOS DE UREA PIRIMIDINICA PARA LA ELABORACION DE UN MEDICAMENTO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS.,,CIBER DE ENFERMEDADES RESPIRATORIAS;;SERVICIO CANARIO DE SALUD;;UNIV LA LAGUNA,VILLAR HERNANDEZ JESUS;;PADRON CARRILLO JOSE MANUEL;;CASULA MILENA;;CABRERA BENITEZ NURIA ESTHER;;RAMOS NUEZ ANGELA MARIA,,https://lens.org/083-042-121-619-237,Granted Patent,no,0,0,3,3,0,A61K31/505;;A61K31/513;;A61P29/00;;C07D239/54;;C07D239/54,C07D239/54;;A61K31/505;;A61P29/00,,0,0,,,,INACTIVE
560,ES,B1,ES 2456823 B1,093-683-499-459-848,2015-01-27,2015,ES 201231466 A,2012-09-21,ES 201231466 A,2012-09-21,METODO DE PRODUCCION DE REPERTORIOS COMPLEJOS DE MOLECULAS RECOMBINANTES,,CONSEJO SUPERIOR INVESTIGACION;;UNIV VALENCIA POLITECNICA;;UNIV LAS PALMAS GRAN CANARIA,ORZAEZ CALATAYUD DIEGO VICENTE;;JULVE PARRENO JOSE MANUEL;;GRANELL RICHART ANTONIO;;SARRION-PERDIGONES ALEJANDRO;;GUTIERREZ CABRERA CARLOS,,https://lens.org/093-683-499-459-848,Granted Patent,no,0,0,3,3,0,C12N15/8258,C12N15/82,,0,0,,,,ACTIVE
561,WO,A1,WO 2007/043854 A1,034-588-209-153-862,2007-04-19,2007,MX 2006000093 W,2006-08-29,MX GT05000009 A,2005-08-29,VEGETABLE HARVESTING MACHINE COMPRISING AN UNLOADING SYSTEM AND CONTAINER,"The invention relates to a machine for harvesting vegetables with bulb roots and above-ground stems. The inventive harvester takes the form of an implement which is towed by an agricultural tractor and which is characterised in that it consists of: a frame comprising tyre-equipped wheels, supports for supporting all of the components of the machine and an adjustable towing means for coupling to the tractor, which enables the implement to be aligned with the harvested row(s); a plant-pulling system comprising vertically-opposing bands, which is a characteristic of said class of machine; an adjustable blade which loosens the soil beneath the extracted roots; a standard foliage separation device which is based on the principle patented by William E. Urschel in 1933 (U.S. Patent No. 1,894,802) and which is equipped with two sets of bars that are positioned and actuated using inclined heads; a multiple-axle conveyor comprising elastic rotary elements which remove the soil from the roots by means of scraping and shaking as said elements move forward; a chain elevator comprising bars and strips, which is used to fill the temporary storage hopper; an unloading device which lifts and turns the hopper in order to empty same into a standard transport means; and a hydraulic system for actuating the mechanisms of the harvester, using the power take-off from the tractor as a power source.",UNIV GUANAJUATO;;MONTELLANO ESTRUCTURAS Y CONST;;CABRERA SIXTO JOSE MANUEL;;SERWATOWSKI HLAWINSKA RYSZARD;;FLORES ORTEGA ADRIAN;;QUIROZ RAMIREZ J CONCEPCION;;JUAREZ GUANI J ARMANDO,CABRERA SIXTO JOSE MANUEL;;SERWATOWSKI HLAWINSKA RYSZARD;;FLORES ORTEGA ADRIAN;;QUIROZ RAMIREZ J CONCEPCION;;JUAREZ GUANI J ARMANDO,,https://lens.org/034-588-209-153-862,Patent Application,yes,12,4,2,2,0,A01D33/08;;A01D25/048;;A01D33/10,A01D25/04;;A01D27/04;;A01D31/02;;A01D90/10,,0,0,,,,PENDING
562,CU,A1,CU 22249 A1,072-505-576-584-746,1995-01-31,1995,CU 1992076 A,1992-06-19,CU 1992076 A,1992-06-19,TELEGRAPHIC MULTIPLEX BY DIVISION IN TIME.,"SE RELACIONA CON EL CAMPO DE LAS COMUNICACIONES TELEGRAFICA Y DE DATOS Y SU OBJETIVO ES PERMITIR UN USO OPTIMO DE LOS MEDIOS DE TRANSMISION EXISTENTES, UNA MAYOR FIABILIDAD, UN FACIL MANTENIMIENTO Y REPARACION EN LOS SERVICIOS TELEGRAFICOS Y DE DATOS Y ESTA CONSTITUIDO POR UN BLOQUE DE CONTROL MICROPROGRAMADO 1 QUE COMPRENDE UN MICROPROCESADOR UNICO, UN BLOQUE DE DIRECCIONADO Y ACOPLAMIENTO 2 Y UNA PLURALIDAD DE BLOQUES DE CANAL, QUE COMO EJEMPLO DE EJECUCION PARTICULAR SE HAN REPRESENTADO POR LOS BLOQUES 4 A 26 Y POR LOS BLOQUES DE INTERFAZ 60 Y 61 Y BLOQUE DE CIRCUITO INTEGRADO 62 QUE REPRESENTAN LA COMPOSICION INTERNA DE DICHOS BLOQUES 4 A 26, INTERCONECTADOS ENTRE SI Y CON EL EXTERIOR MEDIANTE SEÑALES. EL NUMERO DE COMPONENTES EMPLEADO EN EL SISTEMA SE REDUCE NOTABLEMENTE MEDIANTE EL EMPLEO DE UN CIRCUITO INTEGRADO DISEÑADO A LA ORDEN PARA ESTA APLICACION, LO QUE PERMITE QUE UNA PLURALIDAD DE CANALES PUEDA SER CONFORMADA EN MENORES DIMENSIONES FISICAS Y CON MENOR CONSUMO DE EN ERGIA. LA EJECUCION PRACTICA DE UN EJEMPLO DE APLICACION PARA GRUPOS DE DOS CANALES, SE MUESTRA EN LA FIGURA 1 Y COMPRENDE DOS BLOQUES DE INTERFAZ 60 Y 61, FORMADOS ESENCIALMENTE POR CIRCUITOS ACOPLADORES ESTANDARES Y UN UNICO CIRCUITO INTEGRADO 62, DISEÑADO A LA ORDEN PARA ESTA APLICACION. EN LA FIGURA 2 SE ILUSTRA LA INTERCONEXION INTERNA DE ESTE BLOQUE 62 QUE COMPRENDE UN BLOQUE DE PRUEBAS 30, BLOQUES DE CANAL 10 Y 20 Y UN BLOQUE DE ENTRADA/SALIDA 40, INTERCONECTADOS ENTRE SI MEDIANTE SEÑALES.\!",INST CENTRAL DE INVESTIGACION,LOPEZ RODRIGUEZ ROLANDO;;FOLGUERAS MENDEZ JOSE;;FORRAY MENENDEZ JULIO;;MILANES CRUZ ALEJANDRO;;MATTOS CABRERA GLANCIA;;NAVARRO CEDENO MANUEL,,https://lens.org/072-505-576-584-746,Limited Patent,no,0,0,1,1,0,,H04J3/00;;H04L5/22,,0,0,,,,EXPIRED
563,BR,A,BR PI0501139 A,180-356-612-051-779,2006-11-28,2006,BR PI0501139 A,2005-04-04,BR PI0501139 A,2005-04-04,processo de produção de polihidroxialcanoatos a partir de glicerol ou resìduos contendo glicerol,"""PROCESSO DE PRODUçãO DE POLIHIDROXIALCANOATOS A PARTIR DE GLICEROL OU RESìDUOS CONTENDO GLICEROL"". Esta invenção trata de um processo de produção de polihidroxialcanoatos, aqui genericamente chamados de PHA, utilizando bactérias selecionadas dos gêneros Burkholderia, Waltersia e Alcalígenes, que são cultivadas em meios de cultura onde a principal fonte de carbono é constituída de glicerol ou resíduos contendo quantidades expressivas dele, provenientes da produção de biodiesel de óleos vegetais como óleo de soja, milho, algodão, amendoim; palma, mamona; entre outros, ou por uma mistura de resíduos de diferentes origens ricos em glicerol. O processo é constituído por quatro etapas, sendo que nas etapa I e II, bactérias selecionas dos gêneros Burkholderia, Waltersia e Alcaligenes são estriadas e cultivadas em meio de cultura contendo as fontes de carbono citadas e suplementadas com outros nutrientes para aporte de nitrogênio, fósforo, enxofre, magnésio, potássio e oxigênio, e de micronutrientes como manganês, cobalto, zinco, molibdênio, níquel, cobre, boro, de modo que ocorra um crescimento balanceado da biomassa nas quais virtualmente não há acúmulo de polihidroxialcanoato intracelular. Em seguida, inicia-se a etapa III do processo, que é a fase de síntese do PHA propriamente dita, através da limitação ou exaustão no meio de cultura de um ou mais dos nutrientes, em conjunto ou separadamente. Durante a etapa III, o PHA produzido é constituído, principalmente, de monómeros de 3-hidroxibutirato. O processo de síntese prossegue até que o conteúdo de PHA intracelular atinja um valor entre 20% e 80% da massa seca da biomassa produzida sendo, então, a biomassa concentrada e o material polimérico extraído pelos métodos convencionais descritos na literatura.",INST PESQUISAS TECH,PRADELLA JOSE GERALDO DA CRUZ;;RODRIGUES MARIA FILOMENA DE AN;;GOMEZ JOSE GREGORIO CABRERA;;SILVA ELDA SABINO DA;;MAIORANO ALFREDO EDUARDO;;CARTER JOSE MARCIO;;TACIRO MARILDA KEICO;;MATSUBARA ROSA MITIKO SAITO,,https://lens.org/180-356-612-051-779,Patent Application,no,0,0,1,1,0,,C12P7/62;;C12R1/00,,0,0,,,,DISCONTINUED
564,US,B1,US 9812015 B1,036-773-011-123-702,2017-11-07,2017,US 201514842736 A,2015-09-01,US 201514842736 A;;US 201462044970 P,2014-09-02,Systems and methods for determining parking information for a vehicle using vehicle data and external parking data,"The present disclosure provides methods and systems for providing parking information. A method for providing parking information comprises obtaining vehicle data from a vehicle, and/or a mobile computing device, and determining whether the vehicle is parked from the vehicle data. Next, using the one or more programmed processors, a parking location of the vehicle can be determined from the vehicle data. Information about the parking location can then be determined, and the information about the parking location can be outputted to the user.",METROMILE INC,COX EVAN GABRIEL TURITZ;;PRIMERO JOSHUA CABRERA;;WALIJI MUHAMMAD;;PRESTON JR DAN RICHARD;;MERCADO JOSE;;GOODMAN DANIEL ERIC,METROMILE INC (2015-09-10),https://lens.org/036-773-011-123-702,Granted Patent,yes,97,27,1,1,0,G08G1/005;;G08G1/147;;G08G1/205;;G08G1/207;;H04W4/027;;H04W4/029;;H04W4/33;;H04W4/44;;G08G1/144;;G08G1/144;;H04W4/029;;G08G1/205;;G08G1/207;;G08G1/005;;H04W4/02;;G08G1/147;;H04W4/027;;H04W4/44;;H04W4/33,G08G1/14,,22,3,025-815-420-647-850;;034-297-132-935-814;;074-030-969-380-951,10.1145/1689239.1689243;;10.3390/s150102059;;25608213;;pmc4327117;;10.1145/2093973.2093982,"Office action dated Dec. 18, 2015 for U.S. Appl. No. 14/177,188.;;U.S. Appl. No. 14/842,753, filed Sep. 1, 2015, Cox et al.;;U.S. Appl. No. 14/843,815, filed Sep. 2, 2015, Cox et al.;;U.S. Appl. No. 14/843,853, filed Sep. 2, 2015, Cox et al.;;Office action dated Apr. 23, 2015 for U.S. Appl. No. 14/177,188.;;Office action dated Sep. 29, 2015 for U.S. Appl. No. 14/177,192.;;Co-pending U.S. Appl. No. 15/476,549, filed Mar. 31, 2017.;;Office Action dated Apr. 21, 2017 for U.S. Appl. No. 14/177,188.;;Office Action dated May 10, 2017 for U.S. Appl. No. 14/177,192.;;Office Action dated May 26, 2017 for U.S. Appl. No. 14/843,815.;;Office Action dated Jan. 27, 2017 for U.S. Appl. No. 14/843,853.;;Hemminki, et al. Accelerometer-Based Transportation Mode. SenSys '13 Proceedings of the 11th ACM Conference on Embedded Networked Sensor Systems. Article No. 13. 2013. 14 pages.;;Office action dated Apr. 18, 2016 for U.S. Appl. No. 14/177,192.;;Office action dated Jun. 7, 2016 for U.S. Appl. No. 14/843,853.;;Office action dated Aug. 17, 2016 for U.S. Appl. No. 14/843,815.;;Office action dated Sep. 12, 2016 for U.S. Appl. No. 14/177,188.;;Office action dated Sep. 29, 2016 for U.S. Appl. No. 14/177,192.;;Reddy, et al. Using mobile phones to determine transportation modes. ACM Trans. Sensor Netw. 6, 2, Article 13 (Feb. 2010), 27 pages. DOI:10.1145/1689239.1689243 http://doi.acm.org/10.1145/1689239.1689243.;;Shoaib, et al. A Survey of Online Activity Recognition Using Mobile Phones. Sensors 2015, 15, 2059-2085; doi:10.3390/s150102059.;;Stenneth, et al. Transportation Mode Detection using Mobile Phones and GIS Information. ACM SIGSPATIAL GIS '11, Nov. 1-4, 2011. Chicago, IL, USA. 54-63.;;Notice of Allowance dated Aug. 15, 2017 for U.S. Appl. No. 14/843,853.;;Office Action dated Sep. 14, 2017 for U.S. Appl. No. 14/842,753.",ACTIVE
565,WO,A2,WO 2011/015692 A2,044-650-587-854-620,2011-02-10,2011,ES 2010000356 W,2010-07-29,ES 200901745 A,2009-07-29,"USE OF MASLINIC ACID FOR TREATING NOCICEPTIVE, INFLAMMATORY AND NEUROGENIC PAIN","Use of maslinic acid for treating nociceptive, inflammatory and neurogenic pain. The present invention relates to the use of maslinic acid and any of the derivatives thereof for treating painful pathological processes of a (1) nociceptive, (2) inflammatory or (3) neurogenic nature by any galenically acceptable means and very especially topically, including compositions that contain maslinic acid, any of the derivates thereof, or natural, synthetic or semi-synthetic mixtures rich in maslinic acid or the derivatives thereof.",UNIV GRANADA;;NIETO LOPEZ FRANCISCO RAFAEL;;BAEYENS CABRERA JOSE MANUEL;;GARCIA-GRANADOS LOPEZ DE HIERRO ANDRES;;ENTRENA FERNANDEZ JOSE MANUEL;;COBOS DEL MORAL ENRIQUE JOSE;;MARTINEZ RODRIGUEZ ANTONIO;;PARRA SANCHEZ ANDRES;;RIVAS SANCHEZ ANTONIO,NIETO LOPEZ FRANCISCO RAFAEL;;BAEYENS CABRERA JOSE MANUEL;;GARCIA-GRANADOS LOPEZ DE HIERRO ANDRES;;ENTRENA FERNANDEZ JOSE MANUEL;;COBOS DEL MORAL ENRIQUE JOSE;;MARTINEZ RODRIGUEZ ANTONIO;;PARRA SANCHEZ ANDRES;;RIVAS SANCHEZ ANTONIO,,https://lens.org/044-650-587-854-620,Patent Application,yes,0,2,4,4,0,A61K31/56;;A61K31/19,,,0,0,,,,PENDING
566,WO,A3,WO 2011/015692 A3,168-252-660-631-371,2011-03-31,2011,ES 2010000356 W,2010-07-29,ES 200901745 A,2009-07-29,"USE OF MASLINIC ACID FOR TREATING NOCICEPTIVE, INFLAMMATORY AND NEUROGENIC PAIN","Use of maslinic acid for treating nociceptive, inflammatory and neurogenic pain. The present invention relates to the use of maslinic acid and any of the derivatives thereof for treating painful pathological processes of a (1) nociceptive, (2) inflammatory or (3) neurogenic nature by any galenically acceptable means and very especially topically, including compositions that contain maslinic acid, any of the derivates thereof, or natural, synthetic or semi-synthetic mixtures rich in maslinic acid or the derivatives thereof.",UNIV GRANADA;;NIETO LOPEZ FRANCISCO RAFAEL;;BAEYENS CABRERA JOSE MANUEL;;GARCIA-GRANADOS LOPEZ DE HIERRO ANDRES;;ENTRENA FERNANDEZ JOSE MANUEL;;COBOS DEL MORAL ENRIQUE JOSE;;MARTINEZ RODRIGUEZ ANTONIO;;PARRA SANCHEZ ANDRES;;RIVAS SANCHEZ ANTONIO,NIETO LOPEZ FRANCISCO RAFAEL;;BAEYENS CABRERA JOSE MANUEL;;GARCIA-GRANADOS LOPEZ DE HIERRO ANDRES;;ENTRENA FERNANDEZ JOSE MANUEL;;COBOS DEL MORAL ENRIQUE JOSE;;MARTINEZ RODRIGUEZ ANTONIO;;PARRA SANCHEZ ANDRES;;RIVAS SANCHEZ ANTONIO,,https://lens.org/168-252-660-631-371,Search Report,yes,2,0,4,4,0,A61K31/56;;A61K31/19,A61K31/56,,2,2,063-119-127-759-916;;097-525-035-558-065,17978478;;10.1248/bpb.30.2075;;3253493;;10.1016/0378-8741(88)90155-9,"JUN L. ET AL: ""Maslinic acid reduces blood glucose in KK-AY mice"", BIOL. PHARM. BULL., vol. 30, 2007, pages 2075 - 2078;;LUTTERODT G.D. ET AL: ""Effects on mice locomotor activity of a narcotic-like principle from Psiddium Guajava leaves"", JOURNAL OF ETHNOPHARMACOLOGY, vol. 24, 1988, pages 219 - 231",PENDING
567,IN,A,IN 3236DEN2015 A,125-468-987-117-57X,2015-10-02,2015,IN 3236DEN2015 A,2015-04-17,US 2013/0064659 W,2013-10-11,NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN WITH A BENEFICIAL GLUCOSE AND INSULIN PROFILE,"The present disclosure is directed to a nutritional powder , a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins , lipids , carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.",ABBOTT LAB,DEWILLE NORMANELLA;;CABRERA RICARDO RUEDA;;MARRIAGE BARBARA;;SHERRY CHRISTINA;;WEARLY DOUGLAS;;PEDROSA JOSE MARIA LOPEZ;;BLUMBERG RACHEL;;MAZER TERRENCE,,https://lens.org/125-468-987-117-57X,Patent Application,no,0,0,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L1/305;;A23L1/30;;A23L1/308;;A23L33/00,,0,0,,,,PENDING
568,SG,A,SG 11201502037Q A,111-685-898-735-088,2015-05-28,2015,SG 11201502037Q A,2013-10-11,US 2013/0064659 W,2013-10-11,NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN WITH A BENEFICIAL GLUCOSE AND INSULIN PROFILE,,ABBOTT LAB,DEWILLE NORMANELLA;;CABRERA RICARDO RUEDA;;MARRIAGE BARBARA;;SHERRY CHRISTINA;;WEARLY DOUGLAS;;PEDROSA JOSE MARIA LOPEZ;;BLUMBERG RACHEL;;MAZER TERRENCE,,https://lens.org/111-685-898-735-088,Unknown,no,0,0,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L2/52;;A23L2/66;;A23L33/00,,0,0,,,,PENDING
569,CN,A,CN 104717891 A,145-530-101-230-451,2015-06-17,2015,CN 201380048043 A,2013-10-11,US 2013/0064659 W,2013-10-11,Nutritional composition for pregnant women with a beneficial glucose and insulin profile,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.",ABBOTT LAB,DEWILLE NORMANELLA;;CABRERA RICARDO RUEDA;;MARRIAGE BARBARA;;SHERRY CHRISTINA;;WEARLY DOUGLAS;;PEDROSA JOSE MARIA LOPEZ;;BLUMBERG RACHEL;;MAZER TERRENCE,,https://lens.org/145-530-101-230-451,Patent Application,no,0,3,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L1/09;;A23L1/30;;A23L1/305;;A23L1/308;;A23L2/52;;A23L2/66;;A23L33/00,,0,0,,,,DISCONTINUED
570,US,B2,US 9217132 B2,153-393-441-527-704,2015-12-22,2015,US 201213355261 A,2012-01-20,US 201213355261 A;;US 201161434704 P,2011-01-20,Microfluidic transducer,"Provided herein are apparatuses and methods for fragmenting nucleic acids or disrupting cells. For example, some embodiments provide a disposable microfluidic device designed to position a sample to be in direct contact with a high frequency vibrating element that emits an ultrasonic frequency into the sample such that the vibrational energy transduced into the sample results in fragmenting nucleic acids or disrupting cells.",ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY;;CHIESL THOMAS N;;IBIS BIOSCIENCES INC,ESHOO MARK W;;GUTIERREZ JOSE R;;DRADER JARED J;;PICURI JOHN;;CABRERA KARL M;;MOTLEY STANLEY;;CHIESL THOMAS N,IBIS BIOSCIENCES INC (2012-03-09),https://lens.org/153-393-441-527-704,Granted Patent,yes,42,2,4,4,0,C12N1/066;;C12N13/00;;Y10T436/25;;C12M47/06;;Y10T436/25;;C12N1/066;;C12N13/00;;C12M47/06;;B01L3/502715;;B01L2200/027;;B01L2300/06;;B01L2300/0816;;C12Q1/6806;;G01N1/30;;G01N1/31,G01N1/28;;B01L3/00;;C12M1/00;;C12N1/06;;C12N13/00,,6,5,038-298-913-388-390;;018-172-278-005-135;;071-670-278-749-859;;054-306-386-671-297;;038-298-913-388-390,10.1021/ac990347o;;10517145;;10.1089/dna.1989.8.697;;2693020;;pmc310446;;1741307;;10.1093/nar/20.3.623;;10.1016/j.ultrasmedbio.2005.05.005;;16176793;;10.1021/ac990347o;;10517145,"Belgrader, Phillip et al. ""A minisonicator to rapidly disrupt bacterial spores for DNA analysis."" Analytical Chemistry (1999) 71 4232-4236.;;Elsner, Henrik I. et al. ""Ultrasonic degradation of DNA."" DNA (1989) 8 697-701.;;Ponce, Maria R. et al. ""PCR amplification of long DNA fragments."" Nucleic Acids Research (1992) 623.;;Marentis, Theodore Cosmo et al. ""Microfluidic sonicator for real-time disruption of eukaryotic cells and bacterial spores for DNA analysis."" Ultrasound in Medicine and Biology (2005) 31 1265-1277.;;Belgrader P., et al., ""A Minisonicator to Rapidly Disrupt Bacterial Spores for DNA Analysis,"" Analytical Chemistry, 1999, vol. 71 (19), pp. 4232-4236.;;International Search Report and Written Opinion for Application No. PCT/US2012/022077, mailed on May 8, 2012, 10 pages.",INACTIVE
571,WO,A1,WO 2013/171542 A1,055-429-832-405-770,2013-11-21,2013,IB 2012052408 W,2012-05-14,IB 2012052408 W,2012-05-14,POLYMER-METALLIC NANOPARTICLE HYBRID MATERIALS,"The present invention discloses new materials elaborated upon organo-heteroatom (silicon or germanium) polymers (poly(amide-imide)s and poly(amide)s) and a metallic film, such as, but not limited to, copper, silver or gold, having the processability and malleability of a polymer and the structural, thermal, optical, electrical and other characteristics from the metals that it absorbs. The polymers of the invention have the capacity to incorporate, with covalent bonds, in coordinated and arranged form, the metals to its structure, generating a new macromolecular material. The invention is also related to a new method to prepare polymer-metallic nanoparticle hybrid materials, comprising the steps of a) providing a polymer solution dissolving the organo- heteroatom (silicon or germanium) polymer (poly(amide-imide)s or poly(amide)s) in an aprotic polar organic solvent; b) providing a metal film from the selected metal; c) dispersing the polymer solution by spin coating on the metal film; and d) simultaneous absorption, nano- encapsulation or incorporation of the metal into the polymer matrix.",UNIV PONTIFICIA CATOLICA CHILE;;GONZALEZ HENRIQUEZ CARMEN MABEL;;TERRAZA INOSTROZA CLAUDIO ALBERTO;;VOLKMANN ULRICH GEORG;;CABRERA OYARZUN ALEJANDRO LEOPOLDO;;RETAMAL PONCE MARIA JOSE,GONZALEZ HENRIQUEZ CARMEN MABEL;;TERRAZA INOSTROZA CLAUDIO ALBERTO;;VOLKMANN ULRICH GEORG;;CABRERA OYARZUN ALEJANDRO LEOPOLDO;;RETAMAL PONCE MARIA JOSE,,https://lens.org/055-429-832-405-770,Patent Application,yes,7,1,1,1,0,C08K3/08,C08K3/08,,35,32,086-014-215-797-473;;012-576-770-083-170;;001-523-102-064-347;;032-881-785-963-37X;;061-951-121-167-621;;049-227-690-141-577;;031-827-769-440-743;;134-668-132-677-080;;097-198-795-520-312;;016-767-796-587-198;;036-401-381-708-348;;178-982-623-270-914;;075-911-974-611-247;;128-324-950-384-443;;012-929-229-522-965;;008-746-914-784-406;;034-298-545-639-794;;019-834-239-742-657;;052-951-737-154-822;;109-428-138-653-03X;;032-212-806-566-405;;059-434-906-316-669;;110-582-856-609-675;;053-782-235-698-223;;059-180-858-379-691;;097-180-466-406-644;;060-574-431-094-475;;038-762-781-557-397;;167-993-781-281-234;;040-341-779-230-391;;090-925-185-563-044;;054-677-179-373-126,10.1016/j.tetlet.2008.03.092;;10.1021/cr068435d;;18651778;;10.1002/adma.201000971;;20661950;;10.1021/am100154e;;20499881;;10.1021/jp075988z;;10.1039/b506028a;;18350078;;10.1364/ao.39.004847;;10.1021/cm034505a;;10.1051/epjap:2006006;;10.1366/000370203322554491;;14658147;;10.1016/s0928-4931(98)00049-6;;10.1002/(sici)1521-4095(199801)10:2<132::aid-adma132>3.3.co;2-p;;10.1021/cm00059a001;;10.1007/s100530050472;;10.1002/1521-4095(200008)12:15<1102::aid-adma1102>3.0.co;2-j;;10.1063/1.3238244;;10.1007/bf03218635;;10.1002/pol.1975.170130609;;10.1002/pi.3169;;10.1021/la0202428;;19404353;;10.1364/oe.6.000213;;10.1021/jp047565s;;10.1039/b003899g;;10.1016/j.snb.2009.02.056;;17999554;;10.1021/cr0680282;;10.1007/978-3-662-09109-8;;16851013;;10.1021/jp0403644;;10.1246/bcsj.34.545;;10.1246/bcsj.34.551;;10.1007/s11671-007-9107-z;;10.1088/0957-4484/17/19/025;;10.1063/1.1901803,"RAFFA P; EVANGELISTI C; VITELLI G; SALVATORI P: ""First examples of gold nanoparticles catalyzed silane alcoholysis and silylative pinacol coupling of carbonyl compounds"", TETRAHED. LETTER., vol. 49, 2008, pages 3221 - 3224, XP022613623, DOI: doi:10.1016/j.tetlet.2008.03.092;;ARCADI A.: ""Alternative Synthetic Methods through New Developments in Catalysis by Gold"", CHEM. REV., vol. 108, 2008, pages 3266 - 3325;;LIN P; YAN F; YU J; CHAN HLW; YANG M: ""The Application of Organic Electrochemical Transistors in Cell-Based Biosensors"", ADV. MATER., vol. 22, 2010, pages 3655 - 3660, XP055057905, DOI: doi:10.1002/adma.201000971;;LIN P; YAN F; CHAN HLW: ""Ion Sensitive Properties of Organic Electrochemical Transistors. ACS Appl. Mater"", INTERFACES, vol. 2, 2010, pages 1637 - 1641;;CHEN Q; ZHAO L; LI C; SHI G: ""Electrochemical Fabrication of a Memory Device Based on Conducting Polymer Nanocomposites"", J. PHYS. CHEM. C., vol. 111, 2007, pages 18392 - 18396;;INNOCENZI P; LEBEAU B: ""Organic-inorganic hybrid materials for nonlinear optics"", J. MATER. CHEM., vol. 15, 2005, pages 3821 - 3831;;DE LEON AG; DIRIX Y; STAEDLER Y; FELDMAN K; HAHNER, G; CASERI, W. R.; SMITH, P.: ""Method for fabricating pixelated, multicolor Polarizing Films"", APPL. OPTICS, vol. 39, 2000, pages 4847 - 4851, XP000968516, DOI: doi:10.1364/AO.39.004847;;MBHELE ZH; SALEMANE MG; E VAN SITTERT CGC; NEDELJKOVIC JM; DJOKOVIC V; LUYT AS: ""Fabrication and Characterization of Silver-Polyvinyl Alcohol Nanocomposites"", CHEM. MATER., vol. 15, 2003, pages 5019 - 5024, XP009117121, DOI: doi:10.1021/cm034505a;;TAKELE H; SCHÜRMANN U; GREVE H; PARETKAR D; ZAPOROJTCHENKO V; FAUPEL F: ""Controlled growth of Au nanoparticles in co-evaporated metal/polymer composite films and their optical and electrical properties"", EUR. PHYS. J. APPL. PHYS., vol. 33, 2006, pages 83 - 89;;GIESFELDT KS; CONNATSER RM; DE JESUS MA; LAVRIK NV; DUTTA P; SEPANIAK MJ: ""Studies of the Optical Properties of Metal-Pliable Polymer Composite Materials"", APPL. SPECTROSCOPY, vol. 57, no. 11, 2003, pages 1346 - 1352, XP009083367, DOI: doi:10.1366/000370203322554491;;""Formation of noble metal nanoparticles within a polymeric matrix: nanoparticle features and overall morphologies"", MATER. SCI. ENG. C, vol. 6, 1998, pages 155 - 166;;SELVAN ST; SPATZ JP; KLOK HA; MOLLER M: ""Gold-Polypyrrole Core-Shell Particles in Diblock Copolymer Micelles"", ADV. MATER., vol. 10, no. 2, 1998, pages 132 - 134, XP000727856, DOI: doi:10.1002/(SICI)1521-4095(199801)10:2<132::AID-ADMA132>3.3.CO;2-P;;WATKINS JJ; MCCARTHY TJ.: ""Polymer/Metal Nanocomposite Synthesis in Supercritical CO2"", CHEM. MATER., vol. 7, 1995, pages 1991 - 1994;;SAYO K; DEKI S; HAYASHI S: ""A novel method of preparing nano-sized gold and palladium particles dispersed in composites that uses the thermal relaxation technique"", EUR. PHYS. J.D., vol. 9, no. 1-4, 1999, pages 429 - 432;;LEE J; SUNDAR VC; HEINE JR; BAWENDI MG; JENSEN KF: ""Full Color Emission from II-VI Semiconductor Quantum Dot-Polymer Composites"", ADV. MATER., vol. 12, no. 15, 2000, pages 1102 - 1105, XP000963569, DOI: doi:10.1002/1521-4095(200008)12:15<1102::AID-ADMA1102>3.0.CO;2-J;;MALLICK K; WITCOMB MJ; ERASMUS R; STRYDOM A: ""Low- temperature magnetic property ofpolymer encapsulated gold nanoparticles"", J. APPL. PHYS., vol. 106, 2009, pages 074303 - 074308;;FAGHIHI K; SHABANIAN M; HAJIBEYGI M: ""Optically Active and Organosoluble Poly(amide-imide)s Derived from N,N'-(Pyromellitoyl)bis-L-histidine and Various Diamines: Synthesis and Characterization"", MACROMOLECULAR RESEARCH, vol. 17, no. 11, 2009, pages 912 - 918;;YAMAZAKI N; MATSUMOTO M.; HIGASHI F: ""Studies on Reactions of the N-Phosphonium Salts of Pyridines. XIV. Wholly Aromatic Polyamides by the Direct Polycondensation Reaction by Using Phosphites in the Presence of Metal Salts"", J. POLYM. SCI., POLYM. CHEM. ED., vol. 13, 1975, pages 1373 - 1380;;GONZALEZ CM; TAGLE LH; TERRAZA CA.; BARRIGA A; VOLKMANN UG; CABRERA AL; RAMOS-MOORE E; PAVEZ-MORENO M: ""Structural symmetry breaking of silicon-containing poly(amidc-imidc) oligomers and their relation with electrical conductivity and Raman active vibrations"", POLYM. INT., vol. 61, no. 2, 2011, pages 197 - 204;;STORHOFF AJJ; ELGHANIAN R; MIRKIN CA; LETSINGER RL: ""Sequence-Dependent Stability of DNA-Modified Gold Nanoparticles"", LANGMUIR, vol. 18, 2002, pages 6666 - 6670;;KOTTMANN AJP; MARTIN OJF; SMITH DR; SCHULTZ S: ""Spectral response of plasmon resonant nanoparticles with a non-regular shape"", OPT. EXPRESS, vol. 6, 2000, pages 213 - 219, XP002982141, DOI: doi:10.1364/OE.6.000213;;EVANOFF JR DD; CHUMANOV G: ""Size-Controlled Synthesis of Nanoparticles. 1. ''Silver-Only'' Aqueous Suspensions via Hydrogen Reduction"", J. PHYS. CHEM., B, vol. 108, 2004, pages 13948 - 13956;;GOTOH Y; IGARASHI R; OHKOSHI Y; NAGURA M; AKAMATSU K; DEKI S: ""Preparation and structure of copper Nanoparticielpoly(acrylic acid) composite films"", J. MATER. CHEM., vol. 10, 2000, pages 2548 - 2552, XP003028481, DOI: doi:10.1039/B003899G;;FILIPPO E; SERRA A; MANNO D: ""Poly(vinyl alcohol) capped silver nanoparticles as localized surface plasmon resonance-based hydrogen peroxide sensor"", SENS. ACTUATORS B, vol. 138, no. 2, 2009, pages 625 - 630, XP026053175, DOI: doi:10.1016/j.snb.2009.02.056;;GHOSH SK; PAL T: ""Interparticle Coupling Effect on the Surface Plasmon Resonance of Gold Nanoparticles: From Theory to Applications"", CHEM. REV., vol. 107, no. 11, 2007, pages 4797 - 4862;;KREIBIG U; VOLLMER M: ""Optical Properties of Metal Clusters"", vol. 25, 1995, SPINGER, pages: 1 - 532;;KAZUO N: ""Infrared and Raman spectra of Inorganic and Coordination Compounds: Part A: Theory and Applications in Inorganic Chemistry"", 1997, JOHN WILEY & SONS, INC, pages: 155;;ITOH K; KUDRYASHOV I; YAMAGATA J; NISHIZAWA T; FUJII M; OSAKA N: ""Raman Microspectroscopic Study on Polymerization and Degradation Processes of a Diacetylene Derivative at Surface Enhanced Raman Scattering Active Substrates. 2. Confocal Raman Microscopic Observation of Polydiacetylene Adsorbed on Active Sites"", J. PHYS. CHEM. B, vol. 109, no. 1, 2005, pages 271 - 276;;UNO T; MACHIDA K: ""Infrared Spectra ofAcyclic Imides. I. Two Modifications of Diacetamide in the Crystalline State"", BULL. CHEM. SOC. JPN., vol. 34, no. 4, 1961, pages 545 - 550;;UNO T; MACHIDA K: ""Infrared Spectra of Acyclic Imides. II. The Characteristic Absorption Bands of Saturated Acyclic Imides in the Crystalline State"", BULL. CHEM. SOC. JPN., vol. 34, no. 4, 1961, pages 551 - 556;;ABROMOVITCH RA: ""The Infrared Spectra of Some Diacylamines in the 6µ Region"", J. CHEM. SOC. LONDON, 1957, pages 1413 - 1417;;FREEMAN SK: ""Applications of Laser Raman Spectroscopy"", 1974, JOHN WILEY & SONS;;KISHORE PS; VISWANATHAN B; VARADARAJAN TK: ""Synthesis and Characterization of Metal Nanoparticle Embedded Conducting Polymer-Polyoxometalate Composites"", NANOSCALE RES. LETT., vol. 3, no. 1, 2008, pages 14 - 20;;JIANG X; ZENG Q; YU A: ""A self-seeding coreduction method for shape control of silver nanoplates"", NANOTECHNOLOGY, vol. 17, 2006, pages 4929 - 4935, XP020104132, DOI: doi:10.1088/0957-4484/17/19/025;;HU J; CAI W; LI C; GAN Y; CHEN L: ""In situ x-ray diffraction study of the thermal expansion of silver nanoparticles in ambient air and vacuum"", APPL. PHYS. LETT., vol. 86, 2005, pages 151915 - 151915,3",PENDING
572,MX,A,MX GT05000009 A,133-498-035-420-800,2007-02-27,2007,MX GT05000009 A,2005-08-29,MX GT05000009 A,2005-08-29,VEGETABLE HARVESTING MACHINE WITH A CONTAINER AND A DISCHARGE SYSTEM.,"The present invention refers to a machine for harvesting bulb and aerial stem vegetables. The inventive machine is an implement dragged by an agricultural tractor, which is characterised in that it has a frame with tires, supports for supporting the whole machine components, and an adjustable draft link for engaging the tractor and allowing the present implement to be aligned with the harvested rows. The machine also comprises a system for pulling plants including opposite bands regarding a vertical plane, the system being particularly useful for this type of machines; an adjustable blade for ploughing the soil is located under the extracted roots; a device for separating conventional foliage based on the principle patented by William E. Urschel in 1993 (US 1,894,802), which consists in two sets of bars positioned and actuated by tilted heads; a multiple axis conveyor having rotating elastic elements useful for removing soil adhered to roots by a scratching and agitating action perfor med while said elements are moved forward; a chain lift having bars and laths useful for filling a temporary storing hopper; a discharge device for lifting and turning the hopper down so as to empty the same into a conventional transport means; a hydraulic system for actuating the harvesting machine mechanisms using a power take-off from the tractor as a power source.",UNIV GUANAJUATO,SIXTO JOSE MANUEL CABRERA;;HLAWINSKA RYSZARD JERZY SERWAT;;ORTEGA ADRIAN FLORES;;RAMIREZ J CONCEPCION QUIROZ;;GUANI J ARMANDO JUAREZ,,https://lens.org/133-498-035-420-800,Patent Application,no,0,0,2,2,0,A01D33/08;;A01D25/048;;A01D33/10,A01D23/00,,0,0,,,,ACTIVE
573,CA,A1,CA 2889312 A1,068-716-666-015-972,2015-04-16,2015,CA 2889312 A,2013-10-11,US 2013/0064659 W,2013-10-11,NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN WITH A BENEFICIAL GLUCOSE AND INSULIN PROFILE,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.",ABBOTT LAB,DEWILLE NORMANELLA;;CABRERA RICARDO RUEDA;;MARRIAGE BARBARA;;SHERRY CHRISTINA;;WEARLY DOUGLAS;;PEDROSA JOSE MARIA LOPEZ;;BLUMBERG RACHEL;;MAZER TERRENCE,,https://lens.org/068-716-666-015-972,Patent Application,no,0,0,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L1/09;;A23L1/30;;A23L1/305;;A23L1/308;;A23L2/52;;A23L2/66;;A23L33/00,,0,0,,,,DISCONTINUED
574,WO,A1,WO 2015/053789 A1,052-743-949-943-94X,2015-04-16,2015,US 2013/0064659 W,2013-10-11,US 2013/0064659 W,2013-10-11,NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN WITH A BENEFICIAL GLUCOSE AND INSULIN PROFILE,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.",ABBOTT LAB,DEWILLE NORMANELLA;;CABRERA RICARDO RUEDA;;MARRIAGE BARBARA;;SHERRY CHRISTINA;;WEARLY DOUGLAS;;PEDROSA JOSE MARIA LOPEZ;;BLUMBERG RACHEL;;MAZER TERRENCE,,https://lens.org/052-743-949-943-94X,Patent Application,yes,7,2,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L1/30;;A23L1/09;;A23L1/305;;A23L1/308;;A23L2/52;;A23L2/66;;A23L33/00,,0,0,,,,PENDING
575,ES,A1,ES 2392059 A1,101-012-162-026-116,2012-12-04,2012,ES 201132056 A,2011-12-20,ES 201132056 A,2011-12-20,"Robot of hybrid cinematic structure for the guidance of the insertion of needles, catheters and surgical elements for minimally invasive surgery procedures. (Machine-translation by Google Translate, not legally binding)","Robot of hybrid kinematic structure for the guidance of the insertion of needles, catheters and surgical elements for minimally invasive surgery procedures, comprising: - a parallel spherical orientation mechanism (c) with: - basic element (10); - mobile element (11) with laser guidance system (37) and inertial unit (30) for calibration; - spherical joint (17); - coupling device (31) of surgical instruments (32); - serial positioning mechanism (b) coupled with the base element (10), with links (5, 7, 9) in series connected by rotary joints (4, 6, 8) driven by actuators (23a, 23b, 23c) for position in space, according to three degrees of freedom, the spherical articulation (17) of the orientation mechanism (c); - base (3), coupled to the positioning mechanism (b), for anchoring the robot on a mobile support (a); - mobile support (a) with fixing system (d) for coupling to the operating table (50). (Machine-translation by Google Translate, not legally binding)",UNIV MADRID POLITECNICA;;GLIATECH S L,SALTAREN PAZMINO ROQUE JACINTO;;ARACIL SANTONJA RAFAEL;;PUGLISI LISANDRO JOSE;;POLETTI GABRIEL ARMANDO;;REY PORTOLES GERMAN;;CABRERA PARRA WALTER,UNIVERSIDAD POLITECNICA DE MADRID (2014-02-06),https://lens.org/101-012-162-026-116,Patent Application,no,3,3,2,2,0,A61B34/30,A61B34/30,,6,1,103-334-595-062-854,10.1109/vecims.2009.5068919,"Can Tang et al. ¿Kinematics analysis for a hybrid robot in minimally invasive surgery¿, Robotics and Biomimetics, 19.12.2009, USA, páginas 1941 ¿ 1946;;Yan Diao et al. ¿Configuration and Kinematic Analysis of a Novel Hybrid Surgical Robot with a Ball joint¿, Intelligent Systems and Applications, 23.05.2009, USA, páginas 1 ¿ 4;;Base de datos INSPEC/IEE, AN 11999282, Yan Diao et al. ¿Kinematic Analysis of a New Hybrid Surgical Robot¿, resumen;;Base de datos INSPEC/IEE, AN 10374047, Tang Can et al. ¿Topological structure analysis for a hybrid robot in CT-guided minimally invasive surgery¿, resumen;;Song Wang et al. ¿Control simulation of a six DOF parallel-serial robot for femur fracture reduction¿, Virtual Environments, Human Computer Interfaces and Measurements Systems, 11.05.2009, USA, páginas 330-335;;Sabater J M et al. ¿Design, modelling and implementation of a 6 URS parallel haptic device¿, Robotics and Autonomous systems, 31.05.2004, NL, vol. 47, nº 1, páginas 1 ¿ 10",ACTIVE
576,BR,A2,BR 112015005933 A2,020-073-481-047-988,2017-07-04,2017,BR 112015005933 A,2013-10-11,US 2013/0064659 W,2013-10-11,composição nutricional para mulher grávida com um perfil benéfico de glicose e insulina,"resumo composição nutricional para mulher grávida com um perfil benéfico de glicose e insulina a presente descrição é orientada a um pó nutricional, uma bebida reconstituível translúcida formada a partir do mesmo, e métodos relativos aos mesmos. o pó nutricional e a bebida são adaptados para incluir o equilíbrio adequado de proteínas, lipídeos, carboidratos, vitaminas e minerais apropriados para uma mulher grávida. as composições nutricionais adicionalmente contêm a resposta glicêmica e aprimora a glicemia e insulinemia durante os períodos gestacional e de lactação para evitar ou reduzir a incidência de intolerância à glicose futuramente na vida.",ABBOTT LAB,BARBARA MARRIAGE;;CHRISTINA SHERRY;;DOUGLAS WEARLY;;JOSE MARIA LOPEZ PEDROSA;;NORMANELLA DEWILLE;;RACHEL BLUMBERG;;RICARDO RUEDA CABRERA;;TERRENCE MAZER,,https://lens.org/020-073-481-047-988,Patent Application,no,0,0,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L2/52;;A23L2/66;;A23L33/00,,0,0,,,,DISCONTINUED
577,PE,A1,PE 20210775 A1,186-431-578-456-662,2021-04-20,2021,PE 2020002076 A,2020-12-15,PE 2020002076 A,2020-12-15,"PROCEDIMIENTO PARA LA OBTENCION DE PECTINASA TERMOESTABLE A PARTIR DE BACTERIAS TERMOFILAS, PREFERENTEMENTE DE GEOBACILLUS SP P4","La presente invencion se refiere a un procedimiento para la produccion de una enzima pectinasa a partir de bacterias termofilas preferentemente de Geobacillus sp P4, dicho procedimiento contiene un medio de produccion en base a fuentes pecticas como pectina de manzana y sustratos naturales como salvado de trigo, ademas utiliza un biorreactor tipo Batch. El procedimiento consta de las siguientes etapas: 1) Reactivacion de la bacteria y obtencion del inoculo, 2) Produccion de la enzima pectinasa termoestable y 3) Determinacion de la actividad enzimatica de la pectinasa. La invencion logra que la produccion de la enzima pectinasa se realice en un menor tiempo de produccion, el cual tiene potencial para ser utilizado a nivel industrial.",UNIV NACIONAL JORGE BASADRE GROHMANN,CASTELLANOS CABRERA ROBERTO;;SALAZAR QUISPE ISRAEL JOSE;;RAMIREZ ARUA HEBER ESAU;;ZUNIGA LLANOS ARIADNA ZATYURI;;YLLANES HUANACUNI MIRELLA VERONICA,,https://lens.org/186-431-578-456-662,Patent Application,no,0,0,1,1,0,,C12N9/54,,0,0,,,,PENDING
578,ES,A1,ES 2391754 A1,098-770-500-790-675,2012-11-29,2012,ES 201030454 A,2010-03-26,ES 201030454 A,2010-03-26,"Procedure for the establishment of connection for wireless networks. (Machine-translation by Google Translate, not legally binding)","Connection establishment procedure for wireless networks. Connection establishment procedure for wireless network provided with mobile terminals and servers, in which a source terminal generates a data message destined for a destination terminal, which comprises the steps of: A) connection establishment of the originating terminal with a server. B) storage of the data message by the server. C) establishment of connection between the server, Where the connection establishment stage comprises: - the generation of a search message of the destination terminal; - the dissemination of said search message over the network through its reception and forwarding by terminals of the network; Which is characterized by the fact that the search messages comprise a forwarding counter, which accumulates the number of times the message has been forwarded, and where the terminals have a maximum number of admissible forwards, so that it is possible to reduce and control the number of forwarded messages. (Machine-translation by Google Translate, not legally binding)",UNIV CARTAGENA POLITECNICA,CERDAN CARTAGENA JOSE FERNANDO;;OLIVARES MARTINEZ JAVIER;;ALMAGRO CARRION SERGIO;;LUJAN FERNANDEZ SERGIO;;CABRERA LOZOYA ANDRES;;GARCIA SANCHEZ DIEGO,,https://lens.org/098-770-500-790-675,Patent Application,no,1,0,2,2,0,H04W84/18,H04W84/18,,0,0,,,,ACTIVE
579,CN,A,CN 105392375 A,134-160-820-259-31X,2016-03-09,2016,CN 201480027093 A,2014-03-12,US 2014/0023971 W;;EP 13382088 A,2013-03-15,Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring,"The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, and a non-absorbent carbohydrate and/or an indigestible carbohydrate.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL CRISTOBAL MANZANO;;MARTIN MARIA-JESUS MARTIN;;DELGADO ELENA OLIVEROS;;CABRERA RICARDO RUEDA;;PEDROSA,,https://lens.org/134-160-820-259-31X,Patent Application,no,7,1,10,10,0,A61K31/70;;A23V2002/00;;A23L29/212;;A23L29/262;;A23L33/10;;A23L33/22;;A61K31/7016;;A61K31/702;;A61K31/715;;A61K31/716;;A61K31/718;;A61P19/08;;A61P25/28;;A61P3/04;;A61P3/10;;A61K31/70;;A23V2002/00;;A23L33/22;;A23L33/10;;A23L29/212;;A23L29/262;;A61K31/7016;;A61K31/702;;A61K31/715;;A61K31/716;;A61K31/718,A23L33/22;;A23L29/212;;A23L29/262;;A23L29/30;;A61K31/70;;A61P3/04;;A61P3/10;;A61P19/08;;A61P25/28,,1,1,014-545-715-375-470,20538025;;10.1016/j.neuint.2010.05.015,"YUSUKE TOZUKA,ET.AL: ""maternal obesity impairs hippocampal BDNF production and spatial learning performance in young mouse offspring"", 《NEUROCHEMISTRY INTERNATIONAL》",DISCONTINUED
580,PH,A1,PH 12015500577 A1,120-963-374-414-973,2015-05-11,2015,PH 12015500577 A,2015-03-17,US 2013/0064659 W,2013-10-11,NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN WITH A BENEFICIAL GLUCOSE AND INSULIN PROFILE,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and mineral appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.",ABBOTT LAB,NORMANELLA DEWILLE;;RUEDA CABRERA RICARDO;;BARBARA MARRIAGE;;CHRISTINA SHERRY;;DOUGLAS WEARLY;;LOPEZ PEDROSA JOSE MARIA;;RACHEL BLUMBERG;;TERRENCE MAZER,,https://lens.org/120-963-374-414-973,Patent Application,no,0,0,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L2/52;;A23L2/66;;A23L33/00,,0,0,,,,PENDING
581,MX,A,MX 2015003499 A,112-085-166-110-389,2015-07-10,2015,MX 2015003499 A,2013-10-11,US 2013/0064659 W,2013-10-11,NUTRITIONAL COMPOSITION FOR PREGNANT WOMEN WITH A BENEFICIAL GLUCOSE AND INSULIN PROFILE.,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;SHERRY CHRISTINA;;CABRERA RICARDO RUEDA;;DEWILLE NORMANELLA;;MARRIAGE BARBARA;;WEARLY DOUGLAS;;BLUMBERG RACHEL;;MAZER TERRENCE,,https://lens.org/112-085-166-110-389,Patent Application,no,0,0,11,11,0,A23L2/52;;A23L2/66;;A23V2002/00;;A23L2/52;;A23L2/66;;A23L29/30;;A23L33/40;;A23L33/115;;A23L33/12;;A23L33/17;;A23L33/21;;A23L5/00;;A23L33/125;;A23L5/00;;A23L33/125;;A23L2/52;;A23L2/66;;A23L33/17;;A23L29/30;;A23L33/40;;A23L33/21;;A23L33/115;;A23L33/12;;A23V2002/00,A23L2/66;;A23L1/09;;A23L1/30;;A23L1/305;;A23L1/308;;A23L2/52;;A23L33/00,,0,0,,,,PENDING
582,CL,A1,CL 2014003074 A1,139-717-770-819-08X,2015-06-05,2015,CL 2014003074 A,2014-11-12,CL 2014003074 A,2014-11-12,Material híbrido de polimero-nanoparticulas metálicas; metodo para preparar el material; y uso de dicho material.,,UNIV PONTIFICIA CATOLICA CHILE,GONZALEZ HERNIQUEZ CARMEN MABEL;;TERRAZA INOSTROZA CLAUDIO ALBERTO;;VOLKMANN ULRICH GEORG;;CABRERA OYARZUN ALEJANDRO LEOPOLDO;;RETAMAL PONCE MARIA JOSE,,https://lens.org/139-717-770-819-08X,Patent Application,no,0,0,1,1,0,,C08K3/08,,0,0,,,,PENDING
583,ES,B2,ES 2392059 B2,149-279-323-114-454,2013-04-10,2013,ES 201132056 A,2011-12-20,ES 201132056 A,2011-12-20,"ROBOT DE ESTRUCTURA CINEMATICA HIBRIDA PARA EL GUIADO DE LA INSERCION DE AGUJAS, CATETERES Y ELEMENTOS QUIRURGICOS PARA PROCEDIMIENTOS DE CIRUGIA MINIMAMENTE INVASIVA.",,UNIV MADRID POLITECNICA;;GLIATECH S L,SALTAREN PAZMINO ROQUE JACINTO;;ARACIL SANTONJA RAFAEL;;PUGLISI LISANDRO JOSE;;POLETTI GABRIEL ARMANDO;;REY PORTOLES GERMAN;;CABRERA PARRA WALTER,UNIVERSIDAD POLITECNICA DE MADRID (2014-02-06),https://lens.org/149-279-323-114-454,Granted Patent,no,0,0,2,2,0,A61B34/30,A61B34/30,,0,0,,,,ACTIVE
584,EP,A1,EP 3671181 A1,165-862-594-365-472,2020-06-24,2020,EP 18020661 A,2018-12-21,EP 18020661 A,2018-12-21,SELF-MIXING PHOTOTHERMAL MICROSCOPE,"A highly sensitive microscope for measuring chemical and photothermal properties of scattering-free liquid and solid samples was developed. It comprises one laser source (3) for sample excitation, another laser source (2) that works both as a probe light and sensor of feedback optical signals, and a microscope system that includes a microfluidic channel (8) with the bottom surface covered with a highly reflecting layer. The microscope associates the photothermal properties of the sample with the feedback signal measured in the sensor, enabling the measurement of concentration at part per trillion levels.
",ABDUS SALAM INT CENTRE FOR THEORETICAL PHYSICS,CABRERA MORALES HUMBERTO DR;;SUAREZ-VARGAS JOSE J DR;;BARRERA-RAMIREZ FREDY DR;;RAMIREZ MIQUET EVELIO;;NIEMELA JOSEPH DR,,https://lens.org/165-862-594-365-472,Patent Application,yes,5,0,1,1,0,G01N21/171;;G01B9/02092;;G01N21/1717;;G01N2021/1712;;G01N2021/1725;;G01N2021/1731;;G02B21/0056,G01N21/17;;B01L3/00;;G01B9/02;;G02B21/00,,12,12,079-202-143-726-610;;053-286-551-115-795;;018-554-193-425-978;;099-057-143-239-676;;068-965-781-429-430;;091-979-327-541-36X;;020-753-749-001-382;;064-132-624-976-914;;045-178-149-415-767;;064-069-475-614-637;;030-677-097-916-085;;091-217-518-426-056,10.3390/s16050694;;27187406;;pmc4883385;;10.1364/aop.7.000570;;10.1117/1.oe.57.5.051506;;10.1088/1464-4258/4/6/371;;29601022;;10.1364/ol.43.001531;;10.1007/s10043-017-0387-y;;10.1109/jsen.2017.2758440;;10.1109/jsen.2017.2781902;;10.1063/1.1147512;;10.1016/j.talanta.2018.02.073;;29567158;;10.1109/jsen.2018.2889600;;10.1109/lsens.2018.2858927,"JULIEN PERCHOUX ET AL: ""Current Developments on Optical Feedback Interferometry as an All-Optical Sensor for Biomedical Applications"", SENSORS, vol. 16, no. 5, 13 May 2016 (2016-05-13), pages 694, XP055376270, DOI: 10.3390/s16050694;;T. TAIMRE; M. NIKOLIC; K. BERTLING; Y. L. LIM; T. BOSCH; A. D. RAKIC: ""Laser feedback interferometry: a tutorial on the self-mixing effect for coherent sensing"", ADVANCES IN OPTICS AND PHOTONICS, vol. 7, no. 3, 2015, pages 570 - 631;;S. DONATI; M. NORGIA: ""Overview of self-mixing interferometer applications to mechanical engineering"", OPTICAL ENGINEERING, vol. 57, no. 5, 2018, pages 051506 - 1,13;;G. GIULIANI; M. NORGIA; S. DONATI; T. BOSCH: ""Laser diode self-mixing technique for sensing applications"", JOURNAL OF OPTICS A: PURE AND APPLIED OPTICS, vol. 4, no. 6, 2002, pages S283 - S294, XP002510274, DOI: doi:10.1088/1464-4258/4/6/371;;B. GAO; C. QING; S. YIN; C. PENG; C. JIANG: ""Measurement of rotation speed based on double-beam self-mixing speckle interference"", OPTICS LETTERS, vol. 43, no. 7, 2018, pages 1531 - 1533;;J. XU; L. HUANG; S. YIN; B. GAO; P. CHEN: ""All-fiber self-mixing interferometer for displacement measurement based on the quadrature demodulation technique"", OPTICAL REVIEW, vol. 25, no. 1, 2018, pages 40 - 45, XP036400588, DOI: doi:10.1007/s10043-017-0387-y;;A. EHTESHAM; U. ZABIT; O. D. BERNAL; G. RAJA; T. BOSCH: ""Analysis and implementation of a direct phase unwrapping method for displacement measurement using self-mixing interferometry"", IEEE SENSORS JOURNAL, vol. 17, no. 22, 2017, pages 7425 - 7432, XP011672357, DOI: doi:10.1109/JSEN.2017.2758440;;R. ATASHKHOOEI; E. E. RAMIREZ-MIQUET; R. DA COSTA MOREIRA; A. QUOTB; S. ROYO; J. PERCHOUX: ""Optical feedback flowmetry: Impact of particle concentration on the signal processing method"", IEEE SENSORS JOURNAL, vol. 18, no. 4, 2018, pages 1457 - 1463;;M. FRANKO; C. D. TRAN: ""Analytical thermal lens instrumentation"", REVIEW OF SCIENTIFIC INSTRUMENTS, vol. 67, no. 1, 1996, pages 1 - 18, XP000554503, DOI: doi:10.1063/1.1147512;;H. CABRERA; J. AKBAR; D. KORTE; E. E. RAMIREZ-MIQUET; E. MARIN; J. NIEMELA; Z. EBRAHIMPOUR; K. MANNATUNGA; M. FRANKO: ""Trace detection and photothermal spectral characterization by a tuneable thermal lens spectrometer with white-light excitation"", TALANTA, vol. 183, 2018, pages 158 - 163;;H. CABRERA; E. RAMIREZ-MIQUET; J. J. SUAREZ-VARGAS; J. F. BARRERA-RAMIREZ; D. KORTE; J. NIEMELA: ""Pump-probe photothermal self-mixing spectrometer for highly sensitive trace detection"", TO BE SUBMITTED;;K. BERTLING; S. HAN; T. WU; C. ZHAO; Y. LENG-LIM; P. DEAN; S. KHANNA; D. INDJIN; E. LINFIELD; A. DAVIES: ""Determining Ethanol Content of Liquid Solutions Using Laser Feedback Interferometry with a Terahertz Quantum Cascade Laser"", IEEE SENSORS LETT., vol. 2, no. 3, 2018, pages 3501604, XP011687906, DOI: doi:10.1109/LSENS.2018.2858927",DISCONTINUED
585,CN,A,CN 106988998 A,122-528-580-743-336,2017-07-28,2017,CN 201710053138 A,2017-01-22,GB 201601214 A,2016-01-21,Compressor housing,A compressor housing (500) includes a compressor inlet duct (535) and an inlet (550) for a compressor wheel (520). The compressor inlet duct (535) has a longitudinal axis (A-A) and connects an air intake duct (205) with the compressor wheel inlet (550). The compressor housing (500) includes at least one appendix (510) positioned between an upstream portion (545) of the compressor inlet duct (535) and the compressor wheel inlet (550). The at least one appendix (510) includes a pipe (600) closed in a distal part thereof with respect to the longitudinal axis (A-A) of the compressor inlet duct (535).,GM GLOBAL TECH OPERATIONS LLC,RACCA ALBERTO;;MEANO CESARE MARIA;;BENAJES CALVO JESUS VICENTE;;DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;NAVARRO GARCIA ROBERTO;;PIQUERAS CABRERA PEDRO;;DE LA MORENA BORJA JOAQUIN,,https://lens.org/122-528-580-743-336,Patent Application,no,5,0,5,5,0,F04B39/0055;;F04D29/441;;F04D29/441;;F04D29/665;;F04B39/12;;F04D29/4213;;F04D29/4213;;F04D29/4213;;F04D29/66;;F04D29/665,F04B39/12;;F04B39/00,,0,0,,,,DISCONTINUED
586,US,A1,US 2017/0211587 A1,060-721-947-951-009,2017-07-27,2017,US 201715413082 A,2017-01-23,GB 201601214 A,2016-01-21,COMPRESSOR HOUSING,A compressor housing includes a compressor inlet duct and an inlet for a compressor wheel. The compressor inlet duct has a longitudinal axis and connects an air intake duct with the compressor wheel inlet. The compressor housing includes at least one appendix positioned between an upstream portion of the compressor inlet duct and the compressor wheel inlet. The appendix includes a pipe closed in a distal part thereof with respect to the longitudinal axis of the compressor inlet duct.,GM GLOBAL TECH OPERATIONS LLC,RACCA ALBERTO;;MEANO CESARE MARIA;;BENAJES CALVO JESUS VICENTE;;DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;NAVARRO GARCIA ROBERTO;;PIQUERAS CABRERA PEDRO;;DE LA MORENA BORJA JOAQUIN,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2017-01-12),https://lens.org/060-721-947-951-009,Patent Application,yes,0,0,5,5,0,F04B39/0055;;F04D29/441;;F04D29/441;;F04D29/665;;F04B39/12;;F04D29/4213;;F04D29/4213;;F04D29/4213;;F04D29/66;;F04D29/665,F04D29/44,,0,0,,,,ACTIVE
587,US,B2,US 10443614 B2,181-236-523-884-533,2019-10-15,2019,US 201715413082 A,2017-01-23,GB 201601214 A,2016-01-21,Compressor housing,A compressor housing includes a compressor inlet duct and an inlet for a compressor wheel. The compressor inlet duct has a longitudinal axis and connects an air intake duct with the compressor wheel inlet. The compressor housing includes at least one appendix positioned between an upstream portion of the compressor inlet duct and the compressor wheel inlet. The appendix includes a pipe closed in a distal part thereof with respect to the longitudinal axis of the compressor inlet duct.,GM GLOBAL TECH OPERATIONS LLC,RACCA ALBERTO;;MEANO CESARE MARIA;;BENAJES CALVO JESUS VICENTE;;DESANTES FERNANDEZ JOSE MARIA;;GALINDO LUCAS JOSE;;NAVARRO GARCIA ROBERTO;;PIQUERAS CABRERA PEDRO;;DE LA MORENA BORJA JOAQUIN,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2017-01-12),https://lens.org/181-236-523-884-533,Granted Patent,yes,12,0,5,5,0,F04B39/0055;;F04D29/441;;F04D29/441;;F04D29/665;;F04B39/12;;F04D29/4213;;F04D29/4213;;F04D29/4213;;F04D29/66;;F04D29/665,F04D29/44;;F04D29/42;;F04D29/66,,2,0,,,"Great Britain Patent Office, Great Britain Search Report for Great Britain Application No. 1601214.8, dated May 31, 2016.;;State Intellectual Property Office of the People's Republic of China, Chinese Search Report for Chinese Application No. 201710053138.1, dated May 29, 2019.",ACTIVE
588,CU,A1,CU 23234 A1,116-182-629-686-30X,2007-09-26,2007,CU 20030134 A,2003-06-18,CU 20030134 A,2003-06-18,PROCESAMIENTO PARA LA SINTESIS DE UN MATERIAL COMPUESTO CERáMICO CON CONTENIDO DE CORDIERITA EMPLEANDO EL MéTODO SOL-GEL,"La invencion se relaciona con la ciencia y la tecnología de nuevos materiales cerAmicos y con la metalUrgia (hidro y pirometalUrgia) y puede emplearse en las fAbricas donde se elaboran cuerpos cerAmicos y/o en fAbricas para síntesis de polvos metAlicos. El presente procedimiento establece un mÉtodo no convencional de síntesis de un material compuesto cerAmico de composicion cordierita-espinela-vidrio a temperatura inferior que la usual, empleando como material de partida caolín activado. El caolín activado es tratado con Acido sulfUrico concentrado para obtener una solucion saturada de sulfato de alumunio la cual se mezcla con un precursor de magnesio hasta la formacion de un gel (1) a pH = 4-9. El residuo solido del tratamiento del caolín es lixiviado con una solucion diluida de NaOH para obtener una solucion estable de silicato de sodio la cual al mezclarse con el gel (1) produce trasnformaciones hasta la formacion de un gel (2) a pH = 9-12. El gel (2) con estequiometría de cordierita (2MgO.2Al2O3.5SiO2), se trata tÉrmicamente a 1100-1300sC durante 2-4 h para obtener un polvo cerAmico con >70% de cordierita y 10-20% de espinela que se caracteriza por ser refractario, resistente al choque tÉrmico y bajo conductor de calor.",CT DE INVESTIGACIONES PARA LA,PACHECO CABRERA PILAR;;ALONSO PEREZ JOSE ANTONIO;;CABRERA DIAZ ILEANA;;VERA BLANCO ANTONIO;;RODRIGUEZ HERNANDEZ JOELIS;;HERNANDEZ MARTINEZ ALEJANDRA N;;HIDALGO NEYRA MIRTA AURORA;;NAVARRETE MARTINEZ CARLOS MANU;;OROPESA SUAREZ EULALIA ELISA,,https://lens.org/116-182-629-686-30X,Limited Patent,no,0,0,1,1,0,,C04B35/00;;C04B35/195;;C04B35/443;;C04B35/624,,0,0,,,,EXPIRED
589,AU,A1,AU 2008/321418 A1,166-119-926-609-038,2009-05-22,2009,AU 2008/321418 A,2008-11-14,US 305807 P;;US 2008/0012819 W,2007-11-14,New extracts of deschampsia antarctica desv. with antineoplastic activity,,BECERA JOSE;;CABRERA GUSTAVO;;CAFFERATA EDUARDO;;GIDEKEL MANUEL;;GUTIERREZ ANA;;MIHOVILOVIC IVAN;;OSORIO JENNIFER;;PODHAJCER OSVALDO;;SUNKEL CARLOS;;WEBER HELGA,GIDEKEL MANUEL;;GUTIERREZ ANA;;CAFFERATA EDUARDO;;CABRERA GUSTAVO;;OSORIO JENNIFER;;WEBER HELGA;;BECERA JOSE;;MIHOVILOVIC IVAN;;SUNKEL CARLOS;;PODHAJCER OSVALDO,,https://lens.org/166-119-926-609-038,Patent Application,no,0,0,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A01N65/00;;C07H21/04,,0,0,,,,DISCONTINUED
590,EP,A4,EP 2257177 A4,196-239-425-237-04X,2012-07-11,2012,EP 08849502 A,2008-11-14,US 2008/0012819 W;;US 305807 P,2007-11-14,NEW EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV. WITH ANTINEOPLASTIC ACTIVITY,,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/196-239-425-237-04X,Search Report,no,0,0,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A01N65/00;;A61K36/899;;A61P35/00;;C07H21/04,,6,5,030-800-855-803-735;;002-369-309-786-105;;031-775-371-983-316;;013-510-654-487-500;;029-242-913-335-708,7765369;;10.1016/s0031-9422(00)89660-0;;10.1007/s11120-004-4277-3;;16143909;;10.1016/s0098-8472(96)01026-x;;10.1562/2004-09-18-ra-321;;15689180;;10.1007/s00792-003-0345-4;;12955601,"WEBBY R F ET AL: ""Isoswertiajaponin 2''-O-beta-arabinopyranoside and other flavone-C-glycosides from the Antarctic grass Deschampsia antarctica"", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 36, no. 5, 10 August 1994 (1994-08-10), pages 1323 - 1326, XP026631232, ISSN: 0031-9422, [retrieved on 19940810], DOI: 10.1016/S0031-9422(00)89660-0;;ALEJANDRA ZÚÑIGA-FEEST ET AL: ""Light regulation of sucrose-phosphate synthase activity in the freezing-tolerant grass Deschampsia antarctica"", PHOTOSYNTHESIS RESEARCH ; OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF PHOTOSYNTHESIS RESEARCH, SPRINGER, BERLIN, DE, vol. 83, no. 1, 1 January 2005 (2005-01-01), pages 75 - 86, XP019263989, ISSN: 1573-5079, DOI: 10.1007/S11120-004-4277-3;;ZUNIGA GUSTAVO E ET AL: ""Non-structural carbohydrates in Deschampsia antarctica Desv. from South Shetland Islands, Maritime Antarctic"", ENVIRONMENTAL AND EXPERIMENTAL BOTANY, vol. 36, no. 4, 1996, pages 393 - 399, XP009159820, ISSN: 0098-8472;;RUHLAND CHRISTOPHER T ET AL: ""The influence of ultraviolet-B radiation on growth, hydroxycinnamic acids and flavonoids of Deschampsia antarctica during Springtime ozone depletion in Antarctica."", PHOTOCHEMISTRY AND PHOTOBIOLOGY 2005 SEP-OCT LNKD- PUBMED:15689180, vol. 81, no. 5, September 2005 (2005-09-01), pages 1086 - 1093, XP002676817, ISSN: 0031-8655;;GIDEKEL: ""Identification and characterization of three novel cold acclimation-responsive genes from the extremophile hair grass Deschampsia antarctica"", EXTREMOPHILES, SPRINGER VERLAG, TOKYO, JP, vol. 7, 2 September 2003 (2003-09-02), pages 459 - 469, XP008069513, ISSN: 1431-0651, DOI: 10.1007/S00792-003-0345-4;;See also references of WO 2009064480A1",DISCONTINUED
591,CA,A1,CA 2705884 A1,075-010-132-408-551,2009-05-22,2009,CA 2705884 A,2008-11-14,US 305807 P;;US 2008/0012819 W,2007-11-14,NEW EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV. WITH ANTINEOPLASTIC ACTIVITY,"The present disclosure provides a novel antineoplastic extract obtained from Deschampsia antarctica plant. Active components of the antineoplastic extract are also disclosed and a method to prevent proliferation of cancerous or tumorous cells with the extract or with components thereof is disclosed. Furthermore, a method to induce production of active ingredients in in vitrogrwon plants by submitting the plants to physical or chemical treatements before preparing the antineoplastic extract is disclosed. This disclosure provides compostions of tablets and pellets for treating patients with cancer or for prevention of occurence of cancerous diseases.",GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/075-010-132-408-551,Patent Application,no,0,0,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A61K36/899;;A61K31/7048;;A61P35/00,,0,0,,,,DISCONTINUED
592,ES,A1,ES 2193823 A1,098-949-201-069-167,2003-11-01,2003,ES 200100304 A,2001-02-02,ES 200100304 A,2001-02-02,"Preparation of e.g. silica oxynitrides consists of activation of the precursor, for controlled thermonitriding","The preparation of e.g. silica oxynitrides comprises activation of the silica or silicometalates as the mesostructured mesoporous precursor. Also claimed is a process using the products. The process provides thermonitriding of the stabilized material incorporating metals of the subgroups (1,2,3,4,5)B and (3,4,5,6,7)A and group 8 of the periodic table.",UNIV VALENCIA ESTUDI GENERAL,AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;GUILLEM VILLAR CARMEN,,https://lens.org/098-949-201-069-167,Patent Application,no,2,0,2,2,0,C01B39/026;;C01B39/46,C01B39/02;;C01B39/46,,0,0,,,,EXPIRED
593,NZ,A,NZ 585393 A,006-594-606-345-302,2012-06-29,2012,NZ 58539308 A,2008-11-14,US 305807 P;;US 2008/0012819 W,2007-11-14,NEW EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV. WITH ANTINEOPLASTIC ACTIVITY,"A method of making an antineoplastic extract, said extract prepared from Deschampsia antarctica plants, wherein the plants are grown in vitro and treated with a physical or chemical process which increases the polyphenol content of plant tissues, wherein the physical process includes UV irradiation provided to the plants for about 2 hours, and wherein the chemical process includes incubation in NaCl salt solution which involves soaking the plant in the solution for about 30 minutes.",MANUEL GIDEKEL;;WEBER HELGA;;GUSTAVO CABRERA;;ANA GUTIERREZ;;JENNIFER OSORIO;;JOSE BECERA;;OSVALDO PODHAJCER;;EDUARDO CAFFERATA;;CARLOS SUNKEL;;IVAN MIHOVILOVIC,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/006-594-606-345-302,Patent Application,no,0,0,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A01N65/00;;C07H21/04,,0,0,,,,DISCONTINUED
594,AU,A1,AU 2012/373760 A1,004-445-106-540-169,2014-10-16,2014,AU 2012/373760 A,2012-03-13,ES 2012070162 W,2012-03-13,"Use of essential oils, supercritical extracts and aqueous residues generated during a process for obtaining organic extracts from the Artemisia absinthium L. plant",The present invention starts with a method for obtaining organic extracts of the,CENTRO DE INVESTIG Y TECNOLOGIA AGROALIMENTARIA DE ARAGON CITA;;CONSEJO SUPERIOR INVESTIGACION;;UNIV LA LAGUNA;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;ANDRES YEVES MARIA FE;;DIAZ HERNANDEZ CARMEN ELISA;;BURILLO ALQUEZAR JESUS;;CABRERA PEREZ RAIMUNDO;;URIETA NAVARRO JOSE,,https://lens.org/004-445-106-540-169,Patent Application,no,0,0,6,6,0,A01N31/04;;A01N31/06;;A01N65/00;;A01N65/12;;A01N31/06;;A01N31/04;;A01N65/00;;A01N65/12,A01N65/12;;A01P3/00;;A01P5/00,,0,0,,,,DISCONTINUED
595,CN,A,CN 117203181 A,029-340-519-890-77X,2023-12-08,2023,CN 202280030666 A,2022-05-05,US 202163185399 P;;US 2022/0027768 W,2021-05-07,Halogenated cyclopropanation process,"The present disclosure relates to halogenated cyclopropanation processes that can be used to form molecules having pesticidal utility on pests in arthropods, mollusks, and nematodes.",KEDIHUA AGRICULTURAL SCIENCE AND TECH CO LTD,BARTON TREVOR J;;CABRERA VENTURA PEDRO JOSE;;GOOD STEVEN N;;LI FANGZHENG;;ROSENTHAL TAL;;SHUTTMAN ANDREW D;;VERMEULEN NICOLAAS A,,https://lens.org/029-340-519-890-77X,Patent Application,no,0,0,3,3,0,C07C41/48;;C07C43/313;;C07C2601/02;;C07F7/1804;;C07F7/188;;C07F7/1892,C07C41/48,,0,0,,,,PENDING
596,WO,A1,WO 2009/064480 A1,131-941-317-927-82X,2009-05-22,2009,US 2008/0012819 W,2008-11-14,US 305807 P,2007-11-14,NEW EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV. WITH ANTINEOPLASTIC ACTIVITY,"The present disclosure provides a novel antineoplastic extract obtained from Deschampsia antarctica plant. Active components of the antineoplastic extract are also disclosed and a method to prevent proliferation of cancerous or tumorous cells with the extract or with components thereof is disclosed. Furthermore, a method to induce production of active ingredients in in vitro grwon plants by submitting the plants to physical or chemical treatements before preparing the antineoplastic extract is disclosed. This disclosure provides compostions of tablets and pellets for treating patients with cancer or for prevention of occurence of cancerous diseases.",GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/131-941-317-927-82X,Patent Application,yes,3,9,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A01N65/00;;C07H21/04,,2,1,030-800-855-803-735,7765369;;10.1016/s0031-9422(00)89660-0,"WEBBY ET AL.: ""Isoswertiajaponin 2""-O-beta-arabinopyranoside and other flavone-C-glycosides from the Antarctic grass Deschampsia Antarctica."", PHYTOCHEMISTRY, vol. 36, no. 5, 1994, pages 1323 - 1326;;See also references of EP 2257177A4",PENDING
597,MX,A,MX 2015013818 A,166-812-920-063-068,2016-08-31,2016,MX 2015013818 A,2015-09-14,MX 2015013818 A,2015-09-14,STACKED AMPLIFIER OF CLASS E.,"The present invention is a stacked amplifier of class E, which is formed by a first MOSFET and a second MOSFET with the same electrical characteristics of operation, which are connected in series and coupled to a voltage supply terminal of DC and a reference terminal. A radio frequency signal is applied to the gate terminal of each of the MOSFET by a coupling circuit that can be formed by pulse transformers, which have the function of isolating the power stage with respect to the control step of both MOSFET. The output signal of the amplifier corresponds to the drain terminal of the upper MOSFET, which is connected to a resonant network formed by an inductor connected in series and subsequently a capacitor coupled to the reference signal. The terminals of the capacitor are used as the output of the amplifier and as a connection of the charge, which is represented by a resistance in the circuit shown in Fig 1.",INST NAC DE INVESTIG NUCLEARES,ROSENDO PEÑA EGUILUZ;;REGULO LOPEZ CALLEJAS;;JOSE ARTURO PEREZ MARTINEZ;;ANTONIO MERCADO CABRERA;;BENJAMIN GONZALO RODRIGUEZ MENDEZ;;RAUL VALENCIA ALVARADO,,https://lens.org/166-812-920-063-068,Patent Application,no,0,0,1,1,0,,H03F1/02;;G08C17/02;;G08C19/36,,0,0,,,,ACTIVE
598,BR,A2,BR 112023020034 A2,177-888-856-983-555,2023-11-14,2023,BR 112023020034 A,2022-05-05,US 2022/0027768 W;;US 202163185399 P,2021-05-07,Processos de halociclopropanação,"processos de halociclopropanação. esta revelação se refere a processos de halociclopropanação úteis na formação de moléculas que têm utilidade pesticida contra pragas dos filos arthropoda, mollusca e nematoda.",CORTEVA AGRISCIENCE LLC,ABRAHAM D SCHUITMAN;;LI FANGZHENG;;NICOLAAS A VERMEULEN;;PABLO JOSE CABRERA VENTURA;;STEFFEN N GOOD;;ROSENTHAL TAY;;THOMAS J BARTON,,https://lens.org/177-888-856-983-555,Patent Application,no,0,0,3,3,0,C07C41/48;;C07C43/313;;C07C2601/02;;C07F7/1804;;C07F7/188;;C07F7/1892,C07C41/48;;C07C43/313;;C07F7/02;;C07F9/66,,0,0,,,,PENDING
599,CO,A2,CO 7141406 A2,148-640-850-861-345,2014-12-12,2014,CO 14201040 A,2014-09-11,CO 14201040 A,2014-09-11,"Uso de aceites esenciales, extractos supercríticos y residuos acuosos generados en un proceso de obtención de extractos orgánicos de la planta artemisia absinthium l","La presente invención parte de un procedimiento de obtención de extractos orgánicos de la planta Artemisia absinthium L.,que comprende: una fase de metodología de producción de dicha planta, una fase de extracción en la que se obtiene dicho aceite esencial y un extracto no volátil, y una fase de extracción con CO2 de extractos supercríticos, y se refiere concretamente al uso del aceite esencial y/o del extracto supercrítico extraídos como fungicida frente a hongos fitopatógenos. Para ello se emplea la planta Artemisia absinthium L., variedad Candial procedente de Teruel y/o de Sierra Nevada. También es otro objeto de la presente memoria el residuo acuoso generado en dicho procedimiento que comprende un componente orgánico que contiene a su vez (Z)-2,6-dimetillocta-5,7-diene-2,3-diol como compuesto orgánico activo frente a los nemátodos. El método de obtención de dicha parte orgánica y de su correspondiente componente orgánico activo es objeto de protección de esta solicitud.",CONSEJO SUPERIOR INVESTIGACION;;CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON CITA;;UNIV LA LAGUNA;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;ANDRES YEVES MARIA FE;;DIAZ HERNANDEZ CARMEN ELISA;;BURILLO ALQUEZAR JESUS;;CABRERA PEREZ RAIMUNDO;;URIETA NAVARRO JOSE,,https://lens.org/148-640-850-861-345,Patent Application,no,0,0,1,1,0,,A01N65/12,,0,0,,,,PENDING
600,US,A1,US 2010/0310686 A1,121-937-566-312-901,2010-12-09,2010,US 73459708 A,2008-11-14,US 73459708 A;;US 305807 P;;US 2008/0012819 W,2007-11-14,"EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV, WITH ANTINEOPLASTIC ACTIVITY","The present disclosure provides a novel antineoplastic extract obtained from Deschampsia antarctica plant. Active components of the antineoplastic extract are also disclosed and a method to prevent proliferation of cancerous or tumorous cells with the extract or with components thereof is disclosed. Furthermore, a method to induce production of active ingredients in in vitro grown plants by submitting the plants to physical or chemical treatements before preparing the antineoplastic extract is disclosed. This disclosure provides compostions of tablets and pellets for treating patients with cancer or for prevention of occurence of cancerous diseases.",UXMAL S A CHILE,GIDEGEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/121-937-566-312-901,Patent Application,yes,6,3,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A61K36/899,424/750,4,2,060-261-576-338-402;;077-163-618-192-64X,11216484;;10.1002/biof.5520120129;;11849977;;10.1016/s1011-1344(01)00269-x,thefreedictionary.com. Retrieved from the internet on 03/22/2012. . 2 pages.;;Shimoi et al. Metabolic fate of luteolin and its functional activity at focal site. BioFactors 12 (2000). 181-186.;;Rozema et al. The role of UV-B radiation in aquatic and terrestrial ecosystems-an experimental and functional analysis of the evolution of UV-absorbing compounds. Journal of Photochemistry and Photobiology B: Biology 66. 2002. Pages 2-12.;;wikipedia.org. Retrieved from the internet on 03/22/2012. . Pages 1-3.,DISCONTINUED
601,ES,B1,ES 2193823 B1,146-913-433-700-231,2005-03-16,2005,ES 200100304 A,2001-02-02,ES 200100304 A,2001-02-02,"PROCEDIMIENTO DE PREPARACION DE OXINITRUROS MESOPOROSOS ORDENADOS, MATERIALES ASI OBTENIDOS Y SUS USOS.","Procedimiento de preparación de oxinitruros mesoporosos ordenados, materiales así obtenidos y sus usos. Se preparan oxinitruros de sílice y también silicometalatos nitrurados mesoporosos, composicionalmente homogéneos y de elevada pureza de fase utilizando un procedimiento que comprende las siguientes etapas: 1ª) preparación/activación del material precursor, es decir de la sílice o del silicometalato mesoporoso mesoestructurado; 2ª) termonitruración del material estabilizado. donde 0 <= x <= 1; 0 < y < 1; z < x/2 (para I y II); z < (1-x) (para III); A y A'' representan metales de los subgrupos (1, 2, 3, 4, 5)B o (3, 4, 5, 6, 7)A, o del grupo 8 de la Tabla periódica, y M representa un elemento monovalente. El contenido en nitrógeno viene definido por los valores de p, q, q'', r, t, o, w y s: 0 <= p, q, q'' <= 1; 0 <= r, t, o, w <= 0,5; 0 <= s <= 0,75. El valor de h (0 <= h, h'', h"", h""'' <= 1) se relaciona con la cantidad de grupos -OH y/o -NHx.",UNIV VALENCIA ESTUDI GENERAL,AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;GUILLEM VILLAR CARMEN,,https://lens.org/146-913-433-700-231,Granted Patent,no,0,0,2,2,0,C01B39/026;;C01B39/46,C01B39/02;;C01B39/46,,0,0,,,,EXPIRED
602,WO,A1,WO 2022/235863 A1,144-960-224-220-96X,2022-11-10,2022,US 2022/0027768 W,2022-05-05,US 202163185399 P,2021-05-07,HALOCYCLOPROPANATION PROCESSES,"This disclosure relates to halocyclopropanation processes useful in forming molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda.",CORTEVA AGRISCIENCE LLC,BARTON THOMAS J;;CABRERA VENTURA PABLO JOSE;;GOOD STEFFEN N;;LI FANGZHENG;;ROSENTHAL TAY;;SCHUITMAN ABRAHAM D;;VERMEULEN NICOLAAS A,,https://lens.org/144-960-224-220-96X,Patent Application,yes,7,0,3,3,0,C07C41/48;;C07C43/313;;C07C2601/02;;C07F7/1804;;C07F7/188;;C07F7/1892,C07C41/48;;C07C43/313;;C07F7/02;;C07F9/66,,0,0,,,,PENDING
603,CU,A1,CU 22044 A1,142-502-765-529-934,1992-06-05,1992,CU 3587 A,1987-03-13,CU 3587 A,1987-03-13,PROCEDIMIENTO PARA LA OBTENCIÓN SEMICONTINUA DE ALCOHOL,"La invención se relaciona con la biotecnología, el objetivo técnico que persigue la misma, es desarrollar un procedimiento para producir alcohol utilizando levaduras inmovilizadas en soportes. La esencia de la invención consiste en el empleo como soporte de astillas de madera de balsa, lavadas previamente con agua caliente de 40-100oC y colocadas en un reactor en una proporción con el medio de 5-40% y aireado el mismo de 0.5-1.0 litro de medio por minuto, logrando así la adsorción de las células al empaque, posteriormente se disminuye la aireación y se pasa a la etapa de producción de alcohol que dura de 4-8 horas. La invención puede ser aplicada en la producción de vinagre, antibióticos o cualquier proceso de biosíntesis de productos orgánicos por vía microbiana donde el producto final no sea biomasa.",CUBANO INST INVEST,CANTALLOPS MULET HAROLDO;;SAEZ MARTINEZ AGUSTIN;;GARCIA REVILLA JOSE LUIS;;BELL GARCIA ANTONIO;;CABRERA RIVERY RAQUEL;;SUAREZ ARIAS MANUEL BENITO,,https://lens.org/142-502-765-529-934,Limited Patent,no,0,0,1,1,0,Y02E50/10,C12N11/02;;C12P7/06,,0,0,,,,EXPIRED
604,ES,Y,ES 1047263 Y,078-107-689-523-303,2001-08-16,2001,ES 200001360 U,2000-05-23,VE 95200 A,2000-05-02,TABLA PARA ESCRITURA BRAILLE.,,QUILEN MYERSTON SILVIA ELENA,SUCRE CABRERA MARIA TERESA;;BOCCARDO IRIGOYEN RENZO JOSE;;TORREALBA ALGARRA RAFAEL RICAR;;RIVAS ORELLANA LAURA CRISTINA;;CASANAS CALCINES AURORA E,,https://lens.org/078-107-689-523-303,Limited Patent,no,0,0,2,2,0,,B41J3/32;;G09B21/02,,0,0,,,,EXPIRED
605,CA,A1,CA 3169881 A1,097-171-895-820-232,2023-02-09,2023,CA 3169881 A,2022-08-08,MX 2021009548 A,2021-08-09,HETEROGENEOUS CATALYST WITH MULTICATALYTIC ACTIVITY,"In this invention is described: a) the preparation of a new heterogeneous catalyst based on mesoporous silica with variable geometry of pore arrangement, covalently functionalized by an ionic liquid and as a counterion a tungsten polyoxometalate (Keggin acid); b) the application of this catalyst with dual action: Bronsted-Lowry acid and oxidizing agent; and c) its application in chemical reactions is described as: condensation, oxidation, polymerization, and esterification. This type of catalyst offers the following advantages in the chemical industry 1) reusable; 2) promotes different transformations in a single stage, attributed to their acidic and oxidizing characteristics (dual action); and 3) efficiency in the chemical transformations described, which allow to obtain precursors of homogeneous hydroprocessing catalysts, of interest for some projects of transformation of heavy crude oils in situ.",INSTITUTO MEXICANO DEL PETROLEO UNIV DE GUANAJUATO,DOMINGUEZ ESQUIVEL JOSE MANUEL;;MIRANDA OLVERA ALMA DELIA;;VAZQUEZ GUEVARA MIGUEL ANGEL;;GALVAN CABRERA ADRIANA DEL CARMEN;;MARTINEZ ROSALES MERCED,,https://lens.org/097-171-895-820-232,Patent Application,no,0,0,3,3,0,B01J27/188;;B01J31/0284;;B01J35/617;;B01J35/615;;B01J35/635;;B01J35/633;;B01J35/647;;B01J31/0295;;B01J2231/49;;B01J2231/349;;B01J2231/14;;B01J21/08;;B01J31/0284,B01J31/22;;C07D213/64;;C08G8/10,,0,0,,,,PENDING
606,US,A1,US 2015/0030706 A1,116-340-928-996-173,2015-01-29,2015,US 201214384822 A,2012-03-13,ES 2012070162 W,2012-03-13,"USE OF ESSENTIAL OILS, SUPERCRITICAL EXTRACTS AND AQUEOUS RESIDUES GENERATED DURING A PROCESS FOR OBTAINING ORGANIC EXTRACTS FROM THE ARTEMISIA ABSINTHIUM L. PLANT","The present invention starts with a method for obtaining organic extracts of the Artemisia absinthium L. plant, which includes: a methodology phase for producing said plant, an extraction phase during which said essential oil and a non-volatile extract are obtained, and a phase of extracting supercritical extracts with CO 2 , and refers specifically to the use of the essential oil and/or the supercritical extract extracted as fungicides against phytopathogenic fungi. For said purpose, the Artemisia absinthium L. plant is used, specifically the Candial variety from Teruel and/or Sierra Nevada in Spain. The present invention also relates to the aqueous residue generated during said method, which includes an organic compound which in turn contains (Z)-2,6-dimethylocta-5,7-diene-2,3-diol as an active organic compound against nematodes. The method for obtaining said organic portion and the corresponding active organic component thereof is protected by the present application.",GONZÁLEZ COLOMA AZUCENA;;ANDRES YEVES MARIA FE;;DIAZ HERNANDEZ CARMEN ELISA;;BURILLO ALQUEZAR JESUS;;CABRERA PEREZ RAIMUNDO;;URIETA NAVARRO JOSE;;CONSEJO SUPERIOR INVESTIGACION;;CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON CITA;;UNIV ZARAGOZA;;UNIV LA LAGUNA,GONZÁLEZ COLOMA AZUCENA;;ANDRES YEVES MARIA FE;;DIAZ HERNANDEZ CARMEN ELISA;;BURILLO ALQUEZAR JESUS;;CABRERA PEREZ RAIMUNDO;;URIETA NAVARRO JOSE,CENTRO DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON (CITA) (2014-09-22);;UNIVERSIDAD DE ZARAGOZA (2014-09-22);;CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS(CSIC) (2014-09-22);;UNIVERSIDAD DE LA LAGUNA (2014-09-22),https://lens.org/116-340-928-996-173,Patent Application,yes,0,2,6,6,0,A01N31/04;;A01N31/06;;A01N65/00;;A01N65/12;;A01N31/06;;A01N31/04;;A01N65/00;;A01N65/12,A01N65/12,424/740,0,0,,,,DISCONTINUED
607,EP,A1,EP 2257177 A1,152-494-177-814-136,2010-12-08,2010,EP 08849502 A,2008-11-14,US 2008/0012819 W;;US 305807 P,2007-11-14,NEW EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV. WITH ANTINEOPLASTIC ACTIVITY,,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/152-494-177-814-136,Patent Application,yes,0,0,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A01N65/00;;A61K36/899;;A61P35/00;;C07H21/04,,0,0,,,,DISCONTINUED
608,BR,A2,BR PI0819824 A2,115-844-597-634-057,2014-10-07,2014,BR PI0819824 A,2008-11-14,US 305807 P;;US 2008/0012819 W,2007-11-14,NOVOS EXTRATOS DE DESCHAMPSIA ANTARTICA DESV. COM ATIVIDADE ANTINEOPLÁSICA,,GIDEKEL MANUEL;;GUTIERREZ ANA;;WEBER HELGA;;CABRERA GUSTAVO;;OSORIO JENNIFER;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN;;JOSE BECERA,GIDEKEL MANUEL;;WEBER HELGA;;CABRERA GUSTAVO;;GUTIERREZ ANA;;OSORIO JENNIFER;;BECERA JOSE;;PODHAJCER OSVALDO;;CAFFERATA EDUARDO;;SUNKEL CARLOS;;MIHOVILOVIC IVAN,,https://lens.org/115-844-597-634-057,Patent Application,no,0,0,10,12,0,A61K36/899;;A61K36/899;;A61P35/00;;A61P43/00,A01N65/00;;C07H21/04,,0,0,,,,DISCONTINUED
609,WO,A1,WO 2013/135915 A1,136-744-093-695-327,2013-09-19,2013,ES 2012070162 W,2012-03-13,ES 2012070162 W,2012-03-13,"USE OF ESSENTIAL OILS, SUPERCRITICAL EXTRACTS AND AQUEOUS RESIDUES GENERATED DURING A PROCESS FOR OBTAINING ORGANIC EXTRACTS FROM THE ARTEMISIA ABSINTHIUM L. PLANT","The present invention starts with a method for obtaining organic extracts of the Artemisia absinthium L. plant, which includes: a methodology phase for producing said plant, an extraction phase during which said essential oil and a non-volatile extract are obtained, and a phase of extracting supercritical extracts with CO 2 , and refers specifically to the use of the essential oil and/or the supercritical extract extracted as fungicides against phytopathogenic fungi. For said purpose, the Artemisia absinthium L . plant is used, specifically the Candial variety from Teruel and/or Sierra Nevada in Spain. The present invention also relates to the aqueous residue generated during said method, which includes an organic compound which in turn contains (Z)-2,6-dimethylocta-5,7-diene-2,3-diol as an active organic compound against nematodes. The method for obtaining said organic portion and the corresponding active organic component thereof is protected by the present application.",CONSEJO SUPERIOR INVESTIGACION;;CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON CITA;;UNIV ZARAGOZA;;UNIV LA LAGUNA;;GONZALEZ COLOMA AZUCENA;;ANDRES YEVES MARIA FE;;DIAZ HERNANDEZ CARMEN ELISA;;BURILLO ALQUEZAR JESUS;;CABRERA PEREZ RAIMUNDO;;URIETA NAVARRO JOSE,GONZALEZ COLOMA AZUCENA;;ANDRES YEVES MARIA FE;;DIAZ HERNANDEZ CARMEN ELISA;;BURILLO ALQUEZAR JESUS;;CABRERA PEREZ RAIMUNDO;;URIETA NAVARRO JOSE,,https://lens.org/136-744-093-695-327,Patent Application,yes,5,0,6,6,0,A01N31/04;;A01N31/06;;A01N65/00;;A01N65/12;;A01N31/06;;A01N31/04;;A01N65/00;;A01N65/12,A01P3/00;;A01N65/12;;A01P5/00,,7,5,165-162-825-818-479;;109-654-762-317-481;;005-407-866-643-725;;109-654-762-317-481;;165-162-825-818-479,10.1016/j.indcrop.2011.06.006;;10.1016/j.supflu.2010.11.017;;10.1016/j.indcrop.2011.12.025;;10.1016/j.supflu.2010.11.017;;10.1016/j.indcrop.2011.06.006,"MARTIN L. ET AL.: ""Comparative chemistry and insect antifeedant action of traditional(Clevenger and Soxhlet) and supercritical extracts (C02) of two cultivated wormwood (Artemisia absinthium L.) populations"", INDUSTRIAL CROPS AND PRODUCTS, vol. 34, 24 June 2011 (2011-06-24), pages 1615 - 1621, XP055017296;;MARTIN L. ET AL.: ""Supercritical fluid extraction of wormwood (Artemisia absinthium L.)"", THE JOURNAL OF SUPERCRITICAL FLUIDS, vol. 56, 2011, pages 64 - 70, XP055153780;;GHASEMI E. ET AL.: ""Comparitive analysis of the oil and supercritical C02 extract of Artemisia sieberi"", JOURNAL OF FOOD ENGINEERING, vol. 79, 10 March 2006 (2006-03-10), pages 306 - 311, XP005664712;;GONZALEZ-COLOMA A. ET AL.: ""Major components of Spanish cultivated Artemisia absinthium populations: antifeedant, antiparasitic, and antioxidant effects"", INDUSTRIAL CROPS AND PRODUCTS, vol. 37, 25 January 2012 (2012-01-25), pages 401 - 407, XP055153781;;L. MARTIN ET AL.: ""Supercritical fluid extraction of wormwood (Artemisia absinthium L.)"", J. SUPERCRIT. FLUIDS, vol. 56, 2011, pages 64 - 71, XP055153780, DOI: doi:10.1016/j.supflu.2010.11.017;;""Comparative chemistry and insect antifeedant action of traditional (Clevenger and Soxhlet) and supercritical extracts (C0 ) of two cultivated wormwood (Artemisia absinthium L.) populations"", IND. CROP. PROD., vol. 34, 2011, pages 1615 - 1621;;See also references of EP 2826372A4",PENDING
610,MX,A,MX 2009001928 A,030-690-511-290-222,2010-08-12,2010,MX 2009001928 A,2009-02-10,MX 2009001928 A,2009-02-10,SYSTEM FOR UPPER LIMB MOTIVATIONAL REHABILITATION.,"Described is a computed assisted motivational rehabilitation system for upper limbs, which is intended for the recovery of patients with hemiplegia caused by a cerebral vascular event and physical traumas in upper limbs. The design of the system allows the 4 pillars of brain plasticity to be integrated: Motivation, therapy, multisensorial stimulation and equipment. The system includes: (1) a central processing unit, the CPu of the computer that contains the software designed for rehabilitation; (2) screen; (3) keyboard; (4) lever and (5) optical device. The main element for exercising the affected limb is the lever. The lever allows the arm to perform movements in the sagittal and medial plane, which provides freedom degrees. The aforementioned aspect means that the arm may perform flexion- extension and abduction-adduction movements as an advance function in the motive recovery. The developed videogame may be programmed at different speeds and difficulty levels, and has a record of t he patient evolution, also statistically measuring the therapy response of the user.",LELIS JOSE MARIA RODRIGUEZ,GALINDO SERGIO REYES;;LELIS JOSE MARIA RODRIGUEZ;;OTTALENGO OSCAR PAREDES;;TREVINO MARCIANO VARGAS;;GUTIERREZ ESTHER WICAB;;PLIEGO ARTURO ABUNDEZ;;TORRES JOSE NAVARRO;;ARVIZO DAGOBERTO VELA;;CABRERA ANTONIO ARELLANO,,https://lens.org/030-690-511-290-222,Patent Application,no,0,1,1,1,0,,A61F2/50;;A61F2/70,,0,0,,,,PENDING
611,ES,B1,ES 2181528 B1,134-692-046-201-14X,2004-06-16,2004,ES 200000787 A,2000-03-28,ES 200000787 A,2000-03-28,"PROCEDIMIENTO DE PREPARACION DE OXIDOS MIXTOS POROSOS, MATERIALES ASI OBTENIDOS Y SUS USOS.","Procedimiento de preparación de óxidos mixtos porosos, materiales así obtenidos y sus usos. Se preparan óxidos, en particular silicometalatos porosos, composicionalmente homogéneos y de elevada pureza de fase utilizando un procedimiento que comprende las siguientes etapas: 1ª) Preparación de disoluciones hidroalcohólicas estables de complejos atranos de los metales y/o metaloides incluidos en la composición del producto deseado; 2ª) Hidrólisis inducida química y/o térmicamente de los complejos atranos en presencia de un compuesto con efecto plantilla; 3ª) Envejecimiento del producto de la reacción de hidrólisis, y 4ª) Obtención del producto poroso mediante pirolisis del producto envejecido. Los materiales porosos obtenidos tienen las composiciones I, II y III: **FIGURA** donde 0 <= x <= 1; 0 < y < 1; z < x/2 (para I y II); z < (1-x) (para III); A y A'' representan metales de los subgrupos (1, 2, 3, 4, 5)B o (3, 4, 5, 6, 7)A, o del grupo 8 de la tabla periódica, y M representa un elemento monovalente. Los silicotitanatos mesoporosos obtenidos se usan como catalizadores de oxidación.",UNIV VALENCIA ESTUDI GENERAL,AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;MARCOS MARTINEZ M DOLORES,,https://lens.org/134-692-046-201-14X,Granted Patent,no,0,0,5,5,0,B01J21/04;;B01J21/063;;B01J21/066;;B01J29/03;;B01J29/0308;;B01J29/041;;B01J29/89;;C01B37/04;;C01B37/06;;C01B37/08;;B01J35/647,C01B37/04;;C01B37/06;;C01B37/08;;C01B39/04;;C01B39/48,,0,0,,,,EXPIRED
612,ES,A1,ES 2181528 A1,051-592-272-771-565,2003-02-16,2003,ES 200000787 A,2000-03-28,ES 200000787 A,2000-03-28,"METHOD FOR PREPARING MIXED POROUS OXIDES, MATERIALS THUS OBTAINED AND THE USES THEREOF","Oxides, particularly compositionally homogenous porous silicometalates exhibiting high phase purity, are prepared using a method involving the following steps: 1) Preparing stable hydroalcoholic solutions of atrane complexes of the metals and/or metalloids included in the composition of the desired product 2) Conducting chemically and/or thermally induced hydrolysis of the atrane complexes in the presence of a compound with template effect 3) aging the product from the hydrolysis reaction and 4) obtaining the porous material by conducting pyrolysis of the aged product. The resulting porous materials have compositions I, II and III: (SiO2)1-x(AmOn) x/m (M2O)z (I) (SiO2)1-x((AmOn)1-y(A'm'On')my/m)x/m(M2O)z (II) (Al2O3)t-x((P2O5)1-y(A'm'On')2y/m')x/2(M2O)z (III), wherein 0 x 1 0 < y < 1 z < x/2 (for I and II) z < (1-x) (for III) A and A' represent metals from subgroups (1, 2, 3, 4, 5)B or (3, 4, 5, 6, 7)A, or group 8 of the periodic table and M represents a monovalent element. The mesoporous silicotitanates obtained are used as oxidation catalysts.",UNIV VALENCIA ESTUDI GENERAL,AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;MARCOS MARTINEZ M DOLORES,,https://lens.org/051-592-272-771-565,Patent Application,no,0,0,5,5,0,B01J21/04;;B01J21/063;;B01J21/066;;B01J29/03;;B01J29/0308;;B01J29/041;;B01J29/89;;C01B37/04;;C01B37/06;;C01B37/08;;B01J35/647,C01B37/04;;C01B37/06;;C01B37/08;;C01B39/04;;C01B39/48,,2,2,014-654-262-568-191;;140-505-260-308-184,10.1002/(sici)1521-4095(199903)11:5<379::aid-adma379>3.0.co;2-6;;10.1039/a904762j,"CABRERA, S. et al., Surfactant-Assisted Synthesis of Mesoporous Alumina Showing Continously Pore Sizes, Adv. Mater., 1999, 11, nö 5, páginas 379-381, ISSN 0935-9648.;;, S. et al. Towards the Loewenstein Limit (Si/Al=1) in thermally stable mesoporous aluminosilicates, Chem. Commun., 1999, (17), pßginas 1679-1680, ISSN 1359-7345.",EXPIRED
613,ES,B1,ES 2184541 B1,134-855-049-203-523,2004-01-16,2004,ES 9902738 A,1999-12-02,ES 9902738 A,1999-12-02,ROBOT MOVIL INTERACTIVO PARA SERVICIOS EN MUSEOS.,"Se patenta la integración de dispositivos para un robot móvil interactivo para servicios en museos. El robot móvil resultado está dividido en dos partes principales, una inferior constituida por la plataforma móvil y otra superior que la forma el sistema de control de la interacción donde radican la toma de decisiones y la planificación. La primera está destinada a proporcionar movilidad y, junto con la segunda garantizar su autonomía en entornos con personas y objetos en movimiento. Para la navegación y prevención de colisiones se utiliza una plataforma móvil que integra un anillo de sensores ultrasónicos e infrarrojos (6) a la que se incorpora un sistema de posicionamiento láser por triangulación (7) basado en balizas activas que se sitúan en el área de trabajo del robot. El sistema de control de la interacción con personas y entorno integra una placa de adquisición de video para tareas visuales (reconocimiento de personas, navegación visual, identificación de objetos y seguimiento de objetivos) desde imágenes que provienen de un par estereoscópico de cámaras motorizadas (1) situadas sobre una cabeza móvil con dos grados de libertad (2). El sistema puede enviar imágenes al exterior mediante un emisor de vídeo (3) y comunicarse además con los usuarios mediante comandos de voz, que interpreta el ordenador de control de la interacción (4), y a través de una pantalla táctil (5).",UNIV LAS PALMAS GRAN CANARIA,HERNANDEZ TEJERA FRANCISCO M;;FALCON MARTEL ANTONIO;;MENDEZ RODRIGUEZ JUAN A;;CABRERA GAMEZ JORGE;;LORENZO NAVARRO JAVIER;;HERNANDEZ SOSA JOSE D,,https://lens.org/134-855-049-203-523,Granted Patent,no,0,5,2,2,0,B25J9/16;;G09F27/00,B25J9/16;;G09F27/00,,0,0,,,,EXPIRED
614,ES,A1,ES 2184541 A1,146-164-440-875-376,2003-04-01,2003,ES 9902738 A,1999-12-02,ES 9902738 A,1999-12-02,Interactive mobile robot for museum services,"Interactive mobile robot for museum services that includes a holonomic mobile platform with four wheels, an ultrasound sensor system, an infrared sensor system, a contact sensor system, an stereoscopic pair of motorised chambers, a touch screen, an interaction control computer, a pan/tilt base platform, an AC/DC converter and energy control card, a triangulation laser positioning system, a voice command system, and an image capturing and processing system that allows programming of the following activities: a) public information tasks regarding the various attractions in the museum that execute commented guides, b) transportation that move small loads and independent navigation in controlled environments, and c) entertainment, such as games on a panel with people.<IMAGE>",UNIV LAS PALMAS GRAN CANARIA,HERNANDEZ TEJERA FRANCISCO M;;FALCON MARTEL ANTONIO;;MENDEZ RODRIGUEZ JUAN A;;CABRERA GAMEZ JORGE;;LORENZO NAVARRO JAVIER;;HERNANDEZ SOSA JOSE D,,https://lens.org/146-164-440-875-376,Patent Application,no,1,6,2,2,0,B25J9/16;;G09F27/00,B25J9/16;;G09F27/00,,1,0,,,"Recuperado de World Patents Index. & EP 0958897 A1 (LANDERT, H.) 24.11.1999 (resumen) [en línea]",EXPIRED
615,AU,A,AU 2001/042535 A,021-284-676-334-334,2001-10-08,2001,AU 2001/042535 A,2001-03-27,ES 200000787 A;;ES 0100122 W,2000-03-28,"Method for preparing mixed porous oxides, materials thus obtained and the uses thereof",,UNIV VALENCIA,TORO PEDRO JOSE AMOROS DEL;;PORTER AURELIO BELTRAN;;PORTER DANIEL BELTRAN;;MEDINA SAUL CABRERA;;HASKOURI JAMAL EL;;MARTINEZ M DOLORES MARCOS,,https://lens.org/021-284-676-334-334,Patent Application,no,0,0,5,5,0,B01J21/04;;B01J21/063;;B01J21/066;;B01J29/03;;B01J29/0308;;B01J29/041;;B01J29/89;;C01B37/04;;C01B37/06;;C01B37/08;;B01J35/647,C01B37/04;;C01B37/06;;C01B37/08;;C01B39/04;;C01B39/48,,0,0,,,,DISCONTINUED
616,WO,A1,WO 2001/072635 A1,023-201-917-036-810,2001-10-04,2001,ES 0100122 W,2001-03-27,ES 200000787 A,2000-03-28,"METHOD FOR PREPARING MIXED POROUS OXIDES, MATERIALS THUS OBTAINED AND THE USES THEREOF","Oxides, particularly compositionally homogenous porous silicometalates exhibiting high phase purity, are prepared using a method involving the following steps: 1) Preparing stable hydroalcoholic solutions of atrane complexes of the metals and/or metalloids included in the composition of the desired product; 2) Conducting chemically and/or thermally induced hydrolysis of the atrane complexes in the presence of a compound with template effect; 3) aging the product from the hydrolysis reaction and 4) obtaining the porous material by conducting pyrolysis of the aged product. The resulting porous materials have compositions I, II and III: (SiO2)1-x(AmOn) x/m (M2O)z (I); (SiO2)1-x((AmOn)1-y(A'm'On')my/m)x/m(M2O)z (II); (Al2O3)t-x((P2O5)1-y(A'm'On')2y/m')x/2(M2O)z (III), wherein 0 x 1; 0 ឬ y ឬ 1; z ឬ x/2 (for I and II); z ឬ (1-x) (for III); A and A' represent metals from subgroups (1, 2, 3, 4, 5)B or (3, 4, 5, 6, 7)A, or group 8 of the periodic table and M represents a monovalent element. The mesoporous silicotitanates obtained are used as oxidation catalysts.",UNIV VALENCIA;;AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;MARCOS MARTINEZ M DOLORES,AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;MARCOS MARTINEZ M DOLORES,,https://lens.org/023-201-917-036-810,Patent Application,yes,0,13,5,5,0,B01J21/04;;B01J21/063;;B01J21/066;;B01J29/03;;B01J29/0308;;B01J29/041;;B01J29/89;;C01B37/04;;C01B37/06;;C01B37/08;;B01J35/647,C01B37/04;;C01B37/06;;C01B37/08;;C01B39/04;;C01B39/48,,4,4,014-654-262-568-191;;140-505-260-308-184;;105-657-588-247-016;;074-023-894-224-325,10.1002/(sici)1521-4095(199903)11:5<379::aid-adma379>3.0.co;2-6;;10.1039/a904762j;;10.1016/s1293-2558(00)00152-7;;10.1016/s1293-2558(00)00057-1,"CABRERA S. ET AL.: ""Surfactant-assisted synthesis of mesoporous alumina showing continuously adjustable pore sizes"", ADV. MATER., vol. 11, no. 5, 1999, pages 379 - 381, ISSN 0935-9648;;CABRERA S. ET AL.: ""Towards the Loewestein limit (Si/A1=1) in thermally stable mesoporous aluminosilicates"", CHEM. COMMUN., no. 17, 1999, pages 1679 - 1680, ISSN 1359-7345;;CABRERA S. ET AL.: ""Generalised synthetase of ordered mesoporous oxides: the atrane route"", SOLID STATE SCI., vol. 2, no. 4, 2000, pages 405 - 420, ISSN 1293-2558;;CABRERA S. ET AL.: ""Enhanced surface area in thermally stable pure mesoporous TiO2"", SOLID STATE SCI., vol. 2, no. 5, 2000, pages 513 - 518, ISSN 1293-2558",PENDING
617,WO,A9,WO 2001/072635 A9,167-103-634-078-992,2001-11-22,2001,ES 0100122 W,2001-03-27,ES 200000787 A,2000-03-28,"METHOD FOR PREPARING MIXED POROUS OXIDES, MATERIALS THUS OBTAINED AND THE USES THEREOF","Oxides, particularly compositionally homogenous porous silicometalates exhibiting high phase purity, are prepared using a method involving the following steps: 1) Preparing stable hydroalcoholic solutions of atrane complexes of the metals and/or metalloids included in the composition of the desired product; 2) Conducting chemically and/or thermally induced hydrolysis of the atrane complexes in the presence of a compound with template effect; 3) aging the product from the hydrolysis reaction and 4) obtaining the porous material by conducting pyrolysis of the aged product. The resulting porous materials have compositions I, II and III: (SiO2)1-x(AmOn) x/m (M2O)z (I); (SiO2)1-x((AmOn)1-y(A'm'On')my/m)x/m(M2O)z (II); (Al2O3)t-x((P2O5)1-y(A'm'On')2y/m')x/2(M2O)z (III), wherein 0 x 1; 0 < y < 1; z < x/2 (for I and II); z < (1-x) (for III); A and A' represent metals from subgroups (1, 2, 3, 4, 5)B or (3, 4, 5, 6, 7)A, or group 8 of the periodic table and M represents a monovalent element. The mesoporous silicotitanates obtained are used as oxidation catalysts.",UNIV VALENCIA;;AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;MARCOS MARTINEZ M DOLORES,AMOROS DEL TORO PEDRO JOSE;;BELTRAN PORTER AURELIO;;BELTRAN PORTER DANIEL;;CABRERA MEDINA SAUL;;EL HASKOURI JAMAL;;MARCOS MARTINEZ M DOLORES,,https://lens.org/167-103-634-078-992,Patent Application,no,0,0,5,5,0,B01J21/04;;B01J21/063;;B01J21/066;;B01J29/03;;B01J29/0308;;B01J29/041;;B01J29/89;;C01B37/04;;C01B37/06;;C01B37/08;;B01J35/647,C01B37/04;;C01B37/06;;C01B37/08;;C01B39/04;;C01B39/48,,0,0,,,,PENDING
618,MX,A,MX 2010014428 A,069-891-174-438-404,2012-06-21,2012,MX 2010014428 A,2010-12-21,MX 2010014428 A,2010-12-21,METHOD FOR THE POSITIVE SELECTION OF GENETICALLY TRANSFORMED VEGETABLE CELLS OF MAIZE AND OTHER SPECIES.,"The present invention provides a non-toxic method for the selection of transformed cells from a population consisting in transformed and non-transformed cells. The method comprises the following steps: a) introducing to a cell at least a nucleotide sequence of interest and at least a nucleotide sequence of selection for obtaining genetically transformed cells, where the nucleotide sequence of selection comprises a sequence that promotes the inhibition of the endogenous trehalase enzyme; b) locating the population with transformed and non-transformed cells in a culture medium containing an osmoregulating substance such as PEG 8000 and c) selecting the transformed cells from the population based on the capacity of the transformed cells to survive and develop in the presence of the osmoregulating substance, thus providing the plants resulting from these genetic transformation events with the capacity to tolerate drought and cold.",CT INVESTIG Y ESTUDIOS DEL IPN,PONCE JOSE LUIS CABRERA;;MEDRANO ROBERTO RUIZ;;CAZARES BEATRIZ XOCONOSTLE;;LUNA ROBERTO MONTES DE OCA;;ESCOBEDO ANALI GAMEZ;;ESTRELLA LUIS RAFAEL HERRERA,,https://lens.org/069-891-174-438-404,Patent Application,no,0,0,2,9,0,,C12N15/00,,0,0,,,,ACTIVE
619,US,A1,US 2019/0330101 A1,055-254-028-807-021,2019-10-31,2019,US 201616471094 A,2016-12-20,MX 2016000188 W,2016-12-20,Low-Emissivity Coating for a Glass Substrate,"The present invention relates to a glass substrate provided with a stack of thin coating layers formed by a first layer of anti-reflective dielectric material, with a refractive index of 1.65 to 2.65, located above the glass substrate. At least one structure of two layers formed by a first layer of an anti-reflective transparent dielectric material with a refractive index of 1.32 to 1.55, located in the bottom position, and a second layer of a metal functional layer with reflective properties in the infrared range, located in the top position, said structure being located above the first layer of anti-reflective dielectric material. A second layer of absorbent material forming an anti-corrosion barrier for protecting the metal functional layer against oxidation and corrosion. A third layer of an anti-reflective material, said layer being selected from a metal oxide with a refractive index of 1.32 to 1.55, a metal oxide with a refractive index of 1.65 to 1.95 or an aluminum-doped zinc oxide (AZO); and a fourth protective layer made of an anti-reflective material, for increasing the transmission of visible light and the scratch resistance of the substrate, having high transmission of visible light (60%), a solar transmission of less than 60%, a resistance of less than 10 per square and an emissivity of less than 0.10.",VIDRIO PLANO MEXICO SA DE CV,CID AGUILAR JOSÉ GUADALUPE;;CABRERA LLANOS ROBERTO;;HERNÁNDEZ CARRILLO RUBI AGLAÉ;;TAVARES CORTES JOSE LUIS;;JERG CARMEN;;WEGENER INGO;;XU JIA LIN,VIDRIO PLANO DE MÉXICO S.A. DE C.V (2019-08-09),https://lens.org/055-254-028-807-021,Patent Application,yes,13,9,13,13,0,B32B15/00;;B32B17/06;;C03C17/36;;C03C17/3644;;C03C17/366;;C03C17/3655;;C03C17/3652;;C03C17/3639;;B32B17/061;;C03C17/3615;;C03C17/3636;;C03C17/3644;;C03C17/366,C03C17/36;;B32B17/06,,0,0,,,,PENDING
620,CU,A1,CU 21683 A1,095-334-164-267-93X,1991-07-15,1991,CU 35969 A,1983-11-15,CU 35969 A,1983-11-15,SISTEMA DE EXTRACCION DE JUGO DE LA CANA DE AZUCAR Y EL EQUIPAMIENTO PARA LOGRARLO,"Sistema de extracción de jugo de la cana de azúcar donde intervienen equipos para la preparación inicial de la cana, cuchillas picadoras tradicionales, así como desmenuzadora, desfibradora, conductor de lavado y molinos de dos, tres o más mazas, caracterizado porque la preparación inicial se completa mediante el uso de una desfibradora alimentada a presión por una desmenuzadora mediante un conducto cerrado cuyas paredes superiores e inferiores poseen en sus extremos unos dientes que penetran en el perfil de las mazas de la desmenuzadora, a continuación de la desfibradora se ubica un molino de 3,4 ó 6 mazas que alimenta a un conductor de lavado de 9 a 10m de longitud formado por 3 módulos de difusión a contracorriente, llevando cada uno alimentación de jugo de maceración y artesas que recogen el jugo percolado a través del colchón de bagazo, posterior al conductor se dispone un molino lavador de 2 mazas seguido de un conjunto de molinos secadores también de 2 mazas previos a un molino de 3 ó más mazas.",MINISTERIO IND AZUCARERA,MANRESA JIMENEZ JOSE;;GOROSTIAGA CANEPA JUAN;;ESPINOSA HERNANDEZ RAUL;;MARTINEZ RODRIGUEZ EMILIO;;CUELLAR CABRERA MIGUEL ANGEL;;HERRERA CASTRO EDMUNDO;;VALDES PENA JUAN,,https://lens.org/095-334-164-267-93X,Limited Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
621,MX,B,MX 366670 B,182-017-164-488-50X,2019-07-12,2019,MX 2010014428 A,2010-12-21,MX 2010014428 A,2010-12-21,METHOD FOR THE POSITIVE SELECTION OF GENETICALLY TRANSFORMED VEGETABLE CELLS OF MAIZE AND OTHER SPECIES.,"The present invention provides a non-toxic method for the selection of transformed cells from a population consisting in transformed and non-transformed cells. The method comprises the following steps: a) introducing to a cell at least a nucleotide sequence of interest and at least a nucleotide sequence of selection for obtaining genetically transformed cells, where the nucleotide sequence of selection comprises a sequence that promotes the inhibition of the endogenous trehalase enzyme; b) locating the population with transformed and non-transformed cells in a culture medium containing an osmoregulating substance such as PEG 8000 and c) selecting the transformed cells from the population based on the capacity of the transformed cells to survive and develop in the presence of the osmoregulating substance, thus providing the plants resulting from these genetic transformation events with the capacity to tolerate drought and cold.",CENTRO DE INVESTIG Y DE ESTUDIOS AVANZADOS DEL I P N,JOSE LUIS CABRERA PONCE;;ROBERTO RUIZ MEDRANO;;BEATRIZ XOCONOSTLE CÁZARES;;ROBERTO MONTES DE OCA LUNA;;ANALI GAMEZ ESCOBEDO;;LUIS RAFAEL HERRERA ESTRELLA,,https://lens.org/182-017-164-488-50X,Granted Patent,no,0,0,2,9,0,,A01H4/00;;A01H5/00;;C12N5/04;;C12N5/14;;C12N9/10;;C12N9/16;;C12N9/24;;C12N15/31;;C12N15/54;;C12N15/55;;C12N15/82;;C12P19/12,,0,0,,,,ACTIVE
622,PH,A1,PH 12015502132 A1,042-879-987-463-509,2016-01-25,2016,PH 12015502132 A,2015-09-15,EP 13382088 A;;US 2014/0023971 W,2013-03-15,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR IMPROVING BONE DEVELOPMENT AND FORMATION AND/OR FOR IMPROVING COGNITIVE AND CNS DEVELOPMENT IN OFFSPRING,"The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, and a non-absorbent carbohydrate and/or an indigestible carbohydrate.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;MANZANO MARTIN MANUEL CRISTOBAL;;MARTIN MARTIN MARIA-JESUS;;OLIVEROS DELGADO ELENA;;RUEDA CABRERA RICARDO;;BUENO VARGAS MARIA DEL PILAR,,https://lens.org/042-879-987-463-509,Patent Application,no,0,0,10,10,0,A61K31/70;;A23V2002/00;;A23L29/212;;A23L29/262;;A23L33/10;;A23L33/22;;A61K31/7016;;A61K31/702;;A61K31/715;;A61K31/716;;A61K31/718;;A61P19/08;;A61P25/28;;A61P3/04;;A61P3/10;;A61K31/70;;A23V2002/00;;A23L33/22;;A23L33/10;;A23L29/212;;A23L29/262;;A61K31/7016;;A61K31/702;;A61K31/715;;A61K31/716;;A61K31/718,A61P3/04;;A61K31/70;;A61P3/10;;A61P19/08;;A61P25/28,,0,0,,,,PENDING
623,CU,A,CU 35497 A,067-098-826-412-191,1982-12-22,1982,CU 35497 A,1981-07-14,CU 35497 A,1981-07-14,PROCEDURE-INSTALLATION TO THE ALKALINIZATION OF ANY CHEMICAL SUBSTANCE,,BURO SAD PT,AVDEEV OLEG N;;ARAGON HAZA ALICIA;;ALADRO CABRERA LOURDES;;VARELA BELTRAN LILIANA;;RIVERO AGUDO ADEA;;VALDES PRADO JOSE R;;FERNANDEZ FUENTES MANUEL P,,https://lens.org/067-098-826-412-191,Unknown,no,0,0,1,1,0,,B01F13/00;;G05D21/00,,0,0,,,,DISCONTINUED
624,WO,A1,WO 2014/058627 A1,016-625-197-626-008,2014-04-17,2014,US 2013/0062005 W,2013-09-26,US 201261713373 P;;US 201313800659 A,2012-10-12,COLLECTING AND TRANSFERRING PHYSIOLOGICAL DATA,"The present invention extends to methods, systems, and computer program products for collecting and transferring physiological data. Different physiological monitoring appliances can be attached to a portable physiological data collection device. Each physiological monitoring appliance can collect a different physiological data (blood glucose data, heart rate data, etc.) from an individual. Different physiological data can be collected and stored at the portable physiological data collection device. In response to a triggering event, a connection can be established to an external computer system. The stored physiological data can be transferred over the established connection to the external computer system. In some embodiments, the external computer system is a healthcare server that shares collected physiological data as well as other healthcare information with designated entities (e.g., family, doctors, etc.). The healthcare server can share healthcare information in accordance with patient configured rules so that patients have control over dissemination their healthcare information.",CYTRON MEDICAL INTERNAT INC;;ECHEVERRIA CABRERA RUBEN GERARDO;;VILLALOBOS CANTO HUGO LUIS;;MUNOZ UBANDO LUIS ALBERTO;;ATOCHE ENSENAT JOSE RAMON;;IX ANDRADE FREDDY ANTONION;;SHAFTMAN ALEJANDRO COVALIN,ECHEVERRIA CABRERA RUBEN GERARDO;;VILLALOBOS CANTO HUGO LUIS;;MUNOZ UBANDO LUIS ALBERTO;;ATOCHE ENSENAT JOSE RAMON;;IX ANDRADE FREDDY ANTONION;;SHAFTMAN ALEJANDRO COVALIN,,https://lens.org/016-625-197-626-008,Patent Application,yes,6,0,3,3,0,G16H10/60;;G16H10/60;;G16H40/67;;G16H40/67,G06Q50/22;;G16H10/60,,0,0,,,,PENDING
625,CA,A1,CA 2904157 A1,058-943-859-696-29X,2014-09-25,2014,CA 2904157 A,2014-03-12,EP 13382088 A;;US 2014/0023971 W,2013-03-15,USE OF SPECIFIC CARBOHYDRATE SYSTEMS DURING PREGNANCY FOR IMPROVING BONE DEVELOPMENT AND FORMATION AND/OR FOR IMPROVING COGNITIVE AND CNS DEVELOPMENT IN OFFSPRING,"The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohydrate system may include a slow rate of digestion simple carbohydrate, a complex carbohydrate, and a non-absorbent carbohydrate and/or an indigestible carbohydrate.",ABBOTT LAB,PEDROSA JOSE MARIA LOPEZ;;MARTIN MANUEL CRISTOBAL MANZANO;;MARTIN MARIA-JESUS MARTIN;;DELGADO ELENA OLIVEROS;;CABRERA RICARDO RUEDA;;VARGAS MARIA DEL PILAR BUENO,,https://lens.org/058-943-859-696-29X,Patent Application,no,0,0,10,10,0,A61K31/70;;A23V2002/00;;A23L29/212;;A23L29/262;;A23L33/10;;A23L33/22;;A61K31/7016;;A61K31/702;;A61K31/715;;A61K31/716;;A61K31/718;;A61P19/08;;A61P25/28;;A61P3/04;;A61P3/10;;A61K31/70;;A23V2002/00;;A23L33/22;;A23L33/10;;A23L29/212;;A23L29/262;;A61K31/7016;;A61K31/702;;A61K31/715;;A61K31/716;;A61K31/718,A23L1/09;;A61K31/70;;A61P3/04;;A61P3/10;;A61P19/08;;A61P25/28,,0,0,,,,DISCONTINUED
626,CU,A,CU 35428 A,139-618-015-866-532,1982-12-22,1982,CU 35428 A,1981-03-06,CU 35428 A,1981-03-06,PROCEDURE OF THE ALKALINIZATION PROCESS CONTROL,,BURO SAD PT,AVDEEV OLEG N;;ALADRO CABRERA LOURDES;;ARAGON HAZA ALICIA;;VARELA BELTRAN LILIANA;;RIVERO AGUDO ADEA;;VALDES PRADO JOSE R;;FERNANDEZ FUENTES MANUEL P,,https://lens.org/139-618-015-866-532,Unknown,no,0,0,1,1,0,,C13B20/00;;G05D21/00,,0,0,,,,DISCONTINUED
627,MX,A,MX 2016005655 A,074-464-043-319-231,2017-10-30,2017,MX 2016005655 A,2016-04-29,MX 2016005655 A,2016-04-29,HARVESTER MACHINE FOR AGAVE SHREDDING.,"The invention relates to the harvesting machine for agave, which when advancing along a row of plants, chopped the whole pieces (leaves and pineapples), without removing the roots of the soil, to produce raw material for the subsequent process. Said process is for obtaining bioethanol in the processing industries that employ the diffusion method. Said machine is pulled and driven by an agricultural tractor, which consists of a head formed by two counter-rotating rollers with blades on its periphery and a sheet cover that facilitates the entry of plants into the cutting area. Further, it involves a belt conveyor, which receives the chopped material for unloading it in the containers placed on the rear platform and a frame to which said components are attached which also is composed by wheels and a drawbar serving for coupling to the agricultural tractor. All the operating movements and position adjustment are actuated with a hydraulic system of the machine itself, formed by a revolutio ns amplifier, a pump, oil reservoir with coolant, motors, cylinders and hydraulic valves, thus receiving the energy from the power intake of the tractor by the Cardan arrow.",UNIV GUANAJUATO,NOE SALDAÑA ROBLES;;JOSE MANUEL CABRERA SIXTO;;ADRIÁN FLORES ORTEGA;;CESAR GUTIERREZ VACA;;ALBERTO SALDAÑA ROBLES;;PEDRO ANTONIO ALATORRE BRAVO;;RYSZARD JERZY SERWATOWSKI,,https://lens.org/074-464-043-319-231,Patent Application,no,0,2,1,1,0,,A01D34/135;;A01D34/125;;A01D91/04,,0,0,,,,PENDING
628,CA,A1,CA 3121165 A1,142-389-583-549-625,2020-06-04,2020,CA 3121165 A,2019-11-27,EP 18382874 A;;US 2019/0063669 W,2018-11-30,METHODS OF PROMOTING HEALTHY CATCH-UP GROWTH,"A method of promoting healthy catch-up growth in a moderately malnourished individual is provided. The method includes administering to the moderately malnourished individual a nutritional composition that contains a carbohydrate blend, wherein the carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;MANZANO MARTIN MANUEL;;GARCIA MARTINEZ JORGE;;CAMPRUBI ROBLES MARIA;;BUENO VARGAS PILAR;;WALTON JOSEPH;;MUSTAD VIKKIE,,https://lens.org/142-389-583-549-625,Patent Application,no,0,0,9,9,0,A61K45/06;;A61K31/70;;A61K31/7016;;A61P3/02;;A61P43/00;;A23L33/40;;A23L33/125;;A23V2002/00;;A23L33/125;;A23L33/40;;A23V2002/00;;A23V2200/30;;A23V2250/28;;A23V2250/5062;;A23V2250/5114;;A23V2250/5118;;A23V2250/62;;A23V2250/628;;A61K31/70;;A61K31/7016;;A61K45/06;;A61K2300/00;;A61P3/02;;A61P43/00;;A23L33/125;;A23L33/40;;A61P3/02;;A23V2002/00;;A61K31/7004;;A61K31/7016;;A61K31/702;;A61K31/718;;A61K31/733,A61K45/06;;A23L33/00;;A61K31/70;;A61K31/7016;;A61P3/02;;A61P43/00,,0,0,,,,PENDING
629,US,A1,US 2014/0108025 A1,109-265-391-750-569,2014-04-17,2014,US 201313800659 A,2013-03-13,US 201313800659 A;;US 201261713373 P,2012-10-12,COLLECTING AND TRANSFERRING PHYSIOLOGICAL DATA,"The present invention extends to methods, systems, and computer program products for collecting and transferring physiological data. Different physiological monitoring appliances can be attached to a portable physiological data collection device. Each physiological monitoring appliance can collect a different physiological data (blood glucose data, heart rate data, etc.) from an individual. Different physiological data can be collected and stored at the portable physiological data collection device. In response to a triggering event, a connection can be established to an external computer system. The stored physiological data can be transferred over the established connection to the external computer system. In some embodiments, the external computer system is a healthcare server that shares collected physiological data as well as other healthcare information with designated entities (e.g., family, doctors, etc.). The healthcare server can share healthcare information in accordance with patient configured rules so that patients have control over dissemination their healthcare information.",ECHEVERRIA CABRERA RUBEN GERARDO;;VILLALOBOS CANTO HUGO LUIS;;MUNOZ UBANDO LUIS ALBERTO;;ATOCHE ENSENAT JOSE RAMON;;IX ANDRADE FREDDY ANTONIO;;SHAFTMAN ALEJANDRO COVALIN,ECHEVERRIA CABRERA RUBEN GERARDO;;VILLALOBOS CANTO HUGO LUIS;;MUNOZ UBANDO LUIS ALBERTO;;ATOCHE ENSENAT JOSE RAMON;;IX ANDRADE FREDDY ANTONIO;;SHAFTMAN ALEJANDRO COVALIN,,https://lens.org/109-265-391-750-569,Patent Application,yes,5,10,3,3,0,G16H10/60;;G16H10/60;;G16H40/67;;G16H40/67,G06F19/00;;G16H10/60,705/2,0,0,,,,DISCONTINUED
630,MX,A,MX 2015004549 A,169-635-044-940-95X,2017-05-15,2017,MX 2015004549 A,2013-09-26,US 201261713373 P;;US 201313800659 A;;US 2013/0062005 W,2012-10-12,COLLECTING AND TRANSFERRING PHYSIOLOGICAL DATA.,"The present invention extends to methods, systems, and computer program products for collecting and transferring physiological data. Different physiological monitoring appliances can be attached to a portable physiological data collection device. Each physiological monitoring appliance can collect a different physiological data (blood glucose data, heart rate data, etc.) from an individual. Different physiological data can be collected and stored at the portable physiological data collection device. In response to a triggering event, a connection can be established to an external computer system. The stored physiological data can be transferred over the established connection to the external computer system. In some embodiments, the external computer system is a healthcare server that shares collected physiological data as well as other healthcare information with designated entities (e.g., family, doctors, etc.). The healthcare server can share healthcare information in accordance with patient configured rules so that patients have control over dissemination their healthcare information.",RUBEN GERARDO ECHEVERRIA CABRERA,RUBEN GERARDO ECHEVERRIA CABRERA;;HUGO LUIS VILLALOBOS CANTO;;LUIS ALBERTO MUNOZ UBANDO;;JOSE RAMON ATOCHE ENSENAT;;FREDDY ANTONION IX ANDRADE;;ALEJANDRO COVALIN SHAFTMAN,,https://lens.org/169-635-044-940-95X,Patent Application,no,0,0,3,3,0,G16H10/60;;G16H10/60;;G16H40/67;;G16H40/67,G06Q50/22;;G16H10/60,,0,0,,,,PENDING
631,CN,A,CN 113226373 A,191-506-518-442-263,2021-08-06,2021,CN 201980084475 A,2019-11-27,EP 18382874 A;;US 2019/0063669 W,2018-11-30,METHODS OF PROMOTING HEALTHY CATCH-UP GROWTH,"A method of promoting healthy catch-up growth in a moderately malnourished individual is provided. The method includes administering to the moderately malnourished individual a nutritional composition that contains a carbohydrate blend, wherein the carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.",ABBOTT LAB,LOPEZ PEDROSA JOSE MARIA;;RUEDA CABRERA RICARDO;;MANZANO MARTIN MANUEL;;GARCIA MARTINEZ JORGE;;CAMPRUBI ROBLES MARIA;;BUENO VARGAS PILAR;;WALTON JOSEPH;;MUSTAD VIKKIE,,https://lens.org/191-506-518-442-263,Patent Application,no,2,1,9,9,0,A61K45/06;;A61K31/70;;A61K31/7016;;A61P3/02;;A61P43/00;;A23L33/40;;A23L33/125;;A23V2002/00;;A23L33/125;;A23L33/40;;A23V2002/00;;A23V2200/30;;A23V2250/28;;A23V2250/5062;;A23V2250/5114;;A23V2250/5118;;A23V2250/62;;A23V2250/628;;A61K31/70;;A61K31/7016;;A61K45/06;;A61K2300/00;;A61P3/02;;A61P43/00;;A23L33/125;;A23L33/40;;A61P3/02;;A23V2002/00;;A61K31/7004;;A61K31/7016;;A61K31/702;;A61K31/718;;A61K31/733,A61K45/06;;A23L33/00;;A61K31/70;;A61K31/7016;;A61P3/02;;A61P43/00,,0,0,,,,PENDING
632,WO,A2,WO 2008/011599 A2,066-634-113-297-867,2008-01-24,2008,US 2007/0074029 W,2007-07-20,US 83231606 P,2006-07-20,PRODUCTS FOR RECEPTOR MEDIATED ACTIVATION AND MATURATION OF MONOCYTE-DERIVED DENDRITIC CELLS BY A PHOSPHORYLATED GLUCOMANNANE POLYSACCHARIDE,"Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.",GOURMETCEUTICALS LLC;;TUDURI JOSE ANTONIO MATJI;;RODRIGUEZ PEDRO MAJANO;;CABRERA MANUEL LOPEZ;;LOPEZ ANGEL CORBI;;GOMEZ DIEGO SERRANO;;LEBRERO JOSE LUIS AONSO;;GOMEZ-PAMO ANTONIO F GUERRERO;;VILCHEZ SAMUEL MARTIN;;LINDEMANN GARRETT;;OTERO RICARDO MORENO,TUDURI JOSE ANTONIO MATJI;;RODRIGUEZ PEDRO MAJANO;;CABRERA MANUEL LOPEZ;;LOPEZ ANGEL CORBI;;GOMEZ DIEGO SERRANO;;LEBRERO JOSE LUIS AONSO;;GOMEZ-PAMO ANTONIO F GUERRERO;;VILCHEZ SAMUEL MARTIN;;LINDEMANN GARRETT;;OTERO RICARDO MORENO,,https://lens.org/066-634-113-297-867,Patent Application,yes,0,12,4,4,0,A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10;;A61P37/02;;A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10,,,0,0,,,,PENDING
633,WO,A3,WO 2008/011599 A3,069-491-678-383-539,2009-02-12,2009,US 2007/0074029 W,2007-07-20,US 83231606 P,2006-07-20,PHOSPHORYLATED GLUCOMANNAN POLYSACCHARIDE FOR RECEPTOR MEDIATED ACTIVATION AND MATURATION OF MONOCYTE-DERIVED DENDRITIC CELLS,"Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.",GOURMETCEUTICALS LLC;;TUDURI JOSE ANTONIO MATJI;;RODRIGUEZ PEDRO MAJANO;;CABRERA MANUEL LOPEZ;;LOPEZ ANGEL CORBI;;GOMEZ DIEGO SERRANO;;LEBRERO JOSE LUIS AONSO;;GOMEZ-PAMO ANTONIO F GUERRERO;;VILCHEZ SAMUEL MARTIN;;LINDEMANN GARRETT;;OTERO RICARDO MORENO,TUDURI JOSE ANTONIO MATJI;;RODRIGUEZ PEDRO MAJANO;;CABRERA MANUEL LOPEZ;;LOPEZ ANGEL CORBI;;GOMEZ DIEGO SERRANO;;LEBRERO JOSE LUIS AONSO;;GOMEZ-PAMO ANTONIO F GUERRERO;;VILCHEZ SAMUEL MARTIN;;LINDEMANN GARRETT;;OTERO RICARDO MORENO,,https://lens.org/069-491-678-383-539,Search Report,yes,4,0,4,4,0,A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10;;A61P37/02;;A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10,A61K31/736,,9,7,049-468-482-209-490;;008-261-077-660-59X;;086-082-104-764-411;;007-736-013-411-834;;013-422-536-043-933;;034-809-607-679-25X;;017-077-347-283-410,11967036;;10.1046/j.1523-1755.2002.00335.x;;12542167;;10.2527/2002.80123257x;;10.1016/j.tiv.2005.12.001;;16413741;;10.1007/bf02814381;;8365697;;7751580;;10.1016/0168-8278(95)80271-1;;10.1038/bjp.2008.87;;pmc2439514;;18414382;;10.1128/aac.01289-06;;17452477;;pmc1913256,"PÉREZ-GARCÍA RAFAEL ET AL: ""AM3 (Inmunoferón) as an adjuvant to hepatitis B vaccination in hemodialysis patients."", KIDNEY INTERNATIONAL MAY 2002, vol. 61, no. 5, May 2002 (2002-05-01), pages 1845 - 1852, XP002487610, ISSN: 0085-2538;;SWAMY H V L N ET AL: ""Effects of feeding a blend of grains-naturally contaminated with Fusarium mycotoxins on swine performance, brain regional neurochemistry, and serum chemistry and the efficacy of a polymeric glucomannan mycotoxin adsorbent."", JOURNAL OF ANIMAL SCIENCE, vol. 80, no. 12, December 2002 (2002-12-01), pages 3257 - 3267, XP002503127, ISSN: 0021-8812;;DATABASE WPI Week 200121, Derwent World Patents Index; AN 2001-205416, XP002503129;;MIADOKOVÁ EVA ET AL: ""Diverse biomodulatory effects of glucomannan from Candida utilis."", TOXICOLOGY IN VITRO, vol. 20, no. 5, 18 January 2006 (2006-01-18), pages 649 - 657, XP005480919, ISSN: 0887-2333;;KOGAN G ET AL: ""GLUCOMANNAN FROM CANDIDA UTILIS: STRUCTURAL INVESTIGATION"", FOLIA MICROBIOLOGICA, PRAQUE, CZ, vol. 38, no. 3, 1 January 1993 (1993-01-01), pages 219 - 224, XP009075449, ISSN: 0015-5632;;SÁNCHEZ L ET AL: ""AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons."", JOURNAL OF HEPATOLOGY JAN 1995, vol. 22, no. 1, January 1995 (1995-01-01), pages 119 - 121, XP002487611, ISSN: 0168-8278;;MARTÍN-VILCHEZ S ET AL: ""AM3, a natural glycoconjugate, induces the functional maturation of human dendritic cells."", BRITISH JOURNAL OF PHARMACOLOGY JUN 2008, vol. 154, no. 3, June 2008 (2008-06-01), pages 698 - 708, XP002487612, ISSN: 0007-1188;;SERRANO-GÓMEZ DIEGO ET AL: ""AM3 modulates dendritic cell pathogen recognition capabilities by targeting DC-SIGN."", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY JUL 2007, vol. 51, no. 7, July 2007 (2007-07-01), pages 2313 - 2323, XP002487613, ISSN: 0066-4804;;SPAGNOLI G ET AL: ""CANDIDA ALBICANS AND A PHOSPHORYLATED GLUCOMANNAN-PROTEIN FRACTION OF ITS CELL WALL INDUCE PRODUCTION OF IMMUNE INTERFERON BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS"", IRCS MEDICAL SCIENCE, vol. 13, no. 12, 1985, pages 1190/1191, XP009075382",PENDING
634,US,A1,US 2008/0171002 A1,105-468-901-429-180,2008-07-17,2008,US 78113507 A,2007-07-20,US 78113507 A;;US 83231606 P,2006-07-20,Products For Receptor Mediated Activation And Maturation Of Monocyte-Derived Dendritic Cells By A Phosphorylated Glucomannane Polysaccharide,"Phosphorylated glucomannan polysaccharide compositions are shown to effectively enhance healthy immune function. Dosage forms including pills, sprays, functional foods and cosmetics may achieve this benefit while being essentially free of storage protein from nongerminated seeds of Ricinus communis.",GOURMETCEUTICALS LLC,TUDURI JOSE ANTONIO MATJI;;GOMEZ-PAMO ANTONIO F GUERRERO;;LEBRERO JOSE LUIS ALONSO;;LINDEMANN GARRETT;;CABRERA MANUEL LOPEZ;;RODRIGUEZ PEDRO MAJANO;;OTERO RICARDO MORENO;;GOMEZ DIEGO SERRANO;;LOPEZ ANGEL CORBI;;VILCHEZ SAMUEL MARTIN,GOURMETCEUTICALS LLC (2008-02-26);;CANTABRIA GROUP LLC (2009-03-19),https://lens.org/105-468-901-429-180,Patent Application,yes,4,7,4,4,1,A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10;;A61P37/02;;A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10,A61K31/715;;A61K8/60;;A61K39/00;;A61K39/008;;A61K39/02;;A61K39/04;;A61K39/108;;A61K39/12;;A61K39/21;;A61K39/245;;A61K39/29;;A61K39/395;;A61P37/02;;A61Q1/00;;A61Q1/06;;A61Q1/10;;A61Q3/02;;A61Q9/00;;A61Q17/04;;A61Q19/00,424/59;;514/54;;424/184.1;;424/208.1;;424/204.1;;424/269.1;;424/230.1;;424/228.1;;424/218.1;;424/234.1;;424/259.1;;424/248.1;;424/133.1;;424/64;;424/61;;424/63;;424/65;;424/70.1,0,0,,,,DISCONTINUED
635,EP,A2,EP 2046347 A2,155-061-644-728-92X,2009-04-15,2009,EP 07813187 A,2007-07-20,US 2007/0074029 W;;US 83231606 P,2006-07-20,PHOSPHORYLATED GLUCOMANNAN POLYSACCHARIDE FOR RECEPTOR MEDIATED ACTIVATION AND MATURATION OF MONOCYTE-DERIVED DENDRITIC CELLS,,GOURMETCEUTICALS LLC,TUDURI JOSE ANTONIO MATJI;;RODRIGUEZ PEDRO MAJANO;;CABRERA MANUEL LOPEZ;;LOPEZ ANGEL CORBI;;GOMEZ DIEGO SERRANO;;LEBRERO JOSE LUIS AONSO;;GOMEZ-PAMO ANTONIO F GUERRERO;;VILCHEZ SAMUEL MARTIN;;LINDEMANN GARRETT;;OTERO RICARDO MORENO,,https://lens.org/155-061-644-728-92X,Patent Application,yes,0,0,4,4,0,A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10;;A61P37/02;;A61K31/736;;A61K45/06;;A23L29/244;;A23L33/10,A61K31/736,,0,0,,,,DISCONTINUED
636,CU,A1,CU 22822 A1,184-939-577-465-73X,2003-01-29,2003,CU 1998134 A,1998-09-22,CU 1998134 A,1998-09-22,COMPOSICIONES Y MÉTODOS PARA INHIBIR LA FLORACIÓN DE LA CANA DE AZÚCAR,"La floración de la cana de azúcar puede inhibirse cuando se aplica sobre el follaje, composiciones que contienen cierta cantidad de 1,3-bis-(2,2,2-tricloro-1-hidroxietil) urea con o sin 2,2,2-tricloro-1-1 hidroxietil urea, convenientemente formuladas, después que el cultivo ha ""cerrado"" y antes de que se forme el primordio floral.",CUBANO INST INVEST,ZUAZNABAR ZUAZNABAR RAFAEL;;CABRERA RODRIGUEZ JUAN ADRIANO;;DIAZ DIAZ JUAN CARLOS;;DIAZ DE ARCE PEREIRA CALIXTO JUSTO;;TERRY BELEN JOSE;;MONTANO MARTINEZ RAMON LUIS,,https://lens.org/184-939-577-465-73X,Limited Patent,no,0,0,1,1,0,,A01N47/28,,0,0,,,,EXPIRED
637,EP,A1,EP 4139272 A1,198-054-262-794-029,2023-03-01,2023,EP 21724148 A,2021-04-21,US 202063014758 P;;US 2021/0028280 W,2020-04-24,PROCESSES RELATED TO FORMATION OF ARYLCYCLOPROPYL CARBOXYLIC ACIDS,,CORTEVA AGRISCIENCE LLC,CABRERA VENTURA PABLO JOSE;;CHOY NAKYEN;;GOOD STEFFEN N;;LI FANGZHENG;;MCCUSKER ELIZABETH O;;NELSON PATRICK JAMES;;NISSEN JEFFREY;;ROBINSON MATTHEW ARNEL;;ROSENTHAL TAY,,https://lens.org/198-054-262-794-029,Patent Application,yes,0,0,6,6,0,C12P7/40;;C07C2601/02;;C07B2200/07;;C07C51/305;;C07C61/08;;C12Y301/01003;;A01N53/00;;C07C51/305;;C07C61/08;;C12N9/18;;C12P7/40,C07C51/305;;C07C61/08;;C07C61/40;;C07C69/753;;C12P7/40,,0,0,,,,PENDING
638,CN,A,CN 115485260 A,094-037-891-588-177,2022-12-16,2022,CN 202180028763 A,2021-04-21,US 202063014758 P;;US 2021/0028280 W,2020-04-24,Methods relating to formation of arylcyclopropyl carboxylic acids,"The present disclosure relates to methods of forming aryl cyclopropyl carboxylic acids that can be used to form molecules having pesticidal utility on pests in arthropods, mollusks and nematodes.",KEDIHUA AGRICULTURAL SCIENCE AND TECH CO LTD,CABRERA VENTURA PEDRO JOSE;;CHOY NAKYEN;;GOOD STEVEN N;;LI FANGZHENG;;MCCOCK ERIC O;;NIELSEN PETER J;;NISSEN JEFFREY;;ROBINSON MARK A;;ROSENTHAL TAL,,https://lens.org/094-037-891-588-177,Patent Application,no,0,0,6,6,0,C12P7/40;;C07C2601/02;;C07B2200/07;;C07C51/305;;C07C61/08;;C12Y301/01003;;A01N53/00;;C07C51/305;;C07C61/08;;C12N9/18;;C12P7/40,C07C51/305;;C07C61/08;;C07C61/40;;C07C69/753;;C12P7/40,,0,0,,,,PENDING
639,WO,A1,WO 2021/216629 A1,089-833-107-818-52X,2021-10-28,2021,US 2021/0028280 W,2021-04-21,US 202063014758 P,2020-04-24,PROCESSES RELATED TO FORMATION OF ARYLCYCLOPROPYL CARBOXYLIC ACIDS,"This disclosure relates to processes to form arylcyclopropyl carboxylic acids useful in forming molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda.",CORTEVA AGRISCIENCE LLC,CABRERA VENTURA PABLO JOSE;;CHOY NAKYEN;;GOOD STEFFEN N;;LI FANGZHENG;;MCCUSKER ELIZABETH O;;NELSON PATRICK JAMES;;NISSEN JEFFREY;;ROBINSON MATTHEW ARNEL;;ROSENTHAL TAY,,https://lens.org/089-833-107-818-52X,Patent Application,yes,10,1,6,6,4,C12P7/40;;C07C2601/02;;C07B2200/07;;C07C51/305;;C07C61/08;;C12Y301/01003;;A01N53/00;;C07C51/305;;C07C61/08;;C12N9/18;;C12P7/40,C07C51/305;;C07C61/08;;C07C61/40;;C07C69/753;;C12P7/40,,3,1,002-324-777-090-919,10.1002/1615-4169(20010129)343:1<5::aid-adsc5>3.0.co;2-i,"KEITH, J. M.LARROW, J. F.JACOBSEN, E. N., ADV. SYNTH. CATAL., vol. 343, 2001, pages 5;;DAVID ROZZELL: ""Enzyme Catalysis in Organic Synthesis"", vol. 3, 2012, WILEY-VCH VERLAG GMBH & CO. KGAA, pages: 1849 - 1985;;""UniProt"", Database accession no. P20261",PENDING
640,BR,A2,BR 112022019791 A2,029-408-441-715-119,2022-11-16,2022,BR 112022019791 A,2021-04-21,US 2021/0028280 W;;US 202063014758 P,2020-04-24,PROCESSOS RELACIONADOS À FORMAÇÃO DE ÁCIDOS ARILCICLOPROPIL CARBOXÍLICOS,"PROCESSOS RELACIONADOS À FORMAÇÃO DE ÁCIDOS ARILCICLOPROPIL CARBOXÍLICOS. A presente revelação se refere a processos para formar ácidos arilciclopropilcarboxílicos úteis na formação de moléculas que têm utilidade pesticida contra pragas dos filos Arthropoda, Mollusca e Nematoda.",CORTEVA AGRISCIENCE LLC,FANGZHENG LI;;PABLO JOSE CABRERA VENTURA;;NAKYEN CHOY;;STEFFEN N GOOD;;ELIZABETH O MCCUSKER;;PATRICK JAMES NELSON;;JEFFREY NISSEN;;MATTHEW ARNEL ROBINSON;;TAY ROSENTHAL,,https://lens.org/029-408-441-715-119,Patent Application,no,0,0,6,6,0,C12P7/40;;C07C2601/02;;C07B2200/07;;C07C51/305;;C07C61/08;;C12Y301/01003;;A01N53/00;;C07C51/305;;C07C61/08;;C12N9/18;;C12P7/40,C07C51/305;;C07C61/08;;C07C61/40;;C07C69/753;;C12P7/40,,0,0,,,,PENDING
641,US,A1,US 2023/0220427 A1,039-618-148-098-64X,2023-07-13,2023,US 202117996640 A,2021-04-21,US 202117996640 A;;US 202063014758 P;;US 2021/0028280 W,2020-04-24,PROCESSES RELATED TO FORMATION OF ARYLCYCLOPROPYL CARBOXYLIC ACIDS,"This disclosure relates to processes to form arylcyclopropyl carboxylic acids useful in forming molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda.",CORTEVA AGRISCIENCE LLC,CABRERA VENTURA PABLO JOSE;;CHOY NAKYEN;;GOOD STEFFEN N;;LI FANGZHENG;;MCCUSKER ELIZABETH O;;NELSON PATRICK JAMES;;NISSEN JEFFREY;;ROBINSON MATTHEW ARNEL;;ROSENTHAL TAY,CORTEVA AGRISCIENCE LLC (2021-04-21),https://lens.org/039-618-148-098-64X,Patent Application,yes,0,0,6,6,4,C12P7/40;;C07C2601/02;;C07B2200/07;;C07C51/305;;C07C61/08;;C12Y301/01003;;A01N53/00;;C07C51/305;;C07C61/08;;C12N9/18;;C12P7/40,C12P7/40;;C07C51/305;;C07C61/08;;C12N9/18,,0,0,,,,PENDING
642,AR,A1,AR 054513 A1,032-081-184-046-351,2007-06-27,2007,AR P060102706 A,2006-06-23,CU 20050127 A,2005-06-24,USO DEL INTERFERON ALFA PARA LA OBTENCION DE UN COMPUESTO PARA EL TRATAMIENTO DE LA NEUROMIELITIS OPTICA,La presente esta relacionada con el uso de interferon alfa para la obtencion de un compuesto farmacéutico para el tratamiento de la neuromielitis optica (NMO) o Síndrome de Devic. El IFN alfa (IFN alfa) puede se utilizado como tratamiento en la NMO tanto en la forma monofásica como en la recurrente. El IFN alfa puede combinarse con otros factores de crecimiento como la Eritropoyetina recombinante (EPO rec) aumentando la racionalidad de su uso en esta enfermedad.,CT INGENIERIA GENETICA BIOTECH,CERVANTES LLANOS MAJEL;;PORRERO MARTIN PEDRO JORGE;;BELLO RIVERO IRALDO;;VALENZUELA SILVA CARMEN MARIA;;CABRERA GOMEZ JOSE ANTONIO;;PENTON ROL GISELLE;;LOPEZ SAURA PEDRO,,https://lens.org/032-081-184-046-351,Patent Application,no,0,0,2,2,0,A61K38/212;;A61K38/1816;;A61P27/02,,,0,0,,,,DISCONTINUED
643,EP,A8,EP 2708146 A8,059-445-008-742-58X,2014-09-03,2014,EP 12382360 A,2012-09-17,EP 12382360 A,2012-09-17,Nutritional composition for pregnant women with a beneficial glucose and insulin profile,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.
",ABBOTT LAB,DEWILLE NORMANELLA T;;RUEDA CABRERA RICARDO;;MARRIAGE BARBARA J;;SHERRY CHRISTINA;;WEARLY DOUGLAS J;;LOPEZ PEDROSA JOSE MARIA;;BLUMBERG RACHEL M;;MAZER TERRY B,ABBOTT LABORATORIES (2014-08-20),https://lens.org/059-445-008-742-58X,Patent Application,yes,0,0,2,2,0,A23L2/39;;A23L33/12;;A23L33/15;;A23L33/16;;A23L33/185;;A23L33/19;;A23L33/21;;A23L33/40;;A23P10/40;;A23V2002/00,A23L1/30;;A23L33/00;;A61K31/202,,0,0,,,,DISCONTINUED
644,EP,A1,EP 2708146 A1,090-743-075-340-520,2014-03-19,2014,EP 12382360 A,2012-09-17,EP 12382360 A,2012-09-17,Nutritional composition for pregnant women with a beneficial glucose and insulin profile,"The present disclosure is directed to a nutritional powder, a translucent reconstitutable beverage formed therefrom, and methods relating thereto. The nutritional powder and beverage are adapted to include the proper balance of proteins, lipids, carbohydrates, vitamins and minerals appropriate for a pregnant woman. The nutritional compositions further stem the glycemic response and improve glycemia and insulinemia during gestational and lactating periods for preventing or reduce the incidence of glucose intolerance later in life.
",ABBOTT LAB,DEWILLE NORMANELLA T;;RUEDA CABRERA RICARDO;;MARRIAGE BARBARA J;;SHERRY CHRISTINA;;WEARLY DOUGLAS J;;LOPEZ PEDROSA JOSE MARIA;;BLUMBERG RACHEL M;;MAZER TERRY B,ABBOTT LABORATORIES (2014-08-20),https://lens.org/090-743-075-340-520,Patent Application,yes,7,5,2,2,0,A23L2/39;;A23L33/12;;A23L33/15;;A23L33/16;;A23L33/185;;A23L33/19;;A23L33/21;;A23L33/40;;A23P10/40;;A23V2002/00,A23L33/00;;A23L33/10;;A61K31/202,,0,0,,,,DISCONTINUED
645,MX,A,MX 2009014259 A,147-338-785-492-42X,2011-06-21,2011,MX 2009014259 A,2009-12-21,MX 2009014259 A,2009-12-21,DIDACTIC DEVICE FOR TEACHING THE CHARACTERISTICS OF ANIMAL CELLS AND TISSUES.,"The present invention describes a didactic device for teaching the characteristics of animal cells and tissues 1, which comprises a first three-dimensional model 10 having a forearm and hand shape, and a second three-dimensional model 20 representing an interosseous artery, a third three-dimensional model 40 representing an interosseous vein and a case 60 where the device 1 is stored and transported, each of the aforementioned elements having a structural configuration able to transmit by visual or tactile perception the information and knowledge of the outer anatomy of a posterior forearm, as well as the muscular, venous and arterial anatomy thereof.",CT INVESTIG Y ESTUDIOS DEL IPN,PENA CRISTINA GEHIBIE REYNAGA;;ESCOBEDO DAVID TREVINO;;MORENO JOSE NOE RICO;;PICHARDO MA ELENA BIBRIESCA;;RAMIREZ NORMA CABRERA;;GARCIA ERICK ENRIQUEZ;;ESPINAL LUIS JAVIER MARTINEZ,,https://lens.org/147-338-785-492-42X,Patent Application,no,0,0,1,1,0,,G09B23/00,,0,0,,,,ACTIVE
646,PE,A1,PE 20220535 A1,036-357-938-839-949,2022-04-08,2022,PE 2020001525 A,2020-10-02,PE 2020001525 A,2020-10-02,MODULOS DE HABITABILIDAD E INFRAESTRUCTURA CIVIL POPULAR Y ALTAMENTE RESISTENTES A LAS CONDICIONES AMBIENTALES,"La presente invencion se refiere a un modulo de habitabilidad e infraestructura civil que comprende columnas corredizas, una plataforma inferior, plataforma superior y paneles laterales, en donde la plataforma inferior, la plataforma superior y paneles lat erales estan unidos entre si y con las columnas corredizas por juntas de union. El modulo de la presente invencion puede ser facilmente transportado diferentes lugares, solucionando asi el acceso a la vivienda y a la infraestructura segura.",RAMIREZ OSTOLAZA JOSE ENRIQUE;;QUINTANILLA MORALES JOEL OMAR;;CABRERA COSTA CARLOS ALBERTO;;BOHORQUEZ SOTO HECTOR AUGUSTO;;GALVEZ GARRO SERGIO ANDRES;;BARREDA PEREZ ALCAZAR DIEGO MARTIN,RAMIREZ OSTOLAZA JOSE ENRIQUE;;QUINTANILLA MORALES JOEL OMAR;;CABRERA COSTA CARLOS ALBERTO;;BOHORQUEZ SOTO HECTOR AUGUSTO;;GALVEZ GARRO SERGIO ANDRES;;BARREDA PEREZ ALCAZAR DIEGO MARTIN,,https://lens.org/036-357-938-839-949,Patent Application,no,0,0,1,1,0,,E04B1/19;;E04B1/343,,0,0,,,,PENDING
647,WO,A1,WO 2006/136116 A1,100-909-685-768-063,2006-12-28,2006,CU 2006000005 W,2006-06-23,CU 20050127 A,2005-06-24,USE OF INTERFERON-ALPHA IN ORDER TO OBTAIN A COMPOUND FOR THE TREATMENT OF OPTICAL NEUROMYELITIS,"The invention relates to the use of interferon-alpha in order to obtain a pharmaceutical compound for the treatment of neuromyelitis optica (NMO) or Devic's syndrome. Interferon-alpha (IFN α) can be used as a treatment for NMO in both the monophase form and the relapsing form. In addition, IFN α can be combined with other growth factors such as recombinant erythropoietin (rEPO), thereby increasing the rationale behind its use in relation to said disease.",CT INGENIERIA GENETICA BIOTECH;;PENTON ROL GISELLE;;CERVANTES LLANOS MAJEL;;PORRERO MARTIN PEDRO JORGE;;BELLO RIVERO IRALDO;;VALENZUELA SILVA CARMEN MARIA;;LOPEZ SAURA PEDRO ANTONIO;;CABRERA GOMEZ JOSE ANTONIO,PENTON ROL GISELLE;;CERVANTES LLANOS MAJEL;;PORRERO MARTIN PEDRO JORGE;;BELLO RIVERO IRALDO;;VALENZUELA SILVA CARMEN MARIA;;LOPEZ SAURA PEDRO ANTONIO;;CABRERA GOMEZ JOSE ANTONIO,,https://lens.org/100-909-685-768-063,Patent Application,yes,1,0,2,2,0,A61K38/212;;A61K38/1816;;A61P27/02,A61K38/21;;A61P27/02,,2,1,185-126-898-200-984,12567162;;10.1097/00002826-200301000-00007,"NOSEWORTHY JOHN H: ""Treatment of multiple sclerosis and related disorders: What's new in the past 2 years?"", 2003, CLINICAL NEUROPHARMACOLOGY, VOL. 26, NR. 1, PAGE(S) 28-37, PHILADELPHIA, ISSN: 0362-5664, XP009071976;;DATABASE WPI Section Ch Week 199443, Derwent World Patents Index; Class B04, AN 1994-347064, XP002402334",PENDING
648,WO,A1,WO 2018/178099 A1,039-978-597-957-576,2018-10-04,2018,EP 2018057817 W,2018-03-27,ES 201730595 A,2017-03-31,SYSTEM FOR DISCHARGING A DREDGED MATERIAL COMPRISING A FLOATING MONOBUOY,"The invention relates to a system for discharging a dredged material from the barge of any vessel, hopper or dredger, that is going to discharge to the bed, minimizing dispersion of pollutants and turbidity, and facilitating the connection with the vessel and the discharge, comprising a floating monobuoy and means for guiding material, where the means for guiding material comprise: a) a first section is a floating hose (1) connected between the vessel and an input flange (11); b) a second section is a redirecting circuit of the material; and c) a third submerged section; where the monobuoy (10) is made of two halves that are coupled by means of a screwed joint (14) and where one of the halves of the monobuoy (10) comprises the second section and monobuoy.",NODOSA S L;;CENTRO DE INVESTIG SUBMARINAS S L;;NODOSAFER S L;;SUBSEA MECHATRONICS S L,NOVAS ROSALES JUAN JOSE;;DOPICO MARTINEZ ALBERTO;;DURAN NEIRA CARLOS;;DURAN LOPEZ MIGUEL;;MARTINEZ ROMERO AARON;;SOSA CABRERA DARIO;;SANCHEZ CRESPO LUIS ALBERTO;;VILAN VILAN JOSE ANTONIO;;IZQUIERDO BELMONTE PABLO;;YAÑEZ ALFONSO PABLO;;FERNANDEZ HERMIDA XULIO,,https://lens.org/039-978-597-957-576,Patent Application,yes,4,0,3,3,0,B63B22/00;;B63B22/24;;B63B27/34;;E02F7/10;;E02F7/10,B63B22/00;;E02F7/10,,0,0,,,,PENDING
649,GB,A,GB 2541167 A,100-915-527-779-286,2017-02-15,2017,GB 201513163 A,2015-07-27,GB 201513163 A,2015-07-27,A long route EGR valve for a turbocharged automotive system,"A long route, low pressure Exhaust Gas Recirculation (EGR) valve 500 comprising a three-port valve having a duct 510 with inlet 520 and outlet 530, the outlet 530 being provided with a compressor wheel seat 570, the duct 510 connecting an air intake duct (205, Fig. 3) with a turbocharger compressor (240, Fig. 3) inlet and being intercepted by a first flap 550; a passage 540 connecting a long route EGR circuit outlet with the duct 510 and being intercepted by a second flap 560, wherein the passage 540 is inclined with respect to the duct 510 by an angle of inclination (a) comprised between 30° and 70°; a distance (b) from a downstream outlet 585 of the passage 540 into the duct 510 to the compressor wheel seat 570 is between 0 and 2.5 times the diameter of the compressor wheel, and a distance (c) from the second flap 560 to an upstream outlet 565 of the passage 540 into the duct 510 is between 1 and 3 times the diameter of the passage 540. The duct 510 may have a tapered portion 590.",GM GLOBAL TECH OPERATIONS LLC,JOAQUIN DE LA MORENA;;ALBERTO RACCA;;CESARE MARIA MEANO;;JESÚS VICENTE BENAJES CALVO;;JOSÉ MARIA DESANTES FERNÁNDEZ;;JOSE GALINDO LUCAS;;ROBERTO NAVARRO GARCIA;;PEDRO PIQUERAS CABRERA,,https://lens.org/100-915-527-779-286,Patent Application,no,4,0,2,2,0,F02M26/70;;F02M26/70;;F02M26/06;;F02M26/17;;F02M26/17;;F02M26/19;;F02M26/51;;F02M26/51;;F02M26/64;;F02M26/64;;F16K1/22;;F16K11/10;;F16K11/22,F02M26/70;;F02M26/17;;F02M26/51;;F02M26/64;;F16K11/10,,0,0,,,,DISCONTINUED
650,MX,A,MX 2011013595 A,159-000-711-980-428,2013-06-17,2013,MX 2011013595 A,2011-12-15,MX 2011013595 A,2011-12-15,METHODS TO OBTAIN DROUGHT RESISTANT PLANTS.,"The present invention provides a non-toxic method for the selection of transformed cells from a population consisting in transformed and non-transformed cells. The method comprises the following steps: a) introducing into a cell at least one nucleotide sequence of interest and at least one selection nucleotide sequence to obtain genetically transformed cells, where the selection nucleotide sequence comprises a sequence promoting the inhibition of endogenous trehalase enzyme; b) placing the population of transformed and untransformed cells in a culture medium containing an osmoregulating substance such as PEG 8000; c) selecting the transformed cells from the population based on the ability of transformed cells to survive and grow in the presence of the osmoregulating substance conferring the plants derived from these genetic transformation events, for example, drought and/or cold tolerance capacity.",CT INVESTIG Y ESTUDIOS DEL IPN,PONCE JOSE LUIS CABRERA;;MEDRANO ROBERTO RUIZ;;CAZARES BEATRIZ XOCONOSTLE;;LUNA ROBERTO MONTES DE OCA;;ESTRELLA LUIS RAFAEL HERRERA;;ALEJANDRA AGREDA LAGUNA KENNY;;ESCOBEDO ANALI GAMEZ,,https://lens.org/159-000-711-980-428,Patent Application,no,0,0,2,9,0,,A01H1/00;;C12N15/00,,0,0,,,,ACTIVE
651,PE,A1,PE 20190697 A1,001-715-643-724-674,2019-05-15,2019,PE 2018002266 A,2018-10-29,PE 2018002266 A,2018-10-29,PROCEDIMIENTO PARA LA PRODUCCION DE AMILASA TERMOESTABLE POR GEOBACILLUS THERMOPARAFFINIVORANS,Procedimiento que describe la produccion de una enzima amilasa a partir de una bacteria termofila identificada como Geobacillus thermoparaffinivorans a partir de un medio de induccion que utiliza un sustrato natural basado en almidon de yuca para la obtencion de un extracto crudo parcialmente purificado que contiene una enzima amilasa termoestable con potencial para ser utilizada a nivel industrial,UNIV NACIONAL JORGE BASADRE GROHMANN,DELGADO TELLO PELAYO;;ZUNIGA LLANOS ARIADNA ZATYURI;;NAQUICHE CALERO ANA JULISSA;;SALAZAR QUISPE ISRAEL JOSE;;RAMIREZ ARUA HEBER ESAU;;YLLANES HUANACUNI MIRELLA VERONICA;;CASTELLANOS CABRERA ROBERTO,,https://lens.org/001-715-643-724-674,Patent Application,no,0,0,1,1,0,,C12N9/14,,0,0,,,,PENDING
652,CN,A,CN 103403168 A,078-467-778-832-326,2013-11-20,2013,CN 201180065001 A,2011-12-17,IB 2011055757 W;;MX 2010014428 A;;MX 2011013595 A,2010-12-21,Methods to obtain drought resistant plants,"The present invention provides a nontoxic method for the selection of transformed cells from a cell population consisting of transformed and untransformed cells. The method comprises the following steps: a) introducing into a cell at least one nucleotide sequence of interest and at least one selection nucleotide sequence to obtain genetically transformed cells, where the selection nucleotide sequence comprises a sequence promoting the inhibition of endogenous trehalase enzyme; b) placing the population of transformed and untransformed cells in a culture medium containing an osmoregulating substance such as PEG 8000; c) selecting the transformed cells from the population based on the ability of transformed cells to survive and grow in the presence of the osmoregulating substance conferring the plants derived from these genetic transformation events, for example, drought and/or cold tolerance capacity.",CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV AUTONOMA DE NUEVO LEON,AGREDA LAGUNA KENNY ALEJANDRA;;CABRERA PONCE JOSE LUIS;;GAMEZ ESCOBEDO ANALI;;HERRERA ESTRELLA LUIS RAFAEL;;MONTES DE OCA LUNA ROBERTO;;RUIZ MEDRANO ROBERTO;;XOCONOSTLE CAZARES BEATRIZ,,https://lens.org/078-467-778-832-326,Patent Application,no,3,3,5,9,0,C12N15/82;;C12N15/821;;C12N9/2402;;C12N15/8273,C12N15/82;;C12N9/24,,3,0,,,"GUO BEI等: ""Inhibition of gene expression of trehalase enhances drought resistance in transgenic tobacco"", 《BIOINFORMATICS AND BIOMEDICAL ENGINEERING(ICBBE)，2010 4TH INTERNATIONAL CONFERENCE ON，IEEE》, 18 June 2010 (2010-06-18), pages 3 - 4, XP031713448;;GARCIA-VALENZUELA X等: ""Chlorophyll accumulation is enhanced by osmotic stress in graminaceous chlorophyllic cells"", 《JOURNAL OF PLANT PHYSIOLOGY》, vol. 162, no. 6, 14 June 2005 (2005-06-14), pages 650 - 661;;GODDIJN O J M 等: ""INHIBITION OF TREHALASE ACTIVITY ENHANCES TREHALOSE ACCUMULATION IN TRANSGENIC PLANTS"", 《PLANT PHYSIOLOGY》, vol. 113, no. 1, 31 January 1997 (1997-01-31), pages 181 - 190",DISCONTINUED
653,WO,A1,WO 2012/085806 A1,137-289-473-397-553,2012-06-28,2012,IB 2011055757 W,2011-12-17,MX 2010014428 A;;MX 2011013595 A,2010-12-21,METHODS TO OBTAIN DROUGHT RESISTANT PLANTS,"The present invention provides a nontoxic method for the selection of transformed cells from a cell population consisting of transformed and untransformed cells. The method comprises the following steps: a) introducing into a cell at least one nucleotide sequence of interest and at least one selection nucleotide sequence to obtain genetically transformed cells, where the selection nucleotide sequence comprises a sequence promoting the inhibition of endogenous trehalase enzyme; b) placing the population of transformed and untransformed cells in a culture medium containing an osmoregulating substance such as PEG 8000; c) selecting the transformed cells from the population based on the ability of transformed cells to survive and grow in the presence of the osmoregulating substance conferring the plants derived from these genetic transformation events, for example, drought and/or cold tolerance capacity.",CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV AUTONOMA DE NUEVO LEON;;AGREDA LAGUNA KENNY ALEJANDRA;;CABRERA PONCE JOSE LUIS;;GAMEZ ESCOBEDO ANALI;;HERRERA ESTRELLA LUIS RAFAEL;;MONTES DE OCA LUNA ROBERTO;;RUIZ MEDRANO ROBERTO;;XOCONOSTLE CAZARES BEATRIZ,AGREDA LAGUNA KENNY ALEJANDRA;;CABRERA PONCE JOSE LUIS;;GAMEZ ESCOBEDO ANALI;;HERRERA ESTRELLA LUIS RAFAEL;;MONTES DE OCA LUNA ROBERTO;;RUIZ MEDRANO ROBERTO;;XOCONOSTLE CAZARES BEATRIZ,,https://lens.org/137-289-473-397-553,Patent Application,yes,14,2,5,9,18,C12N15/82;;C12N15/821;;C12N9/2402;;C12N15/8273,C12N15/82;;C12N9/24,,62,36,007-101-342-027-201;;067-176-682-991-059;;037-625-262-431-146;;016-580-821-413-537;;094-178-178-231-198;;115-265-484-058-501;;005-121-586-918-903;;058-931-232-336-479;;052-461-814-608-604;;042-092-149-876-575;;110-585-268-960-411;;114-959-613-324-053;;078-478-916-019-776;;022-649-038-860-554;;059-204-761-350-781;;016-028-774-308-873;;070-670-168-393-832;;045-102-370-451-010;;135-214-954-217-729;;146-311-180-787-296;;103-359-192-903-12X;;106-071-642-863-273;;109-098-879-790-112;;005-426-269-619-00X;;028-023-674-328-597;;063-233-442-483-648;;188-764-498-548-821;;178-802-849-216-987;;064-355-943-218-772;;070-272-395-383-438;;058-816-599-846-72X;;034-783-540-724-358;;138-852-278-572-615;;148-146-081-103-887;;041-297-141-243-194;;049-729-818-340-226,16008087;;10.1016/j.jplph.2004.09.015;;10.1109/icbbe.2010.5516954;;pmc158129;;9008394;;10.1104/pp.113.1.181;;10.1093/pcp/pcm080;;17597080;;10.1007/bf02866600;;10.1023/a:1026077825584;;14606934;;16014364;;10.1093/jxb/eri232;;15592808;;10.1007/s00122-004-1859-6;;10.2135/cropsci1993.0011183x003300020011x;;10.2135/cropsci1993.0011183x003300020012x;;10.1073/pnas.98.4.2104;;11172083;;pmc29389;;10.1007/bf02908218;;10.1139/x91-163;;10.1080/00173139509429031;;10.1007/bf02860472;;10.1002/j.1537-2197.1980.tb07730.x;;10.1093/jhered/esm002;;17400586;;10.1038/72608;;10657121;;10.1007/bf02871713;;10.1007/s001220100549;;10.1073/pnas.80.15.4803;;6308651;;pmc384133;;10.1016/j.fcr.2006.04.005;;17069387;;10.1890/1051-0761(2006)016[1967:rfotvn]2.0.co;2;;10657122;;10.1038/72616;;19865519;;pmc2769160;;10.3390/ijms10093793;;10.2135/cropsci2001.4151551x;;10722384;;10.1126/science.287.5457.1399c;;10.2307/3898455;;10.1111/j.1469-8137.2007.02247.x;;17961132;;10.1021/jf950565s;;10.1038/313810a0;;3974711;;15356392;;10.1023/b:plan.0000040903.66496.a4;;10.2307/1218645;;10.2134/agronj1972.00021962006400040004x;;10.1007/bf02866877;;10.1093/oxfordjournals.pcp.a029156;;9150600,"GARCIA-VALENZUELA X ET AL: ""Chlorophyll accumulation is enhanced by osmotic stress in graminaceous chlorophyllic cells"", JOURNAL OF PLANT PHYSIOLOGY, FISCHER, STUTTGART, DE, vol. 162, no. 6, 14 June 2005 (2005-06-14), pages 650 - 661, XP025312843, ISSN: 0176-1617, [retrieved on 20050614], DOI: 10.1016/J.JPLPH.2004.09.015;;BEI GUO ET AL: ""Inhibition of Gene Expression of Trehalase Enhances Drought Resistance in Transgenic Tobacco"", BIOINFORMATICS AND BIOMEDICAL ENGINEERING (ICBBE), 2010 4TH INTERNATIONAL CONFERENCE ON, IEEE, PISCATAWAY, NJ, USA, 18 June 2010 (2010-06-18), pages 1 - 4, XP031713448, ISBN: 978-1-4244-4712-1;;GODDIJN O J M ET AL: ""INHIBITION OF TREHALASE ACTIVITY ENHANCES TREHALOSE ACCUMULATION IN TRANSGENIC PLANTS"", PLANT PHYSIOLOGY, AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, US, vol. 113, no. 1, 1 January 1997 (1997-01-01), pages 181 - 190, XP002043745, ISSN: 0032-0889, DOI: 10.1104/PP.113.1.181;;CHANG CHING-CHUN ET AL: ""Transactivation of protein expression by rice HSP101 in planta and using Hsp101 as a selection marker for transformation."", PLANT & CELL PHYSIOLOGY AUG 2007 LNKD- PUBMED:17597080, vol. 48, no. 8, August 2007 (2007-08-01), pages 1098 - 1107, XP009158095, ISSN: 0032-0781;;AGUIRRE-GOMEZ, J.A.: ""A regional analysis of maize biological diversity in Southeastern Guanajuato, Mexico"", ECONOMIC BOTANY, vol. 54, no. 1, 2000, pages 60 - 72;;ALLAGULOVA CHR; GIMALOV FR; SHAKIROVA FM; VAKHITOV VA: ""The plant dehydrins: structure and putative functions"", BIOCHEMISTRY (MOSC, vol. 68, no. 9, September 2003 (2003-09-01), pages 945 - 51, XP009079176, DOI: doi:10.1023/A:1026077825584;;AYLOR E.D.: ""Some physical properties of teosinte (Zea mays subsp. parviglumis) pollen"", J EXP BOT, vol. 56, no. 419, 2005, pages 2401 - 2407;;BALTAZAR M.B: ""Maize pollen biology, pollen drift and transgenes"", PROC 56TH CORNAND SORGHUM SEED RES CONF., 2001;;BALTAZAR M.B.: ""Assessment of potential impact of hybridization between teosinte (Zea spp.) and maize (Zea mays spp. mays) on dormancy characteristics of teosinte"", GENE FLOW SYMPOSIUM AT THE NORTH CENTER, 2007;;BALTAZAR M.B.: ""Pollination between maize and teosinte: an important determinant of gene flow in Mexico"", THEOR APPL GENET., vol. 110, 2005, pages 519 - 526, XP019321822, DOI: doi:10.1007/s00122-004-1859-6;;BASSETTI P.: ""Emergence, elongation, and senescence of maize silks"", CROP SCI., vol. 33, 1993, pages 271 - 275;;BASSETTI P.: ""Senescence and receptivity of maize silks"", CROP SCI., vol. 33, 1993, pages 275 - 278;;BENZ, B.F.: ""Archaeological evidence of teosinte domestication from Guila Naquitz, Oaxaca"", PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 2104 - 2106;;BELLON M.R.: ""Keepers of maize in Chiapas"", MEXICO. ECON. BOT., vol. 48, 1994, pages 196 - 209;;""CIMMYT"", article ""ProcForum: gene flow among maize landraces, improved maize varieties, and teosinte: implications for transgenic maize"", pages: 44 - 53;;CASTILLO G.F.: ""Proc Forum: gene flow among maize landraces, improved maize varieties, and teosinte: implications for transgenic maize"", 1997, article ""Research on gene flow between improved land races"", pages: 67 - 72;;CASTRO-GIL M.: ""Frequencies of maize by teosinte crosses in a simulation of a natural association"", MAIZE GEN. COOP. NEWSLETTER, vol. 44, 1970, pages 21 - 24;;CERVANTES M.J.E.: ""infiitracion genetica entre variedades locales e introducidas de maiz de sistema tradicional de Cuzalapa"", PHD THESIS, 1998, Retrieved from the Internet <URL:http://www.cimmyt.org>;;CLEGG, J.S.: ""Membranes, Metabolism and Dry Organisms"", 1985, CORNELL UNIVERSITY PRESS, article ""The physical properties and metabolic status of Artemia cysts at low water contents: ''The water replacement hypothesis"", pages: 169 - 187;;DE LA CRUZ L.: ""Sistemas de incompatibilidad genetica en maiz y teosinte (Zea spp."", MEXICO.TESIS DOCTORAL., 2007;;DENG, M.Y.: ""Technical Report MSL-16214"", 1999, MONSANTO COMPANY, article ""Molecular Characterization of Roundup Ready Corn Line NK603"";;DI-GIOVANNI F.: ""Factors affecting pollen dynamics and its importance to pollen contamination: a review"", CAN. J. FOR. RES., vol. 21, 1991, pages 1155 - 1170;;DI-GIOVANNI F: ""The variability in settling velocities of some pollen and spores"", GRANA, vol. 34, 1995, pages 39 - 44;;DOEBLEY, J. F.: ""Molecular evidence and the evolution of maize"", ECON. BOT., vol. 44, no. 3, 1990, pages 6 - 27;;DOEBLEY J.F.: ""Taxonomy of Zea (Gramineae). II. A subgeneric classification with key to taxa"", AMER. J. BOTANY, vol. 67, 1980, pages 982 - 993;;ELLSTRAND N.C.: ""Spontaneous hybridization between maize and teosinte"", J. OF HERED., vol. 98, no. 2, 2007, pages 183 - 187;;EROGLU, A.: ""Intracellular trehalose improves the survival of cryopreserved mammalian cells"", NAT. BIOTECHNOL., vol. 18, 2000, pages 163 - 167, XP008119934, DOI: doi:10.1038/72608;;EUBANKS M.W.: ""The mysterious origin of maize"", ECON. BOT., vol. 55, 2001, pages 492 - 514;;EVANS M.M.S.: ""Teosinte crossing barrier1, a locus governing hybridization of teosinte with maize"", THEOR. APPL. GENET., vol. 103, 2001, pages 259 - 265, XP002181800, DOI: doi:10.1007/s001220100549;;FINK, L.A.: ""Expression of bacterial genes in plant cells"", PROC NAT ACAD SCI U.S.A., vol. 80, no. 15, 1983, pages 4803 - 07, XP001062995, DOI: doi:10.1073/pnas.80.15.4803;;GOGGI, A.S.: ""Statistical analysis of outcrossing between adjacent maize grain production fields"", FIELD CROPS RESEARCH, 2006;;GOULD, F.W.: ""Grass Systematics"", 1968, MCGRAW HILL;;GUADAGNUOLO R.: ""Relative fitness of transgenic vs. non-transgenic maize x teosinte hybrids: a field evaluation"", ECOL. APPL., vol. 16, no. 5, 2006, pages 1967 - 1974;;GUO, N.: ""Trehalose expression confers desiccation tolerance on human cells"", NAT. BIOTECH., vol. 18, 2000, pages 168 - 171, XP002952290, DOI: doi:10.1038/72616;;ITURRIAGA G; SUAREZ R; NOVA-FRANCO B.: ""Trehalose metabolism: from osmoprotection to signaling"", INT J MOL SCI., vol. 10, 2009, pages 3793 - 810;;JONES, J.M.: ""Effectiveness and distance of border rows in preventing outcrossing in corn"", OKLAHOMA AGRIC. EXP. POLLEN STA. TECH. BULL. NO. T-38, 1950;;JUGENHEIMER, R.W.: ""Maize Improvement, Seed Production, and Uses"", 1976, JOHN WILEY & SONS, INC.;;KATO Y.T.A., REVIEW OF INTROGRESSION BETWEEN MAIZE AND TEOSINTE, 1997;;KERMICLE J.: ""Proc Forum: Gene flow among maize landraces, improved maize varieties, and teosinte: implications for transgenic maize. CIMMYT"", 1997, article ""Cross compatibility within the genus Zea"", pages: 43;;KIESSELBACH, T.A.: ""Agricultural Experiment Station"", 1949, UNIVERSITY OF NEBRASKA PRESS, article ""The structure and reproduction of corn. Re- print of: Research Bulletin No. 161."", pages: 93;;KERMICLE J.. L.: ""Tables and pathways, p. 306 in Mutants of Maize"", 1997, COLD SPRING HARBOR LABORATORY PRESS;;KIESSELBACH T.A.: ""The structure and reproduction of corn, 50th anniversary"", 1999, COLD SPRING HARBOR LABORATORY PRESS;;LUNA V.S.: ""Maize pollen longevity and distance isolation requirements for effective pollen control"", CROP SCI, vol. 41, 2001, pages 1551 - 1557;;MANGELSDORF, P. C.: ""The probable origin of annual teosintes"", vol. 10, 1981, BUSSEY INST., HARVARD UNIV. PUBL., pages: 1 - 69;;MARTINEZ-SORIANO J.P.R., TRANSGENIC MAIZE IN MEXICO: NO NEED FOR CONCERN. SCI., vol. 278, no. 5457, 2000, pages 1399;;MONDRUS-ENGLE, M.: ""Tetraploid perennial teosinte seed dormancy and germination"", J. OF RANGE MANAG., vol. 34, no. 1, 1981, pages 59 - 61;;MONTALVO-HERNÁNDEZ L; PIEDRA-IBARRA E; G6MEZ-SILVA L; LIRA-CARMONA R; ACOSTA-GALLEGOS JA; VAZQUEZ-MEDRANO J; XOCONOSTIE-CAZARES B: ""Differential accumulation of mRNAs in drought-tolerant and susceptible common bean cultivars in response to water deficit"", NEW PHYTOL., vol. 177, 2008, pages 102 - 13, XP002715271, DOI: doi:10.1111/j.1469-8137.2007.02247.x;;NIDA, D.L.: ""Glyphosate-Tolerant Cotton: The Composition of the Cottonseed Is Equivalent to That of Conventional Cottonseed"", J. AGRIC. FOOD CHEM., vol. 44, 1996, pages 1967 - 1974;;ODE J. T.: ""Identification of DNA sequences required for activity of the cauliflower mosaic virus 35s promoter"", NATURE, vol. 313, 1985, pages 810 - 12, XP002915192, DOI: doi:10.1038/313810a0;;""Consensus document on compositional considerations for new varieties of maize (Zea mays): key food and feed nutrients, anti-nutrients and secondary plant metabolites"", 2002, ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT, ENVIRONMENTAL HEALTH AND SAFETY PUBLICATIONS;;PUHAKAINEN T; HESS MW; MÄKELÄ P; SVENSSON J; HEINO P; PALVA ET: ""Overexpression of multiple dehydrin genes enhances tolerance to freezing stress in Arabidopsis"", PLANT MOL BIOL., vol. 54, no. 5, March 2004 (2004-03-01), pages 743 - 53, XP002550088, DOI: doi:10.1023/B:PLAN.0000040903.66496.a4;;PURSEGLOVE, J. W.: ""Purseglove, J.W."", 1972, LONGMAN GROUP LIMITED., article ""Tropical Crops: Monocotyledons 1"";;RAYNOR, G.S.; OGDEN, E.C.; HAYES, J.V.: ""Dispersion and deposition of corn pollen from experimental sources"", AGRONOMY JOURNAL, vol. 64, 1972, pages 420 - 427;;ROSER, B., A SWEETER WAY TO FRESH FOOD. NEW SCI., vol. 138, 1993, pages 25 - 28;;ROSSI D., MAIZ TOLERANTE A SEQUFA: EL EVENTO ESPERADO, 2009, Retrieved from the Internet <URL:www.engormix.com/MA- agricultura/maiz/foros>;;WATSON, L.: ""Grass Genera of the World: Descriptions, Illustrations, Identification, and Information Retrieval"", SYNONYMS, MORPHOLOGY, ANATOMY, PHYSIOLOGY, PHYTOCHEMISTRY, CYTOLOGY, CLASSIFICATION, PATHOGENS, WORLD AND LOCAL DISTRIBUTION, AND REFERENCES, 1992;;WATSON, S.A.: ""CRC Handbook of Processing and Utilization in Agriculture, Volume II: Part 1 Plant Products"", vol. II, 1982, CRC PRESS, INC., article ""Maize: Amazing Maize. General Properties"", pages: 3 - 29;;WATSON, S.A.: ""Structure and composition"", CORN: CHEMISTRY AND TECHNOLOGY, 1987;;WILKES H.G.: ""Teosinte: the closest relative of maize"", 1967, BUSSEY INST. HARVARD UNIV., pages: 159;;WILKES H.G.: ""Hybridization of maize and teosinte in Mexico and Guatemala and the improvement of maize"", ECON BOT, vol. 31, 1977, pages 254 - 293;;""International Program on Chemical Safety"", 1999, WHO;;YOON IS; MORI H; KIM JH; KANG BG; IMASEKI H.: ""VR-ACS6 is an auxin-inducible 1-aminocyclopropane-1-carboxylate synthase gene in mungbean (Vigna radiata"", PLANT CELL PHYSIOL., vol. 38, no. 3, March 1997 (1997-03-01), pages 217 - 24",PENDING
654,WO,A1,WO 2018/178088 A1,055-210-593-052-800,2018-10-04,2018,EP 2018057800 W,2018-03-27,ES 201730594 A,2017-03-31,AUTONOMUS DREDGING UNDERWATER DEVICE,"An autonomous dredging underwater device for moving along the bed and suction dredging it, mitigating the environmental impact of its operation which operates in cooperation with a surface support unit, whether floating or on land, which carries out functions such as collecting dredged material, supplying the device electrically and hydraulically, and providing communication means for supervision and/or control which comprises: a) a structural frame (1); b) a drive system (2) with four motorized wheels; c) a dredging unit (3) in which the frame (1) and the drive system (2) constitute a hood around the same to contain the turbidity which is produced during displacement and dredging; d) a concentrator (4); e) a guide system which allows displacement, both remote- controlled by an operator and autonomously according to a predefined route; and f) a flexible tube and associated method.",NODOSA S L;;CENTRO DE INVESTIG SUBMARINAS S L;;NODOSAFER S L;;SUBSEA MECHATRONICS S L,NOVAS ROSALES JUAN JOSE;;DOPICO MARTINEZ ALBERTO;;DURAN NEIRA CARLOS;;DURAN LOPEZ MIGUEL;;MARTINEZ ROMERO AARON;;SOSA CABRERA DARIO;;SANCHEZ CRESPO LUIS ALBERTO;;VILAN VILAN JOSE ANTONIO;;IZQUIERDO BELMONTE PABLO;;YAÑEZ ALFONSO PABLO;;FERNANDEZ HERMIDA XULIO,,https://lens.org/055-210-593-052-800,Patent Application,yes,11,5,3,3,0,E02F3/8866;;E02F3/8866;;E02F3/9237;;E02F9/2045,E02F3/88;;B63G8/00;;E02F3/92;;E02F9/20,,0,0,,,,PENDING
655,MX,B,MX 350652 B,165-778-442-091-589,2017-08-22,2017,MX 2011013595 A,2011-12-15,MX 2011013595 A,2011-12-15,METHODS TO OBTAIN DROUGHT RESISTANT PLANTS.,"The present invention provides a non-toxic method for the selection of transformed cells from a population consisting in transformed and non-transformed cells. The method comprises the following steps: a) introducing into a cell at least one nucleotide sequence of interest and at least one selection nucleotide sequence to obtain genetically transformed cells, where the selection nucleotide sequence comprises a sequence promoting the inhibition of endogenous trehalase enzyme; b) placing the population of transformed and untransformed cells in a culture medium containing an osmoregulating substance such as PEG 8000; c) selecting the transformed cells from the population based on the ability of transformed cells to survive and grow in the presence of the osmoregulating substance conferring the plants derived from these genetic transformation events, for example, drought and/or cold tolerance capacity.",CENTRO DE INVESTIGACION Y DE ESTUDIOS AVANZADOS DEL I P N,JOSE LUIS CABRERA PONCE;;ROBERTO RUIZ MEDRANO;;BEATRIZ XOCONOSTLE CÁZARES;;ROBERTO MONTES DE OCA LUNA;;LUIS RAFAEL HERRERA ESTRELLA;;AGREDA LAGUNA KENNY ALEJANDRA;;ANALÍ GAMEZ ESCOBEDO,,https://lens.org/165-778-442-091-589,Granted Patent,no,0,0,2,9,0,,C12N15/82;;A01H1/04,,0,0,,,,ACTIVE
656,GB,A,GB 2546538 A,166-470-353-998-774,2017-07-26,2017,GB 201601214 A,2016-01-21,GB 201601214 A,2016-01-21,A compressor housing,"A compressor housing 500 comprising a compressor inlet duct 535 and an inlet 550 for a compressor wheel 520, the compressor inlet duct having a longitudinal axis A-A and connecting an air intake duct 205 with the compressor wheel inlet. The compressor housing comprises at least one appendix 510, placed between an upstream portion 545 of the compressor inlet duct and the compressor wheel inlet. The appendix comprises a pipe 600 closed in a distal part 560 thereof with respect to the longitudinal axis A-A of the compressor inlet duct. The appendix may protrude externally to the surface 555 of the compressor housing, the appendix may have an inclined axis in respect to the compressor inlet duct axis, the angle of inclination of said axis may be between 10 to 170 degrees or 10 to 90 degrees. The compressor may also be combined with an automotive system. The compressor may furthermore form part of a turbocharger, rotationally coupled to a turbine. The compressor appendix may enlarge the operative portion of the compressor and may reduce and dampen compressor noise.",GM GLOBAL TECH OPERATIONS LLC,ALBERTO RACCA;;CESARE MARIA MEANO;;JESÚS VICENTE BENAJES CALVO;;JOSÉ MARIA DESANTES FERNÁNDEZ;;JOSE GALINDO LUCAS;;ROBERTO NAVARRO GARCIA;;PEDRO PIQUERAS CABRERA;;JOAQUIN DE LA MORENA BORJA,,https://lens.org/166-470-353-998-774,Patent Application,no,4,0,5,5,0,F04B39/0055;;F04D29/441;;F04D29/441;;F04D29/665;;F04B39/12;;F04D29/4213;;F04D29/4213;;F04D29/4213;;F04D29/66;;F04D29/665,F04D29/66;;F04D29/42,,0,0,,,,DISCONTINUED
657,US,A1,US 2012/0303337 A1,108-576-010-248-412,2012-11-29,2012,US 201113229946 A,2011-09-12,ES 201130884 A,2011-05-27,SYSTEMS AND METHODS FOR IMPROVING THE EXECUTION OF COMPUTATIONAL ALGORITHMS,"The invention refers to systems and methods to optimize the memory and communications that suits the memory organization of many scientific codes, such as Computer Fluid Dynamics codes, that operate on meshes, such the mesh of an object that moves through a fluid medium. The methods adjust the order in which the data are used inside the algorithm, by means of traversing and ordering the mesh. This ordered mesh is streamed into the lower memory levels and allows for minimal data transfer requirements. The method also reduces the memory needs dramatically and improves the execution time of the scientific code. The systems and methods are particularly useful in the aeronautic industry for designing new aircrafts.",BARRIO LOPEZ-CORTIJO PABLO;;CARRERAS VAQUER CARLOS;;SIERRA CABRERA ROBERTO;;LOPEZ MARTIN JUAN ANTONIO;;CAFFARENA FERNANDEZ GABRIEL;;SEDANO ALGARABEL ENRIQUE;;FERNANDEZ DE BLAS JOSE ANTONIO;;JEVTIC RUZICA;;UNIV MADRID POLITECNICA;;AIRBUS OPERATIONS SL,BARRIO LOPEZ-CORTIJO PABLO;;CARRERAS VAQUER CARLOS;;SIERRA CABRERA ROBERTO;;LOPEZ MARTIN JUAN ANTONIO;;CAFFARENA FERNANDEZ GABRIEL;;SEDANO ALGARABEL ENRIQUE;;FERNANDEZ DE BLAS JOSE ANTONIO;;JEVTIC RUZICA,AIRBUS OPERATIONS S.L (2011-12-19);;UNIVERSIDAD POLITECNICA DE MADRID (2011-12-19),https://lens.org/108-576-010-248-412,Patent Application,yes,4,1,2,2,0,G06F2111/10;;G06F30/23;;G06F30/20;;G06F30/20;;G06F30/23;;G06F2111/10;;G06F30/28,G06F17/13;;G06F7/00;;G06F17/10;;G06F17/16;;G06G7/72,703/2;;708/520;;708/207,0,0,,,,INACTIVE
658,ES,B1,ES 2461896 B1,156-992-917-880-196,2015-03-18,2015,ES 201350005 A,2011-12-17,MX 2010014428 A;;MX 2011013595 A;;IB 2011055757 W,2010-12-21,Métodos para obtener plantas resistentes a sequía,,,AGREDA LAGUNA KENNY ALEJANDRA;;RUIZ MEDRANO ROBERTO;;XOCONOSTLE CAZARES GUADALUPE BEATRIZ;;CABRERA PONCE JOSE LUIS;;HERRERA ESTRELLA LUIS RAFAEL;;MONTES DE OCA LUNA ROBERTO;;GAMEZ ESCOBEDO IDALIA ANALI,,https://lens.org/156-992-917-880-196,Granted Patent,no,0,0,5,9,0,C12N15/82;;C12N15/821;;C12N9/2402;;C12N15/8273,C12N15/82,,0,0,,,,ACTIVE
659,ES,B2,ES 2337756 B2,051-357-876-596-673,2011-09-14,2011,ES 200930476 A,2009-07-17,ES 200930476 A,2009-07-17,FILTRO MULTIMODO DE MICROONDAS ABIERTO EN TECNOLOGIA DE GUIA DE ONDA MEDIANTE LA COMBINACION DE POSTES E IRIS PARA HORNOS DE CALENTAMIENTO POR MICROONDAS,,UNIV CARTAGENA POLITECNICA,LOZANO GUERRERO ANTONIO;;DIAZ MORCILLO ALEJANDRO;;PEDRENO MOLINA JUAN LUIS;;DIAZ GARCIA JOSEFA;;MONZO CABRERA JUAN;;BANOS TUDELA JOSE MARIA;;MENDEZ HERNANDEZ PEDRO ANDRES;;CLEMENTE FERNANDEZ FRANCISCO JAVIE,,https://lens.org/051-357-876-596-673,Granted Patent,no,0,0,2,2,0,H01P1/207;;H05B6/76,H01P1/207;;H05B6/76,,0,0,,,,ACTIVE
660,ES,R1,ES 2461896 R1,033-025-834-658-596,2014-06-02,2014,ES 201350005 A,2011-12-17,MX 2010014428 A;;MX 2011013595 A;;IB 2011055757 W,2010-12-21,Métodos para obtener plantas resistentes a sequía,,,AGREDA LAGUNA KENNY ALEJANDRA;;RUIZ MEDRANO ROBERTO;;XOCONOSTLE CAZARES GUADALUPE BEATRIZ;;CABRERA PONCE JOSE LUIS;;HERRERA ESTRELLA LUIS RAFAEL;;MONTES DE OCA LUNA ROBERTO;;GAMEZ ESCOBEDO IDALIA ANALI,,https://lens.org/033-025-834-658-596,Unknown,no,6,0,5,9,0,C12N15/82;;C12N15/821;;C12N9/2402;;C12N15/8273,C12N15/82,,1,1,007-101-342-027-201,16008087;;10.1016/j.jplph.2004.09.015,"GARCIA-VALENZUELA X et al. Chlorophyll accumulation is enhanced by osmotic stress in graminaceous chlorophyllic cells.JOURNAL OF PLANT PHYSIOLOGY, 20050614 Urban & Fischer 14/06/2005 VOL: 162 No: 6 Pags: 650 - 661 ISSN 0176-1617",ACTIVE
661,ES,A2,ES 2461896 A2,051-975-164-520-011,2014-05-21,2014,ES 201350005 A,2011-12-17,MX 2010014428 A;;MX 2011013595 A;;IB 2011055757 W,2010-12-21,METHODS TO OBTAIN DROUGHT RESISTANT PLANTS,"The present invention provides a nontoxic method for the selection of transformed cells from a cell population consisting of transformed and untransformed cells. The method comprises the following steps: a) introducing into a cell at least one nucleotide sequence of interest and at least one selection nucleotide sequence to obtain genetically transformed cells, where the selection nucleotide sequence comprises a sequence promoting the inhibition of endogenous trehalase enzyme b) placing the population of transformed and untransformed cells in a culture medium containing an osmoregulating substance such as PEG 8000 c) selecting the transformed cells from the population based on the ability of transformed cells to survive and grow in the presence of the osmoregulating substance conferring the plants derived from these genetic transformation events, for example, drought and/or cold tolerance capacity.",,AGREDA LAGUNA KENNY ALEJANDRA;;RUIZ MEDRANO ROBERTO;;XOCONOSTLE CAZARES GUADALUPE BEATRIZ;;CABRERA PONCE JOSE LUIS;;HERRERA ESTRELLA LUIS RAFAEL;;MONTES DE OCA LUNA ROBERTO;;GAMEZ ESCOBEDO IDALIA ANALI,,https://lens.org/051-975-164-520-011,Patent Application,no,0,0,5,9,0,C12N15/82;;C12N15/821;;C12N9/2402;;C12N15/8273,C12N15/82,,0,0,,,,ACTIVE
662,CU,A1,CU 22100 A1,196-205-183-185-199,1993-04-30,1993,CU 1991152 A,1991-09-06,CU 1991152 A,1991-09-06,SYSTEM FOR THE AUTOMATIC PROCESSING OF ELECTRO-CARDIOGRAPH SIGNALS.,"ESTA RELACIONADO DIRECTAMENTE CON LA APLICACION DE LA ELECTRONICA Y LA COMPUTACION EN LA RAMA DE LA MEDICINA Y MUY ESPECIFICAMENTE EN LA CARDIOLOGIA. DESARROLLADO PARA EL ESTUDIO ESPECIAL DE LA SEÑAL ELECTROCARDIOGRAFICA ESTE SISTEMA ESTA CONSTITUIDO POR UN CONJUNTO DE TRES AMPLIFICADORES BIOFISICOS,UNA MICROCOMPUTADORA IBM COMPATIBLE Y UN INTERFASE CON CONVERSOR ANALOGICO DIGITAL QUE MANTIENE EL CONTROL DEL REGISTRO ELECTROCARDIOGRAFICO. EL SOFTWARE DESARROLLADO PARA ESTE SISTEMA PERMITE ADEMAS DEL CONTROL DEL REGISTRO Y GRABACION DEL ELECTROCARDIOGRAMA REALIZAR EL CALCULO DE DURACION Y AMPLITUD DE CADA UNA DE LAS ONDAS, Y CON ESTOS VALORES HACE LA INTERPRETACION Y OFRECE UN INFORME COMPLETO DEL ESTADO ELECTROCARDIOGRAFICO DEL PACIENTE. EL SISTEMA ESTA TAMBIEN HABILITADO PARA REALIZAR EL MONITOREO CONTINUO DEL PACIENTE Y ESTABLECE NIVELES DE ALARMAS PARA LA DETECCION DE ALTERACIONES DEL RITMO CARDIACO. PERMITE ADEMAS LA REALIZACION DE ESTUDIOS VECTORCARDIOGRAFICOS EFICIENTES CON REPRESENTACION GRAFICA DE RESULTADOS Y DATOS DE UTILIDAD PARA LOS ESPECIALISTAS.\!",MINISTERIO DE LAS FUERZAS ARMA,PEREZ PINEIRO JUAN OMAR;;CABRERA SANTOS ANASTASIO;;ENRIQUEZ LANDEIRO JUAN ALBERTO;;PEREZ PINEIRO JUAN OSCAR;;DE LA RUA BARRERA JESUS;;HEDIAS PARRA JOSE;;RODRIGUEZ MACHADO JORGE LUIS;;LOPEZ RUBIRA LEANDRO,,https://lens.org/196-205-183-185-199,Limited Patent,no,0,0,1,1,0,,A61B5/0402,,0,0,,,,EXPIRED
663,ES,B1,ES 2370720 B1,072-168-927-866-864,2013-03-25,2013,ES 200930372 A,2009-06-29,ES 200930372 A,2009-06-29,"MOLDES PARA LA FABRICACION DE MUELAS ABRASIVAS, PROCEDIMIENTO PARA OBTENER LOS MOLDES Y USO DE LOS MOLDES EN UN PROCEDIMIENTO DE FABRICACION EN CONTINUO DE MUELAS ABRASIVAS USANDO ENERGIA DE MICROONDAS.",,EMPRESARIAL DE INVESTIGACION CT TECNOLOGICO DEL MARMOL Y LA PIEDRA ASOC,FERNANDEZ CORTES FRANCISCO JAVIER;;LOPEZ MARTINEZ ELENA;;VILLALBA LOPEZ ANTONIO JAVIER;;RUEDA DIAZ CARLOS MAURICIO;;MONZO CABRERA JUAN;;PEDRENO MOLINA JUAN LUIS;;DIAZ MORCILLO ALEJANDRO BENEDICTO;;LOZANO GUERRERO ANTONIO JOSE,,https://lens.org/072-168-927-866-864,Granted Patent,no,0,0,2,2,0,B22C1/02;;B22C9/12,B22C1/02;;B22C9/12,,0,0,,,,INACTIVE
664,ES,A1,ES 2370720 A1,069-151-883-463-430,2011-12-22,2011,ES 200930372 A,2009-06-29,ES 200930372 A,2009-06-29,"Molds for the manufacture of abrasive wheels, procedure to obtain the molds and use of the molds in a continuous manufacturing process of abrasive wheels using microwave energy. (Machine-translation by Google Translate, not legally binding)","Molds for the manufacture of abrasive wheels, procedure to obtain the molds and use of the molds in a continuous manufacturing process of abrasive wheels using microwave energy. Molds for the manufacture of abrasive wheels each comprising a mold body with an interior cavity for housing a composition (3) comprising abrasive grains and at least one binding agent, and made of a dielectric material that is not degraded by effect of heat generated when microwave energy is applied to a magnetron (6) to said composition (3) in a microwave oven; wherein the dielectric material, the predetermined composition of the dielectric material, the dimensions and the geometrical shape of the mold (2) are selected as a function of the frequency of the microwave energy applied in a plurality of relative positions of the composition contained in the mold (2) in its displacement by a microwave oven, and determined in such a way that the mold and the composition (3) (2) have an average reflection coefficient of the microwave energy applied as low as possible. (Machine-translation by Google Translate, not legally binding)",EMPRESARIAL DE INVESTIGACION CT TECNOLOGICO DEL MARMOL Y LA PIEDRA ASOC,FERNANDEZ CORTES FRANCISCO JAVIER;;LOPEZ MARTINEZ ELENA;;VILLALBA LOPEZ ANTONIO JAVIER;;RUEDA DIAZ CARLOS MAURICIO;;MONZO CABRERA JUAN;;PEDRENO MOLINA JUAN LUIS;;DIAZ MORCILLO ALEJANDRO BENEDICTO;;LOZANO GUERRERO ANTONIO JOSE,,https://lens.org/069-151-883-463-430,Patent Application,no,3,0,2,2,0,B22C1/02;;B22C9/12,B22C1/02;;B22C9/12,,0,0,,,,INACTIVE
665,WO,A1,WO 2012/035187 A1,048-278-505-765-649,2012-03-22,2012,ES 2011070641 W,2011-09-14,ES 201031389 A,2010-09-16,METHOD FOR EXTRACTING BIOINSECTICIDE DERIVATIVES FROM THE PLANT ARTEMISIA ABSINTHIUM L,"The invention relates to a method for the extraction of bioinsecticide derivatives from the plant Artemisia absinthium L, characterised by agronomic and economic parameters relating to the organic production of the plant with a specific chemotype in order to produce organic extracts consisting of essential oil and a non-volatile extract, and in another phase supercritical extracts of characterised chemical composition, obtained with pressurised CO 2 as the main solvent. The main industrial applications of the extracts and oils thus extracted include the use thereof: as a base material for natural insecticide formulations; in organic farming for pest control, particularly in relation to aphids and Lepidoptera; and as an ingredient for mixed formulations, synergistically combined with other natural active components.",CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON;;CONSEJO SUPERIOR INVESTIGACION;;UNIV ZARAGOZA;;GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE SANTIAGO;;SANZ PERUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA M,GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE SANTIAGO;;SANZ PERUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA M,,https://lens.org/048-278-505-765-649,Patent Application,yes,1,0,6,6,0,A01N65/12;;A01N65/00;;A01N65/12;;B01D11/0203;;B01D11/028,A01N65/12;;A01P7/04,,3,3,022-993-807-343-096;;004-194-003-234-819;;061-661-250-862-190,10.1016/j.supflu.2008.11.022;;10.1016/j.supflu.2008.12.007;;17624357;;10.1016/j.chroma.2007.06.021,"E. LANGA ET AL.: ""The evolution of hyssop oil composition in the supercritical extraction curve: Modelling of the oil extraction process"", THE JOURNAL OF SUPERCRITICAL FLUIDS, vol. 49, no. 1, May 2009 (2009-05-01), pages 37 - 44;;E. LANGA ET AL.: ""Supercritical fluid extraction of Spanish sage essential oil: Optimization of the process parameters and modelling"", THE JOURNAL OF SUPERCRITICAL FLUIDS, vol. 49, no. 2, June 2009 (2009-06-01), pages 174 - 181, XP026091816, DOI: doi:10.1016/j.supflu.2008.12.007;;S.M. POURMORTAZAVI ET AL.: ""Supercritical fluid extraction in plant essential and volatile oil analysis"", JOURNAL OF CHROMATOGRAPHY A, vol. 1163, no. 1-2, 17 June 2007 (2007-06-17), pages 2 - 24, XP022202188, DOI: doi:10.1016/j.chroma.2007.06.021",PENDING
666,ES,A1,ES 2405210 A1,148-763-424-400-52X,2013-05-30,2013,ES 201390029 A,2011-09-14,ES 201031389 A;;ES 2011070641 W;;ES 201390029 A,2010-09-16,METHOD FOR EXTRACTING BIOINSECTICIDE DERIVATIVES FROM THE PLANT ARTEMISIA ABSINTHIUM L,"The invention relates to a method for the extraction of bioinsecticide derivatives from the plant Artemisia absinthium L, characterised by agronomic and economic parameters relating to the organic production of the plant with a specific chemotype in order to produce organic extracts consisting of essential oil and a non-volatile extract, and in another phase supercritical extracts of characterised chemical composition, obtained with pressurised CO2 as the main solvent. The main industrial applications of the extracts and oils thus extracted include the use thereof: as a base material for natural insecticide formulations in organic farming for pest control, particularly in relation to aphids and Lepidoptera and as an ingredient for mixed formulations, synergistically combined with other natural active components.",CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON;;CONSEJO SUPERIOR INVESTIGACION;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE SANTIAGO;;SANZ PERUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA MARIA,,https://lens.org/148-763-424-400-52X,Patent Application,no,0,0,6,6,0,A01N65/12;;A01N65/00;;A01N65/12;;B01D11/0203;;B01D11/028,A01N65/12;;A01P7/04,,0,0,,,,INACTIVE
667,ES,B1,ES 2405210 B1,134-940-857-843-736,2014-04-02,2014,ES 201390029 A,2011-09-14,ES 201031389 A;;ES 2011070641 W;;ES 201390029 A,2010-09-16,PROCEDIMIENTO DE EXTRACCION DE DERIVADOS BIOINSECTICIDAS DE LA PLANTA ARTEMISIA ABSINTHIUM L.,,CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON;;CONSEJO SUPERIOR INVESTIGACION;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE SANTIAGO;;SANZ PERUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA MARIA,,https://lens.org/134-940-857-843-736,Granted Patent,no,0,0,6,6,0,A01N65/12;;A01N65/00;;A01N65/12;;B01D11/0203;;B01D11/028,A01N65/12;;A01P7/04,,0,0,,,,INACTIVE
668,ES,B1,ES 2378809 B1,146-275-225-476-585,2013-02-27,2013,ES 201031389 A,2010-09-16,ES 201031389 A,2010-09-16,PROCEDIMIENTO DE EXTRACCION DE DERIVADOS BIOINSECTICIDAS DE LA PLANTA ARTEMISIA ABSINTHIUM L.,,CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON;;CONSEJO SUPERIOR INVESTIGACION;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE SANTIAGO;;SANZ PERUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA M,,https://lens.org/146-275-225-476-585,Granted Patent,no,0,0,6,6,0,A01N65/12;;A01N65/00;;A01N65/12;;B01D11/0203;;B01D11/028,A01N65/12;;A01P7/04,,0,0,,,,ACTIVE
669,CO,A2,CO 6680690 A2,108-927-274-466-722,2013-05-31,2013,CO 13041759 A,2013-03-01,ES 201031389 A,2010-09-16,Procedimiento de extracción de derivados bioinsecticidas de la planta (artemisia absinthium l.),"Procedimiento de extracción de derivados bioinsecticidas de la planta Artemisia absinthium L., caracterizado por unos parámetros agronómicos y económicos de producción orgánica de la planta con un quimiotipo específico con el fin de producir extractos orgánicos consistentes en aceite esencial y extracto no volátil, y en otra fase extractos supercríticos de composición química caracterizada, obtenidos con CO2 a presión como disolvente mayoritario, siendo las principales aplicaciones industriales de los extractos y aceites así extraídos su uso como materia base para formulaciones de insecticidas naturales, de especial aplicación en agricultura ecológica para el control de insectos plaga, especialmente áfidos y lepidópteros, así como su uso como ingrediente para formulaciones mixtas, en combinaciones sinergistas junto con otros componentes activos naturales.",CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON;;CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE SANTIAGO;;SANZ PERCUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA M,,https://lens.org/108-927-274-466-722,Patent Application,no,0,0,6,6,0,A01N65/12;;A01N65/00;;A01N65/12;;B01D11/0203;;B01D11/028,A01N65/12;;A01P7/04,,0,0,,,,PENDING
670,ES,A1,ES 2378809 A1,016-917-378-937-141,2012-04-18,2012,ES 201031389 A,2010-09-16,ES 201031389 A,2010-09-16,METHOD FOR EXTRACTING BIOINSECTICIDE DERIVATIVES FROM THE PLANT ARTEMISIA ABSINTHIUM L,"The invention relates to a method for the extraction of bioinsecticide derivatives from the plant Artemisia absinthium L, characterised by agronomic and economic parameters relating to the organic production of the plant with a specific chemotype in order to produce organic extracts consisting of essential oil and a non-volatile extract, and in another phase supercritical extracts of characterised chemical composition, obtained with pressurised CO2 as the main solvent. The main industrial applications of the extracts and oils thus extracted include the use thereof: as a base material for natural insecticide formulations in organic farming for pest control, particularly in relation to aphids and Lepidoptera and as an ingredient for mixed formulations, synergistically combined with other natural active components.",CT DE INVESTIGACION Y TECNOLOGIA AGROALIMENTARIA DE ARAGON;;CONSEJO SUPERIOR INVESTIGACION;;UNIV ZARAGOZA,GONZALEZ COLOMA AZUCENA;;BURILLO ALQUEZAR JESUS;;URIETA NAVARRO JOSE ANTONIO;;SANZ PERUCHA JESUS;;DIAZ HERNANDEZ CARMEN ELISA;;FRAGA GONZALEZ MANUEL;;REINA ARTILES MATIAS;;CABRERA PEREZ RAIMUNDO;;MARTINEZ DIAZ RAFAEL;;MAINAR FERNANDEZ ANA M,,https://lens.org/016-917-378-937-141,Patent Application,no,1,0,6,6,0,A01N65/12;;A01N65/00;;A01N65/12;;B01D11/0203;;B01D11/028,A01N65/12;;A01P7/04,,3,3,022-993-807-343-096;;004-194-003-234-819;;061-661-250-862-190,10.1016/j.supflu.2008.11.022;;10.1016/j.supflu.2008.12.007;;17624357;;10.1016/j.chroma.2007.06.021,"01.05.2009, E. Langa et al. ""The evolution of hyssop oil composition in the supercritical extraction curve: Modelling of the oil extraction process"" The Journal of Supercritical Fluid (mayo 2009) Vol. 49, N °. 1, páginas 37 - 44; DOI 10.1016/j.supflu.2008.11.022; todo el documento.;;01.06.2009, E. Langa et al. ""Supercritical fluid extraction of Spanish sage essential oil: optimization of the process parameters and modelling"" The Journal of SupercriticalFluids (junio 2009) Vol. 49, N °. 2, páginas 174 - 181; DOI 10.1016/j.supflu.2008.12.007; todo el documento.;;17.06.2007, S.M. Pourmortazavi et al. ""Supercritical fluid extraction in plant essential and volatile oil analysis"" Journal of Chromatography A (17 junio 2007) Vol. 1163, N °. 1-2, páginas 2 - 24; DOI 10.1016/j.chroma.2007.06.021; todo el documento.",ACTIVE
671,CU,A1,CU 22330 A1,195-944-080-442-685,1995-01-31,1995,CU 1992002 A,1992-01-20,CU 1992002 A,1992-01-20,PROCEDURE FOR OBTAINING TRANSGENIC TILAPIES AND THE TRANSGENIC LINE THUS OBTAINED.,"LA PRESENTE INVENCION ESTA RELACIONADA CON EL CAMPO DE LA INGENIERIA OC, Y UN FOTOPERIODO DE 12 -16H LUZ Y 12 - 8H DE OSCURIDAD Y SIGUIENDO EL COPMPORTAMIENTO SEXUAL DE LA HEMBRA A PARTIR DE LAS MANIFESTACIONES DEL MACHO, SE ESPERA QUE ESTA REALICE LA SEGUNDA OVIPOSICION Y UNA VEZ QUE EL MACHO FERTILIZA LOS HUEVOS Y LA HEMBRA LOS TOMA EN SU BOCA, ESTA ES SECADA DEL ESTANQUE Y LOS HUEVOS SON REMOVIDOS Y SOMETIDOS A LA INMEDIATA MICROINYECCION DEL ADN QUE CONTIENE EL TRANGEN. EL GENOMA DE LA LINEA DE TILAPIAS ES MODIFICADO MEDIANTE LA INTRODUCCION DE UN SEGMENTO DE ACIDO DESOXIRIBONUCLEICO QUE CONTIENE UN PROMOTOR/ENHACER DE CITOMEGALOVIRUS HUMANO, UN ADN COMPLEMENTARIO CODIFICANTE PARA LA HORMONA DE CRECIMIENTO DE TILAPIA (OREOCROMIS SP.) OBTENIDO POR REACCION QUE SE OBTIENE POR TRANSCRIPCION REVERSA DE ARN DE PITUITARIA DE TILAPIAS, ACOP LADA A REACCION EN CADENA DE LA POLIMERASA (PCR), UN SEGMENTO DE ADN CODIFICANTE PARA LA ENZIMA BACTERIANA CLORANFENICOL ACETIL TRANSFERASA Y UNA SECUENCIA DE TERMINACION Y POLIADENILACION DEL VIRUS SV40. MEDIANTE CRUZAMIENTOS SE OBTUVIERON LOS ANIMALES HOMOCIGOTICOS PARA EL NUEVO CARACTER, CON LOS CUALES SE OBTUVO UNA LINEA ESTABLE DE TILAPIAS TRANSGENICAS. LA TILAPIA (OREOCHROMIS SP) ES UNA ESPECIE QUE REPRESENTA UNA SERIE DE VENTAJAS ADAPTATIVAS Y CONSTITUYE UNA FUENTE IMPORTANTE DE PROTEINA DE ORIGEN ANIMAL, DE AHI LA UTILIDAD QUE TIENE ESTA LINEA DE PECES. GENETICA Y LA BIOTECNOLOGIA, Y ESPECIFICAMENTE CON LA OBTENCION DE ANIMALES TRANSGENICOS. EL OBJETIVO DE LA PRESENTE INVENCION CONSISTE EN CREAR CONDICIONES REPRODUCIBLES PARA EL MANTENIMIENTO DE EMBRIONES DE TILAPIA DESDE SU ESTADIO UNICELULAR, LO QUE PERMITE DISPONER DE UN MATERIAL GENETICAMENTE TRANSFORMABLE Y POR CONSIGUIENTE LA OBTENCION DE LINEAS DE PECES TRANSGENICOS MEJORADOS GENETICAMENTE DENTRO DE ESTA ESPECIE. COMO RESULTADO DE ESTE PROCEDIMIENTO FUE POSIBLE LOGRAR LA EXPRESION MANTENIDA DE HORMONA DE CRECIMIENTO ENDOGENA EN UNA NUEVA LINEA DE TILAPIA TRANSGENICA QUE ALCANZA SU TAMAÑO COMERCIAL EN UN PERIODO DE TIEMPO MENOR, POR INCREMENTAR SU VELOCIDAD DE CRECIMIENTO EN COMPARACION CON LA LINEA PARENTAL. SU ESENCIA CONSISTE EN EL EMPLEO DE UN PROCEDIMIENTO QUE PERMITE LOGRAR UNA LINEA DE TILAPIAS TRANSGENICAS ESTABLE PARA EL CUAL SE SELECCIONAN REPRODUCTORES MACHOS Y HEMBRAS QUE SE ALMACENAN EN PROPOR CION ADECUADA, SE LES SUMINISTRA UNA DIETA QUE CUBRE SUS REQUERIMIENTOS NUTRICIONALES Y SE DEPOSITAN ES ESTANQUES PARA SU REPRODUCCION. ESTOS REPRODUCTORES SE MANTIENEN A TEMPERATURA REGULADA EN UN RANGO DE 28 - 30\!",CIGB,MARTINEZ RODRIGUEZ REBECA;;HERNANDEZ BETANCOURT OSCAR;;LLIONART CRUZ RICARDO L;;DE LA FUENTE GARCIA JOSE DE J;;GARCIA DEL BARCO HERRERA DIANA;;MARALES ROJAS ANTONIO;;MIYARES HERRERA FIDEL;;CABRERA GONZALEZ EDENAIDA;;GUILLEN PEREZ ISABEL,,https://lens.org/195-944-080-442-685,Limited Patent,no,0,0,1,1,0,,C12N15/89,,0,0,,,,EXPIRED
672,MX,A,MX 2008006604 A,103-721-732-151-782,2009-11-23,2009,MX 2008006604 A,2008-05-22,MX 2008006604 A,2008-05-22,METHOD FOR THE PRODUCTION OF RECOMBINANT ANTIGENS FOR USE AS VACCINES AGAINST CYSTICERCOSIS-TAENIASIS.,"The present invention consists in using the recombinant protein expression system in embryogenic cells of papaya for the expression and production of protective recombinant proteins against cysticercosis and taeniasis. Three genetic constructions were performed, wherein the sequences encoding for peptides KETc1, KETc7 and KETc12 from the cysticercus T. crassiceps were independently donated to the expression vector pUl235-5.1. Said constructions were used for transforming, by biobalistics, embryogenic papaya (Carica papaya) callus. The embryogenic callus were co-transformed with each one of the genetic construction in the vector pUl235-5.1 and the vector pWRG1515 which contain the GUS reporter gene that encodes for the (-glucuronidase) enzyme (Christou et al., 1995). The transformed callus were selected and isolated in a selective medium with antibiotics. The ability of expression and immunogenicity of the produced clones were confirmed. Based on the immunogenic ability of the clones, the clones 6p (KETC12.6 His), 9p (KETc1. 6 His) and 23p (KETc7) were selected therefrom, the same being spread, preserved and started the regeneration process in vitro.",UNIV MEXICO NACIONAL AUTONOMA,ESTRELLA LUIS HERRERA;;CONDE EDDA LYDIA SCIUTTO;;GONZALEZ RUTILIA MARISELA HERNANDEZ;;GONZALEZ GLADIS DEL CARMEN FRAGOSO;;CERVANTES JACQUELYNNE BRENDA;;CASILLAS FERNANDO LOPEZ;;GARCIA ANGEL ARTURO GUEVARA;;PONCE JOSE LUIS CABRERA;;RAMIREZ CLAUDIA GERALDINE LEON;;SALGADO GABRIELA ROSAS,,https://lens.org/103-721-732-151-782,Patent Application,no,0,0,1,1,0,,C12N15/00,,0,0,,,,DISCONTINUED
673,BR,A2,BR 112014032919 A2,063-816-933-601-746,2017-08-22,2017,BR 112014032919 A,2013-06-28,EP 2013063646 W;;ES 201231020 A,2012-06-29,lipossomas funcionalizados úteis para a entrega de compostos bioativos,,CENTRO DE INVESTIG BIOMEDICA EN RED;;CONSEJO SUPERIOR INVESTIGACION;;FUNDACIO HOSPITAL UNIV VALL D´HEBRON INSTITUT DE RECERCA;;FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA;;FUND PARC CIENTIFIC DE BARCELONA;;UNIV AUTÒNOMA DE BARCELONA;;UNIV BARCELONA,ANTONIO PEDRO VILLAVERDE CORRALES;;DANIEL PULIDO MARTINEZ;;ELISA ELIZONDO SAEZ DE VICUÑA;;FERNANDO ALBERICIO PALOMERA;;IBANE ABASOLO OLAORTUA;;INGRID CABRERA PUIG;;JAUME VECIANA MIRÓ;;JOSE LUIS CORCHERO NIETO;;LEONOR VENTOSA RULL;;MARTA MELGAREJO DIAZ;;MIRIAM ROYO EXPÓSITO;;SANTIAGO SALA VERGÉS;;SIMÓN SCHWARTZ NAVARRO,,https://lens.org/063-816-933-601-746,Patent Application,no,0,0,13,13,0,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,,,0,0,,,,ACTIVE
674,CN,A,CN 104507503 A,140-725-067-818-283,2015-04-08,2015,CN 201380034806 A,2013-06-28,EP 2013063646 W;;ES 201231020 A,2012-06-29,Functionalized liposomes useful for the delivery of bioactive compounds,"The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.",CONSEJO SUPERIOR INVESTIGACION;;FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA;;CT DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA CIBER BBN;;FUNDACIO PRIVADA INST DE RECERCA BIOMEDICA;;UNIV BARCELONA;;FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA;;UNIV BARCELONA AUTONOMA,VENTOSA RULL LEONOR;;VECIANA MIRO JAUME;;CABRERA PUIG INGRID;;ELIZONDO SAEZ DE VICUNA ELISA;;MELGAREJO DIAZ MARTA;;ROYO EXPOSITO MIRIAM;;ALBERICIO PALOMERA FERNANDO;;PULIDO MARTINEZ DANIEL;;SALA VERGES SANTIAGO;;CORCHERO NIETO JOSE LUIS;;SCHWARTZ NAVARRO SIMON;;ABASOLO OLAORTUA IBANE;;VILLAVERDE CORRALES ANTONIO PEDRO,,https://lens.org/140-725-067-818-283,Patent Application,no,1,1,13,13,0,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/48,,4,1,117-461-691-893-711,10.1016/s0927-7765(98)00009-5,"QING LIN JIANG,ET AL.: ""Synthesis of a novel multivalent galactoside with high hepatocyte targeting for gene delivery"", 《CHINESE CHEMICAL LETTERS》;;FAN LEI, ET AL: ""Design,synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligand for brain targeting liposomes"", 《CHINESE CHEMICAL LETTERS》;;MICAELE GELHAUSEN ET AL.: ""Lectin recognition of liposomes containing neoglycolipids.Influence of their lipidic anchor and spacer length"", 《COLLOIDS AND SURFACE B:BIOINTERFACES 10》;;CQS: ""重组α-半乳糖苷酶A替代治疗法布里病的安全性和有效性"", 《中华医学信息导报》",DISCONTINUED
675,BR,A8,BR 112014032919 A8,109-569-257-015-339,2021-07-13,2021,BR 112014032919 A,2013-06-28,EP 2013063646 W;;ES 201231020 A,2012-06-29,lipossomas funcionalizados úteis para a entrega de compostos bioativos,"lipossomas funcionalizados úteis para a entrega de compostos bioativos. a presente invenção refere-se aos conjugados em que um esterol é funcionalizado por meio de uma ligação éter, com um polímero solúvel em água para o qual um ligante de orientação é ligado. estes conjugados melhoram as propriedades físico-químicas e de entrega de suas vesículas de transporte, tornando estes mais estáveis, homogêneos e eficazes. um método para a sua preparação, uma composição farmacêutica contendo os referidos lipossomas, e o seu uso terapêutico são também descritos.",CENTRO DE INVESTIG BIOMEDICA EN RED;;CONSEJO SUPERIOR INVESTIGACION;;FUNDACIO HOSPITAL UNIV VALL D´HEBRON INSTITUT DE RECERCA;;FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA;;FUND PARC CIENTIFIC DE BARCELONA;;UNIV AUTÒNOMA DE BARCELONA;;UNIV BARCELONA,ANTONIO PEDRO VILLAVERDE CORRALES;;DANIEL PULIDO MARTINEZ;;ELISA ELIZONDO SAEZ DE VICUÑA;;FERNANDO ALBERICIO PALOMERA;;IBANE ABASOLO OLAORTUA;;INGRID CABRERA PUIG;;JAUME VECIANA MIRÓ;;JOSE LUIS CORCHERO NIETO;;LEONOR VENTOSA RULL;;MARTA MELGAREJO DIAZ;;MIRIAM ROYO EXPÓSITO;;SANTIAGO SALA VERGÉS;;SIMÓN SCHWARTZ NAVARRO,,https://lens.org/109-569-257-015-339,Patent Application,no,0,0,13,13,0,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/00,,0,0,,,,ACTIVE
676,EP,A1,EP 2866839 A1,187-528-493-638-86X,2015-05-06,2015,EP 13732179 A,2013-06-28,ES 201231020 A;;EP 2013063646 W,2012-06-29,FUNCTIONALIZED LIPOSOMES USEFUL FOR THE DELIVERY OF BIOACTIVE COMPOUNDS,,CONSEJO SUPERIOR INVESTIGACION;;FUNDACIÓ PARC CIENTÍFIC DE BARCELONA;;CIBER CT DE INVESTIGACIÓN BIOMÉDICA EN RED;;FUNDACIÓ INST DE RECERCA BIOMÈDICA IRB BARCELONA;;UNIV BARCELONA;;FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA;;UNI AUT NOMA DE BARCELONA,VENTOSA RULL LEONOR;;VECIANA MIRÓ JAUME;;CABRERA PUIG INGRID;;ELIZONDO SAEZ DE VICUÑA ELISA;;MELGAREJO DIAZ MARTA;;ROYO EXPÓSITO MIRIAM;;ALBERICIO PALOMERA FERNANDO;;PULIDO MARTINEZ DANIEL;;SALA VERGÉS SANTIAGO;;CORCHERO NIETO JOSE LUIS;;SCHWARTZ NAVARRO SIMÓN;;ABASOLO OLAORTUA IBANE;;VILLAVERDE CORRALES ANTONIO PEDRO,,https://lens.org/187-528-493-638-86X,Patent Application,yes,0,0,13,13,0,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/48,,0,0,,,,ACTIVE
677,WO,A1,WO 2014/001509 A1,128-989-569-309-491,2014-01-03,2014,EP 2013063646 W,2013-06-28,ES 201231020 A,2012-06-29,FUNCTIONALIZED LIPOSOMES USEFUL FOR THE DELIVERY OF BIOACTIVE COMPOUNDS,"The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.",CONSEJO SUPERIOR INVESTIGACION;;FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA;;CT DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA CIBER BBN;;FUNDACIO PRIVADA INST DE RECERCA BIOMEDICA;;UNIV BARCELONA;;FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA;;UNIV BARCELONA AUTONOMA,VENTOSA RULL LEONOR;;VECIANA MIRO JAUME;;CABRERA PUIG INGRID;;ELIZONDO SAEZ DE VICUNA ELISA;;MELGAREJO DIAZ MARTA;;ROYO EXPOSITO MIRIAM;;ALBERICIO PALOMERA FERNANDO;;PULIDO MARTINEZ DANIEL;;SALA VERGES SANTIAGO;;CORCHERO NIETO JOSE LUIS;;SCHWARTZ NAVARRO SIMON;;ABASOLO OLAORTUA IBANE;;VILLAVERDE CORRALES ANTONIO PEDRO,,https://lens.org/128-989-569-309-491,Patent Application,yes,1,7,13,13,1,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/48,,27,23,117-461-691-893-711;;047-113-256-637-344;;039-431-654-044-759;;103-699-343-080-556;;052-159-738-756-447;;121-300-016-603-503;;089-913-348-339-247;;036-008-205-391-555;;007-009-759-276-834;;103-699-343-080-556;;020-986-539-859-732;;047-086-207-619-800;;054-100-839-222-061;;060-872-019-324-609;;001-701-899-803-483;;024-127-211-181-323;;005-491-198-085-792;;015-992-731-071-03X;;089-913-348-339-247;;007-009-759-276-834;;047-086-207-619-800;;001-701-899-803-483;;024-127-211-181-323,10.1016/s0927-7765(98)00009-5;;10.1016/j.cclet.2010.12.056;;12031126;;10.1089/10430340252939041;;10.1021/bc040244z;;15898728;;22019557;;10.1016/j.jconrel.2011.10.004;;10.1038/nrd1632;;15688077;;10.1080/10611860410001728040;;15512776;;20930391;;10.1248/bpb.33.1766;;10.1021/bc060174r;;pmc2719908;;17226962;;10.1021/bc040244z;;15898728;;pmc2693366;;10.1021/bc800239b;;19072698;;10.1016/s0040-4039(00)01060-1;;18229961;;10.1021/la7032109;;16033856;;10.1681/asn.2005040383;;10.1093/nar/gkm047;;17317681;;pmc1874605;;21618456;;10.1002/btpr.637;;4683418;;6263521;;10.1016/0009-8981(81)90384-3;;10.1080/10611860410001728040;;15512776;;10.1021/bc060174r;;pmc2719908;;17226962;;10.1016/s0040-4039(00)01060-1;;10.1093/nar/gkm047;;17317681;;pmc1874605;;21618456;;10.1002/btpr.637,"GELHAUSEN M. ET AL.: ""Lectin recognition of liposomes containing neoglycolipids.influence of their lipidic ancor and spacer length"", COLLOIDS AND SURFACES B: BIOINTERFACES 10 (1998), vol. 10, 1 April 1998 (1998-04-01), pages 395 - 404, XP002705343;;LEI F. ET AL.: ""Design, synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes."", CHINESE CHEMICAL LETTERS, vol. 22, 17 April 2011 (2011-04-17), pages 831 - 834, XP002705344;;JIANG Q. L. ET AL.: ""Synthesis of a novel multivalent galactosidewith high hepatocyte targeting for gene delivery"", CHINESE EMICAL LETTERS, vol. 19, 2 December 2007 (2007-12-02), pages 127 - 128, XP002705345;;ZIEGLER R. J. ET AL.: ""Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry Disease."", HUMAN GENE THERAPY, vol. 3, 20 May 2002 (2002-05-20), pages 935 - 945, XP002705346;;THOMPSON , B. ET AL.: ""Neutral Postgrafted colloidal particles for Gene Delivery"", BIOCONJUGATE CHEMISTRY, vol. 16, 30 April 2005 (2005-04-30), pages 608 - 615, XP002705347;;YONEHAGA, N. ET AL.: ""RGD-based active targeting of novel polycation liposomes beaing siRNA for cancer treatment"", JOURNAL OF CONTROLLED RELEASE, vol. 160, 13 October 2011 (2011-10-13), pages 177 - 181, XP002705348;;TORCHILIN V.: ""Recent advances with liposomes as pharmaceutical carriers"", NATURE REV. DRUG DISC., vol. 4, 2005, pages 145 - 160, XP008047949, DOI: doi:10.1038/nrd1632;;DUBEY P.: ""Liposomes modified with cyclic RGD peptide for tumor targeting"", J. DRUG TARG, vol. 12, 2004, pages 257 - 264, XP008077599, DOI: doi:10.1080/10611860410001728040;;NEGISHI Y.: ""Preparation and characterization of laminin-derived peptide AG73- coated liposomes as a selective gene delivery tool"", BIOL. PHARM. BULL, vol. 33, 2010, pages 1766 - 1769;;PAN X.: ""Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR"", BIOCONOUGATE CHEM., vol. 18, 2007, pages 101 - 108, XP002660205, DOI: doi:10.1021/BC060174R;;THOMSON B.: ""Neutral postgrafted colloidal particles for gene delivery"", BIOCONJ. CHEM., vol. 16, 2005, pages 608 - 614;;BOOMER J.: ""Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate"", BIOCONJ. CHEM., vol. 20, 2009, pages 47 - 69;;DAI X.: ""An improved synthesis of a selective ?v?3-integrin antagonist cyclo (-RGDfK"", TETRAHEDRON LETTERS, vol. 41, 2000, pages 6295 - 6298, XP004215053, DOI: doi:10.1016/S0040-4039(00)01060-1;;CANO-SARABIA, M.: ""Preparation of Uniform Rich Cholesterol Unilamellar Nanovesicles Using C02-Expanded Solvents"", LANGMUIR, vol. 24, 2008, pages 2433 - 2437;;SHU L. ET AL.: ""An in vitro model of Fabry disease"", J. AM. SOC. NEPHROL, vol. 16, 2005, pages 2636 - 45;;BERROW NS ET AL.: ""A versatile ligation-independent cloning method suitable for high- throughput expression screening applications"", NUCLEIC ACIDS RES, vol. 35, 2007, pages E45;;CORCHERO JL ET AL.: ""Integrated approach to produce a recombinant, his- tagged human alpha-galactosidase a in mammalian cells"", BIOTECHNOL PROQ, vol. 27, 2011, pages 1206 - 1217;;DESNICK RJ ET AL.: ""Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes"", J. LAB. CLIN. MED., vol. 81, 1973, pages 157 - 171;;MAYES JS. ET AL.: ""Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease"", CLIN. CHIM. ACTA, vol. 112, 1981, pages 247 - 251, XP023399120, DOI: doi:10.1016/0009-8981(81)90384-3;;TORCHILIN V: ""Recent advances with liposomes as pharmaceutical carriers"", NATURE REV. DRUG DISC, vol. 4, 2005, pages 145 - 160, XP008047949, DOI: doi:10.1038/nrd1632;;DUBEY P.: ""Liposomes modified with cyclic RGD peptide for tumor targeting"", J. DRUG TARQ., vol. 12, 2004, pages 257 - 264, XP008077599, DOI: doi:10.1080/10611860410001728040;;NEGISHI Y.: ""Preparation and characterization of laminin-derived peptide AG73-coated liposomes as a selective gene delivery tool"", BIOL. PHARM. BULL., vol. 33, 2010, pages 1766 - 1769;;PAN X.: ""Synthesis of cetuximab-immunoliposomes via a cholesterol- based membrane anchor for targeting of EGFR"", BIOCONJUGATE CHEM., vol. 18, 2007, pages 101 - 108, XP002660205, DOI: doi:10.1021/BC060174R;;BOOMER J.: ""Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate"", BIOCONJ. CHEM, vol. 20, 2009, pages 47 - 69;;DAI X: ""An improved synthesis of a selective avp3-integrin antagonist cyclo (-RGDfK"", TETRAHEDRON LETTERS, vol. 41, 2000, pages 6295 - 6298, XP004215053, DOI: doi:10.1016/S0040-4039(00)01060-1;;BERROW NS ET AL.: ""A versatile ligation-independent cloning method suitable for high-throughput expression screening applications"", NUCLEIC ACIDS RES 2007, vol. 35, 2007, pages E45;;CORCHERO JL ET AL.: ""Integrated approach to produce a recombinant, his- tagged human alpha-galactosidase a in mammalian cells"", BIOTECHNOL PROG., vol. 27, 2011, pages 1206 - 1217",PENDING
678,US,B2,US 9744247 B2,186-628-878-302-605,2017-08-29,2017,US 201314411097 A,2013-06-28,ES 201231020 A;;EP 2013063646 W,2012-06-29,Functionalized liposomes useful for the delivery of bioactive compounds,"The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.",CONSEJO SUPERIOR DE INVESTIG CIENTÍFICAS (CSIC);;FUNDACIÓ PARC CIENTÍFIC DE BARCELONA;;CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED;;FUNDACIÓ INST DE RECERCA BIOMÈDICA (IRB BARCELONA);;UNIV BARCELONA;;FUNDACIÓ HOSPITAL UNIV VALL D'HEBRON-INSTITUT DE RECERCA;;UNIV AUTÒNOMA DE BARCELONA;;FUNDACIÓ HOSPITAL UNIV VALL D'HEBRON—INSTITUT DE RECERCA,VENTOSA RULL LEONOR;;VECIANA MIRÓ JAUME;;CABRERA PUIG INGRID;;ELIZONDO SAEZ DE VICUÑA ELISA;;MELGAREJO DIAZ MARTA;;ROYO EXPÓSITO MIRIAM;;ALBERICIO PALOMERA FERNANDO;;PULIDO MARTINEZ DANIEL;;SALA VERGÉS SANTIAGO;;CORCHERO NIETO JOSE LUIS;;SCHWARTZ NAVARRO SIMÓN;;ABASOLO OLAORTUA IBANE;;VILLAVERDE CORRALES ANTONIO PEDRO,CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (2014-11-23);;CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (2014-11-23);;FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (2014-11-23);;FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (2014-11-23);;UNIVERSITAT AUTÒNOMA DE BARCELONA (2014-11-23);;UNIVERSITAT DE BARCELONA (2014-11-23);;FUNDACIÓ PARC CIENTÍFIC DE BARCELONA (2014-11-23),https://lens.org/186-628-878-302-605,Granted Patent,yes,1,1,13,13,1,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K38/00;;A61K38/47,,23,18,117-461-691-893-711;;117-461-691-893-711;;047-113-256-637-344;;001-701-899-803-483;;020-986-539-859-732;;054-100-839-222-061;;005-491-198-085-792;;089-913-348-339-247;;117-461-691-893-711;;047-113-256-637-344;;015-992-731-071-03X;;036-008-205-391-555;;007-009-759-276-834;;060-872-019-324-609;;103-699-343-080-556;;121-300-016-603-503;;052-159-738-756-447;;039-431-654-044-759,10.1016/s0927-7765(98)00009-5;;10.1016/s0927-7765(98)00009-5;;10.1016/j.cclet.2010.12.056;;10.1093/nar/gkm047;;17317681;;pmc1874605;;pmc2693366;;10.1021/bc800239b;;19072698;;18229961;;10.1021/la7032109;;4683418;;10.1080/10611860410001728040;;15512776;;10.1016/s0927-7765(98)00009-5;;10.1016/j.cclet.2010.12.056;;6263521;;10.1016/0009-8981(81)90384-3;;20930391;;10.1248/bpb.33.1766;;10.1021/bc060174r;;pmc2719908;;17226962;;16033856;;10.1681/asn.2005040383;;10.1021/bc040244z;;15898728;;10.1038/nrd1632;;15688077;;22019557;;10.1016/j.jconrel.2011.10.004;;12031126;;10.1089/10430340252939041,"Gelhausen et al. Colloids Surfaces B. Biointerfaces 10 (1998) 395-404.;;Gelhausen (Colloids and Surfaces B: Biointerfaces 10 (1998) 395-404.;;Jiang et al. Chinese Chemical Letters 19, 2008, 127-129.;;Lei et al. Chinese Chemical Letters 22, 2011, 831-834.;;International Search Report and Written Opinion Issued Aug. 7, 2013 in PCT/EP2013/063646, 13 pgs.;;Berrow et al., “A versatile ligation-independent cloning method suitable for high-throughput expression screening applications”, Nucleic Acids Res vol. 35, No. 6, e45, 12 pgs. (2007).;;Boomer et al., “Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl Ether-PEG conjugate”, Bioconj. Chem. vol. 20, pp. 47-59 (2009).;;Cano-Sarabia et al., “Preparation of Uniform Rich Cholesterol Unilamellar Nanovesicles Using CO2-Expanded Solvents”, Langmuir vol. 24, pp. 2433-2437 (2008).;;Corchero et al., “Integrated approach to produce a recombinant, his-tagged human α-galactosidase A in mammalian cells”, Biotechnol Prog. vol. 27, pp. 1206-1217 (2011).;;Dai et. al., “An improved synthesis of a selective αvβ3-integrin antagonist cyclo (-RGDfK-)”, Tetrahedron Letters, vol. 41, pp. 6295-6298 (2000).;;Desnick et al., “Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes, galactosidase activities in plasma, serum, urine, and leukocytes”, J. Lab. and Clin. Med. vol. 81, pp. 157-171 (1973).;;Dubey et al., “Liposomes modified with cyclic RGD peptide for tumor targeting”, J. Drug Targ., vol. 12 (5), pp. 257-264 (2004).;;Gelhausen et al., “Lectin recognition of liposomes containing neoglycolipids. Influence of their lipidic anchor and spacer length”, Colloids and Surfaces B: Biointerfaces, vol. 10, pp. 395-404 (1998).;;Jiang et al.,“Synthesis of a novel multivalent galactoside with high hepatocyte targeting for gene delivery”, Chinese Chemical Lett. vol. 19, pp. 127-129 (2008).;;Lei et al., “Design, synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes”, Chinese Chemical Lett. vol. 22, pp. 831-834 (2011).;;Mayes et al., “Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease”, Clin. Chim. Acta vol. 112, pp. 247-251 (1981).;;Negishi et al., “Preparation and characterization of laminin-derived peptide AG73-coated liposomes as a selective gene delivery tool”, Biol. Pharm. Bull., vol. 33 (10), pp. 1766-1769 (2010).;;Pan et al., “Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR”, Bioconjugate Chem., vol. 18, pp. 101-108 (2007).;;Shu et al., “An in vitro model of Fabry disease”, J. Am. Soc. Nephrol. vol. 16, pp. 2636-2645 (2005).;;Thomson et al., “Neutral postgrafted colloidal particles for gene delivery”, Bioconj. Chem. vol. 16, pp. 608-614 (2005).;;Torchilin “Recent advances with liposomes as pharmaceutical carriers”, Nature Rev. Drug Disc. vol. 4, pp. 145-160 (2005).;;Yonenaga et al., “RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment”, J. Controlled Release vol. 160, pp. 177-181 (2012).;;Ziegler et al., “Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry Disease”, Human Gene Therapy vol. 13, pp. 935-945 (2002).",ACTIVE
679,US,A1,US 2015/0190530 A1,054-340-805-091-887,2015-07-09,2015,US 201314411097 A,2013-06-28,ES 201231020 A;;EP 2013063646 W,2012-06-29,FUNCTIONALIZED LIPOSOMES USEFUL FOR THE DELIVERY OF BIOACTIVE COMPOUNDS,"The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.",CONSEJO SUPERIOR INVESTIGACION;;FUNDACIÓ PRIVADA PARC CIENTÍFIC DE BARCELONA;;CT DE INVESTIGACIÓN BIOMÉDICA EN RED EN BIONG ENIERÍA BIOMATERIALES Y NANOMEDICINA CIBER BBN;;FUNDACIÓ PRIVADA INST DE RECERCA BIOMÈDICA;;UNIV BARCELONA;;FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA;;UNI AUT NOMA DE BARCELONA,VENTOSA RULL LEONOR;;VECIANA MIRÓ JAUME;;CABRERA PUIG INGRID;;ELIZONDO SAEZ DE VICUÑA ELISA;;MELGAREJO DIAZ MARTA;;ROYO EXPÓSITO MIRIAM;;ALBERICIO PALOMERA FERNANDO;;PULIDO MARTINEZ DANIEL;;SALA VERGÉS SANTIAGO;;CORCHERO NIETO JOSE LUIS;;SCHWARTZ NAVARRO SIMÓN;;ABASOLO OLAORTUA IBANE;;VILLAVERDE CORRALES ANTONIO PEDRO,CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (2014-11-23);;CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (2014-11-23);;FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (2014-11-23);;FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (2014-11-23);;UNIVERSITAT AUTÒNOMA DE BARCELONA (2014-11-23);;UNIVERSITAT DE BARCELONA (2014-11-23);;FUNDACIÓ PARC CIENTÍFIC DE BARCELONA (2014-11-23),https://lens.org/054-340-805-091-887,Patent Application,yes,0,4,13,13,1,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/48;;A61K38/47,,4,3,117-461-691-893-711;;117-461-691-893-711;;047-113-256-637-344,10.1016/s0927-7765(98)00009-5;;10.1016/s0927-7765(98)00009-5;;10.1016/j.cclet.2010.12.056,"Gelhausen et al. Colloids Surfaces B. Biointerfaces 10 (1998) 395-404.;;Gelhausen (Colloids and Surfaces B: Biointerfaces 10 (1998) 395-404.;;Jiang et al. Chinese Chemical Letters 19, 2008, 127-129.;;Lei et al. Chinese Chemical Letters 22, 2011, 831-834.",ACTIVE
680,BR,B1,BR 112014032919 B1,134-087-317-717-629,2023-03-28,2023,BR 112014032919 A,2013-06-28,EP 2013063646 W;;ES 201231020 A,2012-06-29,"CONJUGADO E SEU MÉTODO DE PRODUÇÃO, LIPOSSOMAS, USO E MÉTODO DE PRODUÇÃO DOS MESMOS, BEM COMO COMPOSIÇÃO FARMACÊUTICA","CONJUGADO E SEU MÉTODO DE PRODUÇÃO, LIPOSSOMAS, USO E MÉTODO DE PRODUÇÃO DOS MESMOS, BEM COMO COMPOSIÇÃO FARMACÊUTICA. A presente invenção refere-se aos conjugados em que um esterol é funcionalizado por meio de uma ligação éter, com um polímero solúvel em água para o qual um ligante de orientação é ligado. Estes conjugados melhoram as propriedades físico-químicas e de entrega de suas vesículas de transporte, tornando estes mais estáveis, homogêneos e eficazes. Um método para a sua preparação, uma composição farmacêutica contendo os referidos lipossomas, e o seu uso terapêutico são também descritos.",UNIV BARCELONA;;CONSEJO SUPERIOR INVESTIGACION;;FUND PARC CIENTIFIC DE BARCELONA;;CENTRO DE INVESTIG BIOMEDICA EN RED;;FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA;;FUNDACIO HOSPITAL UNIV VALL D´HEBRON INSTITUT DE RECERCA;;UNIV AUTÒNOMA DE BARCELONA,LEONOR VENTOSA RULL;;JAUME VECIANA MIRÓ;;INGRID CABRERA PUIG;;ELISA ELIZONDO SAEZ DE VICUÑA;;MARTA MELGAREJO DIAZ;;MIRIAM ROYO EXPÓSITO;;FERNANDO ALBERICIO PALOMERA;;DANIEL PULIDO MARTINEZ;;SANTIAGO SALA VERGÉS;;JOSE LUIS CORCHERO NIETO;;SIMÓN SCHWARTZ NAVARRO;;IBANE ABASOLO OLAORTUA;;ANTONIO PEDRO VILLAVERDE CORRALES,,https://lens.org/134-087-317-717-629,Granted Patent,no,0,0,13,13,0,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/00,,0,0,,,,ACTIVE
681,EP,B1,EP 2866839 B1,116-702-615-487-795,2018-08-15,2018,EP 13732179 A,2013-06-28,ES 201231020 A;;EP 2013063646 W,2012-06-29,FUNCTIONALIZED LIPOSOMES USEFUL FOR THE DELIVERY OF BIOACTIVE COMPOUNDS,,CONSEJO SUPERIOR INVESTIGACION;;FUND PARC CIENTIFIC DE BARCELONA;;CIBER CENTRO DE INVESTIG BIOMEDICA EN RED;;FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA;;UNIV BARCELONA;;FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA;;UNIV AUTÒNOMA DE BARCELONA,VENTOSA RULL LEONOR;;VECIANA MIRÓ JAUME;;CABRERA PUIG INGRID;;ELIZONDO SAEZ DE VICUÑA ELISA;;MELGAREJO DIAZ MARTA;;ROYO EXPÓSITO MIRIAM;;ALBERICIO PALOMERA FERNANDO;;PULIDO MARTINEZ DANIEL;;SALA VERGÉS SANTIAGO;;CORCHERO NIETO JOSE LUIS;;SCHWARTZ NAVARRO SIMÓN;;ABASOLO OLAORTUA IBANE;;VILLAVERDE CORRALES ANTONIO PEDRO,,https://lens.org/116-702-615-487-795,Granted Patent,yes,1,0,13,13,0,A61K47/554;;A61K47/64;;A61K47/6435;;Y10T428/2982;;A61K47/60;;A61K47/6911;;A61K38/47;;C12Y302/01022;;A61P3/00;;Y10T428/2982;;A61K47/54;;A61K47/6915;;A61K47/646;;A61K47/60;;A61K47/6911;;A61K47/6435;;A61K47/554;;A61K47/64;;A61K38/47;;C12Y302/01022,A61K47/50,,6,0,,,"GELHAUSEN M. ET AL.: ""Lectin recognition of liposomes containing neoglycolipids.influence of their lipidic ancor and spacer length"", COLLOIDS AND SURFACES B: BIOINTERFACES 10 (1998), vol. 10, 1 April 1998 (1998-04-01), pages 395-404, XP002705343,;;LEI F. ET AL.: ""Design, synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes."", CHINESE CHEMICAL LETTERS, vol. 22, 17 April 2011 (2011-04-17), pages 831-834, XP002705344,;;JIANG Q. L. ET AL.: ""Synthesis of a novel multivalent galactosidewith high hepatocyte targeting for gene delivery"", CHINESE EMICAL LETTERS, vol. 19, 2 December 2007 (2007-12-02), pages 127-128, XP002705345,;;ZIEGLER R. J. ET AL.: ""Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry Disease."", HUMAN GENE THERAPY, vol. 3, 20 May 2002 (2002-05-20), pages 935-945, XP002705346,;;THOMPSON , B. ET AL.: ""Neutral Postgrafted colloidal particles for Gene Delivery"", BIOCONJUGATE CHEMISTRY, vol. 16, 30 April 2005 (2005-04-30), pages 608-615, XP002705347, cited in the application;;YONEHAGA, N. ET AL.: ""RGD-based active targeting of novel polycation liposomes beaing siRNA for cancer treatment"", JOURNAL OF CONTROLLED RELEASE, vol. 160, 13 October 2011 (2011-10-13), pages 177-181, XP002705348,",ACTIVE
682,PE,Z,PE 20231113 Z,104-235-606-246-003,2023-07-19,2023,PE 2023000825 U,2023-03-02,PE 2023000825 U,2023-03-02,SISTEMA DE BARRERAS VIALES PROTECTORAS,"El siguiente invento consiste en un sistema de barreras viales protectoras, el cual consiste en un sistema compuesto por una barrera (1) que sube y baja por medio de engranaje (6) y el engranaje sin fin (7) por medio de un motor electrico (5) en funcion a lo que determine el automata (4) en funcion a la informacion suministrada por un sensor de luz (10) por los colores que emita el semaforo (9) el cual recreara una barrera para que los vehiculos no puedan ingresar dentro del area peatonal en la duracion de un semaforo rojo.",YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;VASQUEZ PAUCA MARIO JOSE;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;CASTELLANO SILVA MARCIAL OSWALDO,YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;VASQUEZ PAUCA MARIO JOSE;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;CASTELLANO SILVA MARCIAL OSWALDO,,https://lens.org/104-235-606-246-003,Patent Application,no,0,0,1,1,0,,E01F15/04;;E01F15/08,,0,0,,,,PENDING
683,PE,Z,PE 20231139 Z,043-999-295-014-06X,2023-07-21,2023,PE 2023000824 U,2023-03-02,PE 2023000824 U,2023-03-02,BASURERO AUTOGENERADO DE CONTROL,"El siguiente invento consiste en un Basurero autogenerado de control, el cual consiste en un equipo dentro de un tacho de basura (1) el cual por medio de una pesa (6) permite realizar la medida del peso de los residuos solidos, tambien presenta un sensor (7) para realizar medida del volumen interno de los residuos solidos y presenta en la parte inferior unos piezoelectricos (4) que generan la energia suficiente para el funcionamiento del tacho de basura (1).",YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;VASQUEZ PAUCA MARIO JOSE;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;CASTELLANO SILVA MARCIAL OSWALDO,YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;VASQUEZ PAUCA MARIO JOSE;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;CASTELLANO SILVA MARCIAL OSWALDO,,https://lens.org/043-999-295-014-06X,Patent Application,no,0,0,1,1,0,,B30B9/00;;B65D25/20;;G06Q30/02,,0,0,,,,PENDING
684,PE,Z,PE 20231170 Z,119-116-627-237-109,2023-07-26,2023,PE 2023000826 U,2023-03-02,PE 2023000826 U,2023-03-02,SISTEMA DE GENERACION ELECTRICA PARA SCOOTERS,"El siguiente invento consiste en un sistema de generacion electrica para scooters, el cual consiste en un sistema de dinamo (2) que se dispone con un motor electrico (3) que lo presiona contra la rueda del scooter cuando desacelera de forma que regenere la energia que se usa para el funcionamiento de un scooter electrico, el motor electrico (3) se dispone en el riel (1), y se conecta con el automata (5) a fin de recargar una bateria (4).",YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;BASUALDO GARCIA PERCY EDUARDO;;VASQUEZ PAUCA MARIO JOSE;;DAVILA HONORIO DUANY;;TOVAR NAVARRO ANGELICA MARIA;;CASTELLANO SILVA MARCIAL OSWALDO,YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;VASQUEZ PAUCA MARIO JOSE;;DAVILA HONORIO DUANY;;CASTELLANO SILVA MARCIAL OSWALDO,,https://lens.org/119-116-627-237-109,Patent Application,no,0,0,1,1,0,,B62J6/08;;H02K7/18,,0,0,,,,PENDING
685,PE,Z,PE 20230875 Z,149-925-357-651-171,2023-05-31,2023,PE 2023000821 U,2023-03-02,PE 2023000821 U,2023-03-02,LAPICERO CINETICO,"El siguiente invento consiste en un dispositivo generador electrico denominado lapicero cinetico puesto que el elemento genera electricidad en funcion al movimiento que se produce al usarlo; este elemento presenta un borde piezoelectrico (2) que genera pulsos electricos por medio de la manipulacion del lapicero por la mano, en tanto en la parte interna del lapicero hay un generador piezoelectrico (8), el cual presenta una bola de choque (9) que permite generar presion y por ende electricidad cuando el lapicero este en movimiento, la energia es almacenada en una bateria (7) y se puede emplear por medio de la entrada USB hembra (4), el lapicero se puede conectar con distintos equipos y brinda energia electrica.",YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;RAMIREZ ASIS EDWIN HERNAN;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;VASQUEZ PAUCA MARIO JOSE;;CASTELLANO SILVA MARCIAL OSWALDO,YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;RAMIREZ ASIS EDWIN HERNAN;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;VASQUEZ PAUCA MARIO JOSE;;CASTELLANO SILVA MARCIAL OSWALDO,,https://lens.org/149-925-357-651-171,Patent Application,no,0,0,1,1,0,,G06F1/32;;G06F3/0354,,0,0,,,,PENDING
686,PE,Z,PE 20230955 Z,175-615-017-204-518,2023-06-13,2023,PE 2023000822 U,2023-03-02,PE 2023000822 U,2023-03-02,IDENTIFICADOR ADAPTABLE DE ENVASES,"El siguiente invento consiste en identificador adaptable de envases, el cual consiste en un dispositivo que realiza la grabacion de sonido y reproduccion sonora y textual del termino mencionado para nombrar o referirse al objeto a etiquetar por el identificador de envases; con lo cual las personas con discapacidad visual pueda identificar su objeto; para ello el invento se conforma por una estructura de sujecion (1) el cual presenta una placa de interconexion (4) de circuitos en el que se monta un chip procesador (3) el cual presenta un auricular (2) y bocina (8) para captar y reproducir ruido y tambien una placa electromagnetica (5) que por medio de fluido ferromagnetico (6) se reproduce texto en braille.",YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;RAMIREZ ASIS EDWIN HERNAN;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;VASQUEZ PAUCA MARIO JOSE;;CASTELLANO SILVA MARCIAL OSWALDO,YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;RAMIREZ ASIS EDWIN HERNAN;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;VASQUEZ PAUCA MARIO JOSE;;CASTELLANO SILVA MARCIAL OSWALDO,,https://lens.org/175-615-017-204-518,Patent Application,no,0,0,1,1,0,,G01S1/00;;H04W4/02,,0,0,,,,PENDING
687,PE,Z,PE 20230893 Z,187-253-834-906-173,2023-06-01,2023,PE 2023000823 U,2023-03-02,PE 2023000823 U,2023-03-02,ADAPTADOR DE CANO CONTROLADOR DE CAUDAL,"El siguiente invento consiste en un adaptador de cano controlador de caudal , el cual consiste en un accesorio de fijacion el cual se puede colocar sobre un cano de preferencia no funcionales o problemas en la salida del flujo del agua puesto que con este invento se podra realizar la salida del agua por medio de la malla (1) en el que la abrazadera (3) la fija en el cano actua y su salida de doble boca (6) y la boquilla (7) permite regular el flujo del caudal de forma laminar y de forma turbulenta.",YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;RAMIREZ ASIS EDWIN HERNAN;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;VASQUEZ PAUCA MARIO JOSE;;CASTELLANO SILVA MARCIAL OSWALDO,YARIN ACHACHAGUA ANWAR JULIO;;ALVAREZ QUISPE ALBERT NESTOR;;RUIZ DE LA CRUZ JHONN ROBERT;;FLORES CABRERA DE RUIZ KATHY;;AVALOS DIAZ AYDA GUISELLA;;TOVAR NAVARRO ANGELICA MARIA;;BASUALDO GARCIA PERCY EDUARDO;;RAMIREZ ASIS EDWIN HERNAN;;DAVILA HONORIO DUANY;;BUSTINZA ZUASNABAR EDWARD EDDIE;;PARIAJULCA FERNANDEZ ISRAEL ROBERT;;SURICHAQUI TIZA BEATRIZ SILVIA;;VASQUEZ PAUCA MARIO JOSE;;CASTELLANO SILVA MARCIAL OSWALDO,,https://lens.org/187-253-834-906-173,Patent Application,no,0,0,1,1,0,,F16K27/06;;F17D1/00,,0,0,,,,PENDING
688,CA,A1,CA 2888754 A1,162-504-191-156-124,2013-05-10,2013,CA 2888754 A,2012-11-02,CU 20110202 A;;CU 2012000006 W,2011-11-02,ADJUVANTS FOR POLYSACCHARIDE VACCINES AND RESULTING FORMULATIONS,"The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis; (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route; and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE SUEROS Y VACUNAS,PEREZ MARTIN OLIVER GERMAN;;ROMEU ALVAREZ BELKIS;;LASTRE GONZALEZ MIRIAM DE SAN JUAN BOSCO;;ZAYAS VIGNIER CARIDAD;;GONZALEZ AZNAR ELIZABETH;;BALBOA GONZALEZ JULIO ANTONIO;;CABRERA BLANCO OSMIR;;CUELLO PEREZ MARIBEL;;GARCIA IMIA LUIS GUILLERMO;;ACEVEDO GROGUES REINALDO;;BARBERA GONZALEZ RAMON FAUSTINO;;PEREZ QUINOY JOSE LUIS;;SOTOLONGO PADRON FRANCKLIN TOMAS;;CAMPA HUERGO CONCEPCION;;SIERRA GONZALEZ GUSTAVO VICTORIANO;;MANDIAROTE LLANES ALEIDA;;CARDOSO GONZALEZ DANIEL TOMAS,,https://lens.org/162-504-191-156-124,Patent Application,no,0,0,6,6,0,A61K39/095;;A61K39/0275;;A61K2039/54;;A61K2039/55505;;A61K2039/55594;;A61K2039/57;;A61P37/04;;Y02A50/30,A61K39/095;;A61K39/112;;A61P37/04,,0,0,,,,DISCONTINUED
689,AR,A1,AR 088365 A1,035-468-643-890-435,2014-05-28,2014,AR P120103870 A,2012-10-17,AR P120103870 A,2012-10-17,ADJUVANTES PARA VACUNAS POLISACARIDICAS Y LAS FORMULACIONES RESULTANTES,"Reivindicación 1: Composición inmunogénica adyuvada para la aplicación parenteral, mucosal o simultánea conteniendo antígenos polisacarídicos no conjugados. Reivindicación 2: Composición inmunogénica según la reivindicación 1, que contiene (a) un antígeno capsular de N. meningitidis serogrupo C o el Polisacárido Vi de Salmonella Typhi no conjugados y (b) el AFCo1 como adyuvante para la aplicación mucosal o el AFPL1 como adyuvante para la aplicación parenteral. Reivindicación 4: Las composiciones inmunogénicas de las reivindicaciones 1 - 3, al que se añada un polisacárido conjugado. Reivindicación 6: Composición inmunogénica según reivindicación 1 a 4, donde los antígenos polisacarídicos sean purificados de microbios, convertidos en oligosacáridos, obtenidos de forma recombinante o sintéticos.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE SUEROS Y VACUNAS,BELKIS ROMEU ALVAREZ;;MARIBEL CUELLO PEREZ;;LUIS GUILLERMO GARCIA IMIA;;REINALDO ACEVEDO GROGUES;;RAMON FAUSTINO BARBERA MORALES;;JOSE LUIS PEREZ QUIOY;;FRANCKLIN TOMAS SOTOLONGO PADRON;;CONCEPCION CAMPA HUERGO;;GUSTAVO VICTORIANO SIERRA GONZALEZ;;ALEIDA MANDIAROTE LLANES;;DANIEL TOMAS CARDOSO GONZALEZ;;OLIVER GERMAN PEREZ MARTIN;;MIRIAM DE SAN JUAN BOSCO LASTRE GONZALEZ;;CARIDAD ZAYAS VIGNIER;;JULIO ANTONIO BALBOA GONZALEZ;;OSMIR CABRERA BLANCO;;ELIZABETH GONZALEZ AZNAR,,https://lens.org/035-468-643-890-435,Patent Application,no,0,0,1,1,0,,A61K39/112;;A61P37/04,,0,0,,,,PENDING
690,WO,A1,WO 2013/064129 A1,178-150-942-430-733,2013-05-10,2013,CU 2012000006 W,2012-11-02,CU 20110202 A,2011-11-02,ADJUVANTS FOR POLYSACCHARIDE VACCINES AND RESULTING FORMULATIONS,"The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis; (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route; and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE SUEROS Y VACUNAS;;PEREZ MARTIN OLIVER GERMAN;;ROMEU ALVAREZ BELKIS;;LASTRE GONZALEZ MIRIAM DE SAN JUAN BOSCO;;ZAYAS VIGNIER CARIDAD;;GONZALEZ AZNAR ELIZABETH;;BALBOA GONZALEZ JULIO ANTONIO;;CABRERA BLANCO OSMIR;;CUELLO PEREZ MARIBEL;;GARCIA IMIA LUIS GUILLERMO;;ACEVEDO GROGUES REINALDO;;BARBERA GONZALEZ RAMON FAUSTINO;;PEREZ QUINOY JOSE LUIS;;SOTOLONGO PADRON FRANCKLIN TOMAS;;CAMPA HUERGO CONCEPCION;;SIERRA GONZALEZ GUSTAVO VICTORIANO;;MANDIAROTE LLANES ALEIDA;;CARDOSO GONZALEZ DANIEL TOMAS,PEREZ MARTIN OLIVER GERMAN;;ROMEU ALVAREZ BELKIS;;LASTRE GONZALEZ MIRIAM DE SAN JUAN BOSCO;;ZAYAS VIGNIER CARIDAD;;GONZALEZ AZNAR ELIZABETH;;BALBOA GONZALEZ JULIO ANTONIO;;CABRERA BLANCO OSMIR;;CUELLO PEREZ MARIBEL;;GARCIA IMIA LUIS GUILLERMO;;ACEVEDO GROGUES REINALDO;;BARBERA GONZALEZ RAMON FAUSTINO;;PEREZ QUINOY JOSE LUIS;;SOTOLONGO PADRON FRANCKLIN TOMAS;;CAMPA HUERGO CONCEPCION;;SIERRA GONZALEZ GUSTAVO VICTORIANO;;MANDIAROTE LLANES ALEIDA;;CARDOSO GONZALEZ DANIEL TOMAS,,https://lens.org/178-150-942-430-733,Patent Application,yes,10,0,6,6,0,A61K39/095;;A61K39/0275;;A61K2039/54;;A61K2039/55505;;A61K2039/55594;;A61K2039/57;;A61P37/04;;Y02A50/30,A61K39/095;;A61K39/112;;A61P37/04,,29,22,016-474-848-972-276;;133-379-461-698-790;;009-467-113-246-848;;007-356-098-416-962;;182-779-913-901-551;;166-292-151-949-748;;043-501-676-935-224;;018-043-288-638-058;;091-386-193-584-87X;;068-051-775-563-624;;073-561-256-591-43X;;028-388-527-511-65X;;092-721-060-925-206;;004-024-763-730-32X;;089-204-473-119-356;;041-543-976-640-56X;;021-538-999-092-760;;094-816-709-784-095;;003-955-252-796-238;;092-721-060-925-206;;122-907-348-152-689;;002-438-218-102-851,10.1111/j.1365-3083.2007.01981.x;;17635804;;10.3109/00365548.2011.586648;;21671827;;pmc2662867;;10.1186/1475-2875-8-35;;19250541;;6818232;;10.1016/s0092-1157(82)80010-3;;3933203;;9048846;;17848884;;10.1097/inf.0b013e3180cc2c25;;1523880;;10.1016/0264-410x(92)90091-w;;2110462;;9554280;;10.1038/nature06939;;pmc4804622;;18496530;;12134940;;10.1023/a:1016104910582;;15550118;;10.1111/j.1440-1711.2004.01293.x;;15812492;;10.1038/nm1210;;10.1016/s0076-6879(05)91018-5;;15721389;;17936245;;10.1016/j.bbamem.2007.08.001;;pmc2137893;;10.1016/j.ijpharm.2008.06.026;;18652885;;20575660;;10.1086/653739;;10.1128/iai.69.7.4502-4508.2001;;11401992;;pmc98525;;15550118;;10.1111/j.1440-1711.2004.01293.x;;pmc303053;;10.1128/iai.62.9.3957-3961.1994;;8063413;;10.1128/jvi.73.11.9609-9613.1999;;10516071;;pmc112997,"PEREZ ET AL.: ""New vaccines require potent adjuvants like AFPLl and AFCol."", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 66, 2007, pages 271 - 277, XP008149175;;ROMEU ET AL.: ""AFCol as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses."", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, vol. 43, October 2011 (2011-10-01), pages 809 - 813, XP008173446;;INSTITUTO FINLAY.: ""CENTRO DE INVESTIGACION- PRODUCCION DE SUEROS Y VACUNAS Y UNIVERSIDAD DE CAMBRIDGE"", FACULTAD PARA LAS CIENCIAS VETERINARIAS, 14 July 2005 (2005-07-14);;CABRERA O. ET AL.: ""Preparacion and evaluacion of conjugados of polisacarido Vi de Salmonella typhi con toxoide tetanico."", VACCIMONITOR, 2002, pages 6 - 9, XP055151253;;BRACHO G. ET AL.: ""AFCo I, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5."", MALARIA JOURNAL, vol. 8, 2009, pages 35, XP021049967;;See also references of EP 2777712A4;;ARMAND ET AL., J. BIOL. STAND., vol. 10, 1982, pages 335 - 339;;CADOZ ET AL., VACCINE, vol. 3, 1985, pages 340 - 342;;MMWR, vol. 46, no. RR-5, 1997, pages 1 - 10;;GRANOFF D; POLLARD A J., THE PEDIATRIC INFECTIOUS DISEASE JOURNAL, vol. 26, no. 8, 2007, pages 716 - 22;;COSTANTINO ET AL., VACCINE, vol. 10, 1992, pages 691 - 698;;FRASH: ""Advances in Biotechnological Processes"", vol. 13, 1990, pages: 123 - 145;;VOGEL FR, DEV. BIOL. STAND., vol. 92, 1998, pages 241 - 248;;EISENBARTH SC ET AL., NATURE, vol. 453, 2008, pages 1122 - 1126;;SINGH M; O'HAGAN DT, PHARM. RES., vol. 19, no. 6, 2002, pages 715 - 728;;PÉREZ 0 ET AL., IMMUNOLOGY AND CELL BIOLOGY, vol. 82, 2004, pages 603 - 610;;PASHINE A; VALIANTI NM., NAT. MED., vol. 11, 2005, pages 63 - 68;;O PEREZ ET AL., PHARMACOLOGY ONLINE, vol. 3, 2006, pages 762 - 64;;PEREZ O ET AL., SCAND J IMMUNOLOGY, vol. 66, 2007, pages 271 - 77;;ZARIF, METHODS ENZYMOL, vol. 391, 2005, pages 314 - 29;;MICLEA, VARMA ET AL., BIOCHIM BIOPHYS ACTA, vol. 1768, no. 11, 2007, pages 2890 - 8;;SYED, WOO ET AL., INT J PHARM, vol. 363, no. 1-2, 2008, pages 118 - 25;;SCAND J INFECT DIS, 2011, pages 1 - 5;;EXPERT VACCINE REVIEW, 2011;;TAILLARDET M ET AL., JID, vol. 202, 2010, pages 470 - 479;;PEREZ O ET AL., INFECT IMMUN., vol. 69, no. 7, 2001, pages 4502 - 4508;;PEREZ O ET AL., IMMUNOLOGY AND CELL BIOLOGY., vol. 82, 2004, pages 603 - 610;;BOUVET, J P ET AL., I & 1, vol. 62, 1994, pages 3957 - 3961;;NARDELLI-HAEFLIGER, DR ET AL., J. VIROL., vol. 73, 1999, pages 9609 - 9613",PENDING
691,AU,A1,AU 2012/331548 A1,167-619-334-947-25X,2014-06-26,2014,AU 2012/331548 A,2012-11-02,CU 20110202 A;;CU 2012000006 W,2011-11-02,Adjuvants for polysaccharide vaccines and resulting formulations,"The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis; (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route; and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.",INSTITUTO FINLAY CENTRO DE INVESTIG PRODUCCION DE SUEROS Y VACUNAS,PEREZ MARTIN OLIVER GERMAN;;ROMEU ALVAREZ BELKIS;;LASTRE GONZALEZ MIRIAM DE SAN JUAN BOSCO;;ZAYAS VIGNIER CARIDAD;;GONZALEZ AZNAR ELIZABETH;;BALBOA GONZALEZ JULIO ANTONIO;;CABRERA BLANCO OSMIR;;CUELLO PEREZ MARIBEL;;GARCIA IMIA LUIS GUILLERMO;;ACEVEDO GROGUES REINALDO;;BARBERA GONZALEZ RAMON FAUSTINO;;PEREZ QUINOY JOSE LUIS;;SATOLONGO PADRON FRANCKLIN TOMAS;;CAMPA HUERGO CONCEPCION;;SIERRA GONZALEZ GUSTAVO VICTORIANO;;MANDIAROTE LLANES ALEDA;;CARDOSO GONZALEZ DANIEL TOMAS,,https://lens.org/167-619-334-947-25X,Patent Application,no,0,0,6,6,0,A61K39/095;;A61K39/0275;;A61K2039/54;;A61K2039/55505;;A61K2039/55594;;A61K2039/57;;A61P37/04;;Y02A50/30,A61K39/095;;A61K39/112;;A61P37/04,,0,0,,,,DISCONTINUED
